Clustering O 0 1.7637710698181763e-05
of O 0 1.0013778819484287e-06
missense O 0 0.00025425798958167434
mutations O 0 0.00023016412160359323
in O 0 1.8679801314647193e-06
the O 0 4.022893335786648e-05
ataxia B-Disease 1 0.9999598264694214
- I-Disease 1 0.997962474822998
telangiectasia I-Disease 1 0.9990957975387573
gene O 0 4.665548476623371e-05
in O 0 1.0090932391904062e-06
a O 0 7.622939392604167e-06
sporadic B-Disease 0 0.0018431751523166895
T I-Disease 1 0.9736502170562744
- I-Disease 0 0.21926508843898773
cell I-Disease 0 0.32008516788482666
leukaemia I-Disease 1 0.9920111298561096
. O 0 1.8226168322144076e-05

Ataxia B-Disease 1 0.9994066953659058
- I-Disease 1 0.9984697699546814
telangiectasia I-Disease 1 0.9992641806602478
( O 0 0.0004379902093205601
A B-Disease 1 0.999629020690918
- I-Disease 1 0.9992325305938721
T I-Disease 1 0.999555766582489
) O 0 4.203656445156412e-08
is O 0 2.545827015865143e-08
a O 0 1.4142342763534543e-07
recessive B-Disease 0 0.00011381222429918125
multi I-Disease 0 0.14883601665496826
- I-Disease 1 0.9625056385993958
system I-Disease 0 0.44644397497177124
disorder I-Disease 1 0.9977244734764099
caused O 0 3.278842632425949e-05
by O 0 6.939652053006284e-08
mutations O 0 4.585719750593853e-07
in O 0 6.315755030072978e-09
the O 0 2.8874960200653277e-09
ATM O 0 1.3055866929789772e-06
gene O 0 5.517718477676681e-07
at O 0 1.8638480696608895e-06
11q22 O 0 9.069292900676373e-06
- O 0 2.183722608606331e-05
q23 O 0 3.839102191705024e-06
( O 0 8.328043321625955e-08
ref O 0 2.9711960451095365e-05
. O 0 5.5314018254648545e-08
3 O 0 2.1576323661065544e-07
) O 0 1.162823792810741e-07
. O 0 5.106965659251728e-07

The O 0 1.8005039237323217e-05
risk O 0 0.00017559381376486272
of O 0 3.5778982692136196e-06
cancer B-Disease 1 0.9808906316757202
, O 0 3.385499098840228e-07
especially O 0 4.932809929414361e-07
lymphoid B-Disease 0 0.00022879356401972473
neoplasias I-Disease 0 0.001941510010510683
, O 0 4.186357784874417e-07
is O 0 2.840948525317799e-07
substantially O 0 7.829718924767803e-06
elevated O 0 0.001142414752393961
in O 0 1.7331904018647037e-06
A B-Disease 1 0.9987382292747498
- I-Disease 1 0.9995030164718628
T I-Disease 1 0.9999185800552368
patients O 0 1.0934857527900022e-05
and O 0 6.767526627982079e-08
has O 0 3.9025096043587837e-07
long O 0 5.383217285270803e-07
been O 0 2.534135603582399e-07
associated O 0 5.410350922829821e-07
with O 0 1.3929388842370827e-05
chromosomal O 1 0.9998944997787476
instability O 1 0.9994328618049622
. O 0 4.394851566758007e-05

By O 0 2.3067302663548617e-06
analysing O 0 0.00018962789908982813
tumour B-Disease 1 0.9997455477714539
DNA O 0 6.664232205366716e-05
from O 0 2.646075927259517e-07
patients O 0 8.116554681691923e-07
with O 0 6.530599705456552e-08
sporadic B-Disease 0 0.00028275104705244303
T I-Disease 0 0.2236451804637909
- I-Disease 0 0.0011523436987772584
cell I-Disease 0 0.0007753674290142953
prolymphocytic I-Disease 0 0.0042891777120530605
leukaemia I-Disease 1 0.9403591156005859
( O 0 1.9671631434903247e-06
T B-Disease 0 0.012221798300743103
- I-Disease 0 4.568581061903387e-05
PLL I-Disease 0 1.7168847989523783e-05
) O 0 2.35579893370641e-08
, O 0 1.035690377904075e-08
a O 0 1.0015118334649742e-07
rare O 0 1.8964557284562034e-06
clonal B-Disease 0 5.8484914916334674e-05
malignancy I-Disease 0 0.004026996903121471
with O 0 1.729493170898877e-08
similarities O 0 3.2026857610389925e-08
to O 0 5.3590181181562e-09
a O 0 8.99901522188884e-07
mature B-Disease 0 1.0257729627483059e-05
T I-Disease 0 0.0063176508992910385
- I-Disease 0 0.00015055232506711036
cell I-Disease 0 9.354211942991242e-05
leukaemia I-Disease 0 0.009083118289709091
seen O 0 1.0278461104462622e-06
in O 0 4.77801734177774e-07
A B-Disease 1 0.850199818611145
- I-Disease 1 0.7298336625099182
T I-Disease 1 0.9948898553848267
, O 0 2.049910285961687e-08
we O 0 1.4933944081363393e-09
demonstrate O 0 2.1602393207587056e-09
a O 0 5.3076973927090876e-09
high O 0 2.376386909475059e-08
frequency O 0 1.632629853531853e-08
of O 0 7.802502643983189e-09
ATM O 0 2.1630212359013967e-05
mutations O 0 2.8447615477489308e-05
in O 0 3.274153868915164e-06
T B-Disease 0 0.1482732594013214
- I-Disease 0 0.0008884138660505414
PLL I-Disease 0 0.0007036860333755612
. O 0 4.145763796259416e-06

In O 0 9.850052720139502e-07
marked O 0 1.7900164266393404e-06
contrast O 0 1.824553947926688e-07
to O 0 2.1084554102657194e-09
the O 0 1.691492990119059e-08
ATM O 0 6.261497674131533e-06
mutation O 0 1.7271153183173737e-06
pattern O 0 1.7666296798779513e-06
in O 0 4.4653907593783515e-07
A B-Disease 1 0.9833819270133972
- I-Disease 1 0.9868302941322327
T I-Disease 1 0.999431312084198
, O 0 1.0763725910578614e-08
the O 0 2.5901321087928864e-09
most O 0 9.567390213405247e-10
frequent O 0 1.3096848938687344e-08
nucleotide O 0 4.262059505322213e-08
changes O 0 3.0162063069383294e-08
in O 0 2.7839750060820734e-08
this O 0 3.207496845902824e-08
leukaemia B-Disease 0 0.012675597332417965
were O 0 1.0954114486594335e-06
missense O 0 0.000288273993646726
mutations O 0 0.00039273567381314933
. O 0 2.97033352580911e-06

These O 0 2.0162025293757324e-07
clustered O 0 3.8086955100880004e-06
in O 0 2.1462935251292947e-07
the O 0 5.3542393629868457e-08
region O 0 5.966969496284946e-08
corresponding O 0 1.1671729360784866e-08
to O 0 7.815977864922274e-10
the O 0 5.617948772851378e-09
kinase O 0 1.5066368064253766e-07
domain O 0 2.9811232593601744e-08
, O 0 1.0206354872366319e-08
which O 0 3.903005474370502e-09
is O 0 2.998960635380854e-09
highly O 0 9.890168684023593e-09
conserved O 0 2.600057946722245e-08
in O 0 1.2737022991871072e-08
ATM O 0 3.471153377176961e-06
- O 0 2.624260105221765e-06
related O 0 2.7349384978947455e-08
proteins O 0 1.0056077748288317e-08
in O 0 1.6443115313791168e-08
mouse O 0 3.253257716551161e-07
, O 0 1.0484145995803829e-08
yeast O 0 1.8023361292307527e-07
and O 0 6.201519653359355e-08
Drosophila O 0 1.0810099411173724e-06
. O 0 9.586796068106196e-07

The O 0 9.42562678574177e-07
resulting O 0 1.714534619168262e-06
amino O 0 1.074416786650545e-06
- O 0 9.884598512144294e-06
acid O 0 3.8257144296949264e-07
substitutions O 0 5.153139781555183e-08
are O 0 2.3657218406469838e-09
predicted O 0 3.5481889426591806e-08
to O 0 3.81564613238794e-10
interfere O 0 2.1864925869863328e-08
with O 0 9.000503098377521e-08
ATP O 0 0.0012455336982384324
binding O 0 1.456359200346924e-06
or O 0 2.0282016066630604e-07
substrate O 0 1.1415799235692248e-05
recognition O 0 8.113420335575938e-06
. O 0 4.239344434608938e-06

Two O 0 1.3851885682925058e-07
of O 0 5.935867974926623e-08
seventeen O 0 2.0238323941157432e-06
mutated O 0 6.224108801688999e-05
T B-Disease 0 0.0017672627000138164
- I-Disease 0 8.70600160851609e-06
PLL I-Disease 0 8.003601578820962e-06
samples O 0 4.513531237648749e-08
had O 0 3.8645985966923035e-08
a O 0 7.283576763938981e-08
previously O 0 1.6423672377641196e-06
reported O 0 2.036462137766648e-05
A B-Disease 1 0.8778398633003235
- I-Disease 1 0.9841837882995605
T I-Disease 1 0.9981862902641296
allele O 0 3.063200711039826e-05
. O 0 2.3995439732971136e-06

In O 0 1.3266627547636745e-06
contrast O 0 1.4016787872606074e-06
, O 0 8.069076784522622e-08
no O 0 7.223753328844396e-08
mutations O 0 2.981959426051617e-07
were O 0 1.710439789803786e-08
detected O 0 4.701635418769001e-07
in O 0 4.7013011261753945e-09
the O 0 5.289486182391556e-09
p53 O 0 6.885043291049442e-08
gene O 0 3.0729395916750946e-08
, O 0 3.659184955040473e-09
suggesting O 0 5.3713208103545185e-08
that O 0 2.5080890253548205e-08
this O 0 8.229792456404539e-07
tumour B-Disease 1 0.9999525547027588
suppressor O 0 0.0001313246029894799
is O 0 1.0853884191419638e-07
not O 0 7.507014565533154e-09
frequently O 0 5.653316037523837e-08
altered O 0 9.973578016797546e-07
in O 0 2.3635161028323637e-07
this O 0 6.683612809865735e-07
leukaemia B-Disease 1 0.744175374507904
. O 0 4.197265752736712e-06

Occasional O 0 1.753998913045507e-05
missense O 0 0.00022074564185459167
mutations O 0 3.881733209709637e-05
in O 0 1.617791696162385e-07
ATM O 0 1.1213764992135111e-05
were O 0 1.1552489809218969e-07
also O 0 1.05868743105475e-07
found O 0 1.1890639939338143e-07
in O 0 1.625835807317344e-06
tumour B-Disease 1 0.9999352693557739
DNA O 0 6.995032890699804e-06
from O 0 1.1173993641477864e-07
patients O 0 2.1622855683745001e-07
with O 0 1.3998865178166398e-08
B B-Disease 0 9.32265720621217e-06
- I-Disease 0 9.418297850061208e-05
cell I-Disease 0 0.00011202677706023678
non I-Disease 0 1.4739459402335342e-05
- I-Disease 0 0.04861253499984741
Hodgkins I-Disease 1 0.9989573955535889
lymphomas I-Disease 0 0.10278033465147018
( O 0 1.9342053292348282e-07
B B-Disease 0 2.6776704089570558e-06
- I-Disease 0 2.1463192751980387e-06
NHL I-Disease 0 4.6798808739367814e-07
) O 0 1.6080473619339841e-09
and O 0 2.071558480309932e-09
a O 0 9.76794112261814e-08
B B-Disease 0 5.598500592896016e-06
- I-Disease 0 2.6702837203629315e-05
NHL I-Disease 0 2.809488978527952e-05
cell O 0 4.23518504248932e-05
line O 0 1.914795211632736e-05
. O 0 1.1124250249849865e-06

The O 0 2.531978111619537e-07
evidence O 0 2.7579929451349017e-08
of O 0 6.76736888749474e-09
a O 0 4.125072194938184e-08
significant O 0 2.9691836544998296e-08
proportion O 0 5.3699793056694034e-08
of O 0 2.7883750419732678e-08
loss O 0 3.8982117985142395e-05
- O 0 2.7447533739177743e-06
of O 0 1.333993715491033e-08
- O 0 1.6146756024681963e-05
function O 0 1.4874800058350957e-07
mutations O 0 3.0424820351981907e-07
and O 0 2.6230042582398028e-09
a O 0 2.1579095843549112e-08
complete O 0 7.308180016707411e-08
absence O 0 5.721199869412885e-08
of O 0 1.164435214917603e-09
the O 0 4.147206578153373e-09
normal O 0 2.548528499346503e-08
copy O 0 8.501176651520836e-09
of O 0 6.044075795408332e-10
ATM O 0 3.145740663512697e-07
in O 0 1.1751230211132224e-08
the O 0 8.033507192806155e-09
majority O 0 2.863060188929012e-08
of O 0 6.133901564453481e-08
mutated O 0 9.75620569079183e-05
tumours B-Disease 1 0.9971215128898621
establishes O 0 2.2062631614971906e-06
somatic O 0 1.7698606598059996e-06
inactivation O 0 0.0004952047020196915
of O 0 8.128296258291812e-09
this O 0 4.466972569616701e-09
gene O 0 4.278643217503486e-08
in O 0 1.1251451326188544e-08
the O 0 2.5330740172080368e-08
pathogenesis O 0 7.214503966679331e-06
of O 0 5.3322157356205935e-08
sporadic B-Disease 0 0.00018876594549510628
T I-Disease 0 0.05927913635969162
- I-Disease 0 4.0175291360355914e-05
PLL I-Disease 0 1.5329644156736322e-05
and O 0 3.653969926631362e-08
suggests O 0 3.339514620392947e-08
that O 0 1.8044071792289174e-09
ATM O 0 4.000140449988976e-07
acts O 0 8.475955581843664e-08
as O 0 5.604294415206823e-07
a O 0 0.0005397545173764229
tumour B-Disease 1 0.9999359846115112
suppressor O 0 0.004539569839835167
. O 0 6.2066951613815036e-06

As O 0 6.401966174962581e-07
constitutional O 0 3.0442110983130988e-06
DNA O 0 1.1196494597243145e-05
was O 0 3.5078494420304196e-06
not O 0 2.405874832689392e-09
available O 0 3.827310468551559e-09
, O 0 6.262626417452566e-09
a O 0 2.5130287895080983e-07
putative O 0 5.156715997145511e-05
hereditary O 0 0.31467723846435547
predisposition O 0 0.0007383331540040672
to O 0 1.1063013971579494e-06
T B-Disease 0 0.45538878440856934
- I-Disease 0 9.818175749387592e-05
PLL I-Disease 0 3.411257057450712e-05
will O 0 2.1974340569386186e-08
require O 0 1.9458569866515063e-08
further O 0 3.1126635491318666e-08
investigation O 0 1.0754962431747117e-06
. O 0 1.750655087562336e-07
. O 0 1.0057401595986448e-06

Myotonic B-Disease 1 0.9990701079368591
dystrophy I-Disease 1 0.9995599389076233
protein O 0 0.00023365812376141548
kinase O 0 6.36225231573917e-05
is O 0 2.1140058947821672e-07
involved O 0 1.6719971185352733e-08
in O 0 3.64357055637754e-09
the O 0 1.8267636292534917e-09
modulation O 0 1.8455782679893673e-08
of O 0 1.1504038832654828e-09
the O 0 1.7696629939223385e-08
Ca2 O 0 3.201359504600987e-06
+ O 0 5.086879355076235e-06
homeostasis O 0 0.0019379514269530773
in O 0 2.1814560113853076e-06
skeletal O 0 0.08168196678161621
muscle O 0 0.03933342173695564
cells O 0 0.00015720554802101105
. O 0 3.6514172734314343e-06

Myotonic B-Disease 1 0.9996362924575806
dystrophy I-Disease 1 0.9999419450759888
( O 0 0.0006073240656405687
DM B-Disease 1 0.9996644258499146
) O 0 2.726475543113338e-07
, O 0 3.281700600155091e-08
the O 0 2.855131064904981e-08
most O 0 1.3057019998541364e-07
prevalent O 0 2.98112427117303e-05
muscular B-Disease 1 0.9959618449211121
disorder I-Disease 1 0.9990253448486328
in O 0 1.4495733012154233e-05
adults O 0 1.1719729627657216e-05
, O 0 8.448917583336879e-07
is O 0 8.093304586509475e-07
caused O 0 3.089081928919768e-06
by O 0 3.996166952902058e-08
( O 0 3.2198233412827904e-08
CTG O 0 6.6858078753284644e-06
) O 0 3.0937581385614976e-08
n O 0 5.621777745545842e-07
- O 0 1.058061116054887e-06
repeat O 0 7.671918922369514e-08
expansion O 0 7.651839695199669e-08
in O 0 2.3531705473089914e-09
a O 0 6.410088904118538e-09
gene O 0 6.140500552476169e-09
encoding O 0 1.0834416919180967e-08
a O 0 5.413706816170816e-08
protein O 0 1.0618583701216266e-07
kinase O 0 1.3232662467999035e-06
( O 0 4.307761614086303e-08
DM B-Disease 1 0.7052341103553772
protein O 0 7.1768664611227e-07
kinase O 0 2.2798167265136726e-06
; O 0 1.9414640561876695e-08
DMPK O 0 1.0387079782958608e-05
) O 0 1.8378912836070072e-09
and O 0 1.8040181570810887e-09
involves O 0 2.1535512928494427e-08
changes O 0 4.305658762859821e-08
in O 0 7.0936465590421e-08
cytoarchitecture O 0 1.5203562725218944e-05
and O 0 8.799101465228887e-07
ion O 0 0.0022096827160567045
homeostasis O 1 0.8161640763282776
. O 0 1.51277199620381e-05

To O 0 1.044720079335093e-07
obtain O 0 6.634606108946173e-08
clues O 0 9.209340134930244e-08
to O 0 3.838715567638928e-09
the O 0 1.021887996444093e-08
normal O 0 1.0499558555920885e-07
biological O 0 6.228190585488846e-08
role O 0 2.968764611921415e-08
of O 0 3.477820254005337e-09
DMPK O 0 4.758373052027309e-06
in O 0 3.7549607867504164e-08
cellular O 0 9.146143383986782e-06
ion O 0 4.542844544630498e-05
homeostasis O 0 0.0038558270316570997
, O 0 6.057791779312538e-08
we O 0 7.022496806285972e-09
have O 0 1.3385041963687172e-09
compared O 0 1.4004714721238543e-08
the O 0 8.843417553805466e-09
resting O 0 1.778795081008866e-06
[ O 0 1.057996996678412e-07
Ca2 O 0 6.113787662798131e-07
+ O 0 5.732832164540014e-07
] O 0 2.1422609108867618e-07
i O 0 3.815060622969213e-08
, O 0 1.2346857980460868e-09
the O 0 1.6013382841961743e-09
amplitude O 0 2.0736505845775355e-08
and O 0 6.645571204444423e-09
shape O 0 1.4856567531751352e-07
of O 0 1.5444520329310762e-08
depolarization O 0 3.3498099583084695e-06
- O 0 1.6608270016149618e-05
induced O 0 4.229975729685975e-06
Ca2 O 0 6.203199518495239e-07
+ O 0 2.6505412620281277e-07
transients O 0 3.124995373582351e-07
, O 0 2.1473196554211427e-09
and O 0 8.084998226465245e-10
the O 0 8.285637176363991e-10
content O 0 2.4070410109544582e-09
of O 0 2.7769411214961792e-09
ATP O 0 3.0266481189755723e-05
- O 0 1.0272061672367272e-06
driven O 0 1.5994808677533e-07
ion O 0 1.3033201184953214e-06
pumps O 0 5.123972073306504e-07
in O 0 2.5468567699249434e-08
cultured O 0 6.892696546856314e-07
skeletal O 0 0.00018735510820988566
muscle O 0 2.78498755506007e-05
cells O 0 4.729553779725393e-07
of O 0 1.325552734243729e-08
wild O 0 3.4730035736174614e-07
- O 0 1.2400492778397165e-05
type O 0 1.2375390952001908e-06
and O 0 3.492172950814165e-08
DMPK O 0 0.00010545278928475454
[ O 0 7.65606500863214e-07
- O 0 1.4788810403842945e-05
/ O 0 4.432620244188001e-06
- O 0 8.298429747810587e-05
] O 0 3.94065182263148e-06
knockout O 0 0.0009483782341703773
mice O 0 0.00011217803694307804
. O 0 1.5051286936795805e-06

In O 0 4.635578534362139e-06
vitro O 0 6.353800563374534e-05
- O 0 5.067950041848235e-05
differentiated O 0 9.791416232474148e-06
DMPK O 0 0.0002749580889940262
[ O 0 4.685200110543519e-06
- O 0 1.9494103980832733e-05
/ O 0 6.144666258478537e-06
- O 0 1.4619388821301982e-05
] O 0 3.0879459700372536e-07
myotubes O 0 1.3727940313401632e-06
exhibit O 0 9.292482161527005e-08
a O 0 1.3549524169320648e-07
higher O 0 1.583731261689536e-07
resting O 0 1.888104065983498e-06
[ O 0 9.653312815771642e-08
Ca2 O 0 3.705280846588721e-07
+ O 0 4.846576189265761e-07
] O 0 1.6519638279532955e-07
i O 0 5.975921624212788e-08
than O 0 2.395946774313984e-09
do O 0 4.091594618671479e-09
wild O 0 6.927643880771939e-08
- O 0 6.736901013937313e-06
type O 0 1.5795877743585152e-06
myotubes O 0 6.264042440307094e-06
because O 0 1.248266467968051e-08
of O 0 6.865838453329332e-10
an O 0 4.615191340207048e-09
altered O 0 1.296505161008099e-07
open O 0 7.106497434961057e-08
probability O 0 4.97134422516865e-09
of O 0 1.7455021872336829e-09
voltage O 0 9.104043101615389e-07
- O 0 2.093434886774048e-06
dependent O 0 2.578599946900795e-07
l O 0 3.826604825007962e-06
- O 0 1.1817445511042024e-06
type O 0 3.4320314057367796e-07
Ca2 O 0 4.5493735001400637e-07
+ O 0 1.709176871145246e-07
and O 0 3.069916587605803e-08
Na O 0 8.553390216547996e-06
+ O 0 2.476464487699559e-06
channels O 0 3.400893774596625e-06
. O 0 1.4119879097052035e-06

The O 0 1.254049493581988e-06
mutant O 0 1.552469802845735e-05
myotubes O 0 1.9446182704996318e-05
exhibit O 0 3.235602719087183e-07
smaller O 0 7.122184797481168e-08
and O 0 1.6795402402181026e-08
slower O 0 1.2882584599083202e-07
Ca2 O 0 5.371617248783878e-07
+ O 0 1.4500186296118045e-07
responses O 0 1.11546114567318e-08
upon O 0 1.2995474030219611e-08
triggering O 0 8.878030826053873e-07
by O 0 1.8559353165414905e-08
acetylcholine O 0 2.6511621399549767e-05
or O 0 1.1145725409278384e-07
high O 0 8.039072781684808e-06
external O 0 9.092778782360256e-06
K O 0 4.7928737330948934e-05
+ O 0 3.4825323382392526e-05
. O 0 2.7275807497062488e-06

In O 0 5.744171289734368e-07
addition O 0 2.2912024633114925e-07
, O 0 3.864370157202757e-08
we O 0 3.979788054664368e-09
observed O 0 1.2711951491439777e-08
that O 0 3.067607556861418e-10
these O 0 9.6684504846678e-10
Ca2 O 0 4.131903779125423e-07
+ O 0 8.68054712555022e-07
transients O 0 9.111911822401453e-06
partially O 0 8.319108019350097e-06
result O 0 5.513789957944937e-08
from O 0 2.171483881596714e-09
an O 0 1.0950316209346056e-09
influx O 0 3.957231875517664e-09
of O 0 5.463138275096924e-10
extracellular O 0 2.837855284099078e-08
Ca2 O 0 1.2760261824951158e-07
+ O 0 4.2011158996047016e-08
through O 0 7.079302477563942e-09
the O 0 5.3682793321740974e-08
l O 0 4.436350081959972e-06
- O 0 5.757033250120003e-06
type O 0 1.9805509055004222e-06
Ca2 O 0 3.5274908896099078e-06
+ O 0 4.998219537810655e-06
channel O 0 1.7898468286148272e-05
. O 0 2.723762236200855e-06

Neither O 0 4.7550161070830654e-06
the O 0 9.132011058454736e-08
content O 0 8.148106189764803e-08
nor O 0 7.914002253528452e-08
the O 0 7.4306019115510935e-09
activity O 0 1.528194992772569e-08
of O 0 6.0116569500223704e-09
Na O 0 6.580441095138667e-06
+ O 0 1.5402886219817447e-06
/ O 0 7.213880053313915e-07
K O 0 5.908509024266095e-07
+ O 0 5.650448429150856e-07
ATPase O 0 2.1655680484400364e-06
and O 0 7.013503733332982e-08
sarcoplasmic O 0 2.2010171960573643e-05
reticulum O 0 2.6506360882194713e-05
Ca2 O 0 5.792852789454628e-06
+ O 0 1.859516146396345e-06
- O 0 2.831807705661049e-06
ATPase O 0 1.968899141502334e-06
are O 0 1.287821849160764e-08
affected O 0 1.7811942143453052e-07
by O 0 1.486246361537269e-07
DMPK O 0 0.0014952102210372686
absence O 0 5.068887912784703e-05
. O 0 3.1183226383291185e-06

In O 0 1.3244706451587263e-06
conclusion O 0 3.1037944836498355e-07
, O 0 3.6629156596745815e-08
our O 0 1.4822908234179977e-08
data O 0 4.97031358293043e-08
suggest O 0 2.3248382774454512e-08
that O 0 4.9402646418172935e-09
DMPK O 0 2.2399479348678142e-05
is O 0 3.345609655980297e-08
involved O 0 4.571683032139617e-09
in O 0 5.259285895675703e-09
modulating O 0 1.6132467806073691e-07
the O 0 6.1640990089983916e-09
initial O 0 1.8045112071263247e-08
events O 0 2.7828690463138628e-09
of O 0 4.413903464950408e-09
excitation O 0 1.6884474689504714e-06
- O 0 3.326234218548052e-05
contraction O 0 3.253287104598712e-06
coupling O 0 1.2258141168786096e-06
in O 0 6.893110366945621e-07
skeletal O 0 0.0051732370629906654
muscle O 0 0.00144188164267689
. O 0 4.354776024229068e-07
. O 0 1.173834789369721e-06

Constitutional O 0 0.0004885764210484922
RB1 O 0 0.027024993672966957
- O 0 0.0005253454437479377
gene O 0 2.315230085514486e-05
mutations O 0 9.438877896172926e-05
in O 0 9.743079090185347e-07
patients O 0 6.59214902043459e-06
with O 0 4.502619788127049e-07
isolated O 0 0.0004542024398688227
unilateral B-Disease 0 0.00077851238893345
retinoblastoma I-Disease 0 0.11521561443805695
. O 0 1.919404348882381e-05

In O 0 4.4558423724083696e-06
most O 0 6.742942559867515e-07
patients O 0 3.947760887967888e-06
with O 0 1.5659342977869528e-07
isolated O 0 5.9238020185148343e-05
unilateral B-Disease 0 3.5377972380956635e-05
retinoblastoma I-Disease 0 0.0042311218567192554
, O 0 1.7888143702293746e-05
tumor B-Disease 0 0.14624948799610138
development O 0 8.065752865604736e-08
is O 0 1.849059572123224e-08
initiated O 0 6.45363016360534e-08
by O 0 5.729058560888234e-09
somatic O 0 2.4971942025331373e-07
inactivation O 0 0.000153331522597
of O 0 3.427691686042067e-09
both O 0 3.3769711471620667e-09
alleles O 0 3.904228762507955e-08
of O 0 2.050395231378843e-08
the O 0 1.6181094224521075e-06
RB1 O 0 0.005170992109924555
gene O 0 5.1304890803294256e-05
. O 0 4.231218099448597e-06

However O 0 6.176512101774279e-07
, O 0 3.309698470843614e-08
some O 0 9.407463696931018e-10
of O 0 3.9651348870961556e-09
these O 0 7.777792632168712e-09
patients O 0 4.289375681310048e-07
can O 0 8.434891007880196e-09
transmit O 0 2.694161139515927e-06
retinoblastoma B-Disease 0 0.0010504223173484206
predisposition O 0 7.402666960842907e-05
to O 0 3.211077626019687e-08
their O 0 1.4078732135658356e-07
offspring O 0 1.0005140211433172e-05
. O 0 1.6887421452338458e-06

To O 0 1.9461917588614597e-07
determine O 0 6.923205830844381e-08
the O 0 1.6377573075487817e-08
frequency O 0 1.6699547700227413e-07
and O 0 1.7426387444174907e-08
nature O 0 5.629321719879954e-08
of O 0 2.536375909301114e-08
constitutional O 0 4.912847998639336e-06
RB1 O 0 0.00171267322730273
- O 0 6.701130041619763e-05
gene O 0 5.646264071401674e-06
mutations O 0 1.3871222108718939e-05
in O 0 3.1380821496895805e-07
patients O 0 9.202630621985008e-07
with O 0 6.405483787830235e-08
isolated O 0 1.1460228961368557e-05
unilateral B-Disease 0 2.7652201879391214e-06
retinoblastoma I-Disease 0 5.722932473872788e-05
, O 0 2.5559520722140405e-08
we O 0 6.071254166073459e-09
analyzed O 0 5.2538542405500266e-08
DNA O 0 9.821913948826477e-08
from O 0 1.265507609815586e-08
peripheral O 0 5.749653610109817e-06
blood O 0 1.3021289305470418e-05
and O 0 4.655962584365625e-07
from O 0 6.686158940283349e-06
tumor B-Disease 1 0.9971237778663635
tissue O 0 0.01461258064955473
. O 0 7.308824478968745e-06

The O 0 2.9928543199275737e-07
analysis O 0 2.124406250914035e-07
of O 0 2.1337218925054913e-07
tumors B-Disease 1 0.9996730089187622
from O 0 1.1034463653913917e-07
54 O 0 2.4112057417369215e-07
( O 0 1.034606356142831e-08
71 O 0 8.677105967080934e-08
% O 0 1.1910672448323112e-09
) O 0 8.017889130407241e-10
of O 0 1.6850133510715182e-09
76 O 0 1.7233001869954023e-07
informative O 0 2.517324730888504e-07
patients O 0 9.912881068885326e-06
showed O 0 1.2839700502809137e-05
loss O 0 2.8718150133499876e-05
of O 0 9.122035038444665e-08
constitutional O 0 1.9346354747540317e-05
heterozygosity O 0 0.0014780709752812982
( O 0 4.379249730845913e-06
LOH O 1 0.9901580214500427
) O 0 2.741556670571299e-07
at O 0 4.985304258298129e-06
intragenic O 0 0.00029949095915071666
loci O 0 1.2886672266176902e-05
. O 0 2.3018956198939122e-06

Three O 0 8.553387260690215e-07
of O 0 2.404789540833008e-07
13 O 0 5.091470939078135e-06
uninformative O 0 0.007708343211561441
patients O 0 0.0005645659985020757
had O 0 1.493208583269734e-05
constitutional O 0 1.0524202480155509e-05
deletions O 0 5.220106686465442e-05
. O 0 1.0338358151784632e-05

For O 0 4.996690563530137e-07
39 O 0 1.2512673492892645e-06
randomly O 0 3.462434392531577e-07
selected O 0 9.101967748392781e-07
tumors B-Disease 1 0.9996389150619507
, O 0 1.3357215777887177e-07
SSCP O 0 0.00010877132444875315
, O 0 1.2260474591130333e-07
hetero O 0 1.0037250831373967e-05
- O 0 4.947909928887384e-06
duplex O 0 5.185121608519694e-06
analysis O 0 3.7857397217067046e-08
, O 0 3.3592535420012837e-09
sequencing O 0 2.3335280374681133e-08
, O 0 8.782516935923468e-09
and O 0 7.84346099180766e-09
Southern O 0 8.529115547162291e-08
blot O 0 1.6424329487563227e-06
analysis O 0 8.060182743463429e-09
were O 0 2.692962075556693e-09
used O 0 3.507397705604376e-09
to O 0 5.3160054136469626e-09
identify O 0 6.302952897385694e-07
mutations O 0 2.2845853891340084e-05
. O 0 1.8430475847708294e-06

Mutations O 0 0.00016117224004119635
were O 0 1.1494106502141221e-06
detected O 0 9.659538591222372e-06
in O 0 9.049735183452867e-08
21 O 0 1.146148278508008e-07
( O 0 5.759550614214959e-09
91 O 0 3.990598784753274e-08
% O 0 3.3820504174997268e-09
) O 0 3.3965634749222318e-09
of O 0 2.529578324583781e-08
23 O 0 0.0004446371167432517
tumors B-Disease 1 0.9999188184738159
with O 0 0.00020501705876085907
LOH O 1 0.9994663596153259
. O 0 2.808540921250824e-05

In O 0 2.0743093500641407e-06
6 O 0 6.128533414084814e-07
( O 0 2.246907371272755e-08
38 O 0 7.808803559328226e-08
% O 0 4.135310760489119e-09
) O 0 3.2420746087780117e-09
of O 0 2.3745927890672647e-08
16 O 0 8.899143722373992e-05
tumors B-Disease 1 0.9998956918716431
without O 0 5.547663931793068e-06
LOH O 1 0.9883909225463867
, O 0 9.111150234275556e-08
one O 0 2.227874418281317e-08
mutation O 0 3.572221203285153e-07
was O 0 9.058574050868629e-07
detected O 0 2.433349948205432e-07
, O 0 1.953777584162708e-09
and O 0 2.0532902045289347e-09
in O 0 6.158610510453855e-09
9 O 0 4.119348062658901e-08
( O 0 2.0489163699011215e-09
56 O 0 1.1746614347885043e-08
% O 0 8.388775785128644e-10
) O 0 1.11977938033192e-09
of O 0 5.599142927081857e-09
the O 0 6.798609774705255e-06
tumors B-Disease 1 0.9999316930770874
without O 0 7.202976121334359e-06
LOH O 1 0.9831638932228088
, O 0 6.937905538961786e-08
both O 0 1.814319539050757e-08
mutations O 0 2.6703364710556343e-06
were O 0 1.3356796557673078e-07
found O 0 8.621294114163902e-07
. O 0 9.518669799035706e-07

Thus O 0 1.6700183778084465e-06
, O 0 3.9875708068848326e-08
a O 0 1.9742692813906615e-08
total O 0 4.545321008464498e-09
of O 0 2.8093640747073323e-09
45 O 0 1.648978731338957e-08
mutations O 0 2.4237684215222544e-07
were O 0 2.6242165773737725e-08
identified O 0 8.729693945497274e-07
in O 0 1.0932791383311269e-06
tumors B-Disease 1 0.9996769428253174
of O 0 4.511525730777066e-07
36 O 0 2.7833124477183446e-05
patients O 0 5.1925213483627886e-05
. O 0 1.5655177776352502e-06

Thirty O 0 1.2148825589974876e-05
- O 0 4.332029220677214e-06
nine O 0 7.784548472500319e-08
of O 0 4.067628456283501e-09
the O 0 2.574127400123416e-08
mutations O 0 4.7263208102776844e-07
- O 0 9.556690656609135e-07
including O 0 9.493303032570566e-09
34 O 0 3.911891255370392e-08
small O 0 2.842448942885767e-08
mutations O 0 5.013502004658221e-07
, O 0 8.406013662920486e-09
2 O 0 3.553877903073044e-08
large O 0 7.579256333656303e-08
structural O 0 8.807006088318303e-05
alterations O 0 2.3952590709086508e-05
, O 0 3.823474514774716e-08
and O 0 3.579443230705692e-08
hypermethylation O 0 0.00014091709454078227
in O 0 1.5256138112818007e-06
3 O 0 0.00019972950394731015
tumors O 1 0.9999309778213501
- O 0 9.411285282112658e-05
were O 0 5.6311151297450124e-08
not O 0 3.855121999407629e-09
detected O 0 1.2785001501924853e-07
in O 0 2.9008715429768017e-09
the O 0 5.818967530046848e-09
corresponding O 0 7.975190641218433e-08
peripheral O 0 9.262882667826489e-05
blood O 0 0.0002618086291477084
DNA O 0 6.552891136379912e-05
. O 0 2.2616998194280313e-06

In O 0 3.052638703593402e-06
6 O 0 1.3653519772560685e-06
( O 0 3.7554553244945055e-08
17 O 0 1.0207313749788227e-07
% O 0 2.7004716240952575e-09
) O 0 8.147726382468079e-10
of O 0 6.84795997685228e-10
the O 0 1.6420989012999598e-08
36 O 0 1.5638076433788228e-07
patients O 0 1.318243931791585e-07
, O 0 3.3697649115538297e-09
a O 0 2.8432307885850605e-07
mutation O 0 1.4682268556498457e-06
was O 0 3.206165729352506e-06
detected O 0 5.22947516401473e-07
in O 0 9.79788605803833e-09
constitutional O 0 6.960384268950293e-08
DNA O 0 1.1680642586497925e-07
, O 0 5.580229167634343e-09
and O 0 3.068773457570728e-09
1 O 0 1.4793109848199038e-08
of O 0 2.1994077670228762e-09
these O 0 3.902648426645783e-09
mutations O 0 3.989359242950741e-07
is O 0 2.114424901833445e-08
known O 0 3.357128264269704e-08
to O 0 2.0029962133349954e-09
be O 0 2.154196110382145e-08
associated O 0 1.5019813304206764e-07
with O 0 2.477434861702932e-07
reduced O 0 7.620290853083134e-05
expressivity O 0 0.007186921779066324
. O 0 7.634324902028311e-06

The O 0 3.8879031194483105e-07
presence O 0 5.286332225296064e-07
of O 0 2.0745090978380176e-08
a O 0 3.652047553259763e-07
constitutional O 0 4.7047851694514975e-06
mutation O 0 2.4667184334248304e-05
was O 0 7.724476745352149e-06
not O 0 3.8788567913172756e-09
associated O 0 9.404202749863089e-09
with O 0 2.1487864820812774e-09
an O 0 3.3461777348975374e-08
early O 0 7.31486636595946e-07
age O 0 1.9359174530109158e-06
at O 0 1.232056092703715e-05
treatment O 0 8.955106750363484e-05
. O 0 1.6853666693350533e-06

In O 0 6.076984391256701e-06
1 O 0 4.9738305278879125e-06
patient O 0 1.3466756172419991e-05
, O 0 3.5782964147301755e-08
somatic O 0 9.789630439627217e-07
mosaicism O 0 0.0004168605082668364
was O 0 9.603938451618887e-06
demonstrated O 0 5.974371930506095e-08
by O 0 2.232237505950252e-09
molecular O 0 3.783487656505713e-08
analysis O 0 3.416869231998021e-09
of O 0 1.7187913314842262e-09
DNA O 0 1.881534643644045e-07
and O 0 1.9732228295765708e-08
RNA O 0 1.39228086482035e-06
from O 0 1.1419553658242876e-07
peripheral O 0 0.00020965987641829997
blood O 0 0.0005831322632730007
. O 0 5.930875886406284e-06

In O 0 4.635379355022451e-06
2 O 0 5.07323647980229e-06
patients O 0 2.3870409222581657e-06
without O 0 6.700634713752152e-08
a O 0 3.2256448889711464e-07
detectable O 0 3.707339783431962e-05
mutation O 0 3.1515469345322344e-06
in O 0 6.229593196849237e-08
peripheral O 0 8.293926657643169e-05
blood O 0 0.0001099092623917386
, O 0 2.614519871713128e-07
mosaicism O 0 0.00014881434617564082
was O 0 3.9679507608525455e-05
suggested O 0 2.166872405950926e-07
because O 0 1.6904674993156732e-08
1 O 0 2.438697244144805e-08
of O 0 5.404903191674748e-09
the O 0 8.284126238322642e-07
patients O 0 6.705935811623931e-05
showed O 0 0.0012913806131109595
multifocal O 1 0.9997281432151794
tumors B-Disease 1 0.9999898672103882
and O 0 5.500774591382651e-07
the O 0 2.7058661089540692e-08
other O 0 5.101316258304678e-09
later O 0 2.885180663270148e-07
developed O 0 8.961786193140142e-07
bilateral B-Disease 0 1.2452755072445143e-05
retinoblastoma I-Disease 0 0.018657397478818893
. O 0 1.246927149622934e-05

In O 0 9.030627552419901e-07
conclusion O 0 2.961407972179586e-07
, O 0 3.3729556037087605e-08
our O 0 2.21738645223013e-08
results O 0 1.2170575303116493e-07
emphasize O 0 3.156619143851458e-08
that O 0 4.441663037368926e-09
the O 0 6.637945304532877e-09
manifestation O 0 2.3295220330510347e-07
and O 0 3.060106834595899e-08
transmissibility O 0 2.1435619146359386e-06
of O 0 7.916928446149996e-09
retinoblastoma B-Disease 0 5.4654751693306025e-06
depend O 0 1.5843379941316016e-08
on O 0 3.777545742877919e-08
the O 0 5.441178174692141e-09
nature O 0 1.1428854307382608e-08
of O 0 1.00888852827552e-09
the O 0 5.176632456027619e-09
first O 0 1.965462459452283e-08
mutation O 0 2.911204788347277e-08
, O 0 4.4602788129566306e-10
its O 0 6.260987284179009e-10
time O 0 2.261852483087523e-09
in O 0 2.726265435626374e-09
development O 0 3.170157025778053e-09
, O 0 2.8261539775087385e-09
and O 0 7.995012984984839e-10
the O 0 1.1612811823269453e-09
number O 0 3.0312094501105946e-10
and O 0 1.1379385211895965e-09
types O 0 3.1755429397151147e-09
of O 0 4.704171718827865e-09
cells O 0 1.5445439771610836e-07
that O 0 3.273347592980258e-09
are O 0 1.598756349530106e-09
affected O 0 6.221186055199723e-08
. O 0 8.559265296526064e-08
. O 0 7.628042340002139e-07

Hereditary B-Disease 1 0.9994852542877197
deficiency I-Disease 1 0.9988952279090881
of I-Disease 0 3.5851488178195723e-07
the I-Disease 0 1.593258645016249e-07
fifth I-Disease 0 1.0828879339896957e-06
component I-Disease 0 3.1550186463391583e-07
of I-Disease 0 1.3116948416325158e-08
complement I-Disease 0 5.148198738424981e-07
in O 0 1.459263557990198e-06
man O 0 0.00016569368017371744
. O 0 3.4520066947152372e-06

I O 0 0.004047337453812361
. O 0 4.9958958697970957e-05

Clinical O 0 0.00048207410145550966
, O 0 1.6177683619389427e-06
immunochemical O 0 0.00039747293340042233
, O 0 5.739998982789984e-07
and O 0 4.389219725453586e-07
family O 0 1.426150538463844e-05
studies O 0 6.118732926552184e-06
. O 0 2.589892346804845e-06

The O 0 4.98294355111284e-07
first O 0 3.555370540198055e-07
recognized O 0 4.035895813103707e-07
human O 0 3.869939746437012e-07
kindred O 0 5.5611344578210264e-05
with O 0 3.0019842597539537e-05
hereditary B-Disease 1 0.9998944997787476
deficiency I-Disease 1 0.9984776377677917
of I-Disease 0 2.7128736590498193e-08
the I-Disease 0 4.289330490792054e-08
fifth I-Disease 0 6.260837039917533e-07
component I-Disease 0 2.0661678945543827e-07
of I-Disease 0 4.13249567898788e-09
complement I-Disease 0 1.705500238813329e-07
( O 0 1.6981853434572258e-07
C5 O 0 0.00031531305285170674
) O 0 1.6820062853639683e-07
is O 0 7.614813739564852e-07
described O 0 1.2593919564096723e-05
. O 0 1.2342271702436847e-06

The O 0 1.0579481113381917e-06
proband O 0 3.6745495890500024e-05
, O 0 5.665124902520802e-08
a O 0 1.0997295163406307e-07
20 O 0 1.0109004477953931e-07
- O 0 3.4065030831698095e-06
year O 0 2.1048968790182698e-07
- O 0 5.476902060763678e-06
old O 0 9.76283808995504e-06
black O 0 1.6666485862515401e-06
female O 0 6.890113581903279e-06
with O 0 0.0008341088541783392
systemic B-Disease 1 0.9999918937683105
lupus I-Disease 1 0.9999734163284302
erythematosus I-Disease 1 0.9999828338623047
since O 0 0.006350026000291109
age O 0 3.54225339833647e-05
11 O 0 1.3602079889096785e-06
, O 0 7.660236178708146e-08
lacked O 0 1.3173683328204788e-05
serum O 0 0.00013886555097997189
hemolytic O 0 0.0015360424295067787
complement O 0 4.011708654161339e-07
activity O 0 2.8591020395651867e-07
, O 0 4.785623630709779e-08
even O 0 1.4801895531491027e-07
during O 0 9.60124634730164e-06
remission O 0 0.0005369310383684933
. O 0 3.166562009937479e-06

C5 O 0 0.014681966044008732
was O 0 0.0002448245359119028
undetectable O 0 0.00012509393854998052
in O 0 2.2191767357071512e-07
her O 0 3.579877159154421e-07
serum O 0 2.413668426015647e-06
by O 0 7.860053941044498e-09
both O 0 2.3216479405618884e-08
immunodiffusion O 0 0.00014426372945308685
and O 0 4.101851118321065e-06
hemolytic O 1 0.9876844882965088
assays O 0 0.0004184227727819234
. O 0 5.62782497581793e-06

Other O 0 2.6965768284981095e-08
complement O 0 1.0585198140233842e-07
components O 0 1.4289466321315558e-07
were O 0 4.968105216107688e-08
normal O 0 5.97152450154681e-07
during O 0 3.320775931570097e-06
remission O 0 0.0001015320885926485
of O 0 3.394447958271485e-07
lupus O 1 0.8611948490142822
, O 0 1.2217731182317948e-07
but O 0 1.0311651266192712e-07
C1 O 0 5.7931225455831736e-05
, O 0 4.7646576462057055e-08
C4 O 0 5.433183105196804e-05
, O 0 1.500140456300869e-07
C2 O 0 4.703466038336046e-05
, O 0 1.724828457838612e-08
and O 0 4.925232843788763e-08
C3 O 0 0.0008513444918207824
levels O 0 1.872719258244615e-05
fell O 0 0.0004744459583889693
during O 0 1.1968361832259689e-05
exacerbations O 0 0.005572315771132708
. O 0 6.010862307448406e-06

A O 0 7.6130227171233855e-06
younger O 0 2.361434781050775e-06
half O 0 5.587308464782836e-07
- O 0 2.0420513465069234e-05
sister O 0 2.1844247385160998e-05
, O 0 8.841313103857829e-08
who O 0 2.828240610597277e-07
had O 0 2.1821781501785154e-06
no O 0 1.9721276203199523e-06
underlying O 0 0.0003930056991521269
disease O 0 0.2827706038951874
, O 0 4.26682618126506e-07
was O 0 2.8220965759828687e-05
also O 0 4.1698299924064486e-08
found O 0 1.1084156703589088e-08
to O 0 4.550560372962309e-09
lack O 0 8.891257152754406e-07
immunochemically O 0 0.00816085934638977
detectable O 0 0.0076049515046179295
C5 O 0 0.010713338851928711
. O 0 5.668032827088609e-06

By O 0 1.0362927241658326e-05
hemolytic O 1 0.5715118050575256
assay O 0 8.243251068051904e-05
, O 0 5.451714173432265e-07
she O 0 5.396818778535817e-07
exhibited O 0 3.365624365869735e-07
1 O 0 1.952300152652242e-07
- O 0 9.649977528169984e-07
2 O 0 3.4794805259252826e-08
% O 0 1.196618582000042e-09
of O 0 7.059208217974344e-10
the O 0 1.822233741677337e-08
normal O 0 7.849343433008471e-07
serum O 0 1.5155151231738273e-06
C5 O 0 3.6015367186337244e-06
level O 0 6.331232071943305e-08
and O 0 5.935343772023316e-09
normal O 0 8.279136665123588e-08
concentrations O 0 6.718141065675809e-08
of O 0 7.994067630079371e-10
other O 0 7.852363204108315e-10
complement O 0 5.6344347854064836e-08
components O 0 2.347580448258668e-06
. O 0 2.027572463703109e-06

C5 O 0 0.004720783792436123
levels O 0 1.6482686987728812e-05
of O 0 2.258292930434891e-08
other O 0 4.279612220159379e-09
family O 0 5.609664555095151e-08
members O 0 1.8296543169427082e-09
were O 0 1.0088545110420455e-08
either O 0 1.2334978372052774e-08
normal O 0 1.0073011935674003e-07
or O 0 5.849368545085554e-09
approximately O 0 5.111533418755698e-09
half O 0 2.62147530349921e-08
- O 0 1.5486385791518842e-06
normal O 0 1.913549851906282e-07
, O 0 8.996551947859643e-09
consistent O 0 7.353707331958503e-08
with O 0 3.702108131165005e-08
autosomal O 0 0.00015787505253683776
codominant O 0 3.3610635000513867e-05
inheritance O 0 1.8527734937379137e-06
of O 0 2.4153479216693086e-08
the O 0 1.0512949302210473e-06
gene O 0 0.00010656972153810784
determining O 0 0.0035217900294810534
C5 B-Disease 1 0.9998427629470825
deficiency I-Disease 1 0.9999467134475708
. O 0 6.157844472909346e-05

Normal O 0 0.0051423474214971066
hemolytic O 1 0.980158805847168
titers O 0 0.0010057541076093912
were O 0 7.588324137941527e-07
restored O 0 3.5802809179585893e-06
to O 0 3.815344484792149e-08
both O 0 4.3640471858452656e-07
homozygous O 0 0.0032017603516578674
C5 B-Disease 1 0.999672532081604
- I-Disease 1 0.9993234872817993
deficient I-Disease 1 0.9998795986175537
( O 0 4.2336314436397515e-06
C5D B-Disease 1 0.998869001865387
) O 0 1.773678235394982e-07
sera O 0 4.404392257129075e-06
by O 0 5.176957973418439e-09
addition O 0 9.755537710987028e-09
of O 0 1.29374537749527e-08
highly O 0 1.0944037285298691e-06
purified O 0 1.551007699163165e-05
human O 0 6.493415185104823e-06
C5 O 0 0.003206270979717374
. O 0 5.628608505503507e-06

In O 0 1.8174109754909296e-06
specific O 0 6.923838782313396e-07
C5 O 0 0.0006198717746883631
titrations O 0 0.00025708734756335616
, O 0 5.109343419462675e-07
however O 0 1.0416935936063965e-07
, O 0 1.8948448143873975e-08
it O 0 1.1387597531609117e-08
was O 0 1.9921783405152382e-06
noted O 0 2.0444554493792566e-08
that O 0 6.751971204366214e-10
when O 0 2.9724234185124487e-09
limited O 0 1.3075526217320999e-09
amounts O 0 2.2020523182675333e-09
of O 0 1.6637410338304903e-09
C5 O 0 2.3639922801521607e-06
were O 0 4.4619317129956926e-09
assayed O 0 6.988000222918345e-08
in O 0 4.570201106446348e-09
the O 0 4.496361061256948e-09
presence O 0 1.0940781614010575e-08
of O 0 5.401141756067318e-09
low O 0 1.2000909919152036e-06
dilutions O 0 2.3492400487157283e-06
of O 0 3.474162468819486e-08
either O 0 2.8523609216790646e-06
C5D B-Disease 1 0.9996113181114197
serum O 0 9.060994489118457e-05
, O 0 1.4455005192814951e-08
curving O 0 7.244339883527573e-08
rather O 0 7.922759337475327e-09
than O 0 2.4281969768225053e-09
linear O 0 5.144978487692242e-08
dose O 0 1.781992295946111e-06
- O 0 9.618812555345357e-07
response O 0 1.9162301967412532e-08
plots O 0 2.2254706522062406e-08
were O 0 1.998196808017383e-08
consistently O 0 1.2638943758247478e-07
obtained O 0 4.6662659514140614e-08
, O 0 1.1238152630710374e-08
suggesting O 0 5.764180244227646e-08
some O 0 5.8973599337264204e-09
inhibitory O 0 2.096067873935681e-06
effect O 0 1.5013570191513281e-06
. O 0 8.21124331196188e-07

Further O 0 3.263168309786124e-06
studies O 0 1.0465803370607318e-06
suggested O 0 6.364479645526444e-07
that O 0 2.753661654253392e-08
low O 0 4.97536802868126e-06
dilutions O 0 3.172025753883645e-05
of O 0 6.190069257172581e-07
C5D B-Disease 1 0.9995784163475037
serum O 0 0.00012240197975188494
contain O 0 1.0143673989659874e-07
a O 0 1.4048568175439868e-07
factor O 0 5.006000947105349e-08
( O 0 5.263420366219407e-09
or O 0 6.994171464214105e-09
factors O 0 3.125893321964668e-09
) O 0 1.1893985796262996e-09
interfering O 0 2.48735130270461e-08
at O 0 1.2487598155530577e-07
some O 0 1.7685889419638556e-09
step O 0 1.0731443467193458e-07
in O 0 2.1949666972886916e-08
the O 0 1.2318218978180084e-07
hemolytic O 0 0.0015538438456133008
assay O 0 1.643501605030906e-06
of O 0 5.2358078761471916e-08
C5 O 0 7.839735189918429e-05
, O 0 1.2106230684594266e-08
rather O 0 4.929403107922781e-09
than O 0 2.8369879778722407e-09
a O 0 1.139894507673489e-07
true O 0 6.804076519983937e-07
C5 O 0 0.0005707602249458432
inhibitor O 0 5.788787530036643e-05
or O 0 6.391186957444006e-07
inactivator O 0 0.0007690866477787495
. O 0 4.654409167414997e-06

Of O 0 9.13366250188119e-07
clinical O 0 5.65337177249603e-05
interest O 0 4.52345915391561e-07
are O 0 8.454493105602978e-09
( O 0 2.2797763676862814e-08
a O 0 1.700026075468486e-07
) O 0 7.932587919867728e-09
the O 0 1.2476665922633856e-08
documentation O 0 5.677997592101747e-07
of O 0 5.265843583401875e-07
membranous O 1 0.9981693029403687
glomerulonephritis B-Disease 1 0.9999784231185913
, O 0 0.26148539781570435
vasculitis B-Disease 1 0.9999852180480957
, O 0 0.004085277207195759
and O 0 0.15999935567378998
arthritis B-Disease 1 0.9999978542327881
in O 0 1.7802816500989138e-06
an O 0 1.7510025429601228e-07
individual O 0 6.84680401263904e-08
lacking O 0 1.3514849342755042e-05
C5 O 0 0.0002223016635980457
( O 0 2.3044684382966807e-08
and O 0 6.66364563528532e-09
its O 0 8.777493398781644e-09
biologic O 0 5.17701039370877e-07
functions O 0 2.8691280462567192e-08
) O 0 6.181182232722904e-09
, O 0 4.767745753753161e-09
and O 0 7.2143317986217426e-09
( O 0 9.592025840277074e-09
b O 0 4.767639083524955e-08
) O 0 1.7718775335850978e-09
a O 0 1.45023104636266e-08
remarkable O 0 1.3536970300265239e-07
propensity O 0 3.8096434309409233e-06
to O 0 1.089387637875916e-06
bacterial B-Disease 1 0.9998553991317749
infections I-Disease 1 0.999738872051239
in O 0 2.1721359644288896e-07
the O 0 9.729599526053789e-08
proband O 0 4.044920569867827e-05
, O 0 1.5700969413501298e-08
even O 0 7.824439762771362e-09
during O 0 3.819873484189884e-08
periods O 0 3.03958422875894e-08
of O 0 2.099137974553855e-09
low O 0 3.6046053537575062e-06
- O 0 4.328725026425673e-06
dose O 0 5.57276450763311e-07
or O 0 7.511626876066657e-09
alternate O 0 5.050568674391798e-08
- O 0 1.0910753189818934e-05
day O 0 1.73849275597604e-06
corticosteroid O 0 0.001288154860958457
therapy O 0 0.00026862008962780237
. O 0 2.6996933684131363e-06

Other O 0 1.7759698778263555e-07
observations O 0 1.3553702729041106e-06
indicate O 0 5.536942921935406e-07
that O 0 3.811882365312158e-08
the O 0 5.937860123594874e-07
C5D B-Disease 1 0.9992862343788147
state O 0 4.5921004243609786e-07
is O 0 8.192766465242585e-09
compatible O 0 1.239970526256684e-08
with O 0 8.08272027086332e-09
normal O 0 2.2809382471677964e-07
coagulation O 0 4.1422842400606896e-07
function O 0 4.366544814615736e-08
and O 0 7.012351144197737e-09
the O 0 1.0056499633037674e-08
capacity O 0 6.5803007487375e-08
to O 0 7.352161102147647e-09
mount O 0 7.013877620920539e-06
a O 0 1.4738756362930872e-05
neutrophilic O 0 0.13519906997680664
leukocytosis O 0 0.1537420004606247
during O 0 0.002657039323821664
pyogenic B-Disease 1 0.9518857002258301
infection I-Disease 1 0.8796451091766357
. O 0 1.6142375898198225e-06
. O 0 2.53472285294265e-06

Susceptibility O 1 0.5321701169013977
to O 0 0.0020532705821096897
ankylosing B-Disease 1 0.9999725818634033
spondylitis I-Disease 1 0.9999971389770508
in O 0 0.011562072671949863
twins O 0 0.028793303295969963
: O 0 3.728903053001886e-08
the O 0 8.321593192306409e-09
role O 0 3.0609594858788114e-08
of O 0 5.6812883286738725e-09
genes O 0 7.742302443602966e-08
, O 0 6.170159139173848e-08
HLA O 0 1.671350037213415e-05
, O 0 4.222025395961282e-08
and O 0 6.622784098908596e-08
the O 0 3.115282822818699e-07
environment O 0 2.9772032576147467e-05
. O 0 3.780079623538768e-06

OBJECTIVE O 0 4.257138243701775e-06
To O 0 3.9194048895296874e-08
determine O 0 1.0280308515575598e-07
the O 0 3.036490170416073e-08
relative O 0 2.509194700905937e-07
effects O 0 2.452970591093617e-07
of O 0 1.879181255048934e-08
genetic O 0 9.989742011384806e-07
and O 0 5.491529009304941e-08
environmental O 0 8.0540286262476e-07
factors O 0 2.0879429030173924e-07
in O 0 2.4211792606365634e-06
susceptibility O 0 0.005127359181642532
to O 0 0.0004360531165730208
ankylosing B-Disease 1 0.9999938011169434
spondylitis I-Disease 1 0.9999991655349731
( O 0 0.0007601036923006177
AS B-Disease 1 0.9736853837966919
) O 0 3.95008055420476e-06
. O 0 3.8126204344735015e-06

METHODS O 0 2.967775253637228e-05
Twins O 0 0.00036840990651398897
with O 0 4.862233708990971e-07
AS B-Disease 0 0.0010382323525846004
were O 0 8.167026521732623e-08
identified O 0 7.83846871854621e-08
from O 0 8.899713854759739e-09
the O 0 3.430649897495641e-08
Royal O 0 0.00013392424443736672
National O 0 0.00020008612773381174
Hospital O 1 0.9174901843070984
for O 0 0.0006409937632270157
Rheumatic B-Disease 1 0.9999620914459229
Diseases I-Disease 1 0.9996542930603027
database O 0 0.0009283936815336347
. O 0 1.3990977095090784e-05

Clinical O 0 0.00022153736790642142
and O 0 8.931464208217221e-07
radiographic O 0 0.000150222796946764
examinations O 0 2.5108272893703543e-05
were O 0 1.572613541611645e-07
performed O 0 2.5494966848782497e-07
to O 0 5.291049820499438e-09
establish O 0 3.03946023905155e-07
diagnoses O 0 8.889949094736949e-05
, O 0 2.8668416689470178e-06
and O 0 0.00011592088412726298
disease O 1 0.9967889785766602
severity O 0 0.03482644632458687
was O 0 0.0001640058180782944
assessed O 0 2.953972568775498e-07
using O 0 6.937491914271732e-09
a O 0 3.687210892167059e-08
combination O 0 5.1388290955856064e-08
of O 0 6.242293792979581e-09
validated O 0 6.925556021997181e-07
scoring O 0 9.207511766362586e-07
systems O 0 9.95034642983228e-05
. O 0 2.2517483557749074e-06

HLA O 0 0.0008162814192473888
typing O 0 1.5424850062117912e-05
for O 0 4.091253913429682e-07
HLA O 0 0.00020433831377886236
- O 0 1.5178443391050678e-05
B27 O 0 3.5005875815841137e-06
, O 0 1.7202475532940298e-07
HLA O 0 1.3101844160701148e-05
- O 0 3.250824647693662e-06
B60 O 0 8.768943757786474e-07
, O 0 6.18833340126912e-08
and O 0 2.0416541701706592e-07
HLA O 0 0.0003069665399380028
- O 0 0.0002413121546851471
DR1 O 0 0.007520212326198816
was O 0 5.372640316636534e-06
performed O 0 6.338421343343725e-08
by O 0 3.760033173705324e-09
polymerase O 0 1.8885060626416816e-07
chain O 0 4.821180255021318e-07
reaction O 0 1.8389933131857106e-08
with O 0 2.4546371601985584e-09
sequence O 0 3.67632608799795e-08
- O 0 1.7637228211242473e-07
specific O 0 3.993391395340495e-09
primers O 0 1.4710184359501e-07
, O 0 6.509953021094361e-09
and O 0 2.4641797935487375e-08
zygosity O 0 4.536986307357438e-05
was O 0 1.0791653949127067e-05
assessed O 0 1.034725755744148e-06
using O 0 7.134665338526247e-07
microsatellite O 0 0.00034121598582714796
markers O 0 8.071809861576185e-05
. O 0 4.738357347378042e-06

Genetic O 0 0.00024136737920343876
and O 0 8.330504215336987e-07
environmental O 0 4.1875321699080814e-07
variance O 0 6.008277608771095e-08
components O 0 4.103507933450601e-07
were O 0 1.288183568703971e-07
assessed O 0 2.3651099922972207e-07
with O 0 5.648549183945306e-09
the O 0 4.1004405204603245e-08
program O 0 1.8808815127613343e-07
Mx O 0 1.4761029660803615e-06
, O 0 1.3443685054070897e-09
using O 0 4.971512646001486e-10
data O 0 3.6040352924260333e-09
from O 0 1.213382505582672e-09
this O 0 3.4041564012099457e-10
and O 0 9.790090960137832e-10
previous O 0 2.130220089213708e-08
studies O 0 7.022121994992858e-09
of O 0 8.701282361300855e-09
twins O 0 3.1903582566883415e-05
with O 0 2.3418643024797348e-07
AS B-Disease 0 0.06787768751382828
. O 0 2.7413707357482053e-06

RESULTS O 0 1.993261139432434e-05
Six O 0 3.6326576946521527e-07
of O 0 1.0388166771235774e-07
8 O 0 2.8557901714520995e-06
monozygotic O 0 9.33265037019737e-05
( O 0 1.2456868034860236e-06
MZ O 0 0.08462335914373398
) O 0 3.2760917179075477e-07
twin O 0 0.000160441457410343
pairs O 0 2.6392915515316417e-06
were O 0 4.118757715332322e-06
disease O 0 0.003685565199702978
concordant O 0 7.808466762071475e-06
, O 0 4.194814096081245e-08
compared O 0 4.7281737636239995e-08
with O 0 3.8632479437694656e-09
4 O 0 3.6728849295286636e-08
of O 0 5.722266216423577e-09
15 O 0 8.733309897479558e-08
B27 O 0 2.460526957293041e-06
- O 0 1.2713057913060766e-05
positive O 0 1.4438256812354666e-07
dizygotic O 0 5.3581084102916066e-06
( O 0 4.9676316393743036e-08
DZ O 0 0.000433657958637923
) O 0 2.940183208011149e-08
twin O 0 3.3068515676859533e-06
pairs O 0 4.5905412804359e-08
( O 0 6.8863803548424585e-09
27 O 0 5.693918581073376e-08
% O 0 8.494560055360978e-10
) O 0 3.0417848795316615e-10
and O 0 1.3764277495553756e-09
4 O 0 1.4401204673220036e-08
of O 0 3.6088299015801795e-09
32 O 0 3.354088846663217e-07
DZ O 0 0.0009015952819027007
twin O 0 4.770575469592586e-05
pairs O 0 2.237313623254522e-07
overall O 0 7.191638360382058e-07
( O 0 1.599812726738037e-08
12 O 0 1.8265067680545144e-08
. O 0 4.841071987726764e-09
5 O 0 4.365928774063832e-08
% O 0 2.182925662452817e-08
) O 0 7.101159837930027e-08
. O 0 6.341123821584915e-07

Nonsignificant O 0 0.0026166988536715508
increases O 0 2.093171133310534e-05
in O 0 1.4641352663602447e-07
similarity O 0 8.78366037682099e-08
with O 0 2.0301673231415407e-08
regard O 0 4.089458727207784e-08
to O 0 1.5782514850570806e-08
age O 0 2.475453811712214e-06
at O 0 0.0003149314725305885
disease O 0 0.1477363109588623
onset O 0 0.0006997712189331651
and O 0 1.2843876184831515e-08
all O 0 8.543696305984838e-10
of O 0 8.574244425574307e-09
the O 0 5.015777333028382e-06
disease O 0 0.07419883459806442
severity O 0 5.359426359063946e-05
scores O 0 4.420629409196408e-07
assessed O 0 4.719227320038044e-07
were O 0 5.964125193713699e-08
noted O 0 7.699447905906709e-07
in O 0 6.36793129160651e-06
disease O 1 0.7963619232177734
- O 0 0.05355342477560043
concordant O 0 0.002258572494611144
MZ O 1 0.9233888387680054
twins O 0 0.001106110168620944
compared O 0 4.597499355440959e-06
with O 0 9.862159231488477e-07
concordant O 0 0.006944508757442236
DZ O 1 0.9895609617233276
twins O 0 0.04767519235610962
. O 0 1.285759026359301e-05

HLA O 0 0.011435011401772499
- O 0 0.00024337321519851685
B27 O 0 1.4220408957044128e-05
and O 0 1.2652233749577135e-07
B60 O 0 3.1436823064723285e-06
were O 0 8.718829747067502e-08
associated O 0 1.303037464595036e-07
with O 0 8.170391652129183e-08
the O 0 1.0625371032801922e-05
disease O 0 0.019399501383304596
in O 0 8.508302329346407e-08
probands O 0 1.2876205801148899e-05
, O 0 9.213835028276662e-09
and O 0 5.242920320114308e-09
the O 0 4.0358987263289237e-08
rate O 0 1.0034408433057251e-06
of O 0 2.544603816545532e-08
disease O 0 0.00039504459709860384
concordance O 0 4.816676550944976e-07
was O 0 2.199234359068214e-06
significantly O 0 2.8458836709432944e-07
increased O 0 8.973830745162559e-08
among O 0 3.068909748549231e-08
DZ O 0 0.0017642808379605412
twin O 0 4.19149364461191e-05
pairs O 0 9.145588819592376e-08
in O 0 1.4093355815703035e-08
which O 0 3.9665568607460955e-09
the O 0 1.6782273348781018e-08
co O 0 1.897064794320613e-05
- O 0 5.0763952458510175e-05
twin O 0 9.465774928685278e-05
was O 0 1.545388386148261e-06
positive O 0 3.936589720865413e-09
for O 0 2.3644315394477644e-09
both O 0 1.3824219102787083e-08
B27 O 0 4.13591124015511e-06
and O 0 8.564111908526684e-07
DR1 O 0 0.08550051599740982
. O 0 4.466414793569129e-06

Additive O 0 1.729554969642777e-05
genetic O 0 2.5315935999969952e-05
effects O 0 2.5288122742495034e-06
were O 0 3.10014947046966e-08
estimated O 0 8.668946449574833e-09
to O 0 3.207842325103627e-10
contribute O 0 3.810179283192383e-09
97 O 0 1.2595403831028307e-08
% O 0 6.694956811159614e-10
of O 0 6.230870819301515e-10
the O 0 1.866364840452661e-08
population O 0 2.8781171224068203e-08
variance O 0 4.3699941443264834e-07
. O 0 7.287466701200174e-07

CONCLUSION O 0 2.7203224817640148e-05
Susceptibility O 0 8.968370093498379e-05
to O 0 2.2558332091193734e-07
AS B-Disease 0 0.00524515938013792
is O 0 1.1447009740095382e-07
largely O 0 4.8945906883091084e-08
genetically O 0 1.2379811664686713e-07
determined O 0 1.319619968853658e-07
, O 0 6.1068856638257785e-09
and O 0 8.856128275169795e-09
the O 0 1.07148153460912e-07
environmental O 0 1.4204346143742441e-06
trigger O 0 1.29021248085337e-06
for O 0 7.741091678781231e-08
the O 0 3.206551627954468e-05
disease O 1 0.8045935034751892
is O 0 8.91075558229204e-07
probably O 0 8.482309681312472e-07
ubiquitous O 0 8.290943696920294e-06
. O 0 1.182440200864221e-06

HLA O 0 0.010149018839001656
- O 0 6.804299482610077e-05
B27 O 0 5.9789490478578955e-06
accounts O 0 4.3353910683663344e-08
for O 0 4.190733537967617e-09
a O 0 3.263524206431612e-08
minority O 0 1.4015109073284293e-08
of O 0 8.056335598638498e-10
the O 0 1.2476808031181008e-08
overall O 0 2.6101577077497495e-07
genetic O 0 3.8985508581390604e-06
susceptibility O 0 3.685386400320567e-05
to O 0 1.5631083272182877e-07
AS B-Disease 0 0.1369468867778778
. O 0 1.0360704436607193e-05

Cell O 0 0.0025583996903151274
cycle O 0 0.00017000299703795463
- O 0 2.1326863134163432e-05
dependent O 0 1.011258973449003e-06
colocalization O 0 5.57187331651221e-06
of O 0 2.463493764537361e-08
BARD1 O 0 7.07424187567085e-05
and O 0 8.24380776975886e-08
BRCA1 O 0 3.0948970106692286e-06
proteins O 0 4.809699305496906e-08
in O 0 2.6437698252834707e-08
discrete O 0 2.5002324832712475e-07
nuclear O 0 4.419395190780051e-05
domains O 0 5.873760983376997e-06
. O 0 2.1444534468173515e-06

Germ O 0 0.013950815424323082
- O 0 0.00034134156885556877
line O 0 1.4707095942867454e-05
mutations O 0 3.504295136735891e-06
of O 0 3.7257393614709144e-08
the O 0 1.5203501391169993e-07
BRCA1 O 0 2.1802517949254252e-05
gene O 0 1.0030428256868618e-06
predispose O 0 6.308907245511364e-07
women O 0 3.1295162017386247e-08
to O 0 1.463926668776594e-08
early O 0 5.880890057596844e-06
- O 0 0.13489367067813873
onset O 1 0.9929732084274292
breast B-Disease 1 0.9997745156288147
and I-Disease 1 0.9773962497711182
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999934434890747
by O 0 1.8146089075798955e-07
compromising O 0 5.490944658959052e-06
the O 0 1.602855377313972e-07
genes O 0 4.4555389422384906e-07
presumptive O 0 9.131505066761747e-05
function O 0 3.804361199399864e-07
as O 0 5.562039291362453e-07
a O 0 6.846176984254271e-05
tumor B-Disease 1 0.8723689317703247
suppressor O 0 0.0004769960360135883
. O 0 3.3321009595965734e-06

Although O 0 7.353706337198673e-07
the O 0 9.847331483570088e-08
biochemical O 0 3.4061911264871014e-06
properties O 0 4.821584980163607e-07
of O 0 7.075390584532215e-08
BRCA1 O 0 5.555622192332521e-05
polypeptides O 0 5.284658755044802e-07
are O 0 9.766968567248568e-09
not O 0 4.725169144847996e-09
understood O 0 1.968287399733981e-08
, O 0 7.865329498812912e-10
their O 0 6.414354047912241e-10
expression O 0 1.4992830088544906e-08
pattern O 0 1.94413445342434e-07
and O 0 7.367125576251965e-09
subcellular O 0 5.377152660912543e-07
localization O 0 5.55450185402151e-07
suggest O 0 2.4729938985501576e-08
a O 0 1.6707090821910242e-08
role O 0 6.935338348057485e-08
in O 0 1.9831767872346973e-07
cell O 0 0.0002788680139929056
- O 0 0.00035618775291368365
cycle O 0 2.7211319320485927e-05
regulation O 0 1.4778518561797682e-05
. O 0 1.5655118659196887e-06

When O 0 2.666687942110002e-05
resting O 0 0.00027336148195900023
cells O 0 5.975961812509922e-06
are O 0 1.5811743026006297e-08
induced O 0 7.340001957345521e-07
to O 0 1.5160499522437476e-09
proliferate O 0 1.0140830397631362e-07
, O 0 1.8472113838541304e-09
the O 0 2.3862509745953275e-09
steady O 0 2.3535361037829716e-07
- O 0 4.679698122345144e-07
state O 0 9.950965385030486e-09
levels O 0 1.2400438897941513e-08
of O 0 1.2502386903534557e-09
BRCA1 O 0 3.0805983897153055e-07
increase O 0 4.5715435881277244e-09
in O 0 5.876497954915294e-09
late O 0 1.245116294512627e-07
G1 O 0 3.0106941721896874e-06
and O 0 3.176596985454694e-09
reach O 0 4.735156267088314e-09
a O 0 2.1499682034686884e-08
maximum O 0 1.1455024662154756e-07
during O 0 8.732024525670568e-07
S O 0 7.804468623362482e-05
phase O 0 2.3766106096445583e-05
. O 0 1.4152963103697402e-06

Moreover O 0 8.156049261742737e-06
, O 0 2.4939123477452085e-07
in O 0 2.278164288327389e-07
S O 0 3.4934826544485986e-05
phase O 0 8.96421533980174e-06
cells O 0 1.7557139244672726e-06
, O 0 6.930340390454148e-08
BRCA1 O 0 1.5261579164871364e-06
polypeptides O 0 5.822989734838302e-08
are O 0 2.5382524970751774e-09
hyperphosphorylated O 0 1.386375629408576e-06
and O 0 1.1951526879272478e-08
accumulate O 0 2.171206148204874e-07
into O 0 2.1952345719000732e-08
discrete O 0 3.69306036418493e-07
subnuclear O 0 5.890471220482141e-05
foci O 0 3.876132905134e-05
termed O 0 0.00014549931802321225
" O 0 4.523542884271592e-06
BRCA1 O 0 0.00025673117488622665
nuclear O 0 0.0005814404576085508
dots O 0 0.00017144382582046092
. O 0 9.034831236931495e-06

" O 0 3.521398684824817e-05
BRCA1 O 0 0.0006308507290668786
associates O 0 6.21400322415866e-05
in O 0 5.464581818159786e-07
vivo O 0 2.336664920221665e-06
with O 0 4.280569498860132e-08
a O 0 2.02188402909087e-06
structurally O 0 0.00012909929500892758
related O 0 1.4168953157422948e-06
protein O 0 1.0426898370496929e-05
termed O 0 0.00015278188220690936
BARD1 O 0 0.008645439520478249
. O 0 4.987482498108875e-06

Here O 0 2.2946712761040544e-06
we O 0 5.726789353843742e-08
show O 0 4.0653191035744385e-08
that O 0 1.3248342423111126e-09
the O 0 6.237009575471575e-09
steady O 0 3.5462275604913884e-07
- O 0 2.7844639589602593e-06
state O 0 3.9379660421445806e-08
levels O 0 6.403163155255243e-08
of O 0 2.353924610787317e-09
BARD1 O 0 7.790141353325453e-06
, O 0 9.042967263894752e-09
unlike O 0 1.0456825627613853e-08
those O 0 8.514023930317194e-10
of O 0 5.349632736795229e-09
BRCA1 O 0 4.747720595332794e-06
, O 0 3.187146546679287e-08
remain O 0 3.4970856432892106e-08
relatively O 0 3.774765744424258e-08
constant O 0 1.2357376988347823e-07
during O 0 3.3475041618657997e-06
cell O 0 0.0003114422725047916
cycle O 0 0.00014006361016072333
progression O 0 0.00024663491058163345
. O 0 2.7877958928002045e-06

However O 0 1.076044554793043e-05
, O 0 1.9270923985459376e-06
immunostaining O 0 0.0004264583985786885
revealed O 0 2.5432038455619477e-05
that O 0 1.248247798457669e-07
BARD1 O 0 0.00021023557928856462
resides O 0 8.54617428558413e-06
within O 0 4.182032284916204e-07
BRCA1 O 0 6.477164424723014e-05
nuclear O 0 1.0201585610047914e-05
dots O 0 1.4081339259064407e-06
during O 0 1.1569760545171448e-06
S O 0 2.3884663278295193e-06
phase O 0 5.045263407055245e-08
of O 0 1.0932390548390458e-09
the O 0 1.2216107236895368e-08
cell O 0 1.6797697526271804e-06
cycle O 0 3.8133080693114607e-07
, O 0 3.787239855057578e-09
but O 0 2.581786784361384e-09
not O 0 7.216806041654422e-10
during O 0 2.4284299016130717e-08
the O 0 1.1105110786502337e-07
G1 O 0 0.00029473338508978486
phase O 0 1.772059295035433e-05
. O 0 1.4731075452800724e-06

Nevertheless O 0 0.00010039144399343058
, O 0 1.1418915164540522e-06
BARD1 O 0 9.625263191992417e-05
polypeptides O 0 6.150971785245929e-07
are O 0 5.735826924535559e-09
found O 0 8.334221313077705e-09
exclusively O 0 1.0898999924791042e-08
in O 0 7.1370043208673906e-09
the O 0 6.40472386237434e-09
nuclear O 0 1.0818354923003426e-07
fractions O 0 3.257428105030158e-09
of O 0 7.020456993522828e-10
both O 0 8.374839488567432e-09
G1 O 0 6.222660886123776e-05
- O 0 4.828707915294217e-06
and O 0 1.1664145915801782e-07
S O 0 0.00015750534657854587
- O 0 4.4350796088110656e-05
phase O 0 1.4329098121379502e-05
cells O 0 5.231363502389286e-06
. O 0 6.296513106462953e-07

Therefore O 0 4.825610176339978e-06
, O 0 6.428248866541253e-07
progression O 0 1.608748789294623e-05
to O 0 7.461765250127428e-08
S O 0 5.047076410846785e-05
phase O 0 4.521451046457514e-06
is O 0 2.9504917620215565e-08
accompanied O 0 5.133548697244805e-08
by O 0 3.6907272793484935e-09
the O 0 1.0790921933789832e-08
aggregation O 0 7.428535298004135e-08
of O 0 1.4887453048118005e-08
nuclear O 0 3.4533497910160804e-06
BARD1 O 0 1.5082774552865885e-05
polypeptides O 0 1.9368339110314992e-07
into O 0 2.7561978299672774e-07
BRCA1 O 0 0.00020550635235849768
nuclear O 0 0.00022753987286705524
dots O 0 0.0001129955708165653
. O 0 3.915044999303063e-06

This O 0 5.346045099940966e-07
cell O 0 2.507714270905126e-05
cycle O 0 9.748574484547134e-06
- O 0 2.6365444227849366e-06
dependent O 0 1.4454018071319297e-07
colocalization O 0 3.3720280043780804e-06
of O 0 1.2258143833321355e-08
BARD1 O 0 9.165475785266608e-05
and O 0 3.034353994735284e-07
BRCA1 O 0 2.0075958673260175e-05
indicates O 0 6.365340965430732e-08
a O 0 1.4371240197874613e-08
role O 0 3.029547812616329e-08
for O 0 2.3452185970995743e-08
BARD1 O 0 6.81075980537571e-05
in O 0 9.188598824039218e-07
BRCA1 O 0 0.00045364556717686355
- O 0 0.0011939029209315777
mediated O 0 0.011268512345850468
tumor B-Disease 1 0.9885416030883789
suppression O 0 0.0002568724739830941
. O 0 6.7668429437617306e-06

Ethnic O 0 3.3983096727752127e-06
differences O 0 6.414251856767805e-06
in O 0 7.481344823645486e-07
the O 0 4.550128949176724e-07
HFE O 0 0.00047914645983837545
codon O 0 2.5745313905645162e-05
282 O 0 7.542829280282604e-06
( O 0 1.2493618442022125e-06
Cys O 0 0.0030277601908892393
/ O 0 4.2563846363918856e-05
Tyr O 0 0.00015947171777952462
) O 0 5.043493160883372e-07
polymorphism O 0 2.708068859647028e-05
. O 0 3.311484306323109e-06

Recent O 0 8.267920748039614e-06
studies O 0 1.0701351129682735e-06
have O 0 7.962833592500829e-08
shown O 0 1.2121049621782731e-06
that O 0 8.414722287852783e-06
hereditary B-Disease 1 0.99997878074646
hemochromatosis I-Disease 1 0.9999983310699463
( O 0 0.0003296149370726198
HH B-Disease 1 0.9965695142745972
) O 0 5.524358357433812e-07
is O 0 5.361986268326291e-07
likely O 0 6.683543318786178e-08
to O 0 6.1129457051833924e-09
be O 0 5.2496872626761615e-08
caused O 0 1.2292683493342338e-07
by O 0 9.798726274823366e-09
homozygosity O 0 1.6036274246289395e-06
for O 0 7.1315606753330485e-09
a O 0 1.5222957472360577e-07
Cys282Tyr O 0 9.12538143893471e-06
mutation O 0 3.961350216741266e-07
in O 0 1.5513075268813736e-08
the O 0 4.529114150386704e-08
HFE O 0 7.204450230346993e-05
gene O 0 2.823337581503438e-06
located O 0 4.662783794628922e-06
4 O 0 6.309475338639459e-06
. O 0 2.333754309802316e-06

5 O 0 1.6921383576118387e-05
Mb O 0 0.00021486374316737056
telomeric O 0 0.000398121599573642
to O 0 2.3741908989904914e-06
HLA O 0 0.0070647383108735085
- O 0 0.0012022735318168998
A O 0 3.994047801825218e-05
. O 0 4.018887466372689e-06

Population O 0 7.897911018517334e-07
studies O 0 1.6075996711606422e-07
of O 0 9.50410150579728e-09
this O 0 3.7461460600241026e-09
polymorphism O 0 7.353146003197253e-08
are O 0 3.5935998621283716e-10
facilitated O 0 1.2806546934029939e-08
by O 0 3.6722456187021635e-09
the O 0 7.615901687074711e-09
fact O 0 3.93831678380252e-09
that O 0 1.287830952989566e-09
the O 0 2.5539735659663165e-08
Cys282Tyr O 0 2.9906033887527883e-05
mutation O 0 1.9905717181245564e-06
creates O 0 1.735130723545808e-07
a O 0 7.927310434752144e-07
Rsal O 0 6.21213112026453e-05
restriction O 0 1.974879069166491e-06
site O 0 8.466085091640707e-06
. O 0 1.0960455938402447e-06

We O 0 9.513442478237266e-07
have O 0 5.383557422078411e-08
studied O 0 2.129213214629999e-07
the O 0 5.11011286619123e-08
codon O 0 1.5446428278664825e-06
282 O 0 7.770142929075519e-07
( O 0 1.584728579473449e-07
Cys O 0 0.0004496130277402699
/ O 0 6.820514954597456e-06
Tyr O 0 9.95806749415351e-06
) O 0 1.9074056112344806e-08
polymorphism O 0 1.7549444919495727e-07
in O 0 1.198620314113441e-08
different O 0 3.436266604595062e-09
ethnic O 0 6.201094038260635e-08
groups O 0 1.6207629016662395e-07
. O 0 1.0393888487669756e-06

In O 0 6.787252573303704e-07
agreement O 0 4.0462359152115823e-07
with O 0 3.4430915007988006e-08
previous O 0 1.7720144285249262e-07
observations O 0 1.4787588042963762e-07
the O 0 1.5733411373730632e-07
Tyr O 0 7.307117357413517e-06
allele O 0 3.342223635627306e-07
appeared O 0 2.7536151492313365e-07
to O 0 3.4979779073296413e-09
be O 0 1.4469983433684774e-08
rare O 0 1.198833388116327e-07
or O 0 3.203883025548748e-08
absent O 0 9.749157925398322e-07
in O 0 8.197709178148216e-08
Asiatic O 0 2.1709940938308137e-06
( O 0 1.4564931483107557e-08
Indian O 0 2.9383329547272297e-08
, O 0 1.0326487220879699e-08
Chinese O 0 2.7997902662946217e-08
) O 0 6.900977922441598e-08
populations O 0 9.936856031345087e-07
. O 0 1.560336727379763e-06

The O 0 7.288043661901611e-07
highest O 0 1.2806151516997488e-06
allele O 0 4.911283895125962e-07
frequency O 0 5.54017560716602e-07
( O 0 1.8426096204393616e-08
7 O 0 5.3901636931641406e-08
. O 0 2.296932644085814e-09
5 O 0 8.719390542921701e-09
% O 0 2.320615033468698e-09
) O 0 2.535078369447774e-09
was O 0 9.587454314896604e-07
found O 0 4.2012199941154904e-08
in O 0 7.826785974884842e-08
Swedes O 0 1.0906884199357592e-05
. O 0 1.2799729347534594e-06

Saamis O 0 0.00025612436002120376
( O 0 3.0549173857252754e-07
2 O 0 1.9003704210263095e-07
% O 0 7.728386819394473e-09
) O 0 2.5518831492377103e-09
and O 0 6.682520758971577e-09
Mordvinians O 0 1.85119290563307e-06
( O 0 6.228319193724019e-09
1 O 0 2.5958213356602755e-08
. O 0 2.4403896681235437e-09
8 O 0 2.58965933142008e-08
% O 0 1.714057451529527e-09
) O 0 2.1740327316166486e-09
had O 0 1.4877405085655937e-08
significantly O 0 5.272898206953869e-08
lower O 0 8.629901060430711e-08
frequencies O 0 1.9225087299901134e-08
of O 0 6.123868967478074e-09
the O 0 1.1473873939849e-07
Tyr O 0 4.6742683480260894e-05
allele O 0 7.997176908247638e-06
. O 0 1.340024368801096e-06

Comparisons O 0 7.853820989112137e-07
with O 0 9.574445414273214e-08
allele O 0 9.501184194959933e-07
frequencies O 0 5.64149900128541e-07
based O 0 1.4533468117861048e-07
on O 0 1.696003693041348e-07
prevalence O 0 3.093433178946725e-06
estimates O 0 5.110502598881794e-08
of O 0 1.744361455280341e-08
HH B-Disease 0 0.1882079392671585
showed O 0 2.3560023691970855e-06
some O 0 1.5467270797486776e-09
disagreements O 0 7.414691793883321e-08
with O 0 8.333537415694536e-09
the O 0 3.586119490250894e-08
RFLP O 0 1.6428716662630904e-06
data O 0 3.3513256170181194e-08
, O 0 2.3327404008455233e-08
particularly O 0 5.6239233714450165e-08
in O 0 3.0492648761537566e-07
Finns O 0 1.59537885338068e-05
. O 0 1.780203547241399e-06

The O 0 4.902148702967679e-06
newly O 0 5.3072701120981947e-05
described O 0 2.8246517103980295e-05
HFE O 0 0.0005750683485530317
marker O 0 3.454726538620889e-06
provides O 0 5.707466854687482e-08
a O 0 4.9463960039020094e-08
new O 0 1.2026599272019212e-08
approach O 0 5.223894650185912e-09
to O 0 5.389633739305566e-10
the O 0 3.313524787884603e-09
screening O 0 6.088790627245544e-08
of O 0 9.286312163681032e-09
HH B-Disease 0 0.0003240855585318059
as O 0 2.9363048881236864e-08
well O 0 5.6527094116631815e-09
as O 0 5.058538921076661e-09
studies O 0 1.9597941047777567e-09
of O 0 4.4956213751667917e-10
the O 0 5.669208213987531e-09
relationship O 0 4.62726923444734e-08
between O 0 2.2034313928998017e-08
the O 0 2.0478202600315853e-07
HFE O 0 0.0002302176580997184
Tyr O 0 1.610560320841614e-05
allele O 0 8.50963942866656e-07
and O 0 8.864817857556773e-08
different O 0 4.206564199193963e-07
disorders O 1 0.9949415326118469
including O 0 0.0023032024037092924
cancer B-Disease 1 0.9996401071548462

Autosomal B-Disease 1 0.9923149943351746
dominant I-Disease 1 0.9932969212532043
neurohypophyseal I-Disease 1 0.9995487332344055
diabetes I-Disease 1 0.9999470710754395
insipidus I-Disease 1 0.9952406883239746
associated O 0 1.689422788331285e-05
with O 0 1.0048469079038114e-07
a O 0 6.687394034088356e-07
missense O 0 5.036494258092716e-06
mutation O 0 1.8039627320831642e-06
encoding O 0 6.706163730996195e-07
Gly23 O 0 0.00016505600069649518
- O 0 0.00037134860758669674
- O 0 0.00019418427837081254
> O 0 7.669163096579723e-06
Val O 0 0.00019052898278459907
in O 0 1.0210676464339485e-06
neurophysin O 0 0.001377913518808782
II O 0 0.1366308182477951
. O 0 7.324741545744473e-06

Autosomal B-Disease 1 0.9923031330108643
dominant I-Disease 1 0.9919801950454712
neurohypophyseal I-Disease 1 0.9989651441574097
diabetes I-Disease 1 0.9998881816864014
insipidus I-Disease 1 0.9965057373046875
( O 0 1.1484768037917092e-05
ADNDI B-Disease 0 0.03375399857759476
) O 0 7.300230890905368e-07
is O 0 4.086288754479028e-06
an O 0 0.0004120546509511769
inherited B-Disease 1 0.9999967813491821
disease I-Disease 1 0.9999967813491821
caused O 0 0.15079210698604584
by O 0 9.667188351158984e-06
progressive O 1 0.6093059182167053
degeneration O 1 0.6321728825569153
of O 0 5.868257346719474e-08
the O 0 3.0385501759155886e-07
magnocellular O 0 4.4521195377456024e-05
neurons O 0 1.5519221960857976e-06
of O 0 1.0844630082829099e-08
the O 0 4.4991772085722914e-08
hypothalamus O 0 2.3933002921694424e-06
leading O 0 6.705121791128477e-07
to O 0 6.32374730358265e-09
decreased O 0 1.0858558425752562e-06
ability O 0 2.4059771064344204e-08
to O 0 3.1526221633271234e-09
produce O 0 1.2954838091161491e-08
the O 0 6.584620138028185e-08
hormone O 0 3.6063177049072692e-06
arginine O 0 5.17431089974707e-07
vasopressin O 0 1.5596642697346397e-06
( O 0 9.148327961838731e-08
AVP O 0 2.536789543228224e-05
) O 0 3.2935244576037803e-07
. O 0 7.03756313669146e-07

Affected O 0 1.0237989044981077e-05
individuals O 0 1.7293223208980635e-07
are O 0 1.2004208294058571e-08
not O 0 3.3362550055926476e-08
symptomatic O 0 5.877655348740518e-05
at O 0 6.620551721425727e-05
birth O 0 1.941318259923719e-05
, O 0 1.7204838798079436e-07
but O 0 8.460078504413104e-08
usually O 0 4.614960573690041e-07
develop O 0 4.806082506547682e-05
diabetes B-Disease 1 0.9737845063209534
insipidus I-Disease 0 0.014001689851284027
at O 0 3.090883910772391e-05
1 O 0 4.775183697347529e-06
- O 0 8.43703601276502e-05
6 O 0 6.163323632790707e-06
yr O 0 0.00024479604326188564
of O 0 1.87090961389913e-07
age O 0 6.701658094243612e-06
. O 0 1.5390198768727714e-06

The O 0 1.4046521528143785e-06
genetic O 0 8.746595995035022e-06
locus O 0 9.618375770514831e-06
of O 0 2.2277900768585823e-07
the O 0 1.9596174752223305e-05
disease O 1 0.5817643404006958
is O 0 4.682644600961794e-07
the O 0 1.937308695687534e-07
AVP O 0 0.00013252029020804912
- O 0 0.00015887431800365448
neurophysin O 0 0.00020912398758810014
II O 0 0.007769332267343998
( O 0 6.329216262201953e-08
NPII O 0 9.56174608290894e-06
) O 0 6.77696654349802e-09
gene O 0 2.737386139983755e-08
, O 0 6.221883896984082e-09
and O 0 3.7728799640035504e-08
mutations O 0 2.0192478586977813e-06
that O 0 4.1379163207011516e-08
cause O 0 1.3134920209267875e-06
ADNDI B-Disease 0 0.00036464378354139626
have O 0 4.936226716267811e-08
been O 0 1.1467704297274395e-07
found O 0 1.1676895894652262e-08
in O 0 1.0622301926943578e-09
both O 0 9.235118780814844e-10
the O 0 3.0072433432337675e-09
signal O 0 4.336532199999965e-08
peptide O 0 2.663062126373461e-08
of O 0 9.70605262828883e-10
the O 0 1.1791915000003428e-08
prepro O 0 3.047704740311019e-05
- O 0 5.947547469986603e-05
AVP O 0 3.113212369498797e-05
- O 0 1.0979751095874235e-05
NPII O 0 1.2411022908054292e-05
precursor O 0 1.0179680884903064e-06
and O 0 2.8360913617575534e-08
within O 0 1.522073631576859e-07
NPII O 0 0.000934684241656214
itself O 0 1.922551564348396e-05
. O 0 1.8685395843931474e-06

An O 0 5.374356987886131e-06
affected O 0 1.977900683414191e-05
girl O 0 0.00014080709661357105
who O 0 2.0983088688808493e-07
presented O 0 9.923807908762683e-08
at O 0 9.744269391376292e-07
9 O 0 2.256892059904203e-07
months O 0 4.494837213542269e-08
of O 0 1.5038074119289035e-09
age O 0 7.740472085515648e-08
and O 0 2.147345412595314e-08
her O 0 3.303745472749142e-07
similarly O 0 5.136095637681137e-07
affected O 0 6.590638435000074e-08
younger O 0 1.6666278668253653e-07
brother O 0 9.733755632623797e-07
and O 0 2.7606350982978256e-08
father O 0 1.115373720494972e-06
were O 0 1.0334210820417411e-08
all O 0 3.3615077388304826e-10
found O 0 2.9334876749942396e-09
to O 0 4.880928439199295e-10
have O 0 1.2865200016420886e-09
a O 0 5.992517770891936e-08
novel O 0 2.6583887802189565e-07
missense O 0 3.548910399331362e-06
mutation O 0 1.8054599877359578e-06
( O 0 3.730802689005941e-08
G1758 O 0 4.030559466627892e-06
- O 0 3.54394614987541e-05
- O 0 2.2166428607306443e-05
> O 0 1.147629745901213e-06
T O 0 2.414467189737479e-06
) O 0 8.183329569533271e-10
encoding O 0 1.4302977691116325e-09
the O 0 2.74435874025869e-09
amino O 0 1.715072173169574e-08
acid O 0 8.57135376008955e-08
substitution O 0 3.0638680925676454e-08
Gly23 O 0 6.499833034467883e-06
- O 0 3.915816341759637e-05
- O 0 4.010818884125911e-05
> O 0 4.348188213043613e-06
Val O 0 0.0001557711511850357
within O 0 2.581109356469824e-06
NPII O 0 0.0014224009355530143
. O 0 6.148271040729014e-06

The O 0 1.351670562144136e-05
mutation O 0 0.00033325175172649324
was O 0 3.0065024475334212e-05
confirmed O 0 5.969679364170588e-07
by O 0 2.6053944779391713e-08
restriction O 0 5.429020006886276e-07
endonuclease O 0 3.3031494240276515e-05
analysis O 0 2.25091093852825e-06
. O 0 1.457156713513541e-06

A O 0 1.603981218067929e-05
T1 O 0 0.0017635358963161707
- O 0 6.0013189795427024e-06
weighted O 0 1.7385262651714584e-07
magnetic O 0 1.3671353826794075e-07
resonance O 0 5.249627292869263e-07
imaging O 0 2.009289573834394e-06
of O 0 2.8101963422955123e-08
the O 0 3.8672982327625505e-07
fathers O 0 5.411701295088278e-06
pituitary O 0 0.0015527396462857723
gland O 0 0.0004422941419761628
demonstrates O 0 1.2566690656967694e-06
an O 0 4.051348128086829e-07
attenuated O 0 0.0005349553539417684
posterior O 0 0.003776275785639882
pituitary O 0 0.13558290898799896
bright O 0 0.0006071209791116416
spot O 0 0.00019797305867541581
. O 0 6.622621185670141e-06

This O 0 3.883385033986997e-06
mutation O 0 0.0001259305136045441
may O 0 5.763986905549245e-07
be O 0 6.195535195985258e-09
valuable O 0 1.2476903066271916e-08
for O 0 2.8103503968424093e-09
developing O 0 3.250317348602039e-08
models O 0 1.2944592242547515e-07
of O 0 1.2170968943792104e-07
dominantly B-Disease 0 0.12508288025856018
inherited I-Disease 1 0.9988905787467957
neurodegeneration I-Disease 1 0.9999547004699707
, O 0 9.592063179297838e-07
as O 0 2.4494564598853685e-08
the O 0 1.0713748999080508e-08
early O 0 1.5194891034298053e-07
age O 0 7.10641643308918e-08
of O 0 7.862738016228832e-09
onset O 0 0.0009652572916820645
of O 0 5.507183686859207e-07
symptoms O 0 0.003934395965188742
suggests O 0 1.7935536789082107e-07
that O 0 7.81956099871195e-09
this O 0 2.4455165004155788e-08
mutation O 0 1.4899690086167539e-06
may O 0 1.6437415695236268e-07
be O 0 1.0763643309985582e-08
particularly O 0 3.390422875781951e-08
deleterious O 0 2.943272932043328e-07
to O 0 1.8969096515775163e-08
the O 0 3.939885857562331e-07
magnocellular O 0 0.001075664651580155
neuron O 0 0.0017611762741580606
. O 0 6.312096729743644e-07
. O 0 1.752811385813402e-06

Frequent O 0 0.0001481976651120931
inactivation O 0 0.012965728528797626
of O 0 6.714305072819116e-06
PTEN O 0 0.014164107851684093
/ O 0 0.00018741979147307575
MMAC1 O 0 0.010574598796665668
in O 0 0.00026278369477950037
primary O 1 0.9988176226615906
prostate B-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9999878406524658
. O 0 0.0001721186563372612

Sporadic B-Disease 1 0.9969677329063416
prostate I-Disease 1 0.9999901056289673
carcinoma I-Disease 1 0.9999978542327881
is O 0 3.340809780638665e-05
the O 0 3.9890167613521044e-07
most O 0 6.024583854014054e-08
common O 0 6.705434429932211e-07
male B-Disease 0 2.6963591153617017e-05
cancer I-Disease 1 0.5178183913230896
in O 0 3.303392048792375e-08
the O 0 1.1689887280397215e-08
Western O 0 6.457717915964167e-08
world O 0 1.5359130145498057e-07
, O 0 1.2229839363442352e-08
yet O 0 5.4240292257645706e-09
many O 0 1.226615337079906e-10
of O 0 3.1326721772195754e-10
the O 0 1.0389133109356408e-08
major O 0 9.17700688773948e-08
genetic O 0 6.684027908931967e-08
events O 0 4.3713175301718366e-09
involved O 0 7.301182325392119e-09
in O 0 7.368052390432922e-09
the O 0 2.165326762337827e-08
progression O 0 1.4773281691304874e-06
of O 0 6.844581790232951e-09
this O 0 9.353741603490562e-08
often O 0 1.4869771803205367e-05
fatal O 1 0.9993545413017273
cancer B-Disease 1 0.9988856911659241
remain O 0 2.3032700937619666e-06
to O 0 4.7655845492045046e-08
be O 0 7.430660389218247e-07
elucidated O 0 0.00021234240557532758
. O 0 3.121279860351933e-06

Numerous O 0 4.295251983421622e-06
cytogenetic O 0 0.0009999506874009967
and O 0 1.8727532733464614e-06
allelotype O 0 0.0003349573817104101
studies O 0 1.084239556803368e-06
have O 0 2.1982685893817688e-07
reported O 0 2.2857623207528377e-06
frequent O 0 1.3574995136877988e-06
loss O 0 5.0935126637341455e-05
of O 0 1.1537647992554412e-07
heterozygosity O 0 0.00030562179745174944
on O 0 7.497153546864865e-06
chromosomal O 0 0.05551706254482269
arm O 0 0.012336418963968754
10q O 0 0.0003347604360897094
in O 0 6.739812670275569e-05
sporadic B-Disease 1 0.9953000545501709
prostate I-Disease 1 0.9999980926513672
cancer I-Disease 1 0.9999843835830688
. O 0 7.690313213970512e-05

Deletion O 0 0.00022997283667791635
mapping O 0 4.5403667172649875e-05
studies O 0 1.753560354700312e-06
have O 0 1.5170421363563946e-07
unambiguously O 0 6.563218448718544e-06
identified O 0 5.56797829176503e-07
a O 0 2.925622766269953e-07
region O 0 4.2750295392579574e-07
of O 0 3.770836798366872e-08
chromosome O 0 4.4659800551016815e-06
10q23 O 0 1.2918019365315558e-06
to O 0 3.5255136587863944e-09
be O 0 4.343815085405822e-09
the O 0 8.287032393639038e-09
minimal O 0 3.77434872689264e-07
area O 0 8.000540674402146e-07
of O 0 1.2170146135304094e-07
loss O 0 0.0005941230920143425
. O 0 1.7679949451121502e-06

A O 0 1.938332206918858e-05
new O 0 7.302895483007887e-06
tumor B-Disease 0 0.005007560830563307
suppressor O 0 2.8227828806848265e-05
gene O 0 3.2484199437021744e-06
, O 0 2.753804437816143e-07
PTEN O 0 0.00018866121536120772
/ O 0 8.09332777862437e-06
MMAC1 O 0 0.0005913289496675134
, O 0 3.024294699116581e-07
was O 0 2.4991908503579907e-05
isolated O 0 1.2810519365302753e-05
recently O 0 8.523116775904782e-06
at O 0 3.727587909452268e-07
this O 0 3.2150104800621193e-09
region O 0 2.1180898812644955e-08
of O 0 3.0814719664817858e-09
chromosome O 0 1.0598557764751604e-06
10q23 O 0 8.174100116775662e-07
and O 0 1.5418914145470808e-08
found O 0 1.2001049931598118e-08
to O 0 8.796511297148868e-10
be O 0 5.475576436708707e-09
inactivated O 0 5.155607709639298e-07
by O 0 3.9839576082556505e-09
mutation O 0 3.1019837365420244e-07
in O 0 2.170222899167129e-07
three O 0 0.0006597299361601472
prostate B-Disease 1 0.9999984502792358
cancer I-Disease 1 0.9999920129776001
cell O 0 0.28307846188545227
lines O 0 0.0011352266883477569
. O 0 6.755803497071611e-06

We O 0 9.542661246086936e-06
screened O 0 0.00019221357069909573
80 O 0 0.0010800842428579926
prostate B-Disease 1 0.9998595714569092
tumors I-Disease 1 0.9998575448989868
by O 0 3.5689453170562047e-07
microsatellite O 0 2.277976273035165e-05
analysis O 0 2.4703311396478966e-07
and O 0 5.609921416294128e-08
found O 0 2.009901578503559e-07
chromosome O 0 2.3554048311780207e-06
10q23 O 0 1.1905758583452553e-06
to O 0 6.893976500776944e-09
be O 0 2.0229775188340682e-08
deleted O 0 2.699351284718432e-07
in O 0 2.1929626825567539e-07
23 O 0 1.5057763675940805e-06
cases O 0 3.9813130570109934e-07
. O 0 9.416750117452466e-07

We O 0 5.444512680696789e-07
then O 0 9.841398451726491e-08
proceeded O 0 7.146978475702781e-08
with O 0 7.855708084036905e-09
sequence O 0 1.7936473639679207e-08
analysis O 0 4.286940136211115e-09
of O 0 2.632005058345044e-09
the O 0 3.222833910854206e-08
entire O 0 3.516346851029084e-06
PTEN O 0 0.0004353113763500005
/ O 0 8.842938768793829e-06
MMAC1 O 0 9.022530866786838e-05
coding O 0 1.882244396256283e-05
region O 0 1.6386874222007464e-06
and O 0 8.018722752467511e-08
tested O 0 4.888456714979839e-07
for O 0 8.364080095191184e-09
homozygous O 0 1.6907293343138008e-07
deletion O 0 7.262574541755384e-08
with O 0 5.510065292924082e-09
new O 0 4.6577206092024426e-08
intragenic O 0 6.248172667255858e-06
markers O 0 5.143104999660864e-07
in O 0 1.9383929128480304e-08
these O 0 1.7890542380882835e-09
23 O 0 6.065446456204882e-08
cases O 0 1.0523453219946077e-08
with O 0 5.693418714258769e-08
10q23 O 0 7.285948231583461e-05
loss O 0 8.73382668942213e-05
of O 0 4.934090043207107e-07
heterozygosity O 0 0.0017356672324240208
. O 0 6.041562301106751e-06

The O 0 1.450982836104231e-07
identification O 0 6.877220926071459e-08
of O 0 7.2332637657268606e-09
the O 0 3.4454433972541665e-08
second O 0 3.4789903224918817e-07
mutational O 0 5.491672709467821e-06
event O 0 5.030811394135526e-07
in O 0 2.921980168935079e-08
10 O 0 2.044116165222931e-08
( O 0 5.549194437293181e-09
43 O 0 7.481944663823015e-08
% O 0 6.417982234552255e-08
) O 0 1.1783728268710547e-06
tumors B-Disease 1 0.9995328187942505
establishes O 0 4.352401083451696e-05
PTEN O 0 0.0004587300936691463
/ O 0 4.063275810040068e-06
MMAC1 O 0 3.100259345956147e-05
as O 0 2.0214423912534585e-08
a O 0 8.130285067409204e-08
main O 0 4.734246772386541e-07
inactivation O 0 0.00011038400407414883
target O 0 6.102812477593034e-08
of O 0 1.5551172793948354e-08
10q O 0 7.733749043836724e-06
loss O 0 0.00010209499305346981
in O 0 3.3944990718737245e-05
sporadic B-Disease 1 0.9980949759483337
prostate I-Disease 1 0.999998927116394
cancer I-Disease 1 0.999993085861206
. O 0 1.1242600521654822e-05
. O 0 4.826940312341321e-06

Risk O 0 0.0001859087060438469
reversals O 0 2.0978674001526088e-05
in O 0 7.938068051771552e-07
predictive O 0 1.2029914614686277e-05
testing O 0 0.0001615254586795345
for O 0 0.00026098842499777675
Huntington B-Disease 1 0.999940037727356
disease I-Disease 1 0.9999467134475708
. O 0 0.00010849330283235759

The O 0 3.5803105902232346e-07
first O 0 3.1698991165285406e-07
predictive O 0 3.0615017294621794e-06
testing O 0 3.4115073503926396e-05
for O 0 4.224403164698742e-05
Huntington B-Disease 1 0.9999662637710571
disease I-Disease 1 0.9999409914016724
( O 0 1.9709364096343052e-07
HD B-Disease 0 9.59733733907342e-05
) O 0 3.4274972193770736e-08
was O 0 4.859386990574421e-07
based O 0 6.238686456327969e-09
on O 0 5.368276490003154e-09
analysis O 0 5.314910289655472e-09
of O 0 4.80275730296853e-09
linked O 0 2.1606172140309354e-06
polymorphic O 0 1.3722757330469904e-06
DNA O 0 5.50736217519443e-07
markers O 0 2.6043542789011553e-07
to O 0 3.649245794434819e-09
estimate O 0 1.8743202545579152e-08
the O 0 4.309666401525192e-09
likelihood O 0 1.9099212877904392e-08
of O 0 2.1472048583603964e-09
inheriting O 0 4.2907055330942967e-07
the O 0 4.6094225325532534e-08
mutation O 0 6.244099495233968e-07
for O 0 5.298900163097642e-08
HD B-Disease 0 0.000571034790482372
. O 0 2.0689237771875923e-06

Limits O 0 1.3394468396654702e-06
to O 0 1.6396514368466342e-08
accuracy O 0 3.6484266274783295e-08
included O 0 8.595613110173872e-09
recombination O 0 5.621338772243689e-08
between O 0 1.3208912186257749e-08
the O 0 1.610946043228978e-08
DNA O 0 2.999426271799166e-07
markers O 0 1.4047724050669785e-07
and O 0 6.2892366869959915e-09
the O 0 2.9710758298051587e-08
mutation O 0 3.612426837662497e-07
, O 0 1.0739671374437876e-08
pedigree O 0 8.509314284310676e-07
structure O 0 6.56541317312076e-07
, O 0 5.024959115473848e-09
and O 0 4.108752449383246e-09
whether O 0 4.4857393355357544e-09
DNA O 0 9.372082132586002e-08
samples O 0 6.282235176513495e-09
were O 0 1.6868141328174602e-09
available O 0 4.061333047644666e-09
from O 0 7.784055178206017e-09
family O 0 1.1987717130068631e-07
members O 0 8.072893820099125e-08
. O 0 4.7430458494091e-07

With O 0 8.382418315022733e-08
direct O 0 8.833374209871181e-08
tests O 0 1.6444282380234654e-07
for O 0 3.010870663899823e-09
the O 0 3.29743699012397e-08
HD B-Disease 0 7.75921726017259e-05
mutation O 0 1.6277967915812042e-06
, O 0 9.2861709433123e-09
we O 0 2.2557948842205633e-09
have O 0 7.979534810687028e-10
assessed O 0 7.1763168740801575e-09
the O 0 8.964550213264033e-10
accuracy O 0 1.538023042257919e-08
of O 0 2.3841311147521083e-09
results O 0 2.005183752373796e-08
obtained O 0 5.785744328079545e-09
by O 0 2.6383379925221107e-09
linkage O 0 1.2904828849968908e-07
approaches O 0 6.801819552038069e-08
when O 0 5.333944841368066e-08
requested O 0 1.9388698646594094e-08
to O 0 2.2880257688484562e-09
do O 0 3.121806146921813e-09
so O 0 2.025007272976609e-09
by O 0 1.675910521470314e-09
the O 0 2.3792532388711152e-08
test O 0 1.9062061085151072e-07
individuals O 0 2.4923329178250242e-08
. O 0 6.931700795576035e-07

For O 0 1.6913647016281175e-07
six O 0 1.2672931859469827e-07
such O 0 5.284161996854664e-09
individuals O 0 5.444905415430412e-09
, O 0 2.9005519763813936e-08
there O 0 3.7253276019555415e-08
was O 0 5.001285444450332e-06
significant O 0 8.980456556173522e-08
disparity O 0 5.259338990981632e-07
between O 0 1.1128477694910544e-07
the O 0 1.7204870346176904e-06
tests O 0 8.542832802049816e-06
. O 0 1.7400867591277347e-06

Three O 0 4.771400767822342e-07
went O 0 8.145960350702808e-07
from O 0 2.42979183440184e-08
a O 0 2.8655958317358454e-07
decreased O 0 2.1166064470889978e-05
risk O 0 4.463721836600598e-07
to O 0 1.1727869786426481e-09
an O 0 1.2629083556703335e-08
increased O 0 3.154179069042584e-07
risk O 0 7.507603640988236e-07
, O 0 3.5023040023673957e-09
while O 0 4.275410248055778e-09
in O 0 1.8171169013925237e-09
another O 0 3.1511431242137178e-09
three O 0 7.132731294490213e-09
the O 0 1.209626390163976e-07
risk O 0 2.1120175006217323e-05
was O 0 5.573951420956291e-05
decreased O 0 2.720384691201616e-05
. O 0 1.0645387646945892e-06

Knowledge O 0 5.927608413003327e-07
of O 0 4.946150866658172e-08
the O 0 8.209914881263103e-08
potential O 0 1.0898194346964374e-07
reasons O 0 1.1585274961589676e-08
for O 0 1.5441862233345205e-09
these O 0 5.225158083987935e-10
changes O 0 2.1826510376854458e-08
in O 0 3.597032005586698e-08
results O 0 7.798532664082813e-08
and O 0 5.696457527903931e-09
impact O 0 1.7304962796060863e-08
of O 0 2.0026829083974462e-09
these O 0 2.981559665826694e-09
risk O 0 4.841554641643597e-07
reversals O 0 3.7585658674288425e-07
on O 0 2.1910061320795648e-07
both O 0 8.738609125202856e-08
patients O 0 1.0625568620525883e-06
and O 0 1.0439727304856206e-08
the O 0 6.636377491986423e-08
counseling O 0 6.667538059446088e-07
team O 0 1.771314295240245e-08
can O 0 4.3194076093655553e-10
assist O 0 1.7934445040168612e-09
in O 0 2.608754767763344e-09
the O 0 2.6913293815766792e-09
development O 0 3.825806782487007e-09
of O 0 2.7125410806405625e-09
strategies O 0 3.1624164620325246e-08
for O 0 5.2455111365645735e-09
the O 0 6.381411310485419e-08
prevention O 0 2.5875667688524118e-06
and O 0 1.3920611330320298e-08
, O 0 9.823597046931809e-09
where O 0 1.3234433104969412e-08
necessary O 0 1.3390870634566454e-08
, O 0 1.4434754724845789e-08
management O 0 1.138991549964885e-07
of O 0 3.4455731601212847e-09
a O 0 1.1485406048450386e-06
risk O 0 1.6908500128920423e-06
reversal O 0 2.682071453818935e-07
in O 0 1.3304718216033962e-08
any O 0 3.5897380623595154e-09
predictive O 0 3.09338702209061e-07
testing O 0 9.832230034589884e-07
program O 0 3.593823407754826e-07
. O 0 9.418603497124423e-08
. O 0 3.688058995976462e-07

A O 0 2.8330794521025382e-05
novel O 0 4.6900017878215294e-06
common O 0 2.0192053398204735e-06
missense O 0 8.150478970492259e-05
mutation O 0 1.0334139005863108e-05
G301C O 0 3.036362386410474e-06
in O 0 6.148378872694593e-08
the O 0 9.432032044287553e-08
N O 0 2.1369616661104374e-05
- O 0 2.1210600607446395e-05
acetylgalactosamine O 0 7.067235128488392e-05
- O 0 0.00011255777644691989
6 O 0 5.445065653475467e-06
- O 0 0.00012771060573868454
sulfate O 0 0.00014304788783192635
sulfatase O 0 0.00019203258852940053
gene O 0 9.324676284450106e-06
in O 0 3.1386734917759895e-06
mucopolysaccharidosis B-Disease 0 0.009797864593565464
IVA I-Disease 1 0.8766844868659973
. O 0 1.3333317838259973e-05

Mucopolysaccharidosis B-Disease 1 0.9424972534179688
IVA I-Disease 1 0.9959553480148315
( O 0 0.00021406382438726723
MPS B-Disease 1 0.9986157417297363
IVA I-Disease 1 0.9998804330825806
) O 0 2.701668790905387e-06
is O 0 1.1746410564228427e-06
an O 0 4.765384801430628e-06
autosomal B-Disease 1 0.9956297874450684
recessive I-Disease 1 0.9991651773452759
lysosomal I-Disease 1 0.9998373985290527
storage I-Disease 1 0.9999172687530518
disorder I-Disease 1 0.9999700784683228
caused O 0 0.028425008058547974
by O 0 1.615982796465687e-06
a O 0 0.0002589648647699505
genetic B-Disease 1 0.9987130165100098
defect I-Disease 1 0.9991764426231384
in O 0 2.1056087007309543e-06
N O 0 0.00013958362978883088
- O 0 0.0001177324666059576
acetylgalactosamine O 0 0.00017688743537291884
- O 0 0.0004101617378182709
6 O 0 3.477056452538818e-05
- O 0 0.0018242324003949761
sulfate O 0 0.001713703153654933
sulfatase O 0 0.0012500735465437174
( O 0 4.941049382978235e-07
GALNS O 0 0.0002872451732400805
) O 0 7.419189955726324e-07
. O 0 9.279160053665692e-07

In O 0 1.503385874457308e-06
previous O 0 1.1692205816871137e-06
studies O 0 9.405031420328669e-08
, O 0 1.747231692661444e-08
we O 0 2.5249060620069486e-09
have O 0 1.3229000117576106e-09
found O 0 3.913979362835107e-09
two O 0 1.221379442029047e-09
common O 0 6.8821812249098e-08
mutations O 0 5.438752168629435e-07
in O 0 2.4488116423526662e-08
Caucasians O 0 1.4349907928590255e-07
and O 0 6.219465831236448e-08
Japanese O 0 3.420168241063948e-06
, O 0 2.0030321934427775e-07
respectively O 0 2.5823453597695334e-06
. O 0 1.2169127785455203e-06

To O 0 4.2358831819910847e-07
characterize O 0 4.796297616849188e-06
the O 0 1.0880187062412006e-07
mutational O 0 1.1050213288399391e-05
spectrum O 0 1.5492295233343611e-06
in O 0 1.805099891782902e-08
various O 0 3.3308997782199867e-09
ethnic O 0 1.2566800045021864e-08
groups O 0 9.153247049198399e-09
, O 0 2.8486471848054862e-08
mutations O 0 1.7668104135282192e-07
in O 0 1.5114801854565485e-08
the O 0 3.118011093761197e-08
GALNS O 0 4.7701658331789076e-05
gene O 0 2.093938064717804e-06
in O 0 1.1850953569592093e-06
Colombian O 0 0.00010804297198774293
MPS B-Disease 1 0.985466718673706
IVA I-Disease 1 0.9999090433120728
patients O 0 0.0007330675725825131
were O 0 8.975702030511457e-07
investigated O 0 2.6648091079550795e-05
, O 0 4.434876643699681e-08
and O 0 4.573220380166276e-08
genetic O 0 2.9141222057660343e-07
backgrounds O 0 3.5289666300286626e-08
were O 0 2.5436525774580332e-08
extensively O 0 3.0866416977914923e-07
analyzed O 0 8.360813552599211e-08
to O 0 2.4413300270254013e-09
identify O 0 1.3704112511447875e-08
racial O 0 1.7043305433617206e-08
origin O 0 9.749287599447598e-09
, O 0 9.941422796089228e-09
based O 0 1.2460517062606868e-08
on O 0 5.166849703641674e-08
mitochondrial O 0 6.082998424972175e-07
DNA O 0 1.4120768128123018e-06
( O 0 1.5504909356423013e-08
mtDNA O 0 3.0424791930272477e-07
) O 0 6.822855880272982e-08
lineages O 0 1.1641091077763122e-06
. O 0 1.4326091104521765e-06

Three O 0 3.1136960387811996e-06
novel O 0 7.935684152471367e-06
missense O 0 0.0002561248547863215
mutations O 0 0.00039974472019821405
never O 0 1.5465027900063433e-05
identified O 0 6.265818797146494e-07
previously O 0 2.8833102305725333e-07
in O 0 1.0712237319410178e-08
other O 0 1.2039216290560262e-09
populations O 0 1.008565853055643e-08
and O 0 6.385476147841018e-09
found O 0 2.1967508700981853e-08
in O 0 5.0911879156956275e-09
16 O 0 1.3501663786996687e-08
out O 0 2.1685866435916523e-09
of O 0 3.4835030415791834e-09
19 O 0 8.643159503662901e-07
Colombian O 0 1.4616251974075567e-05
MPS B-Disease 1 0.6990178823471069
IVA I-Disease 1 0.9993544220924377
unrelated O 0 7.601356628583744e-06
alleles O 0 4.849003971685306e-07
account O 0 2.0010426737826492e-07
for O 0 3.432803907799098e-07
84 O 0 1.214305666508153e-05
. O 0 1.4729824897585786e-06

2 O 0 9.553400559525471e-07
% O 0 1.119735060228777e-08
of O 0 2.047955138806401e-09
the O 0 9.988445626163411e-09
alleles O 0 6.149152653733836e-08
in O 0 5.9118011819236926e-08
this O 0 4.908408612891435e-08
study O 0 4.662076094064105e-07
. O 0 7.393945224976051e-07

The O 0 1.5182029073912418e-06
G301C O 0 2.237853368569631e-05
and O 0 3.5944333376392024e-07
S162F O 0 2.0588680854416452e-05
mutations O 0 5.045705165684922e-06
account O 0 1.215313005786811e-07
for O 0 2.0561959956921783e-07
68 O 0 1.4128125258139335e-05
. O 0 3.2244622616417473e-06

4 O 0 7.312080470001092e-06
% O 0 1.9871866641096858e-07
and O 0 2.7066695906796667e-07
10 O 0 1.6481193370054825e-06
. O 0 1.7562213088240242e-06

5 O 0 1.6299203480230062e-06
% O 0 2.67385225072303e-08
of O 0 1.2940513549608568e-08
mutations O 0 2.396971012785798e-06
, O 0 1.8801385337496868e-08
respectively O 0 1.1185422721382565e-07
, O 0 1.2516232494874657e-08
whereas O 0 1.5098780892230934e-08
the O 0 1.3275111676591678e-08
remaining O 0 4.39651337558189e-08
F69V O 0 6.893488898640499e-05
is O 0 2.070643034812747e-08
limited O 0 3.840385343067965e-09
to O 0 1.8150316805076727e-09
a O 0 1.1156488710639678e-07
single O 0 7.411637170662289e-07
allele O 0 4.034905487060314e-06
. O 0 1.310769107476517e-06

The O 0 2.3429215616488364e-06
skewed O 0 7.908140105428174e-06
prevalence O 0 1.772546056599822e-05
of O 0 3.8819077730067875e-08
G301C O 0 4.135986273468006e-06
in O 0 6.065261004550848e-08
only O 0 2.51554830299483e-08
Colombian O 0 1.4106285561865661e-06
patients O 0 3.1069782835402293e-07
and O 0 1.0865250921199276e-08
haplotype O 0 2.1130435925442725e-06
analysis O 0 2.6919929396740372e-08
by O 0 7.954951364297358e-09
restriction O 0 3.75455968537608e-08
fragment O 0 2.893400221637421e-07
length O 0 2.0501416031493136e-07
polymorphisms O 0 3.527150624904607e-07
in O 0 1.2133091864541257e-08
the O 0 2.716073232988947e-08
GALNS O 0 5.520755075849593e-05
gene O 0 4.427506610227283e-07
suggest O 0 8.502996706738486e-08
that O 0 3.3340397109782316e-09
G301C O 0 1.640729863083834e-07
originated O 0 2.5771045741862508e-08
from O 0 7.255343437151396e-09
a O 0 6.552409104187973e-08
common O 0 1.535658213924762e-07
ancestor O 0 4.164622623648029e-06
. O 0 2.8232568638486555e-06

Investigation O 0 1.309705930907512e-05
of O 0 7.300294413425945e-08
the O 0 1.572435053276422e-07
genetic O 0 9.645394811741426e-07
background O 0 2.2960102796787396e-07
by O 0 1.3436359580509816e-08
means O 0 9.354862662291907e-09
of O 0 1.741993327364355e-09
mtDNA O 0 5.1849060156428095e-08
lineages O 0 2.4292637235134862e-08
indicate O 0 1.4198392683795191e-08
that O 0 1.1218102002885644e-09
all O 0 1.8841259663560095e-09
our O 0 1.0344805900786014e-07
patients O 0 7.255553668983339e-07
are O 0 2.6871234126701893e-09
probably O 0 2.8535630747228424e-08
of O 0 3.25315641092061e-09
native O 0 2.505388181361923e-07
American O 0 6.706594376737485e-06
descent O 0 0.00014881660172250122

Low O 0 6.570119694515597e-06
frequency O 0 2.4929568098741584e-06
of O 0 2.3022811035389168e-07
BRCA1 O 0 8.660973981022835e-05
germline O 0 8.604585309512913e-05
mutations O 0 2.138649688276928e-05
in O 0 4.598270493261225e-07
45 O 0 5.911659172852524e-06
German O 1 0.9958140254020691
breast B-Disease 1 0.9999723434448242
/ I-Disease 1 0.9999195337295532
ovarian I-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9999915361404419
families O 0 5.7909575843950734e-05
. O 0 1.6217943993979134e-05

In O 0 8.456608497908746e-07
this O 0 5.3447294590114325e-08
study O 0 8.097661208239515e-08
we O 0 2.7073220110196416e-08
investigated O 0 3.0649664495285833e-06
45 O 0 1.3035513575232471e-06
German O 1 0.8477383852005005
breast B-Disease 1 0.9999455213546753
/ I-Disease 1 0.9999109506607056
ovarian I-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999834299087524
families O 0 4.7599888830518466e-07
for O 0 1.911981257762818e-07
germline O 0 0.00012366547889541835
mutations O 0 6.433366252167616e-06
in O 0 1.0787242388232698e-07
the O 0 8.62841716298135e-07
BRCA1 O 0 0.00036477361572906375
gene O 0 3.333719359943643e-05
. O 0 3.899015609931666e-06

We O 0 2.5385791104781674e-06
identified O 0 1.3353807162275189e-06
four O 0 1.4137502546418546e-07
germline O 0 3.3459753467468545e-05
mutations O 0 1.0969367394864094e-05
in O 0 3.5518391428013274e-07
three O 0 6.945306267880369e-06
breast B-Disease 1 0.9992091059684753
cancer I-Disease 1 0.6824107766151428
families O 0 1.316391617933732e-08
and O 0 4.00751716256309e-08
in O 0 1.0757895552160335e-06
one O 0 0.0003724700363818556
breast B-Disease 1 0.9999723434448242
- I-Disease 1 0.9999945163726807
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999966621398926
family O 0 1.561962199048139e-05
. O 0 1.2136239568860674e-08
among O 0 1.4765844102981873e-09
these O 0 4.2623155005472313e-10
were O 0 3.247700552932997e-09
one O 0 2.5491749156003607e-08
frameshift O 0 2.5018189262482338e-05
mutation O 0 1.0373331633672933e-06
, O 0 1.875135424711516e-08
one O 0 2.4717680346952875e-08
nonsense O 0 3.5580876556196017e-06
mutation O 0 1.01477144198725e-06
, O 0 5.668126412672336e-09
one O 0 4.636826034243313e-09
novel O 0 1.8446421279350034e-08
splice O 0 8.164174687408376e-07
site O 0 2.3633160708413925e-06
mutation O 0 1.018244688566483e-06
, O 0 1.4832637340589372e-08
and O 0 2.5882767928919748e-08
one O 0 4.5871149723097915e-07
missense O 0 0.00013212939666118473
mutation O 0 0.00020716164726763964
. O 0 3.1059671528055333e-06

The O 0 6.630369171034545e-06
missense O 0 0.00024491813383065164
mutation O 0 0.0003411992220208049
was O 0 3.4869917726609856e-05
also O 0 1.5519562168719858e-07
found O 0 1.2991723963295954e-07
in O 0 1.710132266907749e-07
2 O 0 2.735499947448261e-06
. O 0 1.9874721601809142e-06

8 O 0 2.7125638553116005e-06
% O 0 1.7448140710030202e-08
of O 0 3.1685247758872492e-09
the O 0 5.3263988775142934e-09
general O 0 3.2835792751484405e-08
population O 0 6.644455652349279e-09
, O 0 1.0197540589729215e-08
suggesting O 0 1.1276118527803192e-07
that O 0 8.247232230473855e-09
it O 0 5.037532702090175e-08
is O 0 8.156920898727549e-07
not O 0 1.3212197700340766e-06
disease O 0 0.013108699582517147
associated O 0 2.2782674932386726e-05
. O 0 3.018289362444193e-06

The O 0 1.776523276930675e-06
average O 0 4.219524271320552e-06
age O 0 1.1596636113608838e-06
of O 0 4.016692969344149e-07
disease O 1 0.5960339307785034
onset O 0 0.037046536803245544
in O 0 4.356022316187591e-07
those O 0 9.714019810758145e-09
families O 0 5.5332591841761314e-08
harbouring O 0 0.00035053613828495145
causative O 0 0.0005155698163434863
mutations O 0 5.4998516134219244e-05
was O 0 1.2537000657175668e-05
between O 0 4.889118372375378e-07
32 O 0 6.8289496084616985e-06
. O 0 2.0129530184931355e-06

3 O 0 2.4285180188599043e-05
and O 0 3.92513902625069e-06
37 O 0 2.535318890295457e-05
. O 0 3.414868615436717e-06

4 O 0 5.594241429207614e-06
years O 0 4.022964787964156e-07
, O 0 2.2424632817319434e-08
whereas O 0 5.631941846218069e-08
the O 0 6.161244670011001e-08
family O 0 6.216927772584313e-07
harbouring O 0 1.595520370756276e-05
the O 0 1.0845937481462897e-07
missense O 0 4.827474185731262e-06
mutation O 0 1.9091000922344392e-06
had O 0 4.223837635208838e-08
an O 0 4.264480324422948e-09
average O 0 2.0316127802288975e-07
age O 0 4.159915789614388e-08
of O 0 5.931473534559473e-09
onset O 0 8.422398241236806e-05
of O 0 1.275623446872487e-07
51 O 0 1.534094917587936e-05
. O 0 1.4277303534981911e-06

2 O 0 7.294464739970863e-05
years O 0 2.3188804334495217e-05
. O 0 6.512962954730028e-06

These O 0 1.890338552357207e-07
findings O 0 4.0965480252452835e-07
show O 0 2.1609250211440667e-07
that O 0 4.6749878634955166e-08
BRCA1 O 0 1.4246715181798209e-05
is O 0 1.0416400186841202e-07
implicated O 0 5.084010012978979e-07
in O 0 8.377107896251346e-09
a O 0 1.745060274060961e-08
small O 0 3.184108621212545e-08
fraction O 0 2.2302049274003366e-07
of O 0 2.8658196242759004e-06
breast B-Disease 1 0.9998565912246704
/ I-Disease 1 0.9999055862426758
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999938011169434
families O 0 4.313747581363714e-07
suggesting O 0 5.183195526115014e-07
the O 0 3.460571562641235e-08
involvement O 0 9.378555887451512e-08
of O 0 9.430751291006345e-09
another O 0 1.4763226090508397e-06
susceptibility O 0 8.570142381358892e-05
gene O 0 1.5953073670971207e-05
( O 0 1.2318636208874523e-06
s O 0 0.0004080205981153995
) O 0 6.153110462037148e-06

Paternal O 0 0.018763108178973198
transmission O 1 0.9670246243476868
of O 0 0.16179215908050537
congenital B-Disease 1 0.9999756813049316
myotonic I-Disease 1 0.9999704360961914
dystrophy I-Disease 1 0.9999637603759766
. O 0 0.009589295834302902

We O 0 8.24059679871425e-06
report O 0 9.7306917723472e-07
a O 0 2.9672202117581037e-07
rare O 0 2.0744716948684072e-06
case O 0 4.335757239459781e-06
of O 0 3.378037490620045e-06
paternally O 1 0.9900985360145569
transmitted O 1 0.9992910623550415
congenital B-Disease 1 0.999990701675415
myotonic I-Disease 1 0.9999918937683105
dystrophy I-Disease 1 0.9999938011169434
( O 0 0.0643238052725792
DM B-Disease 1 0.999890923500061
) O 0 2.429006781312637e-05
. O 0 7.4586578193702735e-06

The O 0 1.5733696727693314e-06
proband O 0 8.965684537542984e-05
is O 0 1.0043659415259754e-07
a O 0 1.46893668784287e-07
23 O 0 7.331012739086873e-07
year O 0 2.718385587741068e-07
old O 0 0.00011794068268500268
, O 0 3.654894317151047e-05
mentally B-Disease 1 0.9999203681945801
retarded I-Disease 1 0.9982282519340515
male O 0 0.0002103615115629509
who O 0 0.003217375837266445
suffers O 1 0.999432384967804
severe O 1 0.9996956586837769
muscular B-Disease 1 0.9998124241828918
weakness I-Disease 1 0.998723566532135
. O 0 0.00013197048974689096

He O 0 4.112276656087488e-05
presented O 0 7.873441063566133e-06
with O 0 1.9954655726905912e-05
respiratory O 1 0.9976739287376404
and O 0 4.182234533800511e-06
feeding O 0 8.611973316874355e-05
difficulties O 0 0.00044394342694431543
at O 0 0.0005107114557176828
birth O 0 0.0007432536222040653
. O 0 5.705654530174797e-06

His O 0 2.0254414266673848e-05
two O 0 7.269514298968716e-06
sibs O 0 0.09698309749364853
suffer O 0 0.005464022513478994
from O 0 1.8964858099934645e-05
childhood O 1 0.6237794160842896
onset O 1 0.9991782307624817
DM B-Disease 1 0.9998424053192139
. O 0 0.0001207347959280014

Their O 0 4.5571985651804425e-07
late O 0 1.1251256182731595e-05
father O 0 2.234983639937127e-06
had O 0 1.0895886504158625e-07
the O 0 6.645444639019615e-09
adult O 0 5.1927639077575805e-08
type O 0 1.9698306914506247e-06
of O 0 1.1722222126309134e-07
DM B-Disease 1 0.9998283386230469
, O 0 1.2651148040276894e-07
with O 0 3.117261826446338e-08
onset O 0 0.0001691091019893065
around O 0 2.376564367523315e-07
30 O 0 6.456941719079623e-07
years O 0 5.850041020494245e-07
. O 0 6.967171088945179e-07

Only O 0 3.314241041607602e-07
six O 0 5.230786825904943e-08
other O 0 2.939418930480997e-09
cases O 0 9.733976291670388e-09
of O 0 1.1596660520751811e-08
paternal O 0 4.68272264697589e-05
transmission O 0 0.21302291750907898
of O 0 0.00029789909604005516
congenital B-Disease 1 0.9999955892562866
DM I-Disease 1 0.9999933242797852
have O 0 5.022335972171277e-05
been O 0 7.705787720624357e-05
reported O 0 0.0001647094904910773
recently O 0 0.00016107637202367187
. O 0 2.334237478862633e-06

We O 0 6.112558139648172e-07
review O 0 2.676552242064645e-07
the O 0 4.0246142418709496e-08
sex O 0 1.741360335927311e-07
related O 0 1.8922703759471915e-07
effects O 0 2.0623206182790454e-06
on O 0 3.8972088987065945e-06
transmission O 0 0.018264949321746826
of O 0 0.000539525703061372
congenital B-Disease 1 0.9999896287918091
DM I-Disease 1 0.9999632835388184
. O 0 0.0003291708999313414

Decreased O 0 0.0002685719227883965
fertility O 0 8.495122892782092e-05
of O 0 5.512528034046227e-08
males O 0 7.865981643817577e-08
with O 0 9.768798037157467e-08
adult O 0 1.3147454410500359e-05
onset O 1 0.9758532047271729
DM B-Disease 1 0.9999278783798218
and O 0 1.339117375209753e-06
contraction O 0 4.994565188098932e-06
of O 0 5.665629743134559e-09
the O 0 1.6194736218722028e-08
repeat O 0 1.630344996783606e-07
upon O 0 1.2357632250825645e-08
male O 0 1.0141719997136533e-07
transmission O 0 1.8709914684222895e-06
contribute O 0 1.1033365332480116e-08
to O 0 2.043125002515467e-09
the O 0 7.548911717947249e-09
almost O 0 2.8731697909734066e-08
absent O 0 2.4671902565387427e-07
occurrence O 0 3.655517843981215e-07
of O 0 3.495085110216678e-08
paternal O 0 5.105383388581686e-05
transmission O 0 0.041159212589263916
of O 0 0.0004589087620843202
congenital B-Disease 1 0.9999767541885376
DM I-Disease 1 0.9999452829360962
. O 0 0.0006287803989835083

Also O 0 6.535260013151856e-07
the O 0 8.653702110450467e-08
fathers O 0 1.9063823231135757e-07
of O 0 1.4780785484447279e-08
the O 0 2.9658366429430316e-07
reported O 0 2.3857413907535374e-05
congenitally O 0 6.428533379221335e-05
affected O 0 4.505076560690213e-07
children O 0 4.040242629343993e-08
showed O 0 4.135518736347876e-07
, O 0 4.5684926952560545e-09
on O 0 4.095734951192753e-08
average O 0 5.036975494476792e-07
, O 0 2.0458090332908796e-08
shorter O 0 1.1593119779718108e-06
CTG O 0 1.2524739759101067e-05
repeat O 0 1.5818611700524343e-06
lengths O 0 2.347779854972032e-06
and O 0 2.8294238063608645e-08
hence O 0 2.8327187351351313e-07
less O 0 2.2529145553562557e-06
severe O 0 0.2504533529281616
clinical O 0 0.008756626397371292
symptoms O 0 0.004095883574336767
than O 0 3.35226566505753e-08
the O 0 6.349056747012582e-08
mothers O 0 4.6078318405307073e-07
of O 0 3.65762353737864e-08
children O 0 1.554020741423301e-06
with O 0 0.000796911830548197
congenital B-Disease 1 0.999974250793457
DM I-Disease 1 0.9999507665634155
. O 0 0.0007149778539314866

We O 0 1.1607058922891156e-06
conclude O 0 1.0044404916698113e-06
that O 0 2.9221586927974386e-08
paternal O 0 1.3936138202552684e-05
transmission O 0 0.04481932520866394
of O 0 0.0014618326677009463
congenital B-Disease 1 0.9999964237213135
DM I-Disease 1 0.9999953508377075
is O 0 0.00023975905787665397
rare O 0 9.906189916364383e-06
and O 0 1.8953188885006966e-07
preferentially O 0 4.6382083951357345e-07
occurs O 0 1.492701073857461e-07
with O 0 4.06070022052063e-08
onset O 0 0.0001696174731478095
of O 0 2.665039460225671e-07
DM B-Disease 1 0.9992403984069824
past O 0 5.050246159044036e-07
30 O 0 1.3188601144520362e-07
years O 0 5.487518706104311e-08
in O 0 1.3350754279883859e-08
the O 0 6.74103972642115e-08
father O 0 4.173771685600514e-06
. O 0 1.574594534758944e-07
. O 0 6.937229386494437e-07

The O 0 4.418123808136443e-06
RB1 O 0 0.0020522517152130604
gene O 0 1.8371867554378696e-05
mutation O 0 1.9918208636227064e-05
in O 0 1.6477878261866863e-07
a O 0 1.6676135601301212e-06
child O 0 2.1263684175210074e-05
with O 0 1.2548603081086185e-05
ectopic B-Disease 1 0.9980334639549255
intracranial I-Disease 1 0.9998443126678467
retinoblastoma I-Disease 1 0.9951624274253845
. O 0 8.039161912165582e-05

The O 0 9.896464689518325e-06
RB1 O 0 0.003740511368960142
gene O 0 4.5613280235556886e-05
mutation O 0 0.0001761986204655841
was O 0 3.8899157516425475e-05
investigated O 0 7.739046850474551e-06
in O 0 2.093194382268848e-07
a O 0 3.5612449664768064e-06
child O 0 1.4236883544072043e-05
with O 0 1.710507149255136e-06
ectopic B-Disease 0 0.47865989804267883
intracranial I-Disease 1 0.9524312615394592
retinoblastoma I-Disease 0 0.00017455646593589336
using O 0 5.946224845843062e-08
DNA O 0 5.931306077400222e-07
obtained O 0 2.456024539299051e-08
from O 0 3.6722456187021635e-09
both O 0 3.7349874304482e-09
the O 0 9.742525008960001e-08
pineal B-Disease 0 3.404208109714091e-05
and I-Disease 0 3.945254320569802e-06
retinal I-Disease 0 0.4914725124835968
tumours I-Disease 1 0.9998738765716553
of O 0 4.96143400141591e-07
the O 0 1.9950983187300153e-05
patient O 0 0.0066469283774495125
. O 0 4.0680838537809905e-06

A O 0 2.930522350652609e-05
nonsense O 0 7.142568938434124e-05
mutation O 0 2.166588637919631e-05
in O 0 3.693701273732586e-07
exon O 0 1.4109425137576181e-05
17 O 0 6.649618171650218e-07
( O 0 1.3635358619978888e-08
codon O 0 1.205975053153452e-07
556 O 0 6.635656291109626e-08
) O 0 3.5600093983845227e-09
of O 0 1.4219742050514128e-09
the O 0 4.952315180162259e-08
RB1 O 0 5.967374090687372e-05
gene O 0 5.165470611245837e-07
was O 0 2.678776581888087e-06
found O 0 1.1872074878738204e-08
to O 0 3.8907843613600335e-10
be O 0 1.4022266681124052e-09
present O 0 5.2738915456984614e-09
homozygously O 0 1.5883551895967685e-06
in O 0 8.563620923496273e-09
both O 0 3.3795164444683223e-09
the O 0 8.204106904941e-08
retinal B-Disease 0 4.445814556675032e-05
and I-Disease 0 2.1574285824499384e-07
the I-Disease 0 7.971699233166873e-06
pineal I-Disease 1 0.555958092212677
tumours I-Disease 1 0.9998008608818054
. O 0 4.740879012388177e-05

The O 0 7.519885798501491e-07
same O 0 3.7570711697298975e-07
mutation O 0 5.6250992201967165e-06
was O 0 1.2686550689977594e-06
present O 0 2.1414473749814533e-08
heterozygously O 0 3.3136768706754083e-06
in O 0 1.0132860772671393e-08
the O 0 4.234911088474291e-09
DNA O 0 2.5281554627554215e-08
from O 0 9.85359793759244e-10
the O 0 1.8040973159827445e-09
constitutional O 0 4.505987405423184e-08
cells O 0 2.2405350463827745e-08
of O 0 1.8226359310702378e-09
the O 0 1.600776329269138e-07
patient O 0 1.0199571988778189e-05
, O 0 4.4910407837051025e-08
proving O 0 1.9093804439762607e-06
it O 0 4.9467332452479695e-09
to O 0 2.7819988535071616e-09
be O 0 1.0986075160701603e-08
of O 0 3.470877274480699e-08
germline O 0 2.283217509102542e-05
origin O 0 6.953723072911089e-07
. O 0 2.245246605525608e-06

The O 0 9.059403396349808e-07
initial O 0 3.759368610189995e-06
mutation O 0 1.407244326401269e-05
was O 0 3.211738430763944e-06
shown O 0 4.767475303424362e-08
to O 0 3.235507861631959e-09
have O 0 4.011598608855138e-09
occurred O 0 3.690954883950326e-07
in O 0 3.7729304125377894e-08
the O 0 1.0954107665384072e-07
paternally O 0 2.5003280825330876e-05
derived O 0 2.237376293123816e-06
RB1 O 0 0.0009361805859953165
allele O 0 3.186478716088459e-05
. O 0 5.04719719174318e-06

The O 0 4.272382284398191e-06
mutation O 0 3.591575659811497e-05
is O 0 1.0610971656888069e-07
in O 0 6.562337784288275e-09
an O 0 3.872750564681837e-09
area O 0 3.492466404964034e-08
of O 0 6.965889531862501e-10
the O 0 3.377627955103435e-09
gene O 0 8.257637240660642e-09
that O 0 1.471023441945718e-10
encodes O 0 9.87632753357559e-10
the O 0 3.0370097547915975e-09
protein O 0 3.975814877321682e-08
- O 0 4.37940656183855e-07
binding O 0 4.45902408330312e-08
region O 0 9.821726365544237e-08
known O 0 4.091737082489999e-08
as O 0 9.935773981339935e-09
the O 0 2.5041405393722016e-08
pocket O 0 1.1613365131779574e-05
region O 0 2.147898783277924e-07
and O 0 4.8941611652253414e-08
has O 0 8.006206542177097e-08
been O 0 5.5938727427928825e-08
detected O 0 3.462496920292324e-07
in O 0 2.7551942949344266e-09
other O 0 5.697041172147976e-10
cases O 0 8.390252936862908e-09
of O 0 1.7866884860495702e-08
retinoblastoma B-Disease 0 0.0006393372896127403
. O 0 9.31268857584655e-07
. O 0 1.1102733878942672e-06

Low O 0 4.687695764005184e-05
levels O 0 2.555012542870827e-06
of O 0 5.6452989838362555e-08
beta O 0 1.2633439609999186e-06
hexosaminidase O 0 2.8750146157108247e-06
A O 0 8.14765428458486e-07
in O 0 5.6840008255676366e-08
healthy O 0 2.2656237774754118e-07
individuals O 0 6.125644436139055e-09
with O 0 5.162860361451749e-07
apparent O 0 0.2552688419818878
deficiency O 1 0.9908812046051025
of O 0 7.544381475099726e-08
this O 0 2.728129970819282e-07
enzyme O 0 2.007798684644513e-05
. O 0 1.4690588159282925e-06

Appreciable O 0 8.808635175228119e-05
beta O 0 4.6034147089812905e-05
hexosaminidase O 0 6.678634963463992e-05
A O 0 1.3101292779538198e-06
( O 0 1.32588144907686e-08
hex O 0 4.2218161411256006e-07
A O 0 1.194084404687601e-07
) O 0 4.699920452821971e-09
activity O 0 3.792591485307639e-08
has O 0 2.1598077992734943e-08
been O 0 2.0560815272574473e-08
detected O 0 3.2532980753785523e-07
in O 0 1.762857770870596e-08
cultured O 0 1.8365733467362588e-06
skin O 0 9.705329284770414e-05
fibroblasts O 0 3.914238732249942e-06
and O 0 2.285766640852671e-05
melanoma B-Disease 1 0.9996094107627869
tissue O 0 0.0008769659325480461
from O 0 3.383133275747241e-07
healthy O 0 2.2619844912696863e-06
individuals O 0 1.4210720600260629e-08
previously O 0 2.2460048967332114e-06
reported O 0 7.565082796645584e-06
as O 0 6.745624432369368e-07
having O 0 0.00012183791113784537
deficiency B-Disease 0 0.10677783191204071
of I-Disease 0 6.565705312766568e-09
hex I-Disease 0 9.965154958990752e-07
A I-Disease 0 1.2363742030174762e-07
activity O 0 2.103154628230186e-08
indistinguishable O 0 1.9979758292265615e-08
from O 0 2.317434910636962e-09
that O 0 6.133872298974552e-10
of O 0 6.399082597141614e-09
patients O 0 3.0880773920216598e-06
with O 0 0.00038413165020756423
Tay B-Disease 1 0.9999921321868896
- I-Disease 1 0.9999645948410034
Sachs I-Disease 1 0.9999507665634155
disease I-Disease 1 0.9990977048873901
( O 0 4.635870027414057e-06
TSD B-Disease 0 0.007560885976999998
) O 0 2.4802177449601004e-06
. O 0 2.25829035116476e-06

Identification O 0 4.442929821379948e-06
and O 0 3.9319021993833303e-07
quantitation O 0 3.5066736018052325e-05
of O 0 1.0998343924484288e-07
hex O 0 9.779470929061063e-06
A O 0 1.8868871620725258e-06
, O 0 2.252872377539461e-08
amounting O 0 1.1869531846286918e-07
to O 0 2.9138989887655953e-08
3 O 0 3.314691412015236e-06
. O 0 1.7249885786441155e-06

5 O 0 2.2538393750437535e-05
% O 0 2.0396782929310575e-06
- O 0 0.00017458976071793586
6 O 0 1.2261682968528476e-05
. O 0 1.756563165145053e-06

9 O 0 1.258872430298652e-06
% O 0 9.358752883770194e-09
of O 0 2.7642690358931077e-09
total O 0 1.8223900610792043e-08
beta O 0 2.739303965881845e-07
hexosaminidase O 0 1.9232002159697004e-06
activity O 0 6.211238456899082e-08
, O 0 9.765702024822076e-09
has O 0 1.5472560122020695e-08
been O 0 5.312863482487273e-09
obtained O 0 8.808889617739624e-09
by O 0 1.4671916126474116e-08
cellulose O 0 3.4128646802855656e-05
acetate O 0 9.327388397650793e-06
gel O 0 1.4311207451100927e-05
electrophoresis O 0 4.8742581384431105e-06
, O 0 3.418226413032244e-08
DEAE O 0 1.7886301066027954e-05
- O 0 5.254884399619186e-06
cellulose O 0 1.4857667338219471e-05
ion O 0 1.0543570169829763e-05
- O 0 4.419712240633089e-06
exchange O 0 4.443267300757725e-07
chromatography O 0 1.59396295202896e-05
, O 0 9.907543585541134e-08
radial O 0 6.179149750096258e-06
immunodiffusion O 0 2.6935447749565355e-05
, O 0 1.4810706261414452e-07
and O 0 1.8911877930349874e-07
radioimmunoassay O 0 0.0007650406332686543
. O 0 2.6662191885407083e-06

Previous O 0 1.023072672978742e-05
family O 0 8.742025784158614e-06
studies O 0 5.55603321572562e-07
suggested O 0 2.809730688113632e-07
that O 0 6.759216741869523e-09
these O 0 1.1113194808842763e-09
individuals O 0 3.6152989491000653e-09
may O 0 1.8629316400620155e-07
be O 0 2.1375871739337526e-08
compound O 0 2.2737189908639266e-07
heterozygotes O 0 2.316035931926308e-07
for O 0 4.063673397780576e-09
the O 0 1.6010703873803322e-08
common O 0 1.174736894427042e-07
mutant O 0 1.9359636098670308e-06
TSD B-Disease 0 2.075047086691484e-05
gene O 0 2.745397580383724e-07
and O 0 2.447541724848179e-08
a O 0 3.8029139659556677e-07
rare O 0 6.551821911671141e-07
( O 0 2.7765507226718e-08
allelic O 0 3.1399729323311476e-06
) O 0 1.066783283931727e-07
mutant O 0 1.1304224244668148e-05
gene O 0 1.1427813660702668e-05
. O 0 1.304141960645211e-06

Thus O 0 3.678715302157798e-06
, O 0 1.3792713104976428e-07
the O 0 3.7104921801756063e-08
postulated O 0 1.8125471115126857e-06
rate O 0 4.959736088494537e-07
mutant O 0 3.073115806273563e-07
gene O 0 1.381564516123035e-07
appears O 0 4.226182781508214e-08
to O 0 4.215350568603782e-10
code O 0 2.0217423291057912e-09
for O 0 3.022520844719878e-10
the O 0 1.2321569320405956e-09
expression O 0 2.614692684588249e-09
of O 0 2.9958964198328886e-09
low O 0 4.209100268326438e-07
amounts O 0 1.822233741677337e-08
of O 0 9.7544949895223e-09
hex O 0 8.922354936657939e-06
A O 0 1.4962061868573073e-05
. O 0 1.737208322083461e-06

Heterozygotes O 0 8.448687003692612e-05
for O 0 3.3949012845369e-07
the O 0 2.7782070333159936e-07
rare O 0 2.204563770646928e-06
mutant O 0 1.2357933883322403e-05
may O 0 2.2932442789169727e-07
be O 0 4.499741468322327e-09
indistinguishable O 0 5.4385040471061075e-08
from O 0 8.292217579253247e-09
heterozygotes O 0 1.9167863740676694e-07
for O 0 8.194844802744683e-09
the O 0 8.47197938469435e-08
common O 0 2.3307493393076584e-06
TSD B-Disease 0 0.004104129038751125
mutant O 0 0.00017810054123401642
. O 0 4.580558652378386e-06

However O 0 2.084265588564449e-06
, O 0 4.1250800109082775e-08
direct O 0 1.504657376472096e-08
visualization O 0 9.231030730916245e-07
and O 0 5.5750618344063696e-08
quantitation O 0 1.2006486940663308e-05
of O 0 3.5151948907241604e-08
hex O 0 2.0270833829272306e-06
A O 0 2.4357507300010184e-07
by O 0 3.5853244817474206e-09
the O 0 7.085138253870582e-09
methods O 0 7.743897612044748e-08
described O 0 4.523219558905112e-06
may O 0 4.81875360947015e-07
prevent O 0 3.407168094327062e-07
false O 0 1.905330009321915e-07
- O 0 2.1142746845725924e-05
positive O 0 1.638845361640051e-07
prenatal O 0 5.824814070365392e-05
diagnosis O 0 0.0001523332466604188
of O 0 6.799744056706913e-08
TSD B-Disease 0 0.00039113356615416706
in O 0 5.820746196150139e-07
fetuses O 0 5.158940894034458e-06
having O 0 1.8956552594318055e-07
the O 0 5.3330598603906765e-08
incomplete O 0 2.1769317299913382e-06
hex B-Disease 0 6.485947233159095e-05
A I-Disease 0 0.00023935848730616271
deficiency I-Disease 0 0.09744112938642502
of O 0 7.820485592446857e-09
the O 0 1.150540995809024e-07
type O 0 1.0788937288452871e-05
described O 0 1.7301615571341245e-06
in O 0 3.912742130296465e-08
the O 0 4.258029306924982e-08
four O 0 2.545730524161627e-07
healthy O 0 7.562846349173924e-06
individuals O 0 7.60620594064676e-07

The O 0 2.359402787988074e-05
tumor B-Disease 0 0.060912080109119415
suppressor O 0 0.00012819861876778305
gene O 0 1.4895178537699394e-05
Smad4 O 0 0.00012589991092681885
/ O 0 1.583022458362393e-05
Dpc4 O 0 0.00010202181874774396
is O 0 1.4921516822141712e-07
required O 0 2.5515147328292187e-08
for O 0 8.437144316530976e-09
gastrulation O 0 2.234728071925929e-06
and O 0 3.7613048675666505e-08
later O 0 1.9785863969445927e-07
for O 0 1.3548977051414113e-08
anterior O 0 2.055652475974057e-05
development O 0 3.773441292764801e-08
of O 0 5.964373439582005e-09
the O 0 1.211831772707228e-07
mouse O 0 2.9842645744793117e-05
embryo O 0 2.9622726287925616e-05
. O 0 1.6463881138406578e-06

Mutations O 0 0.00030437816167250276
in O 0 1.3334133655007463e-06
the O 0 6.596637263101002e-07
SMAD4 O 0 0.0029304465278983116
/ O 0 0.00021562103938777
DPC4 O 0 0.11727962642908096
tumor B-Disease 1 0.6148808598518372
suppressor O 0 2.8217978979228064e-05
gene O 0 7.675416213714925e-07
, O 0 9.654100630029916e-09
a O 0 2.556122602470623e-08
key O 0 6.434013499756475e-08
signal O 0 2.3204532340059814e-07
transducer O 0 6.149094247120956e-07
in O 0 2.5975845474590642e-08
most O 0 1.7142154362659312e-08
TGFbeta O 0 2.1563562768278643e-05
- O 0 1.417624116584193e-05
related O 0 5.58155228702617e-08
pathways O 0 1.5220142302041495e-07
, O 0 7.53451345758549e-09
are O 0 3.37529504346179e-10
involved O 0 4.380406259940628e-09
in O 0 4.310948931163239e-09
50 O 0 1.2351317302261577e-08
% O 0 1.677190475390944e-08
of O 0 2.219867837993661e-06
pancreatic B-Disease 1 0.9999310970306396
cancers I-Disease 1 0.9993914365768433
. O 0 1.4130308954918291e-05

Homozygous O 0 0.0005040773539803922
Smad4 O 0 0.0010777575662359595
mutant O 0 0.0015461168950423598
mice O 0 0.003270918969064951
die O 0 0.0006387544563040137
before O 0 1.496289883107238e-06
day O 0 1.6209869500016794e-06
7 O 0 4.494135282584466e-06
. O 0 1.2105881523893913e-06

5 O 0 1.391282057738863e-05
of O 0 1.284017344005406e-06
embryogenesis O 0 0.0004891888820566237
. O 0 2.3666791094001383e-05

Mutant O 0 2.0566110833897255e-05
embryos O 0 2.890169980673818e-06
have O 0 9.725721383802011e-08
reduced O 0 8.017680102057057e-07
size O 0 2.4414630388491787e-06
, O 0 2.658824769241619e-07
fail O 0 1.0799641358971712e-06
to O 0 8.027625675310901e-09
gastrulate O 0 3.540946272551082e-05
or O 0 6.886120473836854e-08
express O 0 9.573862058687155e-08
a O 0 1.6469017793951934e-07
mesodermal O 0 4.046300091431476e-06
marker O 0 2.8067308903700905e-06
, O 0 2.309070445960515e-08
and O 0 1.7934350893256124e-08
show O 0 5.95355572841072e-07
abnormal O 0 1.0972224117722362e-05
visceral O 0 1.986065944947768e-05
endoderm O 0 0.0003826151369139552
development O 0 6.938302249182016e-06
. O 0 7.4536233114486095e-06

Growth B-Disease 1 0.9936848282814026
retardation I-Disease 1 0.9982126951217651
of O 0 2.264792016148931e-07
the O 0 9.819514161790721e-07
Smad4 O 0 0.005290675908327103
- O 0 0.011753160506486893
deficient O 0 0.0003120946930721402
embryos O 0 2.614851553062181e-07
results O 0 6.84560248487287e-08
from O 0 1.643164182496548e-08
reduced O 0 4.395083976760361e-07
cell O 0 4.557304237096105e-06
proliferation O 0 1.2338764463493135e-06
rather O 0 1.4294585071183974e-08
than O 0 1.66121445488443e-08
increased O 0 5.887972633900063e-07
apoptosis O 0 4.507261110120453e-05
. O 0 2.30590103456052e-06

Aggregation O 0 1.882291144283954e-05
of O 0 3.7767972571600694e-07
mutant O 0 1.4836939044471364e-05
Smad4 O 0 0.000167677499121055
ES O 0 2.2450056349043734e-05
cells O 0 5.044219619776413e-07
with O 0 4.519130314406539e-08
wild O 0 1.913058667923906e-06
- O 0 0.0001295717665925622
type O 0 1.5859117411309853e-05
tetraploid O 0 2.3807526304153726e-05
morulae O 0 0.0008148549241013825
rescues O 0 0.000124080921523273
the O 0 6.123700586613268e-06
gastrulation B-Disease 0 0.02365867607295513
defect I-Disease 0 0.04614446684718132
. O 0 1.1100278243247885e-05

These O 0 5.438431003312871e-07
results O 0 4.142610123381019e-06
indicate O 0 7.057766993057157e-07
that O 0 2.7170164784706685e-08
Smad4 O 0 1.0621844921843149e-05
is O 0 8.41094163206435e-08
initially O 0 6.051648426819156e-08
required O 0 1.89444637754832e-09
for O 0 3.3433292245810264e-10
the O 0 1.159972895514727e-09
differentiation O 0 6.8365180183604934e-09
of O 0 1.2289858020153588e-09
the O 0 1.0139316941604193e-08
visceral O 0 4.5497688461182406e-07
endoderm O 0 1.0687687790778e-05
and O 0 6.478913405771891e-08
that O 0 7.2313595111950235e-09
the O 0 5.7271609676945445e-08
gastrulation B-Disease 0 0.0001425000373274088
defect I-Disease 0 7.670092600164935e-05
in O 0 5.7506511552674056e-08
the O 0 1.4480730214927462e-07
epiblast O 0 7.063926750561222e-05
is O 0 1.251130754553742e-07
secondary O 0 3.82357711714576e-07
and O 0 3.613439503169502e-08
non O 0 1.6963221014520968e-06
- O 0 0.0011788617121055722
cell O 0 0.00019602931570261717
autonomous O 0 1.9843204427161254e-05
. O 0 3.3676769817247987e-06

Rescued O 0 0.0003853047383017838
embryos O 0 3.87098771170713e-05
show O 0 0.00011558158439584076
severe O 1 0.5603613257408142
anterior O 0 0.010147208347916603
truncations O 0 0.0002615890698507428
, O 0 1.0715689313656185e-06
indicating O 0 7.501155891986855e-07
a O 0 1.2091072676412296e-07
second O 0 7.630007559100704e-08
important O 0 7.376602439990165e-09
role O 0 1.0360424340660757e-07
for O 0 4.1487037805154614e-08
Smad4 O 0 0.0001371214457321912
in O 0 1.0497229823158705e-06
anterior O 0 0.001561334473080933
patterning O 0 0.0004645846493076533
during O 0 4.071204239153303e-05
embryogenesis O 0 0.0002673520357348025
. O 0 6.514701908599818e-06

Prevalence O 0 0.00020798796322196722
of O 0 2.4960775135696167e-07
p16 O 0 1.2661949767789338e-05
and O 0 3.3208982586074853e-07
CDK4 O 0 0.0005894200294278562
germline O 0 0.0003733431512955576
mutations O 0 0.00011894528870470822
in O 0 4.249978701409418e-06
48 O 0 0.0005930786719545722
melanoma B-Disease 1 0.9997827410697937
- O 0 0.3991185128688812
prone O 0 0.0022836504504084587
families O 0 2.625521631216543e-07
in O 0 8.663229209560086e-07
France O 0 8.711202826816589e-05
. O 0 5.147293450136203e-06

The O 0 8.269229510915466e-06
French O 0 0.0032209069468080997
Familial B-Disease 1 0.9968992471694946
Melanoma I-Disease 1 0.9996784925460815
Study O 0 4.428457032190636e-05
Group O 0 2.2008429368725047e-05
. O 0 4.25113375968067e-06

Germline O 0 0.0069271535612642765
mutations O 0 0.00033375475322827697
in O 0 5.909140554649639e-07
the O 0 4.420013866024419e-08
p16 O 0 1.1432906603658921e-06
and O 0 4.560328648040013e-08
CDK4 O 0 3.19491300615482e-05
genes O 0 2.2914559849596117e-07
have O 0 1.7323655399081872e-08
been O 0 6.683530529016934e-08
reported O 0 1.2042787034260982e-07
in O 0 3.4634490830853792e-09
a O 0 2.516330610546902e-08
subset O 0 6.728142665224368e-08
of O 0 2.0774162123871065e-07
melanoma B-Disease 1 0.9276811480522156
pedigrees O 0 5.015404440200655e-06
, O 0 7.11342806880566e-08
but O 0 1.4448526819421659e-08
their O 0 1.3062895654059048e-08
prevalence O 0 1.3842268344887998e-05
is O 0 1.1968296576014836e-07
not O 0 1.8191499862041383e-08
well O 0 8.733826462048455e-08
known O 0 3.82142252419726e-06
. O 0 1.696545382401382e-06

We O 0 1.0807810895130388e-06
searched O 0 2.1903429114900064e-06
for O 0 3.253778402267926e-08
such O 0 5.5505733342897656e-08
germline O 0 5.553387018153444e-05
mutations O 0 1.1325319974275772e-05
in O 0 6.436481498894864e-07
48 O 0 1.0006838238041382e-05
French O 0 0.10458189249038696
melanoma B-Disease 1 0.9999419450759888
- O 1 0.8570151925086975
prone O 0 0.004800777416676283
families O 0 2.1392633442474107e-08
selected O 0 1.0572098751993053e-08
according O 0 4.03386524183702e-09
to O 0 8.037396304061417e-10
two O 0 3.715447949304007e-09
major O 0 1.7411197461569827e-07
criteria O 0 4.942105391592122e-08
families O 0 1.5273082798472615e-09
with O 0 7.908130150724446e-09
at O 0 8.671627256262582e-07
least O 0 6.7551177984626065e-09
three O 0 6.00274230322384e-09
affected O 0 1.333795296432072e-08
members O 0 1.5325258839737899e-09
( O 0 5.217820397973583e-09
n O 0 2.4144409849213844e-07
= O 0 1.5067028868998023e-07
20 O 0 8.636203752132587e-09
) O 0 7.980874294766238e-10
or O 0 1.1111054298851286e-09
families O 0 3.798567294044375e-10
with O 0 1.4909183887468203e-09
two O 0 2.707640778254472e-09
affected O 0 6.9285923665063365e-09
members O 0 4.4661016551650334e-10
, O 0 1.054462517302568e-09
one O 0 5.505220168622316e-10
of O 0 1.4250796376291675e-10
them O 0 2.90533846980523e-10
affected O 0 5.2511563986001875e-09
before O 0 5.658242763217913e-09
the O 0 2.2220381090676256e-09
age O 0 7.152239689389717e-09
of O 0 4.538543985077581e-10
50 O 0 3.635656664613407e-09
( O 0 2.762645445741896e-09
n O 0 2.3049570074817893e-07
= O 0 1.4948834348160744e-07
28 O 0 5.255227364386883e-08
) O 0 2.353121253406698e-09
, O 0 2.113867303421557e-09
and O 0 3.6025233907110987e-09
one O 0 5.8171920613858674e-09
additional O 0 3.859096509017945e-08
minor O 0 0.00012687766866292804
criterion O 0 9.889786451822147e-05
. O 0 3.611008423831663e-06

Sixteen O 0 3.9133501559263095e-06
different O 0 1.802855251753499e-07
p16 O 0 1.0765700608317275e-05
germline O 0 6.881863373564556e-05
mutations O 0 2.339553611818701e-05
were O 0 1.2369474688966875e-07
found O 0 5.401402347615658e-08
in O 0 1.845902275476874e-08
21 O 0 7.134448765100387e-08
families O 0 2.5084561094956825e-09
, O 0 4.4500669815761285e-09
while O 0 9.379857779379108e-09
one O 0 1.4186212204947424e-08
germline O 0 1.8887416217694408e-06
mutation O 0 5.455547125166049e-07
, O 0 9.454706351164077e-09
Arg24His O 0 3.817058768618153e-06
, O 0 8.567758413846605e-08
was O 0 6.75217097523273e-06
detected O 0 7.964638939483848e-07
in O 0 1.9856212674085327e-08
the O 0 1.0308426112715097e-07
CDK4 O 0 0.00046026683412492275
gene O 0 1.5475119653274305e-05
. O 0 1.4178104947859538e-06

The O 0 1.4742163045866619e-07
frequency O 0 4.103390551790653e-07
of O 0 2.7722432349719384e-08
p16 O 0 2.3022337245492963e-06
gene O 0 1.0190481134486618e-06
mutation O 0 1.3582454130300903e-06
in O 0 6.062818247443147e-09
our O 0 4.3423242779283555e-09
sample O 0 7.061851547973674e-09
( O 0 2.000384746736472e-09
44 O 0 6.373842786899786e-09
% O 0 1.1473185734800495e-09
) O 0 8.077384316962366e-10
is O 0 1.19136700504896e-09
among O 0 1.0007815687274046e-09
the O 0 1.5082260773624512e-08
highest O 0 2.637122861415264e-06
rates O 0 5.573221528720751e-07
yet O 0 5.654976931168676e-08
reported O 0 2.0965067903944146e-07
and O 0 2.36931629871151e-09
the O 0 2.4679710719510695e-08
CDK4 O 0 4.5216056605568156e-05
mutation O 0 3.2203092814597767e-07
is O 0 2.1563122398760015e-09
the O 0 2.334711091123154e-09
second O 0 1.2239340207997884e-07
mutation O 0 5.983781079521577e-07
detected O 0 7.026692401268519e-07
in O 0 6.257528273323487e-09
this O 0 3.38116690201673e-09
gene O 0 1.2595481280186505e-07
worldwide O 0 2.558115852480114e-07
. O 0 1.1070486607422936e-06

In O 0 1.5000389339547837e-06
summary O 0 5.917723910897621e-07
, O 0 6.049178580269654e-08
our O 0 1.5389179708336087e-08
results O 0 1.1412445388714332e-07
show O 0 3.317744656783361e-08
frequent O 0 6.270337848945928e-08
involvement O 0 5.32764126148777e-08
of O 0 5.6480859988994325e-09
the O 0 2.9524676037340214e-08
p16 O 0 5.999895051900239e-07
gene O 0 9.016652029458783e-07
in O 0 7.889215680734196e-07
familial B-Disease 1 0.6210721135139465
melanoma I-Disease 1 0.9997499585151672
and O 0 3.239387922349124e-07
confirm O 0 1.29729301079351e-07
the O 0 7.183520445153135e-09
role O 0 2.4068951276490225e-08
of O 0 3.3530758170030595e-09
the O 0 2.0542390899436214e-08
CDK4 O 0 1.5722156604169868e-05
gene O 0 1.931853148562368e-07
as O 0 8.839289478146384e-08
a O 0 1.268124924536096e-05
melanoma B-Disease 1 0.9968823194503784
- O 0 0.00043745781295001507
predisposing O 0 4.15866234106943e-05
gene O 0 8.206474376493134e-06
. O 0 3.0446037158071704e-07
. O 0 1.0252224456053227e-06

Progression O 0 0.00029861251823604107
of O 0 5.224146661930718e-07
somatic O 0 2.3919126761029474e-05
CTG O 0 0.0006525561329908669
repeat O 0 1.3503099580702838e-05
length O 0 1.052955553859647e-06
heterogeneity O 0 3.6174262731947238e-06
in O 0 1.3054255987299257e-07
the O 0 1.2641162072668521e-07
blood O 0 4.2407133150845766e-05
cells O 0 2.180364026571624e-05
of O 0 1.5597874153172597e-05
myotonic B-Disease 1 0.9998890161514282
dystrophy I-Disease 1 0.9999774694442749
patients O 1 0.8724155426025391
. O 0 3.6032804928254336e-05

The O 0 2.008699539146619e-06
genetic O 0 1.0455953088239767e-05
basis O 0 1.0777612260426395e-06
of O 0 2.2232565243029967e-05
myotonic B-Disease 1 0.999942421913147
dystrophy I-Disease 1 0.9999829530715942
( O 0 0.0006796693196520209
DM B-Disease 1 0.9999250173568726
) O 0 1.987414037785129e-07
is O 0 2.459868930770881e-08
the O 0 5.552942550224316e-09
expansion O 0 1.1768618435326061e-07
of O 0 4.889773475014181e-09
an O 0 2.305691424453471e-07
unstable O 0 0.0009877023985609412
CTG O 0 8.793143206276e-05
repeat O 0 1.0281656841470976e-06
in O 0 1.0883502987724114e-08
the O 0 8.07771183275463e-09
34 O 0 2.2549444977926214e-08
UTR O 0 8.932639161685074e-07
of O 0 5.182688056493134e-09
the O 0 1.5561445820821973e-07
DM B-Disease 1 0.8915520906448364
protein O 0 6.908681484674162e-07
kinase O 0 2.2241122223931598e-06
gene O 0 4.410094049944746e-07
on O 0 2.661478504251136e-07
chromosome O 0 4.654678559745662e-05
19 O 0 3.845701940008439e-06
. O 0 1.3070080058241729e-06

One O 0 2.2603578031521465e-07
of O 0 1.1985563652672226e-08
the O 0 2.2162362611766184e-08
principal O 0 1.3406004484295408e-07
features O 0 4.3544023498043316e-08
of O 0 2.5339486953157575e-08
the O 0 4.583897407428594e-06
DM B-Disease 1 0.9999290704727173
mutation O 0 3.9873197238193825e-05
is O 0 2.3593782927378015e-08
an O 0 1.2062875143215024e-08
extraordinarily O 0 4.7997473302530125e-06
high O 0 2.8583679068105994e-06
level O 0 1.4419295268908172e-07
of O 0 9.474201867476495e-09
somatic O 0 1.6655665149301058e-06
mosaicism O 0 0.00019878298917319626
, O 0 1.3836728385285824e-07
due O 0 2.3156140116498136e-07
to O 0 2.2710127112191003e-09
an O 0 1.2296593965288594e-08
extremely O 0 7.623954729751858e-07
high O 0 1.2677395488935872e-06
degree O 0 6.968048893440937e-08
of O 0 5.013375048434909e-09
somatic O 0 4.499022736581537e-07
instability O 0 3.0250641884776996e-06
both O 0 5.849569717497616e-09
within O 0 1.2075189737004166e-08
and O 0 6.427167686950952e-09
between O 0 2.6544512365944684e-08
different O 0 5.3050790427278116e-08
tissues O 0 6.945921631995589e-05
. O 0 2.7222040444030426e-06

This O 0 1.9948208773712395e-06
instability O 0 5.524884181795642e-05
appears O 0 1.5428848882947932e-06
to O 0 5.349694021106188e-09
be O 0 5.633389754677864e-09
biased O 0 3.3520418440957656e-08
towards O 0 7.385922096148079e-09
further O 0 5.653377765924006e-09
expansion O 0 2.7036582750383786e-08
and O 0 2.1922459403356243e-09
continuous O 0 2.941288101965256e-08
throughout O 0 2.0502934461319455e-08
the O 0 7.113736710806506e-09
life O 0 1.7894508985705215e-08
of O 0 4.2950160095145407e-10
an O 0 2.5868440722831565e-09
individual O 0 2.1785031556476042e-09
, O 0 7.226258258441476e-09
features O 0 3.6287719495931015e-08
that O 0 1.1389639453796008e-08
could O 0 2.7373495470328635e-08
be O 0 7.1136829760121145e-09
associated O 0 8.750530078316388e-09
with O 0 6.5920189307178134e-09
the O 0 1.0036765729637409e-07
progressive O 0 3.557009404175915e-05
nature O 0 5.054134248894115e-07
of O 0 9.027943548289841e-08
the O 0 2.6244097171002068e-05
disease O 1 0.8874020576477051
. O 0 4.186400474281982e-06

Although O 0 1.5469529444089858e-06
increasing O 0 3.277654059274937e-07
measured O 0 9.196313612847007e-07
allele O 0 3.922389453236974e-07
size O 0 4.4080800876145076e-07
between O 0 2.825778722126415e-07
patients O 0 2.57609281106852e-06
clearly O 0 5.025680138714961e-08
correlates O 0 4.525737651306372e-08
with O 0 5.197398511569418e-09
an O 0 2.0950350787529715e-08
increased O 0 4.884733471044456e-07
severity O 0 1.2352231351542287e-05
of O 0 7.034886806422946e-08
symptoms O 0 0.00015732852625660598
and O 0 1.842961339093563e-08
an O 0 3.312186791504246e-08
earlier O 0 5.770735924670589e-07
age O 0 9.973884829150848e-08
of O 0 7.938808721519308e-09
onset O 0 0.0001508410059614107
, O 0 2.2502785412825688e-08
this O 0 1.1566744229085657e-09
correlation O 0 1.4023773253768468e-08
is O 0 7.528982770566017e-09
not O 0 3.3378877439815824e-10
precise O 0 4.200176206836659e-09
and O 0 2.9698616899054286e-09
measured O 0 1.1667328436715252e-07
allele O 0 5.455855145442001e-08
length O 0 1.8488027819785202e-07
cannot O 0 1.6666447777424764e-08
be O 0 1.1970546776041147e-09
used O 0 7.027959880723245e-10
as O 0 1.5509870054941644e-09
an O 0 1.5581804735376181e-09
accurate O 0 3.630447409364024e-08
predictor O 0 7.97102927663218e-07
of O 0 9.462499228618526e-09
age O 0 5.43574458333751e-07
of O 0 1.8293697223725758e-07
onset O 0 0.027362367138266563
. O 0 6.850435966043733e-06

In O 0 9.458115073357476e-07
order O 0 3.3049044390054405e-08
to O 0 3.8001490842987096e-09
further O 0 9.704390180331757e-09
characterize O 0 1.9247765692398389e-07
the O 0 7.599479090458772e-08
dynamics O 0 1.5292296666302718e-05
of O 0 1.1185886705789017e-06
DM B-Disease 1 0.9994381070137024
CTG O 0 0.0009223273955285549
repeat O 0 1.2594808140420355e-05
somatic O 0 4.252382950653555e-06
instability O 0 4.0686194552108645e-05
, O 0 9.286935664931661e-08
we O 0 1.230344448543974e-08
have O 0 5.007058323514002e-09
studied O 0 7.480446839736032e-08
repeat O 0 1.291571294359528e-07
length O 0 6.165711852190725e-08
changes O 0 1.0001561356887123e-08
over O 0 5.3593964821629925e-09
time O 0 2.2211875005950787e-08
in O 0 2.757820141141565e-07
111 O 0 0.0001741511805448681
myotonic B-Disease 1 0.999901294708252
dystrophy I-Disease 1 0.9999786615371704
patients O 0 0.00038079076330177486
with O 0 2.3532464865638758e-07
varying O 0 2.024454033744405e-06
clinical O 0 0.0006254811305552721
severity O 0 0.0011246796930208802
and O 0 5.71464454424131e-07
CTG O 0 0.00019051085109822452
repeat O 0 1.9018367538592429e-06
size O 0 8.70131913188743e-08
over O 0 4.228760897007078e-09
time O 0 2.8483089220543434e-09
intervals O 0 2.1493285373708204e-08
of O 0 3.241981794133153e-09
1 O 0 1.6875043229447328e-07
- O 0 6.034317721059779e-06
7 O 0 7.285910328391765e-07
years O 0 5.8444197748031e-07
. O 0 3.98799755885193e-07

We O 0 9.636495406084578e-07
have O 0 3.816858296090686e-08
found O 0 8.630785863772417e-09
a O 0 8.694629904937301e-09
direct O 0 4.862263036642389e-09
progression O 0 1.058779844242963e-06
of O 0 2.2365418406167237e-09
the O 0 8.069966028756426e-09
size O 0 6.388438578142086e-08
heterogeneity O 0 1.094995027983714e-07
over O 0 2.0736941053201008e-08
time O 0 3.227078337886269e-08
related O 0 1.4468713338544603e-08
to O 0 6.334164304178103e-09
initial O 0 2.770135267837759e-07
CTG O 0 1.0242734788334928e-05
repeat O 0 2.855314278349397e-07
size O 0 1.0350193235808547e-07
and O 0 4.4179131464261445e-09
the O 0 2.632336348895592e-09
time O 0 5.682632142622879e-09
interval O 0 7.237103005763856e-08
and O 0 3.968539274978866e-09
always O 0 1.2927094061865319e-08
biased O 0 2.598535964182247e-08
towards O 0 1.8095709819476724e-08
further O 0 8.683728935920954e-08
expansion O 0 5.999625500408001e-06
. O 0 1.3416689625955769e-06

Attempts O 0 2.184714276154409e-06
to O 0 6.899924898107201e-08
mathematically O 0 1.5197355196505669e-06
model O 0 4.175393257810356e-07
the O 0 9.939891043586613e-08
dynamics O 0 1.156237703980878e-05
have O 0 2.5987242580072234e-08
proved O 0 8.384798775296076e-07
only O 0 8.94339535761901e-09
partially O 0 3.593525661926833e-06
successful O 0 4.0928696876108006e-07
suggesting O 0 9.080217466816976e-08
that O 0 1.6558802107269344e-09
individual O 0 8.367969095424144e-10
specific O 0 2.0042190129743176e-09
genetic O 0 2.822199860474939e-07
and O 0 1.3276319066335418e-07
/ O 0 1.276969396712957e-05
or O 0 3.8342761854437413e-07
environmental O 0 1.328944563283585e-06
factors O 0 1.938219185149137e-08
also O 0 1.596252552360511e-08
play O 0 8.550091301628981e-09
a O 0 5.517009071809298e-08
role O 0 1.6529722302038863e-07
in O 0 1.0661322846772237e-07
somatic O 0 7.467412160622189e-06
mosaicism O 0 0.0007899190532043576
. O 0 5.75936610403005e-07
. O 0 9.817865702643758e-07

Aspartylglucosaminuria B-Disease 1 0.9023071527481079
among O 0 5.475627858686494e-06
Palestinian O 0 3.720784661709331e-05
Arabs O 0 4.117496428079903e-05
. O 0 2.1841558918822557e-05

Aspartylglucosaminuria B-Disease 1 0.9979767203330994
( O 0 0.0003235240583308041
AGU B-Disease 1 0.9981398582458496
) O 0 1.6492073200424784e-06
is O 0 3.4846885910155834e-07
a O 0 1.6858938352015684e-06
rare O 0 3.26531553582754e-05
disorder B-Disease 1 0.6314393877983093
of I-Disease 0 7.055028277136444e-07
glycoprotein I-Disease 0 0.009506704285740852
metabolism I-Disease 0 0.020668599754571915
caused O 0 9.468049393035471e-05
by O 0 2.4878406179595913e-07
the O 0 1.785153835953679e-05
deficiency B-Disease 1 0.5516253709793091
of I-Disease 0 4.983936108260423e-08
the I-Disease 0 8.100934110188973e-07
lysosomal I-Disease 0 0.014104134403169155
enzyme I-Disease 0 6.305583519861102e-05
aspartylglucosaminidase I-Disease 0 0.0009216935141012073
( O 0 5.726199105993146e-07
AGA O 0 0.00023941186373122036
) O 0 8.54730444643792e-07
. O 0 1.6281662738037994e-06

AGU B-Disease 1 0.998706579208374
is O 0 0.0003364523872733116
inherited O 0 0.07225818186998367
as O 0 2.426997980364831e-06
an O 0 7.2154471126850694e-06
autosomal O 1 0.9591660499572754
recessive O 1 0.8817474842071533
trait O 0 0.006612767465412617
and O 0 1.6726625062801759e-06
occurs O 0 2.409725254892692e-07
with O 0 1.372438429569911e-08
a O 0 9.240483933581345e-08
high O 0 7.993417625584698e-07
frequency O 0 2.0369050446333858e-07
in O 0 5.4514028846597284e-08
Finland O 0 2.886825768655399e-06
because O 0 3.907730317109781e-08
of O 0 7.810766256000079e-09
a O 0 1.6277471104331198e-06
founder O 0 1.6679041436873376e-05
effect O 0 5.838431206939276e-06
. O 0 1.1981458101217868e-06

While O 0 9.525749192107469e-06
very O 0 2.1252521946735214e-06
few O 0 1.4993081549619092e-06
patients O 0 1.06393645182834e-05
with O 0 1.3318831406650133e-06
AGU B-Disease 1 0.9990955591201782
have O 0 2.1004150596581894e-07
been O 0 2.5485289256721444e-07
reported O 0 2.469330127041758e-07
from O 0 5.145515569182635e-09
non O 0 1.1226781282402953e-07
- O 0 1.2850566236011218e-05
Finnish O 0 9.718740329844877e-06
origin O 0 1.3404720888843258e-08
, O 0 7.119508893538296e-08
we O 0 7.585213097627275e-07
diagnosed O 1 0.7907499074935913
the O 0 2.0506356577243423e-06
disorder O 1 0.6824343204498291
in O 0 1.0797612048918381e-06
8 O 0 2.640626007632818e-06
patients O 0 2.116162249876652e-07
originating O 0 3.03042071436721e-08
from O 0 4.28550350761725e-08
3 O 0 7.547318148226623e-08
unrelated O 0 1.1156318180383096e-07
families O 0 2.947593280566707e-09
, O 0 1.1157413881690559e-09
all O 0 1.4019532756925912e-10
Palestinian O 0 3.7939802410846823e-08
Arabs O 0 1.880407474175172e-08
from O 0 1.2842846786043083e-08
the O 0 2.4350532257244595e-08
region O 0 3.5850086987920804e-07
of O 0 2.6870836222769867e-08
Jerusalem O 0 0.0001561969838803634
. O 0 7.267615274031414e-06

The O 0 2.2089954654802568e-05
clinical O 0 0.0023332834243774414
diagnosis O 1 0.7273244261741638
of O 0 4.568999065668322e-05
AGU B-Disease 1 0.9999316930770874
is O 0 2.7781625249190256e-05
often O 0 1.9643593418550154e-07
difficult O 0 7.563716053482494e-07
, O 0 2.882456939801159e-08
in O 0 7.3057933036579925e-09
particular O 0 2.3632054091393684e-09
early O 0 8.970236820005084e-08
in O 0 6.1440386112110446e-09
the O 0 1.644982816628726e-08
course O 0 2.931163294306316e-07
of O 0 8.988610744609105e-09
the O 0 2.7212774966756115e-06
disease O 0 0.0014888329897075891
, O 0 1.5424678423414662e-08
and O 0 3.4362470646698284e-09
most O 0 1.3417453814668079e-09
of O 0 2.8985596145503223e-09
the O 0 4.712179872967681e-07
patients O 0 4.188317234365968e-06
are O 0 4.943698428405696e-08
diagnosed O 0 0.1427004337310791
after O 0 4.20627543462615e-07
the O 0 2.0761241614764003e-08
age O 0 5.4539615490512006e-08
of O 0 5.887492271483552e-09
5 O 0 4.428249837928888e-07
years O 0 8.370896580345288e-07
. O 0 7.821322469681036e-07

However O 0 4.5672986743738875e-06
, O 0 4.6198880454539903e-07
since O 0 9.86803001978842e-07
these O 0 1.384981995755652e-08
patients O 0 3.760085576232086e-07
excrete O 0 2.7417084424996574e-07
early O 0 4.08800815421273e-08
large O 0 2.0150677570995867e-08
amounts O 0 2.170888713237673e-08
of O 0 5.764726918044971e-09
aspartylglucosamine O 0 6.738738647982245e-06
in O 0 6.070075642128359e-08
urine O 0 3.402057586754381e-07
, O 0 9.916613308291744e-09
biochemical O 0 4.715591899184801e-07
screening O 0 4.461363971586252e-07
is O 0 1.9134690276700894e-08
easy O 0 4.052266788789893e-08
by O 0 4.472533632338127e-08
urine O 0 3.0669311854580883e-06
chromatography O 0 0.00021056097466498613
. O 0 2.2084641670971905e-07
. O 0 8.621705092082266e-07

Detection O 0 5.389737634686753e-05
of O 0 3.117173150712915e-07
heterozygous O 0 3.389758376215468e-06
carriers O 0 2.813403625623323e-06
of O 0 8.736842005419021e-08
the O 0 4.2233961721649393e-05
ataxia B-Disease 1 0.9999593496322632
- I-Disease 1 0.9994351267814636
telangiectasia I-Disease 1 0.9995039701461792
( O 0 9.388799071530229e-07
ATM O 0 4.213656939100474e-05
) O 0 4.141137921465088e-08
gene O 0 1.2578531993767683e-07
by O 0 3.481824251139187e-08
G2 O 0 5.6874167057685554e-05
phase O 0 5.26714666193584e-06
chromosomal O 0 0.00010699851554818451
radiosensitivity O 0 5.0033188017550856e-05
of O 0 2.698975549719762e-07
peripheral O 0 0.04834822565317154
blood O 0 0.23257428407669067
lymphocytes O 0 0.016871998086571693
. O 0 6.083803782530595e-06

In O 0 0.0018090670928359032
ataxia B-Disease 1 0.9997667670249939
- I-Disease 1 0.9986562728881836
telangiectasia I-Disease 1 0.9997047781944275
( O 0 0.00032831027056090534
A B-Disease 1 0.9998382329940796
- I-Disease 1 0.999679446220398
T I-Disease 1 0.99981290102005
) O 0 3.6404611591933644e-07
patients O 0 1.137565618591907e-06
, O 0 2.2244520891945285e-08
mutations O 0 1.2214270839194796e-07
in O 0 8.84755024799233e-09
a O 0 3.0183354482460345e-08
single O 0 2.6931381569283985e-08
gene O 0 5.1217540431025554e-08
, O 0 4.300535039192255e-09
ATM O 0 2.083208300973638e-06
, O 0 5.7828788868619085e-08
result O 0 1.4749348054010625e-07
in O 0 5.100541216052079e-07
an O 0 0.0010817646980285645
autosomal B-Disease 1 0.9999912977218628
recessive I-Disease 1 0.9999923706054688
syndrome I-Disease 1 0.9999995231628418
that O 0 1.4386812381417258e-06
embraces O 0 7.255982836795738e-07
a O 0 2.249618233918227e-07
variety O 0 3.559230421501525e-08
of O 0 3.0241672277497855e-08
clinical O 0 7.835231372155249e-06
features O 0 3.627465048339218e-07
and O 0 2.071400189151973e-07
manifests O 0 1.8805009176503518e-06
extreme O 0 7.058392839098815e-06
radiosensitivity O 0 2.776925430225674e-05
and O 0 7.218271491638006e-08
a O 0 5.264025730866706e-07
strong O 0 6.209911589394324e-07
pre O 0 0.00022191621246747673
- O 0 0.0002217546134488657
disposition O 0 3.510226815706119e-05
to O 0 1.2681325642915908e-06
malignancy B-Disease 1 0.6575794219970703
. O 0 6.563562692463165e-06

Heterozygotes O 0 2.2170150259626098e-05
for O 0 3.9921825845112835e-08
the O 0 5.145459169852984e-08
ATM O 0 9.912654604704585e-06
gene O 0 6.330145083666139e-07
have O 0 2.6332317659694127e-08
no O 0 3.2501873192813946e-08
clinical O 0 2.1317265463949298e-07
expression O 0 7.970810855795207e-08
of O 0 8.794556549673871e-08
A B-Disease 1 0.9979478716850281
- I-Disease 1 0.9980112314224243
T I-Disease 1 0.9998519420623779
but O 0 1.973615781025728e-06
may O 0 8.654032171762083e-06
be O 0 9.372398380946834e-06
cancer B-Disease 1 0.7765369415283203
prone O 0 1.4862597708997782e-05
with O 0 1.268898675022001e-08
a O 0 3.489607252049609e-07
moderate O 0 3.674549816423678e-06
increase O 0 8.37040303736103e-08
in O 0 4.253305618817649e-08
in O 0 1.1766665863888193e-07
vitro O 0 1.6603660697001033e-05
radiosensitivity O 0 0.00036672691931016743
. O 0 2.6125062504434027e-06

We O 0 1.919619762702496e-06
performed O 0 5.169441010366427e-06
a O 0 1.0847297744476236e-06
blind O 0 3.6411381643119967e-06
chromosomal O 0 4.00246208300814e-05
analysis O 0 2.8681881758529926e-07
on O 0 1.0164469586015912e-06
G2 O 0 0.0004156831419095397
- O 0 2.607654641906265e-05
phase O 0 5.065487584943185e-06
lymphocytes O 0 5.111387963552261e-06
from O 0 4.815969134597253e-08
7 O 0 7.139129820643575e-07
unrelated O 0 1.0351282071496826e-05
A B-Disease 1 0.9978011250495911
- I-Disease 1 0.9995538592338562
T I-Disease 1 0.9998971223831177
patients O 0 4.122391328564845e-05
, O 0 3.475394905194662e-08
13 O 0 1.431540823659816e-07
obligate O 0 1.0522709317228873e-06
A B-Disease 1 0.9956606030464172
- I-Disease 1 0.992683470249176
T I-Disease 1 0.9973872303962708
heterozygotes O 0 2.579143483671942e-06
( O 0 9.295562541922209e-09
parents O 0 5.782919920704899e-09
of O 0 2.643102847699197e-09
the O 0 8.679538865408176e-08
patients O 0 6.436272883547645e-07
) O 0 2.253494280068935e-09
, O 0 2.490820438794117e-09
and O 0 3.332024656188537e-09
14 O 0 2.6113946560712975e-08
normal O 0 5.725631524455821e-08
controls O 0 7.728316120392265e-08
following O 0 4.7900435617975745e-08
X O 0 1.6610140392003814e-06
- O 0 1.9537417017545522e-07
irradiation O 0 3.8726046369674805e-08
with O 0 3.9660652539907915e-09
1 O 0 3.618121979798161e-08
Gy O 0 1.1111769708804786e-06
in O 0 8.686656727263653e-09
order O 0 1.6967462990180593e-09
to O 0 5.574737338420732e-10
evaluate O 0 1.3365303530576966e-08
this O 0 1.4310891360835853e-09
cytogenetic O 0 6.864011083962396e-07
method O 0 6.10516215360235e-09
as O 0 3.360932421259122e-09
a O 0 5.637398992064391e-09
tool O 0 1.6125078161621786e-08
for O 0 2.839424029232873e-09
detection O 0 2.0174218207102967e-07
of O 0 2.3373008417593155e-08
ATM O 0 9.344307181891054e-05
carriers O 0 3.6059649573871866e-05
. O 0 2.3149107164499583e-06

Both O 0 2.6421235816087574e-05
A B-Disease 1 0.9969698786735535
- I-Disease 1 0.9976590871810913
T I-Disease 1 0.9975097179412842
homozygotes O 0 6.125258369138464e-05
and O 0 6.887959358437001e-08
heterozygotes O 0 2.1763753466075286e-06
showed O 0 7.341290029216907e-07
significantly O 0 3.197309013103222e-07
increased O 0 9.184991967003953e-08
levels O 0 2.656336164363893e-07
of O 0 5.980916739645181e-08
radiation O 0 0.18838560581207275
- O 0 0.0029012232553213835
induced O 0 0.0008149593486450613
chromatid O 0 0.03267320990562439
damage O 0 0.0001070578073267825
relative O 0 1.2683354100317956e-07
to O 0 3.0472568912642828e-09
that O 0 2.2783364084233426e-09
of O 0 8.789119654295519e-09
normal O 0 1.8273713067173958e-06
controls O 0 1.2746771062666085e-05
. O 0 1.712371044959582e-06

These O 0 1.8608416496590507e-07
results O 0 1.138023435487412e-06
show O 0 3.1161150104708213e-07
that O 0 1.3352461358806522e-08
the O 0 5.1939725409511084e-08
G2 O 0 9.631838474888355e-05
- O 0 1.283209985558642e-05
phase O 0 3.473842525636428e-06
chromosomal O 0 0.00011660881864372641
radiosensitivity O 0 2.5572313461452723e-05
assay O 0 1.4407737580768298e-06
can O 0 3.0633582337458165e-09
be O 0 6.502689497978054e-10
used O 0 6.258527585067952e-10
for O 0 4.001082243298981e-10
the O 0 2.900334861166698e-09
detection O 0 4.017240939901967e-07
of O 0 8.242282945047918e-08
A B-Disease 1 0.9992489218711853
- I-Disease 1 0.998694121837616
T I-Disease 1 0.9989818930625916
heterozygotes O 0 0.0001589769235579297
. O 0 2.336210400244454e-06

In O 0 9.59011458689929e-07
combination O 0 9.128515898737533e-07
with O 0 1.1371518837677286e-07
molecular O 0 9.425587450095918e-06
genetic O 0 2.246403255412588e-06
analyses O 0 3.272157300671097e-07
, O 0 1.269840499418251e-08
this O 0 4.011935672565414e-09
test O 0 5.074941356042473e-08
may O 0 1.2547018535258303e-08
be O 0 2.4394483655321153e-10
of O 0 1.184659315089931e-10
value O 0 6.389638818049548e-10
in O 0 2.728148595920743e-09
studies O 0 3.301941609024084e-09
of O 0 1.5766320471399808e-09
familial B-Disease 0 1.1689568964357022e-05
and I-Disease 0 4.2467152638892003e-07
sporadic I-Disease 0 0.00028913249843753874
cancers I-Disease 0 0.2809733748435974
aimed O 0 1.159127350547351e-06
at O 0 1.3117870594214764e-06
determination O 0 9.668348610603061e-08
of O 0 2.4102841944539932e-09
the O 0 1.2100506374679298e-08
potential O 0 1.7430975773891078e-08
involvement O 0 3.972487050418749e-08
of O 0 1.0188422550072573e-08
ATM O 0 0.0002098318509524688
mutations O 0 0.0001526106643723324
in O 0 4.5142893213778734e-05
tumor B-Disease 1 0.9990378618240356
risk O 0 0.00017034033953677863
or O 0 2.3729295151042606e-07
development O 0 4.715978718650149e-07
. O 0 3.085249602463591e-07
. O 0 1.2040528645229642e-06

Ataxia B-Disease 1 0.9997764229774475
- I-Disease 1 0.9985024929046631
telangiectasia I-Disease 1 0.9992509484291077
: O 0 7.898950684648298e-07
identification O 0 4.093728307452693e-07
and O 0 6.562214593941462e-08
detection O 0 1.2196293255328783e-06
of O 0 3.618708532826531e-08
founder O 0 9.548523848934565e-06
- O 0 3.1558560294797644e-05
effect O 0 3.643110915163561e-07
mutations O 0 1.4119366653631005e-07
in O 0 2.8831041998245155e-09
the O 0 2.991499714610768e-09
ATM O 0 1.0787371138576418e-06
gene O 0 1.7883870384594047e-07
in O 0 5.2553176033143245e-08
ethnic O 0 1.377252374368254e-07
populations O 0 1.5802778534634854e-06
. O 0 2.4868256787158316e-06

To O 0 8.678413365714732e-08
facilitate O 0 1.1814724842906799e-07
the O 0 9.588408289573636e-08
evaluation O 0 1.3257012199119345e-07
of O 0 7.408285096488498e-09
ATM O 0 8.168650310835801e-06
heterozygotes O 0 4.316440481488826e-06
for O 0 4.833960787209435e-08
susceptibility O 0 5.652874733641511e-06
to O 0 1.4056711350463047e-08
other O 0 1.6364965915727225e-07
diseases O 0 0.10723260790109634
, O 0 5.032068273180812e-08
such O 0 2.6161504962374238e-08
as O 0 0.0013920206110924482
breast B-Disease 1 0.9998998641967773
cancer I-Disease 1 0.9991998076438904
, O 0 8.640969895168382e-08
we O 0 6.680341613218843e-09
have O 0 6.753181902574568e-10
attempted O 0 8.026522557713633e-09
to O 0 4.6041809254049326e-10
define O 0 7.756074893450204e-09
the O 0 7.166085946863632e-09
most O 0 3.734075715300378e-09
common O 0 1.860947662635226e-08
mutations O 0 4.371961637161803e-08
and O 0 1.144258909846485e-09
their O 0 2.5666153646852763e-09
frequencies O 0 4.667619464271411e-07
in O 0 7.329968411795562e-06
ataxia B-Disease 1 0.9999428987503052
- I-Disease 1 0.9990346431732178
telangiectasia I-Disease 1 0.9998705387115479
( O 0 6.661823863396421e-05
A B-Disease 1 0.9998237490653992
- I-Disease 1 0.9989874958992004
T I-Disease 1 0.9993133544921875
) O 0 1.0297342356579975e-07
homozygotes O 0 2.0833138023590436e-06
from O 0 2.3168526652739274e-08
10 O 0 2.5872797237980194e-08
ethnic O 0 7.530967849334047e-08
populations O 0 1.554911818857363e-06
. O 0 1.5159690747168497e-06

Both O 0 9.142481758317444e-07
genomic O 0 1.2684031389653683e-05
mutations O 0 2.096855314448476e-05
and O 0 3.661644143448939e-08
their O 0 8.857597322275979e-09
effects O 0 2.6937399866255873e-07
on O 0 7.417973080237061e-08
cDNA O 0 4.528060344455298e-07
were O 0 2.5624302679716493e-07
characterized O 0 3.088387893512845e-05
. O 0 1.687217604739999e-06

Protein O 0 2.288056566612795e-05
- O 0 1.062548290065024e-05
truncation O 0 1.9950225578213576e-06
testing O 0 3.1512234954789164e-07
of O 0 1.975014152222343e-09
the O 0 2.7554991621769886e-09
entire O 0 3.979281970600823e-08
ATM O 0 1.074402462108992e-06
cDNA O 0 6.224818207556382e-07
detected O 0 2.6464015263627516e-06
92 O 0 2.1433665153836046e-07
( O 0 1.4595159747443631e-08
66 O 0 1.8481186714325304e-07
% O 0 5.526801238886492e-09
) O 0 9.490587871141543e-09
truncating O 0 8.435134759565699e-07
mutations O 0 9.025289386954682e-07
in O 0 2.4352992511467164e-08
140 O 0 1.2118408676542458e-07
mutant O 0 2.7950100047746673e-06
alleles O 0 3.7063375657453435e-06
screened O 0 2.0875118934782222e-05
. O 0 2.392205260548508e-06

The O 0 1.5166486946327495e-06
haplotyping O 0 9.562960622133687e-05
of O 0 1.796208692894652e-07
patients O 0 1.994322474274668e-06
with O 0 8.288031239089833e-08
identical O 0 1.581658398208674e-05
mutations O 0 1.706623334030155e-05
indicates O 0 8.6149846367789e-08
that O 0 5.080040277327669e-10
almost O 0 1.89416460294467e-09
all O 0 1.7716536571121821e-10
of O 0 3.603387310757711e-10
these O 0 2.1289059404239197e-10
represent O 0 1.927225268261168e-09
common O 0 2.1643273839799804e-08
ancestry O 0 2.9530083267559348e-08
and O 0 2.047104885605222e-08
that O 0 3.037878615330669e-09
very O 0 1.7298560806011665e-08
few O 0 4.177535473104399e-08
spontaneously O 0 6.468503670475911e-07
recurring O 0 2.4885006496333517e-05
ATM O 0 0.0008358354098163545
mutations O 0 0.00010043472138931975
exist O 0 1.7132989569290658e-06
. O 0 2.1039265902800253e-06

Assays O 0 3.635046959971078e-05
requiring O 0 3.129485548925004e-06
minimal O 0 3.07201321447792e-06
amounts O 0 1.4334726472498005e-07
of O 0 1.006667105230008e-08
genomic O 0 7.635889005541685e-07
DNA O 0 7.809791782165121e-07
were O 0 8.76740369193385e-09
designed O 0 2.1319598531022166e-08
to O 0 6.233200067207179e-10
allow O 0 2.6304693978573823e-09
rapid O 0 4.619491562607436e-07
screening O 0 1.885349689700888e-07
for O 0 4.713899048880421e-09
common O 0 1.2910798830034764e-07
ethnic O 0 1.031083002089872e-06
mutations O 0 0.00012175242591183633
. O 0 2.234651219623629e-06

These O 0 2.1804171979056264e-07
rapid O 0 1.11552271846449e-05
assays O 0 1.7633321476751007e-05
detected O 0 4.348866059444845e-05
mutations O 0 2.498337835277198e-06
in O 0 4.52326105460088e-08
76 O 0 3.592397774809797e-07
% O 0 6.99255764402551e-09
of O 0 1.282123562873494e-08
Costa O 0 2.209703416156117e-05
Rican O 0 6.366476736729965e-05
patients O 0 2.975334609800484e-06
( O 0 8.93664253709403e-09
3 O 0 2.048894032213866e-08
) O 0 1.4655965330234721e-09
, O 0 1.6014909398620603e-09
50 O 0 3.2842790709253222e-09
% O 0 1.3221458372569828e-09
of O 0 3.064380971196101e-09
Norwegian O 0 1.8506654669181444e-05
patients O 0 6.001050678605679e-07
( O 0 3.135818271715607e-09
1 O 0 2.012970412579307e-08
) O 0 1.9601527068147107e-09
, O 0 2.9924698274896855e-09
25 O 0 3.840561202395065e-09
% O 0 1.1821498224762195e-09
of O 0 5.412413628391732e-09
Polish O 0 0.00310516101308167
patients O 0 1.023625100060599e-05
( O 0 9.534023348578557e-09
4 O 0 4.5101060663910175e-08
) O 0 2.5876976117444883e-09
, O 0 2.05060923796907e-09
and O 0 3.877347776182205e-09
14 O 0 3.504844769963711e-08
% O 0 2.74478795248001e-09
of O 0 6.5595719966893284e-09
Italian O 0 3.579030453693122e-05
patients O 0 3.0130063350952696e-06
( O 0 9.256356570119806e-09
1 O 0 3.8754418341113706e-08
) O 0 1.7445269673288522e-09
, O 0 1.910754665601644e-09
as O 0 3.560443717631756e-09
well O 0 2.102944929305295e-09
as O 0 1.1537510502535042e-08
in O 0 4.521785612610074e-08
patients O 0 8.683066710091225e-08
of O 0 4.293994493309583e-09
Amish O 0 7.759967957099434e-07
/ O 0 3.660227775981184e-06
Mennonite O 0 3.317236860311823e-06
and O 0 1.8000343970925314e-07
Irish O 0 1.4413754797715228e-05
English O 0 1.718181465548696e-06
backgrounds O 0 4.642820840672357e-06
. O 0 6.2009917201066855e-06

Additional O 0 9.042347528520622e-07
mutations O 0 8.984002306533512e-06
were O 0 8.752320468374819e-08
observed O 0 1.3500239504082856e-07
in O 0 1.488376177860573e-08
Japanese O 0 3.4281060834473465e-07
, O 0 1.279614547655683e-08
Utah O 0 1.3816001853683701e-07
Mormon O 0 1.671423177640463e-08
, O 0 4.372359807547355e-09
and O 0 4.164129041583919e-09
African O 0 3.912996149324499e-08
American O 0 1.3375538401305676e-06
patients O 0 3.858920172206126e-05
. O 0 3.199061438863282e-06

These O 0 1.7648972061579116e-07
assays O 0 1.0186420240643201e-06
should O 0 1.2434710150444062e-08
facilitate O 0 1.8105513532873374e-08
screening O 0 3.7348826253946754e-07
for O 0 1.4144541182758985e-07
A B-Disease 1 0.9946554899215698
- I-Disease 1 0.9815633296966553
T I-Disease 1 0.9977269768714905
heterozygotes O 0 2.1584298792731715e-06
in O 0 3.7191931312463566e-08
the O 0 1.8585568639650774e-08
populations O 0 9.195596817335172e-08
studied O 0 7.02986937994865e-07
. O 0 5.2049607290882705e-08
. O 0 5.661970021719753e-07

The O 0 5.129241617396474e-05
von B-Disease 1 0.8697928190231323
Hippel I-Disease 1 0.9854493737220764
- I-Disease 1 0.9777209162712097
Lindau I-Disease 1 0.9946839213371277
tumor I-Disease 1 0.9337262511253357
suppressor O 0 5.640539529849775e-05
gene O 0 9.422553262083966e-07
is O 0 1.830657225809773e-08
required O 0 6.684573339299504e-09
for O 0 6.1351621560845615e-09
cell O 0 1.9777156921918504e-05
cycle O 0 3.304209940324654e-06
exit O 0 4.1644357224868145e-06
upon O 0 1.4992165233707055e-06
serum O 0 0.00023832390434108675
withdrawal O 0 0.00011205519695067778
. O 0 3.1164111078396672e-06

The O 0 3.900983301718952e-06
inactivation O 0 0.001520638121291995
of O 0 2.607552858080453e-07
the O 0 4.885534053755691e-06
von B-Disease 1 0.9908415079116821
Hippel I-Disease 1 0.9932936429977417
- I-Disease 1 0.9006884694099426
Lindau I-Disease 1 0.9372584819793701
( I-Disease 0 6.321021373878466e-06
VHL I-Disease 0 0.023101743310689926
) I-Disease 0 3.2624277537252055e-06
tumor I-Disease 0 0.09865621477365494
suppressor O 0 0.00010805160854943097
gene O 0 4.190250820101937e-06
predisposes O 0 9.019214303407352e-06
affected O 0 1.906017104147395e-07
individuals O 0 3.551700933357438e-09
to O 0 5.949761572310308e-09
the O 0 1.167718437500298e-06
human O 0 0.002105433726683259
VHL B-Disease 1 0.9999101161956787
cancer I-Disease 1 0.9999912977218628
syndrome I-Disease 1 0.9999743700027466
and O 0 4.842533599003218e-06
is O 0 5.933891884524201e-07
associated O 0 3.5164165979040263e-07
with O 0 5.842408086209616e-07
sporadic B-Disease 0 0.06879767775535583
renal I-Disease 1 0.9999659061431885
cell I-Disease 1 0.9998593330383301
carcinomas I-Disease 1 0.9999886751174927
( O 0 7.092620944604278e-05
RCC B-Disease 1 0.99800044298172
) O 0 1.326733581663575e-06
and O 0 6.610557647945825e-06
brain B-Disease 1 0.9460905194282532
hemangioblastomas I-Disease 0 0.13264819979667664
. O 0 1.2353903912298847e-05

VHL O 0 0.0546717569231987
- O 0 0.00026890606386587024
negative O 0 4.931681360176299e-06
786 O 0 2.4506758563802578e-05
- O 0 0.00016127967683132738
0 O 0 3.5011883028346347e-06
RCC B-Disease 0 0.009428777731955051
cells O 0 1.5546388567599934e-06
are O 0 1.708340136019615e-08
tumorigenic O 0 1.0530527106311638e-05
in O 0 3.427458636906522e-07
nude O 0 9.650058200350031e-05
mice O 0 2.5063274733838625e-05
which O 0 4.943132836388031e-08
is O 0 2.989870040437381e-08
suppressed O 0 1.376255767127077e-07
by O 0 5.283657955601484e-09
the O 0 2.276942900891754e-08
reintroduction O 0 2.330687038920587e-06
of O 0 2.947657833374251e-07
VHL B-Disease 0 0.00787159614264965
. O 0 4.112951955903554e-06

Remarkably O 0 0.0013442557537928224
, O 0 8.506239623784495e-07
this O 0 4.6062236691568614e-08
occurs O 0 6.876722125070955e-08
without O 0 1.3299694678892138e-08
affecting O 0 3.641405044163548e-08
the O 0 1.5358860849801204e-08
growth O 0 9.804638523291942e-08
rate O 0 7.938312762689748e-08
and O 0 2.80482392867043e-09
cell O 0 1.405313923896756e-06
cycle O 0 1.5405898068365786e-07
profile O 0 3.903811673922064e-08
of O 0 1.201320487531632e-09
these O 0 2.5648680956891212e-09
cells O 0 1.6295940952204546e-07
in O 0 3.853991614732877e-08
culture O 0 1.0982093954226002e-06
. O 0 1.4085610473557608e-06

The O 0 1.5731716302980203e-06
786 O 0 2.5563100280123763e-05
- O 0 1.820912439143285e-05
0 O 0 3.626641671417019e-07
cell O 0 4.323658686189447e-06
line O 0 1.6485467995153158e-06
, O 0 1.187617382214512e-08
like O 0 2.7726080986667512e-08
many O 0 3.545225624179693e-08
cancer B-Disease 0 0.32663285732269287
cells O 0 1.4470903124674805e-06
, O 0 1.0957906582120813e-08
fails O 0 3.320694830222237e-08
to O 0 4.929908148376683e-10
exit O 0 9.881424034574593e-08
the O 0 3.765719469583928e-08
cell O 0 6.516652774735121e-06
cycle O 0 1.8491055016056634e-06
upon O 0 4.4411831368051935e-07
serum O 0 4.702860314864665e-05
withdrawal O 0 5.247487570159137e-05
. O 0 1.919118176374468e-06

Here O 0 2.002403107326245e-06
, O 0 1.1288190648883756e-07
it O 0 1.6513077127910947e-08
is O 0 1.2483472922042438e-08
shown O 0 6.674788721738878e-09
that O 0 6.319849088498586e-10
reintroduction O 0 2.8488210901400635e-08
of O 0 1.3956095168410343e-09
the O 0 2.6301696820496545e-08
wild O 0 6.776348300263635e-07
- O 0 9.730710735311732e-05
type O 0 1.5104366866580676e-05
VHL B-Disease 0 0.00017958891112357378
gene O 0 1.4715994893776951e-06
restores O 0 1.2133111795264995e-06
the O 0 2.6321417934127567e-08
ability O 0 1.3985020075324428e-07
of O 0 1.6218436371673306e-07
VHL O 0 0.006231400649994612
- O 0 0.006781122647225857
negative O 0 5.511833660420962e-05
RCC B-Disease 1 0.9992548823356628
cancer I-Disease 1 0.9650561809539795
cells O 0 6.669222898381122e-07
to O 0 6.5421916772834265e-09
exit O 0 4.1167490394400374e-07
the O 0 1.0953041140737696e-07
cell O 0 5.035918093199143e-06
cycle O 0 7.137373927434965e-07
and O 0 1.5309781886685414e-08
enter O 0 4.676753633248154e-07
G0 O 0 7.028409163467586e-05
/ O 0 5.2474374570010696e-06
quiescence O 0 4.5643566409125924e-05
in O 0 2.9389773317234358e-06
low O 0 0.00016438627790194005
serum O 0 0.0003282942925579846
. O 0 1.4636608511864324e-06

Both O 0 5.99589020566782e-06
VHL O 0 0.015856044366955757
- O 0 0.00021034186647739261
positive O 0 2.62853063759394e-07
and O 0 3.639648582520749e-07
VHL O 0 0.005153595935553312
- O 0 0.0005156046827323735
negative O 0 1.2048891449012444e-06
RCC B-Disease 0 0.006803386379033327
cells O 0 6.982576792324835e-07
exit O 0 3.222189377538598e-07
the O 0 5.957645399234934e-08
cell O 0 1.531564885226544e-05
cycle O 0 1.306488456975785e-06
by O 0 3.2601896293726895e-08
contact O 0 1.4213018175723846e-06
inhibition O 0 1.5593783246004023e-05
. O 0 2.019170779021806e-06

The O 0 2.8733863928209757e-06
cyclin O 0 0.0007142958347685635
- O 0 4.680784695665352e-05
dependent O 0 2.261165036543389e-06
kinase O 0 2.5003066184581257e-05
inhibitor O 0 6.901286724314559e-06
, O 0 3.0265098871495866e-08
p27 O 0 1.9540191260603024e-06
, O 0 2.108593122329694e-08
accumulates O 0 2.0816047197058651e-07
upon O 0 5.460102414645007e-08
serum O 0 6.24714766672696e-06
withdrawal O 0 1.4480634717983776e-06
, O 0 6.458528378772144e-09
only O 0 8.922365624108863e-10
in O 0 2.9582609695211204e-09
the O 0 5.086266963161279e-09
presence O 0 3.687014071829253e-08
of O 0 1.698272100725262e-08
VHL B-Disease 0 6.536488945130259e-05
, O 0 1.0475630141115744e-08
as O 0 9.46325684481053e-09
a O 0 3.341821397384592e-08
result O 0 1.6880701281252186e-08
of O 0 1.467448385028547e-09
the O 0 8.095341286207258e-09
stabilization O 0 1.8667854817522311e-07
of O 0 5.2226991620329954e-09
the O 0 9.940725220758395e-08
protein O 0 1.4479061292149709e-06
. O 0 6.381192747539899e-07

We O 0 1.1287571624052362e-06
propose O 0 1.7006665302687907e-06
that O 0 1.616147216054742e-08
the O 0 5.259810009761168e-08
loss O 0 2.370717766098096e-06
of O 0 2.1854836163015534e-08
wild O 0 3.962913524446776e-06
- O 0 0.0009984237840399146
type O 0 0.00014768516120966524
VHL B-Disease 0 0.0008058379171416163
gene O 0 1.3353883332456462e-06
results O 0 9.852817584032891e-08
in O 0 4.9046251504591964e-09
a O 0 7.512285904454075e-09
specific O 0 6.627596693675741e-09
cellular O 0 0.00013565330300480127
defect O 0 0.00011025534331565723
in O 0 1.7594791756891937e-07
serum O 0 1.7294263670919463e-05
- O 0 3.2704867862776155e-06
dependent O 0 1.2971111118531553e-07
growth O 0 9.03800554397094e-08
control O 0 4.37016495880016e-07
, O 0 2.426272338595936e-08
which O 0 3.715570073836716e-08
may O 0 6.533128384944575e-07
initiate O 0 9.09304799279198e-06
tumor B-Disease 1 0.810612678527832
formation O 0 0.0006940633757039905
. O 0 4.4807316044170875e-06

This O 0 1.9506601347529795e-06
is O 0 8.795183248366811e-07
corrected O 0 5.688252258551074e-06
by O 0 1.0674667372256863e-08
the O 0 2.3710127194931374e-08
reintroduction O 0 5.643727263304754e-07
of O 0 1.6056667107022804e-08
wild O 0 3.6181613722874317e-06
- O 0 0.003571092616766691
type O 0 0.000631587696261704
VHL B-Disease 0 0.011491443030536175
, O 0 5.774688247583981e-07
implicating O 0 6.304225826170295e-05
VHL B-Disease 0 0.0005925136501900852
as O 0 4.283885601807924e-08
the O 0 2.3464624021585223e-08
first O 0 4.5561731099041936e-07
tumor B-Disease 0 0.0007494036108255386
suppressor O 0 1.2071618584741373e-06
involved O 0 2.0896235852774225e-08
in O 0 2.8678299734963275e-09
the O 0 3.0660527450265818e-09
regulation O 0 6.358424542440844e-08
of O 0 6.905530813838823e-09
cell O 0 5.1495917432475835e-06
cycle O 0 1.41200405323616e-06
exit O 0 5.954634616500698e-07
, O 0 2.0060175742742103e-08
which O 0 5.224851218343929e-09
is O 0 4.243789764046824e-09
consistent O 0 6.682100650579059e-09
with O 0 1.3503459461716716e-09
its O 0 1.3221590933198968e-08
gatekeeper O 0 1.480682385590626e-06
function O 0 6.483907810661549e-08
in O 0 7.025795412118896e-08
the O 0 6.918188546478632e-07
kidney O 0 0.1756211817264557
. O 0 4.500589056988247e-07
. O 0 1.5488557210119325e-06

Piebaldism B-Disease 1 0.998505711555481
with O 0 0.001139939995482564
deafness B-Disease 1 0.9999738931655884
: O 0 2.4941552965174196e-06
molecular O 0 7.699882189626805e-06
evidence O 0 1.0846206066617015e-07
for O 0 4.9653010592010105e-08
an O 0 7.323162662942195e-06
expanded O 0 0.04893621429800987
syndrome O 1 0.9998216032981873
. O 0 2.151119042537175e-05

In O 0 6.878821068312391e-07
a O 0 4.5322681785364693e-07
South O 0 1.9211455537515576e-07
African O 0 7.220764075555053e-08
girl O 0 4.125790837861132e-06
of O 0 3.149738958541093e-08
Xhosa O 0 4.663680010708049e-05
stock O 0 9.048058018379379e-06
with O 0 6.792141107325733e-07
severe O 0 0.1279626190662384
piebaldism B-Disease 0 0.122777059674263
and O 0 0.00022842040925752372
profound O 1 0.9407694935798645
congenital O 1 0.9999966621398926
sensorineural B-Disease 1 0.9999929666519165
deafness I-Disease 1 0.9999992847442627
we O 0 0.0010819152230396867
identified O 0 2.183285505452659e-05
a O 0 7.957031584737706e-07
novel O 0 3.2710184427742206e-07
missense O 0 1.10759572180541e-06
substitution O 0 2.3926874703761314e-08
at O 0 8.716867938574069e-08
a O 0 1.50558179257132e-08
highly O 0 4.81788013928508e-08
conserved O 0 5.271440173260089e-08
residue O 0 6.431756105484965e-08
in O 0 2.393434783698467e-09
the O 0 2.006758981210055e-09
intracellular O 0 1.1518583420411233e-07
kinase O 0 1.2486621869811643e-07
domain O 0 9.030746817018098e-09
of O 0 1.7661416773506744e-09
the O 0 3.273336446341091e-08
KIT O 0 3.252322130720131e-05
proto O 0 0.00043534801807254553
- O 0 0.0004889544215984643
oncogene O 0 0.0002964860759675503
, O 0 4.2301022062929405e-07
R796G O 0 2.0579884221660905e-05
. O 0 2.1134123926458415e-06

Though O 0 7.621282293257536e-06
auditory B-Disease 0 0.00011228044604649767
anomalies I-Disease 0 0.001911996747367084
have O 0 1.486874481315681e-07
been O 0 4.3069772459602973e-07
observed O 0 2.713065612169885e-07
in O 0 7.342942609511738e-08
mice O 0 8.704039373697015e-07
with O 0 2.435759149932437e-08
dominant O 0 2.6017602067440748e-05
white O 0 1.0376981663284823e-05
spotting O 0 0.00015045604959595948
( O 0 2.593589840671484e-07
W O 0 0.0006275872001424432
) O 0 1.8264858070438095e-08
due O 0 1.779055196493573e-07
to O 0 3.773988410671336e-08
KIT O 0 0.0010606707073748112
mutations O 0 0.00023319075990002602
, O 0 2.6229783543385565e-05
deafness B-Disease 1 0.9999784231185913
is O 0 4.475171408557799e-06
not O 0 5.119761681271484e-08
typical O 0 9.985598126149853e-07
in O 0 3.9897281567391474e-07
human O 0 1.982245748877176e-06
piebaldism B-Disease 0 0.0017225941410288215
. O 0 3.204426320735365e-06

Thus O 0 3.941606337320991e-06
, O 0 1.7695150233976165e-07
the O 0 1.7589422895980533e-07
occurrence O 0 2.9954127967357635e-05
of O 0 4.508658093982376e-06
sensorineural B-Disease 1 0.9998308420181274
deafness I-Disease 1 0.9999949932098389
in O 0 0.00016322296869475394
this O 0 2.1660596303263446e-06
patient O 0 5.7280809414805844e-05
extends O 0 2.438335116039525e-07
considerably O 0 3.947035338569549e-07
the O 0 6.359319737470059e-09
phenotypic O 0 1.4100837120167853e-07
range O 0 6.248775719086552e-08
of O 0 1.4373653378640938e-08
piebaldism B-Disease 0 3.0385112040676177e-05
due O 0 3.767530358800286e-07
to O 0 1.5108287954035404e-08
KIT O 0 1.1387940503482241e-05
gene O 0 7.59727470267535e-07
mutation O 0 6.345013048303372e-07
in O 0 1.2255010339856653e-08
humans O 0 1.204772193119652e-08
and O 0 2.7069294361581342e-08
tightens O 0 1.3863022104487754e-05
the O 0 4.197823955109925e-08
clinical O 0 3.46343171031549e-07
similarity O 0 2.3317394237665212e-08
between O 0 2.5849120177667828e-08
piebaldism B-Disease 0 1.9943412553402595e-05
and O 0 6.7186634034044346e-09
the O 0 7.431622428555329e-09
various O 0 8.817563568186415e-09
forms O 0 1.250322611667798e-06
of O 0 9.93048888631165e-05
Waardenburg B-Disease 1 0.9999098777770996
syndrome I-Disease 1 0.9999591112136841
. O 0 5.581749974226113e-06
. O 0 5.101268925500335e-06

Cycloheximide O 0 0.00023276780848391354
facilitates O 0 5.39082884642994e-06
the O 0 2.838841339780629e-07
identification O 0 3.0295021247184195e-07
of O 0 2.4633619588598776e-08
aberrant O 0 2.1560208551818505e-06
transcripts O 0 7.736448424111586e-07
resulting O 0 4.794842425326351e-07
from O 0 3.175641793973227e-08
a O 0 7.78607827101041e-08
novel O 0 6.035141808524713e-08
splice O 0 1.562051920700469e-06
- O 0 1.9546117982827127e-05
site O 0 2.346100927752559e-06
mutation O 0 9.815000794333173e-07
in O 0 3.746483301370063e-08
COL17A1 O 0 1.0369719348091166e-05
in O 0 8.123340933252621e-08
a O 0 1.5671340634071385e-06
patient O 0 4.787145007867366e-05
with O 0 4.4846046876045875e-06
generalized O 0 0.02572193369269371
atrophic B-Disease 1 0.9994231462478638
benign I-Disease 1 0.9987568855285645
epidermolysis I-Disease 1 0.9962764382362366
bullosa I-Disease 1 0.9915187954902649
. O 0 0.00022996669576968998

Patients O 0 0.002132493071258068
with O 0 3.6839210224570706e-05
generalized O 0 0.049215082079172134
atrophic B-Disease 1 0.9996845722198486
benign I-Disease 1 0.9989519119262695
epidermolysis I-Disease 1 0.993075966835022
bullosa I-Disease 1 0.5914910435676575
often O 0 2.238289880551747e-06
show O 0 9.708852530820877e-07
decreased O 0 2.9988907499500783e-06
expression O 0 9.492111985309748e-08
of O 0 4.718191704000674e-08
type O 0 0.00012666647671721876
XVII O 0 0.01062789000570774
collagen O 0 0.00010022194328485057
, O 0 4.1300474151739763e-08
a O 0 1.3688405431366846e-07
transmembrane O 0 3.4956931358465226e-06
hemidesmosomal O 0 4.711672318080673e-06
protein O 0 1.7011873865158122e-07
encoded O 0 1.5649429485620203e-07
by O 0 3.3370957908118726e-07
COL17A1 O 0 0.0007043555960990489
. O 0 2.7013879844162147e-06

This O 0 8.973639751275186e-07
report O 0 2.0925158139561972e-07
documents O 0 7.484799624535299e-08
a O 0 1.4083043708978948e-07
novel O 0 3.10149545157401e-07
splice O 0 7.13198369339807e-06
- O 0 4.2199935705866665e-05
site O 0 4.587339390127454e-06
mutation O 0 1.4311357290353044e-06
in O 0 7.011551161895113e-08
COL17A1 O 0 1.7152873624581844e-05
in O 0 5.974622752091818e-08
a O 0 1.4325777328849654e-06
patient O 0 4.368602094473317e-05
with O 0 5.026542567065917e-06
generalized O 0 0.0506000891327858
atrophic B-Disease 1 0.9998183846473694
benign I-Disease 1 0.9994698166847229
epidermolysis I-Disease 1 0.9964877367019653
bullosa I-Disease 1 0.8796339631080627
, O 0 2.279721002196311e-06
and O 0 7.619652819812472e-08
applies O 0 3.465095943511187e-08
a O 0 4.4296772472307566e-08
new O 0 2.60815902208833e-08
methodology O 0 1.9871594147957694e-08
to O 0 6.878499991813669e-10
define O 0 1.5128359009963788e-08
and O 0 5.294179317161252e-09
characterize O 0 1.1473775884951465e-07
the O 0 1.7072846247856432e-08
resulting O 0 1.6290533721985412e-07
mRNA O 0 5.27760278146161e-07
splice O 0 1.89756592590129e-05
variants O 0 1.4841493793937843e-05
. O 0 2.9049704153294442e-06

Mutational O 0 0.0004698603006545454
analysis O 0 1.665039235376753e-06
of O 0 1.5815714959899196e-07
COL17A1 O 0 0.001395807252265513
identified O 0 3.6866665595880477e-06
a O 0 1.024548055283958e-06
maternally O 0 7.408605597447604e-05
inherited O 0 0.15032529830932617
G O 0 0.0027481187134981155
- O 0 2.0224149920977652e-05
to O 0 8.791772643235163e-08
- O 0 0.00011719527537934482
T O 0 4.311363591114059e-05
transversion O 0 1.5012683434179053e-06
at O 0 9.558279856491936e-08
the O 0 1.8493841125177823e-08
- O 0 5.989352871438314e-07
1 O 0 3.2927104598456935e-08
position O 0 5.8149321802147824e-08
of O 0 2.4934076137128613e-08
exon O 0 2.1482366719283164e-05
32 O 0 2.7545972898224136e-06
. O 0 1.2099764035156113e-06

This O 0 2.929145921370946e-07
acceptor O 0 1.338461061095586e-06
splice O 0 1.2315144886088092e-05
- O 0 6.354963988997042e-05
site O 0 2.9152083698136266e-06
mutation O 0 6.273712074289506e-07
led O 0 2.0804687750342055e-08
to O 0 6.04725824970842e-10
the O 0 3.4719347397071942e-09
formation O 0 1.2035805241339403e-07
of O 0 2.818504540869071e-09
aberrant O 0 1.86882687103207e-07
transcripts O 0 2.025851131293166e-07
present O 0 3.607661369642301e-08
at O 0 4.288363470550394e-06
extremely O 0 3.100247340626083e-05
low O 0 0.00018217283650301397
levels O 0 3.188308619428426e-05
. O 0 3.414142838664702e-06

Based O 0 2.5527181151119294e-06
on O 0 2.3192762910184683e-07
our O 0 8.041758547960853e-08
recent O 0 1.2539318561266555e-07
finding O 0 4.735032632652292e-08
that O 0 1.3318073754930992e-08
cycloheximide O 0 9.729460543894675e-06
stabilized O 0 7.528645801357925e-05
mutant O 0 2.0157115159236128e-06
COL17A1 O 0 9.98891300696414e-06
transcripts O 0 3.428452544085303e-07
in O 0 3.1099098407594283e-08
keratinocytes O 0 4.612844008988759e-07
homozygous O 0 3.972457420786668e-07
for O 0 1.0610036405012124e-08
a O 0 6.519995849885163e-07
frameshift O 0 0.00022542882652487606
mutation O 0 4.276083473087056e-06
, O 0 1.2423805095806983e-08
the O 0 6.0402531865122455e-09
effects O 0 2.088499861940818e-08
of O 0 5.447676199032969e-10
the O 0 3.886329036362213e-09
splice O 0 1.1657556342470343e-06
- O 0 5.0062772061210126e-06
site O 0 2.1259789662053663e-07
mutation O 0 3.9287606057314406e-08
on O 0 2.371586038663054e-09
splicing O 0 2.0004925715966237e-08
of O 0 3.839931039806288e-09
COL17A1 O 0 3.0272547064669197e-06
transcripts O 0 7.589642336824909e-08
were O 0 6.9629049193054016e-09
determined O 0 1.6924870394063873e-08
using O 0 7.088273967781333e-09
reverse O 0 2.950340842744481e-07
transcriptase O 0 1.4617831993746222e-06
polymerase O 0 5.785652774648042e-07
chain O 0 4.805238518201804e-07
reaction O 0 2.3086654366011317e-08
of O 0 9.33639054956359e-10
total O 0 2.44391107351305e-09
RNA O 0 5.531465419039705e-08
from O 0 4.662616071016146e-09
keratinocytes O 0 7.604147356232716e-08
incubated O 0 6.20916580373887e-08
for O 0 1.316688003072386e-08
2 O 0 8.085397098511748e-07
. O 0 8.347076914105855e-07

5 O 0 5.338094524631742e-06
h O 0 1.232863542099949e-05
in O 0 7.119318468085112e-08
the O 0 1.442118779948487e-08
presence O 0 8.196474254873465e-08
or O 0 2.9400036183346856e-08
absence O 0 1.1236014785254156e-07
of O 0 1.123991122398138e-08
10 O 0 1.450585642714941e-07
microg O 0 1.424720358045306e-05
cycloheximide O 0 6.764499994460493e-05
per O 0 1.4639177834396833e-06
ml O 0 0.00020550086628645658
. O 0 3.693747430588701e-06

Using O 0 6.84774363435281e-07
this O 0 2.8393603912491017e-08
approach O 0 1.3583060365363053e-07
, O 0 1.190599885347865e-08
an O 0 2.7021012982686443e-08
abnormally O 0 1.685145980445668e-05
spliced O 0 4.4568919292942155e-06
transcript O 0 5.6374581618001685e-05
was O 0 2.4193457647925243e-05
identified O 0 6.70088979859429e-08
that O 0 7.094789755690556e-10
contains O 0 5.09350672750486e-10
an O 0 5.154402460405549e-10
extra O 0 2.1545321082783175e-09
264 O 0 9.002079082165437e-09
bases O 0 1.446656039405525e-08
upstream O 0 3.9384165262390525e-08
from O 0 6.095434823549795e-09
exon O 0 3.711480474066775e-07
32 O 0 5.040858042093532e-08
, O 0 9.332443262621837e-09
resulting O 0 6.23857019377283e-08
in O 0 2.2120637765965512e-08
a O 0 1.2724269708996871e-06
premature O 0 1.407226864102995e-05
termination O 0 2.5638089482526993e-06
codon O 0 1.1775157418014714e-06
27 O 0 9.074657327801106e-07
bp O 0 1.4275451576395426e-06
downstream O 0 1.3584561031620979e-07
from O 0 5.991555696027717e-09
the O 0 1.947371863764147e-08
cryptic O 0 3.1673471312387846e-06
splice O 0 2.3454265829059295e-05
site O 0 2.9901242669438943e-05
. O 0 3.813776856986806e-06

Three O 0 1.146619510450364e-07
other O 0 4.4954004962960425e-09
splice O 0 1.1929910215258133e-06
variants O 0 3.961259551488183e-07
, O 0 4.824151389470899e-08
including O 0 3.3357252515742175e-09
one O 0 8.224251502042534e-09
derived O 0 3.0384463833854625e-09
from O 0 2.1224888513415863e-09
the O 0 2.0753234686310407e-09
skipping O 0 3.252004177056733e-08
of O 0 1.9760164615689746e-09
exon O 0 1.0165827006858308e-06
32 O 0 9.045179183431173e-08
, O 0 1.4967630690421174e-08
were O 0 3.765331513250203e-08
also O 0 3.107559223280987e-07
identified O 0 7.486379217880312e-06
. O 0 1.663677267060848e-06

These O 0 6.822035629738821e-07
results O 0 1.3683527413377305e-06
indicate O 0 1.5244719975271437e-07
the O 0 1.5766779881687398e-08
usefulness O 0 2.852034981515317e-07
of O 0 3.7504371164232e-08
cycloheximide O 0 0.00011689191160257906
treatment O 0 6.077888883737614e-06
in O 0 2.8588258871309336e-08
evaluating O 0 6.00466876221617e-08
the O 0 1.4829807604144207e-08
abnormal O 0 1.1348031137004e-07
processing O 0 1.0531685745718278e-08
of O 0 5.784979717482486e-10
mRNA O 0 1.2145988215195302e-08
due O 0 2.495700890392527e-08
to O 0 1.2873790922185435e-09
splice O 0 1.4284222515925649e-06
- O 0 2.2578709831577726e-05
site O 0 3.004040081577841e-06
mutations O 0 9.511673511042318e-07
, O 0 1.835909202441144e-08
because O 0 1.424081119694165e-08
( O 0 4.422710198070945e-09
i O 0 3.758672662002027e-08
) O 0 1.131031490686496e-09
aberrant O 0 2.3543435645478894e-08
splicing O 0 8.080719737790787e-08
often O 0 1.0425419638693256e-08
generates O 0 2.958093148208718e-08
a O 0 2.4673548182363447e-07
premature O 0 6.428520919143921e-06
termination O 0 1.4488398392131785e-06
codon O 0 3.2563184504397213e-07
, O 0 1.077274269789541e-08
( O 0 9.286028834765148e-09
ii O 0 2.0612253138097003e-05
) O 0 7.855287975644387e-09
transcripts O 0 1.406768603828823e-07
with O 0 6.43038262637674e-08
premature O 0 2.7984804546576925e-05
termination O 0 3.030723746633157e-06
codons O 0 3.261620520333963e-07
can O 0 1.8245220445578525e-08
occur O 0 1.921046255404235e-08
at O 0 2.0577377313202305e-07
low O 0 3.374824018465006e-06
or O 0 1.1165939639568023e-07
undetectable O 0 4.8124664317583665e-05
levels O 0 2.097290519031958e-07
due O 0 3.4631138845497844e-08
to O 0 1.6222428955714463e-09
nonsense O 0 2.4406568854828947e-07
- O 0 1.7816562092320964e-07
mediated O 0 1.4705260298342182e-07
mRNA O 0 8.423560160508714e-08
decay O 0 7.127266599127324e-07
, O 0 8.600106404799135e-09
and O 0 3.990901387140866e-09
( O 0 8.094322545559862e-09
iii O 0 1.548468389955815e-05
) O 0 1.7674895991248718e-09
the O 0 2.4994961655977477e-09
levels O 0 2.153337597121663e-08
of O 0 3.687551652920007e-10
these O 0 3.232976941713872e-10
transcripts O 0 3.098045198157706e-08
can O 0 1.7695809262363582e-09
be O 0 2.0941193223933396e-09
increased O 0 1.9926705618900087e-08
by O 0 6.337864988381625e-08
cycloheximide O 0 0.00019574617908801883
. O 0 1.43788565765135e-06

A O 0 1.3805104572384153e-05
deletion O 0 6.048580689821392e-05
mutation O 0 3.8342070183716714e-05
in O 0 2.7870837016052974e-07
COL17A1 O 0 0.00014468195149675012
in O 0 1.674304996868159e-07
five O 0 1.060866381408232e-07
Austrian O 0 0.00021390792971942574
families O 0 9.389115263047643e-08
with O 0 4.08834694098914e-06
generalized O 0 0.3437526822090149
atrophic B-Disease 1 0.9998577833175659
benign I-Disease 1 0.9995999932289124
epidermolysis I-Disease 1 0.9974644184112549
bullosa I-Disease 1 0.8850501775741577
represents O 0 6.040144398866687e-06
propagation O 0 2.024722334681428e-06
of O 0 4.145690013501735e-08
an O 0 2.578169358002924e-07
ancestral O 0 5.092424908070825e-05
allele O 0 7.542277307948098e-05
. O 0 7.635606380063109e-06

Patients O 0 0.0032532967161387205
with O 0 6.917617429280654e-05
generalized O 0 0.19917038083076477
atrophic B-Disease 1 0.9995635151863098
benign I-Disease 1 0.9994310736656189
epidermolysis I-Disease 1 0.9972303509712219
bullosa I-Disease 1 0.9891831874847412
, O 0 3.811042688539601e-06
a O 0 9.152391839961638e-07
usually O 0 1.0396888683317229e-07
nonlethal O 0 1.0692659770938917e-06
form O 0 3.509133250645391e-07
of O 0 5.949650017100794e-07
junctional B-Disease 1 0.5018172264099121
epidermolysis I-Disease 1 0.9680819511413574
bullosa I-Disease 1 0.7888531684875488
, O 0 1.8917412489827257e-06
have O 0 1.1446921632796148e-07
generalized O 0 3.0687276648677653e-06
blistering B-Disease 0 0.0008689289097674191
, O 0 1.3490459423337597e-05
nail B-Disease 1 0.9988396763801575
dystrophy I-Disease 1 0.9996583461761475
, O 0 9.131748811341822e-05
patchy B-Disease 1 0.9849687814712524
alopecia I-Disease 1 0.9997910857200623
, O 0 5.705614239559509e-05
and O 0 0.0001480591163272038
dental B-Disease 1 0.9995658993721008
abnormalities I-Disease 1 0.9997493624687195
. O 0 5.304097794578411e-05

Skin B-Disease 0 0.21257831156253815
fragility I-Disease 0 0.004252638202160597
in O 0 8.838225085128215e-07
most O 0 9.660404742817263e-08
cases O 0 1.169711865145473e-07
is O 0 9.726668537268779e-08
due O 0 1.1007682587660383e-07
to O 0 6.4757728068798315e-09
mutations O 0 2.2571309443719656e-07
in O 0 1.2018023021198587e-08
the O 0 1.0536065353505819e-08
gene O 0 2.5016254312504316e-07
encoding O 0 9.020143920679402e-07
type O 0 0.00047902658116072416
XVII O 0 0.3870156705379486
collagen O 0 0.00836701039224863
( O 0 1.8607366882861243e-06
COL17A1 O 0 0.0027049710042774677
) O 0 1.0714607014961075e-06
. O 0 1.756598294377909e-06

Recently O 0 0.0004107733257114887
, O 0 7.924030001049687e-07
we O 0 2.2844626812457136e-07
reported O 0 1.4838516335657914e-06
five O 0 5.9350753645048826e-08
Austrian O 0 0.0001470511342631653
families O 0 5.101075828406465e-08
with O 0 1.9070984080826747e-06
generalized O 0 0.044409044086933136
atrophic B-Disease 1 0.999843955039978
benign I-Disease 1 0.9994982481002808
epidermolysis I-Disease 1 0.9950966238975525
bullosa I-Disease 1 0.8947645425796509
who O 0 3.7779534522996983e-06
share O 0 8.757162817119024e-08
the O 0 1.5587184520882147e-07
same O 0 9.218617833539611e-07
COL17A1 O 0 0.00940543320029974
mutation O 0 0.00034792095539160073
. O 0 3.482712600089144e-06

Affected O 0 8.797995178611018e-06
individuals O 0 3.9447993316343855e-08
in O 0 3.5662090169807925e-08
three O 0 1.1166745750301743e-08
families O 0 4.892926508404116e-09
are O 0 8.905075010723351e-10
homozygous O 0 4.202213688131451e-08
for O 0 4.008325671378543e-09
4003delTC O 0 1.6024166598072043e-06
, O 0 6.211922976007145e-09
whereas O 0 5.662453617105712e-09
those O 0 6.307517841364074e-10
in O 0 2.650918373703348e-09
two O 0 2.3959743078449947e-09
others O 0 6.358773507741944e-09
are O 0 4.048278601231914e-09
compound O 0 3.4966303701366996e-06
heterozygotes O 0 2.551881698309444e-05
. O 0 1.596871356923657e-06

To O 0 3.959144123655278e-07
determine O 0 8.979820904642111e-07
if O 0 4.737336212201626e-08
the O 0 3.216196020616735e-08
occurrence O 0 1.000171437226527e-06
of O 0 2.5040401752107755e-08
4003delTC O 0 1.4145044588076416e-05
in O 0 6.911832173273069e-08
these O 0 2.5156383642865876e-09
unrelated O 0 1.745622029147853e-07
families O 0 6.237806271514046e-09
signifies O 0 4.517725216146573e-08
propagation O 0 2.9612545304757987e-08
of O 0 2.874110949235842e-09
an O 0 7.429510340273282e-09
ancestral O 0 7.59971072739063e-08
allele O 0 7.803085821933564e-08
or O 0 1.866421861507206e-08
a O 0 1.813873637956931e-07
mutational O 0 6.091159320931183e-06
hot O 0 3.0811263513896847e-06
spot O 0 7.774827395223838e-07
, O 0 1.3726689118698232e-08
haplotypes O 0 1.6829432070153416e-07
were O 0 2.4212981841742476e-08
determined O 0 9.242493348438074e-08
for O 0 1.070521093993193e-08
polymorphisms O 0 4.752295978960319e-07
both O 0 1.3753997052390332e-08
within O 0 7.441752813974745e-08
and O 0 3.668352235308703e-07
flanking O 0 0.0014062022091820836
COL17A1 O 1 0.5064866542816162
. O 0 2.0596376998582855e-05

Five O 0 2.7695723474607803e-06
intragenic O 0 6.62823294987902e-05
polymorphisms O 0 2.5971739887609147e-05
were O 0 9.50077065908772e-08
chosen O 0 5.8943271596945124e-08
based O 0 5.063155938955788e-08
on O 0 9.290639013670443e-08
their O 0 1.8453764027981379e-07
informativeness O 0 0.0006266696727834642
. O 0 4.03585227104486e-06

One O 0 3.733953235496301e-07
of O 0 1.8486751685031777e-08
these O 0 6.3934217919836556e-09
, O 0 1.6208394626460176e-08
not O 0 8.289466890687436e-09
previously O 0 8.739206123209442e-07
reported O 0 1.986202505577239e-06
, O 0 1.1351253270674988e-08
was O 0 3.0140636226860806e-06
2988 O 0 1.932117811520584e-06
A O 0 8.989640036816127e-07
or O 0 3.9546002028600924e-08
C O 0 3.83979397611256e-07
that O 0 1.311203923215487e-09
introduces O 0 9.106577714135256e-09
a O 0 1.86087660836165e-08
new O 0 1.6795466351027244e-08
restriction O 0 2.362377315989761e-08
site O 0 8.78855388464217e-08
for O 0 3.0783660065480944e-08
Eco0109 O 0 9.046117156685796e-06
I O 0 1.2375423466437496e-05
. O 0 1.0312196536688134e-06

All O 0 1.4931224256997666e-07
the O 0 1.5673552411499259e-07
4003delTC O 0 4.6111731535347644e-06
alleles O 0 2.440386879243306e-07
showed O 0 3.0043960919101664e-07
the O 0 6.931738738558124e-09
same O 0 1.0941658246110819e-08
haplotype O 0 8.010939041014353e-07
for O 0 5.3076267825247214e-09
these O 0 3.146506610818278e-09
five O 0 7.018188341589848e-08
polymorphic O 0 1.735218393150717e-05
markers O 0 8.484387217322364e-05
. O 0 4.379834535939153e-06

Fourteen O 0 5.0174192438134924e-05
microsatellite O 0 0.00021159018797334284
polymorphisms O 0 2.9419186830637045e-05
were O 0 1.1402598687482168e-07
selected O 0 3.6670538605676484e-08
based O 0 1.5068975400822637e-08
on O 0 3.178720220375908e-08
their O 0 2.382150299240493e-08
high O 0 1.293002969759982e-05
heterozygosity O 0 1.5107362742128316e-05
and O 0 1.635834223634447e-08
their O 0 5.815683490340007e-09
location O 0 2.9438314186336356e-07
within O 0 2.0398327649218118e-07
10q23 O 0 1.962119495146908e-05
- O 0 0.00010665440640877932
q25 O 0 4.0901988541008905e-05
near O 0 0.00013843124906998128
COL17A1 O 0 0.0021265684626996517
. O 0 7.461432687705383e-06

Three O 0 6.068802349545876e-07
families O 0 9.070281947742842e-08
shared O 0 3.8056930407037726e-07
microsatellite O 0 7.987147546373308e-05
polymorphisms O 0 1.9642575352918357e-05
covering O 0 2.590232952570659e-06
at O 0 2.369156163695152e-06
most O 0 3.543129878380569e-08
19 O 0 2.1384070691965462e-07
cM O 0 8.054021236603148e-07
, O 0 1.2866679277578896e-08
whereas O 0 2.6065128722052577e-08
the O 0 1.2293451590039695e-08
others O 0 7.080531716496807e-09
shared O 0 1.875736366230285e-08
smaller O 0 1.569474648022151e-07
regions O 0 1.0811259443244126e-07
consistent O 0 1.5872211633904953e-07
with O 0 1.3059183068264701e-08
cross O 0 8.785626732787932e-07
- O 0 1.5724816648798878e-06
over O 0 4.843223599948487e-09
events O 0 4.895969851759219e-09
during O 0 3.76801843060548e-08
passage O 0 4.801493425077297e-09
of O 0 9.189364824635504e-10
this O 0 1.4925031210921702e-09
mutation O 0 3.489982347559817e-08
through O 0 4.555371191372615e-09
several O 0 9.38018018814546e-09
generations O 0 3.277610289842414e-07
. O 0 1.1951568694712478e-06

These O 0 1.4723224239787669e-06
results O 0 9.235774996341206e-06
indicate O 0 1.0694587899706676e-06
that O 0 3.574994522637098e-08
4003delTC O 0 1.020700619847048e-05
occurs O 0 1.5143911014092737e-07
on O 0 2.772407192708215e-08
a O 0 3.830598771514815e-08
single O 0 5.2423832386239155e-08
ancestral O 0 5.388847057474777e-07
allele O 0 2.128213509422494e-06
. O 0 1.745363960026225e-07
. O 0 8.35760715744982e-07

The O 0 6.4525738707743585e-06
haptoglobin O 0 0.0006206943653523922
- O 0 0.00011250250099692494
gene O 0 8.798197086434811e-06
deletion O 0 1.3127808415447362e-05
responsible O 0 2.035430497926427e-06
for O 0 4.894049538961553e-07
anhaptoglobinemia B-Disease 0 0.003106563352048397
. O 0 1.0372825272497721e-05

We O 0 1.4372468513101921e-06
have O 0 4.308353140913823e-08
found O 0 2.1225263324708976e-08
an O 0 7.162287207762574e-09
allelic O 0 6.927788831490034e-07
deletion O 0 6.480000820374698e-07
of O 0 8.921365868275188e-09
the O 0 7.26924014315955e-08
haptoglobin O 0 5.831803719047457e-06
( O 0 1.4814230731019506e-08
Hp O 0 7.243124144906687e-08
) O 0 4.214701476712435e-09
gene O 0 1.3984881697126639e-08
from O 0 1.915673841779153e-09
an O 0 3.0092286440464022e-09
individual O 0 9.408221757212232e-09
with O 0 3.2465629828948295e-07
anhaptoglobinemia B-Disease 0 0.0025665333960205317
. O 0 4.315177193348063e-06

The O 0 1.9195574623154243e-06
Hp O 0 1.0078148989123292e-05
gene O 0 2.954174306069035e-06
cluster O 0 2.035271336353617e-06
consists O 0 7.579834715443212e-08
of O 0 1.0290388985367827e-08
coding O 0 2.693200258363504e-06
regions O 0 8.149878993890525e-08
of O 0 3.8428176196703134e-09
the O 0 1.8028599058084183e-08
alpha O 0 2.147137081465189e-07
chain O 0 4.432102969076368e-07
and O 0 6.7219065869039696e-09
beta O 0 7.115585276551428e-08
chain O 0 1.10580188561471e-07
of O 0 6.23550711065235e-10
the O 0 1.0540769146416551e-08
haptoglobin O 0 1.1496375691422145e-06
gene O 0 9.17460880600629e-08
( O 0 3.392756298126187e-09
Hp O 0 5.2767315850132945e-08
) O 0 1.5387938701039161e-09
and O 0 9.21662524078215e-10
of O 0 1.2799359350168515e-09
the O 0 2.0072345563448835e-08
alpha O 0 2.3081334177277313e-07
chain O 0 4.009972087715141e-07
and O 0 9.86752013432124e-09
beta O 0 1.3167111490020034e-07
chain O 0 2.6391504093226104e-07
of O 0 4.683249787973409e-09
the O 0 4.882469539779777e-08
haptoglobin O 0 1.8642233044374734e-05
- O 0 1.2978084669157397e-05
related O 0 8.703510445684515e-08
gene O 0 1.7693935205898015e-07
( O 0 2.139745092222256e-08
Hpr O 0 1.8499556517781457e-06
) O 0 9.594752548025554e-09
, O 0 1.05130215644067e-08
in O 0 1.2703637253252964e-08
tandem O 0 8.605850894127798e-07
from O 0 2.0812306544826242e-08
the O 0 6.806205732345916e-08
5 O 0 6.492012971648364e-07
side O 0 6.035273145243991e-06
. O 0 1.5961238659656374e-06

Southern O 0 3.5842731449520215e-05
blot O 0 7.691486098337919e-05
and O 0 2.1891241885896306e-07
PCR O 0 3.7148588489799295e-06
analyses O 0 6.087107635721623e-07
have O 0 3.2411303863000285e-08
indicated O 0 6.586768108718388e-08
that O 0 7.943303237389898e-10
the O 0 1.6427370574945144e-09
individual O 0 8.455344202573656e-10
with O 0 1.1989861548045155e-08
anhaptoglobinemia B-Disease 0 5.170040458324365e-05
was O 0 2.7885616873390973e-06
homozygous O 0 3.216877075828961e-08
for O 0 7.94404542148186e-10
the O 0 6.383015893618449e-09
gene O 0 3.9897923187481865e-08
deletion O 0 5.421818727313621e-08
and O 0 3.1882148032735813e-09
that O 0 6.340084013345404e-10
the O 0 4.314065993327176e-09
gene O 0 3.5343489912520454e-08
deletion O 0 1.398712612399322e-07
was O 0 4.772579131895327e-07
included O 0 5.502272859558843e-09
at O 0 1.5392269858693908e-07
least O 0 3.6441474282611352e-09
from O 0 3.4927378766980155e-09
the O 0 7.979417127046418e-09
promoter O 0 2.559919721534243e-06
region O 0 6.256193785247888e-08
of O 0 3.145852467412169e-09
Hp O 0 8.662867401199037e-08
to O 0 7.082381792145043e-09
Hpr O 0 4.6721538637939375e-06
alpha O 0 2.5926948410415207e-07
but O 0 7.249533862108137e-09
not O 0 1.9310706367292596e-09
to O 0 5.50394174680946e-09
Hpr O 0 1.2042449270666111e-05
beta O 0 3.983933311246801e-06
( O 0 7.922294287254772e-08
Hpdel O 0 2.0854065951425582e-05
) O 0 2.892591624004126e-07
. O 0 9.99934968604066e-07

In O 0 1.155933773588913e-06
addition O 0 2.7147973469254794e-07
, O 0 5.4318071818215685e-08
we O 0 6.184955658739e-09
found O 0 6.084469816869387e-09
seven O 0 1.7848892364114022e-09
individuals O 0 1.1637862201707705e-10
with O 0 3.3425846535095616e-09
hypohaptoglobinemia B-Disease 0 6.912886874488322e-06
in O 0 2.9279998869924384e-08
three O 0 5.661211499585761e-09
families O 0 2.1657635684846355e-09
, O 0 5.876654718406371e-09
and O 0 1.8007076940662614e-09
the O 0 5.336872721528607e-09
genotypes O 0 2.230842355288587e-08
of O 0 6.94359181263593e-10
six O 0 2.245029939729193e-09
of O 0 6.00232752390184e-10
the O 0 3.1955569301800324e-09
seven O 0 4.244081086568485e-09
individuals O 0 7.780993627193311e-10
were O 0 4.89898743794015e-09
found O 0 1.5488712534761362e-08
to O 0 5.581591633330163e-09
be O 0 1.6594765384070342e-07
Hp2 O 0 0.00011875558266183361
/ O 0 5.559798955800943e-05
Hpdel O 0 0.0006684709805995226
. O 0 4.5675988076254725e-06

The O 0 1.871746349024761e-06
phenotypes O 0 2.47178140853066e-05
and O 0 1.9690801877914055e-07
genotypes O 0 2.69720476353541e-06
in O 0 3.92483592293047e-08
one O 0 4.115953355920965e-09
of O 0 5.36792554850507e-10
these O 0 2.653780528660832e-10
three O 0 1.554446127371989e-09
families O 0 1.8344731289587912e-09
showed O 0 2.1888507717449102e-07
the O 0 1.879912758795399e-08
father O 0 2.498461526556639e-07
to O 0 3.6101652778341986e-09
be O 0 2.4393486341978132e-08
hypohaptoglobinemic B-Disease 0 4.333442575443769e-06
( O 0 9.841432557777807e-09
Hp2 O 0 2.054727019640268e-06
) O 0 7.2762698088979505e-09
and O 0 1.3865096626375362e-08
Hp2 O 0 8.725260158826131e-06
/ O 0 1.3927855206929962e-06
Hpdel O 0 5.841176971443929e-06
, O 0 1.89603426292706e-08
the O 0 2.1208954592566442e-08
mother O 0 7.397006243081705e-07
to O 0 1.887791478694112e-09
be O 0 1.0095051017344758e-08
Hp2 O 0 1.085749318008311e-06
- O 0 8.908291420084424e-07
1 O 0 4.1889695268082505e-08
and O 0 1.0158907493007518e-08
Hp1 O 0 3.9551055124320555e-06
/ O 0 3.7772798577861977e-07
Hp2 O 0 2.3548118406324647e-06
, O 0 5.901545918618467e-09
one O 0 8.236192838850798e-10
of O 0 3.6802233482902125e-10
the O 0 2.6026512056631645e-09
two O 0 3.089793976229771e-09
children O 0 3.4020550820912376e-09
to O 0 2.420479372489126e-09
be O 0 3.0109756465890314e-08
hypohaptoglobinemic B-Disease 0 5.021482593292603e-06
( O 0 1.577396879781645e-08
Hp2 O 0 2.1883447516302112e-06
) O 0 9.950319679319364e-09
and O 0 1.074036770631892e-08
Hp2 O 0 1.2338208762230352e-05
/ O 0 2.0023419438075507e-06
Hpdel O 0 1.1699238712026272e-05
, O 0 3.803965498150319e-08
and O 0 5.716113804510314e-09
the O 0 5.5966657974693135e-09
other O 0 3.7163268018503004e-09
child O 0 2.161671233125162e-07
to O 0 3.0202691458924846e-09
be O 0 1.82917379021319e-08
Hp1 O 0 3.7522229376918403e-06
and O 0 1.1067661631614101e-07
Hp1 O 0 2.3646760382689536e-05
/ O 0 3.2686314170859987e-06
Hpdel O 0 1.9957853510277346e-05
, O 0 4.712022416697437e-08
showing O 0 1.0143113371441359e-07
an O 0 1.3125256437263033e-08
anomalous O 0 5.642526730298414e-07
inheritance O 0 9.317041076428723e-07
of O 0 2.7748884079414893e-08
Hp O 0 1.5222492493194295e-06
phenotypes O 0 1.9041743826164748e-06
in O 0 4.133640985060083e-08
the O 0 6.975815125542795e-08
child O 0 2.8690326416835887e-06
with O 0 5.231565296526242e-07
Hp1 O 0 0.002129290020093322
. O 0 5.99043187321513e-06

The O 0 5.321737262420356e-06
Hp2 O 0 0.0002755952882580459
/ O 0 1.8375951185589656e-05
Hpdel O 0 4.08795676776208e-05
individuals O 0 2.4612157645265142e-08
had O 0 2.117024138215129e-07
an O 0 3.5351511940007185e-08
extremely O 0 1.491847115175915e-06
low O 0 1.8816363080986775e-06
level O 0 8.758966885125119e-08
of O 0 4.876306025636268e-09
Hp O 0 3.3338255889248103e-07
( O 0 1.3714231528183518e-08
mean O 0 1.2018257677937072e-07
+ O 0 5.124231279296509e-07
/ O 0 4.524123937699187e-07
- O 0 2.5604617803764995e-06
SD O 0 2.779129681584891e-05
= O 0 5.667361619998701e-07
0 O 0 4.867313307954646e-08
. O 0 6.839674604464108e-09
049 O 0 1.3448599247567472e-06
+ O 0 2.598499406758492e-07
/ O 0 4.427186013344908e-07
- O 0 7.55476207814354e-07
0 O 0 7.360456777405489e-08
. O 0 1.0406982831057121e-08
043 O 0 2.2610247469856404e-06
mg O 0 2.684156697796425e-06
/ O 0 5.210096105656703e-07
ml O 0 1.5673927009629551e-06
; O 0 1.4529000225138589e-08
n O 0 1.6824185422592564e-07
= O 0 7.074095265124924e-08
6 O 0 1.552293049655873e-08
) O 0 9.71271840732868e-10
, O 0 8.028784859170912e-10
compared O 0 4.590906765855607e-09
with O 0 8.327781242378762e-10
the O 0 5.7276823284269085e-09
level O 0 4.88894613681623e-08
( O 0 1.6135960345664557e-09
1 O 0 7.58181162296978e-09
. O 0 1.335255683798664e-09
64 O 0 1.0050094978453217e-08
+ O 0 4.120220253867046e-08
/ O 0 1.3557291822507977e-07
- O 0 3.2244886938315176e-07
1 O 0 2.0349627760651856e-08
. O 0 6.1206226753540705e-09
07 O 0 3.724031216734147e-07
mg O 0 8.827080932860554e-07
/ O 0 2.633214819525165e-07
ml O 0 3.399894410449633e-07
) O 0 1.3544370069951128e-09
obtained O 0 3.704267559356822e-09
from O 0 4.6633985562039015e-09
52 O 0 8.6817905753378e-08
healthy O 0 1.1553877499181908e-07
volunteers O 0 5.037109929162398e-08
having O 0 6.20283273633504e-08
phenotype O 0 1.2263075177543215e-06
Hp2 O 0 5.535034233616898e-06
, O 0 1.813482164436664e-08
whereas O 0 1.692467677116838e-08
the O 0 1.2958742523494493e-08
serum O 0 3.8307308614093927e-07
Hp O 0 2.9413159907676345e-08
level O 0 1.0803834271655433e-08
of O 0 5.406076142300265e-10
an O 0 1.479457112374405e-09
individual O 0 1.8427284143029965e-09
with O 0 3.338483267611991e-08
Hp1 O 0 9.920143929775804e-05
/ O 0 1.376180716761155e-05
Hpdel O 0 0.00016920975758694112
was O 0 8.5637548181694e-05
0 O 0 2.122940941262641e-06
. O 0 7.678908104935545e-07

50 O 0 1.1699059541570023e-05
mg O 0 6.713397306157276e-05
/ O 0 5.785841040051309e-06
ml O 0 1.8048154743155465e-05
, O 0 1.676787597659768e-08
which O 0 4.670698494635417e-09
was O 0 4.843512968477626e-08
approximately O 0 8.084382052686578e-10
half O 0 1.5686173471252118e-09
the O 0 5.320557328047926e-10
level O 0 6.765665361285755e-09
of O 0 2.4400825804349324e-09
Hp O 0 1.1911909325590386e-07
in O 0 3.617625310425865e-08
control O 0 1.5912784192551044e-06
sera O 0 9.682162271928973e-06
from O 0 7.228629694822075e-09
the O 0 1.4584196073030853e-08
Hp1 O 0 4.186144906270783e-06
phenotype O 0 5.824444997415412e-07
( O 0 3.4616858268776696e-09
1 O 0 1.1953372514028615e-08
. O 0 2.407284149796851e-09
26 O 0 4.458326685607972e-08
+ O 0 8.668305895298545e-08
/ O 0 1.5269004904894246e-07
- O 0 3.018571987922769e-07
0 O 0 1.505765645504198e-08
. O 0 3.426397388039959e-09
33 O 0 6.404201258192188e-08
mg O 0 7.498301783925854e-07
/ O 0 2.607582700875355e-07
ml O 0 1.080922288565489e-06
; O 0 1.2196014864684912e-08
n O 0 1.8201848206444993e-07
= O 0 1.901064621279147e-07
9 O 0 3.537916626328297e-08
) O 0 1.598658871948544e-09
, O 0 1.9206787271741632e-09
showing O 0 4.214767912458228e-08
a O 0 1.5471297842850618e-07
gene O 0 3.3005881050485186e-06
- O 0 8.553160296287388e-05
dosage O 0 4.10312604799401e-05
effect O 0 3.3482131129858317e-06
. O 0 1.4040252835911815e-06

The O 0 5.069437065685634e-07
other O 0 2.293497303185177e-08
allele O 0 5.348503009372507e-07
( O 0 6.10027584002637e-08
Hp2 O 0 6.3866623349895235e-06
) O 0 6.358894744096233e-09
of O 0 1.3081263849912261e-09
individuals O 0 1.5409850062653163e-09
with O 0 2.4569148493469584e-08
Hp2 O 0 9.911954839481041e-05
/ O 0 8.202484423236456e-06
Hpdel O 0 8.233290282078087e-05
was O 0 4.1705930925672874e-05
found O 0 1.7063209512002686e-08
to O 0 7.083242881122942e-10
have O 0 8.270006346400294e-10
, O 0 1.2046934561027456e-09
in O 0 7.113651889767425e-10
all O 0 2.719393321637398e-10
exons O 0 3.372415235958215e-08
, O 0 9.915517296121834e-09
no O 0 1.0921975324151845e-08
mutation O 0 1.2373615732030885e-07
, O 0 2.360241335708224e-09
by O 0 1.0578412812378701e-08
DNA O 0 9.132225500252389e-07
sequencing O 0 1.3947766319688526e-06
. O 0 1.2289206097193528e-06

On O 0 6.90176022999367e-07
the O 0 2.7800588497939316e-08
basis O 0 9.234895514964592e-09
of O 0 1.864143950314201e-09
the O 0 1.1450454806549715e-08
present O 0 1.0657863036556137e-08
study O 0 7.099585808134634e-09
, O 0 1.9311625631956986e-09
the O 0 3.3807090460413747e-09
mechanism O 0 2.1113580217502204e-08
of O 0 2.6404021191694937e-09
anhaptoglobinemia B-Disease 0 3.6713131521537434e-06
and O 0 5.3906852315321885e-09
the O 0 4.065596304059227e-09
mechanism O 0 3.5519125418659314e-08
of O 0 3.9273952978646776e-09
anomalous O 0 6.629368272115244e-07
inheritance O 0 9.385004204887082e-07
of O 0 4.078529869389058e-08
Hp O 0 4.394938969198847e-06
phenotypes O 0 7.584543254779419e-06
were O 0 1.6806994551643584e-07
well O 0 4.1835761521724635e-07
explained O 0 7.047751751088072e-06
. O 0 1.5161150486164843e-06

However O 0 1.4292070318333572e-06
, O 0 9.108647702760209e-08
the O 0 2.1066153266247056e-08
mechanism O 0 3.2827969675963686e-07
of O 0 2.3646499869300897e-07
hypohaptoglobinemia B-Disease 0 0.0025034057907760143
remains O 0 0.0006473325192928314
unknown O 0 0.00021658535115420818

ATM O 0 0.0016347785713151097
mutations O 0 0.0007995257619768381
and O 0 4.108698703930713e-06
phenotypes O 0 0.0020984725560992956
in O 0 0.00033271146821789443
ataxia B-Disease 1 0.9999724626541138
- I-Disease 1 0.9996696710586548
telangiectasia I-Disease 1 0.9995790123939514
families O 0 2.6570608042675303e-06
in O 0 3.380214650405833e-07
the O 0 5.581519957331693e-08
British O 0 2.015006202782388e-06
Isles O 0 7.631214771208761e-07
: O 0 7.378881505815116e-09
expression O 0 6.928354778779067e-09
of O 0 1.7190667778166357e-09
mutant O 0 9.038176784770258e-08
ATM O 0 1.8924233700090554e-06
and O 0 3.5917668839147154e-08
the O 0 1.587572313610508e-07
risk O 0 6.792240128561389e-06
of O 0 1.5345235624408815e-06
leukemia B-Disease 1 0.9999209642410278
, O 0 0.017851119861006737
lymphoma B-Disease 1 0.9999992847442627
, O 0 0.0003755312936846167
and O 0 0.013358736410737038
breast B-Disease 1 0.9999203681945801
cancer I-Disease 1 0.9998207688331604
. O 0 1.9632949260994792e-05

We O 0 1.1744954235837213e-06
report O 0 4.828975264103974e-08
the O 0 5.957551341140288e-09
spectrum O 0 6.108110994773597e-08
of O 0 1.0345965861802142e-08
59 O 0 4.5898062239757564e-07
ATM O 0 1.9441935364739038e-05
mutations O 0 1.6110914657474495e-05
observed O 0 5.3248845688358415e-06
in O 0 1.3953374036645982e-05
ataxia B-Disease 1 0.9999545812606812
- I-Disease 1 0.9994204044342041
telangiectasia I-Disease 1 0.9998668432235718
( O 0 0.0001113691832870245
A B-Disease 1 0.9998281002044678
- I-Disease 1 0.9996531009674072
T I-Disease 1 0.9999343156814575
) O 0 3.91408661926107e-07
patients O 0 1.2269837270650896e-06
in O 0 2.290620670919452e-08
the O 0 4.626095417847864e-08
British O 0 9.157446584140416e-06
Isles O 0 2.3958165911608376e-05
. O 0 3.548233735273243e-06

Of O 0 9.002388878798229e-07
51 O 0 6.010116521792952e-06
ATM O 0 0.00019094183517154306
mutations O 0 0.00014989270130172372
identified O 0 4.5330652937991545e-06
in O 0 8.281946861643519e-08
families O 0 8.608279422617215e-09
native O 0 2.1246689740905822e-08
to O 0 3.618679134120839e-09
the O 0 1.9422380148625962e-08
British O 0 8.379498694921494e-07
Isles O 0 2.7663284640766506e-07
, O 0 1.5563159649900626e-08
11 O 0 2.995795256310885e-08
were O 0 1.1990021420160701e-08
founder O 0 4.3746521782850323e-07
mutations O 0 4.008488474482874e-07
, O 0 7.465391860250747e-09
and O 0 7.000751089947244e-09
2 O 0 2.835085233243717e-08
of O 0 2.0530395161699744e-09
these O 0 1.4139417414682498e-09
11 O 0 5.716814399647774e-08
conferred O 0 8.592302833676513e-07
a O 0 1.1471175866972771e-06
milder O 0 1.4984238077886403e-05
clinical O 0 1.3261239473649766e-05
phenotype O 0 2.0828172182518756e-06
with O 0 1.1176376268906552e-08
respect O 0 1.0959370300156479e-08
to O 0 1.3234862983324547e-08
both O 0 4.305051390929293e-07
cerebellar B-Disease 1 0.5668236613273621
degeneration I-Disease 1 0.9230996370315552
and O 0 2.9339730645006057e-06
cellular O 0 0.0049570775590837
features O 0 7.753226236673072e-05
. O 0 1.119220360124018e-05

We O 0 1.6924504961934872e-06
report O 0 1.5522374496867997e-07
, O 0 1.0267489081172698e-08
in O 0 1.0706680875216534e-08
two O 0 5.919270762433371e-08
A B-Disease 1 0.9811098575592041
- I-Disease 1 0.9663927555084229
T I-Disease 1 0.9937580823898315
families O 0 1.8872128748625983e-08
, O 0 5.471452180216829e-09
an O 0 1.0259149973990134e-08
ATM O 0 1.1644217011053115e-05
mutation O 0 1.0791908380269888e-06
( O 0 1.3414389599120113e-08
7271T O 0 1.4431624322241987e-06
- O 0 9.282414794142824e-06
- O 0 1.648756006034091e-05
> O 0 1.2845979426856502e-06
G O 0 3.9192664189613424e-06
) O 0 6.1482121616052154e-09
that O 0 2.879433358415895e-09
may O 0 2.0917850562796048e-08
be O 0 1.7534405039043577e-09
associated O 0 2.398594212138505e-09
with O 0 1.2560180673304444e-09
an O 0 3.5220811156477794e-08
increased O 0 1.437175455976103e-06
risk O 0 1.0643809218890965e-05
of O 0 9.053884468812612e-07
breast B-Disease 1 0.9995280504226685
cancer I-Disease 1 0.9399374723434448
in O 0 1.3423033351500635e-07
both O 0 3.930604464130738e-08
homozygotes O 0 1.03472166301799e-05
and O 0 7.817297387191502e-08
heterozygotes O 0 2.388985876677907e-06
( O 0 6.074198211081239e-08
relative O 0 5.343710540728352e-07
risk O 0 2.879841531466809e-06
12 O 0 8.337833179439258e-08
. O 0 8.429246634023002e-09
7 O 0 2.4298250878018735e-07
; O 0 9.924924881943298e-08
P O 0 4.819226887775585e-05
= O 0 5.791604280602769e-07
. O 0 9.070676654232557e-09
0025 O 0 2.1437049326777924e-06
) O 0 6.309951228189448e-09
, O 0 3.994305330934367e-09
although O 0 3.552548033525227e-09
there O 0 2.879927629706458e-09
is O 0 7.87761411658039e-09
a O 0 1.1731034987860767e-07
less O 0 7.044566814329301e-07
severe O 0 0.18007852137088776
A B-Disease 1 0.9996345043182373
- I-Disease 1 0.9981496334075928
T I-Disease 1 0.9992750287055969
phenotype O 0 3.1308468351198826e-06
in O 0 1.0148256457398475e-08
terms O 0 4.950300613870695e-09
of O 0 1.1222296425472678e-09
the O 0 1.9866670086798877e-08
degree O 0 8.538342513020325e-07
of O 0 7.9095639193838e-07
cerebellar B-Disease 1 0.9971394538879395
degeneration I-Disease 1 0.9990229606628418
. O 0 8.948055619839579e-05

This O 0 9.555515134707093e-07
mutation O 0 1.0296562322764657e-05
( O 0 7.357439102406715e-08
7271T O 0 2.919008693424985e-06
- O 0 4.862834612140432e-05
- O 0 2.7753394533647224e-05
> O 0 1.5007715319370618e-06
G O 0 1.95640586753143e-06
) O 0 1.0929388505331872e-09
also O 0 7.717673722318352e-10
allows O 0 2.3673996096817973e-10
expression O 0 8.127362671750404e-10
of O 0 3.1681002266026326e-10
full O 0 9.765590114341194e-09
- O 0 1.277001331345673e-07
length O 0 1.673656235823273e-08
ATM O 0 1.686875350515038e-07
protein O 0 2.1339614519888528e-08
at O 0 1.2124115933431767e-08
a O 0 9.765776631809331e-09
level O 0 2.8182746802940528e-08
comparable O 0 9.146879875743252e-08
with O 0 5.664062996402208e-09
that O 0 4.754233451365053e-09
in O 0 8.216117919346289e-08
unaffected O 0 1.1378410817997064e-05
individuals O 0 1.2842473040564073e-07
. O 0 8.919955121200474e-07

In O 0 8.530333843737026e-07
addition O 0 1.0414314743911746e-07
, O 0 2.6940423225596533e-08
we O 0 6.289668341707966e-09
have O 0 2.782975405679622e-09
studied O 0 1.8333098239509127e-07
18 O 0 1.5339089713961584e-06
A B-Disease 1 0.9885082840919495
- I-Disease 1 0.9992159605026245
T I-Disease 1 0.9998643398284912
patients O 0 7.791121788613964e-06
, O 0 1.1427502499827824e-08
in O 0 9.520176647015433e-09
15 O 0 1.7974008059695734e-08
families O 0 4.283507326618974e-09
, O 0 1.921899972501251e-08
who O 0 6.726012884428201e-07
developed O 0 0.00034690386382862926
leukemia B-Disease 1 0.9999291896820068
, O 0 0.017029602080583572
lymphoma B-Disease 1 0.9999985694885254
, O 0 1.2277690075279679e-05
preleukemic O 0 0.007785979192703962
T O 0 0.061561357229948044
- O 0 0.00018739872029982507
cell O 0 5.337906623026356e-05
proliferation O 0 8.60842628753744e-05
, O 0 1.5440742799910367e-06
or O 0 0.0006976224249228835
Hodgkin B-Disease 1 0.9999936819076538
lymphoma I-Disease 1 0.9999995231628418
, O 0 8.169477041519713e-06
mostly O 0 2.98176615842749e-07
in O 0 4.627605449059047e-06
childhood O 0 0.0013089546700939536
. O 0 8.347265065822285e-06

A O 0 5.433337264548754e-06
wide O 0 4.943401563650696e-07
variety O 0 1.1677902733708834e-07
of O 0 3.300520035054433e-08
ATM O 0 9.864007733995095e-05
mutation O 0 8.29836426419206e-06
types O 0 1.2599218734976603e-07
, O 0 1.2869796783832044e-08
including O 0 2.707952084790577e-08
missense O 0 1.162799344456289e-05
mutations O 0 2.3257534849108197e-06
and O 0 2.299322687804306e-08
in O 0 9.737954087540857e-08
- O 0 7.852377166273072e-06
frame O 0 3.986696356150787e-06
deletions O 0 3.293791621672426e-07
, O 0 2.6066173219874145e-08
were O 0 2.029431556138661e-08
seen O 0 2.7045743422604573e-07
in O 0 3.249089886026013e-08
these O 0 2.7420787418463988e-08
patients O 0 5.105006493977271e-06
. O 0 1.1737296290448285e-06

We O 0 3.859229593672353e-07
also O 0 2.0781842025030528e-08
show O 0 1.4561848615812778e-08
that O 0 7.890753050965316e-10
25 O 0 1.8454154870894968e-09
% O 0 3.222671018932033e-10
of O 0 5.828962312826036e-10
all O 0 1.5150186882806338e-08
A B-Disease 1 0.9974493384361267
- I-Disease 1 0.9973435997962952
T I-Disease 1 0.9998019337654114
patients O 0 3.1678487175668124e-06
carried O 0 7.108097577201988e-08
in O 0 2.303712420825832e-08
- O 0 1.7479370626460877e-06
frame O 0 9.867953849607147e-07
deletions O 0 2.4944188226072583e-07
or O 0 6.399329066653081e-08
missense O 0 8.568738849135116e-06
mutations O 0 3.289677579232375e-06
, O 0 7.224204789935129e-09
many O 0 3.0137647932804157e-10
of O 0 6.947379893595951e-10
which O 0 6.393275242544405e-09
were O 0 8.754152958090344e-09
also O 0 6.0631539788857935e-09
associated O 0 5.928238788754925e-09
with O 0 1.4504377698898452e-09
expression O 0 1.0073623712969493e-08
of O 0 9.859807192924563e-09
mutant O 0 1.453165623388486e-06
ATM O 0 2.6187019102508202e-05
protein O 0 9.904527360049542e-06
. O 0 2.2497522422781913e-06

The O 0 4.071444891451392e-06
DMPK O 0 0.0004408113018143922
gene O 0 4.94604573759716e-05
of O 0 4.872887075180188e-06
severely O 1 0.9948469400405884
affected O 1 0.6364154815673828
myotonic B-Disease 1 0.9999845027923584
dystrophy I-Disease 1 0.9999955892562866
patients O 1 0.9915915727615356
is O 0 2.3670494556427002e-05
hypermethylated O 0 0.000510116689838469
proximal O 0 2.9425527827697806e-05
to O 0 7.345183661300325e-08
the O 0 1.4135035542039986e-07
largely O 0 5.76142042518768e-07
expanded O 0 6.29487112746574e-06
CTG O 0 0.0008189610671252012
repeat O 0 9.337136725662276e-05
. O 0 4.505773631535703e-06

Using O 0 1.3019857760809828e-06
methylation O 0 1.6068674085545354e-05
- O 0 1.2639183296414558e-05
sensitive O 0 2.2459105366579024e-06
restriction O 0 2.7500303190208797e-07
enzymes O 0 2.227630773177225e-07
, O 0 2.4000232912158026e-08
we O 0 5.403264502490401e-09
characterized O 0 8.086979619292833e-08
the O 0 1.0306751008215542e-08
methylation O 0 7.007594149399665e-08
pattern O 0 1.0043832077144543e-07
on O 0 1.2147215677771328e-08
the O 0 6.635008098498929e-09
5 O 0 2.0918328402785846e-08
side O 0 1.9481371182905605e-08
of O 0 3.5840186374258565e-09
the O 0 5.893630117270732e-08
CTG O 0 1.178691309178248e-05
repeat O 0 4.710530845386529e-07
in O 0 9.290546110207742e-09
the O 0 8.89633611222962e-09
DMPK O 0 3.4491765745769953e-06
gene O 0 7.591944495288772e-08
of O 0 4.146305077057377e-09
normal O 0 7.589599704260763e-08
individuals O 0 1.0251437476682668e-09
and O 0 6.913965400201505e-09
of O 0 6.584230760608989e-08
patients O 0 1.3916112038714346e-05
affected O 0 1.6653028751534293e-06
with O 0 9.983011113945395e-05
myotonic B-Disease 1 0.9999850988388062
dystrophy I-Disease 1 0.9999904632568359
, O 0 1.7735034134602756e-06
showing O 0 6.020311502652476e-07
expansions O 0 1.063991589944635e-06
of O 0 4.1021380070560554e-08
the O 0 4.560255035812588e-07
repetitive O 0 0.0003553495043888688
sequence O 0 1.1340754099364858e-05
. O 0 2.420858436380513e-06

The O 0 1.2748198514600517e-06
gene O 0 2.6434277060616296e-06
segment O 0 2.8133447358413832e-06
analyzed O 0 3.993180826000753e-07
corresponds O 0 9.572509895861003e-08
to O 0 5.302698724563015e-09
the O 0 4.0769823073105727e-08
genomic O 0 2.4471878532494884e-06
SacI O 0 1.676627653068863e-05
- O 0 7.799128979968373e-06
HindIII O 0 5.508772119355854e-06
fragment O 0 4.999913016945357e-07
carrying O 0 1.0206612444108032e-07
exons O 0 1.5327948403864866e-06
11 O 0 1.0025206620412064e-06
- O 0 3.240170917706564e-05
15 O 0 1.7590441530046519e-06
. O 0 1.086916881831712e-06

There O 0 1.0322764865122736e-06
is O 0 1.4918414592557383e-07
constitutive O 0 7.754774742352311e-07
methylation O 0 8.083970897132531e-07
in O 0 6.610782321558872e-08
intron O 0 1.1038438060495537e-05
12 O 0 1.4990619945365324e-07
at O 0 5.5995833747601864e-08
restriction O 0 1.1119794862679555e-08
sites O 0 6.132190755181455e-09
of O 0 3.3797742382546403e-09
SacII O 0 1.5554397805317421e-06
and O 0 2.5724782304337168e-08
HhaI O 0 6.3006482378114015e-06
, O 0 2.2331413163101388e-08
localized O 0 5.157776286068838e-07
1 O 0 7.754362485457023e-08
, O 0 5.828075355651663e-09
159 O 0 6.245868888754558e-08
- O 0 1.0620098009894718e-06
1 O 0 2.7657684142923245e-08
, O 0 2.5873276854326832e-09
232 O 0 1.701998009195904e-08
bp O 0 1.027133222919474e-07
upstream O 0 1.67419891283771e-08
of O 0 9.848131199419186e-10
the O 0 1.703179997036841e-08
CTG O 0 6.469715572166024e-06
repeat O 0 5.538939262805798e-07
, O 0 8.074923840695192e-09
whereas O 0 1.5514672213612357e-08
most O 0 5.768895583457834e-09
, O 0 5.932763169624877e-09
if O 0 2.930026443692668e-09
not O 0 3.1651950505029447e-10
all O 0 1.5320486546066547e-10
, O 0 5.750480647215284e-10
of O 0 1.7467435831086675e-10
the O 0 7.148581171456669e-10
other O 0 1.6883068554296443e-10
sites O 0 5.677951886440269e-09
of O 0 3.757065325515896e-09
SacII O 0 4.004822585557122e-06
, O 0 2.7659897483545137e-08
HhaI O 0 1.563578052810044e-06
, O 0 1.0917893256134903e-08
and O 0 1.1956337253593574e-08
HpaII O 0 7.75756507209735e-06
in O 0 8.035303977749209e-08
this O 0 8.659807981814538e-09
region O 0 9.08051163150958e-08
are O 0 3.682767202306536e-09
unmethylated O 0 1.2475830999392201e-06
, O 0 2.759245276706679e-08
in O 0 2.0790803745285302e-08
normal O 0 7.81640281388718e-08
individuals O 0 6.905211402674638e-10
and O 0 2.4409763099697557e-09
most O 0 4.002290054927471e-09
of O 0 1.4953876359413698e-08
the O 0 1.888925339699199e-06
patients O 0 6.780063267797232e-05
. O 0 2.2523840925714467e-06

In O 0 8.271400702142273e-07
a O 0 8.671364781775992e-08
number O 0 8.802222062342935e-09
of O 0 7.400037027593953e-09
young O 0 5.69907285807858e-07
and O 0 2.1622824988298817e-06
severely O 1 0.8475490212440491
affected O 0 2.0580551790772006e-05
patients O 0 3.3129039366031066e-05
, O 0 7.487998487931691e-08
however O 0 1.5778754303141795e-08
, O 0 1.3839250856406693e-09
complete O 0 7.13748082858956e-09
methylation O 0 7.098800658411619e-09
of O 0 3.741802145906803e-10
these O 0 1.9581676558022565e-10
restriction O 0 4.50171588894932e-09
sites O 0 9.786063515093701e-09
was O 0 8.101389994408237e-07
found O 0 1.51852521668161e-08
in O 0 9.704612224936682e-09
the O 0 3.698403361340752e-08
mutated O 0 5.639924893330317e-06
allele O 0 4.8345414143113885e-06
. O 0 1.3640803899761522e-06

In O 0 7.852248131712258e-07
most O 0 3.27408571365595e-08
of O 0 1.187655840340085e-08
these O 0 9.682499246821408e-09
patients O 0 3.031976234524336e-07
, O 0 8.859574407438231e-09
the O 0 3.518750446573904e-08
onset O 0 0.00012894303654320538
of O 0 3.7249157003316213e-07
the O 0 0.000331460585584864
disease O 1 0.9996699094772339
was O 1 0.9963122010231018
congenital O 1 0.9999524354934692
. O 0 0.0001346716016996652

Preliminary O 0 2.3166103346738964e-05
in O 0 2.595440719233011e-06
vivo O 0 4.935999822919257e-05
footprinting O 0 0.00022701108537148684
data O 0 2.133536582960005e-07
gave O 0 5.118834067729949e-08
evidence O 0 4.021220689764959e-09
for O 0 2.3005586324842398e-09
protein O 0 5.6582894814027895e-08
- O 0 6.573815198862576e-07
DNA O 0 1.0612205869620084e-07
contact O 0 2.6118627260984795e-08
in O 0 7.961006964762873e-09
normal O 0 1.6355494381059543e-07
genes O 0 3.328272057956383e-08
at O 0 9.515405707816171e-08
an O 0 8.834296849613565e-09
Sp1 O 0 1.1713254934875295e-06
consensus O 0 1.1909951247446315e-08
binding O 0 3.8022967885353864e-08
site O 0 3.373946810825146e-08
upstream O 0 2.8293589693362264e-08
of O 0 1.39043898617075e-09
the O 0 2.4515175667261246e-08
CTG O 0 3.372398168721702e-06
repeat O 0 2.387481856658269e-07
and O 0 3.6614609122409547e-09
for O 0 9.006093648622482e-10
a O 0 3.02781479888381e-08
significant O 0 2.9680172985990794e-08
reduction O 0 2.3392729531224177e-07
of O 0 6.010083541951872e-10
this O 0 3.1842448122709754e-10
interaction O 0 1.8415617919487204e-09
in O 0 5.156263860328636e-09
cells O 0 1.2989575637334383e-08
with O 0 7.142015423511339e-09
a O 0 2.4310722324116796e-07
hypermethylated O 0 7.488256960641593e-05
DMPK O 0 0.00028836523415520787
gene O 0 2.779961278065457e-06
. O 0 1.5024470201296936e-07
. O 0 8.696082431924879e-07

The O 0 4.3849460780620575e-05
hemochromatosis B-Disease 1 0.9983218312263489
gene O 0 3.5101198591291904e-05
product O 0 7.971713671395264e-07
complexes O 0 8.005700351532141e-07
with O 0 1.7321539758086146e-08
the O 0 4.788016028101083e-08
transferrin O 0 6.54203995509306e-06
receptor O 0 1.2754205727105727e-06
and O 0 3.080932842181028e-08
lowers O 0 1.5642582411601325e-06
its O 0 5.782931022935145e-09
affinity O 0 5.696015037415236e-08
for O 0 1.8121856015795856e-08
ligand O 0 2.1752528027718654e-06
binding O 0 8.557126420782879e-06
. O 0 2.5159379219985567e-06

We O 0 5.032682111050235e-06
recently O 0 2.041743755398784e-05
reported O 0 4.3537463056964043e-07
the O 0 9.851799376292547e-09
positional O 0 1.6724889917441033e-07
cloning O 0 9.821221169659111e-08
of O 0 8.922794947352486e-09
a O 0 4.2292793978049303e-07
candidate O 0 2.4818646124913357e-06
gene O 0 9.450285688217264e-06
for O 0 3.432363155297935e-05
hereditary B-Disease 1 0.9999785423278809
hemochromatosis I-Disease 1 0.9999983310699463
called O 1 0.9369997382164001
HFE O 1 0.9855502843856812
. O 0 6.16862453171052e-05

The O 0 5.651763217429107e-07
gene O 0 1.1605663985392312e-06
product O 0 1.8004858759468334e-07
, O 0 1.5545923659487926e-08
a O 0 2.875318649842029e-08
member O 0 1.6946835046383057e-08
of O 0 1.9220787184082155e-09
the O 0 1.1072813776991097e-07
major O 0 1.076091757568065e-05
histocompatibility O 0 0.3437455892562866
complex O 0 0.0007761369342915714
class O 0 3.802839637501165e-05
I O 0 4.282834197510965e-05
- O 0 6.076381851016777e-06
like O 0 4.5887816213507904e-08
family O 0 7.593175865849844e-08
, O 0 1.8596631790046558e-08
was O 0 9.788827810552903e-07
found O 0 3.157050842972353e-09
to O 0 2.22266025029505e-10
have O 0 6.065649094111336e-10
a O 0 1.3353479211275499e-08
mutation O 0 2.0314267601406755e-07
, O 0 1.5082404658528503e-08
Cys O 0 1.7686321371002123e-05
- O 0 4.249561243341304e-06
282 O 0 9.672605756350094e-07
- O 0 1.2120692190364935e-05
- O 0 1.0104450666403864e-05
> O 0 5.358571115721134e-07
Tyr O 0 1.0238233016934828e-06
( O 0 4.4141397204100485e-09
C282Y O 0 7.156172188160781e-08
) O 0 1.1201383154357814e-09
, O 0 7.159865478278959e-10
in O 0 2.5418278593036803e-09
85 O 0 2.8839638233080223e-08
% O 0 6.485933568001201e-09
of O 0 1.5707376732621015e-08
patient O 0 2.6146446543862112e-05
chromosomes O 0 1.1077805538661778e-05
. O 0 2.2549331788468407e-06

This O 0 2.4322807803400792e-06
mutation O 0 2.422800025669858e-05
eliminates O 0 3.7010040614404716e-06
the O 0 4.672233089308975e-08
ability O 0 6.962960696910159e-08
of O 0 1.5539017184096338e-08
HFE O 0 5.106177559355274e-05
to O 0 1.516614744900835e-08
associate O 0 1.2746019706355582e-07
with O 0 9.317328419911064e-08
beta2 O 0 0.0007769674994051456
- O 0 0.00042098716949112713
microglobulin O 0 8.896191138774157e-05
( O 0 5.502674227386706e-08
beta2m O 0 2.8947354167030426e-06
) O 0 1.035370367219457e-08
and O 0 1.4576687412670708e-08
prevents O 0 1.1212353001610609e-06
cell O 0 0.000334373238729313
- O 0 0.0003223894746042788
surface O 0 9.092230175156146e-05
expression O 0 8.149432687787339e-06
. O 0 2.1433002075355034e-06

A O 0 1.8523851395002566e-05
second O 0 4.018649633508176e-06
mutation O 0 7.3574351517891046e-06
that O 0 2.1335178956860545e-08
has O 0 7.394919521175325e-08
no O 0 1.2876892441227028e-08
effect O 0 3.963019423736114e-08
on O 0 1.954763177991481e-07
beta2m O 0 5.785233952337876e-05
association O 0 4.251237442076672e-07
, O 0 2.470010151967017e-08
H63D O 0 4.256604370311834e-05
, O 0 6.135983454669258e-08
was O 0 2.3495626919611823e-06
found O 0 1.0993328025676874e-08
in O 0 1.078673927956686e-09
eight O 0 8.864370348860007e-10
out O 0 4.090344174478844e-10
of O 0 5.234165323386719e-10
nine O 0 2.9725949701742138e-08
patients O 0 9.477350459974332e-08
heterozygous O 0 2.8934847406958397e-08
for O 0 4.080449755861082e-09
the O 0 1.3449083269279072e-07
C282Y O 0 1.5784427887410857e-05
mutant O 0 2.1820531401317567e-05
. O 0 1.8444719671606435e-06

In O 0 1.7146458048955537e-06
this O 0 1.2622562906017265e-07
report O 0 9.839164505365261e-08
, O 0 6.333004787251184e-09
we O 0 1.4908018153292346e-09
demonstrate O 0 7.2506263215643685e-09
in O 0 7.496169018850196e-09
cultured O 0 3.980048859375529e-07
293 O 0 4.2268922584298707e-07
cells O 0 6.396790581675305e-07
overexpressing O 0 1.0189558452111669e-05
wild O 0 1.9069129848503508e-06
- O 0 3.744541754713282e-05
type O 0 3.826761712844018e-06
or O 0 4.245556795012817e-08
mutant O 0 7.122828833416861e-07
HFE O 0 6.580629360541934e-06
proteins O 0 1.0922975413052427e-08
that O 0 1.298865126564408e-09
both O 0 1.634467339250989e-09
the O 0 1.5494267202598166e-08
wild O 0 4.801752311323071e-07
- O 0 3.608042607083917e-05
type O 0 5.412408427218907e-06
and O 0 6.4507005959058e-08
H63D O 0 7.800391904311255e-05
HFE O 0 4.5392884203465655e-05
proteins O 0 4.628222427527362e-08
form O 0 5.1803983325271474e-08
stable O 0 1.1107903219453874e-06
complexes O 0 2.2175264291490748e-07
with O 0 8.757843339424198e-09
the O 0 3.314778140861563e-08
transferrin O 0 2.941682942037005e-05
receptor O 0 5.74863952351734e-06
( O 0 2.2056585180507682e-07
TfR O 0 8.096770761767402e-05
) O 0 1.5641775519270595e-07
. O 0 8.373083915103052e-07

The O 0 3.280792043369729e-06
C282Y O 0 0.00012066171620972455
mutation O 0 4.509294740273617e-05
nearly O 0 8.147607104547205e-07
completely O 0 1.2421575092957937e-06
prevents O 0 2.0853759963301854e-07
the O 0 3.373727963662532e-08
association O 0 4.23024744122813e-08
of O 0 2.438593549314305e-09
the O 0 3.5710485235540546e-08
mutant O 0 1.2114381888750358e-06
HFE O 0 1.5693229215685278e-05
protein O 0 2.7793251433649857e-07
with O 0 8.515981164691766e-08
the O 0 8.916280762605311e-07
TfR O 0 0.0011374170426279306
. O 0 3.4347071959928144e-06

Studies O 0 3.825130534096388e-06
on O 0 9.501782187726349e-07
cell O 0 7.586843275930732e-05
- O 0 2.6308722226531245e-05
associated O 0 2.874181745937676e-07
transferrin O 0 2.9915695449744817e-06
at O 0 3.3202962868017494e-07
37 O 0 8.55037214364529e-08
degrees O 0 3.8531094759264306e-08
C O 0 1.7994062773141195e-07
suggest O 0 9.139969670002301e-09
that O 0 1.9416890317813795e-09
the O 0 1.8198509366129656e-08
overexpressed O 0 2.559148242653464e-06
wild O 0 3.755373256808525e-07
- O 0 8.637641258246731e-06
type O 0 1.967500793398358e-06
HFE O 0 2.2471431293524802e-05
protein O 0 2.3942811822053045e-07
decreases O 0 9.931230948723169e-08
the O 0 2.03264605147524e-09
affinity O 0 1.3941469312328536e-08
of O 0 4.202756365145888e-09
the O 0 8.455448607946892e-08
TfR O 0 3.181556530762464e-05
for O 0 2.672463779163081e-07
transferrin O 0 0.0002698318858165294
. O 0 4.060610990563873e-06

The O 0 7.772805474814959e-06
overexpressed O 0 0.00044249798520468175
H63D O 0 0.0008518456015735865
protein O 0 7.228408776427386e-06
does O 0 9.271202117133726e-08
not O 0 4.262918906761115e-09
have O 0 1.0396878913354612e-09
this O 0 5.945050562949916e-10
effect O 0 7.751401298605742e-09
, O 0 8.338526535922597e-10
providing O 0 1.0661516114396363e-09
the O 0 9.527473254777874e-10
first O 0 7.638111254593127e-10
direct O 0 6.13076089894804e-10
evidence O 0 2.144205257792464e-09
for O 0 1.3224055184224426e-09
a O 0 4.05514306578425e-08
functional O 0 7.134393342766998e-08
consequence O 0 1.6599103958014894e-07
of O 0 1.0401704386708843e-08
the O 0 5.875827469026262e-07
H63D O 0 0.010105753317475319
mutation O 0 8.702361083123833e-05
. O 0 1.63327979407768e-06

Addition O 0 2.342367452001781e-06
of O 0 3.833303594547033e-07
soluble O 0 0.00019071329734288156
wild O 0 4.562937465379946e-05
- O 0 0.0013495993334800005
type O 0 0.0001324808836216107
HFE O 0 0.0032759816385805607
/ O 0 1.238830645888811e-05
beta2m O 0 2.705791666812729e-05
heterodimers O 0 6.761340500816004e-06
to O 0 2.0092954855499556e-08
cultured O 0 7.720226449237089e-07
cells O 0 4.275457570201979e-07
also O 0 1.705410035413024e-08
decreased O 0 1.4217341970379493e-07
the O 0 5.234646494045592e-09
apparent O 0 8.561093522985175e-08
affinity O 0 2.197622706034963e-08
of O 0 2.0787778165498594e-09
the O 0 1.6873297425945566e-08
TfR O 0 6.316552685348142e-07
for O 0 3.715375229695894e-10
its O 0 1.0853522525167136e-09
ligand O 0 1.2806350646599185e-08
under O 0 3.149690641635061e-08
steady O 0 1.4198982398738735e-06
- O 0 1.6486696040374227e-05
state O 0 1.7246794925540598e-07
conditions O 0 1.007575747280498e-06
, O 0 3.311338980793721e-09
both O 0 1.1834063728954902e-09
in O 0 8.504355442084943e-09
293 O 0 5.4744720756616516e-08
cells O 0 6.377554484515713e-08
and O 0 1.580462694050766e-08
in O 0 3.4066093235196604e-07
HeLa O 0 0.0005197406862862408
cells O 0 1.5051781701913569e-05
. O 0 8.909234452403325e-07

Furthermore O 0 2.8555725748447003e-06
, O 0 1.1662277188406733e-07
at O 0 2.3531768533757713e-07
4 O 0 8.913970361845713e-08
degrees O 0 7.112355859817399e-08
C O 0 2.5710073714435566e-07
, O 0 5.605104824724094e-09
the O 0 1.011459360711342e-08
added O 0 2.086565586978395e-07
soluble O 0 2.6998038720194018e-06
complex O 0 1.338540300821478e-06
of O 0 8.201963197507212e-08
HFE O 0 0.00046556268353015184
/ O 0 6.58812723486335e-06
beta2m O 0 1.2081293789378833e-05
inhibited O 0 4.152354051711882e-07
binding O 0 3.4604596521603526e-08
of O 0 3.4611640220560957e-09
transferrin O 0 1.430838210580987e-06
to O 0 6.98787783193211e-09
HeLa O 0 1.0091979675053153e-05
cell O 0 4.608337803801987e-06
TfR O 0 1.219816658704076e-05
in O 0 4.75129873223068e-08
a O 0 3.526528189468081e-07
concentration O 0 0.0001786338834790513
- O 0 4.9130125262308866e-05
dependent O 0 1.825836534408154e-06
manner O 0 9.387767022417393e-06
. O 0 3.7568056541203987e-06

Scatchard O 0 6.380772538250312e-05
plots O 0 3.0812877866992494e-06
of O 0 4.495968752848967e-08
these O 0 5.0530037931650895e-09
data O 0 5.876489694855991e-08
indicate O 0 4.813085396904171e-08
that O 0 2.716807667724197e-09
the O 0 1.524584902767856e-08
added O 0 9.9718114654479e-08
heterodimer O 0 5.102704108139733e-06
substantially O 0 1.6010785657272208e-06
reduced O 0 1.0353807056162623e-07
the O 0 5.563840943523246e-09
affinity O 0 5.344454478972693e-08
of O 0 3.161487782676886e-08
TfR O 0 5.0022455980069935e-05
for O 0 2.8145848318672506e-07
transferrin O 0 0.00042759740608744323
. O 0 4.508236543188104e-06

These O 0 3.674546178444871e-07
results O 0 4.813861664842989e-07
establish O 0 1.3661501441220025e-07
a O 0 1.930549160533701e-07
molecular O 0 2.5080994419113267e-06
link O 0 1.4783768165216316e-06
between O 0 2.3233140211686987e-07
HFE O 0 0.00015084014739841223
and O 0 3.793017810949095e-08
a O 0 3.9763303760764757e-08
key O 0 1.1172971170481105e-07
protein O 0 4.301816858287566e-08
involved O 0 1.5635817973702615e-08
in O 0 3.0004727591403935e-08
iron O 0 8.995417738333344e-05
transport O 0 1.9085830444964813e-06
, O 0 2.026638767915756e-08
the O 0 2.99787572544119e-08
TfR O 0 2.029436109296512e-05
, O 0 7.027186388341988e-09
and O 0 4.710492440551661e-09
raise O 0 2.3680886584998007e-08
the O 0 1.2539122629107169e-08
possibility O 0 5.3191929083595824e-08
that O 0 1.710739105931225e-09
alterations O 0 2.3663915271754377e-07
in O 0 1.3707954771291497e-08
this O 0 4.542243914329447e-09
regulatory O 0 3.8385346101676987e-07
mechanism O 0 2.8084102154934953e-07
may O 0 2.4775546947353178e-08
play O 0 5.334980013316226e-09
a O 0 2.5421975635708804e-08
role O 0 9.804750789044192e-08
in O 0 4.7971933980761605e-08
the O 0 1.990653970551648e-07
pathogenesis O 0 0.0005738621694035828
of O 0 3.428371928748675e-05
hereditary B-Disease 1 0.9999841451644897
hemochromatosis I-Disease 1 0.9999980926513672
. O 0 0.00025027981610037386
. O 0 2.2317961338558234e-05

Genomic O 0 5.4417545470641926e-05
organization O 0 1.0530258123253589e-06
of O 0 4.4150340272608446e-08
the O 0 2.199828941229498e-07
UBE3A O 0 0.000793329905718565
/ O 0 3.4791326470440254e-05
E6 O 0 0.0008142203441821039
- O 0 0.0004992673057131469
AP O 0 1.5374886061181314e-05
gene O 0 9.366771678287478e-07
and O 0 1.5486297400002513e-07
related O 0 1.2920951348860399e-06
pseudogenes O 0 8.822085510473698e-05
. O 0 5.142220288689714e-06

The O 0 3.3320948205073364e-06
UBE3A O 0 0.00019952775619458407
gene O 0 2.909048589572194e-06
encodes O 0 6.118967803558917e-07
the O 0 3.1388512411467673e-07
E6 O 0 0.00010497391485841945
- O 0 4.8528007027925923e-05
AP O 0 6.085144377721008e-06
ubiquitin O 0 6.844257427474076e-07
- O 0 2.84511247627961e-06
protein O 0 8.201759982284784e-08
ligase O 0 1.0485989321296074e-07
and O 0 1.1665387766868207e-08
has O 0 3.5514386098611794e-08
recently O 0 4.225707357363717e-07
been O 0 7.079464570125538e-09
shown O 0 6.001815489042883e-09
to O 0 3.2074891631594937e-09
be O 0 1.075273132755683e-07
mutated O 0 4.619738683686592e-05
in O 0 0.0021074542310088873
Angelman B-Disease 1 0.9999812841415405
syndrome I-Disease 1 0.9999985694885254
patients O 0 0.0757761150598526
who O 0 7.097602974681649e-06
lack O 0 3.5730427043745294e-06
15q11 O 0 0.0001842867786763236
- O 0 0.00037138041807338595
q13 O 0 1.2812351997126825e-05
deletions O 0 4.6529403334716335e-06
or O 0 8.509176723237033e-07
chromosome O 0 0.00012164912914158776
15 O 0 3.3182052447955357e-06
paternal O 0 0.00023321210755966604
uniparental B-Disease 0 0.3749520778656006
disomy I-Disease 0 0.1546812504529953
. O 0 4.809030724572949e-05

Previous O 0 1.1163357157784048e-05
UBE3A O 0 0.00016107420378830284
cDNA O 0 4.69861515739467e-06
analysis O 0 7.219151711979066e-07
has O 0 1.3347080596304295e-07
shown O 0 5.2289813368133764e-08
a O 0 4.9209976538122646e-08
coding O 0 2.660666496012709e-06
region O 0 4.858636657445459e-07
of O 0 1.618226086463892e-08
approximately O 0 1.6421230952801125e-07
2 O 0 1.371726170873444e-06
. O 0 9.936040896718623e-07

6 O 0 8.112228897516616e-06
kb O 0 1.8799875761033036e-05
and O 0 3.6184468399369507e-07
a O 0 3.4017532470898004e-06
3 O 0 9.353291716251988e-06
- O 0 0.0002933219657279551
untranslated O 0 0.00013828005467075855
region O 0 2.4776409190963022e-06
( O 0 6.252948736573671e-08
UTR O 0 4.0108998291543685e-06
) O 0 9.902947795126238e-09
of O 0 4.070810799561286e-09
< O 0 2.5919086965586757e-07
50 O 0 2.375489493999794e-08
bp O 0 2.741221862834209e-07
, O 0 1.9044348320562676e-09
whereas O 0 2.7112894152026e-09
Northern O 0 1.4241680723614536e-08
analysis O 0 1.1407271571783895e-08
has O 0 1.034860996895759e-08
indicated O 0 6.952765918555315e-09
mRNA O 0 2.6031081734601003e-09
sizes O 0 8.410792950996893e-09
of O 0 4.023430477673173e-09
5 O 0 2.6997426516572887e-07
- O 0 2.1621634004986845e-05
8 O 0 2.2037315829948056e-06
kb O 0 3.765971268876456e-05
. O 0 3.654155534604797e-06

We O 0 1.1988784081040649e-06
have O 0 1.9712516063918883e-08
analyzed O 0 5.559685689604521e-08
additional O 0 6.386084994147723e-09
cDNA O 0 1.1697922275288875e-07
clones O 0 2.2731380511231691e-07
and O 0 5.9487743619968114e-09
provide O 0 2.7800945989753245e-09
evidence O 0 5.063288011086797e-09
for O 0 1.6564045690614648e-09
an O 0 1.0567744013201263e-08
additional O 0 3.825626038178598e-08
0 O 0 1.0623380148899741e-06
. O 0 7.591813186991203e-07

5 O 0 2.1548962649831083e-06
kb O 0 5.4972374528006185e-06
of O 0 1.087923280351788e-07
5 O 0 8.970088742898952e-07
- O 0 1.300587518926477e-05
UTR O 0 8.793398592388257e-06
and O 0 2.9944754231792103e-08
> O 0 1.3342511806513357e-07
2 O 0 4.0754429164735484e-08
kb O 0 5.935442572990723e-07
of O 0 4.34131592896847e-08
3 O 0 7.245317647175398e-06
- O 0 0.0007666733581572771
UTR O 0 0.001128156902268529
. O 0 4.198875103611499e-06

We O 0 2.967882437587832e-07
have O 0 1.026212448351771e-08
established O 0 2.447121438819977e-08
the O 0 1.0653817383854403e-08
genomic O 0 1.602458041816135e-07
organization O 0 1.379795566691655e-08
of O 0 3.6285350279996464e-09
UBE3A O 0 7.938741873658728e-06
and O 0 6.8226713167973685e-09
the O 0 5.348490095258285e-09
sequence O 0 3.967950945593657e-08
of O 0 3.6927708890743816e-08
intron O 0 0.00032742941402830184
- O 0 0.0004633006174117327
exon O 0 0.00020224798936396837
borders O 0 1.042237454385031e-05
. O 0 3.5437428778095637e-06

We O 0 1.5071468624228146e-06
have O 0 5.8279674419736693e-08
also O 0 3.3483164685321753e-08
mapped O 0 2.5947034032469674e-07
two O 0 8.067134515954422e-09
highly O 0 1.0652644277797663e-07
homologous O 0 1.9198506606699084e-07
processed O 0 2.132334486759646e-07
pseudogenes O 0 1.1143339406771702e-06
, O 0 4.4595175552331057e-08
UBE3AP1 O 0 5.331095235305838e-05
and O 0 6.302448696260399e-08
UBE3AP2 O 0 3.306613507447764e-05
, O 0 4.343591264444058e-09
to O 0 4.190619795618744e-10
chromosomes O 0 1.1349434281271442e-08
2 O 0 7.0039027910695495e-09
and O 0 3.41962702599119e-09
21 O 0 3.174575624598219e-08
, O 0 4.354117510985134e-09
respectively O 0 2.625177764059572e-08
, O 0 3.357114142232831e-09
and O 0 3.6753708965164833e-09
determined O 0 6.392156137735583e-08
their O 0 1.364222601552001e-08
genomic O 0 2.949332611024147e-06
organization O 0 5.782960670330795e-07
. O 0 5.195042831473984e-07

These O 0 6.017745590725099e-07
results O 0 2.7576147658692207e-06
will O 0 7.838794502390556e-09
form O 0 5.71740077504046e-09
the O 0 2.5379474077880104e-09
basis O 0 1.9241108706324894e-09
for O 0 1.2112367775429789e-09
studies O 0 7.436074422884076e-09
of O 0 3.911277968171589e-09
mutation O 0 2.780340651042934e-07
and O 0 2.873542293002629e-08
imprinting O 0 6.690993359370623e-06
of O 0 6.578098350473738e-07
UBE3A O 0 0.006847806740552187
. O 0 1.1080964213761035e-05

Mutation O 0 0.00021515158005058765
spectrum O 0 1.872222674137447e-05
and O 0 1.0572380233497825e-06
genotype O 0 6.956129072932526e-05
- O 0 0.0006613144651055336
phenotype O 0 7.426679076161236e-05
analyses O 0 2.9187858672230504e-06
in O 0 2.50501807386172e-06
Cowden B-Disease 1 0.8982818722724915
disease I-Disease 1 0.9315643310546875
and O 0 1.6673095160513185e-05
Bannayan B-Disease 1 0.9968578815460205
- I-Disease 1 0.9998078942298889
Zonana I-Disease 1 0.9998119473457336
syndrome I-Disease 1 0.9999558925628662
, O 0 4.338611688581295e-06
two O 0 6.9544789766951e-06
hamartoma B-Disease 1 0.9818091988563538
syndromes I-Disease 0 0.43108105659484863
with O 0 2.9080334570608102e-05
germline O 0 0.3320672810077667
PTEN O 1 0.8122125267982483
mutation O 0 0.015452644787728786
. O 0 1.1443987204984296e-05

The O 0 0.00015989468374755234
tumour B-Disease 1 0.9995049238204956
suppressor O 0 0.0027712027076631784
gene O 0 0.00015765527496114373
PTEN O 0 0.002324066823348403
, O 0 2.3954760308697587e-07
which O 0 3.69573065484019e-08
maps O 0 2.339656646199728e-07
to O 0 1.025837121915174e-07
10q23 O 0 8.299688488477841e-05
. O 0 4.882562279817648e-06

3 O 0 1.0628284599079052e-06
and O 0 3.077162702425085e-08
encodes O 0 1.2493721612827358e-07
a O 0 1.2392061421451217e-07
403 O 0 1.3830739931108837e-07
amino O 0 6.567950094904518e-08
acid O 0 1.5846892154058878e-07
dual O 0 1.4157430427985673e-07
specificity O 0 2.878323641652969e-07
phosphatase O 0 0.00013533768651541322
( O 0 5.599135022293922e-08
protein O 0 2.8640769755838846e-07
tyrosine O 0 1.7402229559593252e-06
phosphatase O 0 0.00013421419134829193
; O 0 2.4345654381363602e-08
PTPase O 0 1.8349153378949268e-06
) O 0 8.09154432346304e-09
, O 0 9.144957680007337e-09
was O 0 1.0723970262915827e-06
shown O 0 2.6317955814647576e-08
recently O 0 1.0223095614492195e-07
to O 0 2.2237203745056888e-10
play O 0 4.540884113168886e-09
a O 0 1.799815763092738e-08
broad O 0 5.840374939225512e-08
role O 0 6.759759685337485e-07
in O 0 1.5105802049220074e-06
human O 0 1.0974966244248208e-05
malignancy B-Disease 1 0.8371478915214539
. O 0 6.2413532759819645e-06

Somatic O 0 0.0003690033918246627
PTEN O 0 0.001701213070191443
deletions O 0 2.187557765864767e-05
and O 0 8.493852874380536e-07
mutations O 0 1.3410954124992713e-05
were O 0 1.1403012223354381e-07
observed O 0 5.234479658611235e-07
in O 0 1.886875082846018e-07
sporadic B-Disease 0 0.00029539078241214156
breast I-Disease 1 0.988775372505188
, I-Disease 0 1.4881604329275433e-05
brain I-Disease 1 0.8491083383560181
, I-Disease 0 7.199793617473915e-05
prostate I-Disease 1 0.9998277425765991
and I-Disease 0 0.0020263560581952333
kidney I-Disease 1 0.9999113082885742
cancer I-Disease 1 0.9996163845062256
cell O 0 0.000944390834774822
lines O 0 7.500507763325004e-06
and O 0 4.0080525565144853e-08
in O 0 1.5220802396243016e-08
several O 0 3.063967213279284e-08
primary O 0 4.5995042455615476e-05
tumours B-Disease 1 0.9992936849594116
such O 0 1.0332594229112146e-06
as O 0 0.003406341653317213
endometrial B-Disease 1 0.9998825788497925
carcinomas I-Disease 1 0.9999878406524658
, O 1 0.9992352724075317
malignant B-Disease 1 0.9999992847442627
melanoma I-Disease 1 0.9999992847442627
and O 1 0.998977541923523
thyroid B-Disease 1 0.9999899864196777
tumours I-Disease 1 0.9999760389328003
. O 0 0.0009638705523684621

In O 0 1.3263565961096901e-06
addition O 0 5.094289008411579e-07
, O 0 2.2376870845164376e-07
PTEN O 0 0.00014181579172145575
was O 0 1.7778449546312913e-05
identified O 0 1.6577193662214995e-07
as O 0 1.046340880606067e-08
the O 0 1.7889732362164068e-08
susceptibility O 0 1.09363475075952e-06
gene O 0 1.967570995020651e-07
for O 0 6.255454110259961e-08
two O 0 5.544094165088609e-06
hamartoma B-Disease 1 0.997399091720581
syndromes I-Disease 1 0.9988718628883362
Cowden B-Disease 1 0.9994946718215942
disease I-Disease 1 0.9994972944259644
( O 0 4.3148585859853483e-07
CD B-Disease 0 4.350579183665104e-05
; O 0 4.855889415011916e-07
MIM O 0 0.00021824787836521864
158350 O 0 1.9201823306502774e-05
) O 0 2.7349646103402847e-08
and O 0 1.2511581815033423e-07
Bannayan B-Disease 0 0.001471662544645369
- I-Disease 0 0.00863694492727518
Zonana I-Disease 0 0.0072309901006519794
( I-Disease 0 1.565454965657409e-07
BZS I-Disease 0 1.4528950487147085e-05
) I-Disease 0 2.880670635363458e-08
or I-Disease 0 4.877517767454265e-08
Ruvalcaba I-Disease 0 0.00015075560077093542
- I-Disease 0 0.0007019098266027868
Riley I-Disease 0 0.0004244200827088207
- I-Disease 1 0.5196199417114258
Smith I-Disease 0 0.04192609712481499
syndrome I-Disease 1 0.9996107220649719
( O 0 1.2549934353955905e-06
MIM O 0 0.0010535953333601356
153480 O 0 0.00019657512893900275
) O 0 7.609746717207599e-07
. O 0 1.4599595488107298e-06

Constitutive O 0 1.931954648171086e-05
DNA O 0 1.1909553904843051e-05
from O 0 1.5064182434798568e-07
37 O 0 2.7705630145646865e-07
CD B-Disease 0 8.529633532816661e-07
families O 0 2.5618431820362275e-08
and O 0 1.743929090025631e-08
seven O 0 6.673798225165228e-08
BZS B-Disease 0 9.540977771393955e-06
families O 0 4.0606540352428055e-08
was O 0 1.8491160744815716e-06
screened O 0 1.6926441048781271e-06
for O 0 5.311832751431211e-07
germline O 0 0.0012736818753182888
PTEN O 0 0.0198984257876873
mutations O 0 0.001132455188781023
. O 0 9.205560672853608e-06

PTEN O 0 0.01643524318933487
mutations O 0 0.00019966209947597235
were O 0 7.307705232051376e-07
identified O 0 5.182760673960729e-07
in O 0 2.9343732776965226e-08
30 O 0 2.477790950194958e-08
of O 0 4.6982622237123906e-09
37 O 0 4.83565756326243e-08
( O 0 9.677717294209742e-09
81 O 0 7.040107874445312e-08
% O 0 2.1842490038892493e-09
) O 0 1.0869971589499983e-09
CD B-Disease 0 6.891757209359639e-08
families O 0 2.790693454102211e-09
, O 0 6.357475879070762e-09
including O 0 1.52158108335243e-08
missense O 0 2.0045085875608493e-06
and O 0 7.693783032891588e-08
nonsense O 0 1.6655294530210085e-05
point O 0 3.3323872230539564e-06
mutations O 0 1.8757061752694426e-06
, O 0 1.976462016273217e-08
deletions O 0 2.646509926762519e-07
, O 0 1.120724313352639e-08
insertions O 0 3.642023500560754e-07
, O 0 4.0570615311708025e-08
a O 0 1.501673523307545e-07
deletion O 0 1.6441490515717305e-06
/ O 0 5.295934784044221e-07
insertion O 0 4.2270295352864196e-07
and O 0 4.69712695405633e-08
splice O 0 2.0498597223195247e-05
site O 0 5.264077481115237e-05
mutations O 0 8.913411875255406e-05
. O 0 2.14951069210656e-06

These O 0 2.001214483016156e-07
mutations O 0 6.568866410816554e-06
were O 0 5.967834937337102e-08
scattered O 0 4.307367262867956e-08
over O 0 2.3292233919391947e-08
the O 0 1.4060331565701745e-08
entire O 0 7.261258616608757e-08
length O 0 6.500451377178251e-08
of O 0 7.356397269120407e-09
PTEN O 0 1.1194338185305241e-05
, O 0 8.28829715970869e-09
with O 0 1.7093104709431373e-09
the O 0 5.112996248612944e-09
exception O 0 4.090439542636659e-09
of O 0 3.761523315048976e-10
the O 0 6.159339260847219e-09
first O 0 2.4773608942041392e-08
, O 0 1.4767625344802582e-08
fourth O 0 3.590514268125844e-07
and O 0 6.384320982988356e-08
last O 0 1.965477622434264e-06
exons O 0 1.1305894986435305e-05
. O 0 2.252938202218502e-06

A O 0 1.8828675820259377e-05
hot O 0 1.3593775292974897e-05
spot O 0 2.032139036600711e-06
for O 0 5.723163809534526e-08
PTEN O 0 0.00011485317372716963
mutation O 0 1.4961400438551209e-06
in O 0 2.2576211122782297e-08
CD B-Disease 0 1.0485704251550487e-06
was O 0 4.37613925896585e-06
identified O 0 5.994895957428525e-08
in O 0 7.773224730556194e-09
exon O 0 1.158129634859506e-06
5 O 0 7.937070733987639e-08
that O 0 9.634559816618093e-10
contains O 0 1.6339686270683274e-09
the O 0 7.526800516188814e-09
PTPase O 0 1.36297376229777e-06
core O 0 3.9459851564060955e-07
motif O 0 1.7972092791751493e-07
, O 0 1.7836708776641785e-09
with O 0 6.829906640248851e-10
13 O 0 3.77790421168811e-09
of O 0 4.4292672307655323e-10
30 O 0 7.73745778559487e-09
( O 0 1.7913146521664203e-09
43 O 0 1.8758152364739544e-08
% O 0 2.0133916756037706e-09
) O 0 3.2114559900264794e-09
CD B-Disease 0 1.191462956739997e-06
mutations O 0 2.5863282644422725e-06
identified O 0 2.7781621270150936e-07
in O 0 5.5427129552754195e-08
this O 0 1.2854430053721444e-07
exon O 0 7.075036410242319e-05
. O 0 4.078735400980804e-06

Seven O 0 6.267253525038541e-07
of O 0 3.123522773762488e-08
30 O 0 9.592541516667552e-08
( O 0 1.0298988328827363e-08
23 O 0 7.056441830854965e-08
% O 0 1.856681586254183e-09
) O 0 8.505584014883993e-10
were O 0 1.3895163908372865e-09
within O 0 1.677356031848376e-09
the O 0 5.40240918667223e-09
core O 0 2.1811200667798403e-07
motif O 0 3.6468199482442287e-07
, O 0 4.993086832882909e-09
the O 0 5.558982607567486e-09
majority O 0 3.5067355685924895e-09
( O 0 9.502247877435366e-10
five O 0 7.150735559235954e-10
of O 0 2.446726987681558e-10
seven O 0 2.5378843471202117e-09
) O 0 2.7739649466340666e-10
of O 0 1.7720928890962995e-10
which O 0 2.044676650214683e-09
were O 0 2.3757568357041237e-08
missense O 0 4.373648607725045e-06
mutations O 0 1.911530489451252e-06
, O 0 2.6126897978429042e-08
possibly O 0 6.573689859123988e-08
pointing O 0 5.162574368000605e-08
to O 0 9.16035025610995e-10
the O 0 6.62679999763327e-09
functional O 0 5.771132904897058e-08
significance O 0 4.483859328274775e-08
of O 0 1.3798297615608135e-08
this O 0 5.913019407444153e-08
region O 0 3.507043174977298e-06
. O 0 3.18140314448101e-06

Germline O 0 0.04057759791612625
PTEN O 0 0.027427930384874344
mutations O 0 0.0006095219287090003
were O 0 1.7574276398590882e-06
identified O 0 5.636540549858182e-07
in O 0 2.578928715024631e-08
four O 0 8.458090228202764e-09
of O 0 3.6328702268662028e-09
seven O 0 3.064166165245297e-08
( O 0 1.361989276915665e-08
57 O 0 1.1544735656343619e-07
% O 0 1.1484137196760003e-08
) O 0 2.886434913307312e-08
BZS B-Disease 0 1.6013647837098688e-05
families O 0 1.254946511153321e-07
studied O 0 8.206693564716261e-06
. O 0 2.2662122773908777e-06

Interestingly O 0 3.3674772566882893e-05
, O 0 1.92448311508997e-07
none O 0 4.2675587508256285e-08
of O 0 2.679313659825766e-09
these O 0 3.4582210428624194e-09
mutations O 0 8.670700708535151e-07
was O 0 1.354755113425199e-06
observed O 0 6.587345779962561e-08
in O 0 2.3130377613256314e-08
the O 0 4.456125068941219e-08
PTPase O 0 3.108981400146149e-05
core O 0 2.7233592845732346e-05
motif O 0 0.00010288702469551936
. O 0 2.112414904331672e-06

It O 0 1.693309400252474e-06
is O 0 2.458392032167467e-07
also O 0 3.096810630154323e-08
worthy O 0 5.0121538919256636e-08
of O 0 6.498415583422457e-09
note O 0 1.2701366358669475e-07
that O 0 1.7618753123116448e-09
a O 0 2.03798862230542e-08
single O 0 1.1341150951693635e-07
nonsense O 0 2.0802444851142354e-06
point O 0 4.127618637994601e-07
mutation O 0 2.731441384185018e-07
, O 0 9.675244605489297e-09
R233X O 0 3.2087456247609225e-07
, O 0 1.1636520191871114e-08
was O 0 8.849577284308907e-07
observed O 0 1.6512196054918604e-08
in O 0 3.6888199161921875e-09
the O 0 5.9242144523352636e-09
germline O 0 5.368575557440636e-07
DNA O 0 8.512603955068698e-08
from O 0 4.373685857927967e-09
two O 0 1.6304632088903759e-09
unrelated O 0 7.355572506639874e-08
CD B-Disease 0 8.145672723003372e-07
families O 0 1.417393225011665e-08
and O 0 4.4434024459860666e-08
one O 0 4.0853433347365353e-07
BZS B-Disease 0 0.00031331132049672306
family O 0 1.8628086763783358e-05
. O 0 3.3075011742766947e-06

Genotype O 0 0.0009532592375762761
- O 0 0.000808223441708833
phenotype O 0 4.3737916712416336e-05
studies O 0 2.800410641157214e-07
were O 0 1.6463765462049196e-08
not O 0 3.97065935686669e-09
performed O 0 1.3208577342993522e-07
on O 0 3.252425884170407e-08
this O 0 2.4596893410944176e-09
small O 0 1.5231199412824026e-08
group O 0 7.362548615219566e-08
of O 0 3.190443109701846e-08
BZS B-Disease 0 0.00018489224021323025
families O 0 6.944563892830047e-07
. O 0 1.7821196252043592e-06

However O 0 8.112848263408523e-06
, O 0 6.263047112042841e-07
genotype O 0 1.1053818525397219e-05
- O 0 5.801697261631489e-05
phenotype O 0 4.677887318393914e-06
analysis O 0 9.000950029758314e-08
inthe O 0 4.037303369841538e-06
group O 0 4.443860390779264e-08
of O 0 3.044729357526421e-09
CD B-Disease 0 1.9458386759652058e-06
families O 0 1.83141857235114e-08
revealed O 0 3.6921377954968193e-07
two O 0 2.8854092448682422e-09
possible O 0 8.254377625860343e-09
associations O 0 3.2075808675813278e-09
worthy O 0 1.650539438458054e-08
of O 0 1.5086741855796504e-09
follow O 0 3.486955080234111e-08
- O 0 2.575439339125296e-06
up O 0 7.087749764878026e-08
in O 0 4.4740691151901046e-08
independent O 0 1.65455730893882e-07
analyses O 0 1.201400891659432e-06
. O 0 6.936581371519424e-07

The O 0 9.035563834913773e-07
first O 0 3.652827444966533e-07
was O 0 2.580223508630297e-06
an O 0 6.44410960148889e-08
association O 0 2.399049208179349e-07
noted O 0 3.5157718514255976e-08
in O 0 5.370714095676021e-09
the O 0 5.307707606760914e-09
group O 0 9.573875914270502e-09
of O 0 1.865154031222005e-09
CD B-Disease 0 7.47899093767046e-07
families O 0 1.1583522052660555e-07
with O 0 0.00010873130668187514
breast B-Disease 1 0.9998865127563477
disease I-Disease 1 0.9981876015663147
. O 0 1.6180050806724466e-05

A O 0 5.4374422688852064e-06
correlation O 0 1.5114333109522704e-06
was O 0 2.6952043299388606e-06
observed O 0 6.424203746746571e-08
between O 0 1.0170113640128875e-08
the O 0 2.312834723738888e-08
presence O 0 1.3551075994655548e-07
/ O 0 6.078950605115097e-07
absence O 0 6.07891550430395e-08
of O 0 2.4136335152746824e-09
a O 0 6.393582907548989e-07
PTEN O 0 7.41379990358837e-05
mutation O 0 9.78082084657217e-07
and O 0 9.647143528468405e-09
the O 0 3.813976690025811e-08
type O 0 4.291812274459517e-06
of O 0 2.9901497100581764e-07
breast O 0 0.48790475726127625
involvement O 0 1.9649396563181654e-05
( O 0 1.212947950079979e-06
unaffected O 0 0.00047838958562351763
versus O 0 0.005122557748109102
benign O 1 0.9880598187446594
versus O 1 0.9167201519012451
malignant O 1 0.9995918869972229
) O 0 5.134076218382688e-06
. O 0 4.722225185105344e-06

Specifically O 0 2.2196984446054557e-06
and O 0 5.116266876825648e-08
more O 0 2.9474023222064716e-09
directly O 0 1.0823469231979743e-08
, O 0 2.280950539557125e-08
an O 0 5.8526300250605345e-08
association O 0 1.315510417043697e-06
was O 0 9.7564052339294e-06
also O 0 1.5213576176620336e-08
observed O 0 5.1099835474133215e-09
between O 0 9.66928093149022e-10
the O 0 2.9491566966299843e-09
presence O 0 1.0060374755482826e-08
of O 0 6.3950804651824456e-09
a O 0 1.7903885236592032e-06
PTEN O 0 0.003855692921206355
mutation O 0 0.0008206133497878909
and O 0 0.0006533480482175946
malignant B-Disease 1 0.9999725818634033
breast I-Disease 1 0.9999548196792603
disease I-Disease 1 0.9995206594467163
. O 0 2.6746878575067967e-05

Secondly O 0 0.0006158591131679714
, O 0 2.519419695090619e-06
there O 0 2.0723328475469316e-07
appeared O 0 4.849641754844924e-07
to O 0 1.9059791522835212e-09
be O 0 4.4092085538238734e-09
an O 0 5.7055369317993154e-09
interdependent O 0 3.7768438687635353e-06
association O 0 1.854272966284043e-07
between O 0 3.788477442867588e-08
mutations O 0 3.4631807466212194e-07
upstream O 0 9.258266686629213e-08
and O 0 3.04323743982593e-09
within O 0 2.1914099423980815e-09
the O 0 1.1811768452218985e-08
PTPase O 0 3.590566166167264e-06
core O 0 5.698154836863978e-07
motif O 0 1.1100150913989637e-06
, O 0 7.731497220220263e-09
the O 0 2.913186136765944e-09
core O 0 6.709919375680329e-08
motif O 0 8.027583220382439e-08
containing O 0 5.582326600972465e-09
the O 0 4.341876636004827e-09
majority O 0 3.899061962187034e-09
of O 0 4.642223938589041e-09
missense O 0 3.5540724638849497e-06
mutations O 0 1.0117470310433418e-06
, O 0 4.810109643926808e-09
and O 0 3.584537999756776e-09
the O 0 5.31856114704965e-09
involvement O 0 4.685762533540583e-08
of O 0 3.917922875018576e-09
all O 0 5.247982493017389e-09
major O 0 2.1871992430533282e-06
organ O 0 0.0016140959924086928
systems O 0 0.001163917942903936
( O 0 2.4033224121922103e-07
central O 0 8.377338417631108e-06
nervous O 0 0.02244613692164421
system O 0 0.0064515057019889355
, O 0 9.884233440971002e-05
thyroid O 1 0.9998979568481445
, O 0 0.00018914429529104382
breast O 1 0.9964516162872314
, O 0 0.00016201195830944926
skin O 1 0.995895504951477
and O 0 0.07959803193807602
gastrointestinal O 1 0.9999384880065918
tract O 1 0.9995362758636475
) O 0 2.261508234369103e-05
. O 0 8.912574230635073e-06

However O 0 2.393900786046288e-06
, O 0 4.2697649860201636e-08
these O 0 1.6488898024746845e-09
observations O 0 3.082990218672421e-08
would O 0 1.032014740331988e-08
need O 0 3.720525443284828e-09
to O 0 7.727321560402345e-10
be O 0 6.1614779944818565e-09
confirmed O 0 1.3638687512695924e-08
by O 0 7.338455954020162e-10
studying O 0 3.884802257658748e-09
a O 0 7.733886420169256e-09
larger O 0 4.3349257516922535e-09
number O 0 9.003826018094685e-10
of O 0 3.6401390790530286e-09
CD B-Disease 0 3.067709258175455e-06
families O 0 3.2363925583922537e-07
. O 0 1.5927116692182608e-06

Molecular O 0 0.4925004839897156
defects O 1 0.9875929951667786
leading O 0 2.1455625756061636e-05
to O 0 3.0687811403140586e-08
human O 0 2.8945234475941106e-07
complement B-Disease 0 8.330453965754714e-06
component I-Disease 1 0.8348320722579956
C6 I-Disease 1 0.9999878406524658
deficiency I-Disease 1 0.999975323677063
in O 0 2.0807709688597242e-07
an O 0 3.638419698859252e-08
African O 0 9.388113397790221e-08
- O 0 5.1795745093841106e-05
American O 0 4.963540050084703e-07
family O 0 8.73987482918892e-06
. O 0 2.0310637864895398e-06

Complement B-Disease 0 0.001545976265333593
component I-Disease 1 0.983836829662323
C6 I-Disease 1 0.9999390840530396
deficiency I-Disease 1 0.9999613761901855
( O 0 4.402716513141058e-06
C6D B-Disease 0 0.003090605605393648
) O 0 7.488840196856472e-07
was O 0 0.002236759988591075
diagnosed O 0 0.2927491366863251
in O 0 3.070443455044369e-08
a O 0 1.564574461099255e-07
16 O 0 1.4944728832233523e-07
- O 0 5.6521148508181795e-06
year O 0 2.3016797001673694e-07
- O 0 1.5039823892948334e-06
old O 0 1.1797874321928248e-06
African O 0 3.8671132074341585e-08
- O 0 1.1982908745267196e-06
American O 0 1.2944715876983537e-07
male O 0 1.0652090622897958e-06
with O 0 3.1423660402651876e-05
meningococcal B-Disease 1 0.9996176958084106
meningitis I-Disease 1 0.9993888139724731
. O 0 1.6564659745199606e-05

The O 0 7.030874257907271e-06
patients O 0 5.549199340748601e-05
father O 0 9.772683370101731e-06
and O 0 9.407848722275958e-08
two O 0 6.191142887246315e-08
brothers O 0 9.618604963179678e-06
also O 0 1.6448942119495769e-07
had O 0 5.569884820033622e-07
C6D B-Disease 0 4.122477912460454e-05
, O 0 4.0294839465104815e-08
but O 0 9.456941896246462e-09
gave O 0 3.1769499031497617e-08
no O 0 6.903015492554232e-09
history O 0 2.800725162899198e-08
of O 0 1.0392209759402249e-07
meningitis B-Disease 1 0.9778444766998291
or O 0 3.245058621814678e-07
other O 0 4.017604737782676e-07
neisserial B-Disease 1 0.6070490479469299
infection I-Disease 1 0.9643410444259644
. O 0 6.1438518059730995e-06

By O 0 4.1685026985760487e-07
using O 0 3.685509852857649e-07
exon O 0 2.168643186450936e-05
- O 0 4.234342213749187e-06
specific O 0 4.173434220433592e-08
polymerase O 0 2.3322124889091356e-06
chain O 0 5.845841315021971e-06
reaction O 0 1.7803145624384342e-07
( O 0 9.009637480517085e-09
PCR O 0 1.7725687939673662e-07
) O 0 5.273147252182753e-09
/ O 0 4.7747008125043067e-08
single O 0 2.984240765613322e-08
- O 0 8.687122772244038e-07
strand O 0 2.5520458279970626e-07
conformation O 0 1.1391838228291817e-07
polymorphism O 0 3.028369377489071e-08
as O 0 2.895879536168877e-09
a O 0 1.0556180818355188e-08
screening O 0 2.5904300926526957e-08
step O 0 1.3569589008000094e-08
and O 0 1.4712149276618902e-09
nucleotide O 0 8.806134488281714e-09
sequencing O 0 4.6084003280100205e-09
of O 0 4.5200912457410425e-10
target O 0 5.709619443905467e-09
exons O 0 5.981600992299718e-08
, O 0 1.0573792508239421e-08
we O 0 2.6384892048980646e-09
determined O 0 1.7309286448607963e-08
that O 0 6.000187013910363e-10
the O 0 6.385402429032183e-09
proband O 0 5.306988441589056e-06
was O 0 7.91237766861741e-07
a O 0 1.624070122829835e-08
compound O 0 7.272193869312105e-08
heterozygote O 0 1.8333237505885336e-07
for O 0 6.815816799843333e-09
two O 0 7.548224800757453e-08
C6 O 0 0.0031470053363591433
gene O 0 5.377231354941614e-05
mutations O 0 8.178140706149861e-05
. O 0 2.0988322830817197e-06

The O 0 3.3836917623375484e-07
first O 0 1.8107193966443447e-07
, O 0 2.20517204496673e-08
1195delC O 0 1.6462483927170979e-06
located O 0 5.780159995083523e-07
in O 0 6.076422920386904e-08
exon O 0 6.539763489854522e-06
7 O 0 1.3755736745224567e-06
, O 0 2.1324234822373e-08
is O 0 1.6572206718024063e-08
a O 0 5.982422379702257e-08
novel O 0 6.391388041038226e-08
mutation O 0 1.406774146062162e-07
, O 0 3.86427245757659e-09
while O 0 2.9665214729135414e-09
the O 0 4.2545118539294435e-09
second O 0 4.717975699009003e-08
, O 0 1.0592080990079467e-08
1936delG O 0 2.410322679224919e-07
in O 0 2.180379077287853e-08
exon O 0 1.3581210396296228e-06
12 O 0 1.2148981909376744e-07
, O 0 1.2637179302998902e-08
has O 0 3.574571749709321e-08
been O 0 2.0478390538869462e-08
described O 0 1.1139265154724853e-07
before O 0 4.351504756527902e-08
to O 0 9.396959654850434e-09
cause O 0 1.1606748557824176e-06
C6D B-Disease 0 4.6348523028427735e-05
in O 0 3.04121989813666e-08
an O 0 1.7143952035780785e-08
unrelated O 0 4.6558912458749546e-07
African O 0 4.98433543327792e-08
- O 0 1.3157036846678238e-05
American O 0 1.8115363786819216e-07
individual O 0 1.871634225381058e-07
. O 0 1.5173793599387864e-06

Both O 0 3.827637556241825e-06
mutations O 0 0.00014896328502800316
result O 0 1.0032064892584458e-05
in O 0 1.450924855816993e-06
premature O 0 0.00014367287803906947
termination O 0 3.090742393396795e-05
codons O 0 3.919426944776205e-06
and O 0 5.408535344031407e-07
C6 O 0 0.0184392761439085
null O 0 9.974210115615278e-05
alleles O 0 1.7166064935736358e-05
. O 0 6.662238320132019e-06

Allele O 0 7.249701593536884e-05
- O 0 2.3265003619599156e-05
specific O 0 1.0969892372258983e-07
PCR O 0 8.49717889650492e-06
indicated O 0 1.5028583675302798e-06
that O 0 4.643959883310345e-09
the O 0 1.4216251287280102e-08
probands O 0 5.380587936087977e-06
two O 0 3.711284790597347e-08
brothers O 0 4.468544830160681e-06
also O 0 2.0098288189274172e-07
inherited O 0 7.445484516210854e-05
the O 0 7.767122411905802e-08
1195delC O 0 1.2972541298950091e-05
mutation O 0 5.767996071881498e-07
from O 0 6.560347376449727e-09
their O 0 4.932939390300817e-09
heterozygous O 0 1.5199601932636142e-07
mother O 0 7.101090773176111e-07
and O 0 9.927155097955165e-09
the O 0 3.4202354726176054e-08
1936delG O 0 6.353724074870115e-06
mutation O 0 6.050772185517417e-07
from O 0 6.3016525331249795e-09
their O 0 5.292220883745813e-09
homozygous O 0 8.322857070197642e-07
father O 0 3.2994867069646716e-06
. O 0 1.314484165959584e-07
. O 0 9.947133321475121e-07

PAX6 O 1 0.6310694813728333
mutations O 0 0.05546239763498306
reviewed O 0 0.0007763193571008742
. O 0 6.340847176034003e-05

Mutations O 0 0.0007542108069173992
in O 0 1.8805708350555506e-06
PAX6 O 0 0.0003279677184764296
are O 0 3.446981722277087e-08
responsible O 0 6.403883503480756e-07
for O 0 4.558485500183451e-08
human O 0 7.964570727381215e-07
aniridia B-Disease 1 0.996907651424408
and O 0 3.8502156485265004e-07
have O 0 2.8212703284680174e-08
also O 0 5.367276045831204e-08
been O 0 1.4672804127258132e-07
found O 0 7.892175801771373e-08
in O 0 1.5138871845010726e-07
patients O 0 2.3971517748577753e-06
with O 0 1.8348016510572052e-06
Peters B-Disease 1 0.9985633492469788
anomaly I-Disease 1 0.9998315572738647
, O 0 8.981900464277714e-05
with O 0 0.1430308222770691
congenital B-Disease 1 0.9999978542327881
cataracts I-Disease 1 0.9999643564224243
, O 0 8.67664311954286e-06
with O 0 5.603297267953167e-06
autosomal B-Disease 1 0.8799703121185303
dominant I-Disease 0 0.09034072607755661
keratitis I-Disease 1 0.7311427593231201
, O 0 5.628963208437199e-06
and O 0 1.3898400084144669e-06
with O 0 4.8527817853027955e-05
isolated B-Disease 1 0.9735548496246338
foveal I-Disease 1 0.9998359680175781
hypoplasia I-Disease 1 0.9998558759689331
. O 0 0.0002809835714288056

No O 0 1.5519148064413457e-06
locus O 0 2.2112596980150556e-06
other O 0 1.8650339939085825e-08
than O 0 3.6184879093070776e-08
chromosome O 0 3.0442602110269945e-06
11p13 O 0 2.3721788693364942e-06
has O 0 2.4345129645553243e-07
been O 0 2.1146895790025155e-07
implicated O 0 6.811284492869163e-06
in O 0 9.281346251555078e-07
aniridia B-Disease 1 0.9986342787742615
, O 0 8.220975473705039e-07
and O 0 4.1488706870040915e-07
PAX6 O 0 0.0012230980210006237
is O 0 5.110785536999174e-07
clearly O 0 7.633996546019262e-08
the O 0 1.9463470835034968e-08
major O 0 4.679631047110888e-07
, O 0 7.61943539373533e-08
if O 0 1.0269330275036737e-08
not O 0 1.2037563168476595e-09
only O 0 2.743845817221313e-09
, O 0 3.4676151727808247e-08
gene O 0 6.170265578475664e-07
responsible O 0 3.933540483558318e-06
. O 0 2.357211315029417e-06

Twenty O 0 3.915425622835755e-06
- O 0 3.4413303637848003e-06
eight O 0 7.460256767899409e-08
percent O 0 7.326701023657733e-08
of O 0 5.704992922517249e-09
identified O 0 4.915988824905071e-07
PAX6 O 0 0.00010366819333285093
mutations O 0 4.959956640959717e-06
are O 0 3.819363669776976e-08
C O 0 6.83982070768252e-05
- O 0 0.0011304126819595695
T O 0 0.0001642484130570665
changes O 0 1.8625745212830225e-07
at O 0 2.917331300977821e-07
CpG O 0 5.05590890043095e-07
dinucleotides O 0 1.3322820677785785e-06
, O 0 1.0114825421680962e-08
20 O 0 7.859214612437881e-09
% O 0 6.834142141087796e-10
are O 0 3.2159164220502134e-10
splicing O 0 7.071343333109326e-08
errors O 0 3.154828789320163e-07
, O 0 3.924175207004055e-09
and O 0 1.1340297589867987e-09
more O 0 3.6482697418627197e-10
than O 0 1.2464574927761873e-09
30 O 0 7.98026889015091e-09
% O 0 1.0430127872496087e-09
are O 0 7.187189177138009e-10
deletion O 0 1.4812005133535422e-07
or O 0 2.1230325941701267e-08
insertion O 0 1.2478686812755768e-06
events O 0 6.533664418384433e-07
. O 0 1.155041104539123e-06

There O 0 6.513644166261656e-07
is O 0 1.5442185485881055e-07
a O 0 2.0103733788801037e-07
noticeably O 0 1.3515261343854945e-05
elevated O 0 0.00015726582205388695
level O 0 4.492073060191615e-07
of O 0 7.749169306237036e-09
mutation O 0 2.3635767831819976e-07
in O 0 4.3476942046538625e-09
the O 0 2.486519656841324e-09
paired O 0 3.464355913251893e-08
domain O 0 1.661296877841778e-08
compared O 0 2.626134332217589e-08
with O 0 1.4844573348327117e-09
the O 0 5.222648979952282e-09
rest O 0 1.28888837380714e-08
of O 0 5.360398347420414e-09
the O 0 1.416674848542243e-07
gene O 0 4.935181550536072e-06
. O 0 1.161471004706982e-06

Increased O 0 9.822222637012601e-06
mutation O 0 1.435133526683785e-05
in O 0 7.104641497335251e-08
the O 0 3.025759554020624e-08
homeodomain O 0 5.564088951359736e-06
is O 0 3.8641783106641014e-08
accounted O 0 1.5427207955553968e-08
for O 0 1.3532518439163255e-09
by O 0 5.550104376084164e-09
the O 0 7.017705883072267e-08
hypermutable O 0 5.447788134915754e-05
CpG O 0 7.151435511332238e-06
dinucleotide O 0 1.72050731634954e-05
in O 0 4.449772461612156e-07
codon O 0 8.292525308206677e-06
240 O 0 2.873027369787451e-06
. O 0 1.925721790030366e-06

Very O 0 1.4445930673900875e-06
nearly O 0 4.925448706671887e-07
all O 0 2.5871514708342147e-08
mutations O 0 2.277404746564571e-06
appear O 0 2.648302768193389e-07
to O 0 2.7846972727729735e-08
cause O 0 1.458959832234541e-05
loss O 0 9.912521818478126e-06
of O 0 3.233102008337596e-09
function O 0 1.3309692903362702e-08
of O 0 1.1726797310984693e-09
the O 0 1.0005949846458861e-08
mutant O 0 8.677800877876507e-08
allele O 0 2.0831846470059645e-08
, O 0 1.1148670875371636e-09
and O 0 3.290095695884787e-10
more O 0 9.966892589030607e-11
than O 0 3.454033170591231e-10
80 O 0 1.3954338795585386e-09
% O 0 4.0765274489373837e-10
of O 0 1.477891808931986e-09
exonic O 0 1.743934376463585e-06
substitutions O 0 9.241082921107591e-08
result O 0 1.8470156248895364e-07
in O 0 1.5592790703067294e-07
nonsense O 0 1.4574217857443728e-05
codons O 0 1.102625628845999e-05
. O 0 2.107651880578487e-06

In O 0 9.034624213200004e-07
a O 0 2.778893417598738e-07
gene O 0 1.5677110809519945e-07
with O 0 1.7619502301613466e-08
such O 0 1.3247212216072057e-08
extraordinarily O 0 4.391407856019214e-05
high O 0 1.141403572546551e-05
sequence O 0 1.1909489217032387e-07
conservation O 0 3.944137105804657e-08
throughout O 0 8.123026695727731e-09
evolution O 0 1.3347725591472681e-08
, O 0 5.343188114181885e-09
there O 0 3.1585447590742888e-09
are O 0 2.9319719985210213e-09
presumed O 0 2.4195819605665747e-06
undiscovered O 0 1.2948624316777568e-05
missense O 0 9.179313565255143e-06
mutations O 0 2.117723852279596e-06
, O 0 8.402055051703883e-09
these O 0 3.697270822833332e-10
are O 0 6.328364499097461e-10
hypothesized O 0 2.501553275635615e-08
to O 0 1.6469128283347345e-09
exist O 0 7.758530706780675e-09
in O 0 1.2404199445370523e-08
as O 0 9.60777697400772e-08
- O 0 8.629465446574613e-05
yet O 0 5.494179049492232e-07
unidentified O 0 2.2938331312616356e-05
phenotypes O 0 7.495609224861255e-06
. O 0 2.2225761142635747e-07
. O 0 7.245520237120218e-07

Genetic O 0 0.0002146205079043284
heterogeneity O 0 9.523665357846767e-05
and O 0 5.649273475683003e-07
penetrance O 0 7.384729542536661e-05
analysis O 0 9.943854450966683e-08
of O 0 8.586862776382986e-09
the O 0 1.558847770866123e-07
BRCA1 O 0 1.487663666921435e-05
and O 0 1.6779272016265168e-07
BRCA2 O 0 3.0359913580468856e-05
genes O 0 4.692999482358573e-06
in O 0 8.568426710553467e-05
breast B-Disease 1 0.999651312828064
cancer I-Disease 1 0.9987911581993103
families O 0 2.639080321387155e-06
. O 0 5.184508609090699e-06

The O 0 0.015627363696694374
Breast B-Disease 1 0.9999097585678101
Cancer I-Disease 1 0.9998674392700195
Linkage O 0 0.01149248331785202
Consortium O 0 0.001686004106886685
. O 0 2.4053908418864012e-05

The O 0 5.958179372100858e-07
contribution O 0 4.440734073796193e-07
of O 0 6.048394141089375e-08
BRCA1 O 0 6.494079570984468e-05
and O 0 1.7748028540154337e-06
BRCA2 O 0 0.0008142979932017624
to O 0 8.443065598839894e-05
inherited B-Disease 1 0.9999966621398926
breast I-Disease 1 0.9999978542327881
cancer I-Disease 1 0.999998927116394
was O 0 0.012008307501673698
assessed O 0 1.3057485830358928e-06
by O 0 9.585624738406295e-09
linkage O 0 8.7829039330245e-07
and O 0 7.220943132324464e-08
mutation O 0 4.020724873043946e-07
analysis O 0 9.099406561574597e-09
in O 0 1.2599490339937347e-08
237 O 0 1.6703904037740358e-08
families O 0 1.6641059641386846e-09
, O 0 9.094300867928951e-10
each O 0 1.2103217039705072e-10
with O 0 2.653862907209259e-09
at O 0 1.4990106933510106e-07
least O 0 4.040302314933797e-09
four O 0 4.710600354229655e-09
cases O 0 2.0177635562390606e-08
of O 0 5.263323146209586e-07
breast B-Disease 1 0.9995482563972473
cancer I-Disease 1 0.982505202293396
, O 0 2.5095340916436726e-08
collected O 0 1.4795564773351089e-08
by O 0 7.925301304112509e-08
the O 0 0.00012485322076827288
Breast B-Disease 1 0.9999740123748779
Cancer I-Disease 1 0.9999592304229736
Linkage O 0 0.0006739447708241642
Consortium O 0 0.00024132711405400187
. O 0 5.430882083601318e-06

Families O 0 1.6126881519085146e-06
were O 0 3.160243124966655e-07
included O 0 3.337222409527385e-08
without O 0 2.8425898079831313e-08
regard O 0 8.653153749094145e-09
to O 0 2.9306748139390493e-09
the O 0 2.4382879715290073e-08
occurrence O 0 5.389728812588146e-06
of O 0 2.2161320885061286e-06
ovarian B-Disease 1 0.9998051524162292
or I-Disease 0 3.5937521261075744e-06
other I-Disease 0 5.1652123147505336e-06
cancers I-Disease 1 0.9982573390007019
. O 0 1.3359614968067035e-05

Overall O 0 0.0016062372596934438
, O 0 0.00026937125949189067
disease O 1 0.9692351222038269
was O 0 0.0006513699772767723
linked O 0 1.864710429799743e-05
to O 0 2.1508130387815072e-08
BRCA1 O 0 2.79551932180766e-06
in O 0 1.0974137154562413e-08
an O 0 3.968720907465695e-09
estimated O 0 1.251379710964784e-08
52 O 0 1.1459806437130737e-08
% O 0 2.830176648593863e-10
of O 0 3.3862446180421557e-10
families O 0 1.159466411770893e-09
, O 0 4.1731533784172825e-09
to O 0 3.122234915053923e-09
BRCA2 O 0 2.7983284667243424e-07
in O 0 8.252299288358245e-09
32 O 0 8.718227029191894e-09
% O 0 8.142940766120432e-10
of O 0 1.1271270583534942e-09
families O 0 2.9010651658722963e-09
, O 0 3.971508011346714e-09
and O 0 1.2254584014215197e-09
to O 0 9.794386413020106e-10
neither O 0 1.8012032754199936e-08
gene O 0 1.7361562854034673e-08
in O 0 4.437725742434395e-09
16 O 0 8.881026580809248e-09
% O 0 7.357853215594901e-10
( O 0 1.116541969992113e-09
95 O 0 8.315691246707502e-09
% O 0 4.239873785394366e-09
confidence O 0 2.0363067676498758e-07
interval O 0 7.89798605183023e-07
[ O 0 7.034288955765078e-07
CI O 0 0.000184693475603126
] O 0 8.923326788590202e-08
6 O 0 5.3955844236952544e-08
% O 0 7.535648549605867e-09
- O 0 9.065522590390174e-07
28 O 0 9.33105752665142e-08
% O 0 1.8893655528984254e-09
) O 0 3.101342516131922e-09
, O 0 5.117347434691055e-09
suggesting O 0 5.53230918853842e-08
other O 0 1.746192346274711e-08
predisposition O 0 3.657516208477318e-05
genes O 0 3.738239684025757e-06
. O 0 1.3140582950654789e-06

The O 0 2.090657517328509e-06
majority O 0 5.561944362852955e-07
( O 0 4.55858959469424e-08
81 O 0 2.2094037888109597e-07
% O 0 2.984791525051378e-09
) O 0 1.4704125694819936e-09
of O 0 4.67954386351721e-09
the O 0 1.3483064321917482e-05
breast B-Disease 1 0.9999606609344482
- I-Disease 1 0.9999903440475464
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999914169311523
families O 0 2.0295405533943267e-07
were O 0 1.0687240603601822e-07
due O 0 1.9478181911836145e-07
to O 0 6.004631902811752e-09
BRCA1 O 0 3.2955053939076606e-06
, O 0 6.790889184316029e-09
with O 0 6.929583573622722e-09
most O 0 8.174191989951396e-09
others O 0 9.302089765128585e-09
( O 0 6.090727922014594e-09
14 O 0 5.5301786261452435e-08
% O 0 4.621868665566353e-09
) O 0 7.352890296630221e-09
due O 0 2.391250859545835e-07
to O 0 1.138897047781029e-07
BRCA2 O 0 0.00011992609506705776
. O 0 2.9446866847138153e-06

Conversely O 0 1.9737739421543665e-05
, O 0 8.24605663751754e-08
the O 0 1.806577643037599e-08
majority O 0 8.532301087882388e-09
of O 0 1.5681566045699924e-09
families O 0 1.5711414391716971e-09
with O 0 9.8126049508096e-09
male B-Disease 0 1.6725080342894216e-07
and I-Disease 0 2.4046610747063824e-07
female I-Disease 0 0.00016467682144138962
breast I-Disease 1 0.999868631362915
cancer I-Disease 1 0.9972507357597351
were O 0 1.7528971341107535e-07
due O 0 3.418390406295657e-07
to O 0 2.9000927881384087e-08
BRCA2 O 0 1.0048734111478552e-05
( O 0 5.950377257590844e-08
76 O 0 1.9725150650629075e-06
% O 0 6.520119910646827e-08
) O 0 1.5688999610574683e-07
. O 0 7.201109042398457e-07

The O 0 1.5144402141231694e-06
largest O 0 3.5099008073302684e-06
proportion O 0 2.538182002354006e-07
( O 0 3.63407792747239e-08
67 O 0 2.1469978150889801e-07
% O 0 1.885261946554806e-09
) O 0 7.502057863817413e-10
of O 0 6.044514333503059e-10
families O 0 3.0243505477756116e-09
due O 0 6.616282632876391e-08
to O 0 7.557062198237929e-10
other O 0 1.4616658994270892e-09
genes O 0 2.137171151161965e-08
was O 0 2.5467388695687987e-06
found O 0 1.4365101996816065e-08
in O 0 3.159894346183023e-09
families O 0 7.643022326142557e-10
with O 0 2.596047599112694e-09
four O 0 4.541577336425462e-09
or O 0 2.712101432322811e-09
five O 0 8.491680247857403e-09
cases O 0 1.1725974857768051e-08
of O 0 7.961208581264145e-08
female O 0 0.002205873839557171
breast B-Disease 1 0.9999117851257324
cancer I-Disease 1 0.999427080154419
only O 0 1.0532387477724114e-06
. O 0 3.233996949347784e-06

These O 0 2.5635446831984154e-07
estimates O 0 7.682035629841266e-07
were O 0 6.831932353179582e-08
not O 0 1.4817763904773074e-08
substantially O 0 7.436509008584835e-07
affected O 0 2.391720066441394e-08
either O 0 7.784976219227246e-09
by O 0 2.4903927808850312e-09
changing O 0 5.831926230825957e-08
the O 0 3.6142527193305796e-08
assumed O 0 9.223524557455676e-07
penetrance O 0 2.2923966298549203e-06
model O 0 1.1631754404106687e-07
for O 0 1.4040419493710488e-08
BRCA1 O 0 1.6526773833902553e-06
or O 0 8.342507129555088e-09
by O 0 2.3877533283922503e-09
including O 0 5.874032815711416e-09
or O 0 8.734842538160592e-08
excluding O 0 2.6077220809384016e-06
BRCA1 O 0 0.0007369329687207937
mutation O 0 6.689164729323238e-05
data O 0 2.9244781671877718e-06
. O 0 2.2949864160182187e-06

Among O 0 7.039167826405901e-07
those O 0 6.44733049171009e-08
families O 0 7.977320137797506e-08
with O 0 1.4214565453585237e-05
disease O 1 0.932043194770813
due O 0 2.023580418608617e-05
to O 0 6.220664516831675e-08
BRCA1 O 0 3.770096373045817e-05
that O 0 1.3040565072230947e-08
were O 0 2.1183808485147892e-08
tested O 0 1.0772849634577142e-07
by O 0 8.727173428368928e-10
one O 0 6.160299492741217e-10
of O 0 3.6212113863065554e-10
the O 0 1.903704749395274e-09
standard O 0 5.4964228723974884e-08
screening O 0 2.9235856402465288e-08
methods O 0 1.1541230193756746e-08
, O 0 9.273037449020194e-09
mutations O 0 6.817379016865743e-08
were O 0 1.0160341901155334e-08
detected O 0 3.3913093488990853e-07
in O 0 2.786911590391128e-09
the O 0 2.439435542456181e-09
coding O 0 1.1479544070880365e-07
sequence O 0 1.4225174815862829e-08
or O 0 1.4498928724293592e-09
splice O 0 4.596324032490884e-08
sites O 0 9.699541614338614e-09
in O 0 2.847113877990637e-09
an O 0 1.7538219765356189e-09
estimated O 0 9.949199686332122e-09
63 O 0 2.6354424420560463e-08
% O 0 1.0628259383693717e-09
( O 0 1.6148800074944347e-09
95 O 0 1.0781314507823936e-08
% O 0 6.529986773529117e-09
CI O 0 1.8939665096695535e-05
51 O 0 1.2657665138249286e-07
% O 0 1.2038763763655425e-08
- O 0 1.9281640106783016e-06
77 O 0 3.791257370266976e-07
% O 0 3.4638272694564876e-08
) O 0 9.811297729811486e-08
. O 0 6.176388183121162e-07

The O 0 5.466770858220116e-07
estimated O 0 1.5626135052571044e-07
sensitivity O 0 3.36455229899002e-07
was O 0 7.175682412707829e-07
identical O 0 2.0348114304624687e-08
for O 0 5.335903385805807e-10
direct O 0 2.0087886909436747e-09
sequencing O 0 2.5655104707311693e-08
and O 0 5.958233462166618e-09
other O 0 4.375070972173489e-09
techniques O 0 1.137476601797971e-06
. O 0 2.1123100850672927e-06

The O 0 2.920821088991943e-06
penetrance O 0 0.000372905662516132
of O 0 8.03526347681327e-07
BRCA2 O 0 0.0001161124964710325
was O 0 1.1114494554931298e-05
estimated O 0 3.42526220720174e-08
by O 0 4.872874992400966e-09
maximizing O 0 8.088306202580497e-08
the O 0 2.7095950372313382e-08
LOD O 0 4.0669983718544245e-05
score O 0 6.728630808083835e-08
in O 0 6.703906763050327e-08
BRCA2 O 0 6.765461876057088e-06
- O 0 1.5908923160168342e-05
mutation O 0 4.2581433490340714e-07
families O 0 6.203386249126197e-09
, O 0 2.6703852462617306e-09
over O 0 4.620828608636884e-09
all O 0 2.3366490964349396e-09
possible O 0 1.7074499680802546e-07
penetrance O 0 5.331156717147678e-05
functions O 0 1.2279646171009517e-06
. O 0 3.4173970107076457e-06

The O 0 1.4809746744504082e-06
estimated O 0 1.052337211149279e-06
cumulative O 0 3.842292244371492e-06
risk O 0 2.8472448320826516e-05
of O 0 1.8175219338445459e-06
breast B-Disease 1 0.9997857213020325
cancer I-Disease 1 0.9948781728744507
reached O 0 2.320914518350037e-06
28 O 0 1.3929434317105915e-07
% O 0 2.9192599448890633e-09
( O 0 2.455461167727435e-09
95 O 0 1.6645891776079225e-08
% O 0 5.488353771454513e-09
CI O 0 2.5873723643599078e-05
9 O 0 5.6658596037095776e-08
% O 0 3.212374810601659e-09
- O 0 1.9673795748076373e-07
44 O 0 8.370943049840207e-09
% O 0 4.796511521298896e-10
) O 0 4.068681780378114e-10
by O 0 7.734325402353193e-10
age O 0 1.0109578951755793e-08
50 O 0 2.524193520869744e-09
years O 0 4.0046193028331345e-09
and O 0 1.0920219173371493e-09
84 O 0 3.2539460903535655e-08
% O 0 1.4701490025359476e-09
( O 0 1.0297687147442502e-09
95 O 0 1.1287992762731847e-08
% O 0 5.095511124153518e-09
CI O 0 1.0437403943797108e-05
43 O 0 3.265404302510433e-08
% O 0 4.091329053323989e-09
- O 0 1.2714259867152577e-07
95 O 0 1.1699568425171947e-08
% O 0 1.2530939619281867e-09
) O 0 5.925590573774286e-10
by O 0 1.8321267836185484e-09
age O 0 9.497509267930582e-08
70 O 0 1.3798066333947645e-07
years O 0 4.1725033383954724e-07
. O 0 5.440230665954005e-07

The O 0 0.00014383872621692717
corresponding O 1 0.9711286425590515
ovarian B-Disease 1 0.999998927116394
cancer I-Disease 1 0.9999969005584717
risks O 0 0.07234389334917068
were O 0 3.4694853638939094e-06
0 O 0 7.078764156176476e-06
. O 0 1.7031594552463503e-06

4 O 0 2.448511622787919e-06
% O 0 6.310025923994544e-08
( O 0 1.3821319200246762e-08
95 O 0 6.248585293633369e-08
% O 0 2.4536834786204054e-08
CI O 0 5.205551497056149e-05
0 O 0 4.440776280034697e-08
% O 0 6.008836539450613e-09
- O 0 4.099131274415413e-07
1 O 0 1.974291841122522e-08
% O 0 1.591970666403597e-09
) O 0 4.3344441924553223e-10
by O 0 1.097752333478752e-09
age O 0 1.1959233603420216e-08
50 O 0 3.952766114423412e-09
years O 0 7.063064355605775e-09
and O 0 2.2416581924034062e-09
27 O 0 3.18245696462327e-08
% O 0 8.448025057283814e-10
( O 0 9.464985462059872e-10
95 O 0 1.4288806582385405e-08
% O 0 6.744869551766897e-09
CI O 0 1.1139451999042649e-05
0 O 0 3.042432084043867e-08
% O 0 5.605340192005315e-09
- O 0 1.6205835606797336e-07
47 O 0 1.9405939966077312e-08
% O 0 1.390311754612128e-09
) O 0 9.745378948267103e-10
by O 0 2.3451323105661004e-09
age O 0 5.950990455971805e-08
70 O 0 6.716091149883141e-08
years O 0 2.7262311164122366e-07
. O 0 3.8149082115523925e-07

The O 0 5.219891590968473e-06
lifetime O 0 0.0001857843017205596
risk O 0 0.0005230276146903634
of O 0 3.65532650903333e-05
breast B-Disease 1 0.9998835325241089
cancer I-Disease 1 0.9994925260543823
appears O 0 2.4836829197738552e-06
similar O 0 2.2302042879118744e-08
to O 0 5.163605543145877e-09
the O 0 8.243524973750027e-08
risk O 0 1.6575579593336442e-06
in O 0 6.241319283617486e-08
BRCA1 O 0 4.436735252966173e-06
carriers O 0 3.737926022040483e-07
, O 0 1.2302459495572293e-08
but O 0 8.622345504250006e-09
there O 0 3.876726495377625e-09
was O 0 2.8892446835016017e-07
some O 0 5.093147015244881e-10
suggestion O 0 1.8425183156978164e-08
of O 0 1.8590309291965923e-09
a O 0 9.507909908279544e-07
lower O 0 8.749932749196887e-05
risk O 0 8.260606591647957e-06
in O 0 9.233119158125191e-08
BRCA2 O 0 3.1380420750792837e-06
carriers O 0 7.616702077939408e-07
< O 0 6.687011477879423e-07
50 O 0 2.8341768043560478e-08
years O 0 4.14898053691104e-08
of O 0 2.306108548566499e-08
age O 0 1.854185939009767e-06
. O 0 1.0709630942074e-06

Eye B-Disease 0 0.17467105388641357
movement I-Disease 0 0.0005763183580711484
abnormalities I-Disease 0 0.05818798393011093
correlate O 0 4.609581537806662e-06
with O 0 1.138359948527068e-06
genotype O 0 0.00023102025443222374
in O 0 1.5747262295917608e-05
autosomal O 1 0.9870414733886719
dominant O 1 0.9907140731811523
cerebellar B-Disease 1 0.9992923736572266
ataxia I-Disease 1 0.9998779296875
type I-Disease 1 0.9996476173400879
I I-Disease 1 0.8802787065505981
. O 0 2.7073045202996582e-05

We O 0 8.610435543232597e-06
compared O 0 5.747071554651484e-06
horizontal O 0 4.584728958434425e-05
eye O 0 0.0004805156495422125
movements O 0 3.0362898542080075e-06
( O 0 5.8876302944099734e-08
visually O 0 6.9384736889333e-07
guided O 0 8.50651531436597e-07
saccades O 0 5.336848334991373e-05
, O 0 1.334984318646093e-07
antisaccades O 0 5.4938045650487766e-06
, O 0 1.5614956438980698e-08
and O 0 2.92849544614171e-09
smooth O 0 4.0913553789323487e-07
pursuit O 0 7.482486239496211e-07
) O 0 8.138318463579708e-09
in O 0 1.338504862502532e-08
control O 0 1.9943861673255014e-07
subjects O 0 9.001876577485746e-08
( O 0 2.0149448332063002e-08
n O 0 1.093896571546793e-06
= O 0 6.374052077262604e-07
14 O 0 7.345141739278915e-08
) O 0 5.104684230872181e-09
and O 0 1.2212985289750122e-08
patients O 0 7.063147933195069e-08
with O 0 2.6193947011421415e-09
three O 0 8.716199317859719e-09
forms O 0 7.443030369813641e-08
of O 0 1.6651313217153074e-07
autosomal O 0 0.05658877640962601
dominant O 0 0.05132249742746353
cerebellar B-Disease 1 0.9883846044540405
ataxias I-Disease 1 0.9428923726081848
type I-Disease 0 0.2152795046567917
I I-Disease 0 0.0018717083148658276
spinocerebellar B-Disease 1 0.5353217720985413
ataxias I-Disease 0 0.001144031877629459
1 I-Disease 0 1.5780429976075538e-06
and I-Disease 0 8.00200794515149e-08
2 I-Disease 0 3.0178640031408577e-07
( O 0 3.6054121466122524e-08
SCA1 B-Disease 0 6.435844261432067e-05
, O 0 1.2589885045599658e-07
n O 0 9.96817789200577e-07
= O 0 4.323079849655187e-07
11 O 0 4.4808842858401476e-08
; O 0 1.14249090188423e-08
SCA2 B-Disease 0 8.133593837555964e-06
, O 0 6.456399859189332e-08
n O 0 5.709077299798082e-07
= O 0 2.929134836904268e-07
10 O 0 1.9078422397456052e-08
) O 0 1.0627413615793557e-08
and O 0 9.26819652136146e-08
SCA3 B-Disease 1 0.9933880567550659
/ O 0 0.00012520517338998616
Machado B-Disease 0 0.0007918623741716146
- I-Disease 0 0.010891524143517017
Joseph I-Disease 0 0.00216879160143435
disease I-Disease 0 0.4978243112564087
( O 0 4.7122381374720135e-07
MJD B-Disease 1 0.9939800500869751
) O 0 4.671947806400567e-08
( O 0 4.308106937855882e-08
n O 0 3.6742833344760584e-06
= O 0 2.6842258193937596e-06
16 O 0 2.670993239917152e-07
) O 0 1.0722032328658315e-07
. O 0 4.558450541480852e-07

In O 0 3.0295707347249845e-06
SCA1 B-Disease 0 7.907082908786833e-05
, O 0 7.465366991254996e-08
saccade O 0 1.5990033261914505e-06
amplitude O 0 4.729752163257217e-07
was O 0 1.6668440139255836e-06
significantly O 0 3.361768392551312e-07
increased O 0 1.3490252115389012e-07
, O 0 3.967670991755767e-08
resulting O 0 6.490514579127193e-07
in O 0 4.635701031929784e-07
hypermetria B-Disease 0 0.00047867081593722105
. O 0 4.4914659156347625e-06

The O 0 7.792323799549195e-07
smooth O 0 1.331580824626144e-05
pursuit O 0 2.2553207600140013e-05
gain O 0 1.0592550097499043e-05
was O 0 0.0002036369260167703
decreased O 0 0.00012071016681147739
. O 0 6.0342144934111275e-06

In O 0 4.3128729885211214e-06
SCA2 B-Disease 0 0.00010541489609749988
, O 0 2.3247658020864037e-07
saccade O 0 1.1228725270484574e-05
velocity O 0 4.693733444582904e-06
was O 0 2.210424281656742e-05
markedly O 0 4.511535735218786e-05
decreased O 0 7.382730109384283e-05
. O 0 2.3182822133094305e-06

The O 0 8.323436304635834e-07
percentage O 0 1.5492811371586868e-06
of O 0 2.4082636329580964e-08
errors O 0 4.569371867546579e-06
in O 0 2.4940834464359796e-07
antisaccades O 0 0.00013310628128238022
was O 0 4.967715540260542e-06
greatly O 0 1.6735754115870805e-07
increased O 0 2.9976469306802755e-08
and O 0 9.560062963487326e-09
was O 0 6.427439984690864e-07
significantly O 0 1.5627014704477915e-07
correlated O 0 9.630141306615769e-08
with O 0 5.970738214955418e-08
age O 0 8.388066817133222e-06
at O 0 0.0002647043438628316
disease O 1 0.791431725025177
onset O 1 0.8428051471710205
. O 0 9.72686211753171e-06

In O 0 1.125241510635533e-06
addition O 0 2.2374140939973586e-07
, O 0 1.7726966561326662e-08
a O 0 1.7652769912501753e-08
correlation O 0 1.0207543255091878e-08
between O 0 5.260670121742805e-09
smooth O 0 2.742309845871205e-07
pursuit O 0 3.114121511771373e-07
gain O 0 4.579723267283953e-08
and O 0 4.121373464727185e-09
the O 0 5.981347861450104e-09
number O 0 5.117073875737788e-09
of O 0 3.4067323184672205e-08
trinucleotide O 0 0.0003744825371541083
repeats O 0 5.0471579015720636e-05
was O 0 9.262793901143596e-05
found O 0 1.6773781226220308e-06
. O 0 1.5667513935113675e-06

In O 0 2.0272540496080182e-05
SCA3 B-Disease 1 0.9913477301597595
, O 0 2.6027951207652222e-06
gaze B-Disease 0 0.00018292160530108958
- I-Disease 0 0.00042700470658019185
evoked I-Disease 0 3.0371900720638223e-05
nystagmus I-Disease 0 0.000395152106648311
was O 0 3.722662222571671e-05
often O 0 3.6161836192150076e-08
present O 0 1.936024318638374e-08
as O 0 4.736297043450577e-08
was O 0 4.823737072001677e-07
saccade O 0 9.797970506042475e-07
hypometria O 0 2.4375451630476164e-06
and O 0 2.2219884598939643e-08
smooth O 0 7.185098525042122e-07
pursuit O 0 1.5959898291839636e-06
gain O 0 1.1994342230536859e-06
was O 0 4.5514385419664904e-05
markedly O 0 8.945010631578043e-05
decreased O 0 0.0001224289444508031
. O 0 3.415917717575212e-06

Three O 0 1.2872910701844376e-06
major O 0 1.8084655266648042e-06
criteria O 0 4.3070963329228107e-07
, O 0 2.8640926075240714e-08
saccade O 0 2.166836566175334e-06
amplitude O 0 4.851700055041874e-07
, O 0 3.412305460415155e-08
saccade O 0 6.650911359429301e-07
velocity O 0 3.436099120790459e-07
, O 0 1.3375759166933676e-08
and O 0 3.743181764548353e-09
presence O 0 1.5950959664223774e-08
of O 0 1.0705720754344838e-08
gaze B-Disease 0 2.0217517885612324e-05
- I-Disease 0 8.04778392193839e-05
evoked I-Disease 0 4.025838279630989e-06
nystagmus I-Disease 0 1.0235763511445839e-05
, O 0 1.2399184790012896e-08
permitted O 0 7.257945799921117e-09
the O 0 1.17992264847544e-08
correct O 0 1.2046371011820156e-07
assignment O 0 6.568325972011735e-08
of O 0 8.733834766516679e-10
90 O 0 2.7577442551773856e-09
% O 0 6.353109149870306e-10
of O 0 3.3874977822812014e-10
the O 0 5.632712518632843e-09
SCA1 B-Disease 0 2.7980772756563965e-06
, O 0 3.1225384500288556e-09
90 O 0 1.6170406125226577e-09
% O 0 4.030494826778863e-10
of O 0 4.3097134194702846e-10
the O 0 9.01276564491127e-09
SCA2 B-Disease 0 1.031458486977499e-05
, O 0 6.089299287026506e-09
and O 0 2.2402177890512576e-09
93 O 0 1.872490607013333e-08
% O 0 3.9250716565852883e-10
of O 0 6.362179671981494e-10
the O 0 5.74291298960361e-08
patients O 0 4.155337194333697e-07
with O 0 6.109171835078087e-08
SCA3 B-Disease 1 0.970589816570282
to O 0 8.327594613888323e-09
their O 0 2.2290432610816424e-08
genetically O 0 7.244027528940933e-07
confirmed O 0 3.979095708928071e-06
patient O 0 5.985115876683267e-06
group O 0 1.2089044787444436e-07
and O 0 4.679885279301743e-08
, O 0 7.398700319072304e-08
therefore O 0 1.753146250393911e-07
, O 0 6.093809901130953e-08
may O 0 9.356989494335721e-08
help O 0 1.7680367392358676e-08
orient O 0 1.9230212274123915e-05
diagnoses O 0 8.242820513260085e-06
of O 0 3.416910132614248e-08
SCA1 B-Disease 0 0.000576785474549979
, O 0 1.6191886231808894e-07
SCA2 B-Disease 0 9.258925274480134e-05
, O 0 3.559033601163719e-08
and O 0 7.836525384163906e-08
SCA3 B-Disease 1 0.9929625391960144
at O 0 6.067284630262293e-06
early O 0 4.5188716057964484e-07
clinical O 0 1.070648636414262e-06
stages O 0 8.097921977423539e-07
of O 0 2.4805714815556712e-08
the O 0 8.445585990557447e-06
diseases O 0 0.43125641345977783
. O 0 5.063054686615942e-07
. O 0 1.1501156222948339e-06

Genetic O 0 1.5475561667699367e-05
basis O 0 3.4628237699507736e-07
and O 0 1.4078973720188515e-07
molecular O 0 6.143710197648033e-05
mechanism O 0 0.0005744438385590911
for O 0 0.002429095795378089
idiopathic B-Disease 1 0.9999909400939941
ventricular I-Disease 1 0.9999181032180786
fibrillation I-Disease 1 0.9999516010284424
. O 0 0.001170243602246046

Ventricular B-Disease 1 0.988956868648529
fibrillation I-Disease 1 0.9938073754310608
causes O 0 4.923241795040667e-05
more O 0 2.0810640322110885e-08
than O 0 1.2741931065818335e-08
300 O 0 2.1150057705199288e-08
, O 0 1.0977780462440023e-08
000 O 0 4.091393535077259e-08
sudden O 0 1.1754534625652013e-06
deaths O 0 9.239550280426556e-08
each O 0 2.092350515070507e-09
year O 0 3.298996986700331e-08
in O 0 1.1623099815949445e-08
the O 0 1.224485117745644e-07
USA O 0 1.722404886095319e-05
alone O 0 1.5672117115173023e-06
. O 0 6.497103868241538e-07

In O 0 3.297255091183615e-07
approximately O 0 6.482052583578479e-08
5 O 0 9.630967667817458e-08
- O 0 7.158546964092238e-07
12 O 0 6.973457367109859e-09
% O 0 6.673473995633117e-10
of O 0 4.519625507182212e-10
these O 0 8.936842932349975e-10
cases O 0 9.412440604705807e-09
, O 0 7.680260871723021e-09
there O 0 4.242235895901558e-09
are O 0 8.886105740124606e-10
no O 0 7.083871622626248e-08
demonstrable O 0 8.362631342606619e-05
cardiac O 0 0.43882840871810913
or O 0 1.3010698012294597e-06
non O 0 0.00017684035992715508
- O 1 0.9545258283615112
cardiac O 1 0.9893067479133606
causes O 0 5.6600656535010785e-06
to O 0 1.908088798074914e-09
account O 0 2.6011031106776272e-09
for O 0 1.5353521787275781e-09
the O 0 8.441087828714444e-09
episode O 0 1.4590560226679372e-07
, O 0 1.0726794563709063e-08
which O 0 1.4574908391296049e-08
is O 0 4.2055170013099996e-08
therefore O 0 1.1054666515519784e-07
classified O 0 2.1238005501800217e-05
as O 0 0.00197598640806973
idiopathic B-Disease 1 0.9999904632568359
ventricular I-Disease 1 0.9999107122421265
fibrillation I-Disease 1 0.9999823570251465
( O 0 0.0010625730501487851
IVF B-Disease 1 0.9995262622833252
) O 0 1.0852620107471012e-05
. O 0 4.009240456070984e-06

A O 0 2.32244224207534e-06
distinct O 0 4.087291927135084e-07
group O 0 4.835085292143049e-07
of O 0 2.5504547807031486e-07
IVF B-Disease 1 0.9998036026954651
patients O 0 0.00043183050001971424
has O 0 7.501205914195452e-07
been O 0 5.894709431686351e-08
found O 0 4.217330928923957e-09
to O 0 4.1558353980342133e-10
present O 0 1.5375763995351122e-09
with O 0 7.1318062566660956e-09
a O 0 6.658077040810895e-07
characteristic O 0 1.1098965842393227e-05
electrocardiographic O 0 0.0018389846663922071
pattern O 0 0.00019342514860909432
. O 0 4.226475539326202e-06

Because O 0 1.230652856065717e-06
of O 0 6.859322887464714e-09
the O 0 7.350282604789982e-09
small O 0 9.570352510479552e-09
size O 0 4.960416433164028e-08
of O 0 1.073526267880709e-09
most O 0 1.3598262516012483e-09
pedigrees O 0 5.5663065268163336e-08
and O 0 5.407223557796215e-09
the O 0 4.7513530887499655e-08
high O 0 3.325711077195592e-05
incidence O 0 0.00010639456013450399
of O 0 3.288235816967244e-08
sudden B-Disease 0 0.00012771374895237386
death I-Disease 0 9.007369953906164e-06
, O 0 1.6749016396033767e-08
however O 0 3.6774043810083867e-09
, O 0 5.301182159911377e-09
molecular O 0 3.3263054888266197e-07
genetic O 0 2.98781230867462e-07
studies O 0 3.329344977487381e-08
of O 0 2.0505710907059438e-08
IVF B-Disease 1 0.9779742360115051
have O 0 4.6134772446748684e-08
not O 0 6.500138205467465e-09
yet O 0 6.7543474813192e-08
been O 0 2.496244349003973e-07
done O 0 4.672393458804436e-07
. O 0 9.933993396771257e-07

Because O 0 0.0008565199095755816
IVF B-Disease 1 0.9987553358078003
causes O 0 0.16194267570972443
cardiac O 1 0.9989714622497559
rhythm O 1 0.8978714346885681
disturbance O 0 0.3307199776172638
, O 0 1.2713899195659906e-06
we O 0 1.387101349337172e-07
investigated O 0 2.5289086806878913e-06
whether O 0 5.9575089750296684e-08
malfunction O 0 0.00010910136188613251
of O 0 1.0559665142295671e-08
ion O 0 9.96946073428262e-06
channels O 0 1.8429949477649643e-06
could O 0 3.3933326903934358e-06
cause O 0 5.2287446123955306e-06
the O 0 9.220833021572616e-07
disorder O 0 0.00125366379506886
by O 0 1.705683239094924e-08
studying O 0 9.980565351952464e-08
mutations O 0 2.2901778606865264e-07
in O 0 3.039920670744323e-08
the O 0 8.643095839033776e-08
cardiac O 0 0.0009206964750774205
sodium O 0 4.914412784273736e-06
channel O 0 1.5131672626012005e-05
gene O 0 1.1318647011648864e-05
SCN5A O 0 0.0005636796122416854
. O 0 1.8243849808641244e-06

We O 0 1.5121686374186538e-06
have O 0 6.42829789399002e-08
now O 0 9.396568856345766e-08
identified O 0 8.042633226068574e-08
a O 0 1.7193406165461056e-07
missense O 0 8.831384548102506e-06
mutation O 0 1.4975604472056148e-06
, O 0 6.640705763061305e-09
a O 0 3.114658753133881e-08
splice O 0 4.175523372396128e-06
- O 0 2.7889343982678838e-05
donor O 0 8.384830607610638e-07
mutation O 0 1.0834911563506466e-06
, O 0 6.537389740657318e-09
and O 0 7.167056281787154e-09
a O 0 6.014939799570129e-07
frameshift O 0 0.00010344334441469982
mutation O 0 2.019525254581822e-06
in O 0 2.2871368798860203e-08
the O 0 2.2423776613322843e-08
coding O 0 1.7689494598016609e-06
region O 0 2.751530985278805e-07
of O 0 2.1374402692231342e-08
SCN5A O 0 0.0001406761002726853
in O 0 3.4019149097730406e-07
three O 0 4.3404301663940714e-07
IVF B-Disease 1 0.5828122496604919
families O 0 4.833236744161695e-07
. O 0 1.6851320197019959e-06

We O 0 3.3652258935035206e-07
show O 0 8.487636193876824e-08
that O 0 1.4450227681095384e-09
sodium O 0 1.5846826073584452e-08
channels O 0 9.71216795875307e-09
with O 0 3.6223393173884233e-09
the O 0 3.327320285961832e-08
missense O 0 5.588423846347723e-06
mutation O 0 2.968900616906467e-06
recover O 0 1.460033331568411e-06
from O 0 1.973486263295854e-08
inactivation O 0 1.6990201402222738e-05
more O 0 1.1815006750737211e-09
rapidly O 0 1.1396826238296853e-07
than O 0 3.811654547547505e-09
normal O 0 8.930273764917729e-08
and O 0 5.774190459106876e-09
that O 0 2.1893669099881663e-09
the O 0 6.321759826732887e-08
frameshift O 0 0.0001295357069466263
mutation O 0 2.7392225092626177e-06
causes O 0 8.323850408942235e-08
the O 0 3.350953514669186e-09
sodium O 0 4.730320313228731e-08
channel O 0 1.033232308600418e-07
to O 0 1.7300663124331095e-09
be O 0 7.509949995210263e-09
non O 0 7.663904710852876e-08
- O 0 1.42334756674245e-05
functional O 0 4.822495611733757e-06
. O 0 1.005486069516337e-06

Our O 0 3.647505536719109e-06
results O 0 2.014510300796246e-06
indicate O 0 2.0531625466446712e-07
that O 0 1.440818309106362e-08
mutations O 0 3.0108324722277757e-07
in O 0 1.0259702065695819e-07
cardiac O 0 0.00041247668559663
ion O 0 3.886415288434364e-05
- O 0 1.3216142178862356e-05
channel O 0 6.390419002855197e-07
genes O 0 2.7646816391779794e-08
contribute O 0 9.027113279103105e-09
to O 0 1.0568544928091228e-09
the O 0 1.4916956558863603e-08
risk O 0 3.212548733699805e-07
of O 0 1.0224066038233559e-08
developing O 0 6.741773177054711e-06
IVF B-Disease 1 0.9983737468719482
. O 0 6.45300190171838e-07
. O 0 8.019400752345973e-07

Molecular O 0 0.0001559355150675401
heterogeneity O 0 0.00012393984070513397
in O 0 5.926177436776925e-06
mucopolysaccharidosis B-Disease 0 0.005620788317173719
IVA I-Disease 0 0.16832977533340454
in O 0 5.705256285182259e-07
Australia O 0 5.086550913802057e-08
and O 0 2.441517565898721e-08
Northern O 0 8.167242526724294e-07
Ireland O 0 2.960440951937926e-06
: O 0 3.82253375619257e-08
nine O 0 6.494428106407213e-08
novel O 0 1.6348897702300746e-07
mutations O 0 2.122717148722586e-07
including O 0 5.4299502671995015e-09
T312S O 0 1.3599459407487302e-06
, O 0 1.2415750205718723e-08
a O 0 2.2159403201271743e-08
common O 0 2.266630261260616e-08
allele O 0 1.005621541594337e-07
that O 0 1.1627756535403933e-08
confers O 0 2.3081956896930933e-06
a O 0 3.3213877031812444e-05
mild O 0 0.10644268989562988
phenotype O 0 0.0025132368318736553
. O 0 2.486868424966815e-06

Mucopolysaccharidosis B-Disease 1 0.9242165684700012
IVA I-Disease 1 0.9955394864082336
( O 0 0.00030052263173274696
MPS B-Disease 1 0.9987468719482422
IVA I-Disease 1 0.9998194575309753
) O 0 2.4348314582312014e-06
is O 0 8.827780106912542e-07
an O 0 2.6277537017449504e-06
autosomal B-Disease 1 0.996880054473877
recessive I-Disease 1 0.9991368651390076
lysosomal I-Disease 1 0.9998089671134949
storage I-Disease 1 0.9998630285263062
disorder I-Disease 1 0.9999734163284302
caused O 0 0.03642202168703079
by O 0 1.2281590215934557e-06
a O 0 0.0004749029176309705
genetic B-Disease 1 0.9989585876464844
defect I-Disease 1 0.9993155002593994
in O 0 2.267284571644268e-06
N O 0 7.149730663513765e-05
- O 0 7.022533827694133e-05
acetylgalactosamine O 0 0.00027554354164749384
- O 0 0.00014934429782442749
6 O 0 1.940607398864813e-05
- O 0 0.0010006417287513614
sulfate O 0 0.0009533000993542373
sulfatase O 0 0.000692416331730783
( O 0 4.4869054249829787e-07
GALNS O 0 0.00032697271672077477
) O 0 3.573822482394462e-07
. O 0 7.565678288301569e-07

Previous O 0 3.2265111258311663e-06
studies O 0 2.107654637484302e-07
of O 0 3.9856775657654e-08
patients O 0 4.12684329376134e-07
from O 0 1.5039402612160302e-08
a O 0 1.5778263673382753e-07
British O 0 5.272866019367939e-06
- O 0 3.329836908960715e-05
Irish O 0 1.091112608264666e-06
population O 0 1.2164559137772812e-08
showed O 0 1.0034354147592239e-07
that O 0 1.2417781247719972e-09
the O 0 8.989381683477404e-09
I113F O 0 2.707968178583542e-06
mutation O 0 7.589265464957862e-07
is O 0 9.037070647366363e-09
the O 0 2.038975210894023e-09
most O 0 1.7455188405790523e-09
common O 0 1.4484176524831582e-08
single O 0 4.396630970404658e-07
mutation O 0 1.1675240784825291e-05
among O 0 1.24748430607724e-06
MPS B-Disease 1 0.9968652129173279
IVA I-Disease 1 0.9999489784240723
patients O 0 0.0007335955742746592
and O 0 2.8658419637395127e-07
produces O 0 2.1496541648957646e-06
a O 0 5.917732778470963e-05
severe O 1 0.9127278923988342
clinical O 0 0.057928673923015594
phenotype O 0 0.04506838694214821
. O 0 1.1046946383430623e-05

We O 0 1.6425394733232679e-06
studied O 0 3.9119245229812805e-06
mutations O 0 3.217774747099611e-06
in O 0 5.692702487181123e-08
the O 0 5.181169271395447e-08
GALNS O 0 2.7256948669673875e-05
gene O 0 4.987131774214504e-07
from O 0 3.192439379517964e-08
23 O 0 3.4889615108113503e-07
additional O 0 2.875747213693103e-07
MPS B-Disease 1 0.9739437699317932
IVA I-Disease 1 0.9999072551727295
patients O 0 0.0002517591055948287
( O 0 3.991413421999823e-08
15 O 0 5.73542529025417e-08
from O 0 4.750779769580049e-09
Australia O 0 6.288396914300165e-09
, O 0 5.074696662887845e-09
8 O 0 2.214833472180544e-08
from O 0 4.984598955815045e-09
Northern O 0 4.881165693859657e-08
Ireland O 0 7.100847909669028e-08
) O 0 2.231164808463859e-09
, O 0 2.011610655827667e-09
with O 0 1.8836912030195663e-09
various O 0 3.2686696016526184e-08
clinical O 0 0.0001371295511489734
phenotypes O 0 7.301889854716137e-05
( O 0 8.186566446966026e-07
severe O 0 0.007674251217395067
, O 0 8.11075366868863e-08
16 O 0 1.8200232432263874e-07
cases O 0 2.4276426202618495e-08
; O 0 1.0239541659018414e-08
intermediate O 0 1.0946960173896514e-06
, O 0 5.816839987460298e-08
4 O 0 7.221107694022066e-07
cases O 0 1.6395927104895236e-07
; O 0 2.0129594702211762e-07
mild O 0 0.00029291867394931614
, O 0 3.145452751596167e-07
3 O 0 2.42636633629445e-06
cases O 0 3.35549032115523e-07
) O 0 3.5575106949181645e-07
. O 0 1.1968586477451026e-06

We O 0 8.603257697359368e-07
found O 0 1.2460355947041535e-07
two O 0 8.917623084414572e-09
common O 0 7.490697839784843e-08
mutations O 0 2.704195196656656e-07
that O 0 8.921667293826374e-10
together O 0 1.1477694350503498e-09
accounted O 0 7.967509318973498e-09
for O 0 9.670682032947298e-10
32 O 0 6.451670309104429e-09
% O 0 6.240885586095146e-10
of O 0 3.239841173119373e-10
the O 0 4.924704199993357e-09
44 O 0 2.7767944388301657e-08
unrelated O 0 5.307153827516231e-08
alleles O 0 5.421777515834947e-08
in O 0 5.533998148621322e-08
these O 0 6.222135340294699e-08
patients O 0 1.9522422007867135e-05
. O 0 2.5742067464307183e-06

One O 0 9.190185323859623e-07
is O 0 1.298988934195222e-07
the O 0 6.94471040674216e-08
T312S O 0 6.402982307918137e-06
mutation O 0 2.517416533009964e-06
, O 0 1.587541476055776e-08
a O 0 5.947200421019261e-08
novel O 0 2.6004357778219855e-07
mutation O 0 4.487872331537801e-07
found O 0 1.196861276753225e-08
exclusively O 0 2.933427545315226e-08
in O 0 5.340195343706e-07
milder O 0 0.00044186809100210667
patients O 0 9.604689694242552e-05
. O 0 2.4666403533046832e-06

The O 0 4.761809293540864e-07
other O 0 2.1381497461447907e-08
is O 0 5.663039814862714e-08
the O 0 4.272746778610781e-08
previously O 0 7.760701237202738e-07
described O 0 9.234261710844294e-07
I113F O 0 3.1449119433091255e-06
that O 0 3.2665131044495865e-08
produces O 0 8.831265745357086e-07
a O 0 4.5534659875556827e-05
severe O 1 0.6881229281425476
phenotype O 0 0.00588330440223217
. O 0 3.699176431837259e-06

The O 0 1.4188844943419099e-06
I113F O 0 1.9746268662856892e-05
and O 0 2.7886682119060424e-07
T312S O 0 1.0235645277134608e-05
mutations O 0 4.043345143145416e-06
accounted O 0 1.8551008906797506e-07
for O 0 5.541452186008655e-09
8 O 0 5.487926912906005e-08
( O 0 4.0060172956657425e-09
18 O 0 1.1167490931995872e-08
% O 0 5.953300075134393e-10
) O 0 5.944302272631319e-10
and O 0 3.1497793262502682e-09
6 O 0 1.2233320489940525e-07
( O 0 3.2385334414186673e-09
14 O 0 1.2422050943428076e-08
% O 0 1.0738969713486313e-09
) O 0 6.580947453649344e-10
of O 0 1.3110388330517253e-09
44 O 0 3.605783405191687e-08
unrelated O 0 2.0518589849416458e-07
alleles O 0 1.8459414263816143e-07
, O 0 1.0997860755423972e-07
respectively O 0 2.5869844648696017e-06
. O 0 2.765228146017762e-06

The O 0 8.86473117134301e-07
relatively O 0 1.9268718460807577e-06
high O 0 5.5984955906751566e-06
residual O 0 6.561390819115331e-06
GALNS O 0 7.574316259706393e-05
activity O 0 2.6146074105781736e-07
seen O 0 1.3518857144845242e-07
when O 0 1.931907789298748e-08
the O 0 8.074954038761462e-09
T312S O 0 3.229356764222757e-07
mutant O 0 1.9941045081850461e-07
cDNA O 0 2.6902560534836084e-07
is O 0 5.0421757435969994e-08
overexpressed O 0 1.543944676996034e-06
in O 0 2.9635710774300605e-08
mutant O 0 3.3285394351878494e-07
cells O 0 9.05899213421435e-08
provides O 0 8.859439404318437e-09
an O 0 4.825455590662386e-09
explanation O 0 1.6875937092208915e-08
for O 0 6.137550023765925e-09
the O 0 2.130759213514466e-07
mild O 0 0.0004470509011298418
phenotype O 0 3.251041198382154e-05
in O 0 7.456997082044836e-07
patients O 0 1.4650015600636834e-06
with O 0 6.416770048645049e-08
this O 0 2.18880487068418e-07
mutation O 0 2.51321562245721e-05
. O 0 2.1136299892532406e-06

The O 0 2.589413270470686e-07
distribution O 0 7.800050383366397e-08
and O 0 6.735305202454356e-09
relative O 0 3.176762319867521e-08
frequencies O 0 4.712022416697437e-08
of O 0 3.5694192046520357e-09
the O 0 2.5655985780304036e-08
I113F O 0 8.050918722801725e-07
and O 0 4.1070780554264275e-08
T312S O 0 3.1722445328341564e-06
mutations O 0 8.23001244043553e-07
in O 0 9.446972981663748e-09
Australia O 0 5.122620549968815e-09
corresponded O 0 1.3625921724269574e-08
to O 0 8.34247115832909e-10
those O 0 1.2195869869557896e-09
observed O 0 5.474775122138453e-08
in O 0 1.939187832533662e-08
Northern O 0 2.3196942322556424e-07
Ireland O 0 5.875435249436123e-07
and O 0 4.0672738066405145e-08
are O 0 5.824850046742824e-10
unique O 0 1.2150268569044442e-09
to O 0 5.469623642895272e-10
these O 0 3.1965430302705045e-10
two O 0 2.539172205828777e-09
populations O 0 9.939943979020427e-09
, O 0 4.534462583194454e-09
suggesting O 0 1.4316303698080901e-08
that O 0 6.249819550774305e-10
both O 0 2.628944617555362e-09
mutations O 0 1.6498808008691412e-07
were O 0 1.5650796214572438e-08
probably O 0 1.3224314976412188e-08
introduced O 0 3.846388985095928e-09
to O 0 6.436892130423644e-10
Australia O 0 4.019840460500745e-09
by O 0 2.4450115265750583e-09
Irish O 0 1.4745228327228688e-07
migrants O 0 1.2789118208900163e-08
during O 0 7.067541218930273e-08
the O 0 3.047630414698688e-08
19th O 0 1.7955217117560096e-06
century O 0 3.510868054945604e-06
. O 0 1.3963818901174818e-06

Haplotype O 0 6.136975571280345e-05
analysis O 0 3.3171153290822986e-07
using O 0 1.008412340297582e-07
6 O 0 3.3652230513325776e-07
RFLPs O 0 3.60015974365524e-06
provides O 0 1.4963662309241954e-08
additional O 0 4.649383988919453e-09
data O 0 1.7870497970307042e-08
that O 0 2.2233228591517218e-09
the O 0 1.0434749952992206e-08
I113F O 0 1.4034631021786481e-06
mutation O 0 2.0088859287170635e-07
originated O 0 1.2404554716738403e-08
from O 0 1.3501792572867544e-08
a O 0 1.107581297787874e-07
common O 0 4.2528756694082404e-07
ancestor O 0 3.8635562304989435e-06
. O 0 4.6850750550220255e-06

The O 0 3.429545074595808e-07
other O 0 3.752340660412301e-08
9 O 0 1.3670509133589803e-06
novel O 0 1.0607708418319817e-06
mutations O 0 3.4487718494347064e-06
identified O 0 3.021766303845652e-07
in O 0 1.6037231986842926e-08
these O 0 3.4239933111024357e-09
23 O 0 9.366146400680009e-07
patients O 0 1.981974406817244e-07
were O 0 1.5407969344849448e-09
each O 0 4.31405577927535e-10
limited O 0 2.588077974152725e-09
to O 0 1.5026719868416194e-09
a O 0 1.963113902547775e-07
single O 0 1.1147825489388197e-06
family O 0 1.1504412213980686e-05
. O 0 3.590306050682557e-06

These O 0 9.309352577702157e-08
data O 0 3.7405072816909524e-08
provide O 0 5.331277197484496e-09
further O 0 8.666929396383694e-09
evidence O 0 1.648066927373293e-08
for O 0 4.9930770629202925e-09
extensive O 0 2.510497324692551e-06
allelic O 0 5.348438935470767e-05
heterogeneity O 0 0.0001312361127929762
in O 0 3.394719533389434e-05
MPS B-Disease 1 0.9024817943572998
IVA I-Disease 1 0.9994138479232788
in O 0 7.146022198867286e-06
British O 0 0.0004811706894543022
- O 0 0.05893692746758461
Irish O 0 0.0004692748188972473
patients O 0 5.5229434110515285e-06
and O 0 5.181946871601895e-09
provide O 0 2.681378896696174e-09
evidence O 0 4.908855544272228e-09
for O 0 1.2110497049633295e-09
their O 0 2.6573832023757404e-09
transmission O 0 6.384431117112399e-07
to O 0 1.6414685166665777e-09
Australia O 0 3.6784424395364113e-09
by O 0 7.734299423134416e-09
British O 0 4.690735295298509e-06
- O 0 7.656303205294535e-05
Irish O 0 3.9996125451580156e-06
migrants O 0 8.60997388940632e-08
. O 0 8.621148595011618e-08
. O 0 6.914257824064407e-07

Identification O 0 4.801597242476419e-06
of O 0 5.463185175358376e-07
constitutional O 0 5.8662542869569734e-05
WT1 O 0 0.041207414120435715
mutations O 0 0.00029453562456183136
, O 0 5.368564757191052e-07
in O 0 6.433376142922498e-07
patients O 0 8.296227861137595e-06
with O 0 4.82346149510704e-06
isolated O 0 0.2230411171913147
diffuse B-Disease 1 0.9982232451438904
mesangial I-Disease 1 0.9999631643295288
sclerosis I-Disease 1 0.9999903440475464
, O 0 9.401244369655615e-07
and O 0 3.0029575270873465e-08
analysis O 0 4.279671372842131e-08
of O 0 3.054637076616018e-08
genotype O 0 4.494949735089904e-06
/ O 0 3.2317832392436685e-06
phenotype O 0 1.3772971669823164e-06
correlations O 0 6.824118514714428e-08
by O 0 1.81031567514367e-09
use O 0 3.734488718265538e-09
of O 0 5.349673593002535e-09
a O 0 3.802007597641932e-07
computerized O 0 0.00020344539370853454
mutation O 0 4.677121978602372e-05
database O 0 5.1142651500413194e-06
. O 0 1.8977204945258563e-06

Constitutional O 0 9.146704542217776e-05
mutations O 0 3.0073311791056767e-05
of O 0 5.277838610595609e-08
the O 0 1.4822009575254924e-07
WT1 O 0 4.116687341593206e-05
gene O 0 6.579284104191174e-07
, O 0 1.2932741100257772e-08
encoding O 0 5.019510496140356e-08
a O 0 2.1529654077312443e-06
zinc O 0 0.0002106473402818665
- O 0 8.313588296005037e-06
finger O 0 1.170311634268728e-06
transcription O 0 2.904754978771962e-07
factor O 0 4.396228092673482e-08
involved O 0 2.4188516078993416e-08
in O 0 3.5030546996495104e-07
renal O 1 0.9692376852035522
and O 0 1.3169891417419421e-06
gonadal O 0 0.0007318431744351983
development O 0 3.81234059432245e-07
, O 0 4.174747658680644e-08
are O 0 1.7888565073675977e-09
found O 0 2.5174729856303202e-08
in O 0 1.2351646816455286e-08
most O 0 2.8480005909159445e-08
patients O 0 6.397522724910232e-07
with O 0 1.2986747606191784e-06
Denys B-Disease 1 0.993067741394043
- I-Disease 1 0.9996373653411865
Drash I-Disease 1 0.9991970658302307
syndrome I-Disease 1 0.999954342842102
( O 0 2.1965845007798634e-05
DDS B-Disease 1 0.9995577931404114
) O 0 8.405662583754747e-07
, O 0 7.908764700914617e-07
or O 0 3.423193993512541e-05
diffuse B-Disease 1 0.9977939128875732
mesangial I-Disease 1 0.9999643564224243
sclerosis I-Disease 1 0.9999967813491821
( O 0 0.00012370440526865423
DMS B-Disease 1 0.8663557171821594
) O 0 2.522289719308901e-07
associated O 0 8.183038175957336e-07
with O 0 5.381913865676324e-07
pseudohermaphroditism B-Disease 1 0.9989449381828308
and O 0 2.1916504920227453e-05
/ O 0 0.001305814366787672
or O 0 0.0006146962405182421
Wilms B-Disease 1 0.9993871450424194
tumor I-Disease 1 0.9996308088302612
( O 0 1.3660273907589726e-05
WT B-Disease 1 0.9867563247680664
) O 0 3.0489263735944405e-06
. O 0 3.1083613976079505e-06

Most O 0 9.751792276802007e-06
mutations O 0 0.0009440662106499076
in O 0 4.423426071298309e-05
DDS B-Disease 1 0.999848484992981
patients O 0 0.0014586610486730933
lie O 0 5.59137197342352e-06
in O 0 1.8267286350237555e-07
exon O 0 4.174599325779127e-06
8 O 0 1.4994310504334862e-07
or O 0 1.9280831153878353e-08
exon O 0 2.5273609480791492e-06
9 O 0 5.203492037253454e-07
, O 0 1.8448215399757828e-08
encoding O 0 2.0166024228274182e-07
zinc O 0 0.00018452908261679113
finger O 0 1.072029317583656e-05
2 O 0 2.162962147167491e-07
or O 0 1.302682193227156e-07
zinc O 0 4.486231773626059e-05
finger O 0 3.5651289636007277e-06
3 O 0 5.302458916389696e-08
, O 0 3.903765311008556e-09
respectively O 0 1.362667489956948e-08
, O 0 1.6377752487528596e-09
with O 0 3.316256158569786e-09
a O 0 3.5898361261388345e-07
hot O 0 3.756135811272543e-06
spot O 0 7.97366737970151e-07
( O 0 1.1549818879075247e-08
R394W O 0 5.620352112600813e-07
) O 0 1.3927198061480794e-08
in O 0 4.677297482658105e-08
exon O 0 1.3834032870363444e-05
9 O 0 5.412443897512276e-06
. O 0 1.5661539691791404e-06

We O 0 6.482287631115469e-07
analyzed O 0 2.7149422976435744e-07
a O 0 3.223461320089882e-08
series O 0 3.4194918896446325e-08
of O 0 1.7531705864826108e-08
24 O 0 2.9201196412032004e-06
patients O 0 2.206835461038281e-06
, O 0 4.9727884032790826e-08
10 O 0 4.3825817641618414e-08
with O 0 3.6314244766799675e-07
isolated B-Disease 0 0.0011986654717475176
DMS I-Disease 1 0.5729480385780334
( O 0 5.804615170745819e-07
IDMS B-Disease 0 0.0004173634806647897
) O 0 3.778929524855812e-08
, O 0 2.036442126041038e-08
10 O 0 2.0943717871091394e-08
with O 0 8.703494103201592e-08
DDS B-Disease 1 0.9991828799247742
, O 0 2.487589085831132e-07
and O 0 7.545115465745766e-08
4 O 0 1.9318358681630343e-06
with O 0 3.830186415143544e-06
urogenital B-Disease 1 0.9903481006622314
abnormalities I-Disease 1 0.9991318583488464
and O 0 2.5792054657358676e-05
/ O 0 0.001756217097863555
or O 0 0.00022230230388231575
WT B-Disease 1 0.9981305003166199
. O 0 1.977881765924394e-05

We O 0 8.27300755190663e-06
report O 0 3.730244770849822e-06
WT1 O 0 0.0002428632287774235
heterozygous O 0 1.0942170774796978e-05
mutations O 0 2.180950468755327e-05
in O 0 5.433313958747021e-07
16 O 0 2.025593403232051e-06
patients O 0 1.5713033008069033e-06
, O 0 1.825998374727078e-08
4 O 0 5.2940109185328765e-08
of O 0 9.716131899040192e-09
whom O 0 1.688088673290622e-07
presented O 0 1.4134941466181772e-06
with O 0 3.144054062431678e-06
IDMS B-Disease 1 0.7477657794952393
. O 0 1.1358039955666754e-05

One O 0 6.057896371203242e-07
male O 0 5.533480020858406e-07
and O 0 9.563349578911584e-08
two O 0 7.22615070003485e-08
female O 0 5.789064289274393e-06
IDMS B-Disease 0 0.12235477566719055
patients O 0 2.881471300497651e-05
with O 0 1.5616616337865707e-06
WT1 O 0 0.39279818534851074
mutations O 0 0.006473921705037355
underwent O 1 0.9766205549240112
normal O 0 0.0003604683734010905
puberty O 0 0.0030431628692895174
. O 0 7.106075827323366e-06

Two O 0 4.4953267206437886e-06
mutations O 0 0.0002796049229800701
associated O 0 5.694977971870685e-06
with O 0 3.9612177715753205e-07
IDMS B-Disease 0 0.006792228203266859
are O 0 7.2628201230884315e-09
different O 0 2.2836919022495294e-09
from O 0 1.3283672828379167e-08
those O 0 1.0268468741969627e-08
described O 0 1.2760125173372217e-05
in O 0 3.087966615566984e-05
DDS B-Disease 1 0.9998723268508911
patients O 0 0.04389769211411476
. O 0 8.635220183350611e-06

No O 0 2.851437784556765e-05
WT1 O 0 0.002561229048296809
mutations O 0 0.00012615491868928075
were O 0 3.0998899092082866e-07
detected O 0 6.4620944613125175e-06
in O 0 2.5852276763771442e-08
the O 0 1.1690422851984295e-08
six O 0 5.1816630985968004e-08
other O 0 2.0919125987006737e-08
IDMS B-Disease 0 0.058282919228076935
patients O 0 3.4197746572317556e-05
, O 0 5.6947552451447336e-08
suggesting O 0 3.159203458835691e-07
genetic O 0 1.1465816669442574e-06
heterogeneity O 0 4.928967882733559e-06
of O 0 3.1823179824641556e-07
this O 0 7.413478215312352e-06
disease O 1 0.7583192586898804
. O 0 6.129882422101218e-06

We O 0 1.3372872444961104e-06
analyzed O 0 2.4906041744543472e-06
genotype O 0 1.2271146260900423e-05
/ O 0 6.022486104484415e-06
phenotype O 0 3.228484047212987e-06
correlations O 0 2.732272434968763e-07
, O 0 1.5924209506579245e-08
on O 0 9.615510165872365e-09
the O 0 2.1112360748531955e-09
basis O 0 1.841891972276244e-09
of O 0 9.6374275226907e-10
the O 0 8.798512141083847e-09
constitution O 0 1.5681873577477745e-08
of O 0 2.453541814162463e-09
a O 0 1.6848413508796511e-07
WT1 O 0 3.413899685256183e-05
mutation O 0 2.4526923425582936e-07
database O 0 1.673828542436695e-08
of O 0 5.003411462922713e-09
84 O 0 8.0023642112792e-07
germ O 0 0.00018875118985306472
- O 0 8.102686842903495e-05
line O 0 1.0756935807876289e-05
mutations O 0 7.157618711062241e-07
, O 0 3.5644800444600833e-09
to O 0 6.730139223698473e-10
compare O 0 4.281277554696317e-09
the O 0 7.912576704960372e-10
distribution O 0 3.8467922180984715e-09
and O 0 6.835684018824395e-09
type O 0 4.954705445925356e-07
of O 0 8.154540154237111e-09
mutations O 0 9.085516126106086e-07
, O 0 1.2154099060524004e-08
according O 0 2.2480763917087643e-09
to O 0 1.2683873951147007e-09
the O 0 4.337889336625267e-08
different O 0 1.1709686731364854e-07
symptoms O 0 0.0017174737295135856
. O 0 2.4868445507308934e-06

This O 0 3.9561098219564883e-07
demonstrated O 0 6.759333928130218e-07
( O 0 3.2563363561166625e-08
1 O 0 9.376999798860197e-08
) O 0 3.911814872026298e-09
the O 0 1.337178012761342e-08
association O 0 4.709731271645978e-08
between O 0 2.3923680814164072e-08
mutations O 0 4.681483574131562e-07
in O 0 2.665796294820666e-08
exons O 0 2.891003134664061e-07
8 O 0 1.6333844143900933e-07
and O 0 2.930693021596653e-08
9 O 0 1.1779392252719845e-06
and O 0 1.2197160970117693e-07
DMS B-Disease 0 0.001916880370117724
; O 0 4.271337061823033e-08
( O 0 1.1278222800115145e-08
2 O 0 7.176456051638525e-08
) O 0 9.933613931423224e-09
among O 0 2.0355257035475915e-08
patients O 0 3.410081035326584e-07
with O 0 3.4136007798224455e-08
DMS B-Disease 0 0.000592575001064688
, O 0 5.0042610055811565e-09
a O 0 6.73016842256402e-09
higher O 0 8.72128769202618e-09
frequency O 0 1.329690402229744e-08
of O 0 3.189127406599823e-09
exon O 0 1.1896167961822357e-06
8 O 0 1.8869614848426863e-07
mutations O 0 2.5605933728911623e-07
among O 0 9.056275729335539e-09
46 O 0 1.5053585400437441e-07
, O 0 7.251708211697405e-08
XY O 0 3.809206100413576e-05
patients O 0 3.0994169719633646e-07
with O 0 8.538552087600237e-09
female O 0 1.7263596419070382e-07
phenotype O 0 5.677418357663555e-07
than O 0 5.326804775052096e-09
among O 0 9.738990947028014e-09
46 O 0 2.621056012230838e-07
, O 0 1.6137545344463433e-07
XY O 0 0.00017420233052689582
patients O 0 1.6812634839880047e-06
with O 0 2.5699771200038413e-08
sexual O 0 1.4008125504005875e-07
ambiguity O 0 1.8897996767464065e-07
or O 0 1.7031238996878528e-07
male O 0 3.693659209602629e-07
phenotype O 0 2.3596721803187393e-06
; O 0 1.916153458125791e-08
and O 0 7.663901513410565e-09
( O 0 6.066438462681845e-09
3 O 0 1.9129144490648287e-08
) O 0 1.6491602528034832e-09
statistically O 0 1.1673800592859607e-08
significant O 0 4.002992604057454e-09
evidence O 0 4.226728744782804e-09
that O 0 2.424194178729522e-09
mutations O 0 3.290952577117423e-08
in O 0 2.1753598922202855e-09
exons O 0 9.031301573259043e-08
8 O 0 8.34999269727632e-08
and O 0 1.2561169882019385e-08
9 O 0 7.584997518961245e-08
preferentially O 0 2.4302554635369233e-08
affect O 0 1.1662717902538589e-08
amino O 0 2.9478970375862446e-09
acids O 0 8.1004963847775e-10
with O 0 2.330652337789729e-10
different O 0 3.677262383483537e-10
functions O 0 1.5567227507062853e-08
. O 0 3.8833444904184944e-08
. O 0 3.730888522568421e-07

The O 0 2.9461671147146262e-06
185delAG O 0 0.00041301772580482066
BRCA1 O 0 0.0011775592574849725
mutation O 0 9.508983566774987e-06
originated O 0 1.158494740138849e-07
before O 0 2.201360516096429e-08
the O 0 3.1873759187561745e-09
dispersion O 0 3.423302885607882e-08
of O 0 2.148171862614845e-09
Jews O 0 1.391734638644948e-08
in O 0 2.2942147737126106e-08
the O 0 1.0174557196762635e-08
diaspora O 0 4.665296060579749e-08
and O 0 5.4929014225990613e-08
is O 0 5.23670635743656e-08
not O 0 3.7840486299955955e-09
limited O 0 2.3454779451981267e-08
to O 0 5.904994182515111e-08
Ashkenazim O 0 5.01304748468101e-05
. O 0 3.242350658183568e-06

The O 0 2.516293079679599e-06
185delAG O 0 0.00011412892490625381
mutation O 0 4.228171019349247e-05
in O 0 8.3981552734258e-07
BRCA1 O 0 0.0001225701707880944
is O 0 2.7244223588240857e-07
detected O 0 1.6820910104797804e-06
in O 0 1.407388072749427e-08
Ashkenazi O 0 9.55946120484441e-07
Jews O 0 2.7116735523691204e-08
both O 0 2.105121055251402e-08
in O 0 1.1012582490366185e-06
familial B-Disease 1 0.9737462997436523
breast I-Disease 1 0.9999512434005737
and I-Disease 1 0.9988092184066772
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.999997615814209
and O 0 4.890717718808446e-06
in O 0 2.027547907346161e-07
the O 0 7.339232155345599e-08
general O 0 3.1546784384772764e-07
population O 0 2.586644143320882e-07
. O 0 1.3559881608671276e-06

All O 0 1.812834057091095e-06
tested O 0 4.276182153262198e-05
Ashkenazi O 0 8.831024751998484e-05
mutation O 0 1.5560328392894007e-05
carriers O 0 6.838541821707622e-07
share O 0 2.1654134485515897e-08
the O 0 1.0165633668179908e-08
same O 0 2.4777058627023507e-08
allelic O 0 1.1501639392008656e-06
pattern O 0 1.5462138662769576e-06
at O 0 2.665346983121708e-06
the O 0 8.436574603365443e-07
BRCA1 O 0 0.00020801990467589349
locus O 0 0.0001065246106008999
. O 0 4.722919129562797e-06

Our O 0 1.69180168541061e-06
previous O 0 1.4068373275222257e-06
study O 0 3.349530857121863e-07
showed O 0 6.5307619934174e-07
that O 0 7.04367808523898e-09
this O 0 1.0037758180203582e-08
Ashkenazi O 0 1.9266903109382838e-05
mutation O 0 6.602089797524968e-06
also O 0 1.100986679603011e-07
occurs O 0 2.5085959975967853e-08
in O 0 4.940330367020351e-09
Iraqi O 0 1.3413724353483758e-08
Jews O 0 8.139389606753866e-09
with O 0 2.001679710872395e-08
a O 0 5.412642849478289e-07
similar O 0 8.265218411906972e-07
allelic O 0 7.990957237780094e-05
pattern O 0 0.00030404143035411835
. O 0 8.216035894292872e-06

We O 0 2.8221649017723394e-07
extended O 0 8.725317712787728e-08
our O 0 1.584700726198207e-08
analysis O 0 1.0827681862224381e-08
to O 0 7.535414514592276e-10
other O 0 7.9591055968109e-10
non O 0 2.615222527424521e-08
- O 0 8.178373036571429e-07
Ashkenazi O 0 4.1070316569857823e-07
subsets O 0 4.602745562465316e-08
354 O 0 4.8946372288583007e-08
of O 0 1.6969922134180138e-09
Moroccan O 0 3.793405483065726e-07
origin O 0 1.0231518743353263e-08
, O 0 1.7650279460212914e-08
200 O 0 1.4782787438605283e-08
Yemenites O 0 6.884773711135495e-07
and O 0 2.4173619550538206e-08
150 O 0 1.0008129436300806e-07
Iranian O 0 3.4400005688439705e-07
Jews O 0 7.612025569869729e-07
. O 0 1.3782931773675955e-06

Heteroduplex O 0 0.00010276016109855846
analysis O 0 3.4757073308355757e-07
complemented O 0 2.84692077912041e-07
by O 0 7.435620563711609e-09
direct O 0 7.25467907969346e-09
DNA O 0 1.0996141952546168e-07
sequencing O 0 4.7062918895335315e-08
of O 0 9.952237256527496e-09
abnormally O 0 3.433001211305964e-06
migrating O 0 1.0152925966622206e-07
bands O 0 6.026538130754489e-07
were O 0 1.0643118741882063e-07
employed O 0 1.894405841085245e-06
. O 0 1.6840588159539038e-06

Four O 0 4.914202236250276e-07
of O 0 5.5567170420545153e-08
Moroccan O 0 3.7348829664551886e-06
origin O 0 3.8457233841882044e-08
( O 0 1.888671263827746e-08
1 O 0 5.317265916460201e-08
. O 0 3.5132092790490788e-09
1 O 0 1.839249463841952e-08
% O 0 1.0419589635546345e-09
) O 0 9.133848677400636e-10
and O 0 2.55506837909536e-09
none O 0 4.931095531901519e-09
of O 0 9.307622450549502e-10
the O 0 1.243826819319338e-08
Yemenites O 0 6.438445439016505e-07
or O 0 1.6620955278767724e-08
Iranians O 0 4.147833365664155e-08
was O 0 9.559170166539843e-07
a O 0 7.607484064919845e-08
carrier O 0 9.165956953438581e-07
of O 0 8.651305449802749e-09
the O 0 2.422439706606383e-07
185delAG O 0 0.00015555947902612388
mutation O 0 4.4237003749003634e-05
. O 0 1.5421993566633319e-06

BRCA1 O 0 0.0038176914677023888
allelic O 0 0.00017054445925168693
patterns O 0 1.3446941011352465e-05
were O 0 1.913327309921442e-07
determined O 0 1.3256266129246796e-07
for O 0 2.2753310346956823e-09
four O 0 3.6197560504547255e-09
of O 0 4.783611284864264e-10
these O 0 4.3904249680259966e-10
individuals O 0 3.337664866709389e-10
and O 0 1.6489212217862814e-09
for O 0 1.902550561538874e-09
12 O 0 1.1860214144121528e-08
additional O 0 6.1697917885794595e-09
non O 0 2.256201270256497e-07
- O 0 1.740188235999085e-05
Ashkenazi O 0 1.943194365594536e-05
185delAG O 0 1.7443338947487064e-05
mutation O 0 7.428971002809703e-06
carriers O 0 3.007485702255508e-06
who O 0 4.4485686885309406e-06
had O 0 0.001834228402003646
breast B-Disease 1 0.999798595905304
/ I-Disease 1 0.9998185038566589
ovarian I-Disease 1 0.9999986886978149
cancer I-Disease 1 0.9999871253967285
. O 0 0.00025387280038557947

Six O 0 6.591068085981533e-06
non O 0 4.1036828406504355e-06
- O 0 0.0001294641988351941
Ashkenazi O 0 4.183818236924708e-05
individuals O 0 1.7798484464037756e-08
shared O 0 4.586393131944533e-08
the O 0 1.1344526029688495e-07
common O 0 2.2663152776658535e-07
Ashkenazi O 0 2.3640741346753202e-05
haplotype O 0 2.0940315152984113e-05
, O 0 4.0095510911442034e-08
four O 0 3.18980397651103e-08
had O 0 1.8339166274472518e-07
a O 0 6.387939066598847e-08
closely O 0 1.0171844166961819e-07
related O 0 1.4534342085426033e-07
pattern O 0 1.2469026842154562e-06
, O 0 3.185724395393663e-08
and O 0 1.1272243582993724e-08
the O 0 4.0597090134042446e-08
rest O 0 1.0310904485777428e-07
( O 0 1.5873627745577323e-08
n O 0 7.476544396922691e-07
= O 0 4.682559620050597e-07
6 O 0 6.219192982825916e-08
) O 0 3.1988500737156755e-09
displayed O 0 4.7009809378550926e-08
a O 0 9.676207923803304e-08
distinct O 0 4.0097580722431303e-07
BRCA1 O 0 0.00010338072752347216
allelic O 0 7.06062710378319e-05
pattern O 0 0.00010045349335996434
. O 0 5.21843821843504e-06

We O 0 2.4637745354993967e-06
conclude O 0 2.3562743081129156e-06
that O 0 3.9495500203656775e-08
the O 0 1.4975718443110964e-07
185delAG O 0 8.471387991448864e-05
BRCA1 O 0 0.00022857791918795556
mutation O 0 1.2322523616603576e-05
occurs O 0 1.5902135430678754e-07
in O 0 6.61726407003016e-09
some O 0 1.566877072534112e-09
non O 0 1.2613199373845418e-07
- O 0 7.877504685893655e-06
Ashkenazi O 0 5.8549921959638596e-06
populations O 0 1.8853712902000552e-07
at O 0 1.2718653579213424e-06
rates O 0 1.4922925117843988e-07
comparable O 0 7.815895486373847e-08
with O 0 8.068042234299355e-09
that O 0 6.233560778667879e-09
of O 0 2.352902583879768e-08
Ashkenazim O 0 4.2655152356019244e-05
. O 0 2.275789483974222e-06

The O 0 6.709944955218816e-07
majority O 0 4.223660710067634e-07
of O 0 4.0789736033275403e-08
Jewish O 0 1.500054736425227e-06
185delAG O 0 6.246186239877716e-05
mutation O 0 1.3435942491923925e-05
carriers O 0 1.0228717428617529e-06
have O 0 1.1183989734320221e-08
a O 0 4.4189263803673384e-08
common O 0 1.3645224328229233e-07
allelic O 0 1.4101985470915679e-05
pattern O 0 7.660157280042768e-06
, O 0 3.152948480078521e-08
supporting O 0 7.14798744638756e-08
the O 0 4.4593729597863785e-08
founder O 0 5.641950906465354e-07
effect O 0 5.446985795742876e-08
notion O 0 3.804349901770365e-08
, O 0 8.58892690303037e-09
but O 0 2.870286897049823e-09
dating O 0 3.968450457136896e-08
the O 0 9.037329107286496e-09
mutations O 0 3.333303766339668e-08
origin O 0 1.0015014373365716e-09
to O 0 3.0644611848096304e-10
an O 0 4.970491129796528e-09
earlier O 0 1.102979254596903e-07
date O 0 8.027445375091702e-08
than O 0 1.768589719119973e-08
currently O 0 2.1992478593801934e-07
estimated O 0 4.812879410565074e-07
. O 0 6.538863317473442e-07

However O 0 8.189877576114668e-07
, O 0 4.173044487743027e-08
the O 0 5.165043504007372e-09
different O 0 4.38250413736796e-09
allelic O 0 1.7923122186402907e-06
pattern O 0 3.040650653929333e-06
at O 0 1.4937106698198477e-06
the O 0 2.2134234711757017e-07
BRCA1 O 0 1.3282225154398475e-05
locus O 0 1.623643242965045e-06
even O 0 2.988906189216323e-08
in O 0 5.269387148842952e-09
some O 0 1.3572507562287228e-09
Jewish O 0 1.866418841700579e-07
mutation O 0 1.6350502392015187e-06
carriers O 0 1.3293806659930851e-06
, O 0 6.884098269210881e-08
might O 0 3.086331901158701e-08
suggest O 0 8.236511916948075e-09
that O 0 1.8267636292534917e-09
the O 0 2.652376274170365e-08
mutation O 0 4.965414746038732e-07
arose O 0 1.0164667685330642e-07
independently O 0 9.896872654735489e-08
. O 0 1.463583885197295e-07
. O 0 6.961233793845167e-07

Crystal O 0 0.0008906314033083618
structure O 0 3.792634015553631e-05
of O 0 2.5922719260051963e-07
the O 0 4.024809186375933e-06
hemochromatosis B-Disease 1 0.9998050332069397
protein O 0 4.337881546234712e-05
HFE O 0 0.0007192724733613431
and O 0 4.9733955620467896e-08
characterization O 0 1.5172476253155764e-07
of O 0 2.2889163897588105e-09
its O 0 3.764137890271968e-09
interaction O 0 2.836329215938349e-08
with O 0 8.47260963610097e-08
transferrin O 0 0.00012474230607040226
receptor O 0 6.594113074243069e-05
. O 0 1.8649612911758595e-06

HFE O 0 0.015510003082454205
is O 0 4.397991233417997e-06
an O 0 5.734253818445723e-07
MHC O 0 0.0005579274147748947
- O 0 7.057240873109549e-05
related O 0 3.582015040137776e-07
protein O 0 1.1453114012738297e-07
that O 0 3.280322236065558e-09
is O 0 5.336974862046873e-09
mutated O 0 8.690224007068537e-08
in O 0 3.2242482461697364e-08
the O 0 8.055450280153309e-07
iron B-Disease 1 0.9810776114463806
- I-Disease 1 0.9985679388046265
overload I-Disease 1 0.998554527759552
disease I-Disease 1 0.9997637867927551
hereditary B-Disease 1 0.999976396560669
hemochromatosis I-Disease 1 0.999995231628418
. O 0 0.005598763935267925

HFE O 0 0.002544533694162965
binds O 0 1.4040792848390993e-05
to O 0 2.7738730068449513e-07
transferrin O 0 4.121888196095824e-05
receptor O 0 9.545573448122013e-06
( O 0 1.3522169695079356e-07
TfR O 0 1.9317039914312772e-05
) O 0 2.099523399579084e-08
and O 0 5.3914255282450085e-09
reduces O 0 8.047528154975225e-08
its O 0 3.5283322930013128e-09
affinity O 0 4.194134106683123e-08
for O 0 2.3121996761688024e-08
iron O 0 9.229078568750992e-05
- O 0 4.997332780476427e-06
loaded O 0 5.537861511584197e-07
transferrin O 0 1.3657004274136852e-05
, O 0 1.0163175545585545e-07
implicating O 0 1.6475049051223323e-05
HFE O 0 0.0015891864895820618
in O 0 3.0062240057304734e-06
iron O 0 0.013606471940875053
metabolism O 0 0.0020356974564492702
. O 0 4.994964911020361e-06

The O 0 1.629581856832374e-05
2 O 0 3.5975328501081094e-05
. O 0 9.546266483084764e-06

6 O 0 1.9542445443221368e-05
A O 0 8.008350050658919e-06
crystal O 0 8.739375334698707e-05
structure O 0 8.997772056318354e-06
of O 0 7.19021215900284e-08
HFE O 0 0.0002873292251024395
reveals O 0 4.7260638780244335e-07
the O 0 2.447583646869589e-08
locations O 0 9.965879144147038e-08
of O 0 7.203046266113233e-07
hemochromatosis B-Disease 1 0.9999690055847168
mutations O 0 0.002482642652466893
and O 0 1.2025083151456784e-06
a O 0 1.0952475349768065e-05
patch O 0 0.005089855287224054
of O 0 9.655909138928109e-08
histidines O 0 0.00015781050024088472
that O 0 2.7861315032851053e-08
could O 0 2.0510601217438307e-08
be O 0 6.1579532584232766e-09
involved O 0 1.3224970452085927e-08
in O 0 1.6308690931055025e-07
pH O 0 0.00012705853441730142
- O 0 1.9296987375128083e-05
dependent O 0 5.486670602294907e-07
interactions O 0 1.1801598702732008e-06
. O 0 1.1685160643537529e-06

We O 0 1.3728450767303002e-06
also O 0 9.211852614043892e-08
demonstrate O 0 2.0228394248533732e-07
that O 0 5.56836674547867e-08
soluble O 0 6.0804231907241046e-05
TfR O 0 9.476178820477799e-05
and O 0 7.881961039402086e-08
HFE O 0 5.896754373679869e-05
bind O 0 1.9715417920451728e-07
tightly O 0 1.380819185214932e-06
at O 0 3.6805082004320866e-07
the O 0 1.110195135822778e-08
basic O 0 3.201128606633574e-08
pH O 0 8.201507739613589e-07
of O 0 2.2270492117115737e-09
the O 0 2.0639477682493634e-08
cell O 0 3.0783185138716362e-06
surface O 0 3.7391419027699158e-06
, O 0 2.041092805882272e-08
but O 0 4.071649239989483e-09
not O 0 1.399816373925944e-09
at O 0 7.443343008617376e-08
the O 0 4.280945020695981e-08
acidic O 0 3.2357957024942152e-06
pH O 0 5.853182756254682e-06
of O 0 4.32174367404059e-08
intracellular O 0 4.712131340056658e-05
vesicles O 0 0.0002057959500234574
. O 0 3.2808734431455377e-06

TfR O 0 0.04798935726284981
HFE O 0 0.004145551007241011
stoichiometry O 0 0.00010811850370373577
( O 0 6.978196438467421e-07
2 O 0 4.2005390810118115e-07
1 O 0 3.1001206934888614e-07
) O 0 2.1056351329207246e-08
differs O 0 1.7790058848277113e-07
from O 0 5.3578148140331905e-08
TfR O 0 1.5063887985888869e-05
transferrin O 0 4.812085535377264e-06
stoichiometry O 0 8.762139032114646e-07
( O 0 3.268407766654491e-08
2 O 0 4.9381384314983734e-08
2 O 0 4.189025304413008e-08
) O 0 6.8049832435690405e-09
, O 0 5.686621840084172e-09
implying O 0 1.8262838352711697e-08
a O 0 4.01639121960784e-09
different O 0 2.544164323659004e-10
mode O 0 1.1575622238524375e-08
of O 0 9.348400942243984e-10
binding O 0 1.861686094173365e-08
for O 0 5.473561159874407e-09
HFE O 0 2.0233585019013844e-05
and O 0 2.0529466127072737e-08
transferrin O 0 2.6900559078057995e-06
to O 0 7.845525118455043e-09
TfR O 0 1.8028680642601103e-05
, O 0 1.0942743600139693e-08
consistent O 0 3.969843476170354e-08
with O 0 4.490773086729405e-09
our O 0 1.8252913847049967e-08
demonstration O 0 4.27945934688978e-07
that O 0 1.5382900286908807e-08
HFE O 0 1.3303571904543787e-05
, O 0 1.8434533899380767e-08
transferrin O 0 2.4767052764218533e-06
, O 0 2.8478432056999736e-08
and O 0 3.027936301691625e-08
TfR O 0 3.307051883894019e-05
form O 0 2.2156683598950622e-07
a O 0 2.1694791030313354e-06
ternary O 0 0.00015190406702458858
complex O 0 0.000980667071416974
. O 0 9.161944944935385e-06

Identification O 0 8.451754638372222e-07
of O 0 5.143575165789116e-08
three O 0 8.76727384024889e-08
novel O 0 3.4733150755528186e-07
mutations O 0 9.268935627915198e-07
and O 0 5.587407425622359e-09
a O 0 5.720260887187578e-08
high O 0 2.8639018978537933e-07
frequency O 0 3.278516302884782e-08
of O 0 1.2376331071095592e-09
the O 0 1.146835604259877e-08
Arg778Leu O 0 9.077358299691696e-06
mutation O 0 1.2298831961743417e-06
in O 0 5.7288762178586694e-08
Korean O 0 6.8260455918789376e-06
patients O 0 5.567719654209213e-06
with O 0 4.186911610304378e-06
Wilson B-Disease 0 0.12218723446130753
disease I-Disease 1 0.9586317539215088
. O 0 1.2083633009751793e-05

Four O 0 1.3389537343755364e-05
mutations O 0 0.00027347123250365257
- O 0 0.0002039173268713057
- O 0 2.4977660359581932e-05
R778L O 0 4.467875896807527e-06
, O 0 6.751989900521949e-08
A874V O 0 6.925806701474357e-07
, O 0 1.8875224938597057e-08
L1083F O 0 4.0814566659719276e-07
, O 0 9.314482518618661e-09
and O 0 9.239440323938197e-09
2304delC O 0 2.674847564776428e-06
- O 0 8.398625141126104e-06
- O 0 1.8974869817611761e-06
in O 0 9.172558712577938e-09
the O 0 1.6462728069654986e-08
copper O 0 6.407343335013138e-06
- O 0 2.7865948482030944e-07
transporting O 0 9.010740598114353e-08
enzyme O 0 1.738171562237767e-07
, O 0 2.0910947640118138e-08
P O 0 5.731887995352736e-06
- O 0 3.3249114039790584e-06
type O 0 4.515769660429214e-07
ATPase O 0 7.692269718972966e-07
( O 0 1.4384678337364676e-08
ATP7B O 0 4.548342531052185e-06
) O 0 3.547361293598783e-09
, O 0 2.198635939976157e-09
were O 0 4.30279945007328e-09
identified O 0 4.688927290885658e-08
in O 0 6.873484181824097e-08
Korean O 0 2.1087809727760032e-05
Patients O 0 1.1128356163681019e-05
with O 0 5.965017862763489e-06
Wilson B-Disease 0 0.060977037996053696
disease I-Disease 1 0.9785341024398804
. O 0 1.1575284588616341e-05

Arg778Leu O 0 0.0004848835524171591
, O 0 3.3674862720545207e-07
the O 0 4.364330052908372e-08
most O 0 1.9552247820797675e-08
frequently O 0 2.772995060240646e-07
reported O 0 1.7957099771592766e-06
mutation O 0 1.2538686178231728e-07
of O 0 1.3630202522207924e-09
this O 0 1.5216846671606277e-09
enzyme O 0 2.784118358079013e-08
, O 0 7.577503957634235e-09
was O 0 2.224182026111521e-06
found O 0 9.303756876022362e-09
in O 0 1.775971703033008e-09
six O 0 1.45980483257091e-09
of O 0 9.62405488635909e-10
eight O 0 5.8957660087344266e-08
unrelated O 0 2.8078393370378762e-06
patients O 0 7.447105190294678e-07
studied O 0 9.63920072649671e-08
, O 0 1.1398587629329882e-09
an O 0 1.4897557631954328e-09
allele O 0 1.742598954024288e-08
frequency O 0 6.482844128186116e-08
of O 0 4.817530552259086e-08
37 O 0 2.1344962988223415e-06
. O 0 6.349480941025831e-07

5 O 0 2.9560849270637846e-06
% O 0 9.14691540288004e-08
, O 0 1.876580846271736e-08
which O 0 3.791591041135689e-09
is O 0 6.6709069379555785e-09
considerably O 0 1.182067563831879e-07
higher O 0 2.96036777314157e-08
than O 0 1.399036997362657e-09
those O 0 1.1146077394386111e-09
in O 0 5.08365793905341e-09
other O 0 3.3915465991185556e-09
Asian O 0 2.1805793437579268e-07
populations O 0 1.6876779227459338e-06
. O 0 1.1100363508376176e-06

The O 0 1.1773551022997708e-06
novel O 0 1.109339905269735e-06
single O 0 2.889228198910132e-07
nucleotide O 0 1.2696899602815392e-06
deletion O 0 2.8762074180122e-06
, O 0 5.8385705159480494e-08
2304delC O 0 2.3330487692874158e-06
, O 0 1.096541666356643e-07
was O 0 5.536770913749933e-06
found O 0 5.620073650902668e-08
in O 0 6.117870299249262e-08
one O 0 6.303061468315718e-07
patient O 0 8.546426397515461e-05
. O 0 2.1934135929768672e-06

Since O 0 6.4196742641797755e-06
a O 0 6.199857693900412e-07
mutation O 0 2.7757307634601602e-06
at O 0 2.6622757332006586e-07
cDNA O 0 9.057036436388444e-07
nucleotide O 0 3.984244813182158e-06
2302 O 0 5.9836835134774446e-05
( O 0 3.32847527317881e-08
2302insC O 0 1.5448814565388602e-06
) O 0 1.2395685367039277e-08
had O 0 1.5598352831602824e-07
been O 0 6.563166010664645e-08
previously O 0 1.1758532281191947e-07
described O 0 1.58095474489528e-07
, O 0 6.600800794842598e-09
this O 0 1.3516318064787924e-09
region O 0 9.10739395010296e-09
of O 0 6.387981810185295e-10
the O 0 2.0652471732773847e-08
ATP7B O 0 8.569880446884781e-05
gene O 0 8.189666687030694e-07
may O 0 2.7012774239665305e-07
be O 0 1.0350939660952463e-08
susceptible O 0 6.519138082694553e-07
to O 0 1.5992421609212215e-08
gene O 0 1.0663825378287584e-05
rearrangements O 0 0.006841852329671383
causing O 1 0.7138248085975647
Wilson B-Disease 1 0.861358106136322
disease I-Disease 1 0.9977237582206726
. O 0 1.2749566849379335e-05

Disruption O 0 5.283535938360728e-05
of O 0 1.215084779460085e-07
splicing O 0 3.594495638026274e-06
regulated O 0 2.3526299628429115e-06
by O 0 9.336701367601563e-08
a O 0 4.6372090878321615e-07
CUG O 0 0.00016885195509530604
- O 0 2.8727379685733467e-05
binding O 0 2.7594351195148192e-06
protein O 0 9.076128662854899e-06
in O 0 1.9092321963398717e-05
myotonic B-Disease 1 0.9994567036628723
dystrophy I-Disease 1 0.999864935874939
. O 0 0.0001324745680904016

Myotonic B-Disease 1 0.999530553817749
dystrophy I-Disease 1 0.999925971031189
( O 0 0.0033180001191794872
DM B-Disease 1 0.9998412132263184
) O 0 3.378240535312216e-06
is O 0 1.1918948530365014e-06
caused O 0 1.3622486676467815e-06
by O 0 9.95669857672965e-09
a O 0 1.480635631878613e-07
CTG O 0 4.095737949683098e-06
expansion O 0 2.5063462771868217e-07
in O 0 3.5061553660398204e-08
the O 0 2.0751897977788758e-08
3 O 0 8.927395356295165e-08
untranslated O 0 2.627305093483301e-06
region O 0 2.852361262739578e-07
of O 0 6.382629180734511e-08
the O 0 1.1164390343765263e-05
DM B-Disease 1 0.9996486902236938
gene O 0 0.00016598717775195837
. O 0 2.2523281586472876e-06

One O 0 8.073092203630949e-07
model O 0 4.346542482380755e-06
of O 0 2.641038918227423e-06
DM B-Disease 1 0.9998512268066406
pathogenesis O 0 0.031760506331920624
suggests O 0 1.1144337577206898e-06
that O 0 2.6819837017910686e-08
RNAs O 0 3.0305880045489175e-06
from O 0 6.738080315926709e-09
the O 0 1.753701517337447e-09
expanded O 0 1.2268529303582909e-08
allele O 0 1.3678442378761702e-08
create O 0 2.472643645390349e-09
a O 0 1.3834295486958581e-08
gain O 0 4.410152598666173e-08
- O 0 4.1305682429992885e-07
of O 0 1.0335512001802272e-08
- O 0 2.8323993319645524e-06
function O 0 4.7837620087420873e-08
mutation O 0 9.782801413393827e-08
by O 0 1.0609302325548242e-09
the O 0 2.210535976487904e-09
inappropriate O 0 9.656089261511624e-09
binding O 0 8.245031324349839e-09
of O 0 6.554053411100824e-10
proteins O 0 2.247887653794578e-09
to O 0 1.4335806985954491e-09
the O 0 9.672351808376334e-08
CUG O 0 0.000416873226640746
repeats O 0 3.002911944349762e-05
. O 0 1.3935189144831384e-06

Data O 0 9.066889106179588e-06
presented O 0 4.141527824685909e-06
here O 0 4.2395771515657543e-07
indicate O 0 1.9353900881924346e-07
that O 0 4.535829045693163e-09
the O 0 1.0441619124890167e-08
conserved O 0 3.6353748100736993e-07
heterogeneous O 0 4.55620920547517e-06
nuclear O 0 0.00015661036013625562
ribonucleoprotein O 0 0.0001606716978130862
, O 0 6.80499852023786e-08
CUG O 0 4.354385600890964e-05
- O 0 2.0110339846723946e-06
binding O 0 1.2243998526173527e-07
protein O 0 1.3505713525319152e-07
( O 0 1.994784781800263e-08
CUG O 0 1.655349478824064e-05
- O 0 2.0268056687200442e-05
BP O 0 9.247469279216602e-06
) O 0 6.716446954158073e-09
, O 0 6.008940012236508e-09
may O 0 1.2662513704242429e-08
mediate O 0 8.143243235281261e-08
the O 0 4.364330052908372e-08
trans O 0 2.094069941449561e-06
- O 0 4.408430413604947e-06
dominant O 0 6.617770509365073e-07
effect O 0 7.525252954110329e-08
of O 0 5.824230875361991e-09
the O 0 1.7063381108073372e-07
RNA O 0 1.171222174889408e-05
. O 0 1.1224270792808966e-06

CUG O 0 0.028228668496012688
- O 0 0.003756423480808735
BP O 0 0.0008522247080691159
was O 0 8.882994734449312e-06
found O 0 1.6729762464251507e-08
to O 0 3.31480010107299e-10
bind O 0 6.960116483156753e-09
to O 0 1.7142895991639762e-09
the O 0 5.7957095123128965e-08
human O 0 4.922715561406221e-06
cardiac O 1 0.9767682552337646
troponin O 1 0.9545323848724365
T O 0 0.008320648223161697
( O 0 5.33711990158281e-08
cTNT O 0 1.1609361081355019e-06
) O 0 1.6974526673152468e-08
pre O 0 1.144012685472262e-06
- O 0 1.166921265394194e-06
messenger O 0 2.793422027025372e-07
RNA O 0 2.1537489658385311e-07
and O 0 3.13176573563112e-09
regulate O 0 3.369278189779834e-08
its O 0 1.1239997377288091e-08
alternative O 0 2.2583023451261397e-07
splicing O 0 8.71788233780535e-06
. O 0 1.8797172742779367e-06

Splicing O 0 5.1560964493546635e-05
of O 0 8.094555710158602e-07
cTNT O 0 0.00013703516742680222
was O 0 0.00018184447253588587
disrupted O 0 0.002625524764880538
in O 0 7.806999929016456e-05
DM B-Disease 1 0.9996979236602783
striated O 1 0.7414498329162598
muscle O 0 0.0014469367451965809
and O 0 1.850361854849325e-07
in O 0 1.6291838278448267e-07
normal O 0 1.1382838920326321e-06
cells O 0 3.7038603295513894e-07
expressing O 0 1.3443721513795026e-07
transcripts O 0 7.373819244094193e-07
that O 0 3.8947533198552264e-08
contain O 0 1.0628284599079052e-06
CUG O 0 0.0024253111332654953
repeats O 0 0.00011578965495573357
. O 0 6.358227892633295e-06

Altered O 0 2.8726832169923e-05
expression O 0 1.8607011043059174e-06
of O 0 9.365988518084123e-08
genes O 0 7.967814212861413e-07
regulated O 0 2.444691972414148e-06
posttranscriptionally O 0 1.8864964658860117e-05
by O 0 2.835161865277769e-07
CUG O 0 0.0007505552493967116
- O 0 0.0003802581049967557
BP O 0 4.1027116822078824e-05
therefore O 0 8.272758833527405e-08
may O 0 7.767091858568165e-08
contribute O 0 6.336801305906192e-08
to O 0 3.553844862835831e-07
DM B-Disease 1 0.9997625946998596
pathogenesis O 0 0.03747572749853134
. O 0 1.3757008900938672e-06
. O 0 1.8268258372700075e-06

Identification O 0 3.1079762266017497e-06
of O 0 1.9653954552723008e-07
a O 0 2.0527645574475173e-06
novel O 0 1.4773310113014304e-06
nonsense O 0 9.36029482545564e-06
mutation O 0 9.438004440198711e-07
and O 0 7.581552274871228e-09
a O 0 2.5381568846682967e-08
missense O 0 2.482503305145656e-07
substitution O 0 1.0516731485665787e-08
in O 0 1.4131470216227626e-08
the O 0 4.081238103026408e-08
vasopressin O 0 2.3780182800692273e-06
- O 0 1.1642373465292621e-05
neurophysin O 0 2.485476761648897e-05
II O 0 0.0003753487253561616
gene O 0 3.479455017441069e-07
in O 0 2.249360164796599e-08
two O 0 1.4446708718196533e-08
Spanish O 0 1.331226599177171e-06
kindreds O 0 2.623726504680235e-05
with O 0 5.950404556642752e-06
familial B-Disease 1 0.9941977262496948
neurohypophyseal I-Disease 1 0.998836100101471
diabetes I-Disease 1 0.9997947812080383
insipidus I-Disease 1 0.9965667724609375
. O 0 9.789363684831187e-05

Familial B-Disease 1 0.9903344511985779
neurohypophyseal I-Disease 1 0.9971650242805481
diabetes I-Disease 1 0.9998181462287903
insipidus I-Disease 1 0.9975507855415344
( O 0 0.0003122408234048635
FNDI B-Disease 1 0.9997919201850891
) O 0 1.099006681215542e-06
is O 0 8.038244345698331e-07
an O 0 1.8556223722043796e-06
autosomal B-Disease 1 0.980911135673523
dominant I-Disease 1 0.9990231990814209
disease I-Disease 1 0.9999008178710938
caused O 0 0.41225892305374146
by O 0 0.0003106961084995419
deficiency O 1 0.9989872574806213
in O 0 7.235266252791916e-07
the O 0 1.4307262290458311e-06
antidiuretic O 0 0.00030766736017540097
hormone O 0 3.450690201134421e-05
arginine O 0 1.7795247231333633e-06
vasopressin O 0 2.4772439246589784e-06
( O 0 2.1850251386013042e-08
AVP O 0 9.528151849735877e-07
) O 0 3.0262545802628438e-09
encoded O 0 3.0569669018376544e-09
by O 0 7.170911864307072e-09
the O 0 5.980346173828366e-08
AVP O 0 4.5573153329314664e-05
- O 0 8.264550706371665e-05
neurophysin O 0 0.00013004224456381053
II O 0 0.0034866533242166042
( O 0 2.3392773584873794e-07
AVP O 0 3.161606582580134e-05
- O 0 2.6917086870525964e-05
NPII O 0 5.2051043894607574e-05
) O 0 3.0245882243207234e-08
gene O 0 4.960847377333266e-07
on O 0 1.0836730552910012e-06
chromosome O 0 7.976438791956753e-05
20p13 O 0 5.880935714230873e-05
. O 0 3.325973693790729e-06

In O 0 1.6174398069779272e-06
this O 0 8.625375613746655e-08
study O 0 4.60561722093189e-08
, O 0 6.5147474082039025e-09
we O 0 2.2195687510162543e-09
analyzed O 0 7.0330057333478635e-09
two O 0 1.3751759730951107e-09
families O 0 1.0841481046242052e-09
with O 0 1.1712518066531175e-08
FNDI B-Disease 0 0.0031325719319283962
using O 0 3.146326754688289e-09
direct O 0 5.530259805652804e-09
automated O 0 2.6775990136229666e-07
fluorescent O 0 4.874663090959075e-07
, O 0 4.595585245681377e-09
solid O 0 6.594259360781507e-08
phase O 0 2.2367781582488533e-07
, O 0 3.3152318668072667e-09
single O 0 1.594344567479311e-08
- O 0 4.4894480311086227e-07
stranded O 0 4.96652283743515e-08
DNA O 0 2.7149752668265137e-08
sequencing O 0 3.0613620083386195e-08
of O 0 6.014570175238987e-09
PCR O 0 1.5174140344242915e-06
- O 0 4.330921910877805e-06
amplified O 0 5.301172222971218e-06
AVP O 0 8.168537897290662e-05
- O 0 9.501677413936704e-05
NPII O 0 0.0002507821482140571
DNA O 0 3.339676186442375e-05
. O 0 1.9437670744082425e-06

In O 0 6.732777251272637e-07
one O 0 2.479559135792897e-08
of O 0 2.430587953128338e-09
the O 0 2.296465062556763e-08
families O 0 1.8559212833224592e-08
, O 0 9.66645004041311e-08
affected O 0 9.716840310147745e-08
individuals O 0 1.829176365930607e-09
presented O 0 7.213233743641467e-08
a O 0 2.7527698875928763e-07
novel O 0 1.2381228486901819e-07
nonsense O 0 1.6334479369106703e-06
mutation O 0 3.6208911069479655e-07
in O 0 6.802777452463715e-09
exon O 0 1.9522312300068734e-07
3 O 0 1.3306342694363593e-08
of O 0 6.395845519868715e-10
the O 0 5.182549500659661e-09
gene O 0 2.4725316905005457e-08
, O 0 2.202438675880103e-09
consisting O 0 4.4760986028791194e-09
in O 0 7.605768459484352e-09
a O 0 2.632396274293569e-07
G O 0 3.379832378413994e-06
to O 0 6.297518950759695e-09
T O 0 9.218246304953936e-06
transition O 0 1.0685589302283915e-07
at O 0 1.5211479365007108e-07
nucleotide O 0 2.3356794542905845e-07
2101 O 0 2.9222671855677618e-06
, O 0 4.529655761587037e-09
which O 0 1.1283919354454497e-09
produces O 0 5.912474954072877e-09
a O 0 8.491146452627163e-09
stop O 0 2.5275383563894138e-08
signal O 0 1.012444101888832e-07
in O 0 2.1216642664967367e-08
codon O 0 6.787679467379348e-07
82 O 0 4.583310726502532e-07
( O 0 3.58665310784545e-08
Glu O 0 0.00011004968837369233
) O 0 2.9405756052369725e-08
of O 0 1.2176100483429764e-07
NPII O 0 0.001090852776542306
. O 0 6.49074627290247e-06

The O 0 6.045146619726438e-06
premature O 0 0.0002004957786994055
termination O 0 1.677025829849299e-05
eliminates O 0 2.2809128950029844e-06
part O 0 5.300537608832201e-08
of O 0 4.187713287251427e-09
the O 0 4.845675150022544e-08
C O 0 5.249474725133041e-06
- O 0 4.340142368164379e-06
terminal O 0 2.272241545142606e-06
domain O 0 2.304837565247908e-08
of O 0 4.64764626784131e-09
NPII O 0 7.989295227162074e-06
, O 0 7.098515997228105e-09
including O 0 1.494622647868482e-09
a O 0 1.5163255540073806e-08
cysteine O 0 1.1166532587481015e-08
residue O 0 4.334514613901774e-08
in O 0 3.0181612764579313e-09
position O 0 2.7850106221194437e-08
85 O 0 1.9941229112419023e-08
, O 0 3.6399172564927085e-09
which O 0 2.329799908551422e-09
could O 0 3.883327881482046e-09
be O 0 1.2000196392136786e-09
involved O 0 3.737260279024213e-09
in O 0 7.1191119666025315e-09
the O 0 1.7191988277431847e-08
correct O 0 2.689602069949615e-07
folding O 0 8.777159337114426e-07
of O 0 1.8487352093643494e-08
the O 0 8.388574315176811e-07
prohormone O 0 0.00244136736728251
. O 0 6.960649898246629e-06

In O 0 6.779541195101046e-07
the O 0 8.964729403260208e-08
second O 0 2.7244612965660053e-07
family O 0 1.3509345819784357e-07
, O 0 8.443679533343129e-09
a O 0 1.8029149728704397e-08
G279A O 0 1.0656403048869834e-07
substitution O 0 1.2285856776372839e-08
at O 0 1.0082238333097848e-07
position O 0 8.956833141837706e-08
- O 0 3.1936093591866666e-07
1 O 0 7.1216383901173685e-09
of O 0 4.459768387921059e-10
the O 0 4.059768965447574e-09
signal O 0 1.206006032816731e-07
peptide O 0 2.867033970233024e-07
was O 0 3.379012696314021e-07
observed O 0 2.6130985375516502e-08
in O 0 5.212528630949009e-09
all O 0 2.4428392642050767e-09
affected O 0 8.641183768531846e-08
individuals O 0 4.239310058551382e-08
. O 0 7.852457883927855e-07

This O 0 2.4999417291837744e-06
missense O 0 0.0002905063156504184
mutation O 0 0.00014159499551169574
, O 0 5.089472097097314e-07
which O 0 1.3069778503904672e-07
replaces O 0 4.471300053410232e-05
Ala O 0 8.946689922595397e-05
with O 0 2.818926247982745e-07
Thr O 0 0.0005621823947876692
, O 0 3.8250797729233454e-07
is O 0 7.562722004195166e-08
frequent O 0 5.797666062790086e-07
among O 0 9.361815500597004e-07
FNDI B-Disease 1 0.9999352693557739
patients O 0 0.00022690616606269032
and O 0 3.708278484282346e-07
is O 0 1.2748972721965401e-07
thought O 0 1.2679502781054452e-08
to O 0 6.233818461431895e-10
reduce O 0 1.7422433273850402e-08
the O 0 5.319312101903506e-09
efficiency O 0 7.930079704010495e-08
of O 0 4.393116093126537e-09
cleavage O 0 2.552214255047147e-06
by O 0 4.4670855459116865e-08
signal O 0 2.7678481728798943e-06
peptidases O 0 1.548108230053913e-05
. O 0 3.019424354988587e-07
. O 0 7.821606118341151e-07

Genetic O 0 0.00016753943054936826
heterogeneity O 0 0.00013338311691768467
of O 0 1.1645683116512373e-05
Saethre B-Disease 1 0.9907917976379395
- I-Disease 1 0.99928879737854
Chotzen I-Disease 1 0.9991266131401062
syndrome I-Disease 1 0.9999451637268066
, O 0 1.7842454553829157e-06
due O 0 1.8542212956162984e-06
to O 0 3.019578898033615e-08
TWIST O 0 6.155188202683348e-06
and O 0 9.775561693459167e-07
FGFR O 0 0.018406393006443977
mutations O 0 0.0008009666344150901
. O 0 5.424339178716764e-06

Thirty O 0 3.549482789821923e-05
- O 0 9.247216075891629e-05
two O 0 1.2743150534788583e-07
unrelated O 0 5.0675548664003145e-06
patients O 0 5.353769552129961e-07
with O 0 6.595163082323552e-09
features O 0 8.928536487928795e-08
of O 0 1.4647106638676632e-07
Saethre B-Disease 0 0.2750663757324219
- I-Disease 1 0.9968315958976746
Chotzen I-Disease 1 0.9983528852462769
syndrome I-Disease 1 0.9999111890792847
, O 0 3.3155879464175086e-07
a O 0 1.4778072454646463e-06
common O 0 1.3072987712803297e-05
autosomal B-Disease 1 0.8870775699615479
dominant I-Disease 1 0.6345797777175903
condition I-Disease 1 0.9955677390098572
of O 0 2.3765018340782262e-05
craniosynostosis B-Disease 1 0.9995453953742981
and O 0 0.00224697170779109
limb B-Disease 1 0.9958488941192627
anomalies I-Disease 0 0.05030371993780136
, O 0 2.8696490517177153e-07
were O 0 2.6522497975633996e-08
screened O 0 1.8413909685932595e-07
for O 0 1.6091343368884736e-08
mutations O 0 3.434919619849097e-07
in O 0 1.8865218720520716e-08
TWIST O 0 1.5168656091191224e-06
, O 0 1.0062662170184922e-07
FGFR2 O 0 6.481871969299391e-05
, O 0 9.139468204466539e-08
and O 0 6.366105935740052e-07
FGFR3 O 0 0.004560363478958607
. O 0 3.453099679973093e-06

Nine O 0 4.672287559515098e-06
novel O 0 1.7056626120393048e-06
and O 0 1.6433747873634275e-07
three O 0 2.4594004344180576e-07
recurrent O 0 0.0003960181784350425
TWIST O 0 2.515891901566647e-05
mutations O 0 1.5180498849076685e-05
were O 0 1.2770962598551705e-07
found O 0 1.5389790064546105e-07
in O 0 4.56417517114005e-08
12 O 0 2.644981123012258e-07
families O 0 1.7452025247166603e-07
. O 0 1.1798324521805625e-06

Seven O 0 1.4343411294248654e-06
families O 0 1.45772361292984e-07
were O 0 4.7173280393053574e-08
found O 0 2.2017133005647338e-08
to O 0 9.97909088695792e-10
have O 0 2.655797137762761e-09
the O 0 1.6858113127682373e-08
FGFR3 O 0 8.315032027894631e-05
P250R O 0 3.1799743283045245e-06
mutation O 0 8.335892403010803e-07
, O 0 4.3472883071160595e-09
and O 0 2.5496793565338294e-09
one O 0 2.5451558638422966e-09
individual O 0 3.9558885056578674e-09
was O 0 1.1341489880578592e-05
found O 0 2.3126936810058396e-08
to O 0 7.011304314907818e-10
have O 0 1.5730096114552339e-09
an O 0 1.9082863289554552e-08
FGFR2 O 0 6.233707972569391e-05
VV269 O 0 1.3134196706232615e-05
- O 0 3.15577162837144e-05
270 O 0 2.5620201995479874e-06
deletion O 0 3.0276556572061963e-05
. O 0 2.93145899377123e-06

To O 0 2.347228473809082e-07
date O 0 4.597981444476318e-07
, O 0 1.1156547685686746e-08
our O 0 8.653978866846046e-09
detection O 0 9.88905753729341e-07
rate O 0 2.5173105200337886e-07
for O 0 2.960388822970117e-09
TWIST O 0 5.216609224589774e-07
or O 0 1.0568231800789363e-07
FGFR O 0 0.00012362895358819515
mutations O 0 1.4491243973679957e-06
is O 0 1.9313109334007095e-08
68 O 0 3.611881993492716e-08
% O 0 1.4898922096051592e-09
in O 0 6.406629893263016e-09
our O 0 1.288906048557692e-07
Saethre B-Disease 0 0.0033330824226140976
- I-Disease 1 0.969641387462616
Chotzen I-Disease 1 0.9971641898155212
syndrome I-Disease 1 0.9999401569366455
patients O 0 0.00011736122542060912
, O 0 2.055540448964166e-08
including O 0 9.177178128538799e-09
our O 0 1.1851400216755792e-07
five O 0 3.8158327697601635e-07
patients O 0 1.9056948303841637e-06
elsewhere O 0 4.958808403898729e-07
reported O 0 1.4140497341941227e-06
with O 0 1.309378205860412e-07
TWIST O 0 0.00015161652117967606
mutations O 0 0.00018444305169396102
. O 0 2.372235258008004e-06

More O 0 3.2700789631689986e-08
than O 0 8.518300731452655e-09
35 O 0 1.9018765229361634e-08
different O 0 1.2517276104517805e-09
TWIST O 0 8.788232435108512e-07
mutations O 0 9.518561228105682e-07
are O 0 4.700377864708116e-09
now O 0 6.377371875032622e-08
known O 0 1.5689599308643665e-07
in O 0 6.26427762995263e-08
the O 0 2.0299702896409144e-07
literature O 0 4.65814736116954e-07
. O 0 1.314236328653351e-06

The O 0 6.141727908470784e-07
most O 0 9.168940806603132e-08
common O 0 7.555470205033998e-08
phenotypic O 0 6.03010278155125e-07
features O 0 2.443148616748658e-07
, O 0 2.2277809819115646e-08
present O 0 4.7407411329913884e-09
in O 0 2.1834785091101594e-09
more O 0 1.4465967312915495e-10
than O 0 5.193699359473669e-10
a O 0 1.1067805338882408e-08
third O 0 2.4498069350897822e-08
of O 0 1.9712806942351335e-09
our O 0 3.5037821533023816e-08
patients O 0 1.370456317317803e-07
with O 0 2.1088746748887388e-08
TWIST O 0 1.1819310202554334e-05
mutations O 0 4.113674094696762e-06
, O 0 1.2564596474362588e-08
are O 0 2.0888895058135404e-09
coronal B-Disease 0 3.137895419058623e-06
synostosis I-Disease 0 5.5714644986437634e-05
, O 0 1.359734085326636e-07
brachycephaly B-Disease 0 9.729727753438056e-05
, O 0 9.012929922391777e-07
low B-Disease 0 0.0007239555707201362
frontal I-Disease 1 0.997747004032135
hairline I-Disease 1 0.9998656511306763
, O 0 1.6141520973178558e-05
facial B-Disease 1 0.8945455551147461
asymmetry I-Disease 0 0.008587540127336979
, O 0 4.584423004416749e-05
ptosis B-Disease 1 0.9435639381408691
, O 0 2.969653678519535e-06
hypertelorism B-Disease 0 0.008541875518858433
, O 0 5.496988251252333e-07
broad B-Disease 0 3.7090953810547944e-06
great I-Disease 0 3.6321289371699095e-05
toes I-Disease 0 0.0002902131527662277
, O 0 1.9213764801406796e-07
and O 0 4.3715076003536524e-07
clinodactyly B-Disease 0 0.0008786118705756962
. O 0 6.059709903638577e-06

Significant O 0 3.742884246094036e-06
intra O 0 5.32179547008127e-05
- O 0 9.181650966638699e-05
and O 0 1.1754922724094286e-07
interfamilial O 0 1.6011326806619763e-05
phenotypic O 0 1.2265378245501779e-05
variability O 0 5.469395546242595e-05
is O 0 1.1212743800115277e-07
present O 0 2.0795443589349816e-08
for O 0 1.2813338834405386e-08
either O 0 1.7757294301645743e-07
TWIST O 0 1.2154109754192177e-05
mutations O 0 1.1716533663275186e-05
or O 0 7.9455054446953e-07
FGFR O 0 0.038347382098436356
mutations O 0 0.0006886188057251275
. O 0 2.9322698082978604e-06

The O 0 6.03974854129774e-07
overlap O 0 7.925843874545535e-07
in O 0 2.8385679229359084e-07
clinical O 0 1.4521708635584218e-06
features O 0 1.343485394045274e-07
and O 0 2.4912681695354877e-08
the O 0 1.9963074748829968e-08
presence O 0 7.387503586642197e-08
, O 0 8.027472020444293e-09
in O 0 1.848332265019792e-09
the O 0 1.2804829419010844e-09
same O 0 1.5980246015345756e-09
genes O 0 2.955542699467628e-09
, O 0 6.503892979736747e-10
of O 0 7.13735459623166e-10
mutations O 0 2.5307656414952362e-08
for O 0 7.483136887920239e-10
more O 0 3.2559352436400957e-10
than O 0 1.6459267282442624e-09
one O 0 2.3306100160880305e-08
craniosynostotic B-Disease 0 5.8266032283427194e-05
condition I-Disease 0 0.00031321871210820973
- O 0 2.438605406496208e-06
such O 0 5.3120929877081835e-09
as O 0 7.430987380985243e-08
Saethre B-Disease 0 1.740259540383704e-05
- I-Disease 0 1.1781407010857947e-05
Chotzen I-Disease 0 1.1671277206914965e-05
, I-Disease 0 8.000771600791268e-08
Crouzon I-Disease 0 1.1448561053839512e-05
, I-Disease 0 1.1495253460225285e-07
and I-Disease 0 5.893343200114032e-07
Pfeiffer I-Disease 0 0.13702617585659027
syndromes I-Disease 0 0.1448313593864441
- O 0 7.808719965396449e-05
support O 0 6.702986610207518e-08
the O 0 3.104694101807581e-08
hypothesis O 0 5.54257546525605e-08
that O 0 8.727740197223e-10
TWIST O 0 7.12039138761611e-08
and O 0 6.749708347797423e-09
FGFRs O 0 8.236340249823115e-07
are O 0 3.328853026562939e-10
components O 0 4.569433720291727e-09
of O 0 5.471710862181567e-10
the O 0 1.4984703478049255e-09
same O 0 2.499539242251103e-09
molecular O 0 6.874807922940818e-08
pathway O 0 2.213296212971727e-08
involved O 0 6.391470908084784e-09
in O 0 4.435762868126858e-09
the O 0 9.650897858648477e-09
modulation O 0 6.541058610309847e-07
of O 0 1.9898737946277834e-07
craniofacial O 1 0.9081821441650391
and O 0 1.3188857337809168e-05
limb O 0 0.13312934339046478
development O 0 1.2591293625519029e-06
in O 0 4.6992687430247315e-07
humans O 0 4.238614792484441e-07
. O 0 1.7293307053023455e-07
. O 0 1.1694012300722534e-06

Mutation O 0 0.0003026962513104081
analysis O 0 6.144876806501998e-06
of O 0 2.8879767342004925e-06
UBE3A O 1 0.8963899612426758
in O 0 0.4600578546524048
Angelman B-Disease 1 0.999970555305481
syndrome I-Disease 1 0.9999978542327881
patients O 1 0.99183589220047
. O 0 8.12752841738984e-05

Angelman B-Disease 1 0.9999620914459229
syndrome I-Disease 1 0.9999938011169434
( O 0 0.00024361023679375648
AS B-Disease 1 0.9069880247116089
) O 0 9.941263670043554e-07
is O 0 6.938103069842327e-07
caused O 0 2.9623756745422725e-06
by O 0 6.200679791845687e-08
chromosome O 0 1.6507747204741463e-05
15q11 O 0 1.1298286153760273e-05
- O 0 1.0362166904087644e-05
q13 O 0 1.411912535331794e-06
deletions O 0 3.4556387618067674e-07
of O 0 8.534400741666559e-09
maternal O 0 2.992362851728103e-06
origin O 0 4.5338417464790837e-08
, O 0 5.0328839762414646e-08
by O 0 7.923578948521026e-08
paternal O 0 0.00016826966020744294
uniparental B-Disease 0 0.27553030848503113
disomy I-Disease 0 0.2831399440765381
( O 0 5.124195013195276e-06
UPD B-Disease 1 0.9938442707061768
) O 0 1.1015664114211177e-07
15 O 0 1.3512089935829863e-07
, O 0 1.1683646938820402e-08
by O 0 3.554461258659103e-08
imprinting O 0 0.00027209677500650287
defects O 0 0.267149955034256
, O 0 3.436464979245102e-08
and O 0 1.9167126552588343e-08
by O 0 3.582509933153233e-08
mutations O 0 1.3613240525955916e-06
in O 0 6.596825841143072e-08
the O 0 4.2251591025888047e-07
UBE3A O 0 0.0013663708232343197
gene O 0 3.351410123286769e-05
. O 0 3.379365125510958e-06

UBE3A O 0 0.00044657662510871887
encodes O 0 4.3300797187839635e-06
a O 0 9.269058978134126e-07
ubiquitin O 0 2.4943742573668715e-06
- O 0 5.5740151765348855e-06
protein O 0 1.4447485341406718e-07
ligase O 0 5.231086674939434e-07
and O 0 3.713182294973194e-08
shows O 0 1.0141174016098375e-06
brain O 0 0.01799626834690571
- O 0 5.3975039918441325e-05
specific O 0 4.719587138879433e-07
imprinting O 0 0.00015266872651409358
. O 0 2.7792109449364943e-06

Here O 0 5.884272923140088e-06
we O 0 7.422084422614716e-07
describe O 0 1.7070557305487455e-06
UBE3A O 0 0.00040858163265511394
coding O 0 0.0003370626945979893
- O 0 0.0004763837205246091
region O 0 1.1629324035311583e-05
mutations O 0 1.9716484530363232e-05
detected O 0 5.840035100845853e-06
by O 0 1.918585468274614e-08
SSCP O 0 5.941286417510128e-06
analysis O 0 3.623170385935737e-08
in O 0 4.6234578832127227e-08
13 O 0 1.7718387823606463e-07
AS B-Disease 0 0.00014781787467654794
individuals O 0 6.557632659109913e-09
or O 0 9.196666894695227e-08
families O 0 1.609253246215303e-07
. O 0 1.1551303487067344e-06

Two O 0 8.538497127119626e-07
identical O 0 1.2296977729420178e-05
de O 0 4.1605821024859324e-05
novo O 0 1.2480336408771109e-05
5 O 0 6.618042220907228e-07
- O 0 3.2432690204586834e-06
bp O 0 2.0475947621889645e-06
duplications O 0 6.97065388521878e-07
in O 0 1.229753792131305e-07
exon O 0 5.966047410765896e-06
16 O 0 4.265878317255556e-07
were O 0 9.351475682706223e-08
found O 0 7.553105660917936e-07
. O 0 7.854922614569659e-07

Among O 0 1.8035792948012386e-07
the O 0 3.11540127029275e-08
other O 0 4.439207224038455e-09
11 O 0 3.809134696552974e-08
unique O 0 3.197387954401165e-08
mutations O 0 1.4917632142896764e-06
, O 0 3.096615586173357e-08
8 O 0 9.27679195683595e-08
were O 0 4.809430631524947e-09
small O 0 9.718467808284004e-09
deletions O 0 1.870927519576071e-07
or O 0 3.161041561838829e-08
insertions O 0 1.5373389032902196e-06
predicted O 0 4.462625383894192e-06
to O 0 1.9499440284675984e-08
cause O 0 1.9259423424955457e-06
frameshifts O 0 1.90331647900166e-05
, O 0 5.0086178760011535e-08
1 O 0 1.7140231989287713e-07
was O 0 2.6819641334441258e-06
a O 0 6.475269032080178e-08
mutation O 0 3.050340424692877e-08
to O 0 4.155724653287507e-10
a O 0 1.4060304920349154e-08
stop O 0 2.200734883217592e-08
codon O 0 4.006416531865398e-08
, O 0 4.137125309000567e-09
1 O 0 9.382506327426654e-09
was O 0 1.5107704598449345e-07
a O 0 2.4515035335070934e-08
missense O 0 9.613731890567578e-07
mutation O 0 4.105723689917795e-07
, O 0 9.240515908004454e-09
and O 0 1.7764197224323652e-08
1 O 0 9.959064755094005e-07
was O 0 4.355353303253651e-05
predicted O 0 3.4112386515516846e-07
to O 0 1.5097276762077172e-09
cause O 0 3.241303403456186e-08
insertion O 0 4.1568540609659976e-08
of O 0 1.7252750339480372e-09
an O 0 2.26273826342549e-08
isoleucine O 0 4.974504463461926e-06
in O 0 1.3300506473967744e-08
the O 0 9.682240786901275e-09
hect O 0 3.843223055355338e-07
domain O 0 7.610180041695003e-09
of O 0 1.1829076607128286e-09
the O 0 8.087532421541255e-09
UBE3A O 0 2.3703132683294825e-06
protein O 0 3.861967812213152e-08
, O 0 2.7113977729698036e-09
which O 0 8.933553341528011e-10
functions O 0 3.692360639462322e-09
in O 0 1.7835629861906455e-08
E2 O 0 9.89745444712753e-07
binding O 0 1.1999613036550727e-07
and O 0 3.042786289597643e-08
ubiquitin O 0 5.105914056002803e-07
transfer O 0 1.034063757288095e-06
. O 0 2.3755135316605447e-06

Eight O 0 5.429952238955593e-07
of O 0 1.6209693143309778e-08
the O 0 3.669516601689793e-08
cases O 0 1.9684488705706826e-08
were O 0 2.9973612925005e-08
familial O 0 6.904218753334135e-05
, O 0 1.0209727463461604e-07
and O 0 3.008885940403161e-08
five O 0 4.233508477113901e-08
were O 0 1.2620178324596054e-07
sporadic O 0 1.8868042388930917e-05
. O 0 1.916555675052223e-06

In O 0 1.3273601098262588e-06
two O 0 2.583522871191235e-07
familial O 0 0.0010388141963630915
cases O 0 1.1693945225488278e-06
and O 0 8.488186153954302e-08
one O 0 1.0352246704314894e-07
sporadic O 0 8.974359843705315e-06
case O 0 1.1344280892444658e-06
, O 0 8.117965677456596e-08
mosaicism O 0 1.9050270566367544e-05
for O 0 6.530848395414068e-08
UBE3A O 0 0.00020804943051189184
mutations O 0 2.0074137864867225e-05
was O 0 1.4464058040175587e-05
detected O 0 4.944589363731211e-06
in O 0 9.57405799084654e-09
the O 0 1.1419157175396322e-08
mother O 0 1.1465510851849103e-06
of O 0 4.566637290537301e-09
three O 0 6.784095063494533e-08
AS B-Disease 0 0.015001657418906689
sons O 0 7.030203505564714e-06
, O 0 2.6443446543567006e-08
in O 0 7.245607669403853e-09
the O 0 8.458090228202764e-09
maternal O 0 9.297904171035043e-07
grandfather O 0 1.150641196545621e-06
of O 0 2.713001601151177e-09
two O 0 9.015447943738764e-09
AS B-Disease 0 6.341910921037197e-05
first O 0 5.281212267504998e-08
cousins O 0 1.5601595748648833e-07
, O 0 7.107769484093751e-09
and O 0 2.9581592730920647e-09
in O 0 8.44361558449691e-09
the O 0 2.5298872330381528e-08
mother O 0 1.0268438472849084e-06
of O 0 6.526587270627715e-09
an O 0 9.817491672947654e-07
AS B-Disease 1 0.9302108287811279
daughter O 0 0.05711927264928818
. O 0 5.411556230683345e-06

The O 0 1.733090044808705e-07
frequencies O 0 7.573171387775801e-07
with O 0 5.263493463303348e-08
which O 0 3.9812174890130336e-08
we O 0 3.121307301512388e-08
detected O 0 1.0512959534025867e-06
mutations O 0 1.8806501600465708e-07
were O 0 4.017302934755662e-09
5 O 0 7.53163931221934e-09
( O 0 1.6187995388605714e-09
14 O 0 9.679286705477352e-09
% O 0 4.465692537980459e-10
) O 0 2.7345339881357233e-10
of O 0 2.850003011367619e-10
35 O 0 4.490567473425244e-09
in O 0 3.0756235336326654e-09
sporadic O 0 2.181698448566749e-07
cases O 0 1.3892150541039427e-08
and O 0 8.302837528617601e-09
8 O 0 2.7563730853330526e-08
( O 0 2.8765019255416746e-09
80 O 0 5.102454903038733e-09
% O 0 9.35145072489263e-10
) O 0 3.4727543063439725e-10
of O 0 5.413474113424854e-10
10 O 0 1.1514405429124963e-08
in O 0 4.623642979595388e-08
familial O 0 0.0004358675214461982
cases O 0 3.6556925806507934e-06
. O 0 4.154394162014796e-07
. O 0 1.207356376653479e-06

The O 0 8.623486064607278e-05
hemochromatosis B-Disease 1 0.9989460110664368
845 O 0 0.003149215364828706
G O 0 0.004704579245299101
- O 0 8.348521078005433e-05
- O 0 9.304252671427093e-06
> O 0 3.5185698266104737e-07
A O 0 9.118016919273941e-08
and O 0 1.5362786598416278e-08
187 O 0 1.5281372611752886e-07
C O 0 7.449704639839183e-07
- O 0 3.2710763662180398e-06
- O 0 5.465626600198448e-06
> O 0 1.7247747337023611e-06
G O 0 1.440541473129997e-05
mutations O 0 1.20261950087297e-06
: O 0 2.3543885063759262e-08
prevalence O 0 6.326017114588467e-07
in O 0 4.866552316684647e-08
non O 0 2.0579668671416584e-06
- O 0 0.0005467238952405751
Caucasian O 0 8.781830547377467e-05
populations O 0 3.3585363325983053e-06
. O 0 2.276460008943104e-06

Hemochromatosis B-Disease 1 0.9914577603340149
, O 0 0.00021458123228512704
the O 0 0.0013389697996899486
inherited B-Disease 1 0.9999715089797974
disorder I-Disease 1 0.9999806880950928
of I-Disease 0 1.4092076526139863e-05
iron I-Disease 1 0.931258499622345
metabolism I-Disease 0 0.016568506136536598
, O 0 8.099064530142641e-07
leads O 0 1.839286596805323e-06
, O 0 2.501899700746435e-07
if O 0 6.10796064393071e-07
untreated O 0 0.0001495321048423648
, O 0 4.5100115642071614e-08
to O 0 3.6302260753018345e-08
progressive O 0 0.003956726286560297
iron B-Disease 1 0.938612699508667
overload I-Disease 0 0.03700343891978264
and O 0 9.29162615648238e-06
premature B-Disease 0 0.03388160839676857
death I-Disease 0 0.0005026154685765505
. O 0 1.5948821783240419e-06

The O 0 9.272780152969062e-05
hemochromatosis B-Disease 1 0.99930739402771
gene O 0 0.00017450256564188749
, O 0 1.4544481246048235e-06
HFE O 0 0.0010427222587168217
, O 0 7.95577193457575e-07
recently O 0 5.2370098273968324e-05
has O 0 5.092433639219962e-07
been O 0 2.2223366613616236e-07
identified O 0 7.855666694922547e-08
, O 0 3.1092555197176353e-09
and O 0 3.724665020854445e-09
characterization O 0 5.414677772819232e-08
of O 0 3.0721467592087492e-09
this O 0 8.632152770360335e-09
gene O 0 5.310495154731143e-08
has O 0 3.491593858484521e-08
shown O 0 5.229158439590265e-09
that O 0 3.8656344791832e-10
it O 0 3.3852370906473084e-10
contains O 0 3.9893471859286933e-10
two O 0 1.7973209587296424e-09
mutations O 0 4.2384854737065325e-08
that O 0 9.229713104907944e-10
result O 0 7.67463870232632e-09
in O 0 7.010171110266583e-09
amino O 0 1.4105322243551655e-08
acid O 0 4.668117625783452e-08
substitutions O 0 1.8987449834639847e-08
- O 0 9.479483509267084e-08
cDNA O 0 1.3341735893845907e-07
nucleotides O 0 2.7311912731420307e-07
845 O 0 7.320581971725915e-07
G O 0 5.6750695875962265e-06
- O 0 4.584155249176547e-06
- O 0 4.613121745933313e-06
> O 0 1.6093375165837642e-07
A O 0 1.305374581761498e-07
( O 0 5.1958917168803964e-09
C282Y O 0 7.686008984819637e-08
) O 0 2.474861204859735e-09
and O 0 5.414654058455426e-09
187 O 0 8.751619162694624e-08
C O 0 1.0570686299615772e-06
- O 0 9.099468115891796e-06
- O 0 3.682231545099057e-05
> O 0 3.381882834219141e-06
G O 0 1.6666035662638023e-05
( O 0 6.163525512192791e-08
H63D O 0 5.985292591503821e-05
) O 0 3.367210013038857e-07
. O 0 7.613187449351244e-07

Although O 0 0.0020763978827744722
hemochromatosis B-Disease 1 0.9998376369476318
is O 0 1.6362577298423275e-05
common O 0 1.52692666688381e-06
in O 0 3.349587984757818e-07
Caucasians O 0 1.2516229617176577e-06
, O 0 5.891404697422331e-08
affecting O 0 4.98494443945674e-07
> O 0 2.5599174477974884e-06
= O 0 7.524420198024018e-07
1 O 0 7.510197264082308e-08
/ O 0 1.0964182450834414e-07
300 O 0 3.729008213326779e-09
individuals O 0 2.8092769777110504e-10
of O 0 5.840369299292547e-10
northern O 0 5.251609991319128e-08
European O 0 7.187003348008147e-08
origin O 0 1.1131338517600398e-08
, O 0 3.447889085350653e-08
it O 0 1.3538178578187399e-08
has O 0 5.052081419876231e-08
not O 0 2.138613730551242e-09
been O 0 1.809957517195926e-08
recognized O 0 2.1397490002073027e-08
in O 0 2.2212681471955875e-08
other O 0 2.7245100397976785e-08
populations O 0 8.119187100419367e-07
. O 0 1.323104697803501e-06

The O 0 6.068906373002392e-07
present O 0 7.008689806298207e-08
study O 0 2.4754386984682242e-08
used O 0 5.021308702168881e-09
PCR O 0 1.474573423365655e-07
and O 0 9.529732558632986e-09
restriction O 0 4.5722956087956845e-08
- O 0 8.233740800278611e-07
enzyme O 0 3.0315248977785814e-08
digestion O 0 8.12730789334637e-08
to O 0 5.127740454469176e-10
analyze O 0 4.053671620596333e-09
the O 0 1.1663957577567885e-09
frequency O 0 9.325254346492784e-09
of O 0 1.115984082922239e-09
the O 0 1.4812055582069661e-08
845 O 0 6.207673663993774e-07
G O 0 1.1792018085543532e-05
- O 0 2.9995658223924693e-06
- O 0 1.2441920489436598e-06
> O 0 7.007326274788284e-08
A O 0 1.717625508490528e-08
and O 0 4.388116536802045e-09
187 O 0 6.011120490256872e-08
C O 0 2.2052083181733906e-07
- O 0 1.1897484455403173e-06
- O 0 2.813876108120894e-06
> O 0 4.875099648415926e-07
G O 0 1.4616299495173735e-06
mutations O 0 3.011883507042512e-07
in O 0 1.8534379364609777e-08
HLA O 0 3.101645688730059e-06
- O 0 4.5915925284134573e-07
typed O 0 4.508179429763004e-08
samples O 0 7.65005570002586e-09
from O 0 3.1821638657447693e-09
non O 0 6.993399637167386e-08
- O 0 1.0232054592052009e-05
Caucasian O 0 1.328463099525834e-06
populations O 0 4.539527154179268e-08
, O 0 4.088177352201683e-09
comprising O 0 7.48439710207549e-09
Australian O 0 9.163102276943391e-08
Aboriginal O 0 2.7427692117498736e-08
, O 0 1.6847184980406382e-08
Chinese O 0 1.3177883673165525e-08
, O 0 3.375877710709574e-08
and O 0 2.2266004862103728e-07
Pacific O 0 1.274122860195348e-05
Islanders O 0 4.228175021125935e-05
. O 0 1.921326656884048e-06

Results O 0 2.2838927179691382e-05
showed O 0 3.538194505381398e-06
that O 0 1.450991948814817e-08
the O 0 5.6117297475566374e-08
845 O 0 3.4010818126262166e-06
G O 0 2.4772276447038166e-05
- O 0 6.42625309410505e-06
- O 0 2.6846457785723032e-06
> O 0 1.1527232146590904e-07
A O 0 1.7791535356082022e-07
mutation O 0 5.693538014384103e-07
was O 0 1.5203603709323943e-07
present O 0 2.6562279042963155e-09
in O 0 2.802294618575729e-09
these O 0 3.1002764244725256e-10
populations O 0 2.0725543503630206e-09
( O 0 6.808575925276728e-10
allele O 0 4.181136770142757e-09
frequency O 0 1.2185040532131097e-08
0 O 0 6.092226723097838e-09
. O 0 6.725853207711907e-10
32 O 0 5.116137291594214e-09
% O 0 5.345631715059085e-10
) O 0 5.361090460453966e-10
, O 0 1.8186598893521477e-09
and O 0 6.6655014840932836e-09
, O 0 8.43959035989883e-09
furthermore O 0 4.01833979424282e-08
, O 0 1.1917131281791171e-08
it O 0 1.3940884002749954e-08
was O 0 1.4564564025931759e-06
always O 0 1.392475379446978e-08
seen O 0 2.525524145369218e-08
in O 0 3.1907700925870586e-09
conjunction O 0 2.580498303927925e-08
with O 0 3.699694417491628e-08
HLA O 0 2.569243406469468e-05
haplotypes O 0 4.908520736535138e-07
common O 0 8.545481477995054e-08
in O 0 5.071012765256455e-08
Caucasians O 0 2.561548342328024e-07
, O 0 2.6134673092315097e-08
suggesting O 0 1.2847580421748717e-07
that O 0 1.5283115217812338e-08
845 O 0 2.3341483483818593e-06
G O 0 6.368310278048739e-05
- O 0 1.9405480998102576e-05
- O 0 1.3966380720376037e-05
> O 0 4.952891003995319e-07
A O 0 1.9559038264560513e-06
may O 0 7.415935954213637e-08
have O 0 1.051048914568753e-09
been O 0 1.6144271475226901e-09
introduced O 0 1.2292554751880402e-09
into O 0 9.459750760498764e-10
these O 0 4.609707893177273e-10
populations O 0 1.0047526366463444e-08
by O 0 1.9236422232893347e-08
Caucasian O 0 9.01319526747102e-06
admixture O 0 2.81382781395223e-05
. O 0 2.657055574672995e-06

187 O 0 4.302032175473869e-05
C O 0 2.257405867567286e-05
- O 0 2.9860722861485556e-05
- O 0 2.3977412638487294e-05
> O 0 1.1202348559891107e-06
G O 0 3.316863967484096e-06
was O 0 7.758578846051023e-08
present O 0 2.6985460532813477e-09
at O 0 7.3622370422299355e-09
an O 0 5.660863444667541e-10
allele O 0 9.902891839885797e-09
frequency O 0 3.527069125652815e-08
of O 0 2.0853315518820636e-08
2 O 0 1.0624149808791117e-06
. O 0 1.296956838814367e-06

68 O 0 1.6902577044675127e-05
% O 0 5.1781857024479905e-08
in O 0 1.1908360519896632e-08
the O 0 9.749640206280219e-09
two O 0 8.933677797529072e-09
populations O 0 5.797213376013133e-08
analyzed O 0 1.243592464561516e-07
( O 0 5.853174833703179e-09
Australian O 0 1.3970023360343475e-07
Aboriginal O 0 8.294657760643531e-08
and O 0 3.750465893403998e-08
Chinese O 0 7.30528100234551e-08
) O 0 1.5104347994565614e-07
. O 0 7.896796319073474e-07

In O 0 8.830027695694298e-07
the O 0 8.333064727139572e-08
Australian O 0 3.442468710090907e-07
Aboriginal O 0 7.135523105716857e-08
samples O 0 3.2209658940018926e-08
, O 0 1.3820423028221285e-08
187 O 0 5.119380830365117e-08
C O 0 4.3662700477398175e-07
- O 0 3.820533038378926e-06
- O 0 3.315295316497213e-06
> O 0 4.078180495525885e-07
G O 0 4.5626966311829165e-06
was O 0 9.417360615771031e-07
found O 0 6.974123056835424e-09
to O 0 6.510396111103489e-10
be O 0 5.38351319079311e-09
associated O 0 5.1766249953288934e-08
with O 0 6.489425885547462e-08
HLA O 0 7.908063707873225e-05
haplotypes O 0 5.461736805045803e-07
common O 0 9.890513297250436e-08
in O 0 6.990132561668361e-08
Caucasians O 0 2.604391511340509e-07
, O 0 2.798311449225821e-08
suggesting O 0 1.2708005669992417e-07
that O 0 2.461716830381988e-09
it O 0 5.71005553950954e-09
was O 0 1.943765397527386e-07
introduced O 0 2.7730047591489893e-08
by O 0 2.3507180202386735e-08
recent O 0 5.185218014958082e-07
admixture O 0 1.2197247087897267e-05
. O 0 3.817969172814628e-06

In O 0 5.512511620509031e-07
the O 0 3.121903091596323e-08
Chinese O 0 1.4962264316409346e-08
samples O 0 4.0619397623231634e-08
analyzed O 0 9.016310542619976e-08
, O 0 1.902754576121879e-08
187 O 0 7.550153924285041e-08
C O 0 3.309730800538091e-07
- O 0 2.888930112021626e-06
- O 0 6.388874226104235e-06
> O 0 6.845640996289148e-07
G O 0 5.260098987491801e-06
was O 0 2.5218375299118634e-07
present O 0 3.7189360480027744e-09
in O 0 7.0023804532581835e-09
association O 0 1.3061076664655502e-08
with O 0 2.093484274823254e-09
a O 0 1.8297285464541346e-08
wide O 0 2.1267529959345666e-08
variety O 0 3.1498586849920684e-08
of O 0 2.5309102369419634e-08
HLA O 0 4.172275657765567e-05
haplotypes O 0 5.991752800582617e-07
, O 0 2.792888764702184e-08
showing O 0 5.735666164241593e-08
this O 0 4.743273773755163e-09
mutation O 0 6.124619034153511e-08
to O 0 1.172467234411556e-09
be O 0 7.977621230281784e-09
widespread O 0 6.049248213457759e-08
and O 0 9.885986429480909e-08
likely O 0 5.922432677607503e-08
to O 0 1.2324482545622573e-09
predate O 0 1.232488102687057e-07
the O 0 4.6900878736266804e-09
more O 0 1.2418420736182156e-09
genetically O 0 3.040738150161815e-08
restricted O 0 2.7775360678106154e-08
845 O 0 1.5917944438115228e-06
G O 0 4.933938544127159e-05
- O 0 3.1508760002907366e-05
- O 0 3.3902808354469016e-05
> O 0 1.6500316633027978e-06
A O 0 4.927271675114753e-06
mutation O 0 1.896053618111182e-05
. O 0 6.959620577617898e-07

Genotype O 0 0.004108356777578592
- O 0 0.004281431436538696
phenotype O 0 0.0010725846514105797
correlations O 0 0.00032642082078382373
in O 0 0.00040248213917948306
attenuated B-Disease 1 0.9916129112243652
adenomatous I-Disease 1 0.9997637867927551
polyposis I-Disease 1 0.9995323419570923
coli I-Disease 1 0.999234676361084
. O 0 0.0005044554127380252

Germ O 0 0.004144635517150164
- O 0 0.00034499456523917615
line O 0 8.211610293074045e-06
mutations O 0 2.765584213193506e-06
of O 0 2.569403534380399e-08
the O 0 8.489658398502797e-07
tumor B-Disease 0 0.1356612592935562
suppressor O 0 4.205106233712286e-05
APC O 0 7.217139682325069e-06
are O 0 6.77328628739815e-08
implicated O 0 7.162512338254601e-05
in O 0 3.952210317947902e-05
attenuated B-Disease 1 0.9904822111129761
adenomatous I-Disease 1 0.9999289512634277
polyposis I-Disease 1 0.9999274015426636
coli I-Disease 1 0.999893307685852
( O 0 0.00022082205396145582
AAPC B-Disease 1 0.9983281493186951
) O 0 5.339126118997228e-07
, O 0 1.2524689907422726e-07
a O 0 9.846352213571663e-07
variant O 0 0.0007569700246676803
of O 0 8.031192555790767e-05
familial B-Disease 1 0.9999184608459473
adenomatous I-Disease 1 0.9998366832733154
polyposis I-Disease 1 0.9999608993530273
( O 0 0.0012088743969798088
FAP B-Disease 0 0.08148907124996185
) O 0 5.709148808819009e-06
. O 0 6.948313966859132e-06

AAPC B-Disease 1 0.9966200590133667
is O 0 6.619477062486112e-06
recognized O 0 8.695717497175792e-07
by O 0 5.1325113048505955e-08
the O 0 3.227447820108864e-08
occurrence O 0 1.4784105815124349e-06
of O 0 6.425282350619455e-08
< O 0 9.738214430399239e-06
100 O 0 2.895760360388522e-07
colonic B-Disease 0 0.0012743087718263268
adenomas I-Disease 0 6.594126170966774e-05
and O 0 2.4343099980228544e-08
a O 0 3.0924667271392536e-07
later O 0 9.026709449244663e-06
onset O 1 0.7022718787193298
of O 0 0.040032655000686646
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
( O 0 7.429753736687417e-07
age O 0 3.2953857953543775e-06
> O 0 8.093775818451832e-07
40 O 0 1.7445951527861325e-07
years O 0 3.427576587000658e-07
) O 0 1.3344114790925232e-07
. O 0 5.586141469393624e-07

The O 0 5.471778194987564e-07
aim O 0 3.100368815012189e-07
of O 0 1.1071774608240048e-08
this O 0 9.08953623479647e-09
study O 0 1.684005290769619e-08
was O 0 1.8054309691706294e-07
to O 0 4.407854525823041e-09
assess O 0 6.012209610162245e-07
genotype O 0 7.480762178602163e-06
- O 0 0.00010806005593622103
phenotype O 0 2.7418247555033304e-05
correlations O 0 1.2884005627711304e-05
in O 0 1.689772579993587e-05
AAPC B-Disease 1 0.9955306649208069
families O 0 4.183430974080693e-06
. O 0 7.84311123425141e-06

By O 0 6.131252234808926e-07
protein O 0 1.8423693290969823e-06
- O 0 4.744751549878856e-06
truncation O 0 3.7833040096302284e-06
test O 0 3.4795547776411695e-07
( O 0 1.7400415330826036e-08
PTT O 0 1.8892856132879388e-06
) O 0 9.677108003813828e-09
assay O 0 1.650936809483028e-07
, O 0 7.444702632142253e-09
the O 0 4.918677465326482e-09
entire O 0 1.2754166789363808e-07
coding O 0 2.1714952254114905e-06
region O 0 6.387195838897242e-08
of O 0 2.325404757641536e-09
the O 0 1.7469318436269532e-08
APC B-Disease 0 6.051579930499429e-07
gene O 0 1.9421719343881705e-07
was O 0 1.3224890835772385e-06
screened O 0 2.571762820480217e-07
in O 0 2.1579712239372384e-08
affected O 0 3.223768629823098e-08
individuals O 0 2.4987765190331857e-09
from O 0 1.2820812855807162e-07
11 O 0 5.731734290748136e-06
AAPC B-Disease 1 0.9930704236030579
kindreds O 0 3.216855111531913e-05
, O 0 4.1187036003975663e-08
and O 0 5.722047724532331e-09
their O 0 3.3624971695900285e-09
phenotypic O 0 1.473329461987305e-06
differences O 0 1.419307977812423e-06
were O 0 1.4989278724897304e-06
examined O 0 0.00014368549454957247
. O 0 2.0985480659874156e-06

Five O 0 4.513442036113702e-06
novel O 0 1.2602113201864995e-05
germ O 0 0.00048163457540795207
- O 0 7.529385038651526e-05
line O 0 1.392046488035703e-05
APC B-Disease 0 1.2362612324068323e-05
mutations O 0 3.193541033397196e-06
were O 0 5.867137886639284e-08
identified O 0 2.2809599897755106e-07
in O 0 1.0408753325918951e-07
seven O 0 1.1127834795843228e-06
kindreds O 0 0.00013705594756174833
. O 0 7.6226192504691426e-06

Mutations O 0 0.0002852203033398837
were O 0 9.416373245585419e-07
located O 0 1.0493447462067707e-06
in O 0 2.0372269204926852e-08
three O 0 2.081047112412193e-09
different O 0 1.0418038653980943e-09
regions O 0 1.310524488928877e-08
of O 0 1.4951757609793503e-09
the O 0 1.8816596281112652e-08
APC B-Disease 0 6.526677225338062e-07
gene O 0 7.297398951777723e-08
( O 0 5.6191491459856024e-09
1 O 0 1.4226097633240897e-08
) O 0 2.310073909939092e-09
at O 0 4.432863676129273e-08
the O 0 7.792642087167678e-09
5 O 0 1.0920016890736406e-08
end O 0 1.3252342334624245e-08
spanning O 0 4.492008542911208e-08
exons O 0 1.362326287335236e-07
4 O 0 6.501393556845869e-08
and O 0 1.0394980876071713e-08
5 O 0 7.18571584457095e-08
, O 0 6.242626859886968e-09
( O 0 3.4253060388067524e-09
2 O 0 1.231260071676843e-08
) O 0 1.7851513600675162e-09
within O 0 8.422095021387577e-09
exon O 0 6.217306918188115e-07
9 O 0 2.1529930904762296e-07
, O 0 6.233227267671282e-09
and O 0 3.3508062990961207e-09
( O 0 3.146962912481399e-09
3 O 0 1.8149737712747083e-08
) O 0 1.930926973869873e-09
at O 0 6.461832668946954e-08
the O 0 7.081625508220668e-09
3 O 0 2.095234918897404e-08
distal O 0 2.444423614633706e-07
end O 0 5.1573877613009245e-08
of O 0 7.628214504507014e-09
the O 0 1.3008077814902208e-07
gene O 0 3.5017360460187774e-06
. O 0 1.2156903039794997e-06

Variability O 0 0.00014871350140310824
in O 0 2.729766777065379e-07
the O 0 7.309517968678847e-08
number O 0 2.3690087402883364e-07
of O 0 0.00013130696606822312
colorectal B-Disease 1 0.9999998807907104
adenomas I-Disease 1 0.9999629259109497
was O 0 0.09002144634723663
most O 0 2.545604331771756e-07
apparent O 0 2.8745348572556395e-06
in O 0 1.862843923561286e-08
individuals O 0 1.972235930125521e-09
with O 0 3.717994800922497e-08
mutations O 0 9.25263236695173e-07
in O 0 4.728534364062398e-08
region O 0 2.7907222488465777e-07
1 O 0 4.191639106920775e-07
, O 0 7.498788789916944e-08
and O 0 8.643092996862833e-07
upper O 1 0.9057708978652954
- O 1 0.9899716377258301
gastrointestinal O 1 0.9817798733711243
manifestations O 0 1.9479222828522325e-05
were O 0 5.469430561788613e-07
more O 0 7.923004119447796e-08
severe O 0 0.007950921542942524
in O 0 2.3630539658370253e-07
them O 0 5.3113261344606144e-08
. O 0 1.4146755802357802e-06

In O 0 1.323647438766784e-06
individuals O 0 5.444482553684793e-08
with O 0 1.5354208926510182e-07
mutations O 0 1.8935546904685907e-05
in O 0 1.7787530737223278e-07
either O 0 7.75880053538458e-08
region O 0 5.862092393726925e-07
2 O 0 1.761021906077076e-07
or O 0 2.420864042562698e-08
region O 0 1.3092282813431666e-07
3 O 0 4.5344993537810296e-08
, O 0 3.97329591450557e-09
the O 0 4.19561230202703e-09
average O 0 2.941989407645451e-08
number O 0 1.4325858277430825e-09
of O 0 6.480863401492343e-09
adenomas B-Disease 0 1.8316775822313502e-05
tended O 0 1.7084890657770302e-07
to O 0 2.7481301678733416e-09
be O 0 1.5681633769304426e-08
lower O 0 2.3140137273003347e-07
than O 0 1.1075951267258688e-09
those O 0 5.178100725977686e-10
in O 0 1.4972704187599106e-09
individuals O 0 1.7278495301198404e-10
with O 0 8.639532644849623e-09
mutations O 0 4.24146151090099e-07
in O 0 3.199150810928586e-08
region O 0 1.4964496131142369e-07
1 O 0 6.846908462421197e-08
, O 0 9.795886768415585e-09
although O 0 2.8248187788904033e-08
age O 0 3.157221613037109e-07
at O 0 6.603399924642872e-06
diagnosis O 0 0.002794908359646797
was O 0 4.9147412937600166e-05
similar O 0 7.5386270736999e-07
. O 0 1.1836779094664962e-06

In O 0 5.667173809342785e-06
all O 0 1.2392160897434223e-06
AAPC B-Disease 1 0.9936937689781189
kindreds O 0 0.00010877090971916914
, O 0 2.5122119495790685e-07
a O 0 1.5568095079743216e-07
predominance O 0 3.405275265322416e-06
of O 0 4.2108106867999595e-07
right O 0 0.012397770769894123
- O 1 0.9991592168807983
sided O 1 0.999750554561615
colorectal B-Disease 1 0.9999995231628418
adenomas I-Disease 1 0.9999431371688843
and O 0 0.028332745656371117
rectal B-Disease 1 0.9998800754547119
polyp I-Disease 1 0.9989861845970154
sparing O 0 0.00022728896874468774
was O 0 0.00047802855260670185
observed O 0 1.27703760881559e-05
. O 0 1.8312495058125933e-06

No O 0 0.00016185878484975547
desmoid B-Disease 1 0.9742669463157654
tumors I-Disease 1 0.9999392032623291
were O 0 1.0762939382402692e-05
found O 0 1.8833562762665679e-06
in O 0 1.9020293962057622e-07
these O 0 8.041727994623216e-08
kindreds O 0 0.00016188071458600461
. O 0 3.24324423672806e-06

Our O 0 1.8957269958264078e-06
data O 0 1.0721986427597585e-06
suggest O 0 2.6170994260610314e-07
that O 0 1.9291755748440664e-08
, O 0 8.816608954020921e-08
in O 0 3.437491784552549e-07
AAPC B-Disease 1 0.9809238910675049
families O 0 5.446289463861831e-08
, O 0 9.941480527686508e-09
the O 0 3.083541422199687e-09
location O 0 4.012794718732948e-08
of O 0 4.257604935276049e-09
the O 0 2.0784031562470773e-07
APC B-Disease 0 0.00014973613724578172
mutation O 0 5.770264033344574e-05
may O 0 9.228689350493369e-07
partially O 0 2.7396590667194687e-06
predict O 0 1.7099954163768416e-07
specific O 0 2.72704703263571e-08
phenotypic O 0 9.664192475611344e-06
expression O 0 1.1211380297027063e-05
. O 0 3.707192945512361e-06

This O 0 2.2712050906648074e-07
should O 0 3.92064620768906e-08
help O 0 1.3358931738594038e-08
in O 0 4.600724690106972e-09
the O 0 2.935592435804324e-09
design O 0 4.687639787448461e-08
of O 0 8.832965470162435e-09
tailored O 0 1.2487853382481262e-06
clinical O 0 6.180870695970953e-05
- O 0 0.00015009722847025841
management O 0 1.2195965837236145e-06
protocols O 0 1.955404513864778e-07
in O 0 8.092469805376368e-09
this O 0 1.8267252155368396e-09
subset O 0 3.1970341041187567e-08
of O 0 8.530059147915381e-08
FAP B-Disease 0 0.0009997220477089286
patients O 0 2.6549923859420232e-05
. O 0 2.1704008190681634e-07
. O 0 1.364625632049865e-06

Wilms B-Disease 1 0.9737197160720825
' I-Disease 0 0.0009553195559419692
tumor I-Disease 0 0.04030025005340576
1 O 0 5.658639565808699e-07
and O 0 6.58699406130836e-08
Dax O 0 0.010650485754013062
- O 0 1.778713340172544e-05
1 O 0 2.0327753702531481e-07
modulate O 0 4.624366454208939e-07
the O 0 1.0513866754990886e-07
orphan O 0 7.528276910306886e-06
nuclear O 0 5.86493933951715e-06
receptor O 0 3.3831443033705e-06
SF O 0 0.001085492316633463
- O 0 2.998458739966736e-06
1 O 0 4.9204533780766724e-08
in O 0 8.42877945217424e-09
sex O 0 4.370327744140923e-08
- O 0 8.440880492344149e-07
specific O 0 3.3383557251909224e-08
gene O 0 9.415296062798006e-07
expression O 0 2.7412374947743956e-06
. O 0 2.1508067220565863e-06

Products O 0 1.7144921002909541e-06
of O 0 4.1906798742274987e-07
steroidogenic O 0 0.00016120480722747743
factor O 0 2.779123633445124e-06
1 O 0 1.226525000674883e-06
( O 0 2.6778315032061073e-07
SF O 0 0.01705906353890896
- O 0 4.042089858558029e-05
1 O 0 2.910872751726856e-07
) O 0 2.1364295221815155e-08
and O 0 2.0558233870815457e-07
Wilms B-Disease 1 0.9964426159858704
tumor I-Disease 1 0.97025066614151
1 O 0 5.81390565912443e-07
( O 0 3.908684220732539e-08
WT1 O 0 9.323742233391386e-06
) O 0 5.248403489588327e-09
genes O 0 1.1560485901895845e-08
are O 0 3.8504679999995517e-10
essential O 0 1.98799621209389e-09
for O 0 2.4152821964662508e-09
mammalian O 0 2.7789278078671487e-07
gonadogenesis O 0 5.881596734980121e-06
prior O 0 6.594951429406137e-08
to O 0 9.468420714142667e-09
sexual O 0 4.0655248767507146e-07
differentiation O 0 9.667639460531063e-06
. O 0 2.47194816438423e-06

In O 0 2.1573289359366754e-06
males O 0 1.5481247146453825e-06
, O 0 3.422435099764698e-07
SF O 0 0.02661578543484211
- O 0 2.3078408048604615e-05
1 O 0 1.5017278087725572e-07
participates O 0 9.388005395294385e-08
in O 0 1.4797201686178596e-08
sexual O 0 1.0018783136445109e-08
development O 0 7.031288440373373e-09
by O 0 4.356094596147386e-09
regulating O 0 1.4335081743865885e-07
expression O 0 2.0978822234951622e-08
of O 0 5.1496393815853025e-09
the O 0 1.0506329317649943e-07
polypeptide O 0 1.4118334547674749e-05
hormone O 0 2.323504668311216e-05
Mullerian O 0 0.0001817141310311854
inhibiting O 0 3.977437154389918e-05
substance O 0 6.848122575320303e-05
( O 0 8.945817739913764e-07
MIS O 0 0.0018463225569576025
) O 0 9.515928809378238e-07
. O 0 1.5406398006234667e-06

Here O 0 3.7861625514779007e-06
, O 0 2.0453181548418797e-07
we O 0 4.376733997446536e-08
show O 0 1.0631573843511433e-07
that O 0 3.466193376766569e-08
WT1 O 0 5.595243419520557e-05
- O 0 2.0180186766083352e-05
KTS O 0 4.0810547943692654e-05
isoforms O 0 1.7533436391659052e-07
associate O 0 2.8917807526340766e-07
and O 0 5.622518273185051e-08
synergize O 0 1.0139558980881702e-05
with O 0 7.715177616773872e-07
SF O 0 0.493857741355896
- O 0 3.4523618523962796e-05
1 O 0 8.86830235913294e-08
to O 0 1.3729228420800155e-08
promote O 0 3.334477582939144e-07
MIS O 0 0.0013211274053901434
expression O 0 8.560000424040481e-06
. O 0 3.156299499096349e-06

In O 0 2.4867308638931718e-06
contrast O 0 7.019980330369435e-06
, O 0 2.816705773511785e-06
WT1 O 0 0.004801194183528423
missense O 0 0.00080528249964118
mutations O 0 0.00017572329670656472
, O 0 2.875451059480838e-07
associated O 0 1.8979996241341723e-07
with O 0 5.81466608196024e-08
male B-Disease 0 4.925861958327005e-06
pseudohermaphroditism I-Disease 1 0.9966381788253784
in O 0 3.0520212021656334e-05
Denys B-Disease 1 0.9801257252693176
- I-Disease 1 0.9992941617965698
Drash I-Disease 1 0.9986452460289001
syndrome I-Disease 1 0.9999315738677979
, O 0 9.508689799986314e-07
fail O 0 1.4104805359238526e-06
to O 0 1.2689397976828332e-08
synergize O 0 1.9485818484099582e-05
with O 0 5.338084065442672e-06
SF O 1 0.9910882711410522
- O 0 0.002929228125140071
1 O 0 5.118481112731388e-06
. O 0 1.7204147297888994e-06

Additionally O 0 8.74988290888723e-06
, O 0 3.0589373523071117e-07
the O 0 1.742576500873838e-07
X O 0 0.0002911473857238889
- O 0 0.00023423005768563598
linked O 0 3.1102332286536694e-05
, O 0 5.3032074731618195e-08
candidate O 0 3.6026389693688543e-07
dosage O 0 1.9674071154440753e-06
- O 0 1.1641158152997377e-06
sensitive O 0 2.6065532665597857e-07
sex O 0 1.3820006472542445e-07
- O 0 2.1537171051022597e-06
reversal O 0 4.5324756570153113e-07
gene O 0 1.83643507511988e-07
, O 0 2.5748246201828806e-08
Dax O 0 0.0004954641917720437
- O 0 1.1566909051907714e-05
1 O 0 1.9459318423287186e-07
, O 0 1.8683952163200956e-08
antagonizes O 0 6.567029231518973e-07
synergy O 0 2.558640517236199e-07
between O 0 2.706377983940911e-07
SF O 0 0.013534999452531338
- O 0 1.4913485756551381e-05
1 O 0 1.3609925986202143e-07
and O 0 1.8790128564205588e-08
WT1 O 0 2.007276088988874e-05
, O 0 1.117492764990402e-08
most O 0 2.523678377386318e-09
likely O 0 3.0925886296273575e-09
through O 0 1.1839822455783633e-09
a O 0 3.5032992062866697e-09
direct O 0 2.401849164002101e-09
interaction O 0 1.933234905493464e-08
with O 0 1.224823222401028e-06
SF O 1 0.9847961664199829
- O 0 0.0009978105081245303
1 O 0 7.876392373873387e-06
. O 0 1.521522108305362e-06

We O 0 1.4118829767539864e-06
propose O 0 1.3082664054309134e-06
that O 0 3.32001732772369e-08
WT1 O 0 1.4680232197861187e-05
and O 0 1.658166723927934e-07
Dax O 0 0.06963913142681122
- O 0 0.0001613388885743916
1 O 0 5.584463451668853e-07
functionally O 0 5.360585078051372e-07
oppose O 0 1.4308443319066555e-08
each O 0 1.2738328170058821e-09
other O 0 1.1009646527782024e-09
in O 0 2.7183485684645348e-08
testis O 0 6.04965680395253e-06
development O 0 5.205477293657168e-08
by O 0 7.789226685872563e-08
modulating O 0 8.673818228999153e-05
SF O 1 0.8014063239097595
- O 0 0.00013491556455846876
1 O 0 2.857484787455178e-06
- O 0 2.1478474081959575e-05
mediated O 0 3.434223253862001e-05
transactivation O 0 9.193171717924997e-05
. O 0 7.096731451383675e-07
. O 0 9.786214150153683e-07

A O 0 3.343978096381761e-05
mouse O 0 0.00010555832704994828
model O 0 4.0144768718164414e-05
for O 0 2.8525964808068238e-05
Prader B-Disease 1 0.9998124241828918
- I-Disease 1 0.999799907207489
Willi I-Disease 1 0.9999172687530518
syndrome I-Disease 1 0.9999167919158936
imprinting O 1 0.9732270836830139
- O 1 0.9013806581497192
centre O 0 0.010249138809740543
mutations O 0 0.003858946729451418
. O 0 1.5697540220571682e-05

Imprinting O 0 0.00028630817541852593
in O 0 2.131135943272966e-06
the O 0 8.018674293452932e-07
15q11 O 0 5.9095727920066565e-05
- O 0 6.429697532439604e-05
q13 O 0 7.479057330783689e-06
region O 0 5.239494385023136e-07
involves O 0 1.5757886728806625e-07
an O 0 6.488125592341021e-08
imprinting O 0 1.1458774679340422e-05
centre O 0 8.094740223896224e-06
( O 0 5.7111257945052785e-08
IC O 0 3.0335027076944243e-06
) O 0 1.527256721089998e-08
, O 0 7.652712241679183e-09
mapping O 0 8.547974772454836e-08
in O 0 4.858833335674717e-09
part O 0 4.910934325863536e-09
to O 0 6.851069711544255e-10
the O 0 1.2561623741191852e-08
promoter O 0 5.613481334876269e-06
and O 0 2.0755500429459062e-08
first O 0 1.6563366500577104e-07
exon O 0 8.30960925668478e-06
of O 0 4.412134444464755e-07
SNRPN O 0 0.006744790822267532
. O 0 7.256783192133298e-06

Deletion O 0 5.3515410399995744e-05
of O 0 3.1512806231148716e-07
this O 0 1.696844975640488e-07
IC O 0 2.534439045120962e-05
abolishes O 0 1.6698237232048996e-05
local O 0 2.0056087635111908e-07
paternally O 0 5.043559667683439e-06
derived O 0 1.3261248454909946e-07
gene O 0 3.241881927351642e-07
expression O 0 8.587669242388074e-08
and O 0 6.930115148406912e-08
results O 0 7.145122708607232e-06
in O 0 0.00011778906628023833
Prader B-Disease 1 0.9999799728393555
- I-Disease 1 0.9999905824661255
Willi I-Disease 1 0.9999955892562866
syndrome I-Disease 1 0.9999951124191284
( O 0 0.0031428493093699217
PWS B-Disease 1 0.9995453953742981
) O 0 2.541114008636214e-05
. O 0 1.4497198208118789e-05

We O 0 8.814917009658529e-07
have O 0 3.0672712370005684e-08
created O 0 3.806011861229308e-08
two O 0 1.2897687362567467e-08
deletion O 0 2.4647260943311267e-06
mutations O 0 1.064364732883405e-05
in O 0 4.671457816129987e-07
mice O 0 4.473959052120335e-06
to O 0 1.6642273337197366e-08
understand O 0 7.49981836634106e-07
PWS B-Disease 1 0.9975413084030151
and O 0 6.074765934727111e-08
the O 0 2.187368686179525e-08
mechanism O 0 1.3095154827169608e-07
of O 0 1.565336305020537e-08
this O 0 1.2387252468215593e-07
IC O 0 0.00016268070612568408
. O 0 3.6000978980155196e-06

Mice O 0 0.0026751526165753603
harbouring O 0 0.0008324818918481469
an O 0 9.825181450651144e-07
intragenic O 0 0.00021930335788056254
deletion O 0 1.6440048057120293e-05
in O 0 3.8044083794375183e-07
Snrpn O 0 4.4525095290737227e-05
are O 0 4.13900593798644e-08
phenotypically O 0 9.73855821939651e-06
normal O 0 2.6495404199522454e-06
, O 0 6.245367956125847e-08
suggesting O 0 2.2691180845413328e-07
that O 0 7.841650884188311e-09
mutations O 0 1.100153284028238e-07
of O 0 5.6387534641544335e-09
SNRPN O 0 0.00010645028669387102
are O 0 3.401393389168561e-09
not O 0 1.4377373735996457e-09
sufficient O 0 1.7796176976503375e-08
to O 0 6.536107122201429e-08
induce O 0 6.497226422652602e-05
PWS B-Disease 1 0.9989758729934692
. O 0 1.6781345038907602e-05

Mice O 0 0.00018916669068858027
with O 0 2.2023563417405967e-07
a O 0 5.898994004382985e-07
larger O 0 1.9992152999748214e-07
deletion O 0 1.8203355693913181e-06
involving O 0 2.3673690918712964e-07
both O 0 4.274067322285191e-08
Snrpn O 0 6.66112537146546e-05
and O 0 2.976215398575732e-07
the O 0 8.932971127251221e-07
putative O 0 0.0002153578243451193
PWS O 1 0.9986611604690552
- O 0 0.0004961174563504755
IC O 0 1.5544343114015646e-05
lack O 0 2.0872141703875968e-07
expression O 0 8.791504768623781e-08
of O 0 7.160565473895986e-09
the O 0 8.045778798759784e-08
imprinted O 0 7.004432518442627e-06
genes O 0 4.038140275497426e-07
Zfp127 O 0 7.399457444989821e-06
( O 0 4.9043283212313327e-08
mouse O 0 7.368216756731272e-07
homologue O 0 7.877254688537505e-07
of O 0 1.9893780844881803e-08
ZNF127 O 0 4.25818761868868e-05
) O 0 2.5112289137041444e-08
, O 0 2.700390666632302e-08
Ndn O 0 1.5358737073256634e-05
and O 0 4.074199466685968e-08
Ipw O 0 7.049714440654498e-06
, O 0 7.346122998797e-08
and O 0 3.8121147127867516e-08
manifest O 0 7.279423357431369e-07
several O 0 6.856121359533063e-08
phenotypes O 0 1.0890680641750805e-05
common O 0 2.4031076009123353e-06
to O 0 1.079022422345588e-05
PWS B-Disease 1 0.9996863603591919
infants O 0 0.28099682927131653
. O 0 1.937156957865227e-05

These O 0 7.18856654202682e-08
data O 0 7.252580047634183e-08
demonstrate O 0 4.361275784958707e-08
that O 0 1.6218221210451134e-09
both O 0 8.355879876909e-10
the O 0 2.0206782913589905e-09
position O 0 1.2297250329140752e-08
of O 0 4.920241991612784e-10
the O 0 6.11170980491238e-09
IC O 0 1.1341836625433643e-06
and O 0 5.194633612148891e-09
its O 0 3.6866607544538965e-09
role O 0 5.8272117797741885e-08
in O 0 1.0265237548878758e-08
the O 0 1.4724894636941599e-09
coordinate O 0 5.840360639552955e-09
expression O 0 6.449935696650755e-09
of O 0 2.7966506888077447e-09
genes O 0 1.4519081936725797e-08
is O 0 4.192732383501152e-09
conserved O 0 7.4329831178943095e-09
between O 0 4.223505101208502e-09
mouse O 0 2.3126722226152197e-07
and O 0 4.6223980199044945e-09
human O 0 1.5334622460727587e-08
, O 0 1.4741172726928653e-08
and O 0 2.0663819100263936e-08
indicate O 0 4.841628964413758e-08
that O 0 1.8958272729463488e-09
the O 0 1.7298560806011665e-08
mouse O 0 4.3886379330615455e-07
is O 0 1.5541150588660457e-08
a O 0 1.1908360519896632e-08
suitable O 0 3.289408923023984e-08
model O 0 3.714454805958667e-07
system O 0 1.6665961766193504e-06
in O 0 1.6238409727975522e-08
which O 0 1.912628944111816e-09
to O 0 3.5156744182529565e-10
investigate O 0 7.3340937767341075e-09
the O 0 4.078831494780388e-09
molecular O 0 7.636413812406317e-08
mechanisms O 0 1.6412347036975916e-08
of O 0 3.421688488103314e-09
imprinting O 0 2.4731461962801404e-06
in O 0 5.400670843869193e-08
this O 0 4.83723194832919e-09
region O 0 3.257087755059729e-08
of O 0 4.872587222592983e-09
the O 0 1.1266359223327527e-07
genome O 0 1.1248638429606217e-06
. O 0 1.2221542533552565e-07
. O 0 6.149493287921359e-07

Mutations O 0 6.666990520898253e-05
of O 0 8.954732066968063e-08
the O 0 6.097786098280267e-08
ATM O 0 2.4727105483179912e-05
gene O 0 1.3199440218158998e-05
detected O 0 6.13106822129339e-05
in O 0 1.3380207519730902e-06
Japanese O 0 0.0020288070663809776
ataxia B-Disease 1 0.999982476234436
- I-Disease 1 0.9999308586120605
telangiectasia I-Disease 1 0.9999681711196899
patients O 0 0.12462449818849564
: O 0 1.061582963757246e-07
possible O 0 7.25411553048616e-08
preponderance O 0 5.782624157291139e-07
of O 0 6.494215387675695e-09
the O 0 2.3880188493308196e-08
two O 0 4.019903698804228e-08
founder O 0 9.944117664417718e-06
mutations O 0 6.550249963765964e-06
4612del165 O 0 9.239131031790748e-06
and O 0 5.390039063968288e-07
7883del5 O 0 0.00014008030120749027
. O 0 5.791593139292672e-06

The O 0 1.7856310705610667e-06
ATM O 0 0.00021645486413035542
( O 0 5.051839252701029e-06
A O 1 0.965419590473175
- O 1 0.9925221800804138
T O 1 0.9987560510635376
, O 0 7.416642944235718e-08
mutated O 0 3.9753297187417047e-07
) O 0 1.0288092155974482e-08
gene O 0 1.0384838589061474e-07
on O 0 8.633984549533125e-08
human O 0 6.283028142206604e-07
chromosome O 0 5.104024967295118e-05
11q22 O 0 6.911154196131974e-05
. O 0 2.9122822979843477e-06

3 O 0 1.686724863247946e-05
has O 0 1.7559166280989302e-06
recently O 0 5.741198947362136e-06
been O 0 4.342889425856811e-08
identified O 0 2.0025082037022912e-08
as O 0 2.9446038940506014e-09
the O 0 3.027640138597576e-09
gene O 0 4.6586535518144956e-08
responsible O 0 2.995795256310885e-08
for O 0 6.508066086041708e-09
the O 0 3.860900790186861e-07
human O 0 6.0616646806010976e-05
recessive B-Disease 1 0.9992293119430542
disease I-Disease 1 0.9999573230743408
ataxia B-Disease 1 0.9999926090240479
- I-Disease 1 0.9998941421508789
telangiectasia I-Disease 1 0.9999051094055176
( O 0 0.0011107578175142407
A B-Disease 1 0.9999223947525024
- I-Disease 1 0.9998261332511902
T I-Disease 1 0.9997132420539856
) O 0 1.0929998097708449e-06
. O 0 2.3197792415885488e-06

In O 0 1.0813089375005802e-06
order O 0 7.499289012002919e-08
to O 0 4.447877177682358e-09
define O 0 3.507707546646088e-08
the O 0 1.561888751666629e-08
types O 0 1.59752786998979e-07
of O 0 5.355138341656129e-07
disease O 1 0.6484567523002625
- O 0 0.0006505808560177684
causing O 0 9.719630725157913e-06
ATM O 0 7.981170347193256e-05
mutations O 0 7.54189386498183e-06
in O 0 1.756940690711417e-07
Japanese O 0 3.739880776265636e-05
A B-Disease 1 0.9995514750480652
- I-Disease 1 0.9995443224906921
T I-Disease 1 0.9999443292617798
patients O 0 5.147441243025241e-06
as O 0 1.4925950253541487e-08
well O 0 4.814846299439068e-09
as O 0 3.6881797615961887e-09
to O 0 7.414203695432775e-10
look O 0 1.042810460205601e-08
for O 0 1.6501986443984151e-09
possible O 0 5.033460226400166e-08
mutational O 0 2.1710357032134198e-06
hotspots O 0 7.342928256548475e-07
, O 0 3.187723862652092e-08
reverse O 0 7.275092457348364e-07
- O 0 1.5961938970576739e-06
transcribed O 0 1.0947841388997404e-07
RNA O 0 4.936753938977745e-08
derived O 0 1.8209437291361041e-09
from O 0 1.1639134100960291e-09
ten O 0 9.117839816497053e-09
patients O 0 2.8782379146718995e-08
belonging O 0 1.670715477075646e-08
to O 0 2.6959428023332066e-09
eight O 0 3.3510382024815044e-08
unrelated O 0 9.681521078164224e-07
Japanese O 0 2.1744690457126126e-05
A B-Disease 1 0.9979481101036072
- I-Disease 1 0.9731298685073853
T I-Disease 1 0.9941921830177307
families O 0 3.3801558885215854e-08
was O 0 7.738234444332193e-07
analyzed O 0 3.363274814205397e-08
for O 0 2.1764638979959727e-09
mutations O 0 2.8861100176413856e-08
by O 0 9.783855947631537e-10
the O 0 2.272438237582719e-09
restriction O 0 3.2603260535779555e-08
endonuclease O 0 1.2804345033146092e-06
fingerprinting O 0 1.357047722194693e-06
method O 0 4.467086114345875e-07
. O 0 7.114003892638721e-07

As O 0 3.205440862075193e-06
has O 0 1.4904179579389165e-06
been O 0 3.9763915538060246e-07
reported O 0 4.808855464943917e-07
by O 0 7.05608904638666e-09
others O 0 1.4488762190012494e-08
, O 0 2.5825958260838888e-08
mutations O 0 1.6449114070837823e-07
that O 0 3.5770253425937426e-09
lead O 0 5.5412858301906454e-08
to O 0 5.060633245790314e-09
exon O 0 3.379858071639319e-06
skipping O 0 1.2794653230230324e-06
or O 0 8.562629005837152e-08
premature O 0 1.5485809399251593e-06
protein O 0 3.8401818613920113e-08
truncation O 0 2.53636699198978e-07
were O 0 1.0691742602375598e-08
also O 0 1.0129034500039324e-08
predominant O 0 1.409540431041023e-07
in O 0 5.258716484490833e-08
our O 0 3.202005132152408e-07
mutants O 0 1.0042574103863444e-05
. O 0 9.321165066467074e-07

Six O 0 3.485492925392464e-07
different O 0 2.026209777739041e-08
mutations O 0 1.0749957937150612e-06
were O 0 2.698305578974214e-08
identified O 0 3.664697700855868e-08
on O 0 1.2999242571254399e-08
12 O 0 9.104059728315406e-09
of O 0 7.559657344557991e-10
the O 0 1.8995418571421396e-08
16 O 0 4.3442898345347203e-07
alleles O 0 6.508776095870417e-07
examined O 0 2.816829328367021e-05
. O 0 1.91386880032951e-06

Four O 0 9.877388720269664e-07
were O 0 1.8068881502131262e-07
deletions O 0 8.218223683797987e-07
involving O 0 8.567232612222142e-07
a O 0 1.2218494703120086e-05
loss O 0 4.4708052882924676e-05
of O 0 7.617048325414544e-09
a O 0 1.614182423281818e-07
single O 0 2.717343647873349e-07
exon O 0 1.5498928405577317e-05
exon O 0 9.99319127004128e-06
7 O 0 5.387521468946943e-07
, O 0 2.336253679402489e-08
exon O 0 2.265583589178277e-06
16 O 0 1.7187144862873538e-07
, O 0 3.7155064802618654e-08
exon O 0 4.816970431420486e-06
33 O 0 8.501681350026047e-07
or O 0 1.6059399854384537e-07
exon O 0 4.446247112355195e-05
35 O 0 4.697620624938281e-06
. O 0 1.6851865893841023e-06

The O 0 4.823065751224931e-07
others O 0 6.486901327207306e-08
were O 0 1.1069114513873046e-08
minute O 0 5.3267061872475097e-08
deletions O 0 3.1497242503064626e-07
, O 0 2.73886424650982e-08
4649delA O 0 7.134808015507588e-07
in O 0 1.932961879447248e-08
exon O 0 1.7975090713662212e-06
33 O 0 1.6304973371461529e-07
and O 0 1.896160917169709e-08
7883del5 O 0 1.5213016695270198e-06
in O 0 1.6736424868213362e-07
exon O 0 4.57492824352812e-05
55 O 0 6.4948021645250265e-06
. O 0 1.569690311953309e-06

The O 0 2.3192108073999407e-06
mutations O 0 2.4352810214622878e-05
4612del165 O 0 1.0457768439664505e-05
and O 0 6.168323096744643e-08
7883del5 O 0 3.7754537061118754e-06
were O 0 5.04776629384196e-08
found O 0 1.755998368935252e-08
in O 0 2.146254951540527e-09
more O 0 3.5936958964200016e-10
than O 0 6.741368019369531e-10
two O 0 1.0152277907238272e-09
unrelated O 0 4.177982049213824e-08
families O 0 1.5743962800129907e-09
; O 0 2.3251298664206388e-09
44 O 0 9.997212835344271e-09
% O 0 9.709032466886924e-10
( O 0 1.4662004943488682e-09
7 O 0 1.3765439454971329e-08
of O 0 1.3496816997360384e-09
16 O 0 1.5131705666249218e-08
) O 0 5.016203563634747e-10
of O 0 3.6199754305243914e-10
the O 0 2.319522129923257e-09
mutant O 0 8.696640918515186e-08
alleles O 0 1.2493191370310797e-08
had O 0 1.4732571607112277e-08
one O 0 7.070312113555133e-10
of O 0 5.865833929696862e-10
the O 0 1.2138045235587924e-08
two O 0 1.6452284512524784e-07
mutations O 0 1.782680192263797e-05
. O 0 1.6710139334463747e-06

The O 0 1.88116814570094e-06
4612del165 O 0 2.2617865397478454e-05
mutations O 0 4.620752406481188e-06
in O 0 2.470160964662682e-08
three O 0 2.5747497467421e-09
different O 0 5.509085410082548e-10
families O 0 1.1268777022621634e-09
were O 0 2.0028012581718713e-09
all O 0 2.2540778965574049e-10
ascribed O 0 1.278326511311434e-08
to O 0 5.307755901462485e-10
the O 0 3.1657581001098833e-09
same O 0 3.4454696873353896e-08
T O 0 5.119614797877148e-05
- O 0 2.2297124360193266e-06
- O 0 5.719911655432952e-07
> O 0 2.317887215497194e-08
A O 0 4.936703934532716e-09
substitution O 0 2.4558921563055947e-09
at O 0 6.71450006706209e-09
the O 0 2.4898418882202122e-09
splice O 0 3.9012070374155883e-07
donor O 0 2.0842347225880076e-07
site O 0 3.7102310557202145e-07
in O 0 1.3726653946832812e-07
intron O 0 0.00012344516289886087
33 O 0 4.90563752464368e-06
. O 0 1.9158301256538834e-06

Microsatellite O 0 0.0005075230728834867
genotyping O 0 5.417140346253291e-05
around O 0 2.801799894314172e-07
the O 0 6.20718836330525e-08
ATM O 0 1.09482352854684e-05
locus O 0 1.3172152648621704e-05
also O 0 6.14504983786901e-07
indicated O 0 1.01882665148878e-06
that O 0 3.3250602271550633e-09
a O 0 4.987616009088924e-08
common O 0 1.0316806253740651e-07
haplotype O 0 7.587292202515528e-06
was O 0 2.192152578572859e-06
shared O 0 5.309459538693773e-09
by O 0 2.8343432045829786e-09
the O 0 1.1845023628609397e-08
mutant O 0 2.6629868443706073e-07
alleles O 0 3.9387096251175535e-08
in O 0 2.7433079807792637e-08
both O 0 1.651150967063586e-07
mutations O 0 2.924436194007285e-05
. O 0 2.3819288799131755e-06

This O 0 1.0163616934733e-06
suggests O 0 3.4279361216249526e-07
that O 0 1.5661240082565087e-09
these O 0 3.9043737687372015e-10
two O 0 8.22550649814957e-09
founder O 0 5.686630629497813e-06
mutations O 0 6.596903858735459e-06
may O 0 1.2933880100263195e-07
be O 0 6.055387302694726e-09
predominant O 0 8.056189670924141e-08
among O 0 1.960527562516745e-08
Japanese O 0 6.963637702028791e-07
ATM O 0 5.359344504540786e-05
mutant O 0 5.089084879728034e-05
alleles O 0 1.3321268852450885e-05
. O 0 3.3189899113494903e-06

W474C O 0 0.0001440757914679125
amino O 0 4.01314218834159e-06
acid O 0 1.4019741456650081e-06
substitution O 0 7.044097571906605e-08
affects O 0 3.938604464792661e-08
early O 0 1.0852244436421188e-08
processing O 0 5.719538176407468e-09
of O 0 4.961300814620984e-10
the O 0 1.7442207678186605e-09
alpha O 0 1.4539090820164802e-08
- O 0 2.1041456577108875e-08
subunit O 0 6.429754506598329e-09
of O 0 1.5087892046850016e-09
beta O 0 2.3953273853294377e-07
- O 0 5.450175422083703e-07
hexosaminidase O 0 1.1673387234623078e-06
A O 0 4.592494349253684e-07
and O 0 6.350679626621059e-08
is O 0 1.0688994223073678e-07
associated O 0 2.734198858433956e-07
with O 0 9.053375151779619e-07
subacute O 1 0.9209295511245728
G B-Disease 0 0.054291799664497375
( I-Disease 0 6.263166483222449e-07
M2 I-Disease 0 0.0031591635197401047
) I-Disease 0 9.360127819491026e-07
gangliosidosis I-Disease 0 0.00022917171008884907
. O 0 3.852187546726782e-06

Mutations O 0 0.00025947371614165604
in O 0 5.001663225812081e-07
the O 0 9.57915844423951e-08
HEXA O 0 8.046755101531744e-05
gene O 0 2.6948319487019035e-07
, O 0 7.476606000977881e-09
encoding O 0 1.1176845227112153e-08
the O 0 1.0604694899996048e-08
alpha O 0 4.480687465502342e-08
- O 0 4.233928052599367e-08
subunit O 0 2.363792539483711e-08
of O 0 6.729911739000727e-09
beta O 0 7.839976774448587e-07
- O 0 1.6219053122767946e-06
hexosaminidase O 0 1.2206090787003632e-06
A O 0 2.676419512681605e-07
( O 0 4.560291699817753e-09
Hex O 0 1.8121671985227294e-07
A O 0 6.359127979749246e-08
) O 0 2.818520528080626e-09
, O 0 3.341934284861736e-09
that O 0 1.4573844353549248e-09
abolish O 0 1.5555673371636658e-07
Hex O 0 4.666515565077134e-07
A O 0 3.7995206980667717e-07
enzyme O 0 1.3369048019740148e-06
activity O 0 7.05382990418002e-06
cause O 0 0.005287065636366606
Tay B-Disease 1 0.9999731779098511
- I-Disease 1 0.9999364614486694
Sachs I-Disease 1 0.9999288320541382
disease I-Disease 1 0.9934431314468384
( O 0 3.595283430968266e-07
TSD B-Disease 0 0.0004431838169693947
) O 0 6.848527789315995e-08
, O 0 7.445131444683284e-08
the O 0 7.870181661928655e-07
fatal O 0 0.20899580419063568
infantile B-Disease 0 0.0020217609126120806
form I-Disease 0 6.658660822722595e-07
of I-Disease 0 2.357628972049497e-07
G I-Disease 0 0.00017903973639477044
( I-Disease 0 4.4733354798154323e-08
M2 I-Disease 0 6.862111331429332e-05
) I-Disease 0 4.9431140070055335e-08
gangliosidosis I-Disease 0 1.3017886885791086e-05
, I-Disease 0 2.0765209285400488e-07
Type I-Disease 0 1.1384022400307003e-05
1 I-Disease 0 4.01125953430892e-06
. O 0 1.570602194078674e-06

Less O 0 0.00016386825882364064
severe O 1 0.9583746194839478
, O 0 1.6583722754148766e-05
subacute O 1 0.9469856023788452
( O 0 6.518400186905637e-05
juvenile O 1 0.9981322884559631
- O 1 0.8891178369522095
onset O 1 0.829662561416626
) O 0 9.588368357071886e-07
and O 0 4.308947154640919e-06
chronic O 1 0.9849890470504761
( O 0 2.8940624474671495e-07
adult O 0 1.3226494047557935e-05
- O 0 0.010435342788696289
onset O 0 0.0031909144017845392
) O 0 2.0634676189956735e-08
variants O 0 7.324143780351733e-08
are O 0 4.580289036937302e-09
characterized O 0 3.5891787319997093e-07
by O 0 7.99309596288822e-09
a O 0 3.5511270368715486e-08
broad O 0 1.0958495977320126e-07
spectrum O 0 7.685773084631364e-07
of O 0 2.3917749558677315e-08
clinical O 0 3.7828060612810077e-06
manifestations O 0 1.918528823807719e-06
and O 0 7.373792243470234e-08
are O 0 6.514822015191157e-09
associated O 0 1.0975648478961375e-07
with O 0 1.926454551437473e-08
residual O 0 7.63011757953791e-06
levels O 0 8.722894335733145e-07
of O 0 1.6223241416923884e-08
Hex O 0 1.6043923096731305e-06
A O 0 1.4055257224754314e-06
enzyme O 0 3.3969008654821664e-06
activity O 0 1.7879366396300611e-06
. O 0 1.2746035054078675e-06

We O 0 2.339791080885334e-06
identified O 0 2.7326761937729316e-06
a O 0 1.5227531093842117e-06
1422 O 0 0.00038869850686751306
G O 0 0.0004113466420676559
- O 0 5.339199924492277e-05
- O 0 1.0169503184442874e-05
> O 0 5.709022730115976e-07
C O 0 1.743520670061116e-07
( O 0 3.1187765703322157e-09
amino O 0 1.019711248773092e-08
acid O 0 4.4229484075231085e-08
W474C O 0 2.1220488477524668e-08
) O 0 2.2027485391262758e-10
substitution O 0 5.089932919588591e-10
in O 0 3.809145221467247e-10
the O 0 6.329909929547739e-10
first O 0 2.2805755062194066e-09
position O 0 1.1029999136269453e-08
of O 0 1.8478739649552267e-09
exon O 0 4.41994671973589e-07
13 O 0 2.2895287443702728e-08
of O 0 3.10518410984173e-09
HEXA O 0 2.2267873646342196e-05
of O 0 6.000441921116817e-09
a O 0 1.8188052308687475e-07
non O 0 2.886116305944597e-07
- O 0 1.3478717846737709e-05
Jewish O 0 9.468187158745422e-07
proband O 0 8.619235450169072e-05
who O 0 5.315907287695154e-07
manifested O 0 2.388726215940551e-06
a O 0 3.044620143555221e-06
subacute O 0 0.004893224220722914
variant O 0 0.00023145634622778744
of O 0 1.7840820873971097e-06
G B-Disease 0 0.0020129333715885878
( I-Disease 0 4.737823928735452e-07
M2 I-Disease 0 0.0021699147764593363
) I-Disease 0 6.345207452795876e-07
gangliosidosis I-Disease 0 0.00029616343090310693
. O 0 3.1629942895960994e-06

On O 0 2.7141109057993162e-06
the O 0 5.222911454438872e-07
second O 0 2.5838037345238263e-06
maternally O 0 6.669280264759436e-05
inherited O 0 0.0010683571454137564
allele O 0 5.100500402477337e-06
, O 0 1.4485951282949827e-07
we O 0 2.44111717506712e-08
identified O 0 1.123164352634376e-07
the O 0 9.155484548273307e-08
common O 0 2.3470465748687275e-05
infantile O 1 0.9978333115577698
disease O 1 0.9993656277656555
- O 0 0.03040005825459957
causing O 0 0.0001295348338317126
4 O 0 5.323493041942129e-06
- O 0 4.139267184655182e-05
bp O 0 2.2351284769683843e-06
insertion O 0 2.2487044759600394e-07
, O 0 2.976294055656581e-08
+ O 0 7.778699000482447e-07
TATC O 0 4.943895328324288e-05
1278 O 0 4.723180609289557e-05
, O 0 6.668403074172602e-08
in O 0 1.3953020072676736e-07
exon O 0 3.297754665254615e-05
11 O 0 4.642811745725339e-06
. O 0 1.7051178247129428e-06

Pulse O 0 0.0005793916643597186
- O 0 8.015287312446162e-05
chase O 0 4.435931714397157e-06
analysis O 0 1.0720783905071585e-07
using O 0 6.402869701105374e-08
proband O 0 9.317759577243123e-06
fibroblasts O 0 7.855836656744941e-07
revealed O 0 1.1313717322991579e-06
that O 0 2.181667513312391e-09
the O 0 6.831486487612892e-09
W474C O 0 5.799402629236283e-07
- O 0 2.4786234575913113e-07
containing O 0 1.3004102683566998e-08
alpha O 0 4.7202892261566376e-08
- O 0 5.2350490165054e-08
subunit O 0 1.9021813457698045e-08
precursor O 0 6.359758941698601e-08
was O 0 1.1444826242268391e-07
normally O 0 1.106341596113225e-08
synthesized O 0 2.6526091545520103e-08
, O 0 3.800583847635153e-09
but O 0 1.4212366838961543e-09
not O 0 3.4405869819842394e-10
phosphorylated O 0 7.311494520934048e-09
or O 0 1.6696506399682676e-09
secreted O 0 1.2541515381769841e-08
, O 0 2.8874409530033063e-09
and O 0 2.3396145021337134e-09
the O 0 1.5191567115380167e-08
mature O 0 3.5766899486588954e-07
lysosomal O 0 2.873957419069484e-05
alpha O 0 1.31841284201073e-06
- O 0 1.700238385637931e-06
subunit O 0 5.80774326408573e-07
was O 0 3.6182373150950298e-06
not O 0 5.588220730601279e-08
detected O 0 9.627359759178944e-06
. O 0 6.220403179213463e-07

When O 0 2.8888969154650113e-06
the O 0 1.5218385840398696e-07
W474C O 0 1.7479737834946718e-06
- O 0 4.319436754940398e-07
containing O 0 2.0500978692439276e-08
alpha O 0 6.55743548350074e-08
- O 0 8.64192557514798e-08
subunit O 0 6.031091004388145e-08
was O 0 3.5555027011469065e-07
transiently O 0 5.02490877352102e-07
co O 0 9.47011983498669e-07
- O 0 4.408513234466227e-07
expressed O 0 2.668109511105854e-09
with O 0 1.196929000357727e-09
the O 0 4.703310185760756e-09
beta O 0 4.60002489433009e-08
- O 0 3.1002148404013496e-08
subunit O 0 5.776261691181617e-09
to O 0 6.241123173822416e-10
produce O 0 5.273478986822511e-09
Hex O 0 2.220271113628769e-07
A O 0 1.6683645753801102e-07
( O 0 1.4407138593242053e-08
alphabeta O 0 1.3508614529200713e-06
) O 0 8.624944314306049e-09
in O 0 2.798263665226841e-08
COS O 0 1.9200670067220926e-05
- O 0 2.1650807866535615e-06
7 O 0 9.45020204312641e-08
cells O 0 2.0962662716783598e-08
, O 0 9.22019460780632e-10
the O 0 1.2645948732625811e-09
mature O 0 2.0202051587148162e-08
alpha O 0 2.501109364061449e-08
- O 0 6.13786852454723e-08
subunit O 0 2.7333532770512647e-08
was O 0 1.3675749244157487e-07
present O 0 3.0378324300528448e-09
, O 0 1.4776634360558205e-09
but O 0 3.4879826804612435e-10
its O 0 9.062025574380073e-10
level O 0 4.1628048563779885e-08
was O 0 4.3592928022917476e-07
much O 0 3.9816709929141325e-09
lower O 0 1.2603447885339847e-07
than O 0 1.0720223597715517e-09
that O 0 2.0535319278369712e-10
from O 0 7.8517042867432e-10
normal O 0 1.947371863764147e-08
alpha O 0 2.4793509467713193e-08
- O 0 6.465408119993299e-08
subunit O 0 4.131591424538783e-08
transfections O 0 5.656615940097254e-07
, O 0 4.077408188862819e-09
although O 0 2.704791501884074e-09
higher O 0 8.222197145357768e-09
than O 0 8.269028795027111e-10
in O 0 1.3318828262498528e-09
those O 0 6.429395904561375e-10
cells O 0 8.174722232467957e-09
transfected O 0 1.027378075946217e-07
with O 0 2.865397030760164e-09
an O 0 1.5452387813752466e-08
alpha O 0 1.9762742908824293e-07
- O 0 7.547115501438384e-07
subunit O 0 2.5535993586345285e-07
associated O 0 3.0045279686419235e-07
with O 0 8.445662729172909e-07
infantile O 0 0.27765533328056335
TSD B-Disease 0 0.10223986953496933
. O 0 1.9429442545515485e-05

Furthermore O 0 8.00053294369718e-06
, O 0 1.1080609851887857e-07
the O 0 2.375598384674049e-08
precursor O 0 3.130895720460103e-07
level O 0 7.22533783914514e-08
of O 0 1.5243106776807736e-09
the O 0 5.95031757200104e-09
W474C O 0 1.3885281191505783e-07
alpha O 0 4.6049056123820264e-08
- O 0 7.180727834565914e-08
subunit O 0 2.7613721087504928e-08
was O 0 1.9028931319553521e-07
found O 0 4.3019543483069356e-09
to O 0 4.899433636573747e-10
accumulate O 0 6.424706100460753e-08
in O 0 1.8325112538519761e-09
comparison O 0 2.0338404294051315e-09
to O 0 2.0208698603418895e-10
the O 0 2.1226305157995284e-09
normal O 0 5.682418091623731e-08
alpha O 0 5.532446323286422e-08
- O 0 3.8476608210658014e-07
subunit O 0 2.750741145973734e-07
precursor O 0 1.2909620181744685e-06
levels O 0 3.2763057333795587e-06
. O 0 6.216939709702274e-07

We O 0 1.4231940212994232e-06
conclude O 0 6.404946475413453e-07
that O 0 1.8305104987348386e-08
the O 0 7.96351713461263e-08
1422 O 0 7.204889698186889e-05
G O 0 0.00012596871238201857
- O 0 1.7926637156051584e-05
- O 0 9.194785889121704e-06
> O 0 7.186948209891852e-07
C O 0 1.2396440070006065e-06
mutation O 0 4.563992206385592e-07
is O 0 1.6726477980455456e-08
the O 0 6.770764837682464e-09
cause O 0 1.3668224596585787e-07
of O 0 2.8367187709932296e-08
Hex B-Disease 0 6.814351945649832e-05
A I-Disease 0 0.008886344730854034
enzyme I-Disease 1 0.999638557434082
deficiency I-Disease 1 0.9999610185623169
in O 0 1.6770582078606822e-06
the O 0 1.5631128462700872e-06
proband O 0 0.002616122830659151
. O 0 6.3488723753835075e-06

The O 0 6.130071028564998e-07
resulting O 0 5.990987119730562e-07
W474C O 0 1.3830385796609335e-06
substitution O 0 8.591339195618275e-08
clearly O 0 5.291870408541399e-08
interferes O 0 6.757672110779822e-08
with O 0 5.986403817104247e-09
alpha O 0 5.9060642598751656e-08
- O 0 5.919778445218071e-08
subunit O 0 1.4058105790581976e-08
processing O 0 2.9795884870509326e-08
, O 0 5.109193956798208e-09
but O 0 2.2886761374962816e-09
because O 0 1.2582145325623628e-09
the O 0 9.702479930595587e-10
base O 0 2.6100352101821045e-08
substitution O 0 1.5565060351718785e-08
falls O 0 1.7960165905606118e-06
at O 0 3.756035127366886e-08
the O 0 3.626916100785138e-09
first O 0 4.412119558594441e-09
position O 0 1.5946458375992734e-08
of O 0 1.6244722234048936e-09
exon O 0 1.0321082299924456e-06
13 O 0 5.239703781967364e-08
, O 0 4.10145517548699e-09
aberrant O 0 1.1597592930456813e-07
splicing O 0 8.126158945742645e-07
may O 0 2.5126072955572454e-07
also O 0 5.062187113935579e-09
contribute O 0 4.808055287242041e-09
to O 0 1.4502200329502557e-08
Hex B-Disease 0 4.1405699448660016e-05
A I-Disease 0 0.0008681454928591847
deficiency I-Disease 1 0.5814257860183716
in O 0 1.0851627507690864e-07
this O 0 2.3123496006860478e-08
proband O 0 4.1116767533821985e-05
. O 0 1.581714883513996e-07
. O 0 6.808945158809365e-07

Two O 0 3.3610162972763646e-06
frequent O 0 7.227143214549869e-05
missense O 0 0.006618916057050228
mutations O 0 0.1434708833694458
in O 0 0.012662898749113083
Pendred B-Disease 1 0.9998866319656372
syndrome I-Disease 1 0.9999898672103882
. O 0 0.0007175198406912386

Pendred B-Disease 1 0.9997058510780334
syndrome I-Disease 1 0.9999927282333374
is O 0 0.00931398943066597
an O 0 0.10717841237783432
autosomal B-Disease 1 0.9999939203262329
recessive I-Disease 1 0.9999988079071045
disorder I-Disease 1 0.9999998807907104
characterized O 1 0.9976396560668945
by O 0 0.00025405679480172694
early O 0 0.27842065691947937
childhood O 1 0.9996521472930908
deafness B-Disease 1 0.9999977350234985
and O 1 0.9960021376609802
goiter B-Disease 1 0.9999899864196777
. O 0 0.0020669223740696907

A O 0 7.704010386078153e-06
century O 0 7.944763069644978e-07
after O 0 2.8057732492925425e-07
its O 0 1.0237237724197712e-08
recognition O 0 8.785436023117654e-08
as O 0 5.841333177158958e-07
a O 0 0.000337704987032339
syndrome O 1 0.9922267198562622
by O 0 6.895636062154153e-08
Vaughan O 0 2.8753079277521465e-06
Pendred O 0 4.172279659542255e-05
, O 0 1.0620730961363734e-07
the O 0 1.065538185685e-06
disease O 0 0.050182096660137177
gene O 0 3.0442777188000036e-06
( O 0 9.692463009969288e-08
PDS O 0 0.0001727190538076684
) O 0 3.270652726428125e-08
was O 0 1.1310254421914578e-06
mapped O 0 6.47901174488652e-07
to O 0 3.48470123867628e-08
chromosome O 0 4.4281536247581244e-05
7q22 O 0 6.850630597909912e-05
- O 0 0.0003432819794397801
q31 O 0 8.309293480124325e-05
. O 0 2.203762960562017e-06

1 O 0 3.2512307370780036e-06
and O 0 1.6495519616910315e-07
, O 0 1.891324927782989e-07
recently O 0 8.964983862824738e-06
, O 0 2.4477330384797824e-08
found O 0 8.397104345192474e-09
to O 0 9.65888480308763e-10
encode O 0 2.8453726486077358e-08
a O 0 1.2065875125699677e-06
putative O 0 4.4247510231798515e-05
sulfate O 0 0.0016450686380267143
transporter O 0 0.005383548326790333
. O 0 4.448458639672026e-06

We O 0 1.0402129646536196e-06
performed O 0 1.4119865454631508e-06
mutation O 0 1.203826741402736e-06
analysis O 0 2.5783236878851312e-08
of O 0 5.320296647681744e-09
the O 0 6.199969959652663e-08
PDS B-Disease 0 9.242641681339592e-05
gene O 0 1.2703778793365927e-06
in O 0 2.2843384783755027e-07
patients O 0 9.183360702991195e-07
from O 0 1.8543325097652996e-08
14 O 0 8.111774718599918e-08
Pendred B-Disease 0 1.3240666021374636e-06
families O 0 4.9403592328189916e-09
originating O 0 1.7593711376662213e-08
from O 0 6.30064311835099e-09
seven O 0 2.754274808225432e-09
countries O 0 3.1994218385733575e-10
and O 0 9.430427994061574e-09
identified O 0 3.8783821310062194e-07
all O 0 6.134907692967317e-08
mutations O 0 2.0970092009520158e-05
. O 0 1.3970958434583736e-06

The O 0 1.7061312291843933e-06
mutations O 0 9.253512871509884e-06
include O 0 8.062799849994917e-08
three O 0 2.3459790554625215e-08
single O 0 8.841768561751451e-08
base O 0 2.7304619720780465e-07
deletions O 0 2.1480873613199947e-07
, O 0 9.74794822639069e-09
one O 0 8.153886454920212e-09
splice O 0 8.420313406531932e-07
site O 0 1.8926037910205196e-06
mutation O 0 1.21537493669166e-06
and O 0 5.8673055747249236e-08
10 O 0 9.704834837975795e-07
missense O 0 0.00015152373816818
mutations O 0 0.0002845393610186875
. O 0 6.147479780338472e-06

One O 0 1.1410150364099536e-05
missense O 0 0.00034227289143018425
mutation O 0 5.078371032141149e-05
( O 0 8.913426796652857e-08
L236P O 0 2.8216579721629387e-06
) O 0 3.1067969530340633e-08
was O 0 1.1183134347447776e-06
found O 0 1.217440104284151e-08
in O 0 7.242098476467618e-09
a O 0 6.953563769229731e-08
homozygous O 0 1.2039066632496542e-07
state O 0 1.7168984456361613e-08
in O 0 3.3146185796084637e-09
two O 0 3.7199434643753193e-09
consanguineous O 0 1.2230583479322377e-06
families O 0 9.536350376038172e-09
and O 0 8.374999360682978e-09
in O 0 7.876321816979726e-09
a O 0 4.181234558586766e-08
heterozygous O 0 3.106815071873825e-08
state O 0 7.041676575170186e-09
in O 0 2.344488159167213e-09
five O 0 2.2355182149880193e-09
additional O 0 5.60565016627379e-09
non O 0 3.928146838916291e-07
- O 0 8.099382102955133e-05
consanguineous O 0 6.647918780799955e-05
families O 0 6.176082365527691e-07
. O 0 1.5822595287318109e-06

Another O 0 2.1091653252369724e-05
missense O 0 0.0003604611265473068
mutation O 0 5.343433076632209e-05
( O 0 2.0753172691456712e-07
T416P O 0 4.354453722044127e-06
) O 0 4.381812601650381e-08
was O 0 1.662991962803062e-06
found O 0 1.4939052661588903e-08
in O 0 4.00720923110498e-09
a O 0 3.047060559424608e-08
homozygous O 0 6.242391492605748e-08
state O 0 1.4542862913913268e-08
in O 0 4.870152725544585e-09
one O 0 4.290392041639279e-09
family O 0 3.1398176503216746e-08
and O 0 3.769569101308434e-09
in O 0 4.478310611233383e-09
a O 0 3.382348978675509e-08
heterozygous O 0 7.046502759067153e-08
state O 0 1.8163969883744358e-08
in O 0 7.646876021283333e-09
four O 0 3.597930842147434e-08
families O 0 6.959083975743852e-08
. O 0 6.768842695237254e-07

Pendred B-Disease 0 0.011099040508270264
patients O 0 0.0001664782321313396
in O 0 3.2573805697211355e-07
three O 0 5.71190987841419e-08
non O 0 4.189193703041383e-07
- O 0 1.1524177352839615e-05
consanguineous O 0 9.272134775528684e-06
families O 0 1.6550252723845915e-08
were O 0 1.539364191671666e-08
shown O 0 2.13484092626004e-08
to O 0 1.6399319680004965e-09
be O 0 5.883181941612747e-09
compound O 0 2.1812240902363556e-07
heterozygotes O 0 3.5267100884084357e-07
for O 0 1.959346285218544e-08
L236P O 0 3.877552444464527e-06
and O 0 4.209196617921407e-07
T416P O 0 7.75062435423024e-05
. O 0 5.591793524217792e-06

In O 0 3.4429740480845794e-07
total O 0 3.674223236771468e-08
, O 0 1.3008369492695238e-08
one O 0 5.597348806674063e-09
or O 0 3.081225274925714e-09
both O 0 1.1878636962947553e-09
of O 0 9.79548886448356e-10
these O 0 1.1146757961100207e-09
mutations O 0 5.540123382274942e-08
were O 0 4.415571019933395e-09
found O 0 6.391104978575868e-09
in O 0 1.8177824800957865e-09
nine O 0 3.207666354754224e-09
of O 0 1.1442982117415568e-09
the O 0 2.2348542572103725e-08
14 O 0 1.2077151723133284e-07
families O 0 6.082847647803646e-08
analyzed O 0 3.2934256068983814e-06
. O 0 1.0659548479452496e-06

The O 0 2.201667683721098e-07
identification O 0 8.572891374569735e-08
of O 0 1.0815174533718164e-08
two O 0 4.5609638732457825e-08
frequent O 0 6.4337891672039405e-06
PDS B-Disease 0 0.005292856600135565
mutations O 0 4.5519182094722055e-06
will O 0 8.168098197813833e-09
facilitate O 0 1.3713681745741724e-08
the O 0 2.674954941994656e-07
molecular O 0 0.0004878280742559582
diagnosis O 0 0.4831952452659607
of O 0 0.0008402569219470024
Pendred B-Disease 1 0.9999626874923706
syndrome I-Disease 1 0.9999953508377075
. O 0 0.00026882809470407665

Insertional O 0 0.002447603503242135
mutation O 0 8.988284389488399e-05
by O 0 1.7934938512098597e-07
transposable O 0 1.4005127923155669e-05
element O 0 1.0237920378131093e-06
, O 0 1.0476234280076824e-07
L1 O 0 1.921079820021987e-05
, O 0 3.054508823652213e-08
in O 0 3.283773253315303e-08
the O 0 2.0861713778685953e-07
DMD B-Disease 1 0.9334922432899475
gene O 0 4.478757546166889e-06
results O 0 3.1351255529443733e-06
in O 0 2.684630317162373e-06
X B-Disease 1 0.9175038933753967
- I-Disease 1 0.9978578686714172
linked I-Disease 1 0.9751778841018677
dilated I-Disease 1 0.9968087077140808
cardiomyopathy I-Disease 1 0.9999085664749146
. O 0 7.672073843423277e-05

X B-Disease 1 0.9932041168212891
- I-Disease 1 0.9972255825996399
linked I-Disease 1 0.9917153716087341
dilated I-Disease 1 0.9981192946434021
cardiomyopathy I-Disease 1 0.9999659061431885
( O 0 4.079427981196204e-06
XLDCM B-Disease 0 0.0038324485067278147
) O 0 8.254334460389146e-08
is O 0 5.794936086545022e-08
a O 0 2.9318931638044887e-07
clinical O 0 6.896450940985233e-06
phenotype O 0 2.4756402581260772e-06
of O 0 2.0510601217438307e-08
dystrophinopathy B-Disease 0 0.00038661551661789417
which O 0 7.488540063604887e-07
is O 0 1.4388415081612038e-07
characterized O 0 1.245134512828372e-06
by O 0 3.9368018178720376e-08
preferential O 0 3.479532097117044e-06
myocardial B-Disease 1 0.9983224272727966
involvement I-Disease 0 2.3263670300366357e-05
without O 0 1.7582547684469318e-07
any O 0 3.1514755249872906e-08
overt O 0 3.0172070637490833e-06
clinical O 0 0.0003092501137871295
signs O 0 0.001087593729607761
of O 0 0.0001615818327991292
skeletal B-Disease 1 0.9999632835388184
myopathy I-Disease 1 0.9999977350234985
. O 0 0.0022058349568396807

To O 0 1.749972540210365e-07
date O 0 6.174763029775931e-07
, O 0 1.5000324538050336e-08
several O 0 2.1590334853271997e-08
mutations O 0 1.1166061995027121e-06
in O 0 7.915195254781793e-08
the O 0 2.974523113152827e-06
Duchenne B-Disease 1 0.9994839429855347
muscular I-Disease 1 0.9996451139450073
dystrophy I-Disease 1 0.9993559718132019
gene O 0 0.0005580481374636292
, O 0 4.882497705693822e-06
DMD O 1 0.9993659853935242
, O 0 6.071511506888783e-07
have O 0 3.357410349735801e-08
been O 0 2.6060661184601486e-07
identified O 0 5.450705202747486e-07
in O 0 2.1546465234223433e-07
patients O 0 8.40125494505628e-07
with O 0 5.425325610985965e-08
XLDCM B-Disease 0 0.001953648403286934
, O 0 7.370332610889818e-08
but O 0 5.413828052525105e-09
a O 0 1.6680218095643795e-08
pathogenic O 0 5.975055472617896e-08
correlation O 0 9.703465586596849e-09
of O 0 2.1084070045418457e-09
these O 0 3.8306260385923e-09
cardiospecific O 0 2.539410888857674e-05
mutations O 0 7.010961780906655e-06
in O 0 2.472801270414493e-07
DMD O 1 0.9393285512924194
with O 0 1.66164781489897e-07
the O 0 8.080926363618346e-07
XLDCM B-Disease 0 0.006653694901615381
phenotype O 0 0.0001417806197423488
has O 0 8.661807555654377e-07
remained O 0 2.4472346922266297e-06
to O 0 1.5861825630736348e-08
be O 0 1.2347410915936052e-07
elucidated O 0 2.118747215718031e-05
. O 0 1.1409205171730719e-06

We O 0 2.942426817753585e-06
report O 0 1.8464996287548274e-07
here O 0 9.701355274671641e-09
the O 0 2.592227765774169e-09
identification O 0 5.470690567221936e-09
of O 0 2.4180337732104817e-09
a O 0 7.295255244343934e-08
unique O 0 3.790898972511059e-08
de O 0 1.581137212269823e-06
novo O 0 7.477278813894372e-07
L1 O 0 1.5613459254382178e-06
insertion O 0 1.40189371222732e-07
in O 0 1.783576486502625e-08
the O 0 1.6390071522209837e-08
muscle O 0 2.1158384697628208e-06
exon O 0 5.376022727432428e-06
1 O 0 2.906281793002563e-07
in O 0 2.4958967514976393e-07
DMD O 1 0.9944717884063721
in O 0 4.1035551134882553e-07
three O 0 1.7917962225055817e-07
XLDCM B-Disease 0 0.001193222589790821
patients O 0 1.708814806988812e-06
from O 0 1.9923133365296053e-08
two O 0 2.169609736313305e-08
unrelated O 0 3.5231471429142402e-06
Japanese O 0 5.57798784939223e-06
families O 0 5.461736805045803e-07
. O 0 3.205826260455069e-06

The O 0 9.210602911480237e-07
insertion O 0 7.108054887794424e-06
was O 0 6.884826234454522e-06
a O 0 2.518110022720066e-07
5 O 0 2.0467072658902907e-07
- O 0 1.6808897953524138e-06
truncated O 0 3.164226995977515e-07
form O 0 1.7609959712672207e-08
of O 0 3.169328577357078e-09
human O 0 1.3469614756900228e-08
L1 O 0 9.627144663681975e-07
inversely O 0 3.5510802831595356e-07
integrated O 0 5.501582336364663e-07
in O 0 1.8615120112031036e-08
the O 0 2.1525737636807207e-08
5 O 0 3.4059075915138237e-07
- O 0 4.693813934864011e-06
untranslated O 0 2.643231027832371e-06
region O 0 2.5635006295487983e-07
in O 0 1.5726683955108456e-08
the O 0 3.2065120336710606e-08
muscle O 0 1.99939950107364e-06
exon O 0 3.4212837363156723e-06
1 O 0 1.9563670150546386e-07
, O 0 9.753136964718578e-09
which O 0 3.1119968824100397e-09
affected O 0 4.8205799352274425e-09
the O 0 1.4297932837692429e-09
transcription O 0 3.7595903279452614e-08
or O 0 6.3989604726089055e-09
the O 0 6.894752324626552e-09
stability O 0 7.731043893954848e-08
of O 0 5.2191242438937024e-09
the O 0 7.96722403606509e-08
muscle O 0 1.8823004666046472e-06
form O 0 8.252865946190013e-09
of O 0 2.076435912101715e-09
dystrophin O 0 1.9209107904316625e-06
transcripts O 0 2.6570708655526687e-07
but O 0 1.6512196054918604e-08
not O 0 9.940318568268935e-10
that O 0 3.156290784289695e-10
of O 0 1.1627950824433242e-09
the O 0 7.079332675630212e-08
brain O 0 0.0014751391718164086
or O 0 1.453818185837008e-07
Purkinje O 0 0.00015559910389129072
cell O 0 7.739516877336428e-05
form O 0 5.835275374010962e-07
, O 0 1.78047244503432e-07
probably O 0 1.5765026262215542e-07
due O 0 5.4514654124204753e-08
to O 0 6.454707324188291e-10
its O 0 1.887838108061146e-09
unique O 0 7.96196353292089e-09
site O 0 1.9557252528557e-07
of O 0 1.5018361665397606e-08
integration O 0 3.1111608223000076e-06
. O 0 1.8376226762484293e-06

We O 0 1.7322105350103811e-06
speculate O 0 4.40069158003098e-07
that O 0 3.590313379930876e-09
this O 0 9.759552055399467e-10
insertion O 0 3.1489459928479846e-08
of O 0 3.0765741065863494e-09
an O 0 1.4548688476168081e-08
L1 O 0 8.264230928034522e-06
sequence O 0 5.179292088541843e-07
in O 0 8.648270863886864e-07
DMD O 1 0.9970389604568481
is O 0 1.071491766424515e-07
responsible O 0 2.71239759541686e-08
for O 0 6.53657517002415e-10
some O 0 1.415700473517134e-10
of O 0 5.495474075800644e-10
the O 0 7.686269398732293e-09
population O 0 3.046030538911282e-09
of O 0 1.0582549059279245e-08
Japanese O 0 3.198616013833089e-06
patients O 0 1.4720022818437428e-06
with O 0 2.2967307700128003e-07
XLDCM B-Disease 0 0.007689758203923702
. O 0 9.747047897690209e-07
. O 0 1.2277960195206106e-06

Severe O 1 0.7226724624633789
early O 0 0.004055310506373644
- O 1 0.9957938194274902
onset O 1 0.9994978904724121
obesity B-Disease 1 0.9999783039093018
, O 0 0.026965681463479996
adrenal B-Disease 1 0.9999535083770752
insufficiency I-Disease 1 0.9999481439590454
and O 0 0.00030489746131934226
red O 0 0.42323777079582214
hair O 1 0.9772167205810547
pigmentation O 0 0.36214572191238403
caused O 0 0.0004071173898410052
by O 0 1.9388608052395284e-06
POMC O 0 0.05083680897951126
mutations O 0 0.00020790370763279498
in O 0 6.161586725283996e-07
humans O 0 1.5895493561401963e-06
. O 0 2.001925622607814e-06

Sequential O 0 1.5663345038774423e-05
cleavage O 0 3.585237209335901e-05
of O 0 5.269942349173107e-08
the O 0 3.153935068667124e-08
precursor O 0 9.338372706224618e-07
protein O 0 7.603304652548104e-07
pre O 0 2.948342080344446e-05
- O 0 3.8075428165029734e-05
pro O 0 2.830513949447777e-05
- O 0 7.370828097919002e-05
opiomelanocortin O 0 3.993594509665854e-05
( O 0 1.337377426580133e-07
POMC O 0 2.3829514248063788e-05
) O 0 2.2402915078600927e-08
generates O 0 5.604637465239648e-08
the O 0 9.684737989346104e-08
melanocortin O 0 0.00023933130432851613
peptides O 0 3.9021106204018e-06
adrenocorticotrophin O 0 2.7544778276933357e-05
( O 0 8.449919164377206e-08
ACTH O 0 6.153356935101328e-06
) O 0 1.845845964965065e-08
, O 0 2.524122599822931e-08
melanocyte O 0 2.293354191351682e-05
- O 0 5.236630386207253e-05
stimulating O 0 5.976030024612555e-06
hormones O 0 3.843651938950643e-06
( O 0 3.012917204614496e-08
MSH O 0 1.1159675523231272e-05
) O 0 8.178870913866376e-09
alpha O 0 2.0582435311666814e-08
, O 0 2.0440995562864828e-09
beta O 0 1.881304356743385e-08
and O 0 6.174485922549877e-10
gamma O 0 9.214397245216333e-09
as O 0 9.319738314417236e-10
well O 0 7.060393936164644e-10
as O 0 2.2995758630628416e-09
the O 0 9.692440627873111e-09
opioid O 0 1.0088641602123971e-06
- O 0 1.2595700127349119e-06
receptor O 0 5.92160802170838e-07
ligand O 0 1.9788703866652213e-06
beta O 0 1.5341665857704356e-05
- O 0 7.078093767631799e-05
endorphin O 0 0.0004795207059942186
. O 0 2.07235189009225e-06

While O 0 3.6463193282543216e-06
a O 0 9.958798727893736e-07
few O 0 1.7519697337320395e-07
cases O 0 1.984277844258031e-07
of O 0 4.7434213001906755e-07
isolated O 0 0.20007279515266418
ACTH B-Disease 1 0.9940692186355591
deficiency I-Disease 1 0.9993797540664673
have O 0 8.347777793460409e-07
been O 0 3.7384502320492174e-06
reported O 0 2.4156846848200075e-05
( O 0 1.9264111017491814e-07
OMIM O 0 0.0008556055254302919
201400 O 0 5.1604209147626534e-05
) O 0 4.200066072712616e-08
, O 0 5.008847381304804e-08
an O 0 1.4126143241810496e-06
inherited O 1 0.9818539023399353
POMC O 1 0.9891200065612793
defect O 0 0.1453523188829422
has O 0 2.186423444072716e-06
not O 0 2.5341707399206825e-08
been O 0 2.220095467464489e-07
described O 0 1.043500674313691e-06
so O 0 6.67323831748945e-08
far O 0 2.797266347442928e-07
. O 0 4.0877245055526146e-07

Recent O 0 1.0189597560383845e-05
studies O 0 6.376952796927071e-07
in O 0 7.285327541239894e-08
animal O 0 1.1824136691984677e-07
models O 0 7.461566298161415e-08
elucidated O 0 1.184165626000322e-06
a O 0 4.4332018944714946e-08
central O 0 4.4106659657927594e-08
role O 0 2.857135861233928e-08
of O 0 1.7196908785876985e-08
alpha O 0 1.9803146642516367e-06
- O 0 1.455638266634196e-05
MSH O 0 4.63723081338685e-05
in O 0 7.51999884585075e-09
the O 0 5.0647561700145616e-09
regulation O 0 3.2901869673196416e-08
of O 0 1.3440710766587927e-09
food O 0 1.2245758185258637e-08
intake O 0 5.7209380344147576e-08
by O 0 1.7276921004949486e-09
activation O 0 2.6577291478702136e-08
of O 0 4.478848403266511e-09
the O 0 1.9865349543124466e-07
brain O 0 0.00041951966704800725
melanocortin O 0 0.00021428108448162675
- O 0 2.2285124941845424e-05
4 O 0 8.262286428362131e-07
- O 0 4.800095211976441e-06
receptor O 0 1.837515810620971e-06
( O 0 7.909716259746347e-08
MC4 O 0 0.00018967673531733453
- O 0 3.0694238375872374e-05
R O 0 1.0322575690224767e-05
; O 0 5.426792348828258e-09
refs O 0 1.261063857782574e-07
3 O 0 4.403697317911792e-08
- O 0 3.849459062621463e-07
5 O 0 9.82738335153499e-09
) O 0 6.478746428228987e-10
and O 0 4.817847787386142e-10
the O 0 2.802374776678107e-09
linkage O 0 1.5884037907198945e-07
of O 0 1.944714433932404e-08
human O 0 4.030293894174974e-06
obesity B-Disease 1 0.9881195425987244
to O 0 8.434119180833477e-09
chromosome O 0 2.637915258674184e-06
2 O 0 3.416245064613577e-08
in O 0 9.382846499761399e-09
close O 0 2.7087683207582813e-08
proximity O 0 6.584004808019017e-08
to O 0 4.079757420782926e-09
the O 0 2.983011526680457e-08
POMC O 0 3.755548823392019e-05
locus O 0 6.903557618898049e-07
, O 0 9.765738440137284e-09
led O 0 1.6066316277374426e-08
to O 0 8.830383646518669e-10
the O 0 8.734338585725254e-09
proposal O 0 3.47062574235224e-08
of O 0 1.3713127300363226e-09
an O 0 2.669877297023504e-08
association O 0 1.1866058002851787e-07
of O 0 5.728570329210925e-08
POMC O 0 0.0006342351553030312
with O 0 2.309274805156747e-06
human O 0 0.0002919244871009141
obesity B-Disease 1 0.999650239944458
. O 0 1.2477717973524705e-05

The O 0 2.5470566811236495e-07
dual O 0 1.4660554370493628e-06
role O 0 1.0760174973256653e-06
of O 0 1.3980246649225592e-07
alpha O 0 7.10513404555968e-06
- O 0 4.514530883170664e-05
MSH O 0 0.00011199920845683664
in O 0 3.461251907310725e-08
regulating O 0 2.2194815585407923e-07
food O 0 3.588089825257157e-08
intake O 0 2.86014625316966e-07
and O 0 1.119933745741264e-08
influencing O 0 7.846140306355665e-07
hair O 0 0.03314293920993805
pigmentation O 0 0.0019166029524058104
predicts O 0 9.821455023484305e-06
that O 0 8.838307863356931e-09
the O 0 5.580913509106722e-08
phenotype O 0 1.7749551943779807e-06
associated O 0 7.251611577885342e-08
with O 0 4.068158077075168e-08
a O 0 1.9598641301854514e-05
defect O 0 0.0008220760500989854
in O 0 5.153336815055809e-07
POMC O 0 0.00034360549761913717
function O 0 9.778732419363223e-07
would O 0 2.2254711495861557e-07
include O 0 1.969657887457288e-06
obesity B-Disease 1 0.9993853569030762
, O 0 5.225442123446555e-07
alteration O 0 5.744141526520252e-05
in O 0 6.272596237977268e-06
pigmentation O 0 0.10228981822729111
and O 0 0.00043738397653214633
ACTH B-Disease 1 0.9968143105506897
deficiency I-Disease 1 0.9985260367393494
. O 0 1.1960465599258896e-05

The O 0 4.940380335938244e-07
observation O 0 3.950796781282406e-06
of O 0 5.598590036015594e-08
these O 0 5.00835035666114e-08
symptoms O 0 7.738379645161331e-05
in O 0 4.588965651919352e-08
two O 0 3.268501558295611e-08
probands O 0 1.553613219584804e-05
prompted O 0 2.4454539016005583e-07
us O 0 1.4883251076014403e-08
to O 0 1.0235651215495523e-09
search O 0 2.0272496570328258e-08
for O 0 1.0067015665526924e-08
mutations O 0 3.380466182534292e-07
within O 0 4.643005624416219e-08
their O 0 9.907543585541134e-08
POMC O 0 0.0007661000709049404
genes O 0 9.156136002275161e-06
. O 0 2.0832342215726385e-06

Patient O 0 0.0011009926674887538
1 O 0 4.299247848393861e-06
was O 0 2.7096111807622947e-05
found O 0 3.772563417214769e-08
to O 0 8.595903433494811e-10
be O 0 2.750374150650714e-09
a O 0 1.915952374531571e-08
compound O 0 9.32682269194629e-08
heterozygote O 0 1.248278778120948e-07
for O 0 1.3008784049972633e-09
two O 0 7.13362879878332e-09
mutations O 0 2.1912232739396131e-07
in O 0 3.1931218558156615e-08
exon O 0 5.8963955780200195e-06
3 O 0 2.201277027324977e-07
( O 0 2.090022199752184e-08
G7013T O 0 1.3409679695541854e-06
, O 0 4.2275857481399726e-08
C7133delta O 0 4.386355158203514e-06
) O 0 5.445435213857763e-09
which O 0 1.6231341826156154e-09
interfere O 0 5.7065494551977736e-09
with O 0 1.2342171729073925e-09
appropriate O 0 4.752637838834062e-09
synthesis O 0 4.9560664905357044e-08
of O 0 1.462626020298785e-08
ACTH O 0 1.5470692233066075e-05
and O 0 3.7511819073188235e-07
alpha O 0 2.588742063380778e-05
- O 0 0.0012330531608313322
MSH O 0 0.010749736800789833
. O 0 6.717257747368421e-06

Patient O 0 0.0009452066151425242
2 O 0 2.9180037017795257e-06
was O 0 2.001994289457798e-06
homozygous O 0 1.2898431123176124e-07
for O 0 2.3848270025439433e-09
a O 0 6.158824561453002e-08
mutation O 0 4.1433665387557994e-07
in O 0 2.996800674281985e-08
exon O 0 4.217351488478016e-06
2 O 0 3.240605224164028e-07
( O 0 4.949793819264414e-08
C3804A O 0 1.9624228571046842e-06
) O 0 3.4937389870037805e-08
which O 0 6.47345359539031e-08
abolishes O 0 5.880514800082892e-05
POMC O 0 0.001187720918096602
translation O 0 7.77914647187572e-06
. O 0 3.3783244361984544e-06

These O 0 1.7365361770771415e-07
findings O 0 8.440044751978348e-08
represent O 0 4.55014381728347e-09
the O 0 4.687529919777944e-09
first O 0 8.699722719995862e-09
examples O 0 8.298942866247216e-09
of O 0 1.1342899064459289e-08
a O 0 6.326605216600001e-05
genetic B-Disease 1 0.9952865839004517
defect I-Disease 1 0.9984983205795288
within O 0 1.7763663606729097e-07
the O 0 2.080604417642462e-07
POMC O 0 0.00015366492152679712
gene O 0 2.773153653379268e-07
and O 0 2.295247725214722e-08
define O 0 1.310918804620087e-07
a O 0 1.1862996416311944e-06
new O 0 2.1217720131971873e-05
monogenic B-Disease 1 0.9903283715248108
endocrine I-Disease 1 0.9997183680534363
disorder I-Disease 1 0.9972724318504333
resulting O 0 1.482712286815513e-05
in O 0 1.093020614462148e-06
early O 0 0.00022604111291002482
- O 1 0.9970318078994751
onset O 1 0.9997721314430237
obesity B-Disease 1 0.9999880790710449
, O 0 0.01736084558069706
adrenal B-Disease 1 0.9999380111694336
insufficiency I-Disease 1 0.9999207258224487
and O 0 0.0002282702043885365
red O 0 0.16789279878139496
hair O 1 0.8189588785171509
pigmentation O 0 0.05899827554821968
. O 0 2.2694218841934344e-06
. O 0 2.852806801456609e-06

A O 0 4.020515189040452e-05
European O 0 4.1987670556409284e-05
multicenter O 0 0.008702108636498451
study O 0 1.1233459190407302e-05
of O 0 2.061864324787166e-05
phenylalanine B-Disease 1 0.9997598528862
hydroxylase I-Disease 1 0.9998400211334229
deficiency I-Disease 1 0.9999855756759644
: O 0 6.519672979266034e-07
classification O 0 6.0247898545640055e-06
of O 0 1.2284685269037254e-08
105 O 0 1.5851365731123224e-07
mutations O 0 2.489046266873629e-07
and O 0 4.326698999079781e-09
a O 0 4.2217514817366464e-08
general O 0 3.922897562347316e-08
system O 0 5.034199830333819e-07
for O 0 1.4720577645732646e-08
genotype O 0 1.2554675095088896e-06
- O 0 3.5651289636007277e-06
based O 0 1.2312827379901137e-07
prediction O 0 1.7648413859205903e-06
of O 0 1.8182640815211926e-07
metabolic O 0 0.01113880705088377
phenotype O 0 0.0010731713846325874
. O 0 6.135503099358175e-06

Phenylketonuria B-Disease 1 0.9526177644729614
( O 0 6.534818385262042e-05
PKU B-Disease 0 0.25899645686149597
) O 0 4.636847279471112e-06
and O 0 1.1094859473814722e-05
mild B-Disease 1 0.9842680096626282
hyperphenylalaninemia I-Disease 1 0.9999513626098633
( O 0 0.0011598527198657393
MHP B-Disease 1 0.9999232292175293
) O 0 7.157372579058574e-07
are O 0 2.2349678374666837e-07
allelic B-Disease 0 0.006259153597056866
disorders I-Disease 1 0.9988910555839539
caused O 0 0.00011229329538764432
by O 0 9.879256879230525e-08
mutations O 0 2.5311962872365257e-06
in O 0 2.688478062395916e-08
the O 0 3.266912074195716e-08
gene O 0 6.548636406478181e-07
encoding O 0 1.9727069684449816e-06
phenylalanine O 0 0.001308900536969304
hydroxylase O 0 0.00672750873491168
( O 0 1.2284881449886598e-05
PAH O 1 0.9982237219810486
) O 0 1.4520517197524896e-06
. O 0 1.5334394447563682e-06

Previous O 0 8.560963578929659e-06
studies O 0 7.374353572231485e-07
have O 0 2.262682130549365e-08
suggested O 0 2.514488173233076e-08
that O 0 7.239940313930049e-10
the O 0 1.2151016193229225e-08
highly O 0 9.208477536049031e-07
variable O 0 1.8555816495791078e-05
metabolic O 0 0.2836807370185852
phenotypes O 0 0.0013807726791128516
of O 0 0.00026151802740059793
PAH B-Disease 1 0.9999656677246094
deficiency I-Disease 1 0.9994307160377502
correlate O 0 0.00012847519246861339
with O 0 0.0003141889756079763
PAH O 1 0.9992696642875671
genotypes O 0 0.005887902341783047
. O 0 1.5967640138114803e-05

We O 0 3.759250148505089e-06
identified O 0 9.168580277219007e-07
both O 0 1.2580692043684394e-07
causative O 0 8.173508831532672e-05
mutations O 0 3.9837770600570366e-05
in O 0 2.7563896765059326e-07
686 O 0 9.646890248404816e-06
patients O 0 3.4911192869913066e-06
from O 0 2.9039563642641042e-08
seven O 0 6.188474799273536e-08
European O 0 2.8725403922180703e-07
centers O 0 2.1695700525015127e-06
. O 0 2.072928964480525e-06

On O 0 6.052225671737688e-07
the O 0 2.231319129464282e-08
basis O 0 1.382464187571486e-08
of O 0 3.6718814655500864e-09
the O 0 1.2042161934289197e-08
phenotypic O 0 4.5672578607991454e-07
characteristics O 0 1.3965107825697487e-07
of O 0 2.4694401190572535e-08
297 O 0 1.8003225932261557e-06
functionally O 0 4.8136735131265596e-05
hemizygous O 0 0.00033048997283913195
patients O 0 2.4866549210855737e-06
, O 0 5.248663725865299e-09
105 O 0 6.337233848796586e-09
of O 0 6.860353396476171e-10
the O 0 7.897924092503672e-09
mutations O 0 7.138967106357086e-08
were O 0 1.2328197351862968e-09
assigned O 0 6.697577603631544e-09
to O 0 2.4728125103123944e-10
one O 0 1.9368731063451605e-09
of O 0 1.3267763554480894e-09
four O 0 1.4685242355483297e-08
arbitrary O 0 2.8803637519558833e-07
phenotype O 0 3.4770033380482346e-05
categories O 0 5.643518306897022e-06
. O 0 2.9154000458220253e-06

We O 0 1.4750335139979143e-06
proposed O 0 1.019318347061926e-06
and O 0 8.530987116728284e-08
tested O 0 7.71458189774421e-07
a O 0 2.135134025138541e-08
simple O 0 8.8225267091957e-09
model O 0 1.0813936413001102e-08
for O 0 5.496899602164262e-10
correlation O 0 1.2882297006910903e-08
between O 0 2.0624524310619563e-08
genotype O 0 6.390961857505317e-07
and O 0 3.688294114567725e-08
phenotypic O 0 9.37153981794836e-06
outcome O 0 1.5163743228185922e-05
. O 0 3.4938036606035894e-06

The O 0 4.651205472328002e-06
observed O 0 9.29870020627277e-06
phenotype O 0 1.699188578641042e-05
matched O 0 1.7858455976238474e-06
the O 0 1.2901161028366914e-07
predicted O 0 2.6254490421706578e-06
phenotype O 0 8.990909350359289e-07
in O 0 1.275219130292271e-08
79 O 0 5.207790820804803e-08
% O 0 5.34329747114981e-10
of O 0 3.4571706608588215e-10
the O 0 7.123567513644957e-09
cases O 0 4.784790341716416e-09
, O 0 1.967967344640442e-09
and O 0 2.1221244761449043e-09
in O 0 3.867745679286827e-09
only O 0 1.0658832705345844e-09
5 O 0 8.54171222641753e-09
of O 0 2.543496302465087e-09
184 O 0 1.1357006712842121e-07
patients O 0 6.260550549086474e-07
was O 0 1.2234980886205449e-06
the O 0 8.83685835617598e-09
observed O 0 3.5135865772417674e-08
phenotype O 0 4.0601118911354206e-08
more O 0 3.0884134138986497e-10
than O 0 5.150029291911551e-10
one O 0 1.4406883463990994e-09
category O 0 1.3153626632345095e-08
away O 0 7.478631935953217e-09
from O 0 5.255455182151536e-09
that O 0 6.097527815995818e-09
expected O 0 2.5738825115695363e-07
. O 0 4.4060206505491806e-07

Among O 0 3.347605002090859e-07
the O 0 7.690349690392395e-08
seven O 0 6.378016337293957e-08
contributing O 0 5.930311175461611e-08
centers O 0 9.462376482360924e-08
, O 0 8.341616286600129e-09
the O 0 3.792806069213839e-09
proportion O 0 1.5964900512699387e-08
of O 0 1.0908151715227632e-08
patients O 0 3.2665667504261364e-07
for O 0 3.79688858131999e-09
whom O 0 2.7528479051852628e-08
the O 0 3.005020232649258e-08
observed O 0 4.625857457085658e-07
phenotype O 0 7.643042749805318e-07
did O 0 1.8393405909478133e-08
not O 0 1.3087503303310655e-09
match O 0 2.94494242325527e-08
the O 0 2.5171848605509695e-08
predicted O 0 8.578278425375174e-07
phenotype O 0 5.368923439164064e-07
was O 0 4.3367145963202347e-07
4 O 0 3.072763732347994e-08
% O 0 6.2835412428796644e-09
- O 0 1.0542497648202698e-06
23 O 0 9.106285858706542e-08
% O 0 6.11929173999215e-09
( O 0 1.4834220962711697e-08
P O 0 5.8161685956292786e-06
< O 0 8.500043691128667e-07
. O 0 1.3744084093048059e-08
0001 O 0 6.07523452345049e-06
) O 0 9.712723070265383e-09
, O 0 8.39646396855187e-09
suggesting O 0 2.3937328563761184e-08
that O 0 1.083424572279057e-09
differences O 0 4.1122492078216055e-09
in O 0 2.531358012092255e-09
methods O 0 1.700089513612113e-09
used O 0 2.3497841450392798e-09
for O 0 9.863267536047715e-09
mutation O 0 6.784508173041104e-07
detection O 0 3.6374383398651844e-06
or O 0 3.701304081005219e-07
phenotype O 0 8.463458652840927e-05
classification O 0 9.285132546210662e-05
may O 0 9.583946081193062e-08
account O 0 1.936311555539305e-09
for O 0 6.796755380733543e-10
a O 0 8.740505208493232e-09
considerable O 0 1.8437980031649204e-08
proportion O 0 3.385743951866971e-08
of O 0 6.129749152705699e-08
genotype O 0 7.910717249615118e-05
- O 0 0.005863025318831205
phenotype O 0 0.0001545144768897444
inconsistencies O 0 3.108934106421657e-05
. O 0 2.935263410108746e-06

Our O 0 1.2562339861688088e-06
data O 0 1.1775954362747143e-06
indicate O 0 5.598018333330401e-07
that O 0 4.7805329472794256e-08
the O 0 1.3765538824372925e-06
PAH O 1 0.9919158816337585
- O 0 0.00019060532213188708
mutation O 0 5.414752195065375e-06
genotype O 0 1.0572219935056637e-06
is O 0 1.3140738275296826e-08
the O 0 3.6945515535791174e-09
main O 0 4.53748398854259e-08
determinant O 0 9.54254133489485e-08
of O 0 1.3822637257021597e-08
metabolic O 0 0.00029324754723347723
phenotype O 0 1.2370727745292243e-05
in O 0 2.536251031415304e-07
most O 0 6.600224082831119e-07
patients O 0 0.0002867241855710745
with O 0 0.05407044664025307
PAH B-Disease 1 0.9999727010726929
deficiency I-Disease 1 0.9996656179428101
. O 0 1.9035778677789494e-05

In O 0 8.197739020943118e-07
the O 0 8.935248274610785e-08
present O 0 8.099267034822333e-08
study O 0 3.4361637091251396e-08
, O 0 1.179839426157514e-08
the O 0 1.4551797100637032e-08
classification O 0 2.0520756152109243e-06
of O 0 5.3358377272161306e-08
105 O 0 2.3014408725430258e-05
PAH O 1 0.9991748929023743
mutations O 0 7.747963536530733e-05
may O 0 6.177342015689646e-08
allow O 0 2.3996238329715425e-09
the O 0 1.695022966430315e-08
prediction O 0 1.2274138327939e-07
of O 0 8.285099828420073e-10
the O 0 1.22673116109695e-08
biochemical O 0 1.6968689351415378e-06
phenotype O 0 8.523925316694658e-07
in O 0 1.7786843997669166e-08
> O 0 1.1813484945832897e-07
10 O 0 9.692847413589334e-09
, O 0 2.851727964880979e-09
000 O 0 1.1547197864558711e-08
genotypes O 0 1.910851068487318e-07
, O 0 2.3519467262644866e-08
which O 0 1.2918368597070184e-08
may O 0 2.6709214395737035e-08
be O 0 5.32269950337394e-10
useful O 0 4.240066076022231e-10
for O 0 1.2042844499404737e-09
the O 0 1.065995736126979e-08
management O 0 5.684282200490998e-07
of O 0 5.1575650417134966e-08
hyperphenylalaninemia B-Disease 1 0.9987077713012695
in O 0 1.617023917788174e-05
newborns O 0 0.0009430278441868722
. O 0 1.8144080513593508e-06

Somatic O 0 0.00019744444580283016
instability O 0 0.00014622198068536818
of O 0 3.5453246027827845e-07
the O 0 4.470295209557662e-07
CTG O 0 0.0001766760542523116
repeat O 0 8.257912668341305e-06
in O 0 3.724319128650677e-07
mice O 0 2.768170134004322e-06
transgenic O 0 1.0919536634901306e-06
for O 0 8.465438128268943e-08
the O 0 3.5830085835186765e-05
myotonic B-Disease 1 0.9999505281448364
dystrophy I-Disease 1 0.9999904632568359
region O 0 0.0015935517149046063
is O 0 3.1623249014955945e-06
age O 0 7.590451787109487e-07
dependent O 0 1.2800471438367822e-07
but O 0 8.859269762240274e-09
not O 0 1.1495966401042779e-09
correlated O 0 8.710149046464721e-09
to O 0 7.394855838782632e-10
the O 0 3.69898667251789e-09
relative O 0 7.350117670057443e-08
intertissue O 0 4.294657628634013e-06
transcription O 0 2.06815047931741e-06
levels O 0 1.4551097820003633e-06
and O 0 2.776578185148537e-07
proliferative O 0 0.02298026531934738
capacities O 0 0.00038097871583886445
. O 0 1.156606049335096e-05

A O 0 4.731263470603153e-05
( O 0 5.938867957411276e-07
CTG O 0 3.9775888581061736e-05
) O 0 5.618380427563352e-08
nexpansion O 0 4.7937955969246104e-06
in O 0 5.1244413157292e-08
the O 0 5.698133875853273e-08
3 O 0 9.685085160526796e-07
- O 0 7.35866415197961e-05
untranslated O 0 5.629002407658845e-05
region O 0 1.9444196368567646e-06
( O 0 4.1711821552326e-08
UTR O 0 2.080561898765154e-06
) O 0 3.4460332365426893e-09
of O 0 1.518437486858204e-09
the O 0 7.253132849882604e-08
DM O 1 0.7002294659614563
protein O 0 8.133811206789687e-07
kinase O 0 2.515626192689524e-06
gene O 0 3.7344622683122e-07
( O 0 2.7415557823928793e-08
DMPK O 0 3.720273889484815e-05
) O 0 1.946855654466617e-08
is O 0 6.205696934102889e-08
responsible O 0 2.0743409550050274e-06
for O 0 7.77145669417223e-06
causing O 1 0.9801100492477417
myotonic B-Disease 1 0.9999781847000122
dystrophy I-Disease 1 0.9999936819076538
( O 0 0.01037550251930952
DM B-Disease 1 0.9999104738235474
) O 0 2.0215085896779783e-05
. O 0 7.448423275491223e-06

Major O 0 0.00035682416637428105
instability O 0 0.0003212661831639707
, O 0 3.619475421601237e-07
with O 0 4.686218346705573e-08
very O 0 3.251997782172111e-08
large O 0 1.4425121541705721e-08
expansions O 0 1.4797379321862536e-07
between O 0 1.5483985649211718e-08
generations O 0 3.073912679951718e-08
and O 0 2.363188578158315e-08
high O 0 1.0944851283056778e-06
levels O 0 1.06388156950743e-07
of O 0 4.218666305177976e-09
somatic O 0 7.820979135431116e-07
mosaicism O 0 6.279085937421769e-05
, O 0 1.753271590132499e-07
is O 0 1.9870159917445562e-07
observed O 0 8.516028060512326e-07
in O 0 1.203322767651116e-06
patients O 0 2.420116652501747e-05
. O 0 2.3072868771123467e-06

There O 0 8.724001077098364e-07
is O 0 9.51669463233884e-08
a O 0 4.129574548983328e-08
good O 0 2.8332472368219896e-08
correlation O 0 2.53550513917844e-08
between O 0 4.110416540470396e-08
repeat O 0 9.411219821231498e-07
size O 0 3.5897537031814863e-07
( O 0 1.105059332928704e-08
at O 0 1.421601183437815e-07
least O 0 8.486822800080063e-09
in O 0 3.7699738442142916e-08
leucocytes O 0 4.076308869116474e-06
) O 0 1.077931965909329e-08
, O 0 2.8551530917297896e-08
clinical O 0 2.1635285065713106e-06
severity O 0 1.6528900232515298e-05
and O 0 2.2256834597556008e-07
age O 0 1.6306153156619985e-06
of O 0 3.4119742053917435e-07
onset O 0 0.28893959522247314
. O 0 6.385590950230835e-06

The O 0 1.3841991858498659e-05
trinucleotide O 0 0.015881570056080818
repeat O 0 0.00016593685722909868
instability O 0 2.114572998834774e-05
mechanisms O 0 6.181825483508874e-06
involved O 0 3.3292803891527e-06
in O 0 9.21223545446992e-06
DM B-Disease 1 0.9998350143432617
and O 0 3.928184071355645e-07
other O 0 1.5107013950910186e-07
human O 0 0.00015551068645436317
genetic B-Disease 1 0.9999029636383057
diseases I-Disease 1 0.9999878406524658
are O 0 1.9198905647499487e-06
unknown O 0 0.00025720649864524603
. O 0 5.244996373221511e-06

We O 0 2.4128212317009456e-06
studied O 0 3.749908728423179e-06
somatic O 0 5.1520869419618975e-06
instability O 0 1.2639087799470872e-05
by O 0 9.07002259964429e-08
measuring O 0 2.1118725271662697e-05
the O 0 3.256538718687807e-07
CTG O 0 7.34502900741063e-05
repeat O 0 7.935766461741878e-07
length O 0 2.3056648501551535e-07
at O 0 6.730209634042694e-08
several O 0 2.4840265400172257e-09
ages O 0 1.4066366738063607e-08
in O 0 2.7778737088368644e-09
various O 0 2.082087391386267e-09
tissues O 0 5.178546302886389e-07
of O 0 1.3630756079408002e-08
transgenic O 0 2.0302427401475143e-06
mice O 0 1.5238979358400684e-06
carrying O 0 1.277548165035114e-07
a O 0 1.73952813042888e-07
( O 0 4.245864815288769e-08
CTG O 0 1.2816223716072273e-05
) O 0 2.5041979156981142e-08
55expansion O 0 1.394270043419965e-06
surrounded O 0 6.260061127250083e-07
by O 0 1.526912996041574e-08
45 O 0 1.6978672690015628e-08
kb O 0 1.821971835624936e-07
of O 0 6.065790980613883e-09
the O 0 1.2432913365501008e-07
human O 0 2.7062951630796306e-06
DM B-Disease 1 0.9996423721313477
region O 0 1.4638061429650406e-06
, O 0 1.1835944668803222e-08
using O 0 1.5893501625896533e-08
small O 0 4.0792542677081656e-07
- O 0 5.642868927679956e-05
pool O 0 2.6745092327473685e-05
PCR O 0 3.5807544918498024e-05
. O 0 1.0402397947473219e-06

These O 0 5.011016241951438e-07
mice O 0 1.4813130292168353e-05
have O 0 3.650041335845344e-08
been O 0 3.345163079870872e-08
shown O 0 1.076785327569496e-08
to O 0 7.223223130736756e-10
reproduce O 0 1.5204728143203283e-08
the O 0 5.921989121304705e-09
intergenerational O 0 2.1060012045381882e-07
and O 0 1.3163464984700113e-08
somatic O 0 2.4885952143449686e-07
instability O 0 1.042710891852039e-06
of O 0 6.112911066225024e-09
the O 0 8.983317911770428e-08
55 O 0 7.399800097118714e-07
CTG O 0 3.82344369427301e-05
repeat O 0 5.029102794651408e-06
suggesting O 0 2.3059287457272148e-07
that O 0 3.2679885464403924e-09
surrounding O 0 3.18706732116425e-08
sequences O 0 1.4845006113262116e-08
and O 0 2.8046740485621058e-09
the O 0 5.781331857690475e-09
chromatin O 0 5.536372782444232e-07
environment O 0 2.0823830482186168e-07
are O 0 3.0635511905074964e-09
involved O 0 5.556886861768362e-08
in O 0 1.4053686925308284e-07
instability O 0 3.244017716497183e-05
mechanisms O 0 2.804962423397228e-05
. O 0 2.9150332920835353e-06

As O 0 5.553071673602972e-07
observed O 0 4.266630924121273e-07
in O 0 1.2198202448132633e-08
some O 0 4.769744044175184e-10
of O 0 9.947184187453217e-10
the O 0 2.5028130679061178e-08
tissues O 0 6.770057552785147e-06
of O 0 1.4210781955625862e-06
DM B-Disease 1 0.999961256980896
patients O 0 0.00016389734810218215
, O 0 1.6311318518091866e-07
there O 0 3.272631232675849e-08
is O 0 2.5366324152287234e-08
a O 0 3.2325612409067617e-08
tendency O 0 3.331295417297042e-08
for O 0 4.506835793449682e-09
repeat O 0 2.758141022241034e-07
length O 0 7.374579524821456e-08
and O 0 5.379110046277447e-09
somatic O 0 1.197620917992026e-07
mosaicism O 0 3.347963911437546e-06
to O 0 2.4086987959748285e-09
increase O 0 5.088945265185885e-09
with O 0 2.8954376674050764e-09
the O 0 2.3526377290750133e-08
age O 0 1.3952036681530444e-07
of O 0 7.373395227716628e-09
the O 0 2.1113183379384282e-07
mouse O 0 2.297517676197458e-05
. O 0 1.5281416381185409e-06

Furthermore O 0 2.8972157451789826e-05
, O 0 3.376880215455458e-07
we O 0 2.84377232873112e-08
observed O 0 2.804975274273147e-08
no O 0 3.3242357755369767e-09
correlation O 0 3.2122524640243455e-09
between O 0 3.08431791218311e-09
the O 0 8.782818028407746e-09
somatic O 0 7.409898898913525e-07
mutation O 0 6.943868811504217e-06
rate O 0 1.449600063097023e-06
and O 0 1.4728558994647756e-07
tissue O 0 0.0010977168567478657
proliferation O 0 0.0009308338048867881
capacity O 0 1.8982211258844472e-05
. O 0 2.823359182002605e-06

The O 0 9.989208820115891e-07
somatic O 0 2.6146919481107034e-05
mutation O 0 0.0003156278980895877
rates O 0 7.609799922647653e-06
in O 0 1.542373695428978e-08
different O 0 2.0290666924438483e-09
tissues O 0 6.590927341676434e-07
were O 0 3.174503149239172e-08
also O 0 1.0023216923116252e-08
not O 0 7.96338772701688e-10
correlated O 0 7.547615865632906e-09
to O 0 3.282711602548005e-10
the O 0 5.4544888605789765e-09
relative O 0 1.7885763270442112e-07
inter O 0 7.451803867297713e-06
- O 0 8.064314897637814e-05
tissue O 0 1.7586081639819895e-06
difference O 0 1.2772931157201128e-08
in O 0 1.7079742065106984e-09
transcriptional O 0 3.2683082906714844e-08
levels O 0 3.0881928125836566e-08
of O 0 3.4735625487058996e-10
the O 0 1.83831205813334e-09
three O 0 3.36271499534746e-09
genes O 0 1.978287400561385e-08
( O 0 5.717847528785569e-09
DMAHP O 0 3.949515757994959e-06
, O 0 1.8162758408379887e-08
DMPK O 0 1.774941301846411e-05
and O 0 1.1290926238416432e-07
59 O 0 6.836559691691946e-07
) O 0 1.105227998010605e-08
surrounding O 0 1.516974208470856e-07
the O 0 1.6485155640566518e-07
repeat O 0 1.1722959243343212e-05
. O 0 1.9838881826217403e-07
. O 0 8.624015777058958e-07

A O 0 2.8466529329307377e-05
novel O 0 1.7786165699362755e-05
missense O 0 0.00020326954836491495
mutation O 0 0.00019377755234017968
in O 0 1.1754647175621358e-06
patients O 0 1.144947077591496e-06
from O 0 2.6848397283174563e-08
a O 0 2.966945658045006e-07
retinoblastoma B-Disease 0 7.820255268597975e-05
pedigree O 0 1.8388151147519238e-05
showing O 0 1.6140097613970283e-06
only O 0 6.562640209040183e-08
mild O 0 1.0107505659107119e-05
expression O 0 2.146393853763584e-07
of O 0 1.449534750008752e-07
the O 0 2.3852817321312614e-05
tumor B-Disease 1 0.9920899868011475
phenotype O 0 0.001075306092388928
. O 0 4.118427568755578e-06

We O 0 5.793763762085291e-07
have O 0 4.8632835536466246e-09
used O 0 3.131550574408948e-09
single O 0 2.37516335488408e-08
strand O 0 2.1479911538335728e-07
conformation O 0 2.3539399762739777e-07
polymorphism O 0 6.93377728566702e-08
analysis O 0 5.134163316711238e-09
to O 0 7.135993462803469e-10
study O 0 1.931671045340977e-09
the O 0 1.7761139226024625e-09
27 O 0 2.790705444510877e-08
exons O 0 2.38229578286564e-08
of O 0 2.138409671559316e-09
the O 0 3.952496285819507e-08
RB1 O 0 4.157306466368027e-05
gene O 0 1.1688554479860613e-07
in O 0 6.823985376769315e-09
individuals O 0 6.301264510177873e-10
from O 0 3.1394089550218496e-09
a O 0 1.431644562899237e-07
family O 0 4.4767156737179903e-07
showing O 0 2.6028819775092416e-06
mild O 0 1.7890224626171403e-05
expression O 0 7.907725319000747e-08
of O 0 2.3978408592029155e-08
the O 0 6.846725000286824e-07
retinoblastoma B-Disease 0 0.0031063775531947613
phenotype O 0 0.0013528862036764622
. O 0 5.385033091442892e-06

In O 0 2.033792952715885e-06
this O 0 1.7222485837464774e-07
family O 0 2.075526253975113e-06
affected O 0 5.523410209207213e-07
individuals O 0 3.645303436883296e-08
developed O 0 5.449014497571625e-05
unilateral B-Disease 0 0.04175432771444321
tumors I-Disease 1 0.9999877214431763
and O 0 1.3427953717837227e-06
, O 0 6.207815772540926e-08
as O 0 1.5463326619169493e-08
a O 0 6.430026644466125e-08
result O 0 1.8273709656568826e-08
of O 0 1.9849046850595187e-09
linkage O 0 1.4524282221373142e-07
analysis O 0 3.774643531073707e-08
, O 0 2.7567516269755288e-08
unaffected O 0 3.0579478789150016e-06
mutation O 0 1.2534145525933127e-06
carriers O 0 4.494065422022686e-07
were O 0 3.2732366150867165e-08
also O 0 3.747619814475911e-08
identified O 0 1.3410570431915403e-07
within O 0 4.6308713308462757e-08
the O 0 4.3977885866297584e-07
pedigree O 0 0.00011125241871923208
. O 0 1.6919242398216738e-06

A O 0 4.164253368799109e-06
single O 0 4.3726211629291356e-07
band O 0 3.447666188094445e-07
shift O 0 1.0926125071364368e-07
using O 0 2.8436961230227098e-08
SSCP O 0 3.434557220316492e-05
was O 0 3.480020041024545e-06
identified O 0 5.612125875131824e-08
in O 0 1.775478075671799e-08
exon O 0 2.0356226286821766e-06
21 O 0 1.0000077566019172e-07
which O 0 3.089192679439634e-09
resulted O 0 3.784433033615642e-08
in O 0 1.233596602645548e-08
a O 0 1.3782022278974182e-07
missense O 0 2.162507371394895e-06
mutation O 0 4.5633916556653276e-07
converting O 0 1.219739260704955e-07
a O 0 9.036347705659864e-07
cys O 0 0.0006414313684217632
- O 0 6.202145596034825e-05
- O 0 1.9669343600980937e-05
> O 0 9.08406036614906e-07
arg O 0 1.3029173260292737e-06
at O 0 1.2806319205083128e-07
nucleotide O 0 3.15726396138416e-07
position O 0 1.3784415386908222e-07
28 O 0 1.0810887829393323e-07
in O 0 2.7204492880628095e-08
the O 0 1.4432391992613702e-07
exon O 0 8.236165012931451e-05
. O 0 1.987963059946196e-06

The O 0 5.1904344218201e-06
mutation O 0 4.06338476750534e-05
destroyed O 0 1.2741908903990407e-05
an O 0 3.278300937381573e-07
NdeI O 0 0.00011732397979358211
restriction O 0 3.6725807603943394e-06
enzyme O 0 9.222529115504585e-06
site O 0 1.3775907973467838e-05
. O 0 3.129432116111275e-06

Analysis O 0 9.550859658702393e-07
of O 0 3.010545057691161e-08
all O 0 6.0284208736050005e-09
family O 0 1.0667466199265618e-07
members O 0 4.117570728823239e-09
demonstrated O 0 3.259903280650178e-08
that O 0 9.110898702147097e-10
the O 0 1.4329909703292287e-08
missense O 0 2.594213128759293e-06
mutation O 0 2.7992730338155525e-06
co O 0 3.87291129300138e-06
- O 0 1.1756019375752658e-05
segregated O 0 2.1111220576131018e-06
with O 0 4.2242044173690374e-07
patients O 0 2.0245182895450853e-05
with O 0 1.2825981684727594e-05
tumors B-Disease 1 0.9999566078186035
or O 0 1.0966563195324852e-06
who O 0 2.453426759529975e-07
, O 0 5.392618795951876e-09
as O 0 1.3222221539876955e-08
a O 0 5.7086641191972376e-08
result O 0 1.3267770881952856e-08
of O 0 1.2375740432446491e-09
linkage O 0 1.250521250995007e-07
analysis O 0 3.45700286175088e-08
had O 0 1.8745566876532394e-07
been O 0 5.330954877535987e-08
predicted O 0 5.2298787522886414e-08
to O 0 4.369414552396478e-10
carry O 0 1.9738626733101228e-08
the O 0 1.96649224903922e-07
predisposing O 0 6.687021959805861e-05
mutation O 0 0.00010784914047690108
. O 0 3.985552211815957e-06

These O 0 9.757662411402634e-08
observations O 0 4.388370200558711e-07
point O 0 1.735556054427434e-07
to O 0 2.9090050368552056e-09
another O 0 3.3184786474294015e-08
region O 0 5.8485127851781726e-08
of O 0 3.738430010002958e-09
the O 0 1.5038719425319869e-07
RB1 O 0 0.00017368452972732484
gene O 0 3.5087654737253615e-07
where O 0 4.8839687849522306e-08
mutations O 0 1.0246520787404734e-07
only O 0 8.608931345577275e-10
modify O 0 1.0582509091250358e-08
the O 0 1.7094865523148428e-09
function O 0 1.9365258285830578e-09
of O 0 4.721661950313205e-10
the O 0 5.26284793522791e-09
gene O 0 4.101926620592167e-08
and O 0 1.0252224846851732e-08
raise O 0 1.3929455811023672e-08
important O 0 3.8763423582111045e-09
questions O 0 1.0381428161565509e-08
for O 0 6.930720886089148e-09
genetic O 0 5.583648885476578e-07
counseling O 0 3.796601504291175e-07
in O 0 2.49132057206225e-08
families O 0 2.4626656269788327e-09
with O 0 3.588690677958084e-09
these O 0 2.827426515139564e-09
distinctive O 0 3.4472395782358944e-06
phenotypes O 0 5.2030802180524915e-05
. O 0 3.922359610442072e-07
. O 0 1.1703784821293084e-06

Maternal B-Disease 0 0.007989710196852684
disomy I-Disease 0 0.10416770726442337
and O 0 0.004762306809425354
Prader B-Disease 1 0.9999605417251587
- I-Disease 1 0.9999752044677734
Willi I-Disease 1 0.9999897480010986
syndrome I-Disease 1 0.999961256980896
consistent O 0 1.3256890269985888e-05
with O 0 1.0393002014552621e-07
gamete O 0 7.304218343051616e-06
complementation O 0 0.00010991743329213932
in O 0 2.6284152454536525e-07
a O 0 4.4362303697198513e-07
case O 0 1.689715389829871e-07
of O 0 2.2396164922611206e-08
familial O 0 0.0001926664263010025
translocation O 0 3.5889315768145025e-05
( O 0 4.1681836648876924e-08
3 O 0 1.1140115674379558e-07
; O 0 7.087733511212946e-09
15 O 0 5.9463836521445046e-08
) O 0 4.418865273692063e-09
( O 0 6.9098260446764925e-09
p25 O 0 6.626511321883299e-07
; O 0 1.7136791541361163e-08
q11 O 0 7.283479135367088e-07
. O 0 2.053902292686871e-08
2 O 0 2.793195790218306e-07
) O 0 1.3009143629005848e-07
. O 0 3.9981424038160185e-07

Maternal B-Disease 0 0.03763638809323311
uniparental I-Disease 1 0.8551788330078125
disomy I-Disease 0 0.26496994495391846
( I-Disease 0 2.451035652484279e-05
UPD I-Disease 1 0.9858333468437195
) I-Disease 0 1.211998181815943e-07
for I-Disease 0 2.891641948110646e-08
chromosome I-Disease 0 4.246021035214653e-06
15 I-Disease 0 5.540567116213424e-08
is O 0 6.515866068923515e-09
responsible O 0 1.133273563880266e-08
for O 0 5.014462733932135e-10
an O 0 2.1470574207427262e-09
estimated O 0 6.655439754865711e-09
30 O 0 2.8275881636119493e-09
% O 0 8.454085764775243e-10
of O 0 1.2524631332055947e-09
cases O 0 1.1499354712896093e-07
of O 0 8.525441444362514e-06
Prader B-Disease 1 0.9999829530715942
- I-Disease 1 0.9999909400939941
Willi I-Disease 1 0.999995231628418
syndrome I-Disease 1 0.9999910593032837
( O 0 0.0014894960913807154
PWS B-Disease 1 0.9995720982551575
) O 0 1.5851950593059883e-05
. O 0 9.456823136133607e-06

We O 0 1.543959456284938e-06
report O 0 1.5076975046213192e-07
on O 0 2.806773480301672e-08
an O 0 9.83991199632328e-09
unusual O 0 9.18446616537949e-08
case O 0 1.245717271558533e-07
of O 0 1.1422817358663906e-08
maternal B-Disease 0 1.5714153050794266e-05
disomy I-Disease 0 0.00040121801430359483
15 I-Disease 0 3.6703959267470054e-06
in O 0 1.3339042652660282e-06
PWS B-Disease 1 0.9988787770271301
that O 0 1.0251133630845288e-07
is O 0 2.719204239554074e-08
most O 0 1.581843100950664e-09
consistent O 0 9.01530938790529e-09
with O 0 4.432312294966323e-09
adjacent O 0 6.871982236589247e-07
- O 0 5.795029665023321e-06
1 O 0 4.204506609539749e-08
segregation O 0 1.0942539319103162e-07
of O 0 3.781610136144309e-09
a O 0 1.9963840713899117e-07
paternal O 0 6.604458121728385e-06
t O 0 2.514471998438239e-05
( O 0 1.0172849229661551e-08
3 O 0 4.384052942896233e-08
; O 0 6.172004685112142e-09
15 O 0 1.925293879878609e-08
) O 0 5.153707238747529e-09
( O 0 4.2502379393738465e-09
p25 O 0 1.79227981789154e-07
; O 0 9.639602005506731e-09
q11 O 0 1.6510439593275805e-07
. O 0 3.4209644006466533e-09
2 O 0 5.457017504539863e-09
) O 0 7.048580052959608e-10
with O 0 9.978862181014847e-10
simultaneous O 0 5.8232785704603884e-08
maternal O 0 7.0431019594252575e-06
meiotic O 0 0.00011304493091301993
nondisjunction O 0 0.00011135961540276185
for O 0 3.966127906096517e-07
chromosome O 0 6.661703082500026e-05
15 O 0 1.8161531443183776e-06
. O 0 1.6001321228031884e-06

The O 0 1.0212770575890318e-05
patient O 0 0.00010428191308164969
( O 0 2.3258414216797973e-07
J O 0 4.706140316557139e-05
. O 0 2.788045350143875e-08
B O 0 2.728004915297788e-07
. O 0 1.851606645786319e-09
) O 0 1.229246038292331e-09
, O 0 1.139306649022842e-09
a O 0 2.8996170797768173e-08
17 O 0 3.5369527040529647e-07
- O 0 4.296288352634292e-06
year O 0 8.522966368218476e-07
- O 0 1.591653926880099e-05
old O 0 1.7744607248459943e-05
white O 0 4.620227116447495e-07
male O 0 7.043183813948417e-08
with O 0 6.554909504075113e-08
PWS B-Disease 1 0.9950148463249207
, O 0 3.650612825367716e-07
was O 0 5.473988494486548e-06
found O 0 9.726034200241429e-09
to O 0 5.058082841458145e-10
have O 0 8.152762909219291e-10
47 O 0 1.2136748495095162e-08
chromosomes O 0 7.215598341048235e-09
with O 0 3.8400185253806285e-09
a O 0 1.6058267249263736e-07
supernumerary O 0 1.9348568457644433e-05
, O 0 5.71592018161482e-08
paternal O 0 6.540056801895844e-06
der O 0 0.0007354322588071227
( O 0 2.2677719258012985e-08
15 O 0 1.5919288998134107e-08
) O 0 6.728624324381371e-10
consisting O 0 2.3753070621523875e-09
of O 0 1.5683360166107718e-09
the O 0 6.466197532972728e-08
short O 0 8.92619254955207e-07
arm O 0 3.231373557355255e-05
and O 0 1.180185904559039e-08
the O 0 3.071679799404592e-08
proximal O 0 1.0096688129124232e-05
long O 0 9.416315151611343e-06
arm O 0 2.088539258693345e-05
of O 0 1.1191095161677822e-08
chromosome O 0 1.9813478502328508e-06
15 O 0 6.833209909018478e-08
, O 0 1.2353955192168087e-08
and O 0 8.777480786648084e-08
distal O 0 0.000746839854400605
chromosome O 0 0.1289476603269577
arm O 0 0.23784779012203217
3p O 0 0.0871128961443901
. O 0 1.401578811055515e-05

The O 0 4.9717918955138884e-06
t O 0 0.00011201459710719064
( O 0 3.3241800423411405e-08
3 O 0 7.075876595763475e-08
; O 0 5.493737020856315e-09
15 O 0 1.4636027501069293e-08
) O 0 1.9748409574305015e-09
was O 0 8.563102227299169e-08
present O 0 1.8966372916651153e-09
in O 0 2.691863176806919e-09
the O 0 3.691431160746106e-09
balanced O 0 4.304878586935956e-08
state O 0 1.4834249384421128e-08
in O 0 1.7495727533400895e-08
the O 0 1.2969306339982722e-07
patients O 0 1.336672767138225e-06
father O 0 9.202121873386204e-07
and O 0 1.21376672268525e-07
a O 0 1.5023400919744745e-05
sister O 0 0.0018040798604488373
. O 0 3.7621621231664903e-06

Fluorescent O 0 3.631654544733465e-05
in O 0 7.456172852471354e-07
situ O 0 5.828839675814379e-06
hybridization O 0 3.9197342971419857e-07
analysis O 0 7.097679599610274e-08
demonstrated O 0 2.4161593614735466e-07
that O 0 1.3610180538137229e-08
the O 0 4.369377677448938e-07
PWS B-Disease 1 0.9945564270019531
critical O 0 4.875229478784604e-06
region O 0 1.6003061773517402e-06
resided O 0 1.1446827556937933e-06
on O 0 7.085384368110681e-08
the O 0 1.386382741941361e-08
derivative O 0 2.2355797568707203e-07
chromosome O 0 1.2714541526293033e-06
3 O 0 5.574551309450726e-08
and O 0 6.555757270376716e-09
that O 0 2.904220641752886e-09
there O 0 5.325078156204199e-09
was O 0 1.234247065440286e-06
no O 0 1.3772530671474215e-08
deletion O 0 1.0475114464725266e-07
of O 0 5.357822185914074e-09
the O 0 3.2397400673289667e-07
PWS B-Disease 1 0.9884601831436157
region O 0 8.709287726560433e-07
on O 0 6.948340569579159e-08
the O 0 1.62664335334739e-08
normal O 0 1.964672122767297e-07
pair O 0 5.4701821738945e-08
of O 0 1.423328921390521e-08
15s O 0 8.403001743317873e-07
present O 0 1.0022054652836232e-07
in O 0 1.0420646958664292e-06
J O 0 0.0015395933296531439
. O 0 2.5661522613518173e-06

B O 0 0.008025678806006908
. O 0 6.270541780395433e-05

Methylation O 0 1.4188115528668277e-05
analysis O 0 1.1392222631911864e-06
at O 0 1.2926694807902095e-06
exon O 0 9.25519907468697e-06
alpha O 0 5.752658012170286e-07
of O 0 6.9181074202617765e-09
the O 0 2.463456105772366e-08
small O 0 2.090517057240504e-07
nuclear O 0 6.64219114696607e-05
ribonucleoprotein O 0 0.0002825898991432041
- O 0 3.404928793315776e-05
associated O 0 4.1773847669901443e-07
polypeptide O 0 4.4433622861106414e-06
N O 0 3.1449417292606086e-06
( O 0 2.3301211626858276e-08
SNRPN O 0 6.2730632635066286e-06
) O 0 1.13077964769559e-08
gene O 0 1.1016441447964098e-07
showed O 0 9.919909160771567e-08
a O 0 2.3036861307446088e-08
pattern O 0 7.905086363280134e-08
characteristic O 0 1.819476125319852e-08
of O 0 2.010321908940682e-09
only O 0 4.079080184737904e-09
the O 0 1.5412503273637412e-08
maternal O 0 2.8612971618713345e-06
chromosome O 0 9.40433528739959e-06
15 O 0 4.526566499407636e-07
in O 0 6.299329697867506e-07
J O 0 0.0013923321384936571
. O 0 3.04661261907313e-06

B O 0 0.007827535271644592
. O 0 7.150200690375641e-05

Maternal B-Disease 0 0.0020903311669826508
disomy I-Disease 0 0.015603101812303066
was O 0 0.00025815406115725636
confirmed O 0 9.742373094923096e-07
by O 0 2.0615477325236498e-08
polymerase O 0 1.2451369002519641e-06
chain O 0 2.134032229150762e-06
reaction O 0 9.331110817356603e-08
analysis O 0 8.182333921524787e-09
of O 0 3.1450366755336745e-09
microsatellite O 0 1.975904069695389e-06
repeats O 0 4.230674903737963e-07
at O 0 2.3601823784247244e-07
the O 0 5.8149321802147824e-08
gamma O 0 1.297954099754861e-06
- O 0 2.4981734441098524e-06
aminobutyric O 0 5.911603238928365e-06
acid O 0 1.4520684317176347e-06
receptor O 0 6.769810738660453e-07
beta3 O 0 4.195601377432467e-06
subunit O 0 3.427321360049973e-07
( O 0 5.791974189151006e-08
GABRB3 O 0 4.780389281222597e-05
) O 0 2.0497037667155382e-07
locus O 0 1.77065212483285e-05
. O 0 2.5308195290563162e-06

A O 0 0.00013802845205646008
niece O 0 0.000809526420198381
( O 0 3.0264124006862403e-07
B O 0 3.3834830901469104e-06
. O 0 1.8658594669318518e-08
B O 0 2.3578763830300886e-07
. O 0 1.701146890020766e-09
) O 0 7.630538978453671e-10
with O 0 6.571665434051965e-10
45 O 0 2.013698985336987e-09
chromosomes O 0 4.550785970280913e-09
and O 0 1.0684846341035836e-09
the O 0 2.680356381290494e-09
derivative O 0 2.9622034602994063e-08
3 O 0 1.5811803422138837e-08
but O 0 3.90407750572308e-09
without O 0 4.2273251565916325e-09
the O 0 2.9207544827158927e-08
der O 0 3.761337211471982e-05
( O 0 9.193962036135872e-09
15 O 0 1.2998150999976588e-08
) O 0 2.0265218392268025e-09
demonstrated O 0 2.3840321716761537e-08
a O 0 9.557422941952609e-08
phenotype O 0 6.485632866315427e-07
consistent O 0 4.3745309596943116e-08
with O 0 6.267824481653861e-09
that O 0 7.792999134892398e-09
reported O 0 2.4509196805411193e-07
for O 0 6.885302994419362e-09
haploinsufficiency O 0 4.667985194828361e-06
of O 0 4.57248745533434e-08
distal O 0 0.00018161228217650205
3 O 0 6.41508522676304e-05
p O 0 0.0004719213757198304
. O 0 2.919128291978268e-06

Uniparental B-Disease 1 0.9948126077651978
disomy I-Disease 1 0.9947887659072876
associated O 0 4.628624446922913e-05
with O 0 4.7672119762864895e-07
unbalanced O 0 0.00012931738456245512
segregation O 0 1.1819985957117751e-05
of O 0 6.126744978018905e-08
non O 0 1.4499041753879283e-06
- O 0 6.740545359207317e-05
Robertsonian O 0 4.636116500478238e-05
translocations O 0 1.6322072042385116e-05
has O 0 1.5039134950711741e-06
been O 0 5.095513984088029e-07
reported O 0 1.2193058864795603e-06
previously O 0 3.072474328291719e-07
but O 0 2.1948160622287105e-08
has O 0 4.430260247545448e-08
not O 0 1.4025932637551364e-09
, O 0 1.0143587081401506e-09
to O 0 3.106307988609558e-10
our O 0 1.3936330978125966e-09
knowledge O 0 2.4918469510026853e-09
, O 0 7.364006293641978e-09
been O 0 2.260452092173182e-08
observed O 0 1.0872714284460017e-08
in O 0 5.455790041963837e-09
a O 0 1.570061556321889e-07
case O 0 1.4370740473168553e-06
of O 0 1.019928049572627e-06
PWS B-Disease 1 0.9990299940109253
. O 0 2.499782021914143e-05

Furthermore O 0 1.707307092146948e-05
, O 0 2.2864091420160548e-07
our O 0 6.368328087091868e-08
findings O 0 1.0051919474562965e-07
are O 0 1.81804593601953e-09
best O 0 1.0996662247464428e-08
interpreted O 0 1.1119348997112866e-08
as O 0 8.903245252156466e-09
true O 0 3.5678148435636103e-08
gamete O 0 2.8733945782732917e-06
complementation O 0 2.0464647604967467e-05
resulting O 0 3.4621641589183128e-06
in O 0 1.728051188365498e-06
maternal B-Disease 0 0.0027077996637672186
UPD I-Disease 1 0.999068558216095
15 I-Disease 0 0.00010599973029457033
and O 0 6.089713133405894e-05
PWS B-Disease 1 0.9975771307945251

Schwartz B-Disease 0 0.35237911343574524
- I-Disease 1 0.9925702214241028
Jampel I-Disease 1 0.9959775805473328
syndrome I-Disease 1 0.9997907280921936
type I-Disease 0 0.0005866253050044179
2 I-Disease 0 2.063709644062328e-06
and O 0 1.8034364757113508e-06
Stuve B-Disease 1 0.6987891793251038
- I-Disease 1 0.9994027614593506
Wiedemann I-Disease 1 0.9994722008705139
syndrome I-Disease 1 0.9999169111251831
: O 0 1.5513022333379922e-07
a O 0 7.034618079160282e-07
case O 0 3.1457108207177953e-07
for O 0 2.1872185840265956e-08
" O 0 2.1004251493650372e-07
lumping O 0 3.09897859551711e-06
" O 0 2.098139930239995e-06
. O 0 1.745525082696986e-06

Recent O 0 3.925655619241297e-06
studies O 0 3.7847439671168104e-07
demonstrated O 0 3.9890093717076525e-07
the O 0 1.3920372410325399e-08
existence O 0 3.21916644452358e-08
of O 0 7.905264887142494e-09
a O 0 1.1274903499725042e-07
genetically O 0 1.2120398196202586e-07
distinct O 0 2.2539811794786146e-08
, O 0 1.5130030561749663e-08
usually O 0 1.977567087863008e-08
lethal O 0 6.803117003073567e-08
form O 0 7.170925631072578e-09
of O 0 9.808899470442611e-09
the O 0 1.0697148127292166e-06
Schwartz B-Disease 0 0.003005748614668846
- I-Disease 1 0.9714627265930176
Jampel I-Disease 1 0.994536817073822
syndrome I-Disease 1 0.9997814297676086
( O 0 2.9520451789721847e-06
SJS B-Disease 0 0.1270524263381958
) O 0 1.8998105133505305e-07
of O 0 3.6502717648545513e-07
myotonia B-Disease 1 0.523483157157898
and O 0 2.331768519070465e-05
skeletal B-Disease 1 0.9872578978538513
dysplasia I-Disease 1 0.999659538269043
, O 0 2.5685690161481034e-06
which O 0 1.1361416341060249e-07
we O 0 5.789345891571429e-08
called O 0 6.959388883842621e-06
SJS B-Disease 1 0.6403661370277405
type I-Disease 0 0.00021095926058478653
2 I-Disease 0 5.786966539744753e-06
. O 0 2.385115749348188e-06

This O 0 4.107409040443599e-05
disorder O 1 0.975554883480072
is O 0 1.8368308474236983e-06
reminiscent O 0 7.951569386932533e-06
of O 0 8.756712333024552e-08
another O 0 9.918564501276705e-06
rare O 0 6.661105726379901e-05
condition O 0 0.0015531041426584125
, O 0 2.575864073151024e-07
the O 0 1.3942368468633504e-06
Stuve B-Disease 1 0.8882208466529846
- I-Disease 1 0.9992402791976929
Wiedemann I-Disease 1 0.999381422996521
syndrome I-Disease 1 0.9999327659606934
( O 0 1.1254111313974136e-06
SWS B-Disease 0 0.019236383959650993
) O 0 2.423885625546518e-08
, O 0 8.319069877416041e-09
which O 0 4.040980439157238e-09
comprises O 0 1.6352727172375126e-08
campomelia B-Disease 0 1.1892971997440327e-05
at O 0 4.054341843584552e-06
birth O 0 1.1206388080609031e-05
with O 0 3.0405349207285326e-06
skeletal B-Disease 1 0.992553174495697
dysplasia I-Disease 1 0.999541163444519
, O 0 4.648012691177428e-06
contractures B-Disease 0 0.01117914728820324
, O 0 2.2550267431142856e-07
and O 0 1.959924418315495e-07
early B-Disease 0 9.460944966122042e-06
death I-Disease 0 7.357871072599664e-05
. O 0 2.7971273084403947e-06

To O 0 3.56364637355e-07
test O 0 3.598511568725371e-07
for O 0 2.0368462472220017e-08
possible O 0 1.0398554906032587e-07
nosologic O 0 2.4500028303009458e-05
identity O 0 6.539886499012937e-07
between O 0 6.778125225537224e-07
these O 0 3.4758465972117847e-07
disorders O 0 0.4178779125213623
, O 0 1.3180843438931333e-07
we O 0 1.498576907010829e-08
reviewed O 0 2.1355534229883233e-08
the O 0 4.3792200976611184e-09
literature O 0 3.6887424226250687e-09
and O 0 1.411780470306212e-09
obtained O 0 2.336256965662642e-09
a O 0 7.521676614885564e-09
follow O 0 2.620683892118336e-09
- O 0 1.2525514136996208e-07
up O 0 4.385531049422298e-09
of O 0 5.96880822545387e-10
the O 0 2.058697878837279e-09
only O 0 9.94706983448168e-10
two O 0 3.094541733972278e-09
surviving O 0 2.210283582826378e-06
patients O 0 2.9720004590672033e-07
, O 0 3.6097176359106697e-09
one O 0 3.105201651365519e-09
with O 0 6.298554922068433e-08
SJS B-Disease 0 0.004445930477231741
type I-Disease 0 2.290781594638247e-06
2 I-Disease 0 6.001921093456986e-08
at O 0 2.329926189759135e-07
age O 0 4.503736050764928e-08
10 O 0 6.344998748630815e-09
years O 0 4.613061488356607e-09
and O 0 8.067684298396216e-10
another O 0 4.384653085054424e-09
with O 0 4.354534866024551e-08
SWS B-Disease 0 0.0017577743856236339
at O 0 4.8611527745379135e-06
age O 0 4.432392415765207e-06
7 O 0 2.8076517537556356e-06
years O 0 8.2181531979586e-07
. O 0 9.002157526083465e-07

Patients O 0 0.0017029769951477647
reported O 0 4.518097193795256e-05
as O 0 3.244687434289517e-07
having O 0 2.210405682490091e-06
either O 0 1.4461616046901327e-05
neonatal O 1 0.9996401071548462
SJS B-Disease 1 0.9990218877792358
or O 0 2.7277468689135276e-05
SWS B-Disease 0 0.056725770235061646
presented O 0 8.224880616580776e-07
a O 0 2.0569413550219906e-07
combination O 0 3.0549173857252754e-07
of O 0 1.630781198969089e-08
a O 0 4.119185632589506e-06
severe O 0 0.004597711376845837
, O 0 3.367943463672418e-06
prenatal O 1 0.8221489191055298
- O 1 0.9989916682243347
onset O 1 0.9995359182357788
neuromuscular B-Disease 1 0.9999759197235107
disorder I-Disease 1 0.9999531507492065
( O 0 1.371129292238038e-05
with O 0 0.000287096481770277
congenital B-Disease 1 0.9999812841415405
joint I-Disease 1 0.9956961870193481
contractures I-Disease 1 0.9998862743377686
, O 0 0.09401452541351318
respiratory O 1 0.9998667240142822
and O 0 3.353936335770413e-05
feeding O 0 0.0003724072012118995
difficulties O 0 0.00013147560821380466
, O 0 3.3426346135456697e-07
tendency O 0 8.309984309562424e-07
to O 0 1.2022520934351633e-07
hyperthermia B-Disease 0 0.08638953417539597
, O 0 5.482068488049663e-08
and O 0 1.8654040090382296e-08
frequent O 0 1.1336127272443264e-06
death O 0 1.6251062334049493e-05
in O 0 2.1069091360459424e-07
infancy O 0 9.250636139768176e-06
) O 0 5.4177742292438325e-09
with O 0 4.989793023213451e-09
a O 0 1.2513969238625577e-07
distinct O 0 1.0180631306866417e-06
campomelic B-Disease 0 0.012304454110562801
- I-Disease 0 0.3617619276046753
metaphyseal I-Disease 1 0.6216960549354553
skeletal I-Disease 1 0.9976019263267517
dysplasia I-Disease 1 0.9991706609725952
. O 0 3.9496564568253234e-05

The O 0 4.0972005876938056e-07
similarity O 0 2.988456344610313e-07
of O 0 2.4080982541363483e-08
the O 0 1.820393151774624e-07
clinical O 0 7.590230325149605e-06
and O 0 2.862684311821795e-07
radiographic O 0 0.0005799096543341875
findings O 0 2.7883488655788824e-06
is O 0 7.707089366704167e-08
so O 0 9.695047431534931e-09
extensive O 0 2.482134107140155e-07
that O 0 5.606369768429431e-08
these O 0 9.66941797742038e-08
disorders O 0 0.31126898527145386
appear O 0 5.330837780093134e-07
to O 0 1.712068531389832e-08
be O 0 5.10619635463172e-08
a O 0 4.92082449454756e-07
single O 0 8.819499726087088e-07
entity O 0 1.74569522641832e-05
. O 0 4.731705757876625e-06

The O 0 5.277280479276669e-07
follow O 0 2.0942246692357003e-07
- O 0 1.874733243312221e-06
up O 0 3.2674169148094734e-08
observation O 0 1.4523713787184533e-07
of O 0 1.3119193509325555e-09
an O 0 5.440389472255447e-09
identical O 0 5.8430160265743325e-08
and O 0 5.504130928812856e-09
unique O 0 2.36690560484476e-08
pattern O 0 2.252620333820232e-06
of O 0 6.389888653757225e-07
progressive O 1 0.9666541218757629
bone B-Disease 1 0.9995443224906921
dysplasia I-Disease 1 0.9990965127944946
in O 0 1.1116422911072732e-06
the O 0 1.1086275009120072e-07
two O 0 2.04514648771692e-07
patients O 0 7.934011136967456e-07
( O 0 5.090847743360882e-09
one O 0 6.721624590255715e-09
with O 0 8.511190685567271e-08
SJS B-Disease 0 0.05349079892039299
type I-Disease 0 1.6427540685981512e-05
2 I-Disease 0 1.45814624374907e-07
, O 0 8.768022752292381e-09
one O 0 6.1093321512828425e-09
with O 0 4.272331111110361e-08
SWS B-Disease 0 0.006997255142778158
) O 0 2.288568268227209e-08
surviving O 0 3.960500123412203e-07
beyond O 0 1.8168861970480066e-07
infancy O 0 3.13621399072872e-06
adds O 0 6.818758180315854e-08
to O 0 1.196376664402976e-09
the O 0 2.4401896059345063e-09
evidence O 0 5.818701076520938e-09
in O 0 6.9706915795109126e-09
favor O 0 1.9026819231271475e-08
of O 0 1.8111730781811275e-08
identity O 0 2.261518602608703e-06
. O 0 2.4418634438916342e-06

The O 0 3.289551841589855e-06
hypothesis O 0 5.8505825109023135e-06
that O 0 2.2612934458265954e-07
SWS B-Disease 0 0.0014126913156360388
and O 0 9.622885954740923e-07
SJS B-Disease 0 0.20511433482170105
type I-Disease 0 5.562683872994967e-05
2 I-Disease 0 1.8031732906820253e-07
are O 0 4.255769958660949e-09
the O 0 7.28267366412183e-08
same O 0 1.95202233044256e-06
disorder O 1 0.5757077932357788
should O 0 4.506958717342968e-08
be O 0 3.721618346830269e-09
testable O 0 1.195391963193515e-08
by O 0 3.434864614959565e-09
molecular O 0 5.573620001086965e-07
methods O 0 1.9436393472460622e-07
. O 0 1.8675119406452723e-07
. O 0 7.344791583818733e-07

A O 0 2.4024562662816606e-05
mouse O 0 3.740504689631052e-05
model O 0 1.0426928383822087e-05
of O 0 1.4831690350547433e-05
severe O 1 0.9988946318626404
von B-Disease 1 0.9999899864196777
Willebrand I-Disease 1 0.9999841451644897
disease I-Disease 1 0.9999967813491821
: O 0 0.05173657834529877
defects O 1 0.9991211295127869
in O 0 0.00026963133132085204
hemostasis O 1 0.9962272644042969
and O 0 0.003070064587518573
thrombosis B-Disease 1 0.9992079138755798
. O 0 5.524979133042507e-05

von B-Disease 1 0.9671100378036499
Willebrand I-Disease 1 0.9789985418319702
factor I-Disease 0 0.0011442782124504447
( I-Disease 0 2.0974852304789238e-05
vWf I-Disease 0 0.021612094715237617
) I-Disease 0 0.0018440043786540627
deficiency I-Disease 1 0.9994993209838867
causes O 1 0.9902130961418152
severe O 1 0.9998433589935303
von B-Disease 1 0.9999955892562866
Willebrand I-Disease 1 0.9999860525131226
disease I-Disease 1 0.9999915361404419
in O 0 0.00044615924707613885
humans O 0 5.57916282559745e-05
. O 0 1.1812097909569275e-05

We O 0 5.863836918251764e-07
generated O 0 2.525898139538185e-07
a O 0 9.65161888188959e-08
mouse O 0 5.649257559525722e-07
model O 0 8.47944860993266e-08
for O 0 1.1529217580630302e-08
this O 0 4.0189839012327866e-08
disease O 0 2.3076141587807797e-05
by O 0 3.4619234146049394e-09
using O 0 3.180236163302652e-08
gene O 0 5.148453965375666e-07
targeting O 0 7.297759907487489e-07
. O 0 9.132791660704243e-07

vWf B-Disease 0 0.021602734923362732
- I-Disease 1 0.7479458451271057
deficient I-Disease 0 0.3485122323036194
mice O 0 9.553144627716392e-05
appeared O 0 2.099416860801284e-06
normal O 0 1.5587468169542262e-06
at O 0 1.1085656979048508e-06
birth O 0 7.873807135183597e-07
; O 0 1.1925908260934648e-08
they O 0 6.303239263871774e-09
were O 0 1.4580024298993521e-08
viable O 0 6.85357122165442e-07
and O 0 1.6587550533131434e-07
fertile O 0 2.3481657990487292e-05
. O 0 5.6678759392525535e-06

Neither O 0 0.0005754017038270831
vWf O 0 0.002138251904398203
nor O 0 0.00014096721133682877
vWf O 0 0.0010688946349546313
propolypeptide O 0 0.004319246392697096
( O 0 3.7922839055681834e-06
von B-Disease 0 0.440555602312088
Willebrand I-Disease 1 0.861297070980072
antigen O 0 0.009525084868073463
II O 0 0.08142761886119843
) O 0 7.344287666910532e-08
were O 0 1.663503823579049e-08
detectable O 0 7.332110385505075e-07
in O 0 1.5551350429632294e-08
plasma O 0 3.6414260762285267e-07
, O 0 1.2713406327691246e-08
platelets O 0 6.617884196202795e-07
, O 0 6.259748275283528e-09
or O 0 7.997258855141354e-09
endothelial O 0 4.5163298523220874e-07
cells O 0 3.435816253727353e-08
of O 0 3.0733011691097545e-09
the O 0 6.914733319263178e-08
homozygous O 0 4.023285782750463e-06
mutant O 0 1.5301297025871463e-05
mice O 0 3.9903468859847635e-05
. O 0 1.068681854121678e-06

The O 0 7.606933650095016e-06
mutant O 0 0.0003842688165605068
mice O 0 0.001454535056836903
exhibited O 0 0.0011893784394487739
defects O 1 0.8464288711547852
in O 0 1.4120822697805124e-06
hemostasis O 0 0.0008307136595249176
with O 0 3.085379205458594e-07
a O 0 7.461375389539171e-06
highly O 0 6.46538392174989e-05
prolonged O 0 0.3558727204799652
bleeding O 1 0.9751467108726501
time O 0 3.304596134512394e-07
and O 0 1.5570664402275725e-07
spontaneous O 0 2.1107811335241422e-05
bleeding O 0 0.29581400752067566
events O 0 3.64401735453157e-08
in O 0 1.563811480309596e-08
approximately O 0 1.388669357282879e-08
10 O 0 1.7795327877934142e-08
% O 0 8.139124929584796e-09
of O 0 7.506989163630351e-08
neonates O 0 0.00014929859025869519
. O 0 2.6843590603675693e-06

As O 0 5.914327516620688e-07
in O 0 1.9738162393423409e-07
the O 0 2.3544249927454075e-07
human O 0 1.3605699678009842e-06
disease O 0 0.005280592013150454
, O 0 2.5153036986580446e-08
the O 0 1.8977239335526974e-08
factor O 0 5.662834823283447e-08
VIII O 0 4.0265927964355797e-05
level O 0 5.371679208110436e-07
in O 0 2.3405709370649674e-08
these O 0 3.2886919854036023e-09
mice O 0 5.336494268703973e-07
was O 0 5.902280690861517e-07
reduced O 0 8.022271913432633e-08
strongly O 0 1.1304798874789412e-08
as O 0 3.781610136144309e-09
a O 0 2.2027590418360887e-08
result O 0 9.465711769962581e-09
of O 0 9.084384355872999e-10
the O 0 8.194110279191591e-09
lack O 0 3.185287056339803e-08
of O 0 7.561449244519736e-09
protection O 0 9.302249850406952e-07
provided O 0 1.2424177953107574e-07
by O 0 5.713249038308277e-07
vWf O 0 9.077563299797475e-05
. O 0 3.7276913644745946e-06

Defective O 1 0.9752519130706787
thrombosis B-Disease 1 0.995680570602417
in O 0 6.914983259775909e-06
mutant O 0 0.00011712912964867428
mice O 0 0.00013347675849217921
was O 0 4.725054168375209e-06
also O 0 1.856232678676406e-08
evident O 0 6.598185109396582e-08
in O 0 7.673320645551485e-09
an O 0 6.735639157540163e-09
in O 0 2.6569535904741315e-08
vivo O 0 1.7518588038001326e-06
model O 0 1.2767374073519022e-06
of O 0 2.787280209304299e-06
vascular B-Disease 1 0.9997972846031189
injury I-Disease 1 0.9985002279281616
. O 0 1.927658922795672e-05

In O 0 1.1949061899940716e-06
this O 0 5.597971153292747e-08
model O 0 2.043847899813045e-07
, O 0 1.4343800813776397e-08
the O 0 3.361062539397608e-08
exteriorized O 0 2.836063868016936e-05
mesentery O 0 8.565909956814721e-05
was O 0 2.3179738491307944e-05
superfused O 0 2.8693402782664634e-05
with O 0 1.5569253264402505e-07
ferric O 0 0.0006430568173527718
chloride O 0 1.4052057849767152e-05
and O 0 3.178889684818387e-08
the O 0 4.2671352673551155e-08
accumulation O 0 1.999658707063645e-06
of O 0 3.1204859141098495e-08
fluorescently O 0 9.747148578753695e-05
labeled O 0 3.2326373911928385e-05
platelets O 0 3.789033507928252e-05
was O 0 4.193577296973672e-06
observed O 0 1.3955016697764222e-07
by O 0 4.1209982981627036e-08
intravital O 0 1.7107166058849543e-05
microscopy O 0 1.1750863450288307e-05
. O 0 3.188884647897794e-06

We O 0 1.717303462100972e-06
conclude O 0 9.611090945327305e-07
that O 0 1.6510620426402056e-08
these O 0 8.489640102027352e-09
mice O 0 1.139393930316146e-06
very O 0 9.21766982742156e-08
closely O 0 9.731016916703084e-07
mimic O 0 0.00027665519155561924
severe O 1 0.8797826766967773
human O 0 0.01340431533753872
von B-Disease 1 0.9999969005584717
Willebrand I-Disease 1 0.9999932050704956
disease I-Disease 1 0.9999974966049194
and O 0 2.1327574359020218e-05
will O 0 2.8288096132200735e-07
be O 0 1.7243284133883208e-08
very O 0 5.151250093149429e-09
useful O 0 3.0650708637836033e-09
for O 0 2.0460968475077834e-09
investigating O 0 4.626792815543013e-08
the O 0 4.119062868568335e-09
role O 0 2.105538676744345e-08
of O 0 5.897067723026339e-09
vWf O 0 5.427943392533052e-07
in O 0 3.740621323800042e-08
normal O 0 6.639934895247279e-07
physiology O 0 3.1684346595284296e-06
and O 0 1.7155146281311318e-07
in O 0 3.938254849344958e-06
disease O 0 0.008937443606555462
models O 0 1.5816543736946187e-06
. O 0 3.0803749950791826e-07
. O 0 1.3244530236988794e-06

Oral O 0 0.0006355923833325505
contraceptives O 0 0.0007441338384523988
and O 0 1.6398161051256466e-06
the O 0 3.301261813248857e-06
risk O 0 0.0008674911223351955
of O 0 0.00026746190269477665
hereditary B-Disease 1 0.9999831914901733
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999953508377075
. O 0 0.0003752967168111354

Hereditary B-Disease 1 0.9994750618934631
Ovarian I-Disease 1 0.9999443292617798
Cancer I-Disease 1 0.9995933175086975
Clinical O 0 0.014801989309489727
Study O 0 1.568658626638353e-05
Group O 0 2.1709236534661613e-05
. O 0 3.949749043385964e-06

BACKGROUND O 0 2.6367797545390204e-05
Women O 0 5.354392556000676e-07
with O 0 1.65834705967427e-07
mutations O 0 3.851842393487459e-06
in O 0 6.450208900332655e-08
either O 0 2.987196623394084e-08
the O 0 4.9692612691387694e-08
BRCA1 O 0 2.4860623852873687e-06
or O 0 2.0721047988558894e-08
the O 0 4.52186341703964e-08
BRCA2 O 0 1.1689462553476915e-06
gene O 0 9.817400581368929e-08
have O 0 4.9382862243874115e-09
a O 0 2.046508313924278e-07
high O 0 2.043646964011714e-05
lifetime O 0 0.00012009282363578677
risk O 0 0.006976795848459005
of O 0 0.008600426837801933
ovarian B-Disease 1 0.9999984502792358
cancer I-Disease 1 0.9999915361404419
. O 0 7.036389433778822e-05

Oral O 0 0.004277483560144901
contraceptives O 0 0.17461910843849182
protect O 0 0.2243906557559967
against O 1 0.99970942735672
ovarian B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999945163726807
in O 0 4.096769316674909e-06
general O 0 4.5891104605289e-07
, O 0 9.51095984191852e-08
but O 0 9.917090437738807e-08
it O 0 1.85178432587918e-08
is O 0 1.3519136032869028e-08
not O 0 1.5951073795150705e-09
known O 0 1.60398005988327e-08
whether O 0 5.316330042859363e-09
they O 0 5.044645146057292e-09
also O 0 2.0097132846785826e-08
protect O 0 3.7844552025489975e-07
against O 0 3.1821282391319983e-06
hereditary B-Disease 0 0.09174907207489014
forms I-Disease 0 0.0007037759060040116
of I-Disease 1 0.8236516714096069
ovarian I-Disease 1 0.999998927116394
cancer I-Disease 1 0.9999921321868896
. O 0 0.00012670332216657698

METHODS O 0 9.426918040844612e-06
We O 0 5.162289085092198e-07
enrolled O 0 1.5774110124766594e-06
207 O 0 1.4075834542381926e-06
women O 0 9.120589083977393e-07
with O 0 0.0002596833510324359
hereditary B-Disease 1 0.9999845027923584
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999951124191284
and O 0 2.732561767970765e-07
161 O 0 4.2595889482299754e-08
of O 0 2.5053432661792385e-09
their O 0 5.481595177769805e-09
sisters O 0 1.958566144821816e-07
as O 0 8.327150524678473e-09
controls O 0 1.3455188252464723e-07
in O 0 1.8005643198648613e-08
a O 0 2.868721367121907e-07
case O 0 1.5085042832652107e-06
- O 0 8.880629320628941e-05
control O 0 1.701312794466503e-05
study O 0 1.2241692957104533e-06
. O 0 1.1400276207496063e-06

All O 0 1.8130901935364818e-07
the O 0 2.98313437951947e-07
patients O 0 2.2875221930007683e-06
carried O 0 1.6997165630527888e-07
a O 0 1.0827252339140614e-07
pathogenic O 0 2.5510196337563684e-06
mutation O 0 2.9973668915772578e-06
in O 0 3.934805192784552e-08
either O 0 1.7576344646386133e-07
BRCA1 O 0 1.2191874702693895e-05
( O 0 3.0777378867696825e-08
179 O 0 1.960595596983694e-07
women O 0 3.2501812796681406e-08
) O 0 2.3470622778631878e-08
or O 0 9.196736527883331e-08
BRCA2 O 0 1.3445697732095141e-05
( O 0 9.916239918084102e-08
28 O 0 2.742963488344685e-06
women O 0 2.183792418009034e-07
) O 0 2.3440138363639562e-07
. O 0 1.0003727766161319e-06

The O 0 2.2972333226789488e-06
control O 0 1.0030055818788242e-05
women O 0 1.7909914618030598e-07
were O 0 5.792438528828825e-08
enrolled O 0 2.322452417047316e-07
regardless O 0 2.377402630315828e-08
of O 0 3.603657150463846e-09
whether O 0 2.678374677600459e-08
or O 0 4.7689489690583287e-08
not O 0 7.99806709750328e-09
they O 0 9.22998211194681e-09
had O 0 1.3781445318272745e-07
either O 0 3.1541100042886683e-07
mutation O 0 1.3932471119915135e-05
. O 0 5.764053412349313e-07

Lifetime O 0 7.46814621379599e-05
histories O 0 4.327899659983814e-06
of O 0 1.2580368036196887e-07
oral O 0 2.94748751912266e-05
- O 0 5.189146031625569e-05
contraceptive O 0 2.2030296804587124e-06
use O 0 8.093473446990629e-09
were O 0 8.53650128362915e-09
obtained O 0 2.018837719219846e-08
by O 0 1.4101127376875411e-08
interview O 0 4.375417574919993e-06
or O 0 1.70176743807815e-08
by O 0 4.163517530741956e-09
written O 0 3.512485635681628e-09
questionnaire O 0 1.629537571545825e-08
and O 0 2.360596829120709e-09
were O 0 6.7165752959397196e-09
compared O 0 6.065850755021529e-08
between O 0 4.732450165079172e-08
patients O 0 6.984135438869998e-07
and O 0 1.7423529286020312e-08
control O 0 1.10621704152436e-06
women O 0 4.4897731754645065e-08
, O 0 1.4845146445452428e-08
after O 0 1.0699049823870155e-07
adjustment O 0 1.7326883039459062e-07
for O 0 3.5749383453520522e-09
year O 0 2.1228949265150732e-08
of O 0 6.101576577322021e-09
birth O 0 8.128894819492416e-07
and O 0 1.4155823180317384e-07
parity O 0 3.398678018129431e-05
. O 0 3.4573897664813558e-06

RESULTS O 0 2.770104219962377e-05
The O 0 5.727214897888189e-07
adjusted O 0 2.4565653802710585e-05
odds O 0 0.00022650799655821174
ratio O 0 0.00013133451284375042
for O 0 0.06087047606706619
ovarian B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999979734420776
associated O 0 1.4679461855848785e-05
with O 0 4.279344878455049e-08
any O 0 5.593464358355504e-09
past O 0 1.139185545895316e-08
use O 0 5.440721650984415e-09
of O 0 3.020281980070649e-08
oral O 0 2.121743636962492e-05
contraceptives O 0 0.001149696996435523
was O 0 0.00021767805446870625
0 O 0 2.17179763239983e-06
. O 0 9.056536214302469e-07

5 O 0 1.8797263692249544e-06
( O 0 5.6714604568242066e-08
95 O 0 1.1172118519198193e-07
percent O 0 1.5763419014547253e-07
confidence O 0 1.0781441517337953e-07
interval O 0 1.0783909232259248e-07
, O 0 6.616733827513599e-09
0 O 0 6.203682012539957e-09
. O 0 9.424129254753666e-10
3 O 0 2.388491182614416e-09
to O 0 6.22172646735919e-10
0 O 0 2.9408449009338256e-08
. O 0 1.0474551892514228e-08
8 O 0 1.9394919092974305e-07
) O 0 6.645890238132779e-08
. O 0 3.5983811130790855e-07

The O 0 1.0060442946269177e-05
risk O 0 4.556511339615099e-05
decreased O 0 2.907364887505537e-06
with O 0 1.067263077914049e-08
increasing O 0 4.27630979515925e-08
duration O 0 1.2860489562172006e-07
of O 0 2.106421481684606e-09
use O 0 3.7257659180056635e-09
( O 0 9.770583453416748e-09
P O 0 1.210659775097156e-06
for O 0 6.791653461846181e-09
trend O 0 1.1833871838007326e-07
, O 0 4.962363409077852e-09
< O 0 9.151975888244124e-08
0 O 0 7.950309743876005e-09
. O 0 8.822235164629433e-10
001 O 0 5.6366271650176714e-08
) O 0 9.403122724904733e-10
; O 0 3.156651884328454e-10
use O 0 2.677340293910646e-10
for O 0 6.024326038023275e-10
six O 0 2.501322926562466e-09
or O 0 8.641307114309882e-10
more O 0 5.222059451526206e-10
years O 0 3.4180700936303765e-08
was O 0 2.6702599598138477e-07
associated O 0 4.971572042933303e-09
with O 0 1.2059946374876063e-09
a O 0 3.995846853399598e-08
60 O 0 7.863116735506992e-08
percent O 0 3.2297327834385214e-07
reduction O 0 1.3203896287450334e-06
in O 0 3.7550901765825984e-07
risk O 0 2.344017593713943e-05
. O 0 9.50520814058109e-07

Oral O 0 0.000651966780424118
- O 0 0.0003238119534216821
contraceptive O 0 5.4102943977341056e-05
use O 0 1.1869718719026423e-06
protected O 0 0.03098640777170658
against O 1 0.9934991598129272
ovarian B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999861717224121
both O 0 3.678724880273876e-08
for O 0 9.328029904054347e-09
carriers O 0 7.681802571823937e-08
of O 0 2.767212459175994e-09
the O 0 2.1522090776215919e-07
BRCA1 O 0 5.7454020861769095e-05
mutation O 0 1.9924138996429974e-06
( O 0 1.454910503184692e-08
odds O 0 9.34356648940593e-07
ratio O 0 1.1677680333832541e-07
, O 0 4.646192319768261e-09
0 O 0 3.479611931922477e-09
. O 0 5.382093659633824e-10
5 O 0 2.430105894291046e-09
; O 0 7.757062214786004e-10
95 O 0 5.949602588373182e-09
percent O 0 1.803609706030329e-08
confidence O 0 1.7471684543579613e-08
interval O 0 2.1769883673528057e-08
, O 0 1.875503086168351e-09
0 O 0 2.0100687780910675e-09
. O 0 5.691762616777396e-10
3 O 0 1.271524330270779e-09
to O 0 1.4120948854667859e-10
0 O 0 4.314502533020459e-09
. O 0 1.1439795777334894e-09
9 O 0 9.820712243424623e-09
) O 0 4.920777119110653e-10
and O 0 5.662396662664548e-10
for O 0 5.168943606470577e-10
carriers O 0 2.5087874888640727e-08
of O 0 2.797216014371884e-09
the O 0 1.7518409833883197e-07
BRCA2 O 0 1.8774437194224447e-05
mutation O 0 1.497370476499782e-06
( O 0 1.443249786348133e-08
odds O 0 8.233042194660811e-07
ratio O 0 9.036212134105881e-08
, O 0 6.940469976512986e-09
0 O 0 7.3781922793614285e-09
. O 0 1.7958989850797025e-09
4 O 0 6.14544504173864e-09
; O 0 9.105183274016326e-10
95 O 0 6.919545825212481e-09
percent O 0 2.595029258145587e-08
confidence O 0 2.919924391164841e-08
interval O 0 2.4371532347799985e-08
, O 0 1.6019888748886046e-09
0 O 0 2.7276072511739358e-09
. O 0 4.68679484111334e-10
2 O 0 2.513235619616694e-09
to O 0 3.8611394637122487e-10
1 O 0 2.0891533836220333e-08
. O 0 5.298735672454313e-09
1 O 0 1.2389946846269595e-07
) O 0 6.020127329975367e-08
. O 0 3.95159645449894e-07

CONCLUSIONS O 0 6.345807923935354e-05
Oral O 0 6.543798372149467e-05
- O 0 7.306124462047592e-05
contraceptive O 0 6.951150226086611e-06
use O 0 5.8589296969557836e-08
may O 0 3.692440486702253e-07
reduce O 0 4.2662892951739195e-07
the O 0 5.14391899741895e-07
risk O 0 0.0003098843735642731
of O 0 0.0012478354619815946
ovarian B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999935626983643
in O 0 1.6133772078319453e-06
women O 0 9.524484312350978e-08
with O 0 7.060561557636902e-08
pathogenic O 0 1.4159836609906051e-05
mutations O 0 4.278073902241886e-06
in O 0 1.2719232245217427e-07
the O 0 5.755292136200296e-07
BRCA1 O 0 0.0002014861674979329
or O 0 1.0852785635506734e-05
BRCA2 O 0 0.00238952343352139
gene O 0 0.0007512597949244082

A O 0 3.4339347621425986e-05
Japanese O 0 1.2763704035023693e-05
family O 0 3.910604391421657e-06
with O 0 2.097759761454654e-06
adrenoleukodystrophy B-Disease 1 0.9995761513710022
with O 0 2.118207760304358e-07
a O 0 6.019599823048338e-07
codon O 0 8.758379976825381e-07
291 O 0 2.1800137517402618e-07
deletion O 0 5.018429192205076e-07
: O 0 1.0157319429993095e-08
a O 0 8.210572133293681e-08
clinical O 0 2.6460809294803767e-06
, O 0 3.599145870225584e-08
biochemical O 0 5.400641839514719e-06
, O 0 1.2497390855514823e-07
pathological O 0 4.1340204916195944e-05
, O 0 1.2980565600173577e-07
and O 0 5.420122306531994e-07
genetic O 0 0.00022135389735922217
report O 0 6.882049092382658e-06
. O 0 1.9289384454168612e-06

We O 0 2.354104481128161e-06
report O 0 3.7816630538145546e-07
a O 0 1.9679801255279017e-07
Japanese O 0 2.7087119178759167e-06
family O 0 1.4133273907646071e-05
with O 0 9.155937004834414e-05
adrenoleukodystrophy B-Disease 1 0.9999560117721558
( O 0 0.00015756752691231668
ALD B-Disease 1 0.999910831451416
) O 0 8.486794200734948e-08
with O 0 9.357717267732824e-09
a O 0 1.3328840964277333e-07
three O 0 1.6419548387602845e-08
base O 0 2.2341048122598295e-07
pair O 0 1.6133697045006556e-07
deletion O 0 4.80966320992593e-07
( O 0 1.2208117183831746e-08
delGAG O 0 8.475662980345078e-07
291 O 0 1.5413215237458644e-07
) O 0 1.062198329293551e-08
in O 0 5.917069501037986e-08
the O 0 2.499043148418423e-06
ALD B-Disease 1 0.9990565180778503
gene O 0 0.00033157787402160466
. O 0 7.80923346610507e-06

A O 0 3.6801191072299844e-06
variety O 0 2.1319075926840014e-07
of O 0 5.8574546102363456e-08
phenotypes O 0 6.852592377981637e-06
were O 0 1.475752355872828e-07
observed O 0 3.834905157873436e-07
within O 0 5.269530589657734e-08
this O 0 5.155833804337817e-08
family O 0 3.67878556062351e-06
. O 0 2.47110438067466e-06

While O 0 3.910320629074704e-06
the O 0 7.085167794684821e-07
proband O 0 0.00010693945660023019
( O 0 3.4256615322192374e-07
patient O 0 2.08216533792438e-05
1 O 0 5.205779984862602e-07
) O 0 3.052039687645447e-08
was O 0 4.362392701295903e-06
classified O 0 3.2469966981807374e-07
as O 0 2.03077910043703e-08
having O 0 8.326359335342204e-08
a O 0 6.342061453779024e-08
rare O 0 1.0494512991954252e-07
intermediate O 0 7.551780072390102e-07
type O 0 9.608910431779805e-07
of O 0 2.2741131644465895e-08
adult O 0 4.708263531938428e-06
cerebral O 0 0.03520019352436066
and O 0 2.5301342247985303e-06
cerebello O 1 0.7741813063621521
- O 1 0.9838619828224182
brain O 1 0.8314558267593384
stem O 0 6.852526894363109e-06
forms O 0 2.2804945842835878e-07
, O 0 4.4482188599204164e-08
his O 0 3.0477877999146585e-07
younger O 0 1.8014355873674504e-06
brother O 0 1.304404668189818e-05
( O 0 1.171974091107586e-07
patient O 0 8.248105586972088e-06
2 O 0 1.1158488177898107e-07
) O 0 5.950328674231287e-09
and O 0 4.729625757704525e-08
nephew O 0 5.650455568684265e-05
( O 0 1.504293720699934e-07
patient O 0 1.5484287359868176e-05
3 O 0 1.259394508679179e-07
) O 0 1.299029506185434e-08
had O 0 6.688426879009057e-07
a O 0 3.294916314189322e-05
childhood O 0 0.34785979986190796
ALD B-Disease 1 0.9998964071273804
type O 0 0.3695012629032135
. O 0 2.7626696464722045e-05

Another O 0 1.65516776178265e-05
nephew O 0 0.00032313872361555696
( O 0 5.137682705935731e-07
patient O 0 1.599525785422884e-05
4 O 0 1.279563690559371e-07
) O 0 5.5424140832371904e-09
of O 0 1.6301344274438634e-08
patient O 0 2.873050470952876e-05
1 O 0 1.074606302609027e-06
was O 0 2.414378832327202e-05
classified O 0 4.958841941515857e-07
as O 0 5.715418893714741e-08
having O 0 1.136737708407054e-07
an O 0 2.748551537479216e-07
adolescent O 0 0.000379920587874949
form O 0 9.388500984641723e-06
. O 0 2.46705667450442e-06

The O 0 1.2244166782693355e-06
tau O 0 7.967511010065209e-06
level O 0 1.7408867734047817e-06
in O 0 1.457807030647018e-07
the O 0 5.007285608371603e-07
cerebrospinal O 0 0.00582049461081624
fluid O 0 0.0005803991807624698
( O 0 6.425325409509242e-07
CSF O 0 0.01154656708240509
) O 0 3.5000685016939315e-08
in O 0 7.854782779759262e-08
patient O 0 4.1851071728160605e-06
1 O 0 1.29618626942829e-07
was O 0 2.2027650175004965e-06
as O 0 2.8695387399579886e-08
high O 0 3.231562857308745e-07
as O 0 5.386317170064103e-09
that O 0 1.4779425461242113e-09
of O 0 9.278876333951303e-09
patients O 0 4.699027613241924e-06
with O 0 1.774447264324408e-05
Alzheimers B-Disease 1 0.9998308420181274
disease I-Disease 1 0.9955209493637085
( O 0 4.142327725276118e-07
AD B-Disease 0 7.193996680143755e-06
) O 0 5.73272359360999e-07
. O 0 1.2249072369741043e-06

His O 0 2.3813974621589296e-05
brain O 0 0.0021031335927546024
magnetic O 0 9.6386229415657e-06
resonance O 0 2.4460854547214694e-05
image O 0 2.1936830307822675e-05
( O 0 4.7282009063565056e-07
MRI O 0 0.0007696900283917785
) O 0 2.2340236682794057e-07
showed O 0 1.4543935321853496e-05
abnormalities B-Disease 0 0.0023421626538038254
in I-Disease 0 7.278258351561817e-08
the I-Disease 0 7.260551626586675e-08
bilateral I-Disease 0 8.041564797167666e-06
cerebellar I-Disease 0 0.007365818601101637
hemispheres I-Disease 0 0.00010383410699432716
and O 0 1.3836501238984056e-05
brain O 1 0.8534347414970398
stem O 0 6.141577614471316e-05
, O 0 3.614115371419757e-07
but O 0 3.88304854936905e-08
not O 0 6.295597376748674e-09
in O 0 2.341964311369793e-08
the O 0 5.639734581563971e-07
cerebral O 0 0.006853971164673567
white O 0 1.4966551589168375e-06
matter O 0 6.722370926581789e-08
, O 0 8.270673035326581e-09
where O 0 1.3999132519870727e-08
marked O 0 2.433117742839386e-07
reductions O 0 9.237794529326493e-07
of O 0 3.4360045919612503e-09
the O 0 1.481906934941435e-07
cerebral O 0 0.0019074894953519106
blood O 0 2.316233576493687e-06
flow O 0 1.0721787191414478e-07
and O 0 2.3078992938962983e-08
oxygen O 0 1.5723511523901834e-06
metabolism O 0 2.253178990940796e-06
were O 0 1.34295961018438e-08
clearly O 0 5.881041786892638e-08
demonstrated O 0 6.442180477961301e-08
by O 0 9.873093453904858e-09
positron O 0 5.139916083862772e-06
emission O 0 6.249263151403284e-06
tomography O 0 1.3123378266755026e-05
( O 0 2.8670777396655467e-07
PET O 0 3.0698563932674006e-05
) O 0 4.6112430140965444e-07
. O 0 1.489971850787697e-06

In O 0 3.7575007354462286e-06
patients O 0 3.1114695957512595e-06
2 O 0 1.755758063382018e-07
and O 0 3.318833208254546e-08
3 O 0 1.5192559033039288e-07
, O 0 3.2289868556745205e-08
the O 0 2.409881574294559e-07
autopsy O 0 0.00037478990270756185
findings O 0 8.347411153408757e-07
showed O 0 2.139779826393351e-05
massive O 0 0.0012361693661659956
demyelination B-Disease 1 0.9996767044067383
of I-Disease 0 5.889825729354925e-07
the I-Disease 0 1.5335463103838265e-05
cerebral I-Disease 1 0.7518665790557861
white I-Disease 0 3.225950877094874e-06
matter I-Disease 0 2.4646592322596916e-08
with O 0 3.5091110017759775e-09
sparing O 0 2.360976303350526e-08
of O 0 4.010451526426095e-09
the O 0 6.897740689737475e-08
U O 0 7.819548045517877e-06
- O 0 1.9586233975132927e-05
fibers O 0 7.109615580702666e-07
, O 0 7.169203009027569e-09
compatible O 0 1.3393425923879931e-08
with O 0 7.72350894351348e-09
the O 0 1.4602601083879563e-07
findings O 0 5.169122232473455e-07
of O 0 6.525557409986504e-07
childhood O 0 0.13696815073490143
ALD B-Disease 1 0.9998425245285034
. O 0 5.8761201216839254e-05

Oleic O 0 0.006540910340845585
and O 0 4.968103894498199e-06
erucic O 0 0.002879240084439516
acids O 0 3.4234872146043926e-06
( O 0 7.388968725763334e-08
Lorenzos O 0 4.724180143966805e-06
Oil O 0 2.7091513743471296e-07
) O 0 8.493429071165792e-09
were O 0 6.773645644386761e-09
administered O 0 6.242677130785523e-08
to O 0 4.137140852122911e-09
patients O 0 1.456935621035882e-07
1 O 0 2.8882576330602205e-08
and O 0 5.267477565240597e-09
4 O 0 7.866836426728696e-08
, O 0 9.188265259751915e-09
but O 0 3.5560596689521162e-09
sufficient O 0 9.08085517892232e-09
effectiveness O 0 3.652569944279094e-07
was O 0 8.517145033692941e-06
not O 0 1.876187205596125e-08
obtained O 0 3.6522146729112137e-07
. O 0 6.830589995843184e-07

The O 0 1.962286205525743e-06
findings O 0 8.778247320151422e-07
in O 0 6.135422125908008e-08
this O 0 9.912453968752288e-09
family O 0 2.026666408028177e-07
suggest O 0 3.5712119483832794e-08
that O 0 6.067989222202641e-09
delGAG291 O 0 1.7012326907206443e-06
is O 0 9.769278719318208e-09
part O 0 4.791119057045989e-09
of O 0 1.7818890807319576e-09
the O 0 1.1828433343907818e-07
cause O 0 8.872664807313413e-07
of O 0 5.963169513734101e-08
Japanese O 0 0.00014588941121473908
ALD B-Disease 1 0.9995458722114563
with O 0 1.7148583992820932e-06
phenotypic O 0 0.00019899290055036545
variations O 0 0.00011351372813805938
. O 0 1.4372371879289858e-05

Moreover O 0 1.4668519725091755e-05
, O 0 1.531390694253787e-07
although O 0 2.9766686893140104e-08
the O 0 1.1833777513459154e-08
scale O 0 5.340297093425761e-07
of O 0 8.192969858100696e-09
the O 0 4.122146179952324e-08
study O 0 1.5765756700147904e-08
is O 0 4.772840789257771e-09
limited O 0 1.2174888652793925e-08
, O 0 8.217117652975503e-09
there O 0 1.1673667366096652e-08
is O 0 1.521842207807822e-08
a O 0 7.552170444569128e-08
possibility O 0 1.035838934626554e-07
that O 0 6.790643158893772e-09
PET O 0 1.3847146647094632e-06
can O 0 1.5757279925310286e-08
detect O 0 2.123860213032458e-06
an O 0 4.2513752873674093e-07
insidious B-Disease 0 0.0010553145548328757
lesion I-Disease 1 0.7733374834060669
which O 0 1.7897860971061164e-07
is O 0 7.910516330866812e-08
undetectable O 0 2.2326062207866926e-06
by O 0 7.323833095540522e-09
computed O 0 3.507340124997427e-07
tomogram O 0 1.3525911526812706e-05
( O 0 4.292801136784874e-08
CT O 0 0.00011742996866814792
) O 0 2.5134319070474476e-09
or O 0 4.875376102830842e-09
MRI O 0 1.6668790294716018e-06
analysis O 0 5.9256839435306574e-09
, O 0 2.546505672995636e-09
and O 0 1.0757235102687446e-09
that O 0 2.8194868662012595e-10
the O 0 2.0024386593320287e-09
higher O 0 1.8877599927691335e-08
level O 0 1.8575857296809772e-08
of O 0 4.185325863659273e-09
tau O 0 2.0171101766663924e-07
reflects O 0 9.965932967759272e-09
the O 0 2.960993006340118e-09
process O 0 1.8276288926699635e-08
of O 0 1.1201948524330874e-07
neuronal B-Disease 0 0.00022481707856059074
degeneration I-Disease 1 0.9918855428695679
in O 0 0.0008951157215051353
ALD B-Disease 1 0.9997366070747375
. O 0 0.00011712622654158622

Lorenzos O 0 0.0006845616735517979
Oil O 0 1.33943776745582e-05
should O 0 1.1271797006884299e-07
be O 0 9.130648237487549e-09
given O 0 1.7756429659954165e-09
in O 0 4.049530044625271e-09
the O 0 6.63642607534598e-09
early O 0 1.7742432589784585e-07
stage O 0 7.531723895226605e-06
. O 0 2.0895404873044754e-07
. O 0 9.619004686101107e-07

Nonsense O 0 0.00020513145136646926
mutation O 0 5.3172650950727984e-05
in O 0 2.1691985807592573e-07
exon O 0 4.711951078206766e-06
4 O 0 1.580265802658687e-07
of O 0 6.40738750945502e-09
human O 0 3.7792325713326136e-08
complement O 0 3.6594209973372926e-07
C9 O 0 0.00028404552722349763
gene O 0 4.083133262611227e-06
is O 0 1.689862045850532e-07
the O 0 4.6838504630386524e-08
major O 0 8.742209502088372e-06
cause O 0 2.123625336025725e-06
of O 0 4.641535866767299e-08
Japanese O 0 2.9913077014498413e-05
complement B-Disease 0 0.00047648794134147465
C9 I-Disease 1 0.9966226816177368
deficiency I-Disease 1 0.9986648559570312
. O 0 1.7082355043385178e-05

Deficiency B-Disease 1 0.9909819960594177
of I-Disease 0 2.0613320828033466e-07
the I-Disease 0 3.419844745167211e-07
ninth I-Disease 0 1.3068325642962009e-05
component I-Disease 0 6.280895945565135e-07
of I-Disease 0 1.46276555312852e-08
human I-Disease 0 5.0702293918902797e-08
complement I-Disease 0 2.154932303710666e-07
( O 0 1.0056311339212698e-07
C9 O 0 0.00013426579243969172
) O 0 2.3553315742219638e-08
is O 0 1.9893324321174077e-08
the O 0 1.0256919757978267e-08
most O 0 3.3562063350700555e-08
common O 0 3.563099653547397e-06
complement B-Disease 1 0.9341630935668945
deficiency I-Disease 1 0.9999655485153198
in O 0 1.3554349607147742e-06
Japan O 0 4.072951469424879e-06
but O 0 1.2944863669872575e-07
is O 0 7.310521965564476e-08
rare O 0 1.5374972406334564e-07
in O 0 1.1544511124839119e-08
other O 0 4.116769591888669e-09
countries O 0 1.994997944620991e-08
. O 0 9.77552417680272e-07

We O 0 6.433099883906834e-07
studied O 0 3.671852084607963e-07
the O 0 1.899165091856503e-08
molecular O 0 4.315517116992851e-07
basis O 0 4.3384350334463306e-08
of O 0 4.6081217419668974e-07
C9 B-Disease 1 0.9918757677078247
deficiency I-Disease 1 0.9900262355804443
in O 0 2.0694039903901285e-07
four O 0 1.419873711938635e-07
Japanese O 0 1.344405609415844e-05
C9 B-Disease 1 0.6016138195991516
- I-Disease 1 0.8413615226745605
deficient I-Disease 1 0.5562503933906555
patients O 0 6.793123611714691e-05
who O 0 4.313675162848085e-06
had O 0 9.710290032671764e-05
suffered O 1 0.9901624917984009
from O 0 0.0007591216708533466
meningococcal B-Disease 1 0.9998728036880493
meningitis I-Disease 1 0.9998326301574707
. O 0 2.307046452187933e-05

Direct O 0 4.078857500644517e-07
sequencing O 0 1.2415736136972555e-06
of O 0 4.9466979845647074e-08
amplified O 0 1.423939352207526e-06
C9 O 0 1.2590233382070437e-05
cDNA O 0 4.338758401445375e-07
and O 0 5.129663094294301e-08
DNA O 0 1.268448158953106e-06
revealed O 0 6.166471280266705e-07
a O 0 1.2758083300923317e-07
nonsense O 0 8.54538086514367e-07
substitution O 0 9.175798965088688e-08
( O 0 3.7556127097104763e-08
CGA O 0 4.838443601329345e-06
- O 0 9.939520168700255e-06
- O 0 9.973206942959223e-06
> O 0 4.336032475293905e-07
TGA O 0 9.58674149842409e-07
) O 0 4.654592267172575e-09
at O 0 1.8542653634767703e-08
codon O 0 6.886698145081027e-08
95 O 0 1.082706191368743e-08
in O 0 5.862783591936704e-09
exon O 0 3.660548486550397e-07
4 O 0 3.2399931626514444e-08
in O 0 4.79709916234583e-09
the O 0 1.1586114290196292e-08
four O 0 2.605872282401833e-07
C9 B-Disease 0 0.029120253399014473
- I-Disease 0 0.23864047229290009
deficient I-Disease 0 0.004745353013277054
individuals O 0 1.896465278150572e-07
. O 0 1.226709969159856e-06

An O 0 8.258442107944575e-07
allele O 0 4.344441094872309e-06
- O 0 3.2209893561230274e-06
specific O 0 3.053017749721221e-08
polymerase O 0 2.1635078155668452e-06
chain O 0 4.679359790316084e-06
reaction O 0 5.120201080899278e-07
system O 0 8.154105444191373e-07
designed O 0 9.641352249900592e-08
to O 0 1.377131408908383e-09
detect O 0 3.5463415315462044e-08
exclusively O 0 1.022476214807e-09
only O 0 4.114977802949227e-10
one O 0 3.094546008330923e-10
of O 0 3.704817008731709e-10
the O 0 3.6228506861135656e-09
normal O 0 6.921582240693169e-08
and O 0 6.07456707157894e-09
mutant O 0 1.1022851964526126e-07
alleles O 0 1.855092968128247e-08
indicated O 0 3.2320432552523926e-08
that O 0 2.472609617054644e-10
all O 0 6.39756303488781e-11
the O 0 1.3516704422400494e-09
four O 0 1.2493811318847747e-08
patients O 0 4.0751938712446645e-08
were O 0 2.6405129194273513e-09
homozygous O 0 1.0983162823663406e-08
for O 0 7.894215281467609e-10
the O 0 6.808904107202807e-09
mutation O 0 5.3559958246296446e-08
in O 0 6.134378782718386e-09
exon O 0 3.151073428853124e-07
4 O 0 5.556908178050435e-08
and O 0 3.932671965856116e-09
that O 0 1.2110449310043236e-09
the O 0 4.4318722025593615e-09
parents O 0 7.621816067171494e-09
of O 0 8.98119001391251e-09
patient O 0 6.219214355951408e-06
2 O 0 3.2487372436662554e-07
were O 0 1.5098774497346312e-07
heterozygous O 0 5.591527042270172e-06
. O 0 1.4032569879418588e-06

The O 0 1.1547283520485507e-06
common O 0 1.5192428008958814e-06
mutation O 0 6.551736532856012e-06
at O 0 6.439981348194124e-07
codon O 0 2.2630668183865055e-07
95 O 0 5.694037952252984e-08
in O 0 2.233022122766215e-08
exon O 0 1.548349132463045e-06
4 O 0 3.25993511296474e-07
might O 0 5.0041009558299265e-08
be O 0 5.6309725771086505e-09
responsible O 0 5.5552121125401754e-08
for O 0 1.532164262130209e-08
most O 0 3.256374441207299e-07
Japanese O 0 0.0006607373943552375
C9 B-Disease 1 0.997963547706604
deficiency I-Disease 1 0.9989410042762756
. O 0 6.78716844504379e-07
. O 0 1.689038526819786e-06

BRCA1 O 0 0.00036947077023796737
required O 0 1.1377846931281965e-06
for O 0 5.474127817706176e-08
transcription O 0 9.503862202109303e-06
- O 0 0.00013742997543886304
coupled O 0 1.3072864021523856e-05
repair O 0 0.0009276685887016356
of O 0 2.152915072883843e-07
oxidative O 0 0.060619134455919266
DNA O 0 0.027798060327768326
damage O 0 0.1317937821149826
. O 0 5.515048542292789e-06

The O 0 0.000171221952768974
breast B-Disease 1 0.9965503215789795
and I-Disease 0 0.36479148268699646
ovarian I-Disease 1 0.9999972581863403
cancer I-Disease 1 0.9999852180480957
susceptibility O 0 0.035697028040885925
gene O 0 3.098515298916027e-05
BRCA1 O 0 5.0290211220271885e-05
encodes O 0 8.653914846945554e-07
a O 0 1.622991476324387e-06
zinc O 0 0.00014771446876693517
finger O 0 3.3624012303334894e-06
protein O 0 1.8849219429739605e-07
of O 0 2.06520773815555e-08
unknown O 0 1.2341942010607454e-06
function O 0 1.85657290785457e-06
. O 0 1.7806961523092468e-06

Association O 0 2.4320188458659686e-06
of O 0 2.1635102598338563e-08
the O 0 6.260467699803485e-08
BRCA1 O 0 2.840460183506366e-06
protein O 0 3.2294551033373864e-08
with O 0 3.5540932419309e-09
the O 0 1.9744049950531917e-08
DNA O 0 1.3155906799511285e-06
repair O 0 0.00010015202133217826
protein O 0 2.940388696970331e-07
Rad51 O 0 6.7908272285421845e-06
and O 0 9.78529879347434e-09
changes O 0 1.0085734913900524e-08
in O 0 1.3388361530530801e-09
the O 0 4.692949362450349e-10
phosphorylation O 0 1.8182781946762816e-09
and O 0 1.1925629372910862e-09
cellular O 0 1.8355333963882003e-07
localization O 0 5.2094005553726674e-08
of O 0 1.086953638207433e-09
the O 0 4.039177436965247e-09
protein O 0 2.0378720932967553e-08
after O 0 5.9269982699561297e-08
exposure O 0 1.2723636189093668e-07
to O 0 2.168078161446374e-09
DNA O 0 8.910416227081441e-07
- O 0 1.2593150131579023e-05
damaging O 0 5.065985078545054e-06
agents O 0 3.6934192593207626e-08
are O 0 5.421048054898847e-10
consistent O 0 2.964366752067349e-09
with O 0 1.9307060394879727e-09
a O 0 2.7611985586872834e-08
role O 0 9.608876183619941e-08
for O 0 6.464150459351004e-08
BRCA1 O 0 3.376316817593761e-05
in O 0 8.24651124275988e-07
DNA O 0 6.934591510798782e-05
repair O 0 0.02934664487838745
. O 0 6.587467396457214e-06

Here O 0 3.1188935736281564e-06
, O 0 2.0023732361096336e-07
it O 0 1.9045266697048646e-08
is O 0 1.6365081734193154e-08
shown O 0 2.2123677112517726e-08
that O 0 3.8785161748933206e-09
mouse O 0 1.054466906680318e-06
embryonic O 0 7.763307621644344e-06
stem O 0 1.1292372619209345e-05
cells O 0 1.145916849054629e-05
deficient B-Disease 0 0.00021280290093272924
in I-Disease 0 1.0511259773693382e-07
BRCA1 I-Disease 0 6.629661584156565e-06
are O 0 4.96334795485609e-09
defective O 0 3.6527162592392415e-06
in O 0 2.105731589097104e-08
the O 0 7.055954487356075e-09
ability O 0 4.289222310660534e-09
to O 0 9.832871183945713e-10
carry O 0 3.483901833689629e-09
out O 0 8.146020746835347e-09
transcription O 0 4.547764262952114e-07
- O 0 1.1345136044838e-05
coupled O 0 1.726191499074048e-06
repair O 0 0.00012008928752038628
of O 0 5.273481562539928e-08
oxidative O 0 0.001265094499103725
DNA O 0 0.0006981504848226905
damage O 0 0.0075247869826853275
, O 0 7.192859641236282e-08
and O 0 1.9778498838718406e-08
are O 0 7.181287120516799e-09
hypersensitive O 0 2.851554745575413e-05
to O 0 1.3167074541797774e-07
ionizing O 0 0.0021925359033048153
radiation O 0 0.009414639323949814
and O 0 1.5754341120555182e-07
hydrogen O 0 1.1396633453841787e-05
peroxide O 0 0.0008156721014529467
. O 0 2.7549178867047885e-06

These O 0 3.2863928822735033e-07
results O 0 1.625317963771522e-06
suggest O 0 1.9245894122832397e-07
that O 0 2.3635898571683356e-08
BRCA1 O 0 9.268580470234156e-06
participates O 0 5.541845666812151e-07
, O 0 1.566387730633778e-08
directly O 0 9.235053610723298e-09
or O 0 1.6211238573760056e-08
indirectly O 0 8.17991931967299e-08
, O 0 8.262883710585811e-09
in O 0 1.3313095514888573e-08
transcription O 0 1.4292547803052003e-06
- O 0 2.863518056983594e-05
coupled O 0 6.482976459665224e-06
repair O 0 0.0002311171847395599
of O 0 1.9611584889389633e-07
oxidative O 0 0.049672190099954605
DNA O 0 0.003984841052442789
damage O 0 0.0650080144405365
. O 0 4.172841556737694e-07
. O 0 1.3253956012704293e-06

Truncation O 0 0.00038027155096642673
mutations O 0 0.00024004043370950967
in O 0 7.873717322581797e-07
the O 0 1.8572248450254847e-07
transactivation O 0 2.2572292436962016e-05
region O 0 1.5007128695287975e-06
of O 0 8.551840124937371e-08
PAX6 O 0 0.0001973319158423692
result O 0 1.8302332591701997e-06
in O 0 4.0692566471989267e-07
dominant O 0 0.00010734310490079224
- O 0 0.001616179128177464
negative O 0 4.2760998439916875e-06
mutants O 0 1.9957053154939786e-05
. O 0 1.9006491811524029e-06

PAX6 O 0 0.0032115685753524303
is O 0 5.998407459628652e-07
a O 0 6.436014388100375e-08
transcription O 0 3.5701026490642107e-07
factor O 0 5.707009265165652e-08
with O 0 5.795817159537364e-09
two O 0 5.625175880652478e-09
DNA O 0 3.316258414542972e-07
- O 0 1.1794386409746949e-06
binding O 0 5.3556998835802005e-08
domains O 0 5.4813884986515404e-08
( O 0 9.60024415519456e-09
paired O 0 1.8844616533897351e-07
box O 0 4.4399547505236114e-07
and O 0 1.572545293981875e-08
homeobox O 0 6.300999757513637e-07
) O 0 3.1080518159143367e-09
and O 0 7.491481213151019e-09
a O 0 1.605655199909961e-07
proline O 0 2.0179079456283944e-06
- O 0 3.165348289257963e-06
serine O 0 7.864156827963598e-07
- O 0 5.0533039939182345e-06
threonine O 0 1.7831976037996355e-06
( O 0 8.476440882532188e-08
PST O 0 3.4818480344256386e-05
) O 0 2.0771902597971348e-07
- O 0 6.622173259529518e-06
rich O 0 1.946634938576608e-06
transactivation O 0 6.180316995596513e-05
domain O 0 1.4792322872381192e-05
. O 0 3.847525022138143e-06

PAX6 O 0 0.041510775685310364
regulates O 0 0.0035079859662801027
eye O 0 0.0011303675128147006
development O 0 1.767155367815576e-06
in O 0 2.952693876068224e-07
animals O 0 6.934544671821641e-08
ranging O 0 3.8083507547526096e-07
from O 0 3.1794172627996886e-08
jellyfish O 0 1.323676031006471e-07
to O 0 1.2420742212526648e-09
Drosophila O 0 1.3484164007593336e-08
to O 0 1.0956987317456424e-08
humans O 0 3.410861495467543e-07
. O 0 7.602652090099582e-07

Heterozygous O 0 0.0001399791071889922
mutations O 0 0.0001467958791181445
in O 0 4.2752250806188385e-07
the O 0 1.5339264791691676e-07
human O 0 3.193907787135686e-07
PAX6 O 0 0.00019730671192519367
gene O 0 2.998610398208257e-06
result O 0 4.8100389449246e-07
in O 0 1.4804909298504754e-08
various O 0 6.1776699311622e-09
phenotypes O 0 1.8594984112496604e-06
, O 0 5.5925280406654565e-08
including O 0 6.77158027428959e-07
aniridia B-Disease 1 0.9997894167900085
, O 0 0.00019185761630069464
Peters B-Disease 1 0.9995613694190979
anomaly I-Disease 1 0.9998451471328735
, O 0 1.2108364899177104e-05
autosomal B-Disease 0 0.08888101577758789
dominant I-Disease 0 0.009383795782923698
keratitis I-Disease 1 0.5674958825111389
, O 0 9.653838787926361e-06
and O 0 2.5139082936220802e-05
familial B-Disease 1 0.9984467625617981
foveal I-Disease 1 0.9992287158966064
dysplasia I-Disease 1 0.9997599720954895
. O 0 0.00014297859161160886

It O 0 1.4550431615134585e-06
is O 0 1.6778055567101546e-07
believed O 0 3.665767067673187e-08
that O 0 6.804564134377244e-10
the O 0 2.888729921934896e-09
mutated O 0 5.3639904962210494e-08
allele O 0 1.9707478315922344e-08
of O 0 3.19195092579605e-09
PAX6 O 0 6.3645916270616e-06
produces O 0 7.959386039146921e-08
an O 0 3.6491226040880065e-08
inactive O 0 1.5638107697668602e-06
protein O 0 3.890618245350197e-07
and O 0 1.7681351494047703e-07
aniridia B-Disease 1 0.9975451827049255
is O 0 4.34261028203764e-06
caused O 0 1.0163869774260093e-05
due O 0 2.8789736461476423e-06
to O 0 1.260627300325723e-07
genetic O 0 0.00020604078599717468
haploinsufficiency O 0 0.008038542233407497
. O 0 7.5265397754264995e-06

However O 0 2.5437798285565805e-06
, O 0 6.959376008808249e-08
several O 0 2.5455552332687148e-08
truncation O 0 5.121170943311881e-06
mutations O 0 8.740783414395992e-06
have O 0 5.096213229194291e-08
been O 0 6.876774705233402e-08
found O 0 1.0754901857978894e-08
to O 0 9.946804491178796e-10
occur O 0 5.131676417136077e-09
in O 0 2.819305455759036e-09
the O 0 3.068909748549231e-08
C O 0 1.1505095471875393e-06
- O 0 2.314787025170517e-06
terminal O 0 1.7116135495598428e-06
half O 0 1.1514559083991571e-08
of O 0 5.508457689984425e-09
PAX6 O 0 8.981569408206269e-06
in O 0 9.606475259715808e-08
patients O 0 2.3598964560278546e-07
with O 0 4.8420535136983744e-08
Aniridia B-Disease 1 0.8301970362663269
resulting O 0 9.273559840039525e-07
in O 0 2.8581277788930493e-08
mutant O 0 9.990544924676215e-08
proteins O 0 5.743533648683297e-09
that O 0 7.028389537033775e-10
retain O 0 4.209238291252859e-09
the O 0 9.044969218052756e-09
DNA O 0 1.3107025154113217e-07
- O 0 1.5401477071463887e-07
binding O 0 1.2576392371954626e-08
domains O 0 1.4311226870233895e-08
but O 0 3.6714051798725222e-09
have O 0 9.61306589886135e-10
lost O 0 8.204529677868777e-08
most O 0 5.508013489752273e-10
of O 0 2.1331383326383957e-09
the O 0 5.625382115681532e-08
transactivation O 0 1.6251247870968655e-05
domain O 0 4.027685008622939e-06
. O 0 2.0910106286464725e-06

It O 0 1.8593672166389297e-06
is O 0 2.045437099695846e-07
not O 0 5.447169826311438e-09
clear O 0 1.4247223845131884e-08
whether O 0 5.309034101230736e-09
such O 0 5.051635110220332e-09
mutants O 0 6.869125286357303e-07
really O 0 1.4293772210294264e-07
behave O 0 9.885401652809378e-08
as O 0 6.304360056219593e-08
loss O 0 3.2898342396947555e-06
- O 0 5.241653298071469e-07
of O 0 5.774047462381304e-09
- O 0 6.428260803659214e-07
function O 0 3.4785980318474685e-08
mutants O 0 2.116697146448132e-07
as O 0 6.886041603593185e-08
predicted O 0 4.7355652554870176e-07
by O 0 8.275378604594152e-08
haploinsufficiency O 0 0.00012861800496466458
. O 0 2.5715003175719175e-06

Contrary O 0 3.905766334355576e-06
to O 0 3.1592211513498114e-08
this O 0 8.052376543332684e-09
theory O 0 8.60936300028925e-09
, O 0 2.337429139132041e-09
our O 0 3.8579019978612905e-09
data O 0 3.200444709250405e-08
showed O 0 1.3414855004612036e-07
that O 0 4.2556705381890936e-10
these O 0 1.6624870924353274e-10
mutants O 0 9.836590209033602e-09
are O 0 7.337084273473238e-10
dominant O 0 6.58985868540185e-07
- O 0 4.656007604353363e-06
negative O 0 2.9671342716142135e-08
in O 0 1.0189199706189811e-08
transient O 0 3.1402674949276843e-07
transfection O 0 3.966676104028011e-06
assays O 0 4.161019830917212e-07
when O 0 4.3783373371297785e-08
they O 0 1.4813970050653325e-09
are O 0 1.2599579157779317e-09
coexpressed O 0 9.073956448446552e-07
with O 0 7.758963249671069e-08
wild O 0 1.5392990462714806e-05
- O 0 0.0024264452513307333
type O 0 0.00048278275062330067
PAX6 O 0 0.005733787082135677
. O 0 8.376139703614172e-06

We O 0 7.444591574312653e-07
found O 0 6.307811872829916e-08
that O 0 2.9483471220004276e-09
the O 0 2.0738127659569727e-08
dominant O 0 9.776449587661773e-06
- O 0 9.01089733815752e-05
negative O 0 9.128266498237281e-08
effects O 0 1.2918779646042822e-07
result O 0 2.535282916937831e-08
from O 0 1.977158881061314e-09
the O 0 2.1772903480155037e-09
enhanced O 0 1.3148388688932755e-07
DNA O 0 1.5763524174872146e-07
binding O 0 3.029432349421768e-08
ability O 0 9.57281720559422e-09
of O 0 4.392881614023736e-09
these O 0 1.5195015024005443e-08
mutants O 0 5.88856755712186e-06
. O 0 1.2639621900234488e-06

Kinetic O 0 9.97643201117171e-06
studies O 0 3.221322799618065e-07
of O 0 1.0025894781051647e-08
binding O 0 1.8183213512656948e-07
and O 0 3.57468081801926e-08
dissociation O 0 6.114637926657451e-06
revealed O 0 7.042027618808788e-07
that O 0 8.586235611396376e-10
various O 0 8.129409367896301e-10
truncation O 0 4.404772937505186e-07
mutants O 0 3.1976384207155206e-07
have O 0 8.565989695341614e-09
3 O 0 5.467418162652393e-08
- O 0 1.3367339306569193e-06
5 O 0 7.28621643020233e-08
- O 0 4.5662389425160654e-07
fold O 0 2.3338216692536662e-08
higher O 0 5.255796242664701e-09
affinity O 0 3.4457507958052247e-09
to O 0 1.8564859372016684e-10
various O 0 8.463637568567606e-10
DNA O 0 4.911367668114508e-08
- O 0 1.0212142598220453e-07
binding O 0 1.3875625981540907e-08
sites O 0 5.420523585542014e-09
when O 0 6.110707495565748e-09
compared O 0 6.912014516302634e-09
with O 0 1.8034712612191584e-09
the O 0 4.293529798360396e-08
wild O 0 2.2811000235378742e-06
- O 0 0.000417511910200119
type O 0 0.00011081513366661966
PAX6 O 0 0.002173652173951268
. O 0 4.467479357117554e-06

These O 0 2.781727630463138e-07
results O 0 3.3685526545923494e-07
provide O 0 1.2523299730560211e-08
a O 0 4.3564703844367614e-08
new O 0 1.0700106578553914e-08
insight O 0 1.0488865775926115e-08
into O 0 3.999001130239321e-09
the O 0 7.4402310978882724e-09
role O 0 4.955631638381419e-08
of O 0 1.7618695835608378e-08
mutant O 0 7.159569577197544e-06
PAX6 O 0 0.0003422398876864463
in O 0 3.9205519897222985e-06
causing O 0 0.0008061885600909591
aniridia B-Disease 1 0.998832643032074
. O 0 1.8732464468484977e-06
. O 0 2.415346898487769e-06

Reversal O 0 0.0032126326113939285
of O 0 0.0003267595893703401
severe O 1 0.9993606209754944
hypertrophic B-Disease 1 0.9999480247497559
cardiomyopathy I-Disease 1 0.9999891519546509
and O 0 3.745956200873479e-05
excellent O 0 5.5616223107790574e-05
neuropsychologic O 0 0.0007818595040589571
outcome O 0 6.183240657264832e-06
in O 0 8.1459756984259e-07
very B-Disease 0 1.3625722203869373e-06
- I-Disease 0 0.0001307579514104873
long I-Disease 0 1.7744978322298266e-05
- I-Disease 0 8.696976146893576e-05
chain I-Disease 0 1.4602641385863535e-05
acyl I-Disease 0 5.6291723922186065e-06
- I-Disease 0 3.238657154724933e-05
coenzyme I-Disease 0 1.021736807160778e-05
A I-Disease 0 0.0004574033373501152
dehydrogenase I-Disease 1 0.6380071640014648
deficiency I-Disease 1 0.9977195858955383
. O 0 1.3639772987517063e-05

Very B-Disease 0 2.5765111786313355e-05
- I-Disease 0 0.0005546977045014501
long I-Disease 0 3.4913111448986456e-05
- I-Disease 0 7.436529267579317e-05
chain I-Disease 0 1.2963513654540293e-05
acyl I-Disease 0 1.979106173166656e-06
- I-Disease 0 1.8601334659251734e-06
coenzyme I-Disease 0 3.760752917969512e-07
A I-Disease 0 1.1711400702552055e-06
dehydrogenase I-Disease 0 1.9796179913100787e-05
( I-Disease 0 4.692049913046503e-07
VLCAD I-Disease 0 0.04727328568696976
) I-Disease 0 1.6290659914375283e-05
deficiency I-Disease 1 0.8446964025497437
is O 0 4.3156157403245743e-07
a O 0 4.120709945709677e-06
disorder O 0 0.09239137172698975
of O 0 1.4866986930428538e-07
fatty O 0 4.385925058159046e-05
acid O 0 3.13430041387619e-06
beta O 0 2.0648619170060556e-07
oxidation O 0 1.9143384122344287e-07
that O 0 5.3755204731942285e-09
reportedly O 0 8.387725642933219e-07
has O 0 7.057976603164207e-08
high O 0 2.6056761726067634e-06
rates O 0 9.97974325400719e-07
of O 0 8.034890441876996e-08
morbidity O 0 0.0031210894230753183
and O 0 2.3916895770526025e-06
mortality O 0 0.0016655352665111423
. O 0 3.4605302516865777e-06

We O 0 8.527958357262833e-07
describe O 0 2.984465936606284e-07
the O 0 3.6089897292868045e-08
outcome O 0 6.723499268446176e-08
of O 0 5.653874257660618e-09
a O 0 1.6336677788331144e-07
5 O 0 2.007246848734212e-07
- O 0 7.996734893822577e-06
year O 0 7.910725798865315e-07
- O 0 2.7558546207728796e-05
old O 0 7.915532478364184e-05
girl O 0 0.0001221601414727047
with O 0 2.3415068426402286e-05
VLCAD B-Disease 1 0.9999595880508423
deficiency I-Disease 1 0.9999797344207764
who O 0 1.7268255305680213e-06
was O 0 2.1733055746153696e-06
first O 0 2.563192147420068e-08
seen O 0 1.9854741140079568e-07
at O 0 1.4850037644009717e-07
5 O 0 4.8414996456358494e-08
months O 0 5.2666766947595534e-08
of O 0 7.1442225468842935e-09
age O 0 2.0605943973350804e-06
with O 0 2.783598938549403e-05
severe O 1 0.9997349381446838
hypertrophic B-Disease 1 0.9999749660491943
cardiomyopathy I-Disease 1 0.9999982118606567
, O 1 0.8420549035072327
hepatomegaly B-Disease 1 0.9999934434890747
, O 1 0.5744192600250244
encephalopathy B-Disease 1 0.9999274015426636
, O 0 3.376574386493303e-05
and O 0 1.6413479897892103e-05
hypotonia B-Disease 1 0.7255806922912598
. O 0 2.6740859539131634e-05

Biochemical O 0 0.0060477168299257755
studies O 0 0.0008285397198051214
indicated O 1 0.9742367267608643
VLCAD B-Disease 1 0.999976634979248
deficiency I-Disease 1 0.9999921321868896
caused O 0 0.0012386160669848323
by O 0 2.6418322818244633e-07
a O 0 6.51078880764544e-06
stable O 0 0.0006533489795401692
yet O 0 1.4663050933449995e-05
inactive O 0 7.484622619813308e-05
enzyme O 0 1.5842610082472675e-05
. O 0 1.4099050531513058e-06

Molecular O 0 7.160122186178342e-05
genetic O 0 1.14426557047409e-05
analysis O 0 6.115379846960423e-07
of O 0 9.169518477847305e-08
her O 0 1.2593126484716777e-05
VLCAD O 0 0.005489557981491089
gene O 0 8.434366463916376e-06
revealed O 0 4.338296548667131e-06
a O 0 1.0929143172688782e-06
T1372C O 0 1.365663865726674e-05
( O 0 1.3164525114461867e-07
F458L O 0 3.2457380712003214e-06
) O 0 1.0969223751544632e-07
missense O 0 1.0135314369108528e-05
mutation O 0 7.919943527667783e-06
and O 0 9.392572763999851e-08
a O 0 8.196790986403357e-06
1668 O 0 0.0035834508016705513
ACAG O 0 0.0035547546576708555
1669 O 0 0.00028587065753526986
splice O 0 0.00023859152861405164
site O 0 0.00018506050400901586
mutation O 0 0.00044160321704111993
. O 0 5.586340648733312e-06

After O 0 2.61538280028617e-05
initial O 0 2.9713535241171485e-06
treatment O 0 2.6647726372175384e-06
with O 0 3.334467280069475e-08
intravenous O 0 3.901373474946013e-06
glucose O 0 5.386392513173632e-05
and O 0 1.6557238780023908e-07
carnitine O 0 7.558485231129453e-05
, O 0 7.134257629104468e-08
the O 0 1.587278717352092e-07
patient O 0 1.1349182386766188e-05
has O 0 7.459131978748701e-08
thrived O 0 3.0898723935024464e-07
on O 0 2.30715997417974e-08
a O 0 1.7568183352523192e-07
low O 0 1.0784989171952475e-05
- O 0 1.796850119717419e-05
fat O 0 1.931762426465866e-06
diet O 0 7.189526485262832e-08
supplemented O 0 1.3063916171063283e-08
with O 0 3.97000787799584e-09
medium O 0 1.9248574290031684e-07
- O 0 4.986169642506866e-06
chain O 0 2.2761994387110462e-06
triglyceride O 0 2.0598085939127486e-06
oil O 0 3.55938709617476e-07
and O 0 3.3110943320480146e-08
carnitine O 0 1.4652064237452578e-05
and O 0 6.145423725456567e-08
avoidance O 0 8.233480002672877e-06
of O 0 2.621678447667364e-07
fasting O 0 1.3128309547028039e-05
. O 0 1.586605094416882e-06

Her O 0 0.00040375764365307987
ventricular O 0 0.46702930331230164
hypertrophy O 0 0.13081800937652588
resolved O 0 3.9939983253134415e-05
significantly O 0 2.764945975286537e-06
over O 0 9.417705371106422e-08
1 O 0 3.409706721413386e-07
year O 0 5.82891246381223e-08
, O 0 4.5807606596781625e-09
and O 0 2.7746027697617137e-08
cognitively O 0 7.723045564489439e-05
, O 0 2.0592042915268394e-07
she O 0 1.2418448704920593e-06
is O 0 1.7355603176838486e-08
in O 0 1.1710127978403762e-08
the O 0 4.2566981051095354e-08
superior O 0 1.3494242011802271e-05
range O 0 4.1963747321460687e-07
for O 0 1.6142317349476798e-07
age O 0 5.729690656153252e-06
. O 0 1.2183318176539615e-06

Clinical O 0 0.0002572603989392519
recognition O 0 4.266190808266401e-05
of O 0 0.0009264038526453078
VLCAD B-Disease 1 0.9999939203262329
deficiency I-Disease 1 0.9999957084655762
is O 0 1.6743268133723177e-05
important O 0 5.654965207213536e-07
because O 0 5.483030349751061e-07
it O 0 3.0052380139977686e-08
is O 0 7.287686454304776e-09
one O 0 1.0960660157266489e-09
of O 0 9.341485363023594e-10
the O 0 1.9751807300849578e-08
few O 0 6.022321485943394e-08
directly O 0 2.9445322979881894e-06
treatable O 1 0.9996341466903687
causes O 0 0.00018823251593858004
of O 0 1.545022678328678e-05
cardiomyopathy B-Disease 1 0.9999878406524658
in O 0 1.6769154171925038e-05
children O 0 1.2984369277546648e-06
. O 0 9.362940431856259e-07
. O 0 1.7020358882291475e-06

Cloning O 0 5.404006515163928e-06
of O 0 6.492545168157449e-08
a O 0 3.9119143480093044e-07
novel O 0 8.842172860568098e-08
member O 0 1.2359941514716866e-08
of O 0 2.131421927842325e-09
the O 0 2.3768945922597595e-08
low O 0 8.88577415025793e-06
- O 0 1.3433521417027805e-05
density O 0 9.133714797826542e-07
lipoprotein O 0 0.009046697989106178
receptor O 0 9.528089867671952e-05
family O 0 1.0451347407069989e-05
. O 0 1.9659294139273698e-06

A O 0 3.1847209811530774e-06
gene O 0 7.461166546818276e-07
encoding O 0 3.0207809231797e-07
a O 0 4.235568269450596e-07
novel O 0 3.615318462379946e-07
transmembrane O 0 5.314119334798306e-06
protein O 0 7.11751226845081e-07
was O 0 2.874956862797262e-06
identified O 0 4.3982915087781294e-08
by O 0 2.238146334931912e-09
DNA O 0 5.691378035521666e-08
sequence O 0 7.910377242126287e-09
analysis O 0 2.92731150430825e-09
within O 0 6.009237552007107e-09
the O 0 1.438366723505169e-07
insulin B-Disease 0 0.0011652873363345861
- I-Disease 0 0.06613421440124512
dependent I-Disease 0 0.013242634013295174
diabetes I-Disease 1 0.999984860420227
mellitus I-Disease 1 0.9998987913131714
( O 0 2.1649134396284353e-06
IDDM B-Disease 0 0.0012983301421627402
) O 0 2.3137310734000494e-07
locus O 0 1.4162456864141859e-05
IDDM4 O 0 0.00016311748186126351
on O 0 8.050940778048243e-06
chromosome O 0 0.00017168298654723912
11q13 O 0 0.00014236613060347736
. O 0 5.403326213127002e-06

Based O 0 8.839961651574413e-07
on O 0 1.696484162039269e-07
its O 0 3.591410546732732e-08
chromosomal O 0 4.2364452383480966e-05
position O 0 5.231355544310645e-07
, O 0 1.3721977332181723e-08
this O 0 2.691493472539719e-09
gene O 0 3.6706786943341285e-08
is O 0 8.157805986286348e-09
a O 0 3.803834758286939e-08
candidate O 0 5.293697569186406e-08
for O 0 1.3496308071125895e-08
conferring O 0 9.991409569920506e-06
susceptibility O 0 0.00030293353484012187
to O 0 1.0212595043412875e-05
diabetes B-Disease 1 0.9987732768058777
. O 0 1.8395901861367747e-05

The O 0 1.1802601420640713e-06
gene O 0 5.736196726502385e-06
, O 0 2.48575844352672e-07
termed O 0 3.848809228657046e-06
low O 0 1.0873297469515819e-05
- O 0 4.004287802672479e-06
density O 0 2.592516636923392e-07
lipoprotein O 0 0.000268948613665998
receptor O 0 2.7512262477102922e-06
related O 0 2.068705384772329e-07
protein O 0 2.7906557420465106e-07
5 O 0 6.58418031207475e-08
( O 0 8.658106231962392e-09
LRP5 O 0 3.7200702536210883e-06
) O 0 2.2635875396304073e-09
, O 0 7.839089377625896e-10
encodes O 0 2.9876392471095414e-09
a O 0 6.4694760659733674e-09
protein O 0 9.386497801244786e-09
of O 0 1.5359847838070095e-09
1615 O 0 4.7593260887879296e-07
amino O 0 1.3526254782902924e-08
acids O 0 6.053724632693047e-09
that O 0 2.3291946149583964e-10
contains O 0 5.746566555941968e-10
conserved O 0 3.5719938118461414e-09
modules O 0 4.4015786571094395e-09
which O 0 4.928987218377756e-10
are O 0 4.4083969114039334e-11
characteristic O 0 3.345142163269088e-09
of O 0 1.215745504268284e-09
the O 0 3.224260680667612e-08
low O 0 8.826416888041422e-06
- O 0 9.910480002872646e-06
density O 0 7.550779628218152e-07
lipoprotein O 0 0.011738458648324013
( O 0 4.2791410237441596e-07
LDL O 0 0.0009426730102859437
) O 0 1.4359190458890225e-07
receptor O 0 5.320219770510448e-06
family O 0 4.684360192186432e-06
. O 0 1.321321747127513e-06

These O 0 1.8125905398846953e-07
modules O 0 3.593196140627697e-07
include O 0 2.762520523447165e-08
a O 0 1.1837823166160888e-07
putative O 0 4.559285287086823e-07
signal O 0 3.628821332313237e-07
peptide O 0 1.1030802937739281e-07
for O 0 1.0702999597711482e-09
protein O 0 5.6517173163683765e-09
export O 0 3.1958253821073868e-09
, O 0 3.3787814768260205e-09
four O 0 8.262158956995336e-09
epidermal O 0 1.8267510313307866e-06
growth O 0 4.1927185634449415e-07
factor O 0 9.713430415558832e-08
( O 0 2.3066231591428732e-08
EGF O 0 5.7852116697176825e-06
) O 0 1.0605988975953551e-08
repeats O 0 9.221257357694412e-08
with O 0 1.552091788425969e-08
associated O 0 6.923390571955679e-08
spacer O 0 6.788126256651594e-07
domains O 0 2.1776948244678351e-07
, O 0 3.313324370424198e-08
three O 0 1.1982595538029273e-07
LDL O 0 0.0038044345565140247
- O 0 2.2532976799993776e-05
receptor O 0 1.3778332004221738e-06
( O 0 2.4247132301979946e-08
LDLR O 0 6.424182174669113e-06
) O 0 6.878976055446628e-09
repeats O 0 9.350763008342255e-08
, O 0 3.923262159588603e-09
a O 0 8.910294724273626e-09
single O 0 2.218325434455437e-08
transmembrane O 0 3.152125316319143e-07
spanning O 0 1.553422066535859e-07
domain O 0 1.1631632190756136e-07
, O 0 6.023938237120774e-09
and O 0 3.6663667657421684e-09
a O 0 1.0352838586413782e-07
cytoplasmic O 0 1.8992792547578574e-06
domain O 0 3.5971875149698462e-06
. O 0 1.3382008319240413e-06

The O 0 1.360001391503829e-07
encoded O 0 1.0990752485895428e-07
protein O 0 3.3700530366331805e-07
has O 0 7.784489497453251e-08
a O 0 1.905929281065255e-08
unique O 0 1.132849902774069e-08
organization O 0 3.6034595751743836e-08
of O 0 5.3834821045484205e-09
EGF O 0 9.719268746266607e-06
and O 0 1.929485335949721e-07
LDLR O 0 0.00045091091305948794
repeats O 0 2.775331040538731e-06
; O 0 1.862751553005637e-08
therefore O 0 1.4285726379625885e-08
, O 0 9.981475201925605e-09
LRP5 O 0 2.2418093067244627e-05
likely O 0 6.018749587610728e-08
represents O 0 5.718251205877323e-09
a O 0 2.6726898028073265e-08
new O 0 1.9934004669153182e-08
category O 0 3.913488555440381e-08
of O 0 3.713279905781519e-09
the O 0 3.505955703531072e-07
LDLR O 0 0.002335404744371772
family O 0 2.0772091374965385e-05
. O 0 4.911044015898369e-06

Both O 0 1.2257182788744103e-06
human O 0 8.872165722095815e-07
and O 0 5.575401473834063e-07
mouse O 0 1.9135959519189782e-05
LRP5 O 0 0.0002747348044067621
cDNAs O 0 3.91812136513181e-05
have O 0 9.826467106677228e-08
been O 0 1.0856224008648496e-07
isolated O 0 1.631727712947395e-07
and O 0 1.952913164515735e-09
the O 0 9.160419645048989e-10
encoded O 0 1.9183137300871067e-09
mature O 0 1.065924504217719e-08
proteins O 0 8.071624479910611e-10
are O 0 1.5113749141093535e-10
95 O 0 2.1784076764674865e-09
% O 0 1.4059224895390798e-09
identical O 0 2.6289058041584212e-08
, O 0 2.1099921809764055e-09
indicating O 0 2.3610349231262262e-08
a O 0 4.815289145199131e-08
high O 0 1.444425038243935e-06
degree O 0 9.278242885102372e-08
of O 0 1.0056172783379225e-08
evolutionary O 0 7.033852966742415e-07
conservation O 0 6.662643272647983e-07
. O 0 7.095527365663656e-08
. O 0 5.46652017874294e-07

The O 0 2.9525376703531947e-06
APC B-Disease 0 2.1790212485939264e-05
variants O 0 2.4140827008523047e-06
I1307K O 0 8.235719178628642e-06
and O 0 1.0205152278786045e-07
E1317Q O 0 5.990477347950218e-06
are O 0 8.859510103320645e-08
associated O 0 6.897959974594414e-05
with O 1 0.9785038828849792
colorectal B-Disease 1 1.0
tumors I-Disease 1 0.9999998807907104
, O 0 6.535953434649855e-05
but O 0 4.17723327927888e-07
not O 0 1.270945393372358e-08
always O 0 1.383065395543781e-08
with O 0 4.715238866026539e-09
a O 0 5.296182621350454e-07
family O 0 2.684458877411089e-06
history O 0 3.3662126952549443e-06
. O 0 2.076274313367321e-06

Classical O 0 0.40998417139053345
familial B-Disease 1 0.9997926354408264
adenomatous I-Disease 1 0.9996873140335083
polyposis I-Disease 1 0.9998835325241089
( O 0 0.0001967536227311939
FAP B-Disease 0 0.003006577491760254
) O 0 4.0102398202179756e-07
is O 0 2.2178353731305833e-07
a O 0 2.8020610898238374e-06
high O 0 0.002342424588277936
- O 1 0.9328992962837219
penetrance O 1 0.8815220594406128
autosomal B-Disease 1 0.9975493550300598
dominant I-Disease 1 0.9965645670890808
disease I-Disease 1 0.9991940855979919
that O 0 1.634269324313209e-07
predisposes O 0 1.6607525594736217e-06
to O 0 7.3473951367475365e-09
hundreds O 0 2.9499739540028713e-08
or O 0 7.256855383275251e-08
thousands O 0 4.0940446410786535e-07
of O 0 0.0003336618538014591
colorectal B-Disease 1 0.9999998807907104
adenomas I-Disease 1 0.999988317489624
and I-Disease 1 0.9900702834129333
carcinoma I-Disease 1 0.9999995231628418
and O 0 2.3029997464618646e-05
that O 0 1.4138782944428385e-07
results O 0 3.8051123851801094e-07
from O 0 5.301265559864987e-08
truncating O 0 1.1281274964858312e-05
mutations O 0 4.045597506774357e-06
in O 0 8.181464039580533e-08
the O 0 2.2703669344537047e-07
APC B-Disease 0 4.099516081623733e-05
gene O 0 1.4748373359907418e-05
. O 0 1.7422022438040585e-06

A O 0 2.4143602786352858e-05
variant O 0 0.00025810752413235605
of O 0 2.3963516468938906e-06
FAP B-Disease 0 0.014873930253088474
is O 0 0.00018453682423569262
attenuated B-Disease 1 0.9697374105453491
adenomatous I-Disease 1 0.999887228012085
polyposis I-Disease 1 0.9997172951698303
coli I-Disease 1 0.9993947744369507
, O 0 4.736306436825544e-06
which O 0 1.2963815265720768e-07
results O 0 2.537218506404315e-07
from O 0 7.270723756391817e-08
germ O 0 0.00012344094284344465
- O 0 3.311517139081843e-05
line O 0 2.934449184976984e-06
mutations O 0 2.1514414072498766e-07
in O 0 4.061472935745769e-09
the O 0 2.8043640742936304e-09
5 O 0 7.754122677283704e-09
and O 0 2.7059783302973983e-09
3 O 0 1.2757932488227652e-08
regions O 0 6.623299686481232e-09
of O 0 4.965203803664053e-09
the O 0 1.5038689582524967e-07
APC B-Disease 0 3.268100772402249e-05
gene O 0 1.1287323104625102e-05
. O 0 1.6360609151888639e-06

Attenuated B-Disease 1 0.9851572513580322
adenomatous I-Disease 1 0.9995005130767822
polyposis I-Disease 1 0.999638557434082
coli I-Disease 1 0.9997033476829529
patients O 0 0.13538211584091187
have O 0 3.1848881008045282e-06
" O 0 3.809091367656947e-06
multiple O 0 0.0006626207032240927
" O 1 0.990146815776825
colorectal B-Disease 1 0.9999997615814209
adenomas I-Disease 1 0.9998608827590942
( O 0 9.458863701183873e-07
typically O 0 1.6647693712457112e-07
fewer O 0 1.1370928199028185e-08
than O 0 3.3246414510301747e-09
100 O 0 5.1486472862904975e-09
) O 0 1.322198683872955e-09
without O 0 3.5365048667301835e-09
the O 0 1.1618423556569724e-08
florid O 0 1.768517540767789e-05
phenotype O 0 2.470011168043129e-06
of O 0 4.813728082808666e-08
classical O 0 1.605573015694972e-05
FAP B-Disease 0 0.0010864378418773413
. O 0 5.158301064511761e-06

Another O 0 9.75785769696813e-06
group O 0 1.0832618499989621e-06
of O 0 9.991764216010779e-08
patients O 0 3.349819508002838e-06
with O 0 1.037697785477576e-07
multiple O 0 1.5339324818341993e-05
adenomas B-Disease 0 0.0812106505036354
has O 0 8.930229341785889e-06
no O 0 2.375639809315544e-07
mutations O 0 3.687358969273191e-07
in O 0 8.663491257721034e-09
the O 0 1.4771766032595224e-08
APC B-Disease 0 5.346707894204883e-07
gene O 0 5.3353492290852955e-08
, O 0 5.063674368699367e-09
and O 0 4.0052916538968475e-09
their O 0 1.1933553700771427e-08
phenotype O 0 5.6583712648716755e-06
probably O 0 4.5791992420163297e-07
results O 0 2.7148510994834396e-08
from O 0 4.1575178855168815e-09
variation O 0 6.441135269596998e-08
at O 0 2.944207722066494e-07
a O 0 1.2021513384752325e-07
locus O 0 3.830949992789101e-07
, O 0 1.1327246696168913e-08
or O 0 5.9806404273388125e-09
loci O 0 9.445444959510496e-08
, O 0 1.3827805567245832e-08
elsewhere O 0 4.2272308320434604e-08
in O 0 1.9841825960043025e-08
the O 0 8.170719212330368e-08
genome O 0 3.3585040455363924e-06
. O 0 7.401917514471279e-07

Recently O 0 0.000147416430991143
, O 0 3.2101843316922896e-07
however O 0 7.755649278351484e-08
, O 0 2.4583304281122764e-08
a O 0 3.2854873666110507e-07
missense O 0 6.673417374258861e-06
variant O 0 8.997429176815785e-06
of O 0 8.564180120629317e-08
APC B-Disease 0 2.156047776225023e-05
( O 0 5.358846877356882e-08
I1307K O 0 1.165646722256497e-06
) O 0 1.964473028692737e-08
was O 0 6.691719249829475e-07
described O 0 3.188106845186667e-08
that O 0 4.81555961773239e-10
confers O 0 2.395344900207874e-08
an O 0 2.1512068570928022e-08
increased O 0 3.7432735098263947e-06
risk O 0 0.0021733411122113466
of O 0 0.15621913969516754
colorectal B-Disease 1 1.0
tumors I-Disease 1 0.9999998807907104
, O 0 1.0829863640537951e-05
including O 0 2.654290085501998e-07
multiple O 0 2.9743314371444285e-05
adenomas B-Disease 0 0.10091634094715118
, O 0 1.7073130038625095e-06
in O 0 1.968732021850883e-06
Ashkenazim O 0 0.0005660043680109084
. O 0 9.326169674750417e-06

We O 0 7.894092846072454e-07
have O 0 3.282276850313792e-08
studied O 0 1.1096769014784513e-07
a O 0 2.43946480793511e-08
set O 0 1.253529724465352e-08
of O 0 8.207296176010459e-09
164 O 0 1.1285710570518859e-06
patients O 0 1.925253627632628e-06
with O 0 5.405078354669968e-06
multiple O 1 0.9854629039764404
colorectal B-Disease 1 0.9999998807907104
adenomas I-Disease 1 0.999919056892395
and I-Disease 0 0.0006505855126306415
/ I-Disease 0 0.07448441535234451
or I-Disease 0 0.008938963524997234
carcinoma I-Disease 1 0.9999984502792358
and O 0 1.0351656783313956e-05
analyzed O 0 1.2895695363113191e-05
codons O 0 6.872342510177987e-06
1263 O 0 7.238323451019824e-05
- O 0 4.1469284042250365e-05
1377 O 0 3.062926043639891e-05
( O 0 9.652244870039794e-08
exon O 0 4.3230984374531545e-06
15G O 0 2.7587063868850237e-06
) O 0 2.5229611733124102e-09
of O 0 1.2165295437682744e-09
the O 0 8.747275792586606e-09
APC B-Disease 0 3.5448411495053733e-07
gene O 0 1.1243218267509292e-07
for O 0 2.5506972534117267e-08
germ O 0 0.0002188751386711374
- O 0 9.772537305252627e-05
line O 0 1.0229106919723563e-05
variants O 0 6.75340743327979e-06
. O 0 2.776895598799456e-06

Three O 0 3.4264105579495663e-06
patients O 0 2.692620000743773e-06
with O 0 1.1737834704206307e-08
the O 0 2.1047517506644908e-08
I1307K O 0 5.121050890011247e-07
allele O 0 8.64985736370727e-08
were O 0 3.865962838744963e-08
detected O 0 7.337272336371825e-07
, O 0 3.124987157931969e-09
each O 0 1.6443546524413932e-09
of O 0 3.286524119516798e-08
Ashkenazi O 0 0.0002949453191831708
descent O 0 9.960456372937188e-05
. O 0 5.87329077461618e-06

Four O 0 1.2124472050345503e-05
patients O 0 2.8471036785049364e-05
had O 0 1.132398324443784e-06
a O 0 7.082032880134648e-07
germ O 0 0.0008924007997848094
- O 0 0.00011815782636404037
line O 0 3.976826974394498e-06
E1317Q O 0 5.117826731293462e-06
missense O 0 2.894870476666256e-06
variant O 0 3.449077894401853e-06
of O 0 2.3145428684756553e-08
APC O 0 3.879594260070007e-06
that O 0 1.1632814711504125e-08
was O 0 2.158512188543682e-06
not O 0 8.4110457487796e-10
present O 0 1.8904433574107316e-09
in O 0 3.50695650297439e-09
controls O 0 7.939856772054554e-08
; O 0 1.9046419996726627e-09
one O 0 5.762074706261444e-10
of O 0 2.0372636910792608e-10
these O 0 1.5989201629373895e-10
individuals O 0 2.9824395730848607e-10
had O 0 1.4676786008749332e-08
an O 0 4.7175054973536135e-09
unusually O 0 2.0783595289231016e-07
large O 0 2.0754985285975636e-08
number O 0 7.429127979463601e-09
of O 0 1.884986033928726e-08
metaplastic B-Disease 0 0.0005512935458682477
polyps I-Disease 0 0.0001679639535723254
of I-Disease 0 1.965590001873352e-08
the I-Disease 0 4.311444286031474e-07
colorectum I-Disease 0 0.0011079531395807862
. O 0 3.741175078175729e-06

There O 0 1.3916436500949203e-06
is O 0 1.1604740279835823e-07
increasing O 0 8.61007265484659e-08
evidence O 0 3.604050746730536e-08
that O 0 4.099296457837909e-09
there O 0 4.643198270315452e-09
exist O 0 2.112828312306192e-08
germ O 0 2.123140438925475e-05
- O 0 5.347245405573631e-06
line O 0 2.2189058768162795e-07
variants O 0 1.6076677766818648e-08
of O 0 1.9873784840029884e-09
the O 0 2.5439097939283783e-08
APC B-Disease 0 6.616300538553332e-07
gene O 0 6.96572399760953e-08
that O 0 1.3275054389083607e-09
predispose O 0 6.022433662877802e-09
to O 0 8.421865982377597e-10
the O 0 7.746420394028064e-09
development O 0 2.5627326039057152e-08
of O 0 5.076975071460765e-07
multiple O 1 0.9062545895576477
colorectal B-Disease 1 0.9999997615814209
adenomas I-Disease 1 0.9999878406524658
and I-Disease 1 0.991802990436554
carcinoma I-Disease 1 0.9999996423721313
, O 0 0.00012818738468922675
but O 0 3.015545075868431e-07
without O 0 7.033035132053556e-08
the O 0 1.452594489137482e-07
florid O 0 6.111709808465093e-05
phenotype O 0 3.3357196116412524e-06
of O 0 1.5134476782918682e-08
classical O 0 1.5227269614115357e-06
FAP B-Disease 0 3.534998177201487e-05
, O 0 2.4088791406029486e-08
and O 0 8.291712205732438e-09
possibly O 0 2.8434033794155766e-08
with O 0 1.7821449205257522e-08
importance O 0 2.676856456673704e-05
for O 1 0.9683271050453186
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
risk O 0 0.014671063050627708
in O 0 1.967034393146605e-07
the O 0 7.578071148373056e-08
general O 0 1.615190967640956e-07
population O 0 6.28401082281016e-08
. O 0 8.028210629618115e-08
. O 0 5.808690843878139e-07

Genomic O 0 7.334347174037248e-05
structure O 0 2.4549566660425626e-05
of O 0 3.0803545314483927e-07
the O 0 1.236816660821205e-05
human O 0 0.012799480929970741
congenital B-Disease 1 0.9999903440475464
chloride I-Disease 1 0.9999569654464722
diarrhea I-Disease 1 0.9999939203262329
( O 0 0.00011839128274004906
CLD B-Disease 1 0.9121368527412415
) O 0 3.614567503973376e-06
gene O 0 7.26070866221562e-05
. O 0 4.814279691345291e-06

Congenital B-Disease 1 0.9999518394470215
chloride I-Disease 1 0.9996134638786316
diarrhea I-Disease 1 0.9999779462814331
( O 0 0.00023330506519414485
CLD B-Disease 1 0.8513005971908569
) O 0 1.195421418742626e-06
is O 0 9.149852644441125e-07
caused O 0 2.130939037670032e-06
by O 0 5.4847145491976335e-08
mutations O 0 1.0283167739544297e-06
in O 0 2.7100808708269142e-08
a O 0 1.4727379493706394e-07
gene O 0 3.5636261941363045e-07
which O 0 1.735017463033728e-08
encodes O 0 3.1073784612090094e-07
an O 0 3.11103644889954e-06
intestinal O 1 0.9980518817901611
anion O 0 0.04328847676515579
transporter O 0 0.38755282759666443
. O 0 2.1483330783667043e-05

We O 0 2.9782245292153675e-06
report O 0 3.070994694098772e-07
here O 0 1.1335804295242724e-08
the O 0 5.636989985902119e-09
complete O 0 7.000299717674352e-08
genomic O 0 4.813875307263515e-07
organization O 0 2.2728816162498333e-08
of O 0 4.261358377277702e-09
the O 0 5.3315549308763366e-08
human O 0 3.140860656003497e-07
CLD B-Disease 0 0.0003582203935366124
gene O 0 5.448730462376261e-07
which O 0 2.8720737788034967e-08
spans O 0 3.2557903750785044e-07
approximately O 0 5.423980908858539e-08
39kb O 0 1.1067615560023114e-05
, O 0 2.5816994764227275e-08
and O 0 1.2721386610792251e-08
comprises O 0 1.455073572742549e-07
21 O 0 2.4343694349227007e-06
exons O 0 1.83522734005237e-05
. O 0 3.3006638204824412e-06

All O 0 1.1809007673946326e-06
exon O 0 0.00017560621199663728
/ O 0 1.3532800039683934e-05
intron O 0 5.362452793633565e-05
boundaries O 0 2.716126061841351e-07
conform O 0 2.612765399589989e-07
to O 0 1.635372548491887e-08
the O 0 1.0816147266723419e-07
GT O 0 0.00012018827692372724
/ O 0 0.00016775492986198515
AG O 1 0.9898436069488525
rule O 0 3.42284474754706e-05
. O 0 3.1765068797540152e-06

An O 0 2.579249098744185e-07
analysis O 0 8.126734485358611e-08
of O 0 1.3787196273540303e-08
the O 0 7.848507266317029e-08
putative O 0 5.347663773136446e-06
promoter O 0 6.962181942071766e-05
region O 0 3.146508902318601e-07
sequence O 0 5.95347664500423e-08
shows O 0 4.336218140110759e-08
a O 0 1.844449286636518e-07
putative O 0 3.959536115871742e-06
TATA O 0 9.599085751688108e-05
box O 0 9.351098810839176e-07
and O 0 2.4198298476107993e-08
predicts O 0 2.6891248694482783e-07
multiple O 0 6.134813901326197e-08
transcription O 0 9.061442938218534e-07
factor O 0 2.838586965481227e-07
binding O 0 5.627351242765144e-07
sites O 0 1.1785122069341014e-06
. O 0 9.95314962892735e-07

The O 0 1.0439129027872696e-06
genomic O 0 9.186546776618343e-06
structure O 0 2.1707312043872662e-05
was O 0 3.611728061514441e-06
determined O 0 4.0913235466177866e-08
using O 0 5.3999884563893374e-09
DNA O 0 1.4033142292646517e-07
from O 0 2.525132547503972e-09
several O 0 1.0814693585103896e-09
sources O 0 2.2637083318954865e-09
including O 0 2.217825256778383e-09
multiple O 0 9.190775074330304e-08
large O 0 1.2327508329690318e-06
- O 0 0.00010256377572659403
insert O 0 2.857784465959412e-06
libaries O 0 3.6457108762988355e-06
and O 0 2.7015857995138504e-08
genomic O 0 8.467131351608259e-07
DNA O 0 1.9994224658148596e-06
from O 0 2.3633559464997234e-07
Finnish O 0 0.004176532384008169
CLD B-Disease 0 0.43236371874809265
patients O 0 8.732052810955793e-05
and O 0 5.350702281248232e-07
controls O 0 7.765967166051269e-05
. O 0 5.227613200986525e-06

Exon O 0 0.0006195179303176701
- O 0 2.384110848652199e-05
specific O 0 1.037521641933381e-07
primers O 0 8.361162713299564e-07
developed O 0 7.682988325541373e-07
in O 0 3.245064306156564e-08
this O 0 2.8572653132385994e-09
study O 0 5.318358642369958e-09
will O 0 5.919377210616972e-10
facilitate O 0 1.0822644114227842e-08
mutation O 0 4.4948285449208925e-07
screening O 0 2.9592001737910323e-07
studies O 0 1.8760225373171124e-08
of O 0 1.0716180831593647e-08
patients O 0 1.577453190293454e-06
with O 0 3.529610239638714e-07
the O 0 0.0001665982708800584
disease O 1 0.951913595199585
. O 0 8.560048627259675e-06

Genomic O 0 1.579933632456232e-05
sequencing O 0 1.3339653150978847e-06
of O 0 8.190269795704808e-08
a O 0 4.56890575151192e-06
BAC O 0 0.0005946150631643832
clone O 0 0.0004319366707932204
H O 1 0.9942981600761414
_ O 0 4.990209276911628e-07
RG364P16 O 0 1.6616983202766278e-06
revealed O 0 2.4274069687635347e-07
the O 0 2.4194501957452985e-09
presence O 0 7.12530656699073e-09
of O 0 1.0530876171088721e-09
another O 0 2.0272148404387735e-08
, O 0 2.7432283111750166e-09
highly O 0 7.640315047297008e-09
homologous O 0 2.5648548174217467e-08
gene O 0 4.638632944420351e-08
3 O 0 1.1274781108738807e-08
of O 0 1.95711935546683e-09
the O 0 5.230756983110041e-08
CLD B-Disease 0 7.555443880846724e-05
gene O 0 2.3790950365309982e-07
, O 0 7.250003708492159e-09
with O 0 2.958667311148133e-09
a O 0 5.139966674505558e-08
similar O 0 3.757654809533051e-08
genomic O 0 4.446124250989669e-07
structure O 0 2.771578010651865e-06
, O 0 6.248561845723088e-08
recently O 0 2.1619878225465072e-06
identified O 0 3.231118910207442e-07
as O 0 1.4675056547730492e-07
the O 0 3.9720929635223e-05
Pendred B-Disease 1 0.9999474287033081
syndrome I-Disease 1 0.9999964237213135
gene O 0 0.0007101230439729989
( O 0 1.0279715070282691e-06
PDS B-Disease 0 0.001700198627077043
) O 0 1.3339509052912035e-07
. O 0 7.394242373948146e-08
. O 0 6.868280593153031e-07

The O 0 3.1874008072918514e-06
APCI1307K O 0 0.0008140132995322347
allele O 0 8.721026824787259e-05
and O 0 0.00021270291472319514
cancer B-Disease 1 0.9985576272010803
risk O 0 6.68966822559014e-05
in O 0 4.889626836757088e-08
a O 0 1.4206403875505202e-07
community O 0 6.750393310994696e-08
- O 0 8.464858183288015e-06
based O 0 3.2563921337214197e-08
study O 0 1.4136943171649818e-08
of O 0 1.2963513817965122e-08
Ashkenazi O 0 1.825039907998871e-05
Jews O 0 1.6721107840567129e-06
. O 0 2.093991952278884e-06

Mutations O 0 0.0016494861338287592
in O 0 7.026946150290314e-06
APC O 0 0.00018039192946162075
are O 0 2.028998693504036e-07
classically O 0 0.00375980488024652
associated O 0 7.059832569211721e-05
with O 0 0.0005168826319277287
familial B-Disease 1 0.9999680519104004
adenomatous I-Disease 1 0.9999243021011353
polyposis I-Disease 1 0.99997878074646
( O 0 0.00010528510028962046
FAP B-Disease 0 0.0009092292166315019
) O 0 8.922476268935498e-08
, O 0 4.913822593266559e-08
a O 0 9.096769986172148e-07
highly O 0 0.0005611240630969405
penetrant O 1 0.9973828196525574
autosomal B-Disease 1 0.9999643564224243
dominant I-Disease 1 0.9999245405197144
disorder I-Disease 1 0.9999971389770508
characterized O 1 0.7634449005126953
by O 0 9.367628808831796e-05
multiple O 1 0.6105397343635559
intestinal O 1 0.9999830722808838
polyps B-Disease 1 0.982130229473114
and O 0 9.784048415895086e-07
, O 0 2.2221564677238348e-07
without O 0 1.441172088334497e-07
surgical O 0 0.00016703108849469572
intervention O 0 1.0337049616282457e-06
, O 0 1.6156478821471865e-08
the O 0 2.7854090589585212e-08
development O 0 8.606031656199775e-07
of O 0 0.0356343649327755
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
( O 0 9.025732288137078e-05
CRC B-Disease 0 0.010855890810489655
) O 0 1.2529269497463247e-06
. O 0 1.7059816173059517e-06

APC B-Disease 0 0.0009299801313318312
is O 0 9.612479516363237e-06
a O 0 6.476169801317155e-05
tumour O 1 0.9998296499252319
- O 0 0.00019965143292210996
suppressor O 0 9.64242917689262e-06
gene O 0 7.735379199402814e-07
, O 0 2.5022213634429136e-08
and O 0 3.155126293563626e-08
somatic O 0 7.551452199550113e-06
loss O 0 0.002312924712896347
occurs O 0 1.3401903743215371e-05
in O 0 5.3811047109775245e-05
tumours B-Disease 1 0.9997712969779968
. O 0 5.459729436552152e-05

The O 0 1.577466173330322e-05
germline O 0 0.0021506985649466515
T O 0 0.0024571549147367477
- O 0 1.1105202247563284e-05
to O 0 2.19674252122104e-08
- O 0 3.734366600838257e-06
A O 0 3.8900540744180034e-07
transversion O 0 1.9116343992209295e-06
responsible O 0 8.631102588196882e-08
for O 0 2.9215216912348296e-09
the O 0 2.5832461503227933e-08
APC O 0 4.225054510698101e-07
I1307K O 0 1.930320934206975e-07
allele O 0 2.0176443626951368e-08
converts O 0 8.96460594645987e-09
the O 0 1.2263685178481865e-08
wild O 0 1.834226281971496e-07
- O 0 4.265697043592809e-06
type O 0 5.267662004371232e-07
sequence O 0 3.2994250886986265e-08
to O 0 4.262024955181687e-09
a O 0 1.6704483414287097e-06
homopolymer O 0 0.003191249445080757
tract O 0 0.017079712823033333
( O 0 1.400175477783705e-07
A8 O 0 0.00022568707936443388
) O 0 3.283723160052432e-08
that O 0 9.710907633575516e-09
is O 0 1.4872104259211483e-07
genetically O 0 2.623376758492668e-06
unstable O 0 0.0073388367891311646
and O 0 1.6217537677221117e-06
prone O 0 0.0003352008352521807
to O 0 9.307488113563522e-08
somatic O 0 6.0567537730094045e-05
mutation O 0 0.0002659132005646825
. O 0 3.944388936361065e-06

The O 0 1.5013771417216049e-06
I1307K O 0 2.68138410319807e-05
allele O 0 8.085751687758602e-06
was O 0 3.7401943700388074e-05
found O 0 5.592858087766217e-07
in O 0 3.3277206057391595e-07
6 O 0 8.634915502625518e-06
. O 0 1.924300931932521e-06

1 O 0 4.689420165959746e-06
% O 0 6.884123848749368e-08
of O 0 2.3791034919895537e-08
unselected O 0 5.7057997764786705e-05
Ashkenazi O 0 5.701144254999235e-05
Jews O 0 5.047900799581839e-07
and O 0 2.4294081413245294e-07
higher O 0 6.543554604832025e-07
proportions O 0 1.172306610897067e-06
of O 0 9.587051152948334e-09
Ashkenazim O 0 5.90986701354268e-06
with O 0 4.4557512524079357e-07
family O 0 1.0952035154332407e-06
or O 0 1.0553809204338904e-07
personal O 0 4.683269878569263e-07
histories O 0 2.0525255877146265e-06
of O 0 2.8968818810426455e-07
CRC B-Disease 0 0.0002628415822982788
( O 0 1.4997770847458014e-07
ref O 0 0.0003669525031000376
. O 0 4.654319241126359e-08
2 O 0 3.437875477629859e-07
) O 0 1.4976617990214436e-07
. O 0 7.401479820146051e-07

To O 0 2.652005264280888e-07
evaluate O 0 5.133382501298911e-07
the O 0 2.479511707065285e-08
role O 0 1.0862727606308908e-07
of O 0 3.83911284984606e-08
I1307K O 0 1.539199183753226e-05
in O 0 9.893577043840196e-06
cancer B-Disease 0 0.14464515447616577
, O 0 4.501477590679315e-08
we O 0 1.3679694710333479e-08
genotyped O 0 3.7557240375463152e-06
5 O 0 1.5097205618985754e-07
, O 0 3.8155334891598613e-08
081 O 0 8.354009878530633e-06
Ashkenazi O 0 1.0352318895456847e-05
volunteers O 0 6.248841373235337e-07
in O 0 7.100319976416358e-08
a O 0 3.897465887803264e-07
community O 0 5.84423617056018e-07
survey O 0 5.706443516828585e-06
. O 0 1.5464822809008183e-06

Risk O 0 0.0003972860286012292
of O 0 2.9423931664496195e-06
developing O 0 0.00494403624907136
colorectal B-Disease 1 0.9999948740005493
, I-Disease 0 0.0002562755544204265
breast I-Disease 1 0.9198024868965149
and I-Disease 0 7.487853963539237e-07
other I-Disease 0 2.1108954229021037e-07
cancers I-Disease 0 0.0429895780980587
were O 0 1.5658058316603274e-07
compared O 0 2.311794702336556e-07
between O 0 6.219786286010276e-08
genotyped O 0 1.6368523574783467e-05
I1307K O 0 2.9563839234469924e-06
carriers O 0 3.933102448172576e-07
and O 0 1.1425759005589953e-08
non O 0 9.090163644032145e-08
- O 0 2.1192472559050657e-06
carriers O 0 8.86351614326486e-08
and O 0 1.524453119294833e-09
their O 0 1.1004271938119814e-09
first O 0 1.1195432847443954e-07
- O 0 1.3964743629912846e-05
degree O 0 1.9889700979547342e-06
relatives O 0 1.7579608311280026e-06
. O 0 1.5068479797264445e-06

Sperm O 0 1.6558846255065873e-05
DNA O 0 5.686337772203842e-06
analysis O 0 6.004577812745993e-07
in O 0 4.537994584552507e-07
a O 0 1.713580422801897e-05
Friedreich B-Disease 0 0.32693618535995483
ataxia I-Disease 1 0.9960960745811462
premutation O 1 0.8310298323631287
carrier O 0 0.03182801976799965
suggests O 0 6.871910045447294e-07
both O 0 3.424086258974057e-08
meiotic O 0 8.800277100817766e-06
and O 0 5.3568026459061e-08
mitotic O 0 3.756444129976444e-06
expansion O 0 1.3597423276223708e-06
in O 0 1.0579364584373252e-07
the O 0 3.3208982586074853e-07
FRDA B-Disease 0 0.001437096856534481
gene O 0 3.186797766829841e-05
. O 0 1.977685769816162e-06

Friedreich B-Disease 1 0.9919204711914062
ataxia I-Disease 1 0.9990878105163574
is O 0 0.001421597902663052
usually O 0 1.3755968211626168e-05
caused O 0 1.3004349966649897e-05
by O 0 2.0666814037895165e-08
an O 0 1.697763529762142e-08
expansion O 0 3.150310021737823e-07
of O 0 1.3660061526366007e-08
a O 0 3.820237907348201e-06
GAA O 0 0.00011133391672046855
trinucleotide O 0 0.00010055239545181394
repeat O 0 9.497533142166503e-07
in O 0 3.4792552838780466e-08
intron O 0 4.10549091611756e-06
1 O 0 6.073955205465609e-08
of O 0 7.16123471633523e-09
the O 0 1.3328039472071396e-07
FRDA B-Disease 0 0.0007249763002619147
gene O 0 2.6651368898455985e-05
. O 0 2.415408971501165e-06

Occasionally O 0 7.596327577630291e-06
, O 0 1.4316255203539185e-07
a O 0 6.818263642571765e-08
fully O 0 7.790207945390648e-08
expanded O 0 5.034842942563955e-08
allele O 0 1.1392522480946354e-07
has O 0 7.323947670556663e-08
been O 0 3.746612264876603e-08
found O 0 7.217442643536742e-09
to O 0 6.14605144555469e-10
arise O 0 7.188591943929623e-09
from O 0 2.906326512785995e-09
a O 0 2.4717067503843282e-08
premutation O 0 6.958684934943449e-07
of O 0 4.0654493105307665e-09
100 O 0 1.0398391481203362e-08
or O 0 2.4590761427134566e-08
less O 0 2.5054143293345987e-07
triplet O 0 0.0010905733797699213
repeats O 0 0.00015453921514563262
. O 0 4.104551408090629e-06

We O 0 1.4106326489127241e-06
have O 0 9.528245215051356e-08
examined O 0 4.236804329593724e-07
the O 0 1.035097874080293e-08
sperm O 0 1.495528039185956e-07
DNA O 0 1.87308415888765e-07
of O 0 2.540152088670311e-08
a O 0 3.327084186821594e-06
premutation O 0 0.0015232762088999152
carrier O 0 0.0017142407596111298
. O 0 5.8719069784274325e-06

This O 0 2.954784008579736e-07
mans O 0 7.666047167731449e-06
leucocyte O 0 3.2761701731942594e-05
DNA O 0 5.414380666479701e-06
showed O 0 3.584813725865388e-07
one O 0 5.3833488777854654e-09
normal O 0 7.353244058094788e-08
allele O 0 4.96808638672519e-08
and O 0 2.165540413656686e-09
one O 0 2.8156728060224623e-09
allele O 0 1.5834530131542124e-08
of O 0 2.3316315544974486e-09
approximately O 0 3.765834222235753e-08
100 O 0 1.0573837272431774e-07
repeats O 0 4.634663582692156e-06
. O 0 1.018811985886714e-06

His O 0 2.235770125480485e-06
sperm O 0 2.3700081328570377e-06
showed O 0 3.07803190935374e-07
an O 0 5.129885405352752e-09
expanded O 0 4.372503781269188e-08
allele O 0 8.189301325955967e-08
in O 0 1.971578633686022e-08
a O 0 3.0266079420471215e-08
tight O 0 2.1929167814960238e-07
range O 0 1.1768995555883066e-08
centering O 0 2.0199854233737824e-08
on O 0 1.3644151586333919e-08
a O 0 1.0286345997201352e-08
size O 0 4.7641123046560097e-08
of O 0 6.0848526217682775e-09
approximately O 0 1.244368377228966e-07
320 O 0 2.076747705359594e-06
trinucleotide O 0 0.0004340632585808635
repeats O 0 6.502469477709383e-05
. O 0 6.823780495324172e-06

His O 0 4.785502460435964e-05
affected O 0 2.977845178975258e-05
son O 0 0.0005099968402646482
has O 0 1.4386565680979402e-06
repeat O 0 1.1636474255283247e-06
sizes O 0 3.2756102541497967e-07
of O 0 6.05415308996271e-08
1040 O 0 2.2616959540755488e-05
and O 0 3.148736311686662e-07
540 O 0 1.2541377145680599e-05
. O 0 3.5156022022420075e-06

These O 0 1.824529647365125e-07
data O 0 3.7384106121862715e-07
suggest O 0 1.0479730860879499e-07
that O 0 6.786577522177595e-09
expansion O 0 2.9405708801277797e-07
occurs O 0 4.5040970064746944e-08
in O 0 4.779436402202464e-09
two O 0 1.8579143779007268e-09
stages O 0 2.5056795038835844e-07
, O 0 2.945514054886189e-09
the O 0 2.248904173995925e-09
first O 0 6.625751503008814e-09
during O 0 3.944724014104395e-08
meiosis O 0 7.202565655006765e-08
followed O 0 2.3085156897195702e-08
by O 0 2.793382858357063e-09
a O 0 5.160615046406747e-08
second O 0 4.630553576134844e-07
mitotic O 0 2.975698771479074e-05
expansion O 0 1.8024229575530626e-05
. O 0 3.51096855411015e-06

We O 0 7.154097261263814e-07
also O 0 5.9432768040323936e-08
show O 0 7.228163667605259e-08
that O 0 2.098649698467625e-09
in O 0 2.4295683243025223e-09
all O 0 5.00936792047213e-10
informative O 0 3.139470550195256e-08
carrier O 0 7.890255801612511e-06
father O 0 5.011867187931784e-07
to O 0 4.258173369464657e-09
affected O 0 7.356316444884214e-08
child O 0 1.3893109951368388e-07
transmissions O 0 7.127966341613501e-07
, O 0 7.901948428923333e-09
with O 0 3.1106910380884756e-09
the O 0 5.849145612302209e-09
notable O 0 1.2387980419248379e-08
exception O 0 7.008206015512997e-09
of O 0 1.1771279506689325e-09
the O 0 3.080180377423858e-08
premutation O 0 3.102341725025326e-05
carrier O 0 1.7678330550552346e-05
, O 0 1.2515133818169488e-08
the O 0 1.950271233397416e-08
expansion O 0 1.0565546517682378e-06
size O 0 2.982277464980143e-06
decreases O 0 1.025678102450911e-05
. O 0 1.8807882895544026e-07
. O 0 7.983391583366028e-07

The O 0 2.7738942662836052e-06
R496H O 0 3.712760371854529e-05
mutation O 0 1.3683546967513394e-05
of O 0 1.0602757782862682e-07
arylsulfatase O 0 0.00029022892704233527
A O 0 6.569671677425504e-05
does O 0 1.6021126612031367e-06
not O 0 1.0016472060669912e-06
cause O 0 0.0008524403092451394
metachromatic B-Disease 1 0.9987881779670715
leukodystrophy I-Disease 1 0.9993828535079956
. O 0 0.00013039735495112836

Deficiency B-Disease 1 0.9957478642463684
of I-Disease 0 1.2667073860939126e-06
arylsulfatase I-Disease 0 0.001900389906950295
A I-Disease 0 0.00011130685015814379
( O 0 1.0419911404824234e-06
ARSA O 0 0.004167898092418909
) O 0 3.2210709832725115e-07
enzyme O 0 1.0402088264527265e-05
activity O 0 2.318791848665569e-05
causes O 0 0.005916215945035219
metachromatic B-Disease 1 0.9997302889823914
leukodystrophy I-Disease 1 0.9998981952667236
( O 0 0.0006971192779019475
MLD B-Disease 1 0.9988014698028564
) O 0 8.583805538364686e-06
. O 0 8.420012818532996e-06

A O 0 2.5543447463860502e-06
number O 0 6.585436551631574e-08
of O 0 1.0437381803285462e-07
ARSA O 0 0.005754017271101475
gene O 0 2.804141149681527e-05
mutations O 0 2.962453436339274e-05
responsible O 0 5.1990696192660835e-06
for O 0 1.6914337948037428e-06
MLD B-Disease 1 0.9993823766708374
have O 0 1.909970478664036e-06
been O 0 5.42526049684966e-06
identified O 0 6.308007414190797e-06
. O 0 1.2031036931148265e-06

Recently O 0 6.984085484873503e-05
, O 0 2.858466814359417e-07
the O 0 9.976377413067894e-08
R496H O 0 7.830749382264912e-06
mutation O 0 3.6399612781679025e-06
of O 0 9.667426326132045e-08
ARSA O 0 0.014664866961538792
was O 0 3.814033334492706e-05
proposed O 0 1.408599814567424e-07
to O 0 3.1730849059385946e-09
be O 0 1.2647307201518743e-08
a O 0 8.137000122587779e-07
cause O 0 2.839718035829719e-06
of O 0 1.890008718419267e-07
MLD B-Disease 1 0.9976123571395874
( O 0 3.758988782465167e-07
Draghia O 0 7.667027966817841e-05
et O 0 5.7833032769849524e-05
al O 0 4.447559149411973e-06
. O 0 7.012327074562563e-08
, O 0 1.5470058656319452e-07
1997 O 0 2.5520560029690387e-06
) O 0 1.902744344306484e-07
. O 0 8.301619800477056e-07

We O 0 8.363379606635135e-07
have O 0 1.1996397120128677e-07
investigated O 0 1.7714176010485971e-06
the O 0 5.8786081780226596e-08
R496H O 0 7.355834895861335e-06
mutation O 0 1.781315972948505e-06
and O 0 3.092495504120052e-08
found O 0 3.4559544559442656e-08
this O 0 3.6846641293664106e-09
mutation O 0 1.6028920413191372e-07
at O 0 6.980885558505179e-08
a O 0 5.371351718963524e-08
relatively O 0 6.057329926534294e-08
high O 0 7.59568195007887e-08
frequency O 0 2.6925219387408106e-08
in O 0 2.275669652718193e-09
an O 0 9.130834977000291e-10
African O 0 1.1004587241458808e-09
American O 0 5.361993515862196e-09
population O 0 1.8334797013963566e-09
( O 0 3.512794055637869e-09
f O 0 4.072479100614146e-07
= O 0 1.285606145984275e-07
0 O 0 1.5547495735290795e-08
. O 0 5.2503654757174445e-09
09 O 0 2.2280110556494037e-07
, O 0 2.5692713734315475e-08
n O 0 9.777639888852718e-07
= O 0 9.11691870442155e-07
61 O 0 3.086520905526413e-07
subjects O 0 4.145449850057048e-07
) O 0 3.0697648867317184e-07
. O 0 6.917898076608253e-07

The O 0 8.963394066086039e-06
ARSA O 0 0.0013271215138956904
enzyme O 0 1.0949634997814428e-05
activity O 0 1.5902256791378022e-06
in O 0 5.886956344625105e-08
subjects O 0 4.66806433507827e-08
with O 0 1.7392983053809985e-08
and O 0 1.8892297504180533e-08
without O 0 1.7746586422617838e-08
the O 0 2.6523863994043495e-08
R496H O 0 2.307139311596984e-06
mutation O 0 1.5797792229932384e-06
was O 0 2.1821365407959092e-06
determined O 0 9.468821815517003e-08
and O 0 8.10454903188429e-09
found O 0 2.2002565103207417e-08
to O 0 6.787405748553965e-09
be O 0 1.4284941585174238e-07
normal O 0 3.626161515057902e-06
. O 0 8.86665873167658e-07

It O 0 1.5229215932777151e-06
is O 0 3.815635807313811e-07
therefore O 0 6.690851961366207e-08
concluded O 0 2.63190173654948e-07
that O 0 2.7604227792465963e-09
the O 0 2.6647491324638395e-08
R496H O 0 2.740861191341537e-06
mutation O 0 1.2682763781413087e-06
of O 0 5.6777164303412064e-08
ARSA O 0 0.002985915867611766
does O 0 9.495262531800108e-08
not O 0 2.78751222104745e-09
negatively O 0 5.0732062994995886e-09
influence O 0 3.300480555523677e-09
the O 0 7.498657694782196e-09
activity O 0 2.891531636350919e-08
of O 0 1.8928256295680512e-08
ARSA O 0 0.0011107164900749922
and O 0 2.705459110075026e-07
is O 0 1.5697710864515102e-07
not O 0 2.0371102138483366e-08
a O 0 3.92523634218378e-06
cause O 0 8.279032044811174e-05
of O 0 1.962913120223675e-05
MLD B-Disease 1 0.9977254271507263

Down O 0 0.00043321456178091466
- O 0 7.095590262906626e-05
regulation O 0 5.2979526117269415e-06
of O 0 3.72117341385092e-07
transmembrane O 0 0.00021890329662710428
carbonic O 0 0.0013535871403291821
anhydrases O 0 0.002493905136361718
in O 0 8.18190019344911e-05
renal B-Disease 1 0.9998495578765869
cell I-Disease 1 0.9997581839561462
carcinoma I-Disease 1 0.999997615814209
cell O 0 0.3096449077129364
lines O 0 0.0001415007864125073
by O 0 3.561166295185103e-07
wild O 0 8.801872354524676e-06
- O 0 0.0030960196163505316
type O 0 0.0026596703100949526
von B-Disease 1 0.976219892501831
Hippel I-Disease 1 0.9864532351493835
- I-Disease 1 0.7144150733947754
Lindau I-Disease 1 0.517473578453064
transgenes O 0 0.0018215072341263294
. O 0 2.0516356016742066e-05

To O 0 4.998682925361209e-07
discover O 0 3.129419837932801e-06
genes O 0 2.24210543819936e-06
involved O 0 1.6784503031885833e-06
in O 0 3.6848950912826695e-06
von B-Disease 1 0.9834638237953186
Hippel I-Disease 1 0.9956883788108826
- I-Disease 1 0.7934847474098206
Lindau I-Disease 1 0.6435753107070923
( O 0 1.18938305604388e-06
VHL B-Disease 0 0.0007831387338228524
) O 0 2.640242939833115e-07
- O 0 1.2813414286938496e-05
mediated O 0 3.4043961932184175e-05
carcinogenesis O 0 0.0008977165562100708
, O 0 1.112228105171198e-07
we O 0 4.1402056893957706e-08
used O 0 2.9255213576107053e-06
renal B-Disease 1 0.999750554561615
cell I-Disease 1 0.9996625185012817
carcinoma I-Disease 1 0.9999977350234985
cell O 0 0.1714145541191101
lines O 0 7.650419865967706e-05
stably O 0 8.231915853684768e-05
transfected O 0 3.203400774509646e-05
with O 0 4.2624461116247403e-07
wild O 0 1.3420934010355268e-05
- O 0 0.0050017149187624454
type O 0 0.0008661815663799644
VHL O 0 0.15882869064807892
- O 0 0.003042754950001836
expressing O 0 1.7073396520572715e-05
transgenes O 0 0.00019283403526060283
. O 0 7.733086022199132e-06

Large O 0 4.9187451622856315e-06
- O 0 1.7864413166535087e-05
scale O 0 3.228696414225851e-06
RNA O 0 1.0129209613296553e-06
differential O 0 3.121168106190453e-07
display O 0 8.909721316285868e-08
technology O 0 2.2901669183283957e-07
applied O 0 1.6205737196628434e-08
to O 0 8.890140290596094e-10
these O 0 7.740523777499675e-10
cell O 0 1.4010425957167172e-06
lines O 0 7.017959546828934e-07
identified O 0 5.0670873719127485e-08
several O 0 2.949483102199224e-09
differentially O 0 1.4850930085685832e-07
expressed O 0 1.0808079764501599e-08
genes O 0 1.98998897360525e-08
, O 0 4.231810457611118e-09
including O 0 2.2474806460337504e-09
an O 0 5.196935504159228e-08
alpha O 0 1.911526851472445e-06
carbonic O 0 2.588816096249502e-05
anhydrase O 0 0.00015416950918734074
gene O 0 5.583847723755753e-06
, O 0 4.477441564176843e-07
termed O 0 5.465897265821695e-05
CA12 O 0 0.0029820336494594812
. O 0 3.7997417621227214e-06

The O 0 3.964744053064351e-07
deduced O 0 1.2189083236080478e-06
protein O 0 2.6229412242173566e-07
sequence O 0 2.769205309505196e-07
was O 0 5.844576094204967e-07
classified O 0 1.1581214209854807e-07
as O 0 9.558220881444868e-09
a O 0 7.020048542472068e-08
one O 0 5.259519397782242e-08
- O 0 2.3549178877146915e-05
pass O 0 4.909242079520482e-07
transmembrane O 0 3.1096515158424154e-05
CA O 0 2.503852556401398e-06
possessing O 0 4.3208125077853765e-08
an O 0 9.339173878686324e-09
apparently O 0 1.518294112656804e-07
intact O 0 1.695015612313e-07
catalytic O 0 2.730008930029726e-07
domain O 0 4.621412585947837e-08
in O 0 1.580981390247871e-08
the O 0 2.939341925412009e-08
extracellular O 0 7.87390581535874e-06
CA O 0 0.00015531019016634673
module O 0 0.0003024279430974275
. O 0 1.2660890433835448e-06

Reintroduced O 0 0.00021401890262495726
wild O 0 0.00010514002497075126
- O 0 0.004758346825838089
type O 0 0.00026457340572960675
VHL B-Disease 0 0.002100160578265786
strongly O 0 3.6535314507091243e-07
inhibited O 0 3.3757947903723107e-07
the O 0 8.915990612479163e-09
overexpression O 0 7.124548773163042e-08
of O 0 2.7741406949388647e-09
the O 0 1.3205410098748871e-08
CA12 O 0 1.3085435057291761e-05
gene O 0 2.2275351341249916e-07
in O 0 3.596270659045331e-08
the O 0 4.2288681356694724e-07
parental O 0 0.0002781062212307006
renal B-Disease 1 0.9999251365661621
cell I-Disease 1 0.9999512434005737
carcinoma I-Disease 1 0.9999992847442627
cell O 1 0.9976632595062256
lines O 0 0.00850260816514492
. O 0 1.5173522115219384e-05

Similar O 0 7.864712642913219e-06
results O 0 2.6644752324500587e-06
were O 0 6.391704943098375e-08
obtained O 0 4.4923943676167255e-08
with O 0 2.8038840582667035e-08
CA9 O 0 0.00020872997993137687
, O 0 2.4481392912889532e-08
encoding O 0 1.1446670811210424e-07
another O 0 2.748719225564855e-06
transmembrane O 0 0.00013022066559642553
CA O 0 7.322031706280541e-06
with O 0 2.441890245563627e-08
an O 0 7.188018713577549e-08
intact O 0 1.0814392226166092e-05
catalytic O 0 2.1121264580870047e-05
domain O 0 5.833377599628875e-06
. O 0 1.6246516452156357e-06

Although O 0 5.513837209036865e-07
both O 0 1.9457827349356194e-08
domains O 0 1.377236458210973e-07
of O 0 1.4348726651292054e-08
the O 0 1.8080154973176832e-07
VHL B-Disease 0 9.697770292405039e-05
protein O 0 1.444141162210144e-07
contribute O 0 1.380008818330225e-08
to O 0 2.0126007527210277e-09
regulation O 0 5.649629741810713e-08
of O 0 6.8090471039283784e-09
CA12 O 0 2.085949745378457e-05
expression O 0 1.3357586681195244e-07
, O 0 1.1793264143022952e-08
the O 0 9.60788248960398e-09
elongin O 0 1.7802969978220062e-06
binding O 0 1.2661057269269804e-07
domain O 0 1.4010116444751475e-07
alone O 0 1.8634379728155182e-07
could O 0 1.3849086144546163e-07
effectively O 0 2.457506525388453e-06
regulate O 0 1.19443593575852e-05
CA9 O 0 0.002097449963912368
expression O 0 1.9573613826651126e-05
. O 0 6.939155355212279e-06

We O 0 7.279136298166122e-06
mapped O 0 7.393968553515151e-05
CA12 O 0 0.0014020062517374754
and O 0 2.319728537258925e-06
CA9 O 0 0.001595490612089634
loci O 0 5.569302174990298e-06
to O 0 1.1270786615114048e-07
chromosome O 0 1.3209664757596329e-05
bands O 0 4.165643531450769e-06
15q22 O 0 1.702908230072353e-05
and O 0 1.3354737120607751e-06
17q21 O 0 0.0001796132419258356
. O 0 7.191307759057963e-06

2 O 0 1.3529744137485977e-05
respectively O 0 4.365755557955708e-06
, O 0 4.0951812252387754e-07
regions O 0 1.1031523854398984e-06
prone O 0 5.4564810852753e-05
to O 0 1.301958896249289e-08
amplification O 0 6.227038511497085e-07
in O 0 2.958623568360963e-08
some O 0 1.4728722241841297e-08
human O 0 4.107018412469188e-06
cancers B-Disease 1 0.9019527435302734
. O 0 6.1261539485713e-06

Additional O 0 4.3872319110960234e-07
experiments O 0 1.547417582514754e-06
are O 0 6.641643235383299e-09
needed O 0 1.7714933520096565e-08
to O 0 9.141988277505675e-10
define O 0 1.330966803436695e-08
the O 0 7.618313091484197e-09
role O 0 2.1435994312923867e-07
of O 0 7.24605300206349e-08
CA O 0 6.056095298845321e-05
IX O 0 0.0004491570289246738
and O 0 1.3750214975516428e-06
CA O 0 2.2741516659152694e-05
XII O 0 4.96647298859898e-05
enzymes O 0 7.973502391678267e-08
in O 0 1.5041782930325098e-08
the O 0 1.037319385943647e-08
regulation O 0 7.599624041176867e-08
of O 0 3.3045497449535333e-09
pH O 0 1.5887218296484207e-06
in O 0 6.0172546945125305e-09
the O 0 6.245294059681328e-09
extracellular O 0 9.484619312161158e-08
microenvironment O 0 1.0213345831289189e-06
and O 0 8.590532729613187e-09
its O 0 7.892052344971034e-09
potential O 0 1.227595305408613e-07
impact O 0 1.0213384484814014e-06
on O 0 3.1777177355252206e-05
cancer B-Disease 1 0.9385187029838562
cell O 0 0.0015318867517635226
growth O 0 1.7212094462593086e-05
. O 0 1.4359370652528014e-06

A O 0 2.3892821445770096e-06
gene O 0 9.230774935531372e-07
encoding O 0 2.7470423447084613e-07
a O 0 3.310993577088084e-07
transmembrane O 0 5.037724349676864e-06
protein O 0 4.7516343215647794e-07
is O 0 3.417822469486964e-08
mutated O 0 7.42129884656606e-07
in O 0 4.354485270141595e-07
patients O 0 3.389906123629771e-05
with O 0 0.0006308831507340074
diabetes B-Disease 1 0.9999938011169434
mellitus I-Disease 1 0.9999821186065674
and O 0 0.4733174741268158
optic B-Disease 1 0.9999911785125732
atrophy I-Disease 1 0.9999608993530273
( O 1 0.8306980133056641
Wolfram B-Disease 1 0.9999083280563354
syndrome I-Disease 1 0.9999973773956299
) O 0 3.613927765400149e-05
. O 0 1.1867005014210008e-05

Wolfram B-Disease 1 0.9990118741989136
syndrome I-Disease 1 0.9999731779098511
( O 0 0.0003549511602614075
WFS B-Disease 1 0.7287836670875549
; O 0 3.876983464579098e-05
OMIM O 0 0.04931022226810455
222300 O 0 0.0005632422398775816
) O 0 3.098707566095982e-07
is O 0 6.485397534561343e-07
an O 0 1.1337034266034607e-05
autosomal B-Disease 1 0.9993501305580139
recessive I-Disease 1 0.9998918771743774
neurodegenerative I-Disease 1 0.9999809265136719
disorder I-Disease 1 0.9998314380645752
defined O 0 4.002550122095272e-05
by O 0 4.852510073760641e-07
young O 0 4.966606866219081e-06
- O 0 0.0011627465719357133
onset O 0 0.005335597787052393
non O 0 1.2128034541092347e-05
- O 0 0.006439228542149067
immune O 0 0.01937147043645382
insulin B-Disease 0 0.06841708719730377
- I-Disease 0 0.06280940026044846
dependent I-Disease 0 0.0021178910974413157
diabetes I-Disease 1 0.9999614953994751
mellitus I-Disease 1 0.9998818635940552
and O 0 0.0005872095935046673
progressive O 1 0.9982839226722717
optic B-Disease 1 0.9999654293060303
atrophy I-Disease 1 0.9997132420539856
. O 0 7.160873065004125e-05

Linkage O 0 4.8585508920950815e-05
to O 0 2.554173761382117e-07
markers O 0 7.454348633473273e-06
on O 0 2.521748683648184e-06
chromosome O 0 0.00021832904894836247
4p O 0 0.0889284610748291
was O 0 0.00015669161803089082
confirmed O 0 1.320399633186753e-06
in O 0 3.8507732114112514e-08
five O 0 5.566678140667136e-08
families O 0 8.831369058270866e-08
. O 0 1.0245910289086169e-06

On O 0 7.210124408629781e-07
the O 0 3.073555276955631e-08
basis O 0 1.785445213897674e-08
of O 0 3.9684199037992585e-08
meiotic O 0 0.00011157666449435055
recombinants O 0 0.006142652127891779
and O 0 0.00010662622662493959
disease O 1 0.9972857236862183
- O 0 0.007589025888592005
associated O 0 4.144728336541448e-06
haplotypes O 0 1.3212397789175157e-06
, O 0 5.6602861064902754e-08
the O 0 7.092117471074744e-08
WFS B-Disease 0 0.00017949510947801173
gene O 0 1.6235487692028983e-06
was O 0 2.1063799522380577e-06
localized O 0 7.162357746892667e-07
to O 0 1.408392336088582e-08
a O 0 9.38487005441857e-07
BAC O 0 5.803025123896077e-05
/ O 0 1.6552027091165655e-06
P1 O 0 2.3490933017455973e-05
contig O 0 2.458599055898958e-06
of O 0 5.399555469409734e-09
less O 0 1.6235622624094503e-08
than O 0 1.736414567687916e-08
250 O 0 2.0067108152943547e-07
kb O 0 2.882774242607411e-05
. O 0 3.6503379305941053e-06

Mutations O 0 0.0005557438707910478
in O 0 1.992708575926372e-06
a O 0 1.7643062619754346e-06
novel O 0 1.2238797353347763e-06
gene O 0 5.447078024189977e-07
( O 0 3.919195634694006e-08
WFS1 O 0 5.688192686648108e-06
) O 0 5.208573128356875e-09
encoding O 0 1.615225819762145e-08
a O 0 7.516072741964308e-08
putative O 0 6.868764899081725e-07
transmembrane O 0 1.722200750009506e-06
protein O 0 1.303783392359037e-07
were O 0 8.15922263086577e-09
found O 0 6.709276689775834e-09
in O 0 2.5858821750546213e-09
all O 0 4.4490633399618673e-10
affected O 0 7.043449823385117e-09
individuals O 0 6.970049537535772e-10
in O 0 1.8211983032756507e-08
six O 0 8.901686499029893e-08
WFS B-Disease 0 3.005659527843818e-05
families O 0 7.937506651956028e-09
, O 0 7.286255598870639e-09
and O 0 5.447200912556127e-09
these O 0 1.2102575608352595e-09
mutations O 0 1.0994401122843556e-07
were O 0 1.1666365651308297e-08
associated O 0 4.897476557630398e-08
with O 0 2.0038268644384516e-07
the O 0 0.00017879185907077044
disease O 1 0.9966452717781067
phenotype O 0 0.0044481223449110985
. O 0 3.52465258401935e-06

WFS1 O 0 0.0023757421877235174
appears O 0 3.4322906685702037e-06
to O 0 1.5755807325490423e-08
function O 0 7.434658755300916e-08
in O 0 4.2157324742220226e-08
survival O 0 1.4264469427871518e-06
of O 0 2.508940433187945e-08
islet O 0 0.00012414589582476765
beta O 0 9.87076145975152e-06
- O 0 1.1591744623729028e-05
cells O 0 4.617905915438314e-07
and O 0 4.695953492728222e-08
neurons O 0 1.2008362091364688e-06
. O 0 1.0776096814879565e-07
. O 0 5.880138473912666e-07

Stable O 0 1.6084850358311087e-05
interaction O 0 1.457983529462581e-07
between O 0 8.313394772585525e-08
the O 0 1.2465533494321335e-08
products O 0 1.0110967174625785e-08
of O 0 2.4750737015466484e-09
the O 0 5.0951829422274386e-08
BRCA1 O 0 1.2751585018122569e-05
and O 0 3.994003350271669e-07
BRCA2 O 0 0.0002191390813095495
tumor B-Disease 0 0.009152598679065704
suppressor O 0 5.99569011683343e-06
genes O 0 1.5982456602614548e-07
in O 0 3.849260465926818e-08
mitotic O 0 1.1409279068175238e-05
and O 0 6.083150196900533e-07
meiotic O 0 0.002700535347685218
cells O 0 0.00030105889891274273
. O 0 3.8554735510842875e-06

BRCA1 O 0 0.017014004290103912
and O 0 5.0859675866377074e-06
BRCA2 O 0 5.696492371498607e-05
account O 0 1.973983785319433e-07
for O 0 2.693687939370193e-08
most O 0 2.1953560747078882e-08
cases O 0 1.5875867731551807e-08
of O 0 1.5131590203054657e-08
familial O 0 0.0001826535735744983
, O 0 7.146637130972522e-07
early O 0 2.3917988073662855e-05
onset O 1 0.6743279099464417
breast B-Disease 1 0.926365852355957
and I-Disease 0 1.734728539304342e-05
/ I-Disease 0 0.13219022750854492
or I-Disease 1 0.9708455204963684
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999970197677612
and O 0 2.738733684282124e-08
encode O 0 4.8247561501568725e-09
products O 0 1.60579833874408e-08
that O 0 8.592723199640773e-10
each O 0 9.421685653876466e-10
interact O 0 2.573067092725978e-08
with O 0 2.9587374683615053e-07
hRAD51 O 0 0.0001977922802325338
. O 0 3.1930903787724674e-06

Results O 0 2.03947438421892e-05
presented O 0 1.2397290447552223e-06
here O 0 1.559142219775822e-07
show O 0 1.8416491798234347e-07
that O 0 2.798370246637205e-08
BRCA1 O 0 5.4778633966634516e-06
and O 0 7.148437219939296e-08
BRCA2 O 0 3.0265127861639485e-06
coexist O 0 2.3349979016984435e-07
in O 0 3.706191620267418e-08
a O 0 7.084492636977302e-08
biochemical O 0 1.6385984054068103e-06
complex O 0 2.0120164663239848e-06
and O 0 1.200579475835184e-07
colocalize O 0 6.677870987914503e-05
in O 0 1.2146225003561995e-07
subnuclear O 0 1.1396327863621991e-05
foci O 0 1.396973175360472e-06
in O 0 1.5658919494399015e-08
somatic O 0 1.7044222033746337e-07
cells O 0 1.373138189819656e-07
and O 0 5.363056665430577e-09
on O 0 7.074699936993056e-09
the O 0 4.500101624671515e-09
axial O 0 5.969610583633767e-08
elements O 0 1.0784563464483199e-08
of O 0 2.3021971884418235e-08
developing O 0 3.0720950690010795e-06
synaptonemal O 0 0.0019377798307687044
complexes O 0 0.0005455989739857614
. O 0 9.41737562243361e-06

Like O 0 3.5318204027134925e-05
BRCA1 O 0 0.0009721784736029804
and O 0 4.17908449890092e-06
RAD51 O 0 0.01735633797943592
, O 0 1.9076587705058046e-06
BRCA2 O 0 2.495651824574452e-05
relocates O 0 3.289169171694084e-06
to O 0 4.781554352462081e-08
PCNA O 0 4.8800789954839274e-05
+ O 0 1.2996808891330147e-06
replication O 0 4.914750775242283e-07
sites O 0 3.8428858317729464e-08
following O 0 2.6582867462821014e-08
exposure O 0 7.728926902927924e-07
of O 0 1.3697970757675648e-08
S O 0 1.9064957086811773e-05
phase O 0 2.208770411016303e-06
cells O 0 3.5308323731442215e-07
to O 0 1.5765486693908315e-08
hydroxyurea O 0 7.459667813236592e-06
or O 0 4.1771454561967403e-07
UV O 0 0.0012293730396777391
irradiation O 0 3.049111728614662e-05
. O 0 3.0804033031017752e-06

Thus O 0 3.0691073334310204e-05
, O 0 2.8299987206992228e-06
BRCA1 O 0 5.96412064624019e-05
and O 0 1.954092141431829e-07
BRCA2 O 0 3.556344154276303e-06
participate O 0 2.3751907107794068e-08
, O 0 1.2145872752000741e-08
together O 0 8.253275396441495e-09
, O 0 1.3484523719853314e-08
in O 0 1.060655652196374e-08
a O 0 1.5990019619493978e-07
pathway O 0 2.3348509614606883e-07
( O 0 3.260419489947708e-08
s O 0 2.275631004522438e-06
) O 0 2.982634583759136e-09
associated O 0 8.24084889217147e-09
with O 0 1.439987795670561e-09
the O 0 5.504330324868079e-09
activation O 0 6.346163416992567e-08
of O 0 7.2308083964856e-09
double O 0 1.425423079126631e-06
- O 0 1.5585874280077405e-05
strand O 0 3.0358846743183676e-06
break O 0 2.7843948373629246e-06
repair O 0 0.0003650943690445274
and O 0 9.210693008299131e-08
/ O 0 1.8543804571891087e-06
or O 0 1.953272317223309e-07
homologous O 0 1.358225563308224e-05
recombination O 0 3.7180143408477306e-05
. O 0 4.114599505555816e-06

Dysfunction O 0 0.004885215777903795
of O 0 3.034654980638152e-07
this O 0 9.404960366055093e-08
pathway O 0 9.721379683469422e-07
may O 0 2.2347312267356756e-07
be O 0 2.7027287075043205e-09
a O 0 3.013319371802936e-08
general O 0 4.4481680561148096e-08
phenomenon O 0 2.0391750865655922e-07
in O 0 6.125469020901164e-09
the O 0 3.1516240728279854e-09
majority O 0 2.955756750466776e-09
of O 0 1.969427954051639e-09
cases O 0 3.26336859757248e-08
of O 0 9.836105618887814e-08
hereditary B-Disease 1 0.9877724051475525
breast I-Disease 1 0.9990059733390808
and I-Disease 0 0.00035025292891077697
/ I-Disease 1 0.8984568119049072
or I-Disease 1 0.9982277750968933
ovarian I-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9999959468841553
. O 0 2.0963974748156033e-05
. O 0 6.2690141930943355e-06

A O 0 2.6200259526376612e-05
novel O 0 5.770775260316441e-06
Arg362Ser O 0 6.448751082643867e-05
mutation O 0 9.236894584319089e-06
in O 0 6.82246579231105e-08
the O 0 1.380443706011647e-07
sterol O 0 0.00012431056529749185
27 O 0 7.2428993007633835e-06
- O 0 2.334300552320201e-05
hydroxylase O 0 1.0043157999461982e-05
gene O 0 5.420091611085809e-07
( O 0 3.2486560996858316e-08
CYP27 O 0 9.893105016089976e-06
) O 0 6.4604006588808716e-09
: O 0 2.387061215358699e-09
its O 0 2.4796145137173653e-09
effects O 0 1.5155736221572624e-08
on O 0 9.2290663999961e-09
pre O 0 2.0537227385375445e-07
- O 0 1.0203770273164992e-07
mRNA O 0 2.0193343885921422e-08
splicing O 0 1.9278722618309985e-07
and O 0 3.6073107168022034e-08
enzyme O 0 6.352581749524688e-07
activity O 0 7.039046749923727e-07
. O 0 4.799797466148448e-07

A O 0 2.3956017685122788e-05
novel O 0 2.4451699118799297e-06
C O 0 1.016132955555804e-06
to O 0 3.963652517313676e-09
A O 0 2.5248888846363116e-07
mutation O 0 4.894217227047193e-07
in O 0 1.8431439485766532e-08
the O 0 2.357039541323047e-08
sterol O 0 2.1839310647919774e-05
27 O 0 2.8551150990097085e-06
- O 0 1.4521995581162628e-05
hydroxylase O 0 5.7727675084606744e-06
gene O 0 1.2799897319837328e-07
( O 0 1.0000836603296648e-08
CYP27 O 0 1.8044642274617217e-05
) O 0 1.3592281078445012e-08
was O 0 2.917122685630602e-07
identified O 0 6.078090031280681e-09
by O 0 1.9499282188917277e-09
sequencing O 0 4.532839170678926e-08
amplified O 0 4.887379532192426e-07
CYP27 O 0 6.901767392264446e-06
gene O 0 9.956531243915379e-08
products O 0 2.64853436959811e-08
from O 0 3.1223077456843384e-08
a O 0 9.368496307615715e-07
patient O 0 0.00010666447633411735
with O 0 1.0171500434807967e-05
cerebrotendinous B-Disease 1 0.9992951154708862
xanthomatosis I-Disease 1 0.9990119934082031
( O 0 1.713899109745398e-05
CTX B-Disease 0 0.11817832291126251
) O 0 2.1355144781409763e-06
. O 0 2.729922698563314e-06

The O 0 2.7316025352774886e-06
mutation O 0 3.230520087527111e-05
changed O 0 1.9226940821681637e-06
the O 0 7.318334382944158e-08
adrenodoxin O 0 7.261600785568589e-06
cofactor O 0 9.838336154643912e-07
binding O 0 9.457637588639045e-07
residue O 0 3.766362397072953e-06
362Arg O 0 7.5435705184645485e-06
to O 0 3.6117441482019785e-08
362Ser O 0 2.1330768504412845e-05
( O 0 1.47711247677762e-07
CGT O 0 0.00012072236859239638
362Arg O 0 1.1641595847322606e-05
to O 0 5.530980118351181e-08
AGT O 0 0.0006854596431367099
362Ser O 0 1.8951299352920614e-05
) O 0 2.927100872796018e-08
, O 0 1.311407160642375e-08
and O 0 1.9968672049230918e-08
was O 0 1.0666642992873676e-05
responsible O 0 3.0845012588542886e-06
for O 0 1.2611121746886056e-06
deficiency O 0 0.14226917922496796
in O 0 3.288254646349742e-08
the O 0 3.675863169405602e-08
sterol O 0 5.814297401229851e-05
27 O 0 1.9000257225343375e-06
- O 0 4.544310286291875e-06
hydroxylase O 0 2.0359041172923753e-06
activity O 0 3.894381706004424e-08
, O 0 2.539254806421809e-09
as O 0 3.333753717527088e-09
confirmed O 0 7.99510857518726e-09
by O 0 3.270063386739963e-10
expression O 0 1.6955103987470466e-09
of O 0 1.1557482748614234e-09
mutant O 0 3.5504225337490425e-08
cDNA O 0 4.608227044400337e-08
into O 0 6.074429848013096e-08
COS O 0 9.01026141946204e-05
- O 0 3.181954161846079e-05
1 O 0 1.94328868019511e-06
cells O 0 5.454529855342116e-06
. O 0 9.388754733663518e-07

Quantitative O 0 3.872919023706345e-06
analysis O 0 5.115184080750623e-07
showed O 0 1.5573366454191273e-06
that O 0 3.0840943132659504e-09
the O 0 2.8316899935987294e-09
expression O 0 6.943409402992984e-09
of O 0 2.12078932193549e-09
CYP27 O 0 2.0952863906131824e-06
gene O 0 5.3071740779842e-08
mRNA O 0 2.6532871899576094e-08
in O 0 1.7561692544632024e-08
the O 0 2.6257236385163196e-08
patient O 0 1.8768334939522902e-06
represented O 0 2.06639455768709e-07
52 O 0 3.7736972444690764e-06
. O 0 1.4599107771573472e-06

5 O 0 9.219830303663912e-07
% O 0 2.3454600039940487e-08
of O 0 5.0055022349226874e-09
the O 0 9.966582581455441e-08
normal O 0 5.5717882787575945e-06
level O 0 1.2428599802660756e-05
. O 0 3.153877287331852e-06

As O 0 6.175110343065171e-07
the O 0 2.9853458727302495e-07
mutation O 0 3.6388435091794236e-06
occurred O 0 1.1263689430052182e-06
at O 0 1.0548898643492066e-07
the O 0 1.0139626915872668e-08
penultimate O 0 3.3474552196821605e-07
nucleotide O 0 8.242220417287172e-08
of O 0 1.1501675167835401e-08
exon O 0 2.2391309357772116e-06
6 O 0 2.3557457495826384e-07
( O 0 1.3003805143796399e-08
- O 0 3.75046653289246e-07
2 O 0 1.5710345024899652e-08
position O 0 1.2828891726712754e-08
of O 0 2.710699886776524e-09
exon O 0 8.703674438947928e-07
6 O 0 4.6010387677597464e-07
- O 0 2.371421032876242e-06
intron O 0 8.487670129397884e-06
6 O 0 6.920486583794627e-08
splice O 0 3.5665703990162e-07
site O 0 1.0444829712241699e-07
) O 0 1.0706512343361396e-09
of O 0 4.6540929443672496e-10
the O 0 6.333850333106739e-09
gene O 0 4.281075405287993e-08
, O 0 4.5597698949961796e-09
we O 0 2.435395662914175e-09
hypothesized O 0 2.5832955330429286e-08
that O 0 2.1100161617937374e-09
the O 0 4.6429082800614196e-08
mutation O 0 3.351560962983058e-06
may O 0 3.032438939953863e-07
partially O 0 1.4733632269781083e-06
affect O 0 1.2517329395222987e-08
the O 0 2.881828775613826e-09
normal O 0 2.491486839062418e-08
splicing O 0 1.2418905726008234e-07
efficiency O 0 2.738990474426828e-07
in O 0 4.2003545530633346e-08
exon O 0 2.346637984373956e-06
6 O 0 2.943205572591978e-07
and O 0 2.4125853315126733e-08
cause O 0 9.173349013735788e-08
alternative O 0 1.1971832414303663e-08
splicing O 0 1.4142720772269968e-07
elsewhere O 0 1.87228579306975e-07
, O 0 7.482427122340596e-09
which O 0 3.1073821293858828e-09
resulted O 0 4.393411501268929e-08
in O 0 2.2538177546493898e-08
decreased O 0 1.3858482361683855e-06
transcript O 0 1.2946743481734302e-06
in O 0 8.293550024518481e-08
the O 0 8.380657163797878e-07
patient O 0 0.00019016856094822288
. O 0 1.974892484213342e-06

Transfection O 0 0.0009028861531987786
of O 0 1.4034040987098706e-06
constructed O 0 6.129244138719514e-05
minigenes O 0 0.00018959498265758157
, O 0 9.224283559206015e-08
with O 0 1.663459414658064e-08
or O 0 3.40039605362108e-08
without O 0 1.952374084623898e-08
the O 0 2.2473532368394444e-08
mutation O 0 2.364525926168426e-07
, O 0 5.161695515454312e-09
into O 0 2.7746027697617137e-08
COS O 0 4.263364098733291e-05
- O 0 3.8018113173166057e-06
1 O 0 7.292807424619241e-08
cells O 0 7.732385398639963e-08
confirmed O 0 3.194663023009525e-08
that O 0 4.792341523618404e-10
the O 0 3.583034313692224e-09
mutant O 0 1.6641931210870098e-07
minigene O 0 3.833014488918707e-06
was O 0 1.1481002957225428e-06
responsible O 0 1.762460932752674e-08
for O 0 7.654124001277296e-10
a O 0 1.1073295169694575e-08
mRNA O 0 3.9440319454797645e-08
species O 0 2.4359159134235142e-09
alternatively O 0 1.621662093498344e-08
spliced O 0 1.627199424092396e-07
at O 0 1.2835872098548862e-07
an O 0 3.1752417584129944e-08
activated O 0 6.437913725676481e-06
cryptic O 0 3.172333720158349e-07
5 O 0 2.3177763708304155e-08
splice O 0 3.559441665856866e-07
site O 0 6.066059654585843e-07
88 O 0 1.2808970950572984e-07
bp O 0 3.246575488446979e-07
upstream O 0 2.406514099106971e-08
from O 0 2.424744405260526e-09
the O 0 3.2075990752389316e-09
3 O 0 1.4736365905321236e-08
end O 0 3.916579771612305e-08
of O 0 2.6787732920752205e-08
exon O 0 4.1829167457763106e-05
6 O 0 8.79242543305736e-06
. O 0 1.2998096963201533e-06

Our O 0 1.1958409231738187e-06
data O 0 4.3511974467946857e-07
suggest O 0 5.1929621491808575e-08
that O 0 1.8538682811097829e-09
the O 0 5.5867466208781025e-09
C O 0 7.688604597433368e-08
to O 0 1.3998804337944648e-09
A O 0 1.213031879387927e-07
mutation O 0 9.795179778393504e-08
at O 0 2.3154125727842256e-08
the O 0 2.380595720552492e-09
penultimate O 0 8.480305524471987e-08
nucleotide O 0 1.6422397663973243e-08
of O 0 2.266481891055605e-09
exon O 0 4.653831524592533e-07
6 O 0 3.753113730908808e-08
of O 0 1.1052990744886415e-09
the O 0 2.6218801352229093e-08
CYP27 O 0 4.3037227442255244e-05
gene O 0 4.167989970937924e-07
not O 0 9.236392983780206e-09
only O 0 1.5903690808727333e-08
causes O 0 1.9820397483272245e-06
the O 0 5.538260211324086e-06
deficiency B-Disease 0 0.09950088709592819
in I-Disease 0 2.23521663400561e-08
the I-Disease 0 2.8266512686059286e-08
sterol I-Disease 0 9.585511725163087e-05
27 I-Disease 0 4.2993665374524426e-06
- I-Disease 0 9.912409041135106e-06
hydroxylase I-Disease 0 3.0197115847840905e-06
activity I-Disease 0 5.803829239425795e-08
, O 0 9.33080546161591e-09
but O 0 9.348084972771176e-09
also O 0 7.0118986172929e-08
partially O 0 3.150023530906765e-06
leads O 0 3.125692416006132e-08
to O 0 8.849588284398635e-10
alternative O 0 1.981731756472982e-08
pre O 0 2.1719453968671587e-07
- O 0 4.487025151433954e-08
mRNA O 0 8.956624775180444e-09
splicing O 0 3.73169939393847e-08
of O 0 3.732366415931665e-09
the O 0 6.082963466269575e-08
gene O 0 3.507478140818421e-06
. O 0 1.0028400083683664e-06

To O 0 1.514097931476499e-07
our O 0 6.168794186578452e-08
knowledge O 0 3.036461038163907e-08
, O 0 3.689644856308405e-08
this O 0 5.95191806951334e-09
is O 0 8.788180849705896e-09
the O 0 6.768027471792948e-09
first O 0 4.8308365308002976e-08
report O 0 1.1363643359629805e-08
regarding O 0 4.459158375880179e-09
effects O 0 4.9010179026254264e-08
on O 0 2.133741716647819e-08
pre O 0 2.7061403784500726e-07
- O 0 2.9805661938553385e-08
mRNA O 0 5.137924752318668e-09
splicing O 0 1.8194690198924945e-08
of O 0 1.893918799567018e-09
a O 0 2.340705052006342e-08
mutation O 0 8.902230064222749e-08
at O 0 6.080365722027636e-08
the O 0 1.4991345054227168e-08
- O 0 9.37976949444419e-07
2 O 0 1.6103840039249917e-08
position O 0 1.800203897062147e-08
of O 0 1.4586525320936516e-09
a O 0 9.203053963346974e-08
5 O 0 1.5604750558395608e-07
splice O 0 8.343134140886832e-06
site O 0 1.029369559546467e-05
. O 0 2.2807735149399377e-06

ATM O 0 0.0023360447958111763
germline O 0 0.007466068957000971
mutations O 0 0.0020120101980865
in O 0 2.2542993974639103e-05
classical O 0 0.017566213384270668
ataxia B-Disease 1 0.9999794960021973
- I-Disease 1 0.9999009370803833
telangiectasia I-Disease 1 0.9999516010284424
patients O 0 0.22846394777297974
in O 0 1.967412572412286e-06
the O 0 1.2972660670129699e-06
Dutch O 0 0.0001478925987612456
population O 0 1.22971562177554e-06
. O 0 1.93818959814962e-06

Germline O 0 0.00472473306581378
mutations O 0 0.000622432678937912
in O 0 3.3348402439514757e-07
the O 0 5.794084856347581e-08
ATM O 0 4.094691576028708e-06
gene O 0 3.364969245467364e-07
are O 0 3.926466263237671e-09
responsible O 0 3.116192317520472e-07
for O 0 5.578789341598167e-07
the O 0 0.016637736931443214
autosomal B-Disease 1 0.9999872446060181
recessive I-Disease 1 0.9999982118606567
disorder I-Disease 1 0.9999998807907104
ataxia B-Disease 1 0.9999988079071045
- I-Disease 1 0.9999771118164062
telangiectasia I-Disease 1 0.99996018409729
( O 0 0.029721206054091454
A B-Disease 1 0.9999135732650757
- I-Disease 1 0.9997900128364563
T I-Disease 1 0.99970942735672
) O 0 3.0052810870984104e-06
. O 0 3.477634436421795e-06

In O 0 9.725033578433795e-07
our O 0 1.2255833325980348e-07
study O 0 7.115422562264939e-08
, O 0 1.4508452217398826e-08
we O 0 2.766004092435992e-09
have O 0 1.533361992933635e-09
determined O 0 1.063907539844422e-08
the O 0 7.91306398184588e-09
ATM O 0 2.5402403025509557e-06
mutation O 0 2.1499850788586627e-07
spectrum O 0 1.0135667594113329e-07
in O 0 2.2095843377201163e-08
19 O 0 1.779017821945672e-07
classical O 0 4.679556241171667e-06
A B-Disease 1 0.9993343949317932
- I-Disease 1 0.9995505213737488
T I-Disease 1 0.9999328851699829
patients O 0 5.479545507114381e-06
, O 0 3.828697803243131e-09
including O 0 7.416339209420642e-10
some O 0 6.100525640206911e-10
immigrant O 0 4.3746140931943955e-08
populations O 0 5.019153981322688e-09
, O 0 1.0431202568383924e-09
as O 0 2.1060677646289605e-09
well O 0 4.152255872469368e-09
as O 0 7.307061622441324e-09
12 O 0 6.908982719266987e-09
of O 0 1.106963631869462e-09
Dutch O 0 9.358128636449692e-07
ethnic O 0 5.338810282751183e-08
origin O 0 3.649564916941017e-07
. O 0 1.1364227248122916e-06

Both O 0 1.5342425285780337e-07
the O 0 1.0867866961916661e-07
protein O 0 3.3652258935035206e-07
truncation O 0 1.3328818795343977e-06
test O 0 2.0788847621133755e-07
( O 0 1.647080161149006e-08
PTT O 0 1.6567393004152109e-06
) O 0 4.909819661946813e-09
and O 0 2.5367035139112204e-09
the O 0 6.956944353930794e-09
restriction O 0 3.493458677894523e-08
endonuclease O 0 1.5115774658625014e-06
fingerprinting O 0 1.4277794662120868e-06
( O 0 3.975594609073596e-08
REF O 0 2.057062192761805e-05
) O 0 1.3773705509478873e-09
method O 0 2.115061015217634e-09
were O 0 6.196666513247351e-10
used O 0 7.088405973298961e-10
and O 0 1.3357905892519284e-09
compared O 0 7.413953007073815e-09
for O 0 1.4973039474952543e-10
their O 0 2.7909155542182873e-10
detection O 0 7.32923055579704e-08
efficiency O 0 1.251346759545413e-07
, O 0 5.440244255083826e-09
identifying O 0 1.9521358751717344e-08
76 O 0 5.179874662530892e-08
% O 0 7.044171357328821e-10
and O 0 8.028938625059823e-10
60 O 0 5.119065615843965e-09
% O 0 7.268969315354923e-10
of O 0 1.455534248684387e-09
the O 0 7.184468131526955e-08
mutations O 0 3.094944304393721e-06
, O 0 1.1363561469579508e-07
respectively O 0 1.728113716126245e-06
. O 0 1.0154712981602643e-06

Most O 0 2.4095056687656324e-06
patients O 0 1.0712025868997443e-05
were O 0 9.631702369006234e-08
found O 0 3.175556884116304e-08
to O 0 4.090845440174462e-09
be O 0 9.189898264594376e-08
compound O 0 1.389652334182756e-05
heterozygote O 0 6.578059401363134e-05
. O 0 3.3090409488067962e-06

Seventeen O 0 1.0793743967951741e-05
mutations O 0 1.4175997421261854e-05
were O 0 4.5347068322598716e-08
distinct O 0 2.5669642411685345e-08
, O 0 8.210740531922056e-09
of O 0 2.86398704751889e-09
which O 0 2.098010298823283e-08
10 O 0 2.6100998695710587e-08
were O 0 2.15310347329023e-08
not O 0 2.9427974723716943e-08
reported O 0 5.674788098986028e-06
previously O 0 3.305070322312531e-06
. O 0 1.0718704288592562e-06

Mutations O 0 0.0004062614170834422
are O 0 9.65281543585661e-08
small O 0 9.868333705753685e-08
deletions O 0 1.8864751609726227e-06
or O 0 3.028906974122947e-07
point O 0 3.0759795208723517e-06
mutations O 0 7.350878149736673e-06
frequently O 0 7.38681933398766e-07
affecting O 0 1.781039145498653e-06
splice O 0 5.6885073718149215e-05
sites O 0 1.1748062206606846e-05
. O 0 6.2630142565467395e-06

Moreover O 0 4.025348607683554e-05
, O 0 6.700838639517315e-07
a O 0 1.570754989188572e-06
16 O 0 3.0124574550427496e-06
. O 0 2.179644752686727e-06

7 O 0 4.731628723675385e-05
- O 0 2.7803836928796954e-05
kb O 0 1.210383834404638e-05
genomic O 0 1.8610028291732306e-06
deletion O 0 1.135248453465465e-06
of O 0 1.3887753169683492e-08
the O 0 1.9412603080581903e-08
3 O 0 2.229651308027769e-08
end O 0 9.520594090872692e-09
of O 0 6.339721525527864e-10
the O 0 6.2264544631318586e-09
gene O 0 2.9246676191974075e-08
, O 0 3.9382417327260555e-09
most O 0 2.173758950618776e-09
likely O 0 1.0880411238645138e-08
a O 0 1.0472393618954356e-08
result O 0 5.385197621166071e-09
of O 0 6.930769846924534e-10
recombination O 0 1.099085356059959e-08
between O 0 3.1359499441663274e-09
two O 0 7.219810527203663e-09
LINE O 0 1.957038421096513e-06
elements O 0 9.431186498431998e-08
, O 0 2.2550696598955255e-07
was O 0 3.4337448596488684e-05
identified O 0 3.6182268559059594e-06
. O 0 1.0488384987183963e-06

The O 0 6.5416696770626e-07
most O 0 6.169911870301803e-08
frequently O 0 2.3261696924237185e-07
found O 0 2.0871804906619218e-07
mutation O 0 7.907753456493083e-07
, O 0 2.493559669858314e-08
identified O 0 6.178991895922081e-08
in O 0 1.0963467467206556e-08
three O 0 1.354184586688234e-08
unrelated O 0 9.857494660536759e-07
Turkish O 0 2.989402855746448e-05
A B-Disease 1 0.9993264675140381
- I-Disease 1 0.99660325050354
T I-Disease 1 0.9990403056144714
individuals O 0 1.3429468204151362e-08
, O 0 1.1290677548458916e-07
was O 0 6.161378223623615e-06
previously O 0 2.9299170023477927e-07
described O 0 5.6486815225298415e-08
to O 0 1.1742127270508718e-09
be O 0 4.782062301700307e-09
a O 0 5.2606129230525767e-08
Turkish O 0 1.1031040230591316e-05
A B-Disease 1 0.9983854293823242
- I-Disease 1 0.9988564252853394
T I-Disease 1 0.9993526339530945
founder O 0 0.0002313899458386004
mutation O 0 0.00011838879436254501
. O 0 2.3130039608076913e-06

The O 0 2.903331619563687e-07
presence O 0 2.129422398411407e-07
of O 0 1.8079356678413205e-08
a O 0 4.2956185097864363e-07
founder O 0 2.361243332416052e-06
mutation O 0 1.3368027111937408e-06
among O 0 6.685465958611303e-09
relatively O 0 5.908227507234187e-08
small O 0 9.141086110275864e-09
ethnic O 0 4.477157311555402e-09
population O 0 7.128651002830111e-09
groups O 0 2.6289646015698054e-09
in O 0 5.022275928467934e-09
Western O 0 1.979797481510559e-08
Europe O 0 1.4465643971561803e-07
could O 0 1.818345118920206e-08
indicate O 0 1.5518638818434738e-08
a O 0 5.813523529241138e-08
high O 0 6.63084790630819e-07
carrier O 0 6.177813816066191e-07
frequency O 0 6.039702071802822e-08
in O 0 1.4485115329421205e-08
such O 0 9.226532426964695e-09
communities O 0 2.1483413092937553e-07
. O 0 1.3669805412064306e-06

In O 0 1.458077986171702e-05
patients O 0 6.5244139477727e-06
of O 0 2.7343441288962822e-08
Dutch O 0 1.9435926787991775e-06
ethnic O 0 2.9621016750525087e-08
origin O 0 2.423663758577277e-08
, O 0 5.6821797045358835e-08
however O 0 4.416449073119111e-08
, O 0 1.858025022727361e-08
no O 0 2.6905352612516253e-08
significant O 0 1.1931349774840783e-07
founder O 0 8.539004738850053e-06
effect O 0 8.536225664101948e-07
could O 0 3.624573992055957e-07
be O 0 1.4709104334542644e-07
identified O 0 2.2670812995784217e-06
. O 0 6.114219672781473e-07

The O 0 1.5927116692182608e-06
observed O 0 2.6579984933050582e-06
genetic O 0 1.2083551155228633e-06
heterogeneity O 0 1.4405731008082512e-06
including O 0 1.8968915327377545e-08
the O 0 2.4836298351260666e-08
relative O 0 2.791414317471208e-07
high O 0 3.257845037296647e-06
percentage O 0 1.0594186505841208e-07
of O 0 2.9915909749433922e-09
splice O 0 2.6466134386282647e-06
- O 0 3.596359601942822e-05
site O 0 2.5146475763904164e-06
mutations O 0 1.7110064618464094e-06
had O 0 1.3756101679973654e-07
no O 0 8.844125432005967e-09
reflection O 0 9.59415231704952e-08
on O 0 1.8736237450411863e-07
the O 0 5.898768904444296e-07
phenotype O 0 0.00010300926078343764
. O 0 2.0286286144255428e-06

All O 0 2.2438448468165006e-06
patients O 0 2.0836016119574197e-05
manifested O 0 1.3747954653808847e-05
classical O 0 3.06159708998166e-05
A B-Disease 1 0.9838931560516357
- I-Disease 0 0.4621644914150238
T I-Disease 1 0.9110104441642761
and O 0 5.33124939749996e-08
increased O 0 1.3322879510724306e-07
cellular O 0 1.175579473056132e-05
radioresistant O 0 4.5532098738476634e-05
DNA O 0 7.93376148067182e-06
synthesis O 0 1.0197918527410366e-05
. O 0 2.1856978946743766e-06

Determination O 0 5.2074656196055e-06
of O 0 4.158916411256541e-08
the O 0 4.7826215876511924e-08
genomic O 0 6.152673108772433e-07
structure O 0 4.2763178953464376e-07
of O 0 6.215229664263688e-09
the O 0 4.0872986772910735e-08
COL4A4 O 0 2.1741061573266052e-05
gene O 0 1.589810239011058e-07
and O 0 1.470735888631225e-08
of O 0 8.465195122653313e-08
novel O 0 3.2750267564551905e-05
mutations O 0 0.001916272914968431
causing O 0 0.13130982220172882
autosomal B-Disease 1 0.9992861151695251
recessive I-Disease 1 0.9998525381088257
Alport I-Disease 1 0.9999618530273438
syndrome I-Disease 1 0.9999798536300659
. O 0 0.0020264354534447193

Autosomal B-Disease 1 0.9978469610214233
recessive I-Disease 1 0.9996008276939392
Alport I-Disease 1 0.99992835521698
syndrome I-Disease 1 0.9999829530715942
is O 0 0.0024827655870467424
a O 0 0.001722899149172008
progressive O 1 0.9943506121635437
hematuric B-Disease 1 0.998164713382721
glomerulonephritis I-Disease 1 0.9999204874038696
characterized O 0 0.07099837064743042
by O 0 1.0062592082249466e-05
glomerular B-Disease 1 0.9934183359146118
basement I-Disease 1 0.905135452747345
membrane I-Disease 0 0.07868614792823792
abnormalities I-Disease 1 0.9950718283653259
and O 0 1.1709211094057537e-06
associated O 0 1.0102544365508948e-06
with O 0 1.7179688427404471e-07
mutations O 0 4.312124474381562e-06
in O 0 4.8085343706816275e-08
either O 0 1.891291923072913e-08
the O 0 5.845691219974469e-08
COL4A3 O 0 3.459381696302444e-05
or O 0 1.6761607213311436e-08
the O 0 3.583282293107004e-08
COL4A4 O 0 2.5973127776524052e-05
gene O 0 1.268064551140924e-07
, O 0 4.168134282167557e-09
which O 0 4.787060747801775e-10
encode O 0 1.7678469799164986e-09
the O 0 1.223674495065552e-08
alpha3 O 0 2.3258376131707337e-06
and O 0 2.8418526198947802e-08
alpha4 O 0 6.648844282608479e-05
type O 0 0.0002947159518953413
IV O 1 0.6972987055778503
collagen O 0 0.0024706246331334114
chains O 0 0.00011714320135070011
, O 0 3.060148401345941e-07
respectively O 0 2.375826170464279e-06
. O 0 1.4927991287549958e-06

To O 0 2.492992052793852e-07
date O 0 6.855049150544801e-07
, O 0 3.4639196400121364e-08
mutation O 0 2.7932358648286026e-07
screening O 0 8.120412786638553e-08
in O 0 3.9091743175845295e-09
the O 0 1.469302457479671e-09
two O 0 2.7235940169845207e-09
genes O 0 1.720586517706124e-08
has O 0 6.46666649117833e-08
been O 0 4.378454221409811e-08
hampered O 0 2.063575720967492e-06
by O 0 2.7380844258573234e-09
the O 0 9.75114655688003e-09
lack O 0 3.986293251045936e-08
of O 0 1.5751780324535503e-08
genomic O 0 2.2431363504438195e-06
structure O 0 9.08478887140518e-06
information O 0 4.968384814674209e-07
. O 0 2.0946970380464336e-06

We O 0 5.1094143600494135e-06
report O 0 3.62029709322087e-07
here O 0 2.0011794887864198e-08
the O 0 3.7018663689991627e-09
complete O 0 2.6649678019907697e-08
characterization O 0 7.182823935636407e-08
of O 0 2.591931114181989e-09
the O 0 1.1093377771942414e-08
48 O 0 2.9846447091586015e-08
exons O 0 3.894804834203569e-08
of O 0 3.5882594673353196e-09
the O 0 2.5146944082621303e-08
COL4A4 O 0 2.6922683900920674e-05
gene O 0 1.9126341044284345e-07
, O 0 4.3179602116083515e-09
a O 0 1.0408788497784371e-08
comprehensive O 0 4.8606800362449576e-08
gene O 0 9.136645218177364e-08
screen O 0 1.3240952512205695e-07
, O 0 7.145258162921664e-09
and O 0 7.727026241077795e-10
the O 0 1.0328451427454866e-09
subsequent O 0 8.674487794735342e-09
detection O 0 5.584896101140657e-08
of O 0 3.374402313127689e-09
10 O 0 3.057003539197467e-08
novel O 0 9.909810927410945e-08
mutations O 0 5.585752660408616e-07
in O 0 7.238924837338345e-08
eight O 0 2.389072506048251e-06
patients O 0 0.0008493561181239784
diagnosed O 1 0.9995896220207214
with O 0 0.002421444747596979
autosomal B-Disease 1 0.9998289346694946
recessive I-Disease 1 0.9999185800552368
Alport I-Disease 1 0.9999395608901978
syndrome I-Disease 1 0.9999574422836304
. O 0 0.0019486184464767575

Furthermore O 0 1.2981575309822802e-05
, O 0 4.641137820726726e-07
we O 0 5.1100542464155296e-08
identified O 0 6.821490217134851e-08
a O 0 6.858096668338476e-08
glycine O 0 3.0222534519452893e-07
to O 0 2.011457000961059e-09
alanine O 0 8.075065238699608e-08
substitution O 0 9.869778772042537e-09
in O 0 6.591063250738216e-09
the O 0 1.3116798314172229e-08
collagenous O 0 3.972255854023388e-06
domain O 0 1.1561482438082749e-07
that O 0 1.0550504470074884e-08
is O 0 2.7292427873248926e-08
apparently O 0 2.03792325237373e-07
silent O 0 7.961145342960663e-07
in O 0 1.0601985067637543e-08
the O 0 1.4190703723215847e-08
heterozygous O 0 1.1547973599590478e-07
carriers O 0 2.6961919274981483e-07
, O 0 2.2268039856498945e-08
in O 0 5.538834457752273e-08
11 O 0 1.0503559906283044e-06
. O 0 6.663723866040527e-07

5 O 0 1.9189808426745003e-06
% O 0 2.3121291548022782e-08
of O 0 2.223823125646618e-09
all O 0 2.850102376328323e-09
control O 0 2.41747301288342e-07
individuals O 0 2.5338988685064123e-09
, O 0 8.623365133075822e-09
and O 0 9.379661491948355e-09
in O 0 1.6761543264465217e-08
one O 0 7.151284897588539e-09
control O 0 1.168766345926997e-07
individual O 0 3.711198459654952e-09
homozygous O 0 9.317221127957964e-08
for O 0 4.915910345459906e-09
this O 0 1.0276285600241408e-08
glycine O 0 8.568605380787631e-07
substitution O 0 5.293067033562693e-07
. O 0 9.72451289271703e-07

There O 0 2.7077303457190283e-06
has O 0 3.7906826833022933e-07
been O 0 4.463678848765085e-08
no O 0 6.00683147666814e-09
previous O 0 9.337393080954826e-09
finding O 0 1.937493721015926e-09
of O 0 6.274663566507854e-10
a O 0 1.5991291846262357e-08
glycine O 0 8.562563635905462e-08
substitution O 0 7.208692309745857e-09
that O 0 4.721079083225277e-09
is O 0 1.4284174731926669e-08
not O 0 1.0340357459170946e-09
associated O 0 5.610174991232952e-09
with O 0 3.832102191125841e-09
any O 0 1.0399660688165113e-08
obvious O 0 5.245919396656973e-07
phenotype O 0 4.403085767989978e-06
in O 0 1.9398359540900856e-07
homozygous O 0 2.3932639123813715e-06
individuals O 0 8.8558273603212e-08
. O 0 6.537423473673698e-07

Founder O 0 0.0005627424106933177
BRCA1 O 0 0.0010533935856074095
and O 0 3.2308712434314657e-06
BRCA2 O 0 0.00018618795729707927
mutations O 0 4.0444534533889964e-05
in O 0 6.994293357820425e-07
French O 0 0.0003456266422290355
Canadian O 0 0.14839692413806915
breast B-Disease 1 0.9998605251312256
and I-Disease 1 0.999030590057373
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999935626983643
families O 0 3.361396738910116e-05
. O 0 1.6528380001545884e-05

We O 0 7.405490123346681e-07
have O 0 2.699958123741908e-08
identified O 0 6.048151846016481e-08
four O 0 7.134145718623586e-09
mutations O 0 9.926022670470047e-08
in O 0 2.7869697660776183e-09
each O 0 1.6618475484619921e-09
of O 0 8.932808270856185e-09
the O 0 1.8400254703010432e-05
breast B-Disease 1 0.9991027116775513
cancer I-Disease 1 0.9980777502059937
- O 0 0.00023244803014677018
susceptibility O 0 9.668579878052697e-06
genes O 0 2.0581892101745325e-07
, O 0 5.968290395230724e-08
BRCA1 O 0 4.569210432237014e-06
and O 0 1.4411844517780992e-07
BRCA2 O 0 6.743226094840793e-06
, O 0 2.6377556139323133e-08
in O 0 6.341952030197717e-08
French O 0 7.73445499362424e-05
Canadian O 0 0.01403145119547844
breast B-Disease 1 0.9997422099113464
cancer I-Disease 1 0.9997668862342834
and O 0 0.05119388550519943
breast B-Disease 1 0.9999854564666748
/ I-Disease 1 0.9999750852584839
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999960660934448
families O 0 7.94345214671921e-06
from O 0 7.124641797418008e-06
Quebec O 0 0.00670253299176693
. O 0 6.595947979803896e-06

To O 0 9.299730550083041e-07
identify O 0 1.4308571962828864e-06
founder O 0 6.008483524055919e-06
effects O 0 7.317731160583207e-06
, O 0 8.46346779326268e-08
we O 0 2.82453864741683e-08
examined O 0 4.2816554923774675e-07
independently O 0 8.651160499084654e-08
ascertained O 0 8.268419264823024e-07
French O 0 1.8446215108269826e-05
Canadian O 0 0.0007643047720193863
cancer B-Disease 0 0.2707580626010895
families O 0 6.596622359467119e-09
for O 0 1.4767083111877355e-09
the O 0 1.5751171478228798e-09
distribution O 0 6.539060404264774e-09
of O 0 2.213160099628908e-09
these O 0 4.8648978179244295e-09
eight O 0 3.908535859409312e-07
mutations O 0 1.3686862075701356e-05
. O 0 1.5110917956917547e-06

Mutations O 0 6.342806591419503e-05
were O 0 2.8197112555972126e-07
found O 0 1.021775375420475e-07
in O 0 1.497294199737098e-08
41 O 0 4.517647766988375e-08
of O 0 5.973891159527511e-09
97 O 0 5.172218493498804e-07
families O 0 1.670768767780828e-07
. O 0 1.0508518926144461e-06

Six O 0 6.73132603878912e-07
of O 0 4.000536790726983e-08
eight O 0 1.2998614806747355e-07
mutations O 0 5.399454039434204e-07
were O 0 1.4154319494252832e-08
observed O 0 1.9170202847362816e-07
at O 0 1.4146795592751005e-06
least O 0 2.3386080272302934e-07
twice O 0 4.275284481991548e-06
. O 0 4.974681360181421e-07

The O 0 7.0790615609439556e-06
BRCA1 O 0 0.0005528513574972749
C4446T O 0 0.00010675156954675913
mutation O 0 9.772742487257347e-05
was O 0 4.23776009483845e-06
the O 0 2.009303123884365e-08
most O 0 7.0187740064397985e-09
common O 0 5.9882907521569e-08
mutation O 0 1.2436867109499872e-06
found O 0 4.2603527816709175e-08
, O 0 7.192650919307653e-09
followed O 0 2.715866109781473e-08
by O 0 1.5483632154200677e-08
the O 0 8.077050210886227e-07
BRCA2 O 0 0.00014118808030616492
8765delAG O 0 0.00031138642225414515
mutation O 0 0.00016236766532529145
. O 0 5.0496910262154415e-06

Together O 0 7.233927590277744e-07
, O 0 6.963544763038954e-08
these O 0 3.5846339230261037e-09
mutations O 0 1.8314226224447339e-07
were O 0 1.4645355150832984e-08
found O 0 1.4562431260856101e-08
in O 0 5.378586465099033e-09
28 O 0 3.517918401030329e-08
of O 0 1.5252996643511096e-09
41 O 0 6.833652577142857e-08
families O 0 2.1306010289379174e-09
identified O 0 2.588089209609734e-08
to O 0 2.3113433389454485e-09
have O 0 1.7440253685663265e-08
a O 0 2.869010813810746e-06
mutation O 0 3.2509418815607205e-05
. O 0 1.193522393805324e-06

The O 0 1.2281661838642322e-06
odds O 0 8.708409040991683e-06
of O 0 1.1031808355710382e-08
detection O 0 4.408685470025375e-07
of O 0 1.613725264526522e-09
any O 0 8.862341416282504e-10
of O 0 9.290436198128305e-10
the O 0 1.7018422227010888e-08
four O 0 1.234345461398334e-07
BRCA1 O 0 3.980594192398712e-05
mutations O 0 1.5125598110898864e-05
was O 0 3.448959250818007e-05
18 O 0 2.4059004317678045e-06
. O 0 7.035328621896042e-07

7x O 0 0.0015202868962660432
greater O 0 2.6134182462556055e-06
if O 0 2.4960681344055047e-07
one O 0 9.862741734423253e-09
or O 0 5.791021440160193e-09
more O 0 3.9963401476939e-09
cases O 0 2.076338887491147e-07
of O 0 0.0004802532494068146
ovarian B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999979734420776
were O 0 1.8817405589288683e-06
also O 0 8.632353853954555e-08
present O 0 2.865802883889046e-08
in O 0 6.219465831236448e-08
the O 0 3.1172297099146817e-07
family O 0 7.531451501563424e-06
. O 0 1.8198860516349669e-06

The O 0 1.9953040464315563e-06
odds O 0 1.0995362572430167e-05
of O 0 1.22026238003059e-08
detection O 0 3.4885289323938196e-07
of O 0 2.6512014805746276e-09
any O 0 2.3234096868662846e-09
of O 0 1.7983737832238944e-09
the O 0 1.776236580042223e-08
four O 0 2.0913626030960586e-07
BRCA2 O 0 3.325133729958907e-05
mutations O 0 7.747133167868014e-06
was O 0 2.212317667726893e-05
5 O 0 1.3437278312267154e-06
. O 0 1.5457671906915493e-06

3x O 0 0.00011469601304270327
greater O 0 1.5822895420569694e-06
if O 0 1.6764332144703076e-07
there O 0 1.160644114150955e-08
were O 0 4.827701793885808e-09
at O 0 3.1854568760536495e-08
least O 0 3.219637667584152e-09
five O 0 5.260439195353683e-09
cases O 0 1.735321930596001e-08
of O 0 6.855780725345539e-07
breast B-Disease 1 0.9997318387031555
cancer I-Disease 1 0.9959898591041565
in O 0 3.1948766832101683e-07
the O 0 5.280759296510951e-07
family O 0 1.1456020729383454e-05
. O 0 2.407194870102103e-06

Interestingly O 0 1.598606104380451e-05
, O 0 1.0444610154536349e-07
the O 0 1.4589928376551597e-08
presence O 0 4.9893575493342723e-08
of O 0 6.022240484071517e-08
a O 0 0.00017818072228692472
breast B-Disease 1 0.9992190599441528
cancer I-Disease 1 0.9260780215263367
case O 0 4.3787551362584054e-07
< O 0 3.262109089519072e-07
36 O 0 1.689377882030385e-08
years O 0 4.57203164216935e-09
of O 0 1.6558233673080736e-09
age O 0 1.6253414969469304e-07
was O 0 3.1792723120815936e-07
strongly O 0 3.2969069696520137e-09
predictive O 0 4.410116716258017e-09
of O 0 4.066773029443027e-10
the O 0 2.274120669554236e-09
presence O 0 4.207953985257973e-09
of O 0 2.5306809425806875e-10
any O 0 4.427679334284562e-10
of O 0 5.871072517038556e-10
the O 0 1.590648146532203e-08
eight O 0 2.185723815273377e-07
mutations O 0 7.362741143879248e-06
screened O 0 1.8468570488039404e-05
. O 0 1.420908802174381e-06

Carriers O 0 1.1932223060284741e-05
of O 0 2.5758268407116702e-08
the O 0 2.4795308917191505e-08
same O 0 3.02738740742825e-08
mutation O 0 5.085877319288556e-07
, O 0 5.652515344678477e-09
from O 0 1.5700900579673771e-09
different O 0 4.318863600083489e-10
families O 0 2.274858079687192e-09
, O 0 2.01687400114281e-09
shared O 0 3.7648413275803705e-09
similar O 0 1.658732351472736e-08
haplotypes O 0 2.052782690498134e-07
, O 0 2.9569536152962428e-08
indicating O 0 5.428451999023309e-08
that O 0 8.958192521113517e-10
the O 0 2.076107286086426e-09
mutant O 0 3.7690320198180416e-08
alleles O 0 6.904872673629825e-09
were O 0 6.3343095213497236e-09
likely O 0 1.393612603095562e-08
to O 0 1.002883442957625e-09
be O 0 5.585170104183135e-09
identical O 0 2.086334127682221e-08
by O 0 3.847056451178332e-09
descent O 0 3.3856405678989177e-08
for O 0 3.733213738144059e-09
a O 0 2.935337022336171e-07
mutation O 0 5.330919066182105e-07
in O 0 2.1024607832487163e-08
the O 0 5.79190810867658e-08
founder O 0 4.535923380899476e-06
population O 0 2.644295022946608e-07
. O 0 7.273969231391675e-07

The O 0 2.7320146500642295e-07
identification O 0 2.2229598073408852e-07
of O 0 3.0325253419505316e-08
common O 0 1.3340479654289084e-06
BRCA1 O 0 0.00026954879285767674
and O 0 1.93603000298026e-06
BRCA2 O 0 0.00012043171591358259
mutations O 0 4.516908575169509e-06
will O 0 9.691811797551964e-09
facilitate O 0 8.549002927793481e-08
carrier O 0 1.1621564226516057e-05
detection O 0 2.9464986255334225e-06
in O 0 1.541856846642986e-07
French O 0 0.00022156230988912284
Canadian O 0 0.09549887478351593
breast B-Disease 1 0.9998067021369934
cancer I-Disease 1 0.9998224377632141
and O 0 0.1196259930729866
breast B-Disease 1 0.9999805688858032
/ I-Disease 1 0.9999459981918335
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999960660934448
families O 0 4.827892917091958e-05
. O 0 1.2608124052349012e-05

Are O 0 7.001928565841808e-07
Dp71 O 0 0.00013077941548544914
and O 0 1.591345153428847e-06
Dp140 O 0 0.00020012811000924557
brain O 0 0.004000185057520866
dystrophin O 0 7.393714622594416e-05
isoforms O 0 8.596720704190375e-07
related O 0 5.555381221711286e-07
to O 0 1.2767551993420057e-07
cognitive B-Disease 0 0.0007490763091482222
impairment I-Disease 1 0.7635696530342102
in O 0 0.00587408896535635
Duchenne B-Disease 1 0.9998782873153687
muscular I-Disease 1 0.9999157190322876
dystrophy I-Disease 1 0.9998124241828918
? O 0 0.018492288887500763

Molecular O 0 0.00011430316953919828
study O 0 1.3523180086849607e-06
and O 0 6.243343619871666e-08
neuropsychological O 0 4.3665800149028655e-06
analysis O 0 2.4444810620138924e-08
were O 0 6.0654437028517805e-09
performed O 0 3.107632906562685e-08
concurrently O 0 2.9330641027058846e-08
on O 0 2.8386463668539363e-07
49 O 0 4.943146450386848e-06
patients O 0 4.548776360024931e-06
with O 0 1.614235225133598e-05
Duchenne B-Disease 1 0.9998832941055298
muscular I-Disease 1 0.9998904466629028
dystrophy I-Disease 1 0.9998825788497925
( O 0 5.7473360357107595e-05
DMD B-Disease 1 0.9994582533836365
) O 0 1.044210122813638e-07
in O 0 1.9281676699733907e-08
order O 0 2.867031501097017e-09
to O 0 4.892831140246301e-10
find O 0 2.707134738599848e-09
a O 0 1.7396665441538062e-08
molecular O 0 9.069070472378371e-08
explanation O 0 8.596202860644553e-09
for O 0 3.5139064991085434e-09
the O 0 7.802594836903154e-08
cognitive B-Disease 0 3.524368003127165e-05
impairment I-Disease 0 0.00018188574176747352
observed O 0 2.145774715245352e-06
in O 0 1.1429156074882485e-06
most O 0 1.7634818505030125e-05
DMD B-Disease 1 0.9996464252471924
patients O 0 0.007921264506876469
. O 0 1.7960124750970863e-05

Complete O 0 1.2542659533210099e-06
analysis O 0 1.929897450736462e-07
of O 0 1.9635066905721033e-08
the O 0 6.57461782793689e-08
dystrophin O 0 2.2338404960464686e-05
gene O 0 4.404946594149806e-06
was O 0 7.707052645855583e-06
performed O 0 1.2405860161379678e-07
to O 0 1.3008312205187167e-09
define O 0 1.1546228861902819e-08
the O 0 4.98733765397219e-09
localization O 0 6.633315052795297e-08
of O 0 4.461369940145232e-09
deletions O 0 1.3537358256598964e-07
and O 0 1.4470922238274397e-08
duplications O 0 8.671214004607464e-07
in O 0 9.661454214437981e-08
relation O 0 7.545806113284925e-08
to O 0 7.076764507729649e-09
the O 0 1.3969089707188687e-07
different O 0 6.471194069490593e-07
DMD B-Disease 1 0.9984762072563171
promoters O 0 0.0005563791492022574
. O 0 1.3556619705923367e-05

Qualitative O 0 2.8662377644650405e-06
analysis O 0 2.6642874217941426e-07
of O 0 1.0907839076423897e-08
the O 0 4.4044195846026923e-08
Dp71 O 0 7.4557701736921445e-06
transcript O 0 3.192880285496358e-06
and O 0 1.6420738546685243e-08
testing O 0 3.48371749225862e-08
for O 0 8.944584517500687e-10
the O 0 2.0953219159736136e-09
specific O 0 5.332230768040347e-10
first O 0 4.248017049235386e-09
exon O 0 2.1373713821049023e-07
of O 0 3.123276970384836e-09
Dp140 O 0 7.420378551614704e-07
were O 0 2.9005189361441808e-08
also O 0 2.073290872317557e-08
carried O 0 3.45076159646851e-07
out O 0 1.5831439270641567e-07
. O 0 5.145322461430624e-07

Neuropsychological O 0 0.0011262831976637244
analysis O 0 6.752995432179887e-06
assessed O 0 6.743856374669122e-06
verbal O 0 2.4388891688431613e-06
and O 0 1.9945800033838168e-07
visuospatial O 0 5.255620999378152e-05
intelligence O 0 2.1231706341495737e-05
, O 0 2.0495747321547242e-07
verbal O 0 3.412316573303542e-06
memory O 0 0.0005357246263884008
, O 0 4.3653625425577047e-07
and O 0 2.3343454813584685e-07
reading O 0 3.90909781344817e-06
skills O 0 9.575105650583282e-06
. O 0 5.707026048185071e-06

Comparison O 0 1.4531793794958503e-06
of O 0 9.564698899566793e-08
molecular O 0 7.43524333302048e-06
and O 0 2.0452830540307332e-07
psychometric O 0 0.000305153924273327
findings O 0 2.187937752751168e-06
demonstrated O 0 1.0404341992398258e-06
that O 0 6.243245920245499e-09
deletions O 0 1.9067297785113624e-07
and O 0 1.3555903954909354e-08
duplications O 0 4.878327217738843e-07
that O 0 1.009324090972541e-08
were O 0 1.3496720185912636e-08
localized O 0 1.6979827250906965e-06
in O 0 4.4330242587875546e-08
the O 0 1.514706760019635e-08
distal O 0 5.12973201693967e-07
part O 0 3.509206436547174e-08
of O 0 1.256233783664129e-09
the O 0 1.766829882399179e-08
gene O 0 1.310600055148825e-07
seemed O 0 1.091096493155419e-07
to O 0 1.0668982364236967e-09
be O 0 7.233842858056505e-09
preferentially O 0 6.525818463387623e-08
associated O 0 2.537315424433473e-07
with O 0 4.805949060937564e-07
cognitive B-Disease 0 0.002361404476687312
impairment I-Disease 0 0.34603583812713623
. O 0 1.8197946701548062e-05

Two O 0 1.129296720137063e-06
altered O 0 1.0216959708486684e-05
Dp71 O 0 2.2934766093385406e-05
transcripts O 0 7.89696912306681e-07
and O 0 1.403827809554059e-08
two O 0 5.188088181284911e-09
deleted O 0 8.884571656153639e-08
Dp140 O 0 3.342689183227776e-07
DNA O 0 6.817795394908899e-08
sequences O 0 1.5519526996854438e-08
were O 0 3.389166725042969e-09
found O 0 7.553031089457818e-09
in O 0 9.513750676148902e-09
four O 0 1.527136390677697e-07
patients O 0 1.3294110431161243e-05
with O 0 5.788776252302341e-05
severe O 1 0.9995570778846741
cerebral B-Disease 1 0.9998276233673096
dysfunction I-Disease 1 0.9992897510528564
. O 0 0.0001346387289231643

These O 0 3.0578610221709823e-07
findings O 0 1.0884052699111635e-06
suggest O 0 8.993158928660705e-08
that O 0 2.276351329655313e-09
some O 0 1.060424414944805e-09
sequences O 0 1.0192951371834624e-08
located O 0 1.0736398081689913e-07
in O 0 7.0201662261126785e-09
the O 0 6.4041496550260035e-09
distal O 0 3.7413281006593024e-07
part O 0 3.5631224193366506e-08
of O 0 1.8362444897945807e-09
the O 0 1.5502898520480812e-08
gene O 0 7.187415462794888e-08
and O 0 2.459859516079632e-08
, O 0 7.5533188592658e-09
in O 0 7.478132779681346e-09
particular O 0 9.077460561002226e-09
, O 0 1.0975519160183467e-08
some O 0 6.836466059922941e-09
DMD B-Disease 0 0.037626415491104126
isoforms O 0 5.9023594900509124e-08
expressed O 0 2.550619271346477e-08
in O 0 5.0605006407522524e-08
the O 0 1.4334606248667114e-06
brain O 0 0.21223556995391846
may O 0 1.1541976618900662e-06
be O 0 5.112937628837244e-09
related O 0 8.70443628286921e-09
to O 0 3.302936812943358e-09
the O 0 3.975345066464797e-07
cognitive B-Disease 0 0.0011096579255536199
impairment I-Disease 0 0.27593496441841125
associated O 0 3.986239607911557e-05
with O 0 8.792220614850521e-05
DMD B-Disease 1 0.9998773336410522
. O 0 6.651750936725875e-06
. O 0 3.3194492061738856e-06

I1307K O 0 0.0004180623509455472
APC O 0 0.00019007410446647555
and O 0 1.6395534885305096e-06
hMLH1 O 0 7.988907600520179e-05
mutations O 0 1.9262346540926956e-05
in O 0 1.978216488396356e-07
a O 0 3.454689760928886e-07
non O 0 8.591369464738818e-07
- O 0 1.4649437616753858e-05
Jewish O 0 7.833878044039011e-07
family O 0 7.624318527632568e-07
with O 0 1.0383367907706997e-06
hereditary B-Disease 1 0.9967401623725891
non I-Disease 1 0.9925416707992554
- I-Disease 1 0.9999533891677856
polyposis I-Disease 1 0.9999747276306152
colorectal I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999940395355225
. O 0 0.0005424767732620239

We O 0 7.434148301399546e-07
describe O 0 8.794503969511425e-07
a O 0 1.315088979936263e-06
French O 0 3.821737118414603e-05
Canadian O 0 0.0001309133949689567
hereditary B-Disease 1 0.996431827545166
non I-Disease 1 0.9954181909561157
- I-Disease 1 0.9999701976776123
polyposis I-Disease 1 0.9999905824661255
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
( O 0 0.00015214770974125713
HNPCC B-Disease 1 0.9823137521743774
) O 0 2.4113757035593153e-07
kindred O 0 7.836338227207307e-06
which O 0 3.4940317306109137e-08
carries O 0 8.422548347652992e-08
a O 0 1.6035052397000982e-07
novel O 0 4.772037982547772e-07
truncating O 0 1.2433744814188685e-05
mutation O 0 1.7622880477574654e-05
in O 0 9.078482889890438e-07
hMLH1 O 0 0.0001509834692114964
. O 0 3.3968747175094904e-06

Interestingly O 0 3.955068677896634e-05
, O 0 2.8454442713155004e-07
the O 0 1.0587237397885474e-07
I1307K O 0 2.203180883952882e-06
APC O 0 3.446388291195035e-06
polymorphism O 0 1.2195025647088187e-06
, O 0 1.7072194324896373e-08
associated O 0 1.250496861615602e-08
with O 0 2.2386843490096453e-09
an O 0 5.059390772998995e-08
increased O 0 5.548018634726759e-06
risk O 0 0.0007553782197646797
of O 0 0.003841441124677658
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
, O 0 1.147625152952969e-05
is O 0 5.32543651843298e-07
also O 0 4.962082300608017e-08
present O 0 2.4495312445083073e-08
in O 0 1.1195582771961199e-07
this O 0 3.259343728245767e-08
family O 0 2.0043785298184957e-06
. O 0 1.2663426787185017e-06

The O 0 1.2355978924460942e-06
I1307K O 0 1.9492950741550885e-05
polymorphism O 0 1.0985563676513266e-05
has O 0 2.594450734250131e-07
previously O 0 7.573432014851278e-08
only O 0 3.966072803507359e-09
been O 0 3.422343297643238e-08
identified O 0 2.5629182331954325e-08
in O 0 4.295075850535568e-09
individuals O 0 7.682366964800735e-10
of O 0 1.3470180526553577e-08
self O 0 2.4383947675232776e-05
- O 0 0.003022608580067754
reported O 0 2.77276812994387e-05
Ashkenazi O 0 1.736884041747544e-05
Jewish O 0 1.6092899386421777e-06
origins O 0 6.302349447651068e-06
. O 0 2.119291593771777e-06

In O 0 8.009250791474187e-07
addition O 0 1.7723661471791274e-07
, O 0 5.488963594757479e-08
in O 0 2.028398427000866e-08
this O 0 5.017220416903001e-09
family O 0 2.504413600945554e-07
, O 0 5.0889283897959103e-08
there O 0 2.629688111710493e-08
appears O 0 6.929995777227305e-08
to O 0 1.2750142053263858e-09
be O 0 3.3978140301371695e-09
no O 0 2.2448327641200194e-09
relationship O 0 8.703307408097771e-09
between O 0 5.061376207038393e-09
the O 0 1.1910654684754718e-08
I1307K O 0 1.4961014471737144e-07
polymorphism O 0 6.016006892650694e-08
and O 0 2.646654229110368e-09
the O 0 1.1428069157659593e-08
presence O 0 4.1170856945882406e-08
or O 0 2.956621081295907e-08
absence O 0 1.2709183465631213e-06
of O 0 2.0145200778642902e-06
cancer B-Disease 1 0.9778113961219788
. O 0 6.235144383026636e-07
. O 0 1.3558175169237074e-06

Identification O 0 1.219190835399786e-06
of O 0 5.670464986451407e-08
a O 0 5.059072805124742e-07
novel O 0 5.387474857343477e-07
mutation O 0 3.04980858345516e-07
of O 0 2.6503219618945195e-09
the O 0 1.9043412180508312e-08
CPO O 0 1.3161729839339387e-06
gene O 0 2.0301330039274035e-07
in O 0 3.8705515237325017e-08
a O 0 4.0315296701010084e-07
Japanese O 0 1.2767734006047249e-05
hereditary B-Disease 1 0.5975448489189148
coproporphyria I-Disease 0 0.19365721940994263
family O 0 0.00013856845907866955
. O 0 8.214915396820288e-06

Hereditary B-Disease 1 0.9894089698791504
coproporphyria I-Disease 1 0.5506301522254944
( O 0 2.3638778657186776e-05
HCP B-Disease 0 0.158710777759552
) O 0 5.9730967905125e-07
is O 0 2.531210441247822e-07
an O 0 1.553885908833763e-06
autosomal B-Disease 1 0.9839719533920288
dominant I-Disease 1 0.9986106157302856
disease I-Disease 1 0.9998276233673096
characterized O 0 0.009380260482430458
by O 0 9.481537745159585e-06
a O 0 0.016339454799890518
deficiency B-Disease 1 0.9626787900924683
of I-Disease 0 1.3214928173965745e-07
coproporphyrinogen I-Disease 0 0.00041407268145121634
oxidase I-Disease 0 8.05161653261166e-06
( O 0 6.592335921595804e-08
CPO O 0 2.457126811350463e-06
) O 0 1.3836485734941562e-08
caused O 0 8.71143299718824e-08
by O 0 5.271327374600787e-09
a O 0 1.9393031891468127e-07
mutation O 0 6.68119753299834e-07
in O 0 3.2560258489411353e-08
the O 0 7.015671599219786e-08
CPO O 0 7.847285814932548e-06
gene O 0 4.422153324412648e-06
. O 0 9.432065439796133e-07

Only O 0 5.886024041501514e-07
11 O 0 4.18137034330357e-07
mutations O 0 5.153597157914191e-07
of O 0 6.0714855365517906e-09
the O 0 2.5730868102868953e-08
gene O 0 2.612102605326072e-07
have O 0 2.227139539456857e-08
been O 0 7.511342232646712e-07
reported O 0 7.319993073906517e-06
in O 0 2.1243263290671166e-06
HCP B-Disease 1 0.9705874919891357
patients O 0 0.0007427781820297241
. O 0 7.089789960446069e-06

We O 0 2.080911144730635e-06
report O 0 2.768275919606822e-07
another O 0 1.2707339180906274e-07
mutation O 0 1.6837183238749276e-06
in O 0 5.148326209791776e-08
a O 0 8.248886729234073e-07
Japanese O 0 1.3358685464481823e-05
family O 0 2.246877738798503e-05
. O 0 5.9159456213819794e-06

Polymerase O 0 0.00023851465084590018
chain O 0 0.00014592392835766077
reaction O 0 1.2567213161673862e-05
- O 0 1.1040290701203048e-05
single O 0 3.628464639859885e-07
strand O 0 1.423010758117016e-06
conformational O 0 2.911694423346489e-07
polymorphism O 0 2.363831441698494e-07
and O 0 3.539912807326573e-09
direct O 0 4.400940945004095e-09
sequence O 0 4.123781849330044e-08
analyses O 0 4.671805342582047e-08
demonstrated O 0 4.974875622565378e-08
a O 0 3.326989883589704e-08
C O 0 1.2462531628898432e-07
to O 0 1.7250250117228916e-09
T O 0 5.613120492853341e-07
substitution O 0 4.7132786562542606e-09
in O 0 4.568440292729292e-09
exon O 0 1.3900174167247314e-07
1 O 0 1.6015070158914568e-08
of O 0 9.022599334329584e-10
the O 0 5.970906435948109e-09
CPO O 0 1.0425960539350854e-07
gene O 0 2.281255184755082e-08
at O 0 3.413014937336811e-08
nucleotide O 0 8.586080468830914e-08
position O 0 7.729436646286558e-08
85 O 0 5.50212888583701e-08
, O 0 6.991983880766384e-09
which O 0 3.685620031390613e-09
lies O 0 7.14231802589893e-08
in O 0 1.445530806165607e-08
the O 0 1.2386137449027501e-08
putative O 0 3.2949100159385125e-07
presequence O 0 1.1213656989639276e-06
for O 0 5.119026535993498e-09
targeting O 0 5.1565223202487687e-08
to O 0 3.299903283959793e-08
mitochondria O 0 5.0194907998957206e-06
. O 0 2.0616362235159613e-06

This O 0 7.950355893626693e-07
mutation O 0 5.985749339743052e-06
changes O 0 1.2304469976243126e-07
the O 0 1.952444783626106e-08
codon O 0 1.1070808625390782e-07
for O 0 2.0476818018977383e-09
glutamine O 0 5.4050296682817134e-08
to O 0 1.0383401916058688e-09
a O 0 2.9742963647549914e-08
termination O 0 3.34786989242275e-07
codon O 0 1.923147294746741e-07
at O 0 2.1875757738598622e-07
amino O 0 1.2663677750879287e-07
acid O 0 1.08305937374098e-06
position O 0 4.314661055104807e-07
29 O 0 2.664780140548828e-06
. O 0 5.974509349471191e-07

MaeI O 0 0.0002146033220924437
restriction O 0 2.7918638352275593e-06
analysis O 0 2.3233363322106015e-07
showed O 0 1.593948582012672e-07
two O 0 4.861298918967805e-09
other O 0 2.3414359340279134e-09
carriers O 0 2.54465305715712e-07
in O 0 5.389608759287512e-08
the O 0 9.563640901433246e-08
family O 0 3.0416167646762915e-06
. O 0 1.3947314982942771e-06

The O 0 8.757513569435105e-06
C O 0 0.0009184735245071352
- O 0 0.05272435396909714
T O 0 0.007170150522142649
mutation O 0 4.244222964189248e-06
is O 0 3.5110005569549685e-08
located O 0 1.0866789068586513e-07
within O 0 2.8484244296578254e-08
a O 0 3.9031198184602545e-07
recently O 0 4.185769739706302e-06
proposed O 0 2.0754596619099175e-07
putative O 0 3.6624271615437465e-07
alternative O 0 8.112610316857172e-08
translation O 0 7.976834126566246e-08
initiation O 0 1.5085907989487168e-07
codon O 0 7.413517550958204e-07
( O 0 5.8228344812505384e-08
TIC O 0 2.0698174921562895e-05
- O 0 2.578349040049943e-06
1 O 0 7.12725380935808e-08
) O 0 4.7020543014753e-09
, O 0 5.605703901068182e-09
supporting O 0 2.8585422029436813e-08
that O 0 2.6153523791094813e-08
TIC O 0 6.584850780200213e-05
- O 0 4.354898010205943e-06
1 O 0 1.0276211526161205e-07
is O 0 1.1483392903244294e-08
the O 0 1.2118868575328179e-08
real O 0 2.403863277322671e-07
TIC O 0 1.075621821655659e-05
rather O 0 1.3692851297264497e-08
than O 0 3.722031749475718e-08
TIC O 0 9.984154166886583e-05
- O 0 9.990065336751286e-06
2 O 0 4.915378895020694e-07
. O 0 1.5433381861384987e-07
. O 0 5.263784714770736e-07

Human B-Disease 0 1.34692227220512e-05
complement I-Disease 0 0.0001319319853791967
factor I-Disease 0 0.11666667461395264
H I-Disease 1 0.9999387264251709
deficiency I-Disease 1 0.9997692704200745
associated O 0 0.02109433524310589
with O 1 0.5045265555381775
hemolytic B-Disease 1 0.9999725818634033
uremic I-Disease 1 0.9999898672103882
syndrome I-Disease 1 0.9999860525131226
. O 0 0.002197739202529192

This O 0 6.522931244035135e-07
study O 0 2.5473042342127883e-07
reports O 0 6.714758882253591e-08
on O 0 4.5476646448605607e-08
six O 0 9.705541970106424e-08
cases O 0 1.6003778569029237e-07
of O 0 7.142759841372026e-07
deficiency B-Disease 1 0.8342660665512085
in I-Disease 0 2.1769714919628314e-08
the I-Disease 0 5.03537833651535e-09
human I-Disease 0 2.640271112852588e-09
complement I-Disease 0 1.5106328632441546e-08
regulatory I-Disease 0 1.0888589940805105e-06
protein I-Disease 0 4.04075223059408e-07
Factor I-Disease 0 6.350207399918872e-07
H I-Disease 0 0.37787142395973206
( O 0 1.2041076047353272e-07
FH O 0 2.1486464902409352e-05
) O 0 4.644340911852396e-09
in O 0 2.2048767256421797e-09
the O 0 1.1477935268899842e-09
context O 0 1.1123041154803559e-08
of O 0 3.1302803904509346e-08
an O 0 7.926348189357668e-05
acute B-Disease 1 0.9998918771743774
renal I-Disease 1 0.9999994039535522
disease I-Disease 1 0.9999970197677612
. O 0 0.0023241376038640738

Five O 0 3.1855063298280584e-07
of O 0 1.4035894224662115e-08
the O 0 2.628915751756722e-08
cases O 0 2.4281101573819797e-08
were O 0 7.583547123601875e-09
observed O 0 4.2467309668836606e-08
in O 0 2.7831148941004358e-08
children O 0 1.347720086641857e-07
presenting O 0 1.984786104003433e-05
with O 0 0.04500764235854149
idiopathic O 1 0.999969482421875
hemolytic B-Disease 1 0.9999955892562866
uremic I-Disease 1 0.999997615814209
syndrome I-Disease 1 0.9999967813491821
( O 0 0.01026947982609272
HUS B-Disease 1 0.9993305206298828
) O 0 3.595200178097002e-05
. O 0 9.944004887074698e-06

Two O 0 1.3662933895375318e-07
of O 0 2.473220384047181e-08
the O 0 1.4785430835217994e-07
children O 0 1.4415019222724368e-07
exhibited O 0 2.0846986444666982e-05
a O 0 0.0011138039408251643
homozygous O 1 0.665740430355072
deficiency O 1 0.993928074836731
characterized O 0 1.4438175639952533e-05
by O 0 1.3890984362774361e-08
the O 0 3.323083319628495e-08
absence O 0 3.562741568430283e-08
of O 0 1.2896401724304951e-09
the O 0 8.034211518292977e-09
150 O 0 1.8851117999929556e-08
- O 0 1.2657558272621827e-06
kD O 0 6.358631026159856e-07
form O 0 1.1288638468442969e-08
of O 0 4.461344627060271e-09
Factor O 0 1.0671678296603204e-07
H O 0 0.019769202917814255
and O 0 1.1061094262743154e-08
the O 0 9.639968823194067e-09
presence O 0 2.0349240514860867e-08
, O 0 1.4680978654979526e-09
upon O 0 2.6862521096404635e-09
immunoblotting O 0 4.5595288611366414e-07
, O 0 1.5361723004758687e-09
of O 0 6.319945122790216e-10
the O 0 4.901912653565432e-09
42 O 0 9.840253767379181e-08
- O 0 6.525606863760913e-07
kD O 0 1.4248793149818084e-06
Factor O 0 1.6469897445858805e-07
H O 0 0.0014851337764412165
- O 0 8.049129860410176e-07
like O 0 1.917619663061032e-08
protein O 0 4.156378352604406e-08
1 O 0 3.599152620381574e-08
( O 0 1.0672549954904298e-08
FHL O 0 7.652037311345339e-06
- O 0 1.1495355920487782e-06
1 O 0 2.794327436106414e-08
) O 0 1.9245218751962057e-09
and O 0 2.8418838393662327e-09
other O 0 4.560474664572212e-09
FH O 0 4.070754221174866e-05
- O 0 1.058248381013982e-05
related O 0 1.1737301974790171e-07
protein O 0 1.8061852813389123e-07
( O 0 3.2735922417259644e-08
FHR O 0 2.704115104279481e-05
) O 0 3.135317427904738e-08
bands O 0 1.2946212564202142e-06
. O 0 1.0427864935991238e-06

Southern O 0 2.2815460397396237e-05
blot O 0 3.848560299957171e-05
and O 0 8.585343636013931e-08
PCR O 0 4.4914435193277313e-07
analysis O 0 1.685740791401713e-08
of O 0 1.5978661727089616e-09
DNA O 0 4.387583274478857e-08
of O 0 2.4626278793959955e-09
one O 0 5.376230305387253e-08
patient O 0 3.968798864661949e-06
with O 0 1.547804345136683e-06
homozygous O 0 0.016674427315592766
deficiency O 1 0.950482964515686
ruled O 0 2.407619604127831e-06
out O 0 2.7481090736358738e-09
the O 0 1.935550830722832e-09
presence O 0 4.698540223557757e-09
of O 0 1.3898477924101371e-09
a O 0 1.8814334978856095e-08
large O 0 7.713232719197549e-09
deletion O 0 6.753831627293039e-08
of O 0 1.6855148388117414e-09
the O 0 3.7118866202945355e-08
FH O 0 2.732438406383153e-05
gene O 0 1.9784995686222828e-07
as O 0 3.274472959446939e-08
the O 0 1.911911908791808e-07
underlying O 0 9.199870692100376e-05
defect O 0 0.0007324192556552589
for O 0 1.6724903844078653e-06
the O 0 0.0004531753365881741
deficiency O 1 0.9977299571037292
. O 0 5.854796654602978e-06

The O 0 2.950850159777474e-07
other O 0 1.0757035262543013e-08
four O 0 1.8452755767839335e-08
children O 0 1.1509092345818317e-08
presented O 0 1.1840612046398746e-07
with O 0 1.329996962340374e-06
heterozygous O 0 0.0005712013226002455
deficiency O 1 0.7199451923370361
and O 0 9.411994028596382e-08
exhibited O 0 4.442201316123828e-06
a O 0 6.986373932704737e-07
normal O 0 7.228741765175073e-07
immunoblotting O 0 5.5953887567739e-06
pattern O 0 2.711865647597733e-07
of O 0 4.1447867360489e-09
proteins O 0 1.6730178131751927e-08
of O 0 1.6718152195949187e-08
the O 0 8.276813332486199e-07
FH O 0 0.0031282936688512564
family O 0 1.4250180356611963e-05
. O 0 3.817889137280872e-06

Factor B-Disease 0 0.48015186190605164
H I-Disease 1 0.9999573230743408
deficiency I-Disease 1 0.9995936751365662
is O 0 1.7199980675286497e-06
the O 0 3.852716758956376e-07
only O 0 3.5855873647960834e-06
complement B-Disease 1 0.9961575865745544
deficiency I-Disease 1 0.9999778270721436
associated O 0 0.0001579330419190228
with O 0 2.2354728571372107e-05
HUS B-Disease 1 0.9989703893661499
. O 0 4.7248922783182934e-05

These O 0 2.174592168557865e-07
observations O 0 6.777116823286633e-07
suggest O 0 1.6506818667494372e-07
a O 0 1.360965313779161e-07
role O 0 4.000010846993973e-07
for O 0 1.376486693516199e-07
FH O 0 0.00035479862708598375
and O 0 1.5894751470568735e-07
/ O 0 4.590100161294686e-06
or O 0 2.851455747077125e-07
FH O 0 4.792919207829982e-05
receptors O 0 1.0621718047332251e-06
in O 0 7.072233643157233e-08
the O 0 2.690109965897136e-07
pathogenesis O 0 0.0009651391301304102
of O 0 6.864770512038376e-06
idiopathic O 1 0.9995377063751221
HUS B-Disease 1 0.9997116923332214
. O 0 2.7829939426737837e-05
. O 0 9.360241165268235e-06

Further O 0 6.052791263755353e-07
evidence O 0 1.4844445672679285e-07
for O 0 1.585598674580524e-08
a O 0 3.922778262221982e-07
major O 0 2.836286057572579e-06
ancient O 0 1.2286966921237763e-05
mutation O 0 0.006473421584814787
underlying O 0 0.09310653805732727
myotonic B-Disease 1 0.9999034404754639
dystrophy I-Disease 1 0.9999164342880249
from O 0 1.1724698651960352e-06
linkage O 0 2.104893428622745e-05
disequilibrium O 0 0.00010974692850140855
studies O 0 7.671317803215061e-07
in O 0 7.562275072814373e-08
the O 0 5.616472975589204e-08
Japanese O 0 1.618462874830584e-06
population O 0 3.2223891821558936e-07
. O 0 1.1808117506006965e-06

The O 0 0.005778051447123289
myotonic B-Disease 1 0.9996950626373291
dystrophy I-Disease 1 0.9999357461929321
( O 0 0.0010952437296509743
DM B-Disease 1 0.9998062252998352
) O 0 5.660605438606581e-06
mutation O 0 0.0001445975503884256
is O 0 5.345117415345157e-07
an O 0 5.011088433093391e-07
unstable O 0 0.002192335668951273
( O 0 1.6521433110483486e-07
CTG O 0 2.2945070668356493e-05
) O 0 1.5441900202972647e-08
n O 0 1.7605552216082287e-07
repeat O 0 3.8694895465596346e-07
, O 0 4.164518507820958e-09
present O 0 2.1934087879316166e-09
at O 0 3.840357720719112e-08
a O 0 3.3914817620939175e-09
copy O 0 4.586994339916828e-09
number O 0 4.027559119545998e-10
of O 0 7.232031640214132e-10
5 O 0 4.1833722264073003e-08
- O 0 5.167988774701371e-07
37 O 0 2.0841623538103704e-08
repeats O 0 3.128280923192506e-08
on O 0 9.34134725127933e-09
normal O 0 2.6895243365743227e-08
chromosomes O 0 1.029547291864219e-08
but O 0 1.9559065478347293e-09
amplified O 0 1.588098719196296e-08
to O 0 7.903164789269113e-10
50 O 0 8.367335269099385e-09
- O 0 1.0385472393181772e-07
3000 O 0 4.644121887054098e-08
copies O 0 2.3943492521993903e-08
on O 0 7.18290607437666e-07
DM B-Disease 1 0.991003155708313
chromosomes O 0 1.8957065549329855e-05
. O 0 2.0984880393370986e-06

Previous O 0 8.075178811850492e-06
findings O 0 1.9481653907860164e-06
in O 0 2.8539341201394564e-07
Caucasian O 0 8.058299499680288e-06
populations O 0 4.923392111777503e-07
of O 0 6.471305624700108e-08
a O 0 0.0001578460360178724
DM B-Disease 1 0.9998575448989868
founder O 0 4.1444804082857445e-05
chromosome O 0 1.4692293007101398e-05
raise O 0 1.7020215636875946e-07
a O 0 7.502952570348498e-08
question O 0 1.1651911435706097e-08
about O 0 1.7045019840011832e-09
the O 0 3.442459650671026e-09
molecular O 0 7.626283604622586e-08
events O 0 5.999537755485562e-09
involved O 0 1.8650339939085825e-08
in O 0 1.9967796305309093e-08
the O 0 9.508710263617104e-08
expansion O 0 3.199450293323025e-05
mutation O 0 7.648450264241546e-05
. O 0 1.6550117152291932e-06

To O 0 5.778986178484047e-07
investigate O 0 1.149080731011054e-06
whether O 0 6.739934121924307e-08
a O 0 5.378927312449377e-07
founder O 0 2.97738961307914e-06
chromosome O 0 3.806970653386088e-06
for O 0 7.555772185696696e-08
the O 0 5.070880888524698e-06
DM B-Disease 1 0.999735414981842
mutation O 0 2.64305344899185e-05
exists O 0 8.66281837375027e-08
in O 0 9.328491756832591e-09
the O 0 1.7208719782502158e-08
Japanese O 0 1.8515605404445523e-07
population O 0 6.099168281537004e-09
, O 0 1.0104142411648809e-08
we O 0 3.6764222777208033e-09
genotyped O 0 6.918762665009126e-07
families O 0 2.6232245264878884e-09
using O 0 1.50711603197351e-08
polymorphic O 0 1.2264443967069383e-06
markers O 0 2.2099484340287745e-06
near O 0 5.198668077355251e-06
the O 0 6.67942714471792e-08
( O 0 3.313741459010089e-08
CTG O 0 5.271921054372797e-06
) O 0 2.0605808614959642e-08
n O 0 5.250508365861606e-07
repeat O 0 1.0983507081618882e-06
region O 0 3.794248470967432e-07
and O 0 8.652233418615651e-08
constructed O 0 6.238619971554726e-05
haplotypes O 0 8.137733675539494e-05
. O 0 5.048444108979311e-06

Six O 0 3.314930268061289e-07
different O 0 2.709491830898969e-08
haplotypes O 0 1.2444993444660213e-06
were O 0 1.4390074909442774e-07
found O 0 1.778020362053212e-07
and O 0 3.91047450420956e-07
DM B-Disease 1 0.9982068538665771
alleles O 0 1.1717477264028275e-06
were O 0 3.727467401404283e-07
always O 0 7.869160754125915e-07
haplotype O 0 2.8518485123640858e-05
A O 0 1.5789049939485267e-05
. O 0 4.2157957977906335e-06

To O 0 1.683366974702949e-07
find O 0 7.083978914579347e-08
an O 0 9.540517709183405e-09
origin O 0 4.329141933823166e-09
of O 0 3.932012049290279e-09
the O 0 2.542779498071468e-08
( O 0 2.3452766839682226e-08
CTG O 0 9.319287528342102e-06
) O 0 1.8161960824158996e-08
n O 0 5.603140493803949e-07
repeat O 0 2.319949771845131e-06
mutation O 0 5.004378067496873e-07
and O 0 3.142212490203633e-09
to O 0 1.166024277132749e-09
investigate O 0 1.6793864077158105e-08
the O 0 4.881852255778085e-09
mechanism O 0 1.6981164918661307e-08
of O 0 1.1990770598657718e-09
the O 0 9.239634835012112e-09
expansion O 0 3.176826339768013e-07
mutation O 0 1.5150902754612616e-07
in O 0 3.85784337808559e-09
the O 0 2.710694557706006e-09
Japanese O 0 5.94096469797023e-08
population O 0 1.2558695194897496e-09
we O 0 1.3679348764839006e-09
have O 0 6.979868349965557e-10
studied O 0 3.700844430909456e-08
90 O 0 2.822352129783212e-08
Japanese O 0 1.173054783976113e-06
DM B-Disease 1 0.989560604095459
families O 0 1.674556671105165e-08
comprising O 0 3.1361427232923234e-08
190 O 0 6.455131540406e-08
affected O 0 1.070255990498481e-07
and O 0 2.713091085126962e-08
130 O 0 2.2371600039150508e-07
unaffected O 0 1.345661348750582e-05
members O 0 1.9037643994579412e-07
. O 0 9.103782190322818e-07

The O 0 1.0813113476615399e-05
results O 0 1.1921291843464132e-05
suggest O 0 4.2490404439377016e-07
that O 0 8.689340802447987e-09
a O 0 3.310557517011148e-08
few O 0 6.3041047937417716e-09
common O 0 2.7508376021501135e-08
ancestral O 0 3.8025297044441686e-07
mutations O 0 1.0903470410994487e-06
in O 0 1.0327393162867793e-08
both O 0 1.1376308783894729e-08
Caucasian O 0 1.7033479480232927e-06
and O 0 9.420687518968407e-08
Japanese O 0 9.592575906935963e-07
populations O 0 4.2703188540826886e-08
have O 0 1.5799735963994976e-09
originated O 0 3.6885174914402796e-09
by O 0 9.037756099061767e-10
expansion O 0 1.939187832533662e-08
of O 0 6.583521505731937e-10
an O 0 4.362554761883075e-09
ancestral O 0 1.936630837917619e-07
n O 0 8.414614285356947e-07
= O 0 3.277516782418388e-07
5 O 0 2.0251393451076183e-08
repeat O 0 7.525468248559264e-08
to O 0 8.389804406760959e-09
n O 0 6.671259029644716e-07
= O 0 8.174848744602059e-07
19 O 0 3.6556087934513926e-07
- O 0 1.4931523537597968e-06
37 O 0 4.5141854343455634e-07
copies O 0 3.2080359346764453e-07
. O 0 5.52789970242884e-07

These O 0 1.3942378984665993e-07
data O 0 1.3208955351728946e-07
support O 0 2.2381176023600347e-08
multistep O 0 6.310820594990219e-07
models O 0 9.008025614321014e-08
of O 0 2.63348276519082e-08
triplet O 0 0.00023520621471107006
repeat O 0 6.4761052271933295e-06
expansion O 0 2.005766873480752e-06
that O 0 5.924869928009002e-09
have O 0 2.5755209076550045e-09
been O 0 7.487966691144265e-09
proposed O 0 1.5254457252922293e-08
for O 0 7.715557970300324e-09
both O 0 3.655225100374082e-07
DM B-Disease 1 0.9998869895935059
and O 0 1.4705931789649185e-05
Friedreichs B-Disease 0 0.19974270462989807
ataxia I-Disease 1 0.9908844828605652
. O 0 1.0258864676870871e-05
. O 0 7.90094054536894e-06

The O 0 5.130681302034645e-07
molecular O 0 1.0840020877367351e-05
basis O 0 1.0315737881683162e-06
of O 0 6.862739974167198e-05
C6 B-Disease 1 0.9999836683273315
deficiency I-Disease 1 0.9999898672103882
in O 0 1.9518436147336615e-06
the O 0 2.2419892786729179e-07
western O 0 2.448301302138134e-06
Cape O 0 1.751952549966518e-05
, O 0 1.061117416156776e-07
South O 0 5.900276960346673e-07
Africa O 0 1.2096326145183411e-06
. O 0 1.8728605937212706e-06

Deficiency B-Disease 1 0.988986611366272
of I-Disease 0 9.344897478058556e-08
the I-Disease 0 1.5150801857544138e-07
sixth I-Disease 0 3.0371038519660942e-06
component I-Disease 0 4.076376285411243e-07
of I-Disease 0 5.877371922480279e-09
human I-Disease 0 2.4353782990260697e-08
complement I-Disease 0 1.524624764215332e-07
( O 0 8.406146179140705e-08
C6 O 0 0.0008492873748764396
) O 0 5.179765949492321e-08
has O 0 1.72244554619283e-07
been O 0 1.2580152031205216e-07
reported O 0 1.8701247483932093e-07
in O 0 1.7176640110250219e-09
a O 0 6.040736799661772e-09
number O 0 7.387778167000647e-10
of O 0 5.697660676595717e-10
families O 0 1.8896322284689404e-09
from O 0 6.421848830484578e-09
the O 0 1.3545927934899282e-08
western O 0 1.7640542182562058e-07
Cape O 0 3.653350631793728e-06
, O 0 2.8596820911275245e-08
South O 0 1.9268740913958027e-07
Africa O 0 4.0878919094211597e-07
. O 0 6.443875690820278e-07

Meningococcal B-Disease 1 0.9951293468475342
disease I-Disease 1 0.9991911053657532
is O 0 0.00012485345359891653
endemic O 0 0.00012562407937366515
in O 0 6.528096605507017e-07
the O 0 2.913466516929475e-07
Cape O 0 1.9363328647159506e-06
and O 0 5.488960841404378e-09
almost O 0 3.938707582307188e-09
all O 0 1.3239955798383107e-09
pedigrees O 0 1.2243951630352967e-07
of O 0 7.25761637454525e-08
total O 0 8.702252671355382e-05
C6 B-Disease 1 0.9999836683273315
deficiency I-Disease 1 0.9999890327453613
( O 0 1.2881727116109687e-06
C6Q0 O 0 0.003714964259415865
) O 0 6.539686125961452e-08
have O 0 1.1666767107954001e-08
been O 0 6.406816055459785e-08
ascertained O 0 8.073553772192099e-07
because O 0 1.5396776120724098e-07
of O 0 1.075732143362984e-06
recurrent O 1 0.9985755681991577
disease O 1 0.9992467164993286
. O 0 1.7499220120953396e-05

We O 0 2.066202796413563e-06
have O 0 1.2416880679211317e-07
sequenced O 0 7.097421530488646e-07
the O 0 2.4299030343399863e-08
expressed O 0 1.4440757922784542e-08
exons O 0 1.6931286950239155e-07
of O 0 1.2387223691234794e-08
the O 0 6.539848129705206e-08
C6 O 0 0.00016904849326238036
gene O 0 1.3819109767609916e-07
from O 0 9.820468882537625e-09
selected O 0 4.826228749976735e-09
cases O 0 8.228786541053523e-09
and O 0 9.916500509632442e-09
have O 0 4.129635744476445e-09
found O 0 1.6474162478630205e-08
three O 0 3.036362627995004e-08
molecular O 0 0.0003288578300271183
defects O 0 0.4715946912765503
leading O 0 8.475633876514621e-06
to O 0 8.173400090072391e-08
total O 0 1.0185876817558892e-05
deficiency O 1 0.9641298055648804
879delG O 0 7.877145253587514e-05
, O 0 1.2619925371382124e-07
which O 0 2.3080621858184713e-08
is O 0 2.641239582601429e-08
the O 0 2.2500724838891983e-08
common O 0 7.746792221041687e-07
defect O 0 0.00026006740517914295
in O 0 1.1211310635417249e-07
the O 0 2.8490501335909357e-07
Cape O 0 1.9144713405694347e-06
and O 0 1.0583881326908795e-08
hitherto O 0 2.827817127126764e-07
unreported O 0 4.869114889061166e-08
, O 0 6.359125670485355e-09
and O 0 4.689488797282593e-09
1195delC O 0 9.201981470141618e-07
and O 0 2.5718403406926882e-08
1936delG O 0 2.9318671295186505e-06
, O 0 1.5719066936981108e-08
which O 0 4.8085047055224095e-09
have O 0 2.138882848612411e-09
been O 0 1.8172841009800322e-08
previously O 0 1.5290935095890745e-07
reported O 0 5.37605558292853e-07
in O 0 1.497042845244323e-08
African O 0 7.193092699253611e-08
- O 0 5.459156818687916e-05
Americans O 0 6.044716087671986e-07
. O 0 8.700902753844275e-07

We O 0 5.121925141793326e-07
also O 0 6.237534933006827e-08
show O 0 3.6697965555276824e-08
that O 0 1.8447046112868293e-09
the O 0 1.3580592650441758e-08
879delG O 0 1.3599611520476174e-05
and O 0 1.0895424793488928e-06
1195delC O 0 0.007279574405401945
defects O 1 0.5135923624038696
are O 0 1.9980140208986086e-08
associated O 0 3.16382255505232e-07
with O 0 1.8201916418547626e-07
characteristic O 0 0.00028118485352024436
C6 O 1 0.9690718054771423
/ O 0 0.000670767156407237
C7 O 0 0.11128659546375275
region O 0 1.9557772247935645e-05
DNA O 0 2.1113850380061194e-05
marker O 0 4.77291678180336e-06
haplotypes O 0 1.1875164318553288e-06
, O 0 6.46632116740875e-08
although O 0 1.9792310013144743e-08
small O 0 2.599110793255477e-08
variations O 0 2.490988606496103e-07
were O 0 1.7232393645372213e-07
observed O 0 2.9758339223917574e-06
. O 0 1.103793238144135e-06

The O 0 7.938378075778019e-06
1936delG O 0 0.0014618516433984041
defect O 0 0.005091231781989336
was O 0 1.6672967831254937e-05
observed O 0 8.40398186596758e-08
only O 0 2.5249735635668458e-09
once O 0 4.4463529746963104e-08
in O 0 5.903415090102726e-09
the O 0 2.3168968965592285e-08
Cape O 0 8.127755108944257e-07
, O 0 6.777483463338285e-09
but O 0 4.0717580418458965e-09
its O 0 8.943923823778732e-09
associated O 0 1.8822632341652934e-07
haplotype O 0 4.7531570999126416e-06
could O 0 6.999151480613364e-08
be O 0 3.7780218065108784e-08
deduced O 0 9.893527703752625e-07
. O 0 4.057905869103706e-07

The O 0 3.958004413107119e-07
data O 0 3.931759806619084e-07
from O 0 2.0358131180842065e-08
the O 0 1.708665919863961e-08
haplotypes O 0 5.250198569228814e-07
indicate O 0 6.604808078236601e-08
that O 0 1.6791068535582099e-09
these O 0 5.881428677412259e-10
three O 0 1.50161838519125e-08
molecular O 0 6.580820627277717e-05
defects O 0 0.0034823750611394644
account O 0 2.1443494091499815e-08
for O 0 2.743784399683591e-08
the O 0 1.4880861272104084e-06
defects O 0 0.041295163333415985
in O 0 1.3920690378199652e-08
all O 0 8.915101434858741e-10
the O 0 2.055454118021771e-08
38 O 0 2.5487233301646484e-07
unrelated O 0 1.1167552429469652e-06
C6Q0 O 0 0.00011123014701297507
individuals O 0 5.8925704315981875e-09
we O 0 9.288579683186526e-09
have O 0 3.2807416783242616e-09
studied O 0 1.247040160023971e-07
from O 0 3.8341511299222475e-08
the O 0 5.402143301580509e-07
Cape O 0 3.703954644151963e-05
. O 0 2.732602979449439e-06

We O 0 2.4543774088670034e-06
have O 0 8.296904496774005e-08
also O 0 4.278871656993033e-08
observed O 0 1.2212419164825405e-07
the O 0 7.433397541944942e-08
879delG O 0 4.601096952683292e-05
defect O 0 6.692527676932514e-05
in O 0 2.25276764354021e-07
two O 0 8.899307886167662e-07
Dutch O 0 0.29412147402763367
C6 B-Disease 1 0.9999351501464844
- I-Disease 1 0.9996840953826904
deficient I-Disease 1 0.9997648596763611
kindreds O 0 9.862974548013881e-05
, O 0 7.882863428676501e-08
but O 0 1.3485347061248376e-08
the O 0 3.781784840839464e-08
879delG O 0 3.0067345505813137e-05
defect O 0 6.73627873766236e-05
in O 0 1.2046979236401967e-07
the O 0 2.8167440291326784e-07
Cape O 0 1.3402146578300744e-05
probably O 0 3.582835006454843e-07
did O 0 8.218779434798762e-09
not O 0 5.272953185198048e-10
come O 0 4.1353562241219777e-10
from O 0 1.9648243032577284e-09
The O 0 1.718487396829005e-08
Netherlands O 0 1.1599136087170336e-06
. O 0 1.0382164816746808e-07
. O 0 6.41369922504964e-07

Complement B-Disease 1 0.6216236352920532
C7 I-Disease 1 0.9999547004699707
deficiency I-Disease 1 0.9999717473983765
: O 0 1.0038965001513134e-06
seven O 0 2.2237442465211643e-07
further O 0 5.392404887061275e-07
molecular O 0 0.00513086561113596
defects O 1 0.6716023087501526
and O 0 8.406034623931191e-08
their O 0 7.428932491393425e-08
associated O 0 1.9852326659020036e-05
marker O 0 0.0002572471566963941
haplotypes O 0 8.049580355873331e-05
. O 0 5.289648015605053e-06

Seven O 0 8.314289061672753e-07
further O 0 1.7796202200770495e-07
molecular O 0 7.078683665895369e-06
bases O 0 5.4770744100096636e-06
of O 0 0.0001530269655631855
C7 B-Disease 1 0.9999856948852539
deficiency I-Disease 1 0.9999912977218628
are O 0 7.786590686009731e-06
described O 0 0.00017595048120711
. O 0 5.832243004988413e-06

All O 0 7.580311489618907e-08
these O 0 1.4326603015035744e-08
new O 0 5.833528007315181e-07
molecular O 0 0.0003238609933760017
defects O 0 0.003917971160262823
involve O 0 7.64058114555155e-08
single O 0 6.658514735136123e-07
- O 0 1.0087785085488576e-05
nucleotide O 0 2.7402811042520625e-07
events O 0 1.778304437038969e-08
, O 0 4.493994509857657e-09
deletions O 0 2.6789775731117516e-08
and O 0 4.9016604108942374e-09
substitutions O 0 1.5140134479452172e-08
, O 0 2.9714031235528182e-09
some O 0 2.2227365781279929e-10
of O 0 1.1801538635225484e-09
which O 0 5.170701644630071e-09
alter O 0 1.70704453239523e-07
splice O 0 4.303729497223685e-07
sites O 0 6.51092406656062e-08
, O 0 1.3274604526714029e-08
and O 0 1.5540972952976517e-08
others O 0 4.8098552696274055e-08
codons O 0 2.951504711745656e-06
. O 0 6.559198482136708e-07

They O 0 3.5449085089567234e-07
are O 0 4.598101455144388e-09
distributed O 0 9.969430614376051e-09
along O 0 3.88207830326337e-08
the O 0 7.624480247159227e-08
C7 O 0 0.0001722187880659476
gene O 0 6.522695343846863e-07
, O 0 1.3309743529532625e-08
but O 0 2.6696620469834897e-09
predominantly O 0 3.6071714504259944e-09
towards O 0 1.1985334502639944e-08
the O 0 6.253855389104501e-08
3 O 0 3.518395317314571e-07
end O 0 2.4964970180008095e-06
. O 0 1.508547484263545e-06

All O 0 1.1646138631249414e-07
were O 0 2.0559880908876949e-07
found O 0 2.1050794885013602e-07
in O 0 1.0691236695947737e-07
compound O 0 6.7225964812678285e-06
heterozygous O 0 3.580956899895682e-06
individuals O 0 1.8733520334990317e-07
. O 0 1.2122147836635122e-06

The O 0 4.8943493311526254e-05
C6 O 1 0.8410997986793518
/ O 0 0.0015931526431813836
C7 O 1 0.6038011312484741
marker O 0 0.00014226813800632954
haplotypes O 0 2.6824811357073486e-05
associated O 0 3.654517740869778e-06
with O 0 5.933421789450222e-07
most O 0 1.877708564279601e-05
C7 B-Disease 1 0.9994217157363892
defects I-Disease 1 0.9995655417442322
are O 0 8.970192197921278e-07
tabulated O 0 0.0003835089155472815
. O 0 4.763030858612183e-07
. O 0 1.8607613583299099e-06

A O 0 1.6055117157520726e-05
genome O 0 9.437640983378515e-06
- O 0 3.494916654744884e-06
wide O 0 1.9730465794509655e-07
search O 0 1.0012043816232108e-07
for O 0 3.984909824339411e-08
chromosomal O 0 0.00032488806755281985
loci O 0 5.678708021150669e-06
linked O 0 0.00012392742792144418
to O 0 9.313132522947853e-07
mental O 1 0.7091447710990906
health O 0 0.0004081043880432844
wellness O 0 0.0001323944889008999
in O 0 3.946862250359118e-07
relatives O 0 7.283902618837601e-07
at O 0 4.463044024305418e-05
high O 0 0.0022509885020554066
risk O 0 0.00019426278595346957
for O 0 5.943649739492685e-06
bipolar B-Disease 1 0.9999431371688843
affective I-Disease 1 0.999738872051239
disorder I-Disease 1 0.9997373223304749
among O 0 7.479625310224947e-07
the O 0 5.680526555806864e-07
Old O 0 0.00013429766113404185
Order O 0 4.4892766482007573e-07
Amish O 0 1.261913166672457e-05
. O 0 3.743059323824127e-06

Bipolar B-Disease 1 0.9990993738174438
affective I-Disease 1 0.998354971408844
disorder I-Disease 1 0.9996671676635742
( O 0 0.0009815857047215104
BPAD B-Disease 1 0.9997218251228333
; O 0 0.0020155753009021282
manic B-Disease 1 0.9998706579208374
- I-Disease 1 0.9999374151229858
depressive I-Disease 1 0.9999808073043823
illness I-Disease 1 0.9997984766960144
) O 0 5.41512122254062e-07
is O 0 1.7588902778697957e-07
characterized O 0 4.705071603439137e-07
by O 0 6.0572125093472096e-09
episodes O 0 5.475359543538616e-08
of O 0 4.555547405971083e-08
mania B-Disease 0 0.0013587955618277192
and O 0 4.489010905217583e-07
/ O 0 2.1669689886039123e-05
or O 0 7.954421334943618e-07
hypomania B-Disease 0 0.0011071834014728665
interspersed O 0 7.63987463869853e-06
with O 0 3.67158975222992e-07
periods O 0 1.7801965441321954e-05
of O 0 1.2265530813238001e-06
depression B-Disease 0 0.3954295217990875
. O 0 4.261972662789049e-06

Compelling O 0 5.482023425429361e-06
evidence O 0 5.011589792047744e-07
supports O 0 2.934838789769856e-07
a O 0 8.403949891544471e-08
significant O 0 4.7781902878796245e-08
genetic O 0 3.9414720731656416e-07
component O 0 5.64938090974465e-07
in O 0 5.8541260727906774e-08
the O 0 8.064922241146633e-08
susceptibility O 0 1.3954759197076783e-05
to O 0 1.4649985757841932e-07
develop O 0 9.631130524212494e-05
BPAD B-Disease 1 0.9992353916168213
. O 0 3.211426883353852e-05

To O 0 1.9263890749243728e-07
date O 0 7.393881560346927e-07
, O 0 3.645581614364346e-08
however O 0 2.1000280625571577e-08
, O 0 9.390867639069711e-09
linkage O 0 6.802921461712685e-07
studies O 0 5.121099988514288e-08
have O 0 3.0005284923362296e-09
attempted O 0 2.0451340176919075e-08
only O 0 1.5768004679728165e-09
to O 0 2.101934404308281e-09
identify O 0 1.2192205645078502e-07
chromosomal O 0 0.00017301012121606618
loci O 0 9.455986287321139e-07
that O 0 6.482473224878049e-08
cause O 0 1.0549134685788886e-06
or O 0 4.82676547619576e-08
increase O 0 5.3463303117951e-08
the O 0 2.0214970675169752e-07
risk O 0 6.664285137958359e-06
of O 0 1.0623851665059192e-07
developing O 0 0.00014568425831384957
BPAD B-Disease 1 0.9996788501739502
. O 0 2.247186057502404e-05

To O 0 2.821481075443444e-07
determine O 0 3.3741727634151175e-07
whether O 0 9.438025472263689e-08
there O 0 3.2649374759330385e-08
could O 0 2.3262977322247025e-08
be O 0 7.688967684771342e-09
protective O 0 1.2367898989396053e-06
alleles O 0 2.506654261935637e-08
that O 0 4.733494929354265e-09
prevent O 0 1.2464491305763659e-07
or O 0 3.0898426928160916e-08
reduce O 0 3.7760085547233757e-07
the O 0 1.5364652483640384e-07
risk O 0 2.0603840766852954e-06
of O 0 1.591880405271695e-08
developing O 0 2.5535216536809457e-06
BPAD B-Disease 1 0.999675989151001
, O 0 1.3510607743683067e-07
similar O 0 1.417301298545226e-08
to O 0 3.4604248355663003e-09
what O 0 7.801296497689236e-09
is O 0 8.140459861749605e-09
observed O 0 2.0519365762083908e-08
in O 0 1.6809822867003277e-08
other O 0 2.257587397025418e-07
genetic B-Disease 1 0.999563992023468
disorders I-Disease 1 0.9999911785125732
, O 0 3.0112714739516377e-06
we O 0 3.3219211559298856e-07
used O 0 4.366034772829153e-06
mental O 1 0.7959017753601074
health O 0 0.0012718950165435672
wellness O 0 0.0003058069269172847
( O 0 6.472663471868145e-08
absence O 0 9.67838218457473e-07
of O 0 8.305327270363705e-08
any O 0 1.8215359887108207e-05
psychiatric B-Disease 1 0.9995867609977722
disorder I-Disease 1 0.9966238737106323
) O 0 3.032947404335573e-08
as O 0 4.5803783876863235e-08
the O 0 5.2324136134984656e-08
phenotype O 0 7.746127153041016e-07
in O 0 1.2462395559964534e-08
our O 0 1.03208561696988e-08
genome O 0 1.0559023877476648e-07
- O 0 3.5207617088417464e-07
wide O 0 2.2547721911791996e-08
linkage O 0 3.389793050700973e-07
scan O 0 8.314233923556458e-07
of O 0 2.5229611733124102e-09
several O 0 6.09787642602555e-09
large O 0 7.481217068061596e-08
multigeneration O 0 1.1296906450297683e-05
Old O 0 2.8934077818121295e-06
Order O 0 1.5133812425460746e-08
Amish O 0 2.0174833537112136e-07
pedigrees O 0 5.187002898310311e-07
exhibiting O 0 3.0042497201066e-07
an O 0 1.3830198497544188e-07
extremely O 0 1.8426311726216227e-05
high O 0 0.00022845524654258043
incidence O 0 0.00862724520266056
of O 0 3.864926839014515e-06
BPAD B-Disease 1 0.9994049072265625
. O 0 2.8874817871837877e-05

We O 0 1.7059229548976873e-06
have O 0 7.410209690306147e-08
found O 0 6.755584536222159e-08
strong O 0 1.531725857262245e-08
evidence O 0 6.017140563585599e-09
for O 0 2.471870264031395e-09
a O 0 1.0903288227837038e-07
locus O 0 9.884549854177749e-07
on O 0 4.83275300666719e-07
chromosome O 0 1.8525193809182383e-05
4p O 0 0.0008099550032056868
at O 0 1.17794593279541e-06
D4S2949 O 0 1.4295846995082684e-06
( O 0 1.393689696982392e-08
maximum O 0 7.536226576121408e-08
GENEHUNTER O 0 1.8682527297642082e-05
- O 0 1.0860256907108123e-06
PLUS O 0 8.233578085992121e-08
nonparametric O 0 2.575100381818629e-07
linkage O 0 2.2034909363810584e-07
score O 0 4.2839346292566916e-08
= O 0 8.946929597186681e-08
4 O 0 2.2028094903703277e-08
. O 0 2.994645420528741e-09
05 O 0 5.509300535777584e-07
, O 0 2.902716111918835e-08
P O 0 2.3301624878513394e-06
= O 0 1.021393458700004e-07
5 O 0 8.64576321646382e-09
. O 0 1.3151011390988288e-09
22 O 0 1.1701823510179565e-08
x O 0 4.572888911980044e-08
10 O 0 7.852831274135497e-09
( O 0 5.620392595773183e-09
- O 0 4.0430651893075265e-07
4 O 0 4.310350476544045e-08
) O 0 6.0548908109581134e-09
; O 0 5.236923339424493e-09
SIBPAL O 0 1.7893677295433008e-06
Pempirical O 0 6.385076858350658e-07
value O 0 1.3028929934932876e-08
< O 0 1.5473541736810148e-07
3 O 0 2.383809416528493e-08
x O 0 1.216378677781904e-07
10 O 0 1.2211401667627797e-08
( O 0 4.982811940834608e-09
- O 0 8.496444934280589e-07
5 O 0 2.4611267690488603e-08
) O 0 1.5145009690797906e-09
) O 0 7.718851113835967e-10
and O 0 1.4082089938582953e-09
suggestive O 0 9.859810745638242e-08
evidence O 0 5.232550392975099e-09
for O 0 1.529739779293493e-09
a O 0 8.032530729451537e-08
locus O 0 2.0739178125950275e-06
on O 0 1.5691917951698997e-06
chromosome O 0 0.00014539835683535784
4q O 0 0.0013665998121723533
at O 0 1.8961375189974206e-06
D4S397 O 0 2.1950813788862433e-06
( O 0 1.4563237726861189e-08
maximum O 0 1.3211776206389914e-07
GENEHUNTER O 0 1.8511171219870448e-05
- O 0 1.2863018810094218e-06
PLUS O 0 1.2409729777118628e-07
nonparametric O 0 3.982760006238095e-07
linkage O 0 4.645313254059147e-07
score O 0 6.278165187723062e-08
= O 0 1.2707181440418935e-07
3 O 0 2.8657920481123256e-08
. O 0 4.943997655715293e-09
29 O 0 7.249619926597006e-08
, O 0 7.435535742672528e-09
P O 0 1.3506372624760843e-06
= O 0 5.783386214375241e-08
2 O 0 7.908627530639478e-09
. O 0 1.7697733278865257e-09
57 O 0 1.67913345450188e-08
x O 0 5.694070281947461e-08
10 O 0 7.403538671013621e-09
( O 0 3.0598252820368543e-09
- O 0 2.3633513990262145e-07
3 O 0 1.8405511781338646e-08
) O 0 1.8937453827305717e-09
; O 0 3.0660589622755197e-09
SIBPAL O 0 9.733532806421863e-07
Pempirical O 0 4.261312085418467e-07
value O 0 1.813499395098006e-08
< O 0 1.5275793430191698e-07
1 O 0 2.4560433686815486e-08
x O 0 1.224071866090526e-07
10 O 0 5.398258284827762e-09
( O 0 4.494131733423501e-09
- O 0 4.249469895967195e-07
3 O 0 1.6570185223940825e-08
) O 0 1.6236172406536298e-09
) O 0 2.008589294888452e-09
that O 0 9.443886783699895e-10
are O 0 3.0028985964491994e-09
linked O 0 7.871255547797773e-06
to O 0 6.665986802545376e-07
mental O 1 0.6798770427703857
health O 0 0.02602073736488819
wellness O 0 0.10109733045101166
. O 0 2.3711005269433372e-05

These O 0 2.1551151974108507e-07
findings O 0 3.1083919793672976e-07
are O 0 4.151020860376775e-09
consistent O 0 5.444669781695666e-08
with O 0 1.2800538407020667e-08
the O 0 1.1306894975859905e-07
hypothesis O 0 1.1142834921429312e-07
that O 0 1.616904832246746e-09
certain O 0 1.269147453797359e-09
alleles O 0 3.095906819794436e-08
could O 0 5.061031416175865e-08
prevent O 0 2.792463362766284e-07
or O 0 3.033896334159181e-08
modify O 0 1.4650053969944565e-07
the O 0 7.938826485087702e-08
clinical O 0 4.3344093683117535e-06
manifestations O 0 3.3497237836854765e-06
of O 0 5.609235813608393e-07
BPAD B-Disease 1 0.9997305274009705
and O 0 5.792393835690746e-07
perhaps O 0 5.512664529305766e-07
other O 0 1.2638099633477395e-07
related O 0 0.0001806020736694336
affective B-Disease 1 0.9993293285369873
disorders I-Disease 1 0.9998987913131714
. O 0 0.00017932333867065609

Segregation O 0 0.01192911434918642
distortion O 0 0.1043507307767868
in O 0 0.008997567929327488
myotonic B-Disease 1 0.9997509121894836
dystrophy I-Disease 1 0.9998798370361328
. O 0 0.0017207191558554769

Myotonic B-Disease 1 0.9995798468589783
dystrophy I-Disease 1 0.9999125003814697
( O 0 0.0014134215889498591
DM B-Disease 1 0.9998866319656372
) O 0 1.3136924508216907e-06
is O 0 6.330133146548178e-07
an O 0 1.6992851215036353e-06
autosomal B-Disease 1 0.9460165500640869
dominant I-Disease 1 0.9944550395011902
disease I-Disease 1 0.9996684789657593
which O 0 1.731660518089484e-06
, O 0 3.701119766219563e-08
in O 0 1.0514664694483145e-08
the O 0 1.0928080662608863e-08
typical O 0 2.764872419902531e-07
pedigree O 0 7.347243240474199e-07
, O 0 3.804268455809279e-09
shows O 0 4.969676226096453e-09
a O 0 1.6862873764011965e-08
three O 0 2.0262522326675025e-08
generation O 0 1.2665685744650546e-06
anticipation O 0 8.101729690679349e-06
cascade O 0 0.0003804249281529337
. O 0 2.101921154462616e-06

This O 0 1.8443664657752379e-06
results O 0 1.125374637922505e-05
in O 0 1.2977812730241567e-05
infertility B-Disease 1 0.9980385899543762
and O 1 0.9760909080505371
congenital B-Disease 1 0.9999990463256836
myotonic I-Disease 1 0.9999980926513672
dystrophy I-Disease 1 0.9999959468841553
( O 0 3.467427086434327e-05
CDM B-Disease 0 0.0001328279759036377
) O 0 3.3285516565229045e-08
with O 0 1.0605139877384318e-08
the O 0 3.4554336281189535e-08
disappearance O 0 1.3510830285667907e-06
of O 0 8.221962843890651e-07
DM B-Disease 1 0.9998440742492676
in O 0 3.388191089470638e-06
that O 0 3.1743701356390375e-07
pedigree O 0 9.267202403862029e-05
. O 0 3.876328719343292e-06

The O 0 1.7635294113915734e-07
concept O 0 3.060615370031883e-07
of O 0 1.014469859228484e-07
segregation O 0 9.863891136774328e-06
distortion O 0 2.057176061498467e-05
, O 0 9.605009410051935e-08
where O 0 4.1569254705109415e-08
there O 0 4.931584474121564e-09
is O 0 3.086518818307127e-09
preferential O 0 1.5039917755643728e-08
transmission O 0 9.128437454819505e-07
of O 0 1.4008206816740199e-09
the O 0 2.330208914713694e-09
larger O 0 1.7679422370520115e-08
allele O 0 5.1118966837293556e-08
at O 0 2.0428930724847305e-07
the O 0 2.0656733568102936e-07
DM B-Disease 1 0.9979140162467957
locus O 0 7.0575174504483584e-06
, O 0 7.030057957990721e-08
has O 0 7.248237210433217e-08
been O 0 1.929484660934122e-08
put O 0 7.838914406477215e-09
forward O 0 6.382967487894575e-09
to O 0 2.5253972246730427e-09
explain O 0 1.9257640815339983e-08
partially O 0 1.198300083160575e-06
the O 0 5.574317540890661e-08
maintenance O 0 0.00011657801223918796
of O 0 3.7416029385894944e-07
DM B-Disease 1 0.9996808767318726
in O 0 2.468056266025087e-07
the O 0 1.3777436436157586e-07
population O 0 3.031808546438697e-07
. O 0 1.265333480660047e-06

In O 0 1.1530975143614342e-06
a O 0 1.2330871186350123e-06
survey O 0 9.054601264324447e-07
of O 0 1.5451732338078727e-07
DM B-Disease 1 0.9984627962112427
in O 0 2.3130340309762687e-07
Northern O 0 8.14201428056549e-07
Ireland O 0 8.972450586952618e-07
, O 0 7.551738434585786e-08
59 O 0 4.2724619220280147e-07
pedigrees O 0 2.1213097625150112e-06
were O 0 4.164545259754959e-07
ascertained O 0 1.124978643929353e-05
. O 0 1.4356220390254748e-06

Sibships O 0 0.0003840989083983004
where O 0 4.998549343326886e-07
the O 0 3.7246877582219895e-08
status O 0 3.2470950372953666e-08
of O 0 1.2745910993317011e-09
all O 0 3.4188621378383743e-10
the O 0 1.9795851624593297e-09
members O 0 2.2111179553974125e-09
had O 0 1.0216272983143426e-07
been O 0 3.8241964261942485e-08
identified O 0 2.8195811907494317e-08
were O 0 6.005238972761617e-09
examined O 0 7.25446085425574e-08
to O 0 4.0590467098589045e-10
determine O 0 4.053764435241192e-09
the O 0 5.496923360936989e-09
transmission O 0 8.415929642069386e-07
of O 0 6.240448158223444e-09
the O 0 1.0175895113206934e-06
DM B-Disease 1 0.9994940757751465
expansion O 0 4.707550033344887e-06
from O 0 6.205767277833729e-08
affected O 0 6.2541772649638e-08
parents O 0 1.479810585180985e-08
to O 0 3.6704947969923296e-09
their O 0 5.992472296156848e-08
offspring O 0 4.080361577507574e-06
. O 0 1.0959306564473081e-06

Where O 0 1.7082608110285946e-06
the O 0 3.105055839114357e-07
transmitting O 0 7.165804709075019e-05
parent O 0 3.523803025018424e-05
was O 0 1.6864192730281502e-05
male O 0 9.26962513858598e-07
, O 0 3.2375038472309825e-07
58 O 0 6.175980161060579e-06
. O 0 2.4614141693746205e-06

3 O 0 1.5356522453657817e-06
% O 0 3.1370340991543344e-08
of O 0 3.902038248071449e-09
the O 0 1.0797529981232401e-08
offspring O 0 6.015375220158603e-08
were O 0 1.6840566274822777e-08
affected O 0 3.624566602411505e-08
, O 0 7.77116415662249e-09
and O 0 3.288020966607519e-09
in O 0 9.643684073523673e-09
the O 0 9.022294022997812e-09
case O 0 1.7048897404947638e-08
of O 0 1.7697531218274776e-09
a O 0 1.2301102003675624e-07
female O 0 2.413414108559664e-07
transmitting O 0 4.3197676859563217e-05
parent O 0 1.5100074051588308e-05
, O 0 3.5069857062808296e-07
68 O 0 5.899112238694215e-06
. O 0 1.5179944057308603e-06

7 O 0 2.6291012545698322e-05
% O 0 5.709861170544173e-07
were O 0 5.878529236724717e-07
affected O 0 9.152740858553443e-06
. O 0 6.06577486905735e-06

Studies O 0 4.515323325904319e-06
on O 0 5.317052682585199e-07
meiotic O 0 3.271817695349455e-05
drive O 0 3.9268684304261114e-06
in O 0 2.4951664272521157e-06
DM B-Disease 1 0.9981375932693481
have O 0 2.5741471176843334e-08
shown O 0 2.1035598152252533e-08
increased O 0 2.705763080257384e-08
transmission O 0 5.748714784203912e-07
of O 0 7.698384707488515e-10
the O 0 3.8743905861338135e-09
larger O 0 1.3781780161536972e-08
allele O 0 6.417419484705533e-08
at O 0 2.4705431656002474e-07
the O 0 2.8421951014934166e-07
DM B-Disease 1 0.9882245063781738
locus O 0 3.1514268812316004e-06
in O 0 2.752486238932761e-07
non O 0 5.700068868463859e-06
- O 0 0.051638830453157425
DM O 1 0.9989489912986755
heterozygotes O 0 2.8034539354848675e-05
for O 0 9.283408530791348e-07
CTGn O 0 0.0005217675934545696
. O 0 3.5383498016017256e-06

This O 0 4.0448003346682526e-07
study O 0 1.6632189669962827e-07
provides O 0 2.3821776551358198e-08
further O 0 9.284824464828034e-09
evidence O 0 3.3611648575515574e-08
that O 0 7.674403335045099e-09
the O 0 7.532087238359964e-07
DM B-Disease 1 0.9994701743125916
expansion O 0 1.5412908396683633e-05
tends O 0 1.2012634442726267e-06
to O 0 1.1569353475238131e-08
be O 0 4.3451265696603514e-08
transmitted O 0 4.172326953266747e-06
preferentially O 0 3.291918346803868e-06
. O 0 1.6354931631212821e-06

Diagnosis O 1 0.9707369804382324
of O 0 0.0004661641432903707
hemochromatosis B-Disease 1 0.9998326301574707
. O 0 0.0007442055502906442

If O 0 0.0003610020794440061
untreated O 1 0.7835224270820618
, O 0 0.00039752808515913785
hemochromatosis B-Disease 1 0.9999775886535645
can O 0 0.0013008428504690528
cause O 0 0.478663831949234
serious O 1 0.9704990983009338
illness O 1 0.9665819406509399
and O 0 1.3704421917282161e-06
early B-Disease 0 1.485725624661427e-05
death I-Disease 0 2.2356625777320005e-05
, O 0 6.639213268044841e-08
but O 0 6.528968299335247e-08
the O 0 1.9715089365490712e-06
disease O 0 0.0687054693698883
is O 0 4.0173901538764767e-07
still O 0 6.137224772828631e-07
substantially O 0 1.0979059879900888e-05
under O 0 4.2344578105257824e-05
- O 1 0.9901400208473206
diagnosed O 1 0.9982945322990417
. O 0 4.601763066602871e-06

The O 0 7.665262842238008e-07
cornerstone O 0 8.61933222040534e-06
of O 0 3.3709621760635855e-08
screening O 0 9.931853810485336e-07
and O 0 3.7755004456130337e-08
case O 0 1.5047325518935395e-07
detection O 0 1.1855667025884031e-06
is O 0 8.457847755494186e-09
the O 0 2.29903207582538e-09
measurement O 0 1.2338605870354513e-07
of O 0 1.1818641176830624e-08
serum O 0 2.052970103250118e-06
transferrin O 0 2.237090484413784e-06
saturation O 0 6.971784500819922e-07
and O 0 2.3378673219554003e-08
the O 0 1.6520330348157586e-07
serum O 0 2.2588357751374133e-05
ferritin O 0 5.874886846868321e-05
level O 0 9.041571502166335e-06
. O 0 1.0735308251241804e-06

Once O 0 4.8445144784636796e-05
the O 0 1.8236613641420263e-06
diagnosis O 0 0.013959214091300964
is O 0 1.3350471590456436e-06
suspected O 0 6.247421879379544e-06
, O 0 1.737959394176869e-07
physicians O 0 3.1260324817594665e-07
must O 0 8.115160099464447e-09
use O 0 2.8730491763440114e-08
serum O 0 3.112586273346096e-05
ferritin O 0 0.00014671443204861134
levels O 0 6.867783213237999e-06
and O 0 4.40762590869781e-07
hepatic O 0 0.01001738104969263
iron O 0 0.0017225481569766998
stores O 0 1.7999124111156561e-06
on O 0 1.936651096912101e-05
liver O 1 0.883107602596283
biopsy O 0 0.01439625769853592
specimens O 0 1.3396692111200537e-06
to O 0 1.8872883700282728e-08
assess O 0 2.4728537937335204e-06
patients O 0 8.280366614599188e-07
for O 0 4.988621959967077e-09
the O 0 2.7628262344592258e-08
presence O 0 2.4616250016151753e-07
of O 0 2.817840254465409e-07
iron B-Disease 0 0.3318886458873749
overload I-Disease 0 0.015242772176861763
. O 0 3.822607141046319e-06

Liver O 1 0.9988918900489807
biopsy O 1 0.947463870048523
is O 0 5.461286036734236e-06
also O 0 9.145623636186428e-08
used O 0 7.160962045560382e-09
to O 0 1.2647879410465634e-09
establish O 0 1.3153099054363793e-08
the O 0 1.4202320208767105e-08
presence O 0 5.460310958937953e-08
or O 0 2.617118788350581e-08
absence O 0 1.929312389847837e-07
of O 0 1.408434542327086e-07
cirrhosis B-Disease 1 0.9506284594535828
, O 0 3.130546417651203e-07
which O 0 1.3339688109681447e-07
can O 0 1.7632183357818576e-07
affect O 0 4.5853184929001145e-06
prognosis O 0 0.11689729243516922
and O 0 2.4726696210564114e-06
management O 0 0.0002327909169252962
. O 0 6.809595561207971e-06

A O 0 9.074674380826764e-06
DNA O 0 1.752163007040508e-05
- O 0 6.897858838783577e-06
based O 0 5.399764546609731e-08
test O 0 4.389223917655727e-08
for O 0 2.3250499303628658e-09
the O 0 1.805860883052901e-08
HFE O 0 1.1625986189756077e-05
gene O 0 1.400044595811778e-07
is O 0 9.70070690442526e-09
commercially O 0 2.0291606617206526e-08
available O 0 5.9270401919775395e-09
, O 0 2.2424964107869982e-09
but O 0 1.2228246193402015e-09
its O 0 9.43497502348123e-10
place O 0 4.214154802895109e-09
in O 0 7.344873154124798e-09
the O 0 6.044231071200556e-08
diagnosis O 0 0.0002388177381362766
of O 0 1.720360614854144e-06
hemochromatosis B-Disease 1 0.9999825954437256
is O 0 3.7993093428667635e-05
still O 0 2.367101160416496e-06
being O 0 3.6390763398230774e-06
evaluated O 0 8.248231097240932e-06
. O 0 9.060751722245186e-07

Currently O 0 2.623161662995699e-06
, O 0 4.1893130742209905e-08
the O 0 1.3114947350345574e-08
most O 0 3.069481779860439e-09
useful O 0 3.708084950204693e-09
role O 0 2.382032171510673e-08
for O 0 4.705840606078482e-09
this O 0 5.717989193243511e-09
test O 0 4.205886128261227e-08
is O 0 2.355932560149654e-09
in O 0 1.2636305335433917e-09
the O 0 5.534037228471789e-09
detection O 0 5.92353956108127e-07
of O 0 6.941558439166329e-08
hemochromatosis B-Disease 1 0.9998078942298889
in O 0 3.701208584061533e-07
the O 0 5.714089112984766e-08
family O 0 4.144677845374645e-08
members O 0 1.2416454531205545e-09
of O 0 3.80897313689843e-09
patients O 0 1.1887578210689753e-07
with O 0 1.3354752859129349e-08
a O 0 1.4023231642568135e-06
proven O 0 3.0240805699577322e-06
case O 0 3.245634445647738e-07
of O 0 8.764615699874412e-08
the O 0 4.510559301706962e-05
disease O 0 0.3349124789237976
. O 0 4.2242513700330164e-06

It O 0 1.770297899383877e-06
is O 0 2.856286585029011e-07
crucial O 0 2.3639743176318007e-06
to O 0 3.05070625472581e-06
diagnose O 1 0.9983841180801392
hemochromatosis B-Disease 1 0.9999754428863525
before O 1 0.5533661246299744
hepatic B-Disease 1 0.9995856881141663
cirrhosis I-Disease 1 0.9997597336769104
develops O 0 0.07454624027013779
because O 0 5.8285706472815946e-05
phlebotomy O 0 0.20829424262046814
therapy O 0 0.042019572108983994
can O 0 1.3386307728069369e-05
avert O 1 0.9322402477264404
serious O 1 0.9998533725738525
chronic O 1 0.9999966621398926
disease O 1 0.9998806715011597
and O 0 3.7313052416720893e-06
can O 0 1.0680862772005639e-07
even O 0 1.319949802791598e-07
lead O 0 1.9939447781780473e-07
to O 0 1.1496476659544896e-08
normal O 0 2.355382321184152e-06
life O 0 1.7094765780711896e-06
expectancy O 0 1.101968518923968e-05
. O 0 1.4328111319628078e-07
. O 0 7.839647651053383e-07

Prevalence O 0 0.00016622616385575384
of O 0 1.85028426358258e-07
the O 0 3.5100572404189734e-07
I1307K O 0 2.3594926460646093e-05
APC B-Disease 0 1.738746686896775e-05
gene O 0 1.689947225713695e-06
variant O 0 8.320061169797555e-06
in O 0 5.854025886264935e-08
Israeli O 0 3.670805313049641e-07
Jews O 0 1.4554073501926723e-08
of O 0 2.7531561475058197e-09
differing O 0 2.5685215732096367e-08
ethnic O 0 4.9162505177946514e-08
origin O 0 1.604831538770668e-07
and O 0 6.6545298977871425e-06
risk O 0 0.1317133605480194
for O 1 0.8456066846847534
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999959468841553
. O 0 0.00039071054197847843

BACKGROUND O 0 8.529165643267334e-05
& O 0 1.962789610843174e-05
AIMS O 0 2.3536128992418526e-06
Israeli O 0 1.4128149814496282e-06
Jews O 0 7.308737792754982e-08
of O 0 1.5623536242515e-08
European O 0 1.0674584700609557e-06
birth O 0 1.5154389984672889e-05
, O 0 4.244180615842197e-07
i O 0 1.634267619010643e-06
. O 0 6.225041371266116e-09
e O 0 3.963593897537976e-08
. O 0 3.5139064991085434e-09
, O 0 5.824497772977111e-09
Ashkenazim O 0 2.3655657344079373e-07
, O 0 1.1721279058463097e-08
have O 0 1.994503229241218e-08
the O 0 3.899536295648431e-06
highest O 1 0.9984315037727356
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999984502792358
incidence O 0 0.3266863524913788
of O 0 4.265215025611724e-08
any O 0 3.6197441488639015e-08
Israeli O 0 8.28623251436511e-06
ethnic O 0 7.534221140303998e-07
group O 0 1.1338905096636154e-05
. O 0 2.2174133391672513e-06

The O 0 4.133738457312575e-06
I1307K O 0 6.660458166152239e-05
APC B-Disease 0 2.2987844204180874e-05
gene O 0 4.592197456076974e-06
variant O 0 0.00012043148308293894
was O 0 7.725609611952677e-05
found O 0 6.37941582226631e-07
in O 0 4.573307705868501e-07
6 O 0 1.0665635272744112e-05
. O 0 3.418753067307989e-06

1 O 0 1.326214942309889e-06
% O 0 2.9938643564264567e-08
of O 0 2.3919970448815775e-09
American O 0 1.1335199445738908e-08
Jews O 0 1.4980596318991957e-08
, O 0 9.750589669010878e-09
28 O 0 3.179338392556019e-08
% O 0 1.0553035112437215e-09
of O 0 8.339102741672377e-09
their O 0 7.427723630826222e-06
familial O 1 0.9999732971191406
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
cases O 0 8.601860463386402e-05
, O 0 1.2639271744774305e-06
but O 0 1.477523881021625e-07
not O 0 7.457066075744478e-09
in O 0 3.478279708701848e-08
non O 0 5.718138709198684e-07
- O 0 5.1893042837036774e-05
Jews O 0 7.262157737386588e-07
. O 0 1.3804992704535834e-06

We O 0 1.633616307117336e-06
assessed O 0 2.0564129954436794e-06
the O 0 1.0963074004166629e-07
I1307K O 0 9.307519576395862e-06
prevalence O 0 8.851807251630817e-06
in O 0 1.5236837569432282e-08
Israeli O 0 1.6436412408893375e-07
Jews O 0 7.882965391559082e-09
of O 0 2.2522868015073527e-09
differing O 0 1.6087106757822767e-08
ethnic O 0 1.461956689041699e-08
origin O 0 5.163430927268564e-08
and O 0 2.2324657038552687e-06
risk O 0 0.150417760014534
for O 1 0.9574346542358398
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999957084655762
. O 0 0.0004775075358338654

METHODS O 0 1.3159471563994884e-05
DNA O 0 1.6958052583504468e-05
samples O 0 3.912630859304045e-07
from O 0 5.301356864606532e-08
500 O 0 7.813243030341255e-08
unrelated O 0 7.857389761056766e-08
Jews O 0 1.0302643183024429e-08
of O 0 2.5163342520784227e-09
European O 0 9.204458706335572e-08
or O 0 7.47531245792743e-08
non O 0 2.9013332891736354e-07
- O 0 9.754396160133183e-06
European O 0 7.696175430282892e-08
origin O 0 8.600499867839062e-09
, O 0 8.727177203127212e-09
with O 0 4.994019864312804e-09
or O 0 1.8138765156550107e-08
without O 0 8.434859033457087e-09
a O 0 3.0773854575727455e-08
personal O 0 8.223627645520537e-08
and O 0 1.4094329969793762e-07
/ O 0 3.7319064176699612e-06
or O 0 1.3966440803869773e-07
family O 0 6.068316338314617e-07
history O 0 1.1575261993357344e-07
of O 0 2.8433328580490524e-08
neoplasia B-Disease 0 0.007255430333316326
, O 0 8.215882729700752e-08
were O 0 3.108178248112381e-08
examined O 0 3.253450131524005e-07
for O 0 1.3338657955941358e-09
the O 0 1.5014981258332227e-08
I1307K O 0 8.835140761220828e-07
variant O 0 4.3830414142576046e-07
by O 0 3.2528524318564678e-09
the O 0 6.5795582315786305e-09
allele O 0 8.183680222373368e-08
- O 0 8.744991646381095e-07
specific O 0 3.337649090440209e-08
oligonucleotide O 0 1.1242890650464687e-05
( O 0 2.6025344368463266e-07
ASO O 0 0.0019648484885692596
) O 0 5.031195016158563e-08
method O 0 4.030645186503534e-07
. O 0 1.1025339290426928e-06

RESULTS O 0 2.1492754967766814e-05
In O 0 1.6208508668569266e-07
persons O 0 3.250156055401021e-08
at O 0 3.5789050798484823e-06
average O 0 5.883184348931536e-05
risk O 0 0.00199809274636209
for O 0 0.02646666020154953
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999973773956299
, O 0 3.7518937006097985e-06
I1307K O 0 6.192316504893824e-05
was O 0 9.832763316808268e-05
found O 0 3.006419433404517e-07
in O 0 1.5833613531412993e-07
5 O 0 7.343446668528486e-07
. O 0 9.068203326023649e-07

0 O 0 1.4830055761194672e-06
% O 0 3.452508678947197e-08
of O 0 2.5830970695750466e-09
120 O 0 1.3473572479938412e-08
European O 0 9.142920731619597e-08
and O 0 1.8144913838114007e-07
1 O 0 6.892585133755347e-06
. O 0 2.2302781417238293e-06

6 O 0 5.049522314948263e-06
% O 0 3.532185743893024e-08
of O 0 5.111007173042026e-09
188 O 0 3.400084835902817e-08
non O 0 1.0980841835817046e-07
- O 0 1.4110967185843037e-06
European O 0 4.008006371236661e-08
Jews O 0 7.037650817665053e-08
( O 0 6.838633481720535e-08
P O 0 1.9158054783474654e-05
= O 0 5.340093593986239e-07
0 O 0 1.1247206543885113e-07
. O 0 2.6846759482168636e-08
08 O 0 7.52145012938854e-07
) O 0 8.420588670787765e-08
. O 0 3.9755192915436055e-07

It O 0 2.330500365133048e-06
occurred O 0 1.3832594959239941e-05
in O 0 8.672470812598476e-07
15 O 0 3.262048267060891e-06
. O 0 1.3457232626024052e-06

4 O 0 2.265918510602205e-06
% O 0 3.508229085014136e-08
of O 0 1.4773344325647031e-08
52 O 0 1.6655236834139941e-07
Ashkenazi O 0 4.269115834176773e-06
Israelis O 0 1.3414846762316301e-06
with O 0 3.4813112961273873e-06
familial O 1 0.9978972673416138
cancer B-Disease 1 0.9995692372322083
( O 0 1.1155758556924411e-06
P O 0 0.00015373584756162018
= O 0 6.706246722387732e-07
0 O 0 5.323984098026813e-08
. O 0 6.3916658632479084e-09
02 O 0 3.457445245658164e-07
) O 0 1.4199414977156266e-09
and O 0 2.7084723352999163e-09
was O 0 6.177684781505377e-07
not O 0 4.081648796727677e-09
detected O 0 1.603362989044399e-07
in O 0 5.102951394775346e-09
51 O 0 2.8688273090438088e-08
non O 0 1.7549670161542963e-08
- O 0 3.0316118682094384e-07
European O 0 2.420245337475535e-08
Jews O 0 6.046433753681413e-08
at O 0 8.919631909520831e-06
increased O 0 0.00011986641766270623
cancer B-Disease 1 0.9974489808082581
risk O 0 0.0009718718356452882
. O 0 3.944280251744203e-06

Colorectal B-Disease 1 0.999257504940033
neoplasia I-Disease 1 0.9969249367713928
occurred O 0 0.004792698193341494
personally O 0 4.212804924463853e-05
or O 0 2.0031123426633712e-07
in O 0 3.472579024332845e-08
the O 0 1.4924243174618823e-08
families O 0 3.388248792646209e-09
of O 0 2.308783164650663e-09
13 O 0 1.760485446311577e-08
of O 0 2.5973252437694327e-09
20 O 0 3.2293691276663594e-08
Ashkenazi O 0 9.71336362454167e-07
I1307K O 0 1.4840497897239402e-06
carriers O 0 3.2588283715995203e-07
, O 0 9.914797871601877e-09
8 O 0 1.2363219781263979e-08
of O 0 4.2630330376880465e-09
whom O 0 8.592535749585295e-08
also O 0 1.1200794602927999e-07
had O 0 2.1860886079139163e-07
a O 0 6.709868216603354e-08
personal O 0 4.077589608186827e-07
or O 0 2.6784672968460654e-07
family O 0 1.601900180503435e-06
history O 0 1.0162143553316128e-06
of O 0 1.56840189902141e-06
noncolonic O 0 0.49427565932273865
neoplasia B-Disease 1 0.9926533699035645
. O 0 1.9247127056587487e-05

CONCLUSIONS O 0 1.5407324099214748e-05
The O 0 1.1101972177129937e-06
I1307K O 0 8.004860137589276e-05
APC O 0 7.414768333546817e-05
variant O 0 0.00010040255438070744
may O 0 2.5224628075193323e-07
represent O 0 7.826260528531748e-09
a O 0 1.5607429304509424e-07
susceptibility O 0 5.1856995924026705e-06
gene O 0 2.698202933970606e-06
for O 0 3.6525352697935887e-06
colorectal B-Disease 1 0.9999953508377075
, I-Disease 0 1.3414846762316301e-06
or I-Disease 0 1.3100725482217968e-07
other I-Disease 0 2.476241434123949e-08
, I-Disease 0 1.992199258893379e-06
cancers I-Disease 0 0.02316662296652794
in O 0 1.3692100253592798e-07
Ashkenazi O 0 2.2691992853651755e-05
Jews O 0 2.8707492560897663e-07
, O 0 1.8787875433190493e-07
and O 0 5.7410730391893594e-08
partially O 0 1.4391916010936256e-05
explains O 0 1.4676875537134038e-07
the O 0 5.889831555805358e-08
higher O 0 7.119846031855559e-06
incidence O 0 0.06611786782741547
of O 0 0.02340109460055828
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999963045120239
in O 0 5.436354058474535e-06
European O 0 7.041006483632373e-06
Israelis O 0 3.571835986804217e-05
. O 0 7.6289761636871845e-06

Systematic O 0 6.318797659332631e-06
analysis O 0 9.355273391520313e-07
of O 0 3.6026699490321334e-07
coproporphyrinogen O 0 0.002335554687306285
oxidase O 0 0.0006407525506801903
gene O 0 0.0009179744520224631
defects O 1 0.909059464931488
in O 0 3.222040277250926e-06
hereditary B-Disease 0 0.39443448185920715
coproporphyria I-Disease 0 0.0647544264793396
and O 0 3.061792813241482e-05
mutation O 0 0.000963159603998065
update O 0 0.0002814219333231449
. O 0 4.463110599317588e-06

Hereditary B-Disease 1 0.9869533181190491
coproporphyria I-Disease 1 0.9003326296806335
( O 0 6.73286194796674e-05
HC B-Disease 1 0.9994194507598877
) O 0 3.928835212718695e-06
is O 0 4.1617522583692335e-06
an O 0 1.55292891577119e-05
acute O 1 0.99715256690979
hepatic B-Disease 1 0.9995834231376648
porphyria I-Disease 1 0.9991987347602844
with O 0 0.00047614582581445575
autosomal O 1 0.9972090125083923
dominant O 0 0.27762189507484436
inheritance O 0 0.08270802348852158
caused O 0 0.0016375903505831957
by O 0 1.397836854266643e-06
deficient B-Disease 0 0.003876152914017439
activity I-Disease 0 6.840381274741958e-07
of I-Disease 0 9.869632577874654e-08
coproporphyrinogen I-Disease 0 0.0007044555968604982
III I-Disease 0 0.11083522439002991
oxidase I-Disease 0 2.747656799328979e-05
( O 0 3.958921581670438e-07
CPO O 0 1.3460516129271127e-05
) O 0 2.9616450092362356e-07
. O 0 9.593509275873657e-07

Clinical O 0 0.00018871377687901258
manifestations O 0 2.6133035134989768e-05
of O 0 8.765331358517869e-07
the O 0 0.00017259987362194806
disease O 1 0.9691140055656433
are O 0 1.1262899590747111e-07
characterized O 0 3.6313322198111564e-05
by O 0 1.0817855127243092e-06
acute O 0 0.2598567306995392
attacks O 0 0.0002689609245862812
of O 0 0.00013361123274080455
neurological B-Disease 1 0.9999808073043823
dysfunction I-Disease 1 0.9964237809181213
often O 0 4.9701134230417665e-06
precipitated O 0 0.00021286157425493002
by O 0 1.4677982562716352e-07
drugs O 0 4.845979901801911e-07
, O 0 2.8108020799777478e-08
fasting O 0 6.501380767076625e-07
, O 0 1.2400136029100395e-07
cyclical O 0 4.236998938722536e-05
hormonal O 0 0.00023783292272128165
changes O 0 1.937862407430657e-06
, O 0 6.655505444541632e-07
or O 0 4.3584481318248436e-05
infectious B-Disease 1 0.9990808963775635
diseases I-Disease 1 0.997683048248291
. O 0 1.913311098178383e-05

Skin O 1 0.9940977096557617
photosensitivity O 1 0.9963914752006531
may O 0 0.0014914660714566708
also O 0 2.317366806892096e-06
be O 0 2.8633721171900106e-07
present O 0 9.185077374240791e-07
. O 0 2.9055411232548067e-06

The O 0 9.967664027499268e-07
seven O 0 2.0852407089932967e-07
exons O 0 1.8270176269652438e-06
, O 0 5.5809028509656855e-08
the O 0 3.343453514048633e-08
exon O 0 3.6481942515820265e-06
/ O 0 6.464736088673817e-07
intron O 0 2.1652645045833196e-06
boundaries O 0 2.793261799638458e-08
and O 0 5.104324074522992e-09
part O 0 1.3888044492205154e-08
of O 0 4.0020307068289185e-09
3 O 0 6.258520812707502e-08
noncoding O 0 1.0288661087543005e-06
sequence O 0 1.7456661893788805e-08
of O 0 1.4723153807238987e-09
the O 0 8.564290610024727e-09
CPO O 0 5.908092362005846e-07
gene O 0 5.041992778842541e-08
were O 0 5.8986540096839235e-09
systematically O 0 4.2477438455534866e-08
analyzed O 0 1.7077049108138453e-08
by O 0 2.327632531162749e-09
an O 0 1.1939928157289614e-08
exon O 0 3.6542530779115623e-06
- O 0 7.59637850933359e-06
by O 0 2.3464764353775536e-07
- O 0 3.5292585380375385e-05
exon O 0 7.024831575108692e-05
denaturing O 0 0.0001992832258110866
gradient O 0 7.4799194408115e-05
gel O 0 6.432972440961748e-05
electrophoresis O 0 1.6812165995361283e-05
( O 0 9.456855565304068e-08
DGGE O 0 6.408486569853267e-06
) O 0 6.7073320231259e-09
strategy O 0 2.1607720057659208e-08
followed O 0 2.8088069647935754e-09
by O 0 3.286269867341929e-10
direct O 0 8.192903022674614e-10
sequencing O 0 1.9405124618288028e-08
in O 0 1.0189102894742064e-08
seven O 0 2.4164076961596948e-08
unrelated O 0 1.8204501657237415e-06
heterozygous O 0 9.6940257208189e-06
HC B-Disease 1 0.995499312877655
patients O 0 3.495378405204974e-05
from O 0 1.0751460166602556e-07
France O 0 6.253597348404583e-06
, O 0 1.6920908763040643e-07
Holland O 0 1.4910982827132102e-05
, O 0 3.6427806548999797e-07
and O 0 1.3508073379853158e-06
Czech O 0 0.09824621677398682
Republic O 0 0.0004740833246614784
. O 0 7.760214430163614e-06

Seven O 0 6.112661139923148e-06
novel O 0 2.4763510282355128e-06
mutations O 0 2.8246249712537974e-06
and O 0 2.4595593117737735e-08
two O 0 2.0017216328938048e-08
new O 0 3.3739988225534034e-07
polymorphisms O 0 1.5572799384244718e-05
were O 0 2.0352015326352557e-06
detected O 0 0.00010107797425007448
. O 0 1.2946533161084517e-06

Among O 0 6.540933554788353e-07
these O 0 6.527287155222439e-08
mutations O 0 1.4691512433273601e-06
two O 0 2.7992671292054183e-08
are O 0 2.5798092551099217e-08
missense O 0 4.642776730179321e-06
( O 0 7.583926731058455e-08
G197W O 0 2.7598564429354155e-06
, O 0 5.733948782449261e-08
W427R O 0 8.347204243364104e-07
) O 0 6.6890244454498315e-09
, O 0 6.885197745276628e-09
two O 0 6.0378568811358946e-09
are O 0 3.8736738261491155e-09
nonsense O 0 5.704102932213573e-07
( O 0 1.7375409555597798e-08
Q306X O 0 7.29945838884305e-07
, O 0 2.286853373334452e-08
Q385X O 0 5.180195898901729e-07
) O 0 4.73300731940185e-09
, O 0 1.9002004414403473e-09
two O 0 9.662054489822935e-10
are O 0 3.5828820466043965e-10
small O 0 1.327637733083975e-08
deletions O 0 1.1081962014714009e-07
( O 0 2.1487219115101652e-08
662de14bp O 0 7.287425205504405e-07
; O 0 1.53869486041458e-08
1168del3bp O 0 2.0265479179215617e-06
removing O 0 3.3940793287001725e-07
a O 0 1.4015569149705698e-07
glycine O 0 8.613322961537051e-07
at O 0 5.326650125425658e-07
position O 0 8.724752120770063e-08
390 O 0 4.482927451476826e-08
) O 0 3.280497651303449e-09
, O 0 3.037878615330669e-09
and O 0 1.723998721558928e-09
one O 0 4.0094798592349434e-09
is O 0 5.733649999228874e-09
a O 0 4.277451992606984e-08
splicing O 0 1.2117062624383834e-06
mutation O 0 3.1065360417414922e-06
( O 0 6.043492817298102e-08
IVS1 O 0 2.43778558797203e-05
- O 0 6.324205514829373e-06
15c O 0 5.096382210467709e-06
- O 0 4.16460261476459e-06
- O 0 5.222550498729106e-06
> O 0 8.014018249014043e-07
g O 0 6.504574798782414e-07
) O 0 5.693720162014415e-09
which O 0 1.8855350614188637e-09
creates O 0 1.3273997012674954e-08
a O 0 1.9868751977014654e-08
new O 0 5.472718100918428e-08
acceptor O 0 9.029076863953378e-07
splice O 0 3.95477436541114e-05
site O 0 3.3741729566827416e-05
. O 0 3.576564267859794e-06

The O 0 1.403950363965123e-06
pathological O 0 2.6588439141050912e-05
significance O 0 4.297085638427234e-07
of O 0 2.8235152882416514e-08
the O 0 8.811750262793794e-08
point O 0 1.2856886542067514e-06
mutations O 0 1.1983823924310855e-06
G197W O 0 9.068895110431185e-07
, O 0 1.0476509437751247e-08
W427R O 0 2.3666082427098445e-07
, O 0 3.942510762300344e-09
and O 0 3.537247161844448e-09
the O 0 1.968614071756747e-08
in O 0 5.777014067120945e-08
- O 0 4.478202754398808e-06
frame O 0 4.121684924029978e-06
deletion O 0 8.681722647452261e-07
390delGly O 0 1.9806677755696e-06
were O 0 1.4712830065377602e-08
assessed O 0 3.210734789149683e-08
by O 0 7.42784889151693e-10
their O 0 3.5584596380644484e-10
respective O 0 5.833480809513958e-09
expression O 0 3.399358305955502e-08
in O 0 9.768365671902757e-09
a O 0 4.302785328036407e-08
prokaryotic O 0 8.283306129897028e-08
system O 0 4.2328386484769e-07
using O 0 3.4481651312034955e-08
site O 0 2.331687483092537e-06
- O 0 6.083850621507736e-06
directed O 0 4.083827889189706e-07
mutagenesis O 0 9.555337783240248e-06
. O 0 1.0529937526371214e-06

These O 0 5.272235057418584e-07
mutations O 0 2.1677789845853113e-05
resulted O 0 2.400139237579424e-06
in O 0 9.691760283203621e-08
the O 0 6.176870925855837e-08
absence O 0 2.6236168082505174e-07
or O 0 1.864600029932717e-08
a O 0 1.1621276030382433e-07
dramatic O 0 2.2506619643536396e-06
decrease O 0 1.4228994587028865e-06
of O 0 4.726622648831835e-08
CPO O 0 1.120266824727878e-05
activity O 0 2.609040620882297e-06
. O 0 7.992929340616683e-07

The O 0 3.8298321669572033e-07
two O 0 9.114591392744842e-08
polymorphisms O 0 2.636594899740885e-06
were O 0 6.328515667064494e-08
localized O 0 2.341929757676553e-06
in O 0 1.718512834258945e-07
noncoding O 0 1.3043450053373817e-05
part O 0 6.427549692489265e-08
of O 0 2.800333742669636e-09
the O 0 1.3987228264511486e-08
gene O 0 4.8490406356904714e-08
1 O 0 2.7305341987471365e-08
) O 0 3.749534016606049e-09
a O 0 6.615373848717354e-08
C O 0 7.848565246604267e-07
/ O 0 8.971996976470109e-07
G O 0 2.3044699446472805e-06
polymorphism O 0 3.002539870067267e-07
in O 0 2.140544985707038e-08
the O 0 2.4780177909633494e-08
promotor O 0 3.6813642509514466e-05
region O 0 7.603870244565769e-07
, O 0 2.0510288578634572e-08
142 O 0 5.444690387435003e-08
bp O 0 4.633919843399781e-07
upstream O 0 1.612962918784433e-08
from O 0 9.909576492717065e-10
the O 0 8.837190978994158e-10
transcriptional O 0 6.286840914526692e-08
initiation O 0 8.652398264530348e-08
site O 0 2.1201498157097376e-07
( O 0 1.6888753506805187e-08
- O 0 8.587371667090338e-07
142C O 0 1.2128762136853766e-06
/ O 0 5.780374863206816e-07
G O 0 9.020135394166573e-07
) O 0 2.47145526266479e-09
, O 0 1.609041344607931e-09
and O 0 1.339221844531835e-09
2 O 0 1.5221818472355153e-08
) O 0 3.3939406840488573e-09
a O 0 5.71010154715168e-08
6 O 0 4.0802891021485266e-07
bp O 0 1.2085740763723152e-06
deletion O 0 1.7970413068724156e-07
polymorphism O 0 1.1891228979266089e-07
in O 0 9.663496669531924e-09
the O 0 6.9205361441504465e-09
3 O 0 3.143749083278635e-08
noncoding O 0 7.870811487009632e-07
part O 0 8.073876678338365e-09
of O 0 1.968571750055048e-09
the O 0 1.4575491036339372e-08
CPO O 0 5.879034006284201e-07
gene O 0 1.0489650748013446e-07
, O 0 9.547234114393177e-09
574 O 0 1.3112051533425984e-07
bp O 0 3.2392949833592866e-07
downstream O 0 3.631542000448462e-08
of O 0 1.0168285102807317e-09
the O 0 6.755040526940093e-09
last O 0 3.375981094677627e-08
base O 0 1.9583898946962108e-08
of O 0 1.7286841957897536e-09
the O 0 3.016171490344277e-08
normal O 0 4.242408238042117e-07
termination O 0 1.2357264722595573e-06
codon O 0 6.172255098135793e-07
( O 0 5.3758103746304187e-08
+ O 0 1.188931832984963e-06
574 O 0 4.158510364504764e-06
delATTCTT O 0 2.2104979507275857e-05
) O 0 4.553362771275715e-07
. O 0 6.875475833112432e-07

Five O 0 4.762631760968361e-06
intragenic O 0 0.00029243595781736076
dimorphisms O 0 0.0005544001469388604
are O 0 1.0420851737080739e-07
now O 0 4.032306151202647e-07
well O 0 8.422018282772115e-08
characterized O 0 1.4967422430345323e-06
and O 0 1.631278934155489e-08
the O 0 2.3426970585660456e-08
high O 0 1.146960016740195e-06
degree O 0 5.688859872066132e-08
of O 0 7.080112940371919e-09
allelic O 0 3.473481456239824e-06
heterogeneity O 0 8.75185287441127e-06
in O 0 4.873388661508216e-06
HC B-Disease 1 0.9989237189292908
is O 0 4.405755760217289e-07
demonstrated O 0 8.830358666500615e-08
with O 0 3.6003113823568356e-09
seven O 0 3.0558418018244993e-09
new O 0 3.8854173212143905e-09
different O 0 4.4561124235009686e-10
mutations O 0 1.2367582513661546e-08
making O 0 5.506091693696646e-10
a O 0 1.9777397497477978e-09
total O 0 1.0714418241519752e-09
of O 0 2.1579620312905945e-09
nineteen O 0 6.916433790138399e-07
CPO O 0 3.592558641685173e-05
gene B-Disease 0 0.0001273836533073336
defects I-Disease 1 0.7713924050331116
reported O 0 1.6658997992635705e-05
so O 0 6.273771191445121e-08
far O 0 1.3061865899999248e-07
. O 0 7.052594241940824e-08
. O 0 5.682889536728908e-07

Coincidence O 0 8.00062480266206e-06
of O 0 1.9302436271573242e-07
two O 0 1.1737392213717612e-07
novel O 0 8.476018820147146e-07
arylsulfatase O 0 1.2701048035523854e-05
A O 0 4.52680382068138e-07
alleles O 0 2.3524610526237666e-07
and O 0 9.117060528751608e-08
mutation O 0 2.7921912533201976e-06
459 O 0 1.0371343250881182e-06
+ O 0 1.2383135299387504e-06
1G O 0 3.927751095034182e-05
> O 0 4.544166074538225e-07
A O 0 1.6907550559608353e-07
within O 0 1.0719594989438974e-08
a O 0 1.3931918374510133e-07
family O 0 1.3155580518287024e-06
with O 0 5.711643098038621e-06
metachromatic B-Disease 1 0.9996722936630249
leukodystrophy I-Disease 1 0.9994310736656189
: O 0 7.052594241940824e-08
molecular O 0 3.1061014738043013e-07
basis O 0 2.1752118328777215e-08
of O 0 4.272754949852242e-08
phenotypic O 0 3.7589601561194286e-05
heterogeneity O 0 0.0004543908580671996
. O 0 9.314419003203511e-06

In O 0 1.5121830756470445e-06
a O 0 8.286922934530594e-07
family O 0 4.7583640139237104e-07
with O 0 1.7492123305373752e-08
three O 0 2.712764946011248e-08
siblings O 0 3.662993037778506e-07
, O 0 1.5001125674984905e-08
one O 0 1.4626651001492519e-08
developed O 0 5.139114023222646e-07
classical O 0 8.583764611103106e-06
late O 0 0.0016187547007575631
infantile O 1 0.9982790946960449
metachromatic B-Disease 1 0.9998607635498047
leukodystrophy I-Disease 1 0.9998177886009216
( O 0 2.9005774194956757e-05
MLD B-Disease 1 0.9982781410217285
) O 0 3.922142468582024e-07
, O 0 2.550048634475388e-07
fatal O 0 0.0018348476151004434
at O 0 9.18526802706765e-06
age O 0 7.456798130078823e-07
5 O 0 9.592212535380895e-08
years O 0 1.4915141832716472e-07
, O 0 1.560188778171323e-08
with O 0 3.3144371514026716e-07
deficient O 0 0.0018984860507771373
arylsulfatase O 0 9.177037281915545e-05
A O 0 4.381605776870856e-06
( O 0 4.9581274197407765e-08
ARSA O 0 5.478290404425934e-05
) O 0 6.789607098767192e-09
activity O 0 2.034733803668587e-08
and O 0 9.295066050185596e-09
increased O 0 2.885857384171686e-07
galactosylsulfatide O 0 0.0001949496945599094
( O 0 1.7445931916881818e-06
GS O 1 0.9971447587013245
) O 0 4.4702909463012475e-07
excretion O 0 1.3100294381729327e-05
. O 0 2.254083710795385e-06

The O 0 3.531856407334999e-07
two O 0 4.175424450636456e-08
other O 0 8.131367579267135e-09
siblings O 0 9.829108194026048e-07
, O 0 1.3841216173204884e-07
apparently O 0 3.002442099386826e-06
healthy O 0 6.779101227039064e-07
at O 0 4.2856510162891936e-07
12 O 0 2.8482560310294502e-08
( O 0 2.4729078784702097e-09
1 O 0 2.835517953769795e-08
/ O 0 5.292436000559064e-08
2 O 0 1.2233664747896e-08
) O 0 7.36228911168979e-10
and O 0 7.350166586483908e-10
15 O 0 4.222039606815997e-09
years O 0 4.0654493105307665e-09
, O 0 1.6637379252060214e-09
respectively O 0 1.1791981613384905e-08
, O 0 3.3141569488748246e-09
and O 0 2.814690258645669e-09
their O 0 4.316971669027225e-09
father O 0 1.5263764225892373e-06
, O 0 6.087606152505032e-08
apparently O 0 6.972874189159484e-07
healthy O 0 2.200206665747828e-07
as O 0 1.2891292477945626e-08
well O 0 1.3113671926134884e-08
, O 0 1.339209632078564e-08
presented O 0 4.5736391030004597e-07
ARSA O 0 0.0014353147707879543
and O 0 1.454529979127983e-06
GS O 1 0.8709567785263062
values O 0 4.470640391218694e-08
within O 0 1.3179568547627696e-08
the O 0 1.998379772771841e-08
range O 0 7.552730494353455e-07
of O 0 1.5046623502712464e-06
MLD B-Disease 1 0.9988620281219482
patients O 0 0.00100351229775697
. O 0 5.01360136695439e-06

Mutation O 0 9.692094317870215e-05
screening O 0 7.5936768553219736e-06
and O 0 7.753460096182607e-08
sequence O 0 1.849894459837742e-07
analysis O 0 1.0500319547190884e-07
disclosed O 0 1.4701071222589235e-06
the O 0 7.247017208555917e-09
involvement O 0 2.5017440563601667e-08
of O 0 1.4011840576699797e-09
three O 0 3.693177763608446e-09
different O 0 5.799134505934944e-09
ARSA O 0 0.001104014809243381
mutations O 0 1.4491714637188124e-06
being O 0 2.742978466585555e-08
the O 0 8.489477565376546e-09
molecular O 0 8.918681260183803e-08
basis O 0 1.1996517557122388e-08
of O 0 3.14315506955154e-08
intrafamilial O 0 4.866991366725415e-05
phenotypic O 0 0.00012213451554998755
heterogeneity O 0 0.0009228925919160247
. O 0 1.8393797290627845e-05

The O 0 1.2630075616471004e-05
late O 0 0.000502069597132504
infantile O 1 0.9773918390274048
patient O 0 0.07675940543413162
inherited O 0 0.23067738115787506
from O 0 9.847441333477036e-07
his O 0 1.2252787655597785e-06
mother O 0 5.135006631462602e-06
the O 0 3.41528760827714e-08
frequent O 0 2.5140573711723846e-07
0 O 0 2.8727322387567256e-07
- O 0 6.59203624309157e-06
type O 0 3.819290668616304e-06
mutation O 0 8.987806268123677e-07
459 O 0 4.442911176738562e-07
+ O 0 3.0982437237980776e-07
1G O 0 6.057427526684478e-06
> O 0 2.1012304785017477e-07
A O 0 2.3382312974717934e-07
, O 0 4.894709526581664e-09
and O 0 3.5392919706112025e-09
from O 0 8.519161376341344e-09
his O 0 1.2746822619646991e-07
father O 0 1.5120821217351477e-06
a O 0 3.738645943940355e-07
novel O 0 1.5538445552465419e-07
, O 0 5.650014678337811e-09
single O 0 2.204902926905561e-08
basepair O 0 1.3850567484041676e-06
microdeletion O 0 4.109981830424658e-07
of O 0 3.3001532617760176e-09
guanine O 0 1.0521008420028011e-07
at O 0 1.044742035105628e-07
nucleotide O 0 2.2368335805822426e-07
7 O 0 1.419003297087329e-07
in O 0 3.286912786393259e-08
exon O 0 5.393718765844824e-06
1 O 0 8.658257115712331e-07
( O 0 1.3775164120488625e-07
7delG O 0 2.3385477106785402e-05
) O 0 4.244439821832202e-07
. O 0 7.921989890746772e-07

The O 0 1.3651566632688628e-06
two O 0 1.1502922916406533e-06
clinically O 0 0.00029570554033853114
unaffected O 0 3.61853490176145e-05
siblings O 0 3.2590819500910584e-06
carried O 0 3.222711768557929e-07
the O 0 8.373421422902538e-08
maternal O 0 4.268741122359643e-06
mutation O 0 3.1161941933532944e-06
459 O 0 1.3890794434701093e-06
+ O 0 1.4544743862643372e-06
1G O 0 2.7672471333062276e-05
> O 0 6.783887442907144e-07
A O 0 5.089035539640463e-07
and O 0 1.0131102179400386e-08
, O 0 3.603251474970648e-09
on O 0 5.3735211835714836e-09
their O 0 9.968512681979291e-10
paternal O 0 1.2086415779322124e-07
allele O 0 5.4556259954097186e-08
, O 0 5.827564653060335e-09
a O 0 3.1936576050384247e-08
novel O 0 1.878941091604247e-08
cytosine O 0 3.184636909736582e-08
to O 0 1.5097536554264934e-09
thymidine O 0 5.991215630274382e-07
transition O 0 4.253792553754465e-07
at O 0 4.437812890500936e-07
nucleotide O 0 9.574351906849188e-07
2435 O 0 1.2910413715871982e-05
in O 0 1.2451720010631107e-07
exon O 0 4.161879132880131e-06
8 O 0 1.9314846610996028e-07
, O 0 7.142097135925951e-09
resulting O 0 1.646357539186738e-08
in O 0 2.9746012319975534e-09
substitution O 0 3.5089300354229636e-09
of O 0 7.47924566724123e-09
alanine O 0 1.9395395156607265e-06
464 O 0 7.136291628739855e-07
by O 0 1.1563202662046024e-07
valine O 0 4.5135060645407066e-05
( O 0 4.183707744687126e-07
A464V O 0 1.5451640138053335e-05
) O 0 4.290222648251074e-07
. O 0 9.965848448700854e-07

The O 0 4.487565547606209e-06
fathers O 0 9.688831596577074e-06
genotype O 0 6.635226600337774e-05
thus O 0 1.0622939953464083e-05
was O 0 8.452650945400819e-05
7delG O 0 0.0002565107133705169
/ O 0 8.921346307033673e-05
A464V O 0 0.0002699260658118874
. O 0 6.5312619881297e-06

Mutation O 0 0.0006050552474334836
A464V O 0 0.00011019491648767143
was O 0 2.403482903901022e-05
not O 0 3.0728866562412804e-08
found O 0 1.0742338218960867e-07
in O 0 1.0705092279295059e-07
18 O 0 2.5660447136033326e-06
unrelated O 0 0.00014139288396108896
MLD B-Disease 1 0.9994283318519592
patients O 0 0.00021264349925331771
and O 0 2.184138168104255e-07
50 O 0 5.362303454603534e-07
controls O 0 1.693917511147447e-05
. O 0 2.2902529508428415e-06

A464V O 0 0.0005338337505236268
, O 0 2.2799952148488956e-06
although O 0 8.926899681682698e-07
clearly O 0 8.703309504198842e-07
modifying O 0 8.410317605012096e-06
ARSA O 0 0.05324265733361244
and O 0 1.773418625816703e-05
GS O 1 0.99946528673172
levels O 0 5.151565346750431e-05
, O 0 1.3646018715007813e-07
apparently O 0 9.283496638090583e-07
bears O 0 1.2664753512581228e-07
little O 0 2.971551893438118e-08
significance O 0 3.452120012070736e-08
for O 0 1.79520096565966e-08
clinical O 0 2.480042667230009e-06
manifestation O 0 5.663791398546891e-06
of O 0 6.461759198828076e-07
MLD B-Disease 1 0.998868465423584
, O 0 7.481565944544855e-07
mimicking O 0 9.361785487271845e-06
the O 0 7.317643166970811e-07
frequent O 0 2.993505222548265e-05
ARSA O 0 0.051366791129112244
pseudodeficiency O 0 0.00262749963440001
allele O 0 0.00019641210383269936
. O 0 1.2405058441800065e-05

Our O 0 2.3621014406671748e-06
results O 0 2.233470922874403e-06
demonstrate O 0 2.0438790215848712e-07
that O 0 9.113476195921066e-09
in O 0 1.5597453995042088e-08
certain O 0 3.8918567923929004e-08
genetic O 0 6.764532008673996e-05
conditions O 0 0.005224319640547037
MLD B-Disease 1 0.9994434714317322
- O 0 0.003539170604199171
like O 0 3.6201906823407626e-06
ARSA O 0 0.006964517291635275
and O 0 2.218445388280088e-06
GS O 1 0.9135279059410095
values O 0 6.373687710947706e-08
need O 0 1.3051463021440668e-08
not O 0 2.547224653426383e-09
be O 0 2.4084645389166326e-09
paralleled O 0 1.0958412133277307e-07
by O 0 1.3186765102091158e-07
clinical O 0 0.0004621566040441394
disease O 0 0.06734295189380646
, O 0 2.7949990766273913e-08
a O 0 1.2193309828489873e-07
finding O 0 3.5689989630327545e-08
with O 0 1.697314360171731e-07
serious O 0 0.00023181457072496414
diagnostic O 0 0.00037783614243380725
and O 0 4.204854121780954e-06
prognostic O 0 0.01702466793358326
implications O 0 0.00025271339109167457
. O 0 5.285482984618284e-06

Moreover O 0 6.412601214833558e-05
, O 0 1.183930748993589e-06
further O 0 9.593746881364495e-07
ARSA O 0 0.002899349434301257
alleles O 0 5.362709089240525e-06
functionally O 0 2.0550976842059754e-05
similar O 0 1.0402919059515625e-07
to O 0 2.377719887647345e-08
A464V O 0 5.098982910567429e-06
might O 0 1.130524509562747e-07
exist O 0 9.463798633646547e-09
which O 0 2.020273726088817e-09
, O 0 9.509428799958641e-10
together O 0 5.308079531474164e-10
with O 0 1.0080928092293107e-08
0 O 0 3.1456568194698775e-07
- O 0 0.00013404511264525354
type O 0 5.324256562744267e-05
mutations O 0 1.6756108379922807e-05
, O 0 2.363189111065367e-07
may O 0 1.6442086234746967e-06
cause O 0 8.367293958144728e-06
pathological O 0 0.0005399135407060385
ARSA O 0 0.45992961525917053
and O 0 2.6737592634162866e-05
GS O 1 0.9995806813240051
levels O 0 1.3384852536546532e-05
, O 0 4.82972168924789e-08
but O 0 1.5887742677023198e-08
not O 0 1.1589098569686485e-08
clinical O 0 3.4636204873095267e-06
outbreak O 0 2.8737684260704555e-05
of O 0 2.979395219426806e-08
the O 0 1.2597210115927737e-05
disease O 0 0.3003447651863098
. O 0 3.839435294139548e-07
. O 0 1.4063624576010625e-06

Human O 0 0.015873009338974953
MLH1 O 1 0.9966405630111694
deficiency O 1 0.9989597797393799
predisposes O 0 0.015660369768738747
to O 0 3.490678500384092e-05
hematological B-Disease 1 0.9963706731796265
malignancy I-Disease 1 0.9989321827888489
and O 0 0.0015212694415822625
neurofibromatosis B-Disease 1 0.9995678067207336
type I-Disease 1 0.7376722693443298
1 I-Disease 0 0.00024079412105493248
. O 0 1.1500222171889618e-05

Heterozygous O 0 0.00013175723142921925
germ O 0 0.0010289517231285572
- O 0 0.00010176123032579198
line O 0 6.069374194339616e-06
mutations O 0 1.9163271645084023e-06
in O 0 2.4911827267715125e-08
the O 0 5.5687063849063634e-08
DNA O 0 5.075763056083815e-06
mismatch O 0 0.000776614819187671
repair O 0 0.005664171185344458
genes O 0 3.7725778838648694e-06
lead O 0 1.390503348375205e-05
to O 0 6.930478775757365e-06
hereditary B-Disease 1 0.999734103679657
nonpolyposis I-Disease 1 0.9999151229858398
colorectal I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999927282333374
. O 0 0.0011828114511445165

The O 0 0.0001275049289688468
disease O 1 0.6533616185188293
susceptibility O 0 8.448936569038779e-05
of O 0 8.106577809030568e-08
individuals O 0 6.120624362893068e-08
who O 0 1.3576808441939647e-06
constitutionally O 0 2.132446206815075e-05
lack O 0 3.971343289776996e-07
both O 0 1.1693794732536844e-07
wild O 0 1.4991426724009216e-05
- O 0 0.00039294088492169976
type O 0 3.1444975320482627e-05
alleles O 0 1.0157521046494367e-06
is O 0 1.1312088190607028e-06
unknown O 0 4.820789399673231e-06
. O 0 1.2442726529116044e-06

We O 0 8.393951134166855e-07
have O 0 3.180260321755668e-08
identified O 0 5.94068154669003e-08
three O 0 8.734505563268158e-09
offspring O 0 1.0214071011205306e-07
in O 0 1.8046648619929329e-07
a O 0 8.671999239595607e-05
hereditary B-Disease 1 0.9998602867126465
nonpolyposis I-Disease 1 0.999966025352478
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
family O 0 0.0036076561082154512
who O 0 4.7529199946438894e-05
developed O 0 0.00013324177416507155
hematological B-Disease 1 0.9469025731086731
malignancy I-Disease 1 0.9857845902442932
at O 0 1.898009213618934e-05
a O 0 2.9449014959936903e-07
very O 0 1.816490602379872e-08
early O 0 1.2272172966731887e-07
age O 0 7.665614276675115e-08
, O 0 2.220555295195936e-09
and O 0 1.2567801244145471e-09
at O 0 4.609616155448748e-08
least O 0 6.034123756215592e-10
two O 0 1.4753562260771957e-10
of O 0 3.230647138696696e-10
them O 0 4.0074366047804233e-10
displayed O 0 2.561912140208733e-07
signs O 0 1.2644733260458452e-06
of O 0 1.9539970708137844e-07
neurofibromatosis B-Disease 1 0.9938766360282898
type I-Disease 0 0.002599559025838971
1 I-Disease 0 3.364571966812946e-05
( O 0 1.760863483468711e-06
NF1 B-Disease 0 0.0017382792429998517
) O 0 9.57620500230405e-07
. O 0 1.4901905842634733e-06

DNA O 0 1.25474307424156e-05
sequence O 0 7.862994380047894e-07
analysis O 0 6.097460669707289e-08
and O 0 1.5358567750922703e-08
allele O 0 3.515169169077126e-07
- O 0 8.422594532930816e-07
specific O 0 7.375899002681763e-09
amplification O 0 5.229180715105031e-07
in O 0 1.9062635914224302e-08
two O 0 1.9922866911770143e-08
siblings O 0 1.9948779481637757e-06
revealed O 0 5.235076514509274e-06
a O 0 2.004917860176647e-06
homozygous O 0 2.399914592388086e-05
MLH1 O 0 0.0024567749351263046
mutation O 0 2.537960790505167e-05
( O 0 1.932048547814702e-07
C676T O 0 1.601077565283049e-05
- O 0 0.0003072347608394921
- O 0 0.00024499755818396807
> O 0 1.1224378795304801e-05
Arg226Stop O 0 7.374440610874444e-05
) O 0 5.604342732112855e-07
. O 0 9.563783578414586e-07

Thus O 0 5.08514312969055e-06
, O 0 4.138217093441199e-07
a O 0 1.185844894280308e-06
homozygous O 0 1.4285134966485202e-05
germ O 0 0.0008377107442356646
- O 0 0.00023400415375363082
line O 0 3.8050235161790624e-05
MLH1 O 0 0.004731480497866869
mutation O 0 0.00011063944839406759
and O 0 1.5533258874711464e-06
consequent O 0 0.013905210420489311
mismatch O 1 0.999718964099884
repair O 1 0.9999204874038696
deficiency O 1 0.9998397827148438
results O 0 7.027578249108046e-05
in O 0 7.236840247060172e-07
a O 0 7.296901003428502e-06
mutator O 0 0.01307260524481535
phenotype O 0 0.0007602659170515835
characterized O 0 0.0002918168029282242
by O 0 1.6733738448238e-05
leukemia B-Disease 1 0.9997184872627258
and O 0 2.2552110749529675e-05
/ O 0 0.1520058661699295
or O 0 0.461325466632843
lymphoma B-Disease 1 0.9999996423721313
associated O 0 0.0005430939490906894
with O 0 3.668086355901323e-05
neurofibromatosis B-Disease 1 0.9998025298118591
type I-Disease 0 0.09091050177812576
1 I-Disease 0 4.8405618144897744e-05
. O 0 4.0802581224852474e-07
. O 0 1.3330649153431295e-06

Missense O 0 0.004663942847400904
mutations O 0 0.0003875648253597319
in O 0 6.516601729344984e-07
the O 0 6.695753995700215e-08
most O 0 9.339138351549536e-09
ancient O 0 2.683815836235226e-08
residues O 0 5.126298674440477e-08
of O 0 4.681418808161197e-09
the O 0 4.870935299550183e-08
PAX6 O 0 2.7687045076163486e-05
paired O 0 8.191830147552537e-07
domain O 0 1.6070032415882451e-07
underlie O 0 1.2017470680802944e-06
a O 0 3.0826379315840313e-07
spectrum O 0 4.539515430224128e-06
of O 0 1.3294973086885875e-06
human O 0 0.008899952284991741
congenital B-Disease 1 0.9999892711639404
eye I-Disease 1 0.9998001456260681
malformations I-Disease 1 0.9998599290847778
. O 0 0.0006796816014684737

Mutations O 0 0.00018939822621177882
of O 0 2.7239286737312796e-07
the O 0 5.570936423282546e-07
human O 0 4.047118181915721e-06
PAX6 O 0 0.019863547757267952
gene O 0 0.0019797554705291986
underlie O 0 0.20067551732063293
aniridia B-Disease 1 0.9998836517333984
( O 0 0.0012320785317569971
congenital B-Disease 1 0.9999434947967529
absence I-Disease 0 0.00013470834528561682
of I-Disease 0 1.4259897795909637e-07
the I-Disease 0 1.676453848631354e-06
iris I-Disease 0 0.0012223859084770083
) O 0 4.433683997717708e-08
, O 0 3.0171268150525066e-08
a O 0 1.3768664075541892e-06
rare O 0 9.576174306857865e-06
dominant O 0 0.028226954862475395
malformation B-Disease 1 0.9997676014900208
of I-Disease 0 6.194367756506836e-07
the I-Disease 0 1.4479984201898333e-05
eye I-Disease 0 0.07022970914840698
. O 0 1.1383468518033624e-05

The O 0 1.2122309271944687e-06
spectrum O 0 6.094134732848033e-06
of O 0 4.721595132650691e-07
PAX6 O 0 0.00703816581517458
mutations O 0 0.0017868304857984185
in O 0 9.648992272559553e-05
aniridia B-Disease 1 0.999868631362915
patients O 0 0.0006195822497829795
is O 0 2.3242337476858665e-07
highly O 0 1.5733051839106338e-07
biased O 0 1.1685055056886995e-07
, O 0 8.212746038793739e-09
with O 0 9.417342461404132e-09
92 O 0 7.284021563691567e-08
% O 0 9.808557299706422e-10
of O 0 7.393586298753974e-10
all O 0 2.5216237986569467e-09
reported O 0 1.0150414482268388e-06
mutations O 0 3.854701446925901e-07
leading O 0 5.236247488937806e-07
to O 0 1.0334013644808238e-08
premature O 0 6.523006277348031e-07
truncation O 0 1.474598718687048e-07
of O 0 1.8531753909201143e-09
the O 0 1.2759100442849558e-08
protein O 0 4.36636149458991e-08
( O 0 3.652532498676919e-09
nonsense O 0 6.61380923361321e-08
, O 0 1.3016899780282642e-09
splicing O 0 3.4233810453088154e-08
, O 0 3.0294655672946647e-09
insertions O 0 3.6208490428180085e-08
and O 0 4.835018163618088e-09
deletions O 0 4.4093035000969394e-08
) O 0 2.305909463373723e-09
and O 0 2.3446491415057835e-09
just O 0 7.800760926102157e-09
2 O 0 9.645909848643441e-09
% O 0 1.0023823993066117e-09
leading O 0 9.577473925048707e-09
to O 0 1.0506034237023343e-10
substitution O 0 9.576465176408533e-10
of O 0 6.194444401863564e-10
one O 0 2.7410158587315436e-09
amino O 0 1.2325100051668869e-08
acid O 0 5.241923162202511e-08
by O 0 2.201976601057254e-09
another O 0 5.508365674700144e-08
( O 0 6.583640299595572e-08
missense O 0 9.233265700459015e-06
) O 0 1.7641653471400787e-07
. O 0 7.721816928096814e-07

The O 0 9.684300721346517e-07
extraordinary O 0 2.4907842544052983e-07
conservation O 0 1.1773423125305271e-07
of O 0 4.1440593179231655e-09
the O 0 1.519898695789834e-08
PAX6 O 0 6.620815838687122e-06
protein O 0 1.0829234753373385e-07
at O 0 1.1226588725321562e-07
the O 0 1.422132189787817e-08
amino O 0 2.368892815240997e-08
acid O 0 1.9774996928845212e-07
level O 0 7.1642297427843e-08
amongst O 0 5.186983287330804e-08
vertebrates O 0 1.489431951995357e-06
predicts O 0 2.021847421929124e-06
that O 0 2.8573756694072472e-08
pathological O 0 6.489585939561948e-05
missense O 0 0.00013514603779185563
mutations O 0 0.00010551808372838423
should O 0 1.3614079819035396e-07
in O 0 4.75263099986023e-08
fact O 0 3.087026811954274e-08
be O 0 1.3233954376801194e-08
common O 0 2.1868805433200578e-08
even O 0 2.749677996405353e-08
though O 0 2.1507474912141333e-08
they O 0 1.9139607676521564e-09
are O 0 9.076036588950842e-10
hardly O 0 6.282621001219013e-08
ever O 0 1.1299069058168243e-07
seen O 0 1.9529086330294376e-06
in O 0 2.5995527721534017e-06
aniridia B-Disease 1 0.999091386795044
patients O 0 0.0009573955903761089
. O 0 3.3576011446712073e-06

This O 0 1.9919768874387955e-06
indicates O 0 1.1065842500102008e-06
that O 0 2.042019708881071e-08
there O 0 7.717824601627399e-09
is O 0 9.831338410037915e-09
a O 0 2.115502439892225e-07
heavy O 0 0.00010239784751320258
ascertainment O 0 8.724138024263084e-05
bias O 0 5.984945232739847e-07
in O 0 1.522870185510783e-08
the O 0 4.558726285353032e-09
selection O 0 1.3466917359039599e-08
of O 0 1.4490863620153505e-08
patients O 0 3.2587539067208127e-07
for O 0 1.1030587998561714e-08
PAX6 O 0 5.8035013353219256e-05
mutation O 0 8.89419993654883e-07
analysis O 0 7.45042738614643e-09
and O 0 4.727179092611777e-09
that O 0 2.4840975942908017e-09
the O 0 8.117640959426353e-08
missing O 0 3.182255795763922e-06
PAX6 O 0 0.0009573331917636096
missense O 0 0.0004530245787464082
mutations O 0 0.00015843137225601822
frequently O 0 4.376493961899541e-06
may O 0 2.4575087991252076e-06
underlie O 0 1.5468922356376424e-05
phenotypes O 0 2.8910802939208224e-05
distinct O 0 1.0410893764856155e-06
from O 0 2.37207927966665e-06
textbook O 0 0.002797038061544299
aniridia B-Disease 1 0.9990087151527405
. O 0 3.610008207033388e-05

Here O 0 3.2077100513561163e-06
we O 0 7.294921289258127e-08
present O 0 5.576444550570159e-08
four O 0 8.173478249773325e-08
novel O 0 1.1608818795139086e-06
PAX6 O 0 0.0002497411041986197
missense O 0 9.041056910064071e-05
mutations O 0 2.0447698261705227e-05
, O 0 3.729707032107399e-08
two O 0 1.3844643653726507e-08
in O 0 1.9790429917065921e-07
association O 0 4.790756520378636e-07
with O 0 3.067897580422141e-07
atypical O 0 0.0004607877053786069
phenotypes O 0 0.00033895199885591865
ectopia B-Disease 0 0.0038405403029173613
pupillae I-Disease 0 0.0009516447898931801
( O 0 1.932496189738231e-07
displaced B-Disease 0 3.7603729197144276e-07
pupils I-Disease 0 7.417322080982558e-07
) O 0 4.4164661971990427e-07
and O 0 2.673642484296579e-05
congenital B-Disease 1 0.999908447265625
nystagmus I-Disease 0 0.00695476308465004
( O 0 1.9796659955773066e-07
searching B-Disease 0 3.329911066884961e-07
gaze I-Disease 0 3.6515775718726218e-06
) O 0 9.01231800298774e-09
, O 0 4.626931282558644e-09
and O 0 2.0846306902910783e-09
two O 0 6.344901937183067e-09
in O 0 1.77834866832427e-08
association O 0 1.9446178001203407e-08
with O 0 5.584317452900223e-09
more O 0 3.7849165579473265e-08
recognizable O 0 0.00021146153449080884
aniridia B-Disease 1 0.9978941082954407
phenotypes O 0 0.0018195022130385041
. O 0 9.07673438632628e-06

Strikingly O 0 5.565230458159931e-05
, O 0 2.7155508064424794e-07
all O 0 1.5836491229492822e-08
four O 0 9.144158497065291e-08
mutations O 0 4.233653783103364e-07
are O 0 2.6821205256766234e-09
located O 0 1.1794843146617495e-07
within O 0 2.6917412299098942e-08
the O 0 1.0800170713309853e-07
PAX6 O 0 2.41580910369521e-05
paired O 0 4.151700920829171e-07
domain O 0 1.0017678420126686e-07
and O 0 1.2979718633232551e-08
affect O 0 3.786281155271354e-08
amino O 0 1.3892309524976554e-08
acids O 0 8.12341394151872e-09
which O 0 1.0868789201978757e-09
are O 0 1.0799167809993904e-10
highly O 0 3.8904377497317455e-09
conserved O 0 2.3382684233297368e-08
in O 0 4.710905887606032e-09
all O 0 1.6436679795006626e-09
known O 0 6.636352622990671e-08
paired O 0 3.719661947343411e-07
domain O 0 4.5465631615115853e-07
proteins O 0 6.811439448028977e-07
. O 0 7.568550586256606e-07

Our O 0 1.769918071659049e-06
results O 0 9.728613576953649e-07
support O 0 5.791863699755595e-08
the O 0 5.6030984296739916e-08
hypothesis O 0 6.467233504281467e-08
that O 0 1.5477306103406363e-09
the O 0 2.2011661382492775e-09
under O 0 1.5279033149795396e-08
- O 0 1.067499724172194e-07
representation O 0 4.057725266903844e-09
of O 0 2.4607887283423224e-08
missense O 0 9.375456284033135e-05
mutations O 0 6.70569934300147e-05
is O 0 5.993707077323052e-07
caused O 0 2.02117848857597e-06
by O 0 5.183047235846061e-08
ascertainment O 0 4.951308073941618e-05
bias O 0 3.1356755698652705e-06
and O 0 8.660488504119712e-08
suggest O 0 7.18449584269365e-08
that O 0 4.8113761863533e-09
a O 0 5.4285965944700365e-08
substantial O 0 2.8804188900721783e-07
burden O 0 1.0901757377723698e-05
of O 0 2.343327594189759e-07
PAX6 B-Disease 0 0.22467917203903198
- I-Disease 1 0.7373108267784119
related I-Disease 0 0.0003488499787636101
disease I-Disease 1 0.9216639399528503
remains O 0 2.785681135719642e-05
to O 0 2.5417708826580565e-08
be O 0 1.1757322226912947e-07
uncovered O 0 9.558089914207812e-06
. O 0 1.4679564230846154e-07
. O 0 9.784972689885763e-07

The O 0 1.7270823491344345e-06
chromosomal O 0 0.00021770336024928838
order O 0 4.3791561665784684e-07
of O 0 4.0425398140087054e-08
genes O 0 3.4952026339851727e-07
controlling O 0 9.800178304431029e-06
the O 0 4.18385127431975e-07
major O 0 2.9616712708957493e-05
histocompatibility O 1 0.6532084941864014
complex O 0 0.0001338180445600301
, O 0 2.4444958057756594e-07
properdin O 0 3.328224192955531e-05
factor O 0 6.046273028914584e-07
B O 0 5.439227152237436e-06
, O 0 1.839607790543596e-07
and O 0 2.564493570389459e-06
deficiency B-Disease 0 0.01044634822756052
of I-Disease 0 2.8210589420041288e-09
the I-Disease 0 2.2544671907098746e-08
second I-Disease 0 1.593030702906617e-07
component I-Disease 0 2.5286672666879895e-07
of I-Disease 0 2.6537984254559888e-08
complement I-Disease 0 1.1747677035600645e-06
. O 0 1.287365989810496e-06

The O 0 3.7398157815005106e-07
relationship O 0 4.487375804274052e-07
of O 0 7.084773656629295e-09
the O 0 2.3008054128581534e-08
genes O 0 6.031298482866987e-08
coding O 0 1.593712909198075e-06
for O 0 3.98272135271327e-08
HLA O 0 2.8015829229843803e-06
to O 0 2.9200619700020525e-09
those O 0 2.656217468199884e-09
coding O 0 2.799497451633215e-07
for O 0 1.2413169159231074e-08
properdin O 0 5.107489869260462e-06
Factor O 0 1.4292886874045507e-07
B O 0 7.125328806978359e-07
allotypes O 0 4.300342880014796e-06
and O 0 8.883284152716442e-08
for O 0 5.220207413003664e-07
deficiency B-Disease 0 0.007237422280013561
of I-Disease 0 1.6254700918594267e-09
the I-Disease 0 5.40729550024821e-09
second I-Disease 0 3.463840414497099e-08
component I-Disease 0 5.442946005018712e-08
of I-Disease 0 1.9434784892524704e-09
complement I-Disease 0 7.869343221500458e-08
( O 0 5.7880210846406044e-08
C2 O 0 1.5872947187745012e-05
) O 0 6.6440253299049346e-09
was O 0 2.93935983108895e-07
studied O 0 5.68480302831631e-08
in O 0 7.1959718184189114e-09
families O 0 2.7918061196174904e-09
of O 0 1.9803261253059645e-08
patients O 0 8.720742698642425e-06
with O 0 1.5779280147398822e-05
connective O 1 0.999342143535614
tissue O 1 0.9998559951782227
disorders O 1 0.9998736381530762
. O 0 0.00010072706209030002

Patients O 0 0.00021301933156792074
were O 0 3.0140958529045747e-07
selected O 0 4.6467089731550004e-08
because O 0 1.4624586874845136e-08
they O 0 1.3368917084477516e-09
were O 0 5.101355338155145e-09
heterozygous O 0 9.19912324093275e-08
or O 0 8.46634193862883e-08
homozygous O 0 3.0206045266822912e-05
for O 0 0.00029841531068086624
C2 B-Disease 1 0.9999605417251587
deficiency I-Disease 1 0.9999527931213379
. O 0 5.2811028581345454e-05

12 O 0 2.367123670410365e-06
families O 0 5.29835411100521e-08
with O 0 2.6116634188610988e-08
15 O 0 1.2298568208279903e-07
matings O 0 3.735634663826204e-06
informative O 0 6.6925122155225836e-06
for O 0 0.002629174618050456
C2 B-Disease 1 0.9999845027923584
deficiency I-Disease 1 0.999980092048645
were O 0 5.572537702391855e-06
found O 0 5.814449195895577e-06
. O 0 1.3325972076927428e-06

Of O 0 8.149705763571546e-07
57 O 0 1.1446543339843629e-06
informative O 0 2.1620009249545546e-07
meioses O 0 1.4561395801138133e-05
, O 0 1.1342704553385374e-08
two O 0 1.883055267271061e-09
crossovers O 0 5.7570161970943445e-08
were O 0 1.6391323853781614e-08
noted O 0 1.1929382992548199e-07
between O 0 6.236975877982331e-07
the O 0 0.0014154271921142936
C2 B-Disease 1 0.9999734163284302
deficiency I-Disease 1 0.9999440908432007
gene O 0 1.4619701005358365e-06
and O 0 2.7372189848051676e-08
the O 0 1.2811926808353746e-07
HLA O 0 5.461333057610318e-05
- O 0 1.287539544136962e-05
B O 0 2.9060794304314186e-07
gene O 0 2.586253522451898e-08
, O 0 1.0203332623248684e-09
with O 0 5.895670063260638e-10
a O 0 1.1342855543716723e-08
recombinant O 0 1.993803522282178e-08
fraction O 0 2.742371485453532e-08
of O 0 1.2644075120249454e-08
0 O 0 7.817325808900932e-07
. O 0 9.817529189604102e-07

035 O 0 0.13956081867218018
. O 0 0.00017961050616577268

A O 0 9.300607416662388e-06
lod O 0 8.110015915008262e-05
score O 0 1.738111876647963e-07
of O 0 1.6680980152727898e-08
13 O 0 1.33562366499973e-07
was O 0 2.4455962943648046e-07
calculated O 0 3.156619143851458e-08
for O 0 7.412878755275187e-09
linkage O 0 1.0445389307278674e-05
between O 0 0.00042394414776936173
C2 B-Disease 1 0.9999589920043945
deficiency I-Disease 1 0.9999418258666992
and O 0 1.2418471442288137e-06
HLA O 0 0.0002227667428087443
- O 0 2.5098721380345523e-05
B O 0 2.792396855966217e-07
at O 0 2.023973166842552e-08
a O 0 9.69395674843554e-09
maximum O 0 1.0949174011898322e-08
likelihood O 0 6.380070693978723e-09
value O 0 4.750913551454516e-10
of O 0 3.549721627749136e-10
the O 0 2.207893867733901e-09
recombinant O 0 3.6230733968523055e-08
fraction O 0 4.794229724325305e-08
of O 0 2.0935930322707463e-08
0 O 0 1.0480935088708065e-06
. O 0 8.432641038780275e-07

04 O 0 0.024570371955633163
. O 0 0.00011741025082301348

18 O 0 6.10859933658503e-06
families O 0 4.823267829578981e-08
with O 0 2.9872417428578046e-08
21 O 0 5.4121791492889315e-08
informative O 0 2.1390960114331392e-08
matings O 0 2.562058796229394e-07
for O 0 6.138709096603634e-09
both O 0 1.187839426819437e-08
properdin O 0 7.022832960501546e-06
Factor O 0 1.7033789845299907e-07
B O 0 4.969872975379985e-07
allotype O 0 3.787773039221065e-06
and O 0 1.0551273277314976e-07
HLA O 0 0.00011360057396814227
- O 0 4.896692917100154e-05
B O 0 3.413579406696954e-06
were O 0 7.640216637128106e-08
found O 0 4.840501901526295e-07
. O 0 3.7470556435437175e-07

Of O 0 1.033093894875492e-06
72 O 0 1.7667509837338002e-06
informative O 0 2.559011420544266e-07
meioses O 0 2.1031537471571937e-05
, O 0 3.309597573775136e-08
three O 0 7.4353083689970845e-09
recombinants O 0 4.325172540120548e-06
were O 0 5.997526386636309e-08
found O 0 3.7392304363947915e-08
, O 0 2.1886319423458644e-09
giving O 0 2.337607440949796e-09
a O 0 8.323275402233321e-09
recombinant O 0 3.6748961207422326e-08
fraction O 0 2.3624943779054774e-08
of O 0 1.2405099170109679e-08
0 O 0 5.903502255932835e-07
. O 0 8.093675205600448e-07

042 O 0 0.02272193320095539
. O 0 0.00016660653636790812

A O 0 1.4971638847782742e-05
lod O 0 4.8848185542738065e-05
score O 0 8.025271114320276e-08
of O 0 8.872595991249455e-09
16 O 0 4.092470717864671e-08
between O 0 6.021206644390986e-08
HLA O 0 3.9290014683501795e-05
- O 0 7.471800472558243e-06
B O 0 1.655133274880427e-07
and O 0 4.630710037645258e-09
Factor O 0 2.420023825777662e-08
B O 0 1.6379985368075722e-07
allotypes O 0 8.811554721432913e-07
was O 0 1.07966904749901e-07
calculated O 0 8.630260062147954e-09
at O 0 7.80474973538503e-09
a O 0 3.2881399825157587e-09
maximum O 0 4.7140518155686095e-09
likelihood O 0 4.873702330598917e-09
value O 0 3.4276245730602284e-10
of O 0 4.317826096666977e-10
the O 0 1.5276403475539269e-09
recombinant O 0 1.937235971638529e-08
fraction O 0 3.525172331819704e-08
of O 0 1.7176583710920568e-08
0 O 0 9.178308459922846e-07
. O 0 8.414999683736823e-07

04 O 0 0.02154609188437462
. O 0 9.900306758936495e-05

A O 0 2.700952563827741e-06
crossover O 0 1.894059096230194e-06
was O 0 7.265591193572618e-06
shown O 0 4.676940790204753e-08
to O 0 1.685109829452358e-09
have O 0 9.79154757274614e-10
occurred O 0 1.261627513571284e-08
between O 0 1.6419914317111761e-09
genes O 0 3.4160023698603936e-09
for O 0 1.1851344350333193e-09
Factor O 0 2.269502630269926e-08
B O 0 2.0374916687160294e-07
and O 0 3.982774643418452e-08
HLA O 0 0.00014480605022981763
- O 0 0.0003415095270611346
D O 0 0.0026110478211194277
, O 0 1.1238538988322944e-08
in O 0 1.3454132030688015e-08
which O 0 4.945000142697609e-08
HLA O 0 6.571439007529989e-05
- O 0 0.00016384762420784682
D O 0 0.0003074416017625481
segregared O 0 5.098448582430137e-06
with O 0 1.8475371632575843e-07
HLA O 0 2.682616832316853e-05
- O 0 8.310718840220943e-06
A O 0 1.621778551452735e-06
and O 0 5.921201591263525e-07
B O 0 2.4239023332484066e-05
. O 0 1.3579500546256895e-06

These O 0 2.704257155983214e-07
studies O 0 3.2648944170432515e-07
suggest O 0 5.387152413049989e-08
that O 0 1.7887950010120335e-09
the O 0 3.755890265466633e-09
genes O 0 1.0906861191983808e-08
for O 0 5.2292978836021575e-09
Factor O 0 4.59639409200463e-07
B O 0 0.00028024037601426244
and O 0 0.0018459002021700144
C2 B-Disease 1 0.999984622001648
deficiency I-Disease 1 0.9999831914901733
are O 0 1.791089943026236e-08
located O 0 1.6563271287850512e-07
outside O 0 4.089162430886972e-08
those O 0 2.022942036106201e-09
for O 0 1.2630239965005785e-08
HLA O 0 6.926666173967533e-06
, O 0 9.081305485381108e-09
that O 0 7.119760891960425e-10
the O 0 1.5607475312151564e-09
order O 0 3.0581566168308427e-09
of O 0 4.306149214983179e-09
genese O 0 9.999721442000009e-06
is O 0 1.3294588541157282e-07
HLA O 0 3.942576313420432e-06
- O 0 1.0893004400713835e-06
A O 0 2.6656903173716273e-07
, O 0 3.7677168052141496e-08
- O 0 1.9573649296944495e-06
B O 0 8.02251406639698e-07
, O 0 6.777163008564457e-08
- O 0 1.5833607903914526e-05
D O 0 9.798946121009067e-05
, O 0 2.263312381955984e-08
Factor O 0 2.2246054243169056e-07
B O 0 6.6440161390346475e-06
allotype O 0 0.0009386666934005916
, O 0 0.001181232393719256
C2 B-Disease 1 0.9999599456787109
deficiency I-Disease 1 0.9999368190765381
, O 0 1.9061619838112165e-08
that O 0 2.324136660902809e-09
the O 0 8.80697470506675e-09
genes O 0 1.717539674928048e-07
coding O 0 2.995967042807024e-05
for O 0 0.00015702129167038947
C2 B-Disease 1 0.9999747276306152
deficiency I-Disease 1 0.9999573230743408
and O 0 1.4456044539201685e-07
Factor O 0 3.141022375530156e-07
B O 0 7.163422992562118e-07
allotypes O 0 1.5113785138964886e-06
are O 0 4.6387521601687354e-10
approximately O 0 5.781023215689629e-09
3 O 0 2.143527666476075e-08
- O 0 8.897424095266615e-07
- O 0 1.0809027344294009e-06
5 O 0 1.690770368156791e-08
centimorgans O 0 1.7458634715694643e-07
from O 0 1.9444017507197486e-09
the O 0 6.216178238815928e-09
HLA O 0 9.393250479661219e-07
- O 0 5.242373504188436e-07
A O 0 1.1211225370288957e-07
and O 0 4.097860184515412e-08
HLA O 0 1.0721439139160793e-05
- O 0 6.157325515232515e-06
B O 0 2.5429304173485434e-07
loci O 0 1.844125030459054e-08
, O 0 4.631292682688581e-09
and O 0 1.6831439575426543e-09
that O 0 1.455778608772107e-09
the O 0 1.1965987312123616e-08
apparent O 0 3.265794248363818e-07
lack O 0 2.371315943605623e-08
of O 0 2.6238851091875404e-09
recombinants O 0 7.376069675046892e-07
between O 0 8.1514919259007e-09
the O 0 2.75682516814868e-08
Factor O 0 1.9272121676294773e-07
B O 0 5.162956767890137e-06
gene O 0 5.911693733651191e-06
and O 0 0.00027676098397932947
C2 B-Disease 1 0.9999847412109375
deficiency I-Disease 1 0.999982476234436
gene O 0 1.1675107998598833e-05
suggests O 0 1.1792661069875976e-07
that O 0 8.450507515966876e-10
these O 0 1.7807839924888214e-10
two O 0 2.6211688375354925e-09
genes O 0 2.268489929235784e-08
lie O 0 1.0764716051880896e-07
in O 0 9.962094260629328e-09
close O 0 4.2879893413783066e-08
proximity O 0 9.898042918621286e-08
to O 0 1.1316405590378054e-08
one O 0 6.153000953190713e-08
another O 0 5.222069603405544e-07
. O 0 5.720467584069411e-07

Distribution O 0 3.029963863809826e-06
of O 0 2.3836325624415622e-07
emerin O 0 0.00010973939060932025
and O 0 5.476152864503092e-07
lamins O 0 0.00015678310592193156
in O 0 4.251874088367913e-07
the O 0 9.795943469725898e-07
heart O 0 0.0006025645416229963
and O 0 7.887856412480687e-08
implications O 0 1.188616579383961e-06
for O 0 5.390882620304183e-07
Emery B-Disease 0 0.00861405674368143
- I-Disease 1 0.9961961507797241
Dreifuss I-Disease 1 0.99837327003479
muscular I-Disease 1 0.9996115565299988
dystrophy I-Disease 1 0.9994307160377502
. O 0 7.197115337476134e-05

Emerin O 0 0.0007845512591302395
is O 0 9.336342827737099e-07
a O 0 2.914088952366001e-07
nuclear O 0 3.544959781720536e-06
membrane O 0 1.2187292668386362e-06
protein O 0 3.8233073951232655e-07
which O 0 2.582275726581429e-08
is O 0 1.878959210444009e-08
missing O 0 6.784431150208547e-08
or O 0 3.027254535936663e-08
defective O 0 8.481658369419165e-06
in O 0 1.5359291865024716e-06
Emery B-Disease 0 0.010640718042850494
- I-Disease 1 0.9973872303962708
Dreifuss I-Disease 1 0.9986116886138916
muscular I-Disease 1 0.9997724890708923
dystrophy I-Disease 1 0.9998764991760254
( O 0 0.00013436070003081113
EDMD B-Disease 1 0.9995521903038025
) O 0 8.741358215047512e-06
. O 0 3.860594915749971e-06

It O 0 8.155739124049433e-07
is O 0 4.010499310425075e-08
one O 0 6.658969819994809e-09
member O 0 8.739737822338611e-09
of O 0 1.7523038575717464e-09
a O 0 1.2925175951750134e-07
family O 0 2.5507807777103153e-07
of O 0 3.8239118538285766e-08
lamina O 0 0.03697291761636734
- O 0 0.00023945160501170903
associated O 0 2.4027355038924725e-07
proteins O 0 9.333475325945528e-09
which O 0 4.02788380426955e-09
includes O 0 1.8188064387913983e-08
LAP1 O 0 5.165462425793521e-05
, O 0 9.13138364921906e-08
LAP2 O 0 7.266450120368972e-05
and O 0 9.347032801088062e-07
lamin O 0 0.00048364410758949816
B O 0 0.0003794762887991965
receptor O 0 0.0002550484787207097
( O 0 3.472676553428755e-06
LBR O 0 0.007452738005667925
) O 0 1.4574708302461659e-06
. O 0 3.634401309682289e-06

A O 0 1.3728798876400106e-05
panel O 0 1.4516501778416568e-06
of O 0 3.538740145359043e-08
16 O 0 3.3530912446622096e-07
monoclonal O 0 7.17752357104473e-07
antibodies O 0 4.936838990943215e-07
( O 0 2.1219070944766827e-08
mAbs O 0 4.98207327837008e-07
) O 0 1.755435796724214e-08
has O 0 4.452565249835061e-08
been O 0 1.2355745759862202e-08
mapped O 0 3.037185081211646e-08
to O 0 3.892543509742552e-10
six O 0 1.4831101902146315e-09
specific O 0 4.170987166762785e-10
sites O 0 4.468864833739872e-09
throughout O 0 1.1194041249495967e-08
the O 0 7.915962108029362e-09
emerin O 0 6.974291295591684e-07
molecule O 0 3.656486669001424e-08
using O 0 1.7826241816010224e-08
phage O 0 4.0383059740634053e-07
- O 0 4.95493225116661e-07
displayed O 0 6.018244391725602e-08
peptide O 0 8.669181994491737e-08
libraries O 0 1.0180206011511927e-08
and O 0 9.585386706589816e-09
has O 0 1.3923558306316863e-08
been O 0 2.714269697889904e-09
used O 0 1.4312474538868969e-09
to O 0 1.2567538121288635e-09
localize O 0 5.856002189830178e-07
emerin O 0 1.530612826172728e-05
in O 0 6.237606697823139e-08
human O 0 1.571863919025418e-07
and O 0 1.7611944258533185e-06
rabbit O 0 0.0039223129861056805
heart O 1 0.613824725151062
. O 0 9.326427971245721e-06

Several O 0 3.440434511503554e-06
mAbs O 0 4.1989995224867016e-05
against O 0 5.572998134084628e-07
different O 0 8.713642785096454e-08
emerin O 0 0.0002685801009647548
epitopes O 0 4.794729466084391e-05
did O 0 2.0258123356597935e-07
not O 0 4.920235330274636e-09
recognize O 0 4.2698626856463306e-08
intercalated O 0 6.070735594221333e-07
discs O 0 8.263972972599731e-07
in O 0 6.799899665566045e-08
the O 0 5.526165978153585e-07
heart O 0 0.008944207802414894
, O 0 4.212959225924351e-08
though O 0 3.194498532366197e-08
they O 0 2.8343376534678555e-09
recognized O 0 3.485478927700569e-08
cardiomyocyte O 0 2.5902825200319057e-06
nuclei O 0 1.7226246029622416e-07
strongly O 0 4.4961058875969684e-08
, O 0 3.3859490766730005e-09
both O 0 2.3149124839250135e-09
at O 0 7.907813710517075e-07
the O 0 3.811932813846397e-08
rim O 0 3.7690469412154926e-07
and O 0 1.6225035537331678e-08
in O 0 2.8919510342007015e-08
intranuclear O 0 9.959339877241291e-06
spots O 0 6.731005441906746e-07
or O 0 1.2063487986324617e-07
channels O 0 1.4001396948515321e-06
. O 0 2.0677994143625256e-06

A O 0 8.16713654785417e-05
polyclonal O 0 0.0005258404416963458
rabbit O 0 0.00025938445469364524
antiserum O 0 0.0003810951311606914
against O 0 2.2571690351469442e-05
emerin O 0 0.0005481374100781977
did O 0 6.090417628001887e-07
recognize O 0 9.339889572856919e-08
both O 0 2.5880989795723508e-08
nuclear O 0 6.710381057928316e-06
membrane O 0 1.2517434697656427e-06
and O 0 9.806358747255217e-08
intercalated O 0 6.467433195211925e-06
discs O 0 2.0315576421126025e-06
but O 0 2.2360950424626935e-08
, O 0 3.797555159223975e-09
after O 0 1.4742044918136799e-08
affinity O 0 1.4240539414345221e-08
purification O 0 2.1468851230110886e-07
against O 0 3.321150998658595e-08
a O 0 7.285633074616271e-08
pure O 0 1.1423649937114533e-07
- O 0 6.025922175467713e-06
emerin O 0 2.3898473955341615e-06
band O 0 3.2477521472173976e-07
on O 0 1.8627446252139634e-08
a O 0 4.190512115087586e-08
western O 0 9.170497605737182e-08
blot O 0 6.257439508772222e-06
, O 0 2.8670712026723777e-08
it O 0 6.358082504931417e-09
stained O 0 6.3127440625976305e-06
only O 0 9.322017824331397e-09
the O 0 7.273192892398583e-08
nuclear O 0 3.1950105039868504e-05
membrane O 0 1.917055487865582e-05
. O 0 1.4019219634064939e-06

These O 0 3.437078817114525e-07
results O 0 1.7684653812466422e-06
would O 0 6.369130289840541e-08
not O 0 5.759088761436715e-09
be O 0 4.627707994586672e-09
expected O 0 1.8486012720586587e-08
if O 0 8.792723882322662e-09
immunostaining O 0 3.0216071991162607e-06
at O 0 4.672411364481377e-07
intercalated O 0 1.5302738347600098e-06
discs O 0 3.4350537703176087e-07
were O 0 1.4824209415564837e-08
due O 0 2.1371263869696122e-08
to O 0 5.413143822075028e-10
a O 0 7.873889096288167e-09
product O 0 5.3465214477910195e-09
of O 0 5.500948030423558e-10
the O 0 7.005426461148545e-09
emerin O 0 2.178426939281053e-06
gene O 0 4.85537050565199e-08
and O 0 1.5605399639184725e-08
, O 0 1.4193573427689898e-08
therefore O 0 1.1275684386191642e-08
, O 0 4.670181574795151e-09
cast O 0 6.944362862526532e-09
some O 0 1.112736347508303e-09
doubt O 0 1.0754449775163266e-08
upon O 0 2.325342807196762e-09
the O 0 1.848319008956878e-08
hypothesis O 0 2.6686154797062045e-07
that O 0 2.1246533776775323e-07
cardiac B-Disease 1 0.8749476671218872
defects I-Disease 1 0.9476169943809509
in O 0 1.4435063349083066e-05
EDMD B-Disease 1 0.999893069267273
are O 0 1.101326887464893e-07
caused O 0 4.106321284780279e-06
by O 0 1.6887272025201128e-08
absence O 0 1.639824063204287e-07
of O 0 1.6483056697325082e-08
emerin O 0 0.0001738979626679793
from O 0 3.593789017486415e-07
intercalated O 0 0.00016106283874250948
discs O 0 5.942558345850557e-05
. O 0 2.7066460006608395e-06

Although O 0 9.790118383534718e-06
emerin O 0 0.00019498523033689708
was O 0 4.583473128150217e-06
abundant O 0 4.647772655630433e-08
in O 0 8.698195941292397e-09
the O 0 2.484907835054173e-09
membranes O 0 2.2560269030691416e-07
of O 0 1.2552763273276923e-08
cardiomyocyte O 0 2.8107138859922998e-05
nuclei O 0 1.989520342249307e-06
, O 0 6.889825243661107e-08
it O 0 2.727494319287871e-08
was O 0 1.2316191941863508e-06
absent O 0 1.0967194441491301e-07
from O 0 3.181338525948263e-09
many O 0 8.687182639910418e-10
non O 0 1.279727257497143e-07
- O 0 2.2559381250175647e-05
myocyte O 0 6.712334288749844e-05
cells O 0 1.047141381604888e-06
in O 0 7.874132990082217e-08
the O 0 5.282753932078776e-07
heart O 0 0.009764363057911396
. O 0 2.2251601876632776e-06

This O 0 1.931116457853932e-07
distribution O 0 1.5641731465620978e-07
of O 0 3.167396656067467e-08
emerin O 0 0.00014916469808667898
was O 0 1.404661907145055e-05
similar O 0 1.4101288137169377e-08
to O 0 1.415738970500513e-09
that O 0 1.4846923690470248e-09
of O 0 4.3426058304874005e-09
lamin O 0 2.700290906432201e-06
A O 0 1.2056316336384043e-06
, O 0 1.8816702862523016e-08
a O 0 1.0958516583059463e-07
candidate O 0 1.4643516976775572e-07
gene O 0 4.8635829585919055e-08
for O 0 4.865510216944813e-09
an O 0 8.113477178994799e-08
autosomal O 0 0.00020621805742848665
form O 0 2.904479970311513e-06
of O 0 5.262627837510081e-06
EDMD B-Disease 1 0.9997383952140808
. O 0 3.835340976365842e-05

In O 0 3.6630246995628113e-06
contrast O 0 5.373521617002552e-06
, O 0 2.329225026187487e-06
lamin O 0 0.003064459655433893
B1 O 1 0.6292498707771301
was O 0 5.233854244579561e-05
absent O 0 1.1005904525518417e-06
from O 0 2.3119969938534268e-08
cardiomyocyte O 0 5.065578989160713e-06
nuclei O 0 8.583310773246922e-07
, O 0 6.84239154224997e-08
showing O 0 1.3711506881008972e-06
that O 0 2.2808882249591989e-07
lamin O 0 0.0007651314954273403
B1 O 0 0.05226067453622818
is O 0 5.2567212804888186e-08
not O 0 8.340020896113742e-10
essential O 0 1.8826100678381863e-09
for O 0 1.8839534376979827e-09
localization O 0 7.123488643401288e-08
of O 0 1.2941105964614508e-08
emerin O 0 9.522751497570425e-06
to O 0 3.212805310681688e-08
the O 0 9.93071694210812e-07
nuclear O 0 0.001797882025130093
lamina O 0 0.026291508227586746
. O 0 7.437959538947325e-06

Lamin O 0 0.4776858687400818
B1 O 1 0.9850032925605774
is O 0 6.056514394003898e-06
also O 0 1.9817797181076457e-07
almost O 0 8.308528265388304e-08
completely O 0 1.8810926576406928e-06
absent O 0 2.699958486118703e-06
from O 0 8.973502758635732e-07
skeletal O 0 0.022557606920599937
muscle O 0 0.013425121083855629
nuclei O 0 0.0002534179075155407
. O 0 6.959667643968714e-06

In O 0 2.999403113790322e-05
EDMD B-Disease 1 0.9939828515052795
, O 0 2.801404264118901e-07
the O 0 1.6619877030166208e-08
additional O 0 1.298878338218401e-08
absence O 0 3.152516114823811e-07
of O 0 5.273572156738737e-08
lamin O 0 0.0014472935581579804
B1 O 0 0.3814108073711395
from O 0 4.1872308429447e-06
heart O 0 0.2337259203195572
and O 0 6.381865205185022e-06
skeletal O 0 0.22055235505104065
muscle O 0 0.003042037831619382
nuclei O 0 3.2537212973693386e-05
which O 0 5.144979127180704e-07
already O 0 1.0560187320152181e-06
lack O 0 4.902205432699702e-07
emerin O 0 0.00038233399391174316
may O 0 4.331006948632421e-07
offer O 0 1.1172070379927845e-08
an O 0 4.724186819515808e-09
alternative O 0 4.285143972992955e-08
explanation O 0 1.632262502937465e-08
of O 0 5.510738088077005e-09
why O 0 2.8876627311547054e-08
these O 0 3.043521656920234e-09
tissues O 0 9.508834750704409e-07
are O 0 1.154821038795717e-08
particularly O 0 3.924237432784139e-07
affected O 0 6.019197940076992e-07
. O 0 1.7782018346679251e-07
. O 0 7.636092504981207e-07

Genetic O 0 4.598824307322502e-05
mapping O 0 5.930830411671195e-06
of O 0 1.597000789388403e-07
the O 0 1.3718831723963376e-06
copper B-Disease 0 0.0037916479632258415
toxicosis I-Disease 0 0.04371098801493645
locus O 0 2.2245161744649522e-05
in O 0 4.3350109990569763e-07
Bedlington O 0 0.00010100985673489049
terriers O 0 4.0806655306369066e-05
to O 0 3.3792083797834493e-08
dog O 0 1.8017457477981225e-05
chromosome O 0 4.7027306209201925e-06
10 O 0 4.638474138118909e-08
, O 0 9.409101053847735e-09
in O 0 1.252934467288469e-08
a O 0 3.1045169635035563e-07
region O 0 1.0457501957716886e-06
syntenic O 0 6.642286280111875e-06
to O 0 2.2336866578598347e-08
human O 0 1.7488446246716194e-07
chromosome O 0 9.336198672826868e-06
region O 0 3.0024191346456064e-06
2p13 O 0 4.3761323468061164e-05
- O 0 0.00042301727808080614
p16 O 0 3.9808826841181144e-05
. O 0 2.408891987215611e-06

Abnormal O 1 0.9821622967720032
hepatic B-Disease 1 0.9990271329879761
copper I-Disease 1 0.9950718283653259
accumulation I-Disease 0 0.007495656609535217
is O 0 3.1009358281153254e-06
recognized O 0 8.44485782636184e-07
as O 0 8.531358730579086e-07
an O 0 0.00016781617887318134
inherited B-Disease 1 0.9999929666519165
disorder I-Disease 1 0.9999963045120239
in O 0 8.425900887232274e-05
man O 0 0.0003442336746957153
, O 0 3.8809386637694843e-07
mouse O 0 9.087144462682772e-06
, O 0 2.564209751199087e-07
rat O 0 0.00021502278104890138
and O 0 2.8890792691527167e-07
dog O 0 0.0002640834718476981
. O 0 1.8185933186032344e-06

The O 0 4.074136541021289e-06
major O 0 3.1176419724943116e-05
cause O 0 8.042413537623361e-05
of O 0 1.658244173086132e-06
hepatic B-Disease 1 0.9979506134986877
copper I-Disease 1 0.7931260466575623
accumulation I-Disease 0 0.0006331545882858336
in O 0 1.8136191783924005e-06
man O 0 2.1411513444036245e-05
is O 0 1.4862123975944996e-07
a O 0 1.0560529517533723e-06
dysfunctional O 0 0.0003747184236999601
ATP7B O 0 0.0018696024781093001
gene O 0 3.217127959942445e-05
, O 0 3.7086249449203024e-06
causing O 0 0.006821127142757177
Wilson B-Disease 0 0.4669454097747803
disease I-Disease 1 0.9984031319618225
( O 0 9.391939784109127e-06
WD B-Disease 1 0.9818339943885803
) O 0 2.544267545090406e-06
. O 0 3.1139215934672393e-06

Mutations O 0 0.00023761896591167897
in O 0 3.7330522673073574e-07
the O 0 1.0104879066830108e-07
ATP7B O 0 8.438090299023315e-05
genes O 0 4.927351824335346e-07
have O 0 1.6105467182114808e-08
also O 0 2.151198685851341e-08
been O 0 4.355614890982906e-08
demonstrated O 0 9.480098839276252e-08
in O 0 8.62144489133243e-08
mouse O 0 4.8129759306903e-06
and O 0 5.432490297607728e-07
rat O 0 0.0019469972467049956
. O 0 1.7123026054832735e-06

The O 0 2.091838268825086e-06
ATP7B O 0 0.0002707911189645529
gene O 0 5.538809546123957e-06
has O 0 4.4488345452009526e-07
been O 0 3.91166032898127e-08
excluded O 0 4.168906997392696e-08
in O 0 7.119628442353587e-09
the O 0 3.394225567276976e-09
much O 0 2.274885169128993e-08
rarer O 0 6.709485660394421e-06
human O 0 2.8331826342764543e-06
copper B-Disease 0 0.2530503273010254
overload I-Disease 1 0.5856391191482544
disease O 1 0.5598850250244141
non B-Disease 0 1.2147875168011524e-05
- I-Disease 0 0.0008165104663930833
Indian I-Disease 0 3.459151002971339e-06
childhood I-Disease 0 0.026925304904580116
cirrhosis I-Disease 1 0.9988351464271545
, O 0 1.1832986501758569e-06
indicating O 0 1.3939887139713392e-05
genetic O 0 7.157774234656245e-05
heterogeneity O 0 0.0002491493651177734
. O 0 1.2202238394820597e-05

By O 0 1.2456630429369397e-06
investigating O 0 1.041829091263935e-05
the O 0 7.091629754540918e-07
common O 0 3.334711436764337e-05
autosomal O 1 0.9968133568763733
recessive O 1 0.9992780089378357
copper B-Disease 1 0.9989377856254578
toxicosis I-Disease 1 0.9964123368263245
( O 0 2.110920604536659e-06
CT B-Disease 0 0.006228271406143904
) O 0 3.60636782659185e-08
in O 0 3.464025155608397e-08
Bedlington O 0 1.1565122804313432e-05
terriers O 0 4.195580550003797e-05
, O 0 2.246333075106577e-08
we O 0 1.7926271578261321e-09
have O 0 6.307950828343678e-10
identified O 0 6.302253385825907e-09
a O 0 1.1853476422629683e-08
new O 0 4.3346801703592064e-08
locus O 0 1.5307292642319226e-06
involved O 0 1.017608838083106e-06
in O 0 4.402242484502494e-05
progressive O 1 0.9996138215065002
liver B-Disease 1 0.999995231628418
disease I-Disease 1 0.9999829530715942
. O 0 0.00029911717865616083

We O 0 3.4710310501395725e-06
examined O 0 5.997743301122682e-06
whether O 0 7.083992414891327e-08
the O 0 1.306169110648625e-07
WD B-Disease 0 0.008369099348783493
gene O 0 1.016065198200522e-05
ATP7B O 0 0.0008462052792310715
was O 0 1.6006531950552016e-05
also O 0 4.744361703501454e-08
causative O 0 8.022284987418971e-07
for O 0 4.320713742345106e-08
CT B-Disease 0 0.0005337106413207948
by O 0 4.755859350780156e-08
investigating O 0 1.1648733106994769e-06
the O 0 2.0450490012535738e-07
chromosomal O 0 0.00031757564283907413
co O 0 2.9497849027393386e-05
- O 0 5.768073606304824e-06
localization O 0 6.999618449299305e-07
of O 0 2.0395829025687817e-08
ATP7B O 0 2.5695764634292573e-05
and O 0 4.1159786690059263e-08
C04107 O 0 4.23390446258054e-07
, O 0 3.971901474386641e-09
using O 0 6.32238394970841e-09
fluorescence O 0 2.6220632776130515e-07
in O 0 8.906798854013687e-08
situ O 0 5.186456291994546e-06
hybridization O 0 4.4074033667129697e-07
( O 0 3.8198663787625264e-08
FISH O 0 3.952429210585251e-07
) O 0 1.6759058496518264e-07
. O 0 7.801908736837504e-07

C04107 O 0 0.0008175004040822387
is O 0 1.088377302949084e-06
an O 0 1.4561548766778287e-07
anonymous O 0 1.2559968354253215e-06
microsatellite O 0 3.5299992305226624e-05
marker O 0 1.090750902221771e-05
closely O 0 1.6952676560322288e-06
linked O 0 2.8021708203596063e-05
to O 0 5.85478460379818e-07
CT B-Disease 0 0.4384605586528778
. O 0 6.6284223976254e-06

However O 0 1.1444162737461738e-05
, O 0 1.5092108469616505e-06
BAC O 0 7.669485785299912e-05
clones O 0 2.2678402729070513e-06
containing O 0 3.234578400679311e-07
ATP7B O 0 0.00017891806783154607
and O 0 1.4080545440720016e-07
C04107 O 0 2.222172270194278e-06
mapped O 0 8.773945978646225e-07
to O 0 5.66535973689497e-09
the O 0 6.218457571094405e-08
canine O 0 7.306026964215562e-05
chromosome O 0 1.7036847566487268e-05
regions O 0 2.669032710400643e-07
CFA22q11 O 0 8.580776921007782e-06
and O 0 4.9729401041531673e-08
CFA10q26 O 0 1.0241220479656477e-05
, O 0 2.3846689956030787e-08
respectively O 0 7.686433889375621e-08
, O 0 1.7990263501133086e-08
demonstrating O 0 1.411149099794784e-07
that O 0 9.524048039111221e-08
WD B-Disease 0 0.006722679827362299
cannot O 0 1.9707860587914183e-07
be O 0 2.1003405237252082e-08
homologous O 0 3.5085110994259594e-07
to O 0 1.6046693929183675e-07
CT B-Disease 0 0.01821591518819332
. O 0 3.58569332092884e-06

The O 0 3.081619979639072e-06
copper O 0 9.612368739908561e-05
transport O 0 1.7450224731874187e-06
genes O 0 9.82050664788403e-07
CTR1 O 0 3.0476265237666667e-05
and O 0 8.776944326882585e-08
CTR2 O 0 0.00012205033999634907
were O 0 8.659068129190928e-08
also O 0 3.110585922172504e-08
excluded O 0 3.677981297300903e-08
as O 0 8.704071241538713e-09
candidate O 0 2.8355071179930746e-08
genes O 0 1.0155014606993973e-08
for O 0 1.6875969066632024e-08
CT B-Disease 0 0.0007443162030540407
since O 0 2.590757048892556e-07
they O 0 1.0432077424127328e-09
both O 0 1.7303468657914323e-09
mapped O 0 2.554298248469422e-07
to O 0 2.8900430493195017e-08
canine O 0 0.0004313129174988717
chromosome O 0 0.00029150702175684273
region O 0 2.6454643375473097e-05
CFA11q22 O 0 0.0016791231464594603
. O 0 3.658744617496268e-06

2 O 0 0.0001592668704688549
- O 0 0.0009103284101001918
22 O 0 2.3316973965847865e-05
. O 0 2.9290667953318916e-06

5 O 0 0.00014030742750037462
. O 0 3.321381154819392e-05

A O 0 9.043891623150557e-06
transcribed O 0 4.18345507569029e-06
sequence O 0 7.222485010061064e-07
identified O 0 1.3688209321571776e-07
from O 0 8.004019669272111e-09
the O 0 2.176199487280428e-08
C04107 O 0 2.1815724267071346e-06
- O 0 2.7746402793127345e-06
containing O 0 1.4072598730763275e-07
BAC O 0 2.389614746789448e-05
was O 0 2.0366653643577592e-06
found O 0 8.782349070202145e-09
to O 0 2.7085897413847704e-10
be O 0 1.1409898581504763e-09
homologous O 0 4.761584015966491e-09
to O 0 6.225951976190913e-10
a O 0 1.6705657301940846e-08
gene O 0 3.79405271644373e-08
expressed O 0 9.786735866157414e-09
from O 0 6.5317808939369115e-09
human O 0 2.072863836133365e-08
chromosome O 0 1.7217245158462902e-06
2p13 O 0 2.154037474610959e-06
- O 0 4.929348961013602e-06
p16 O 0 3.7569421351690835e-07
, O 0 1.1816320366619948e-08
a O 0 4.4085211925448675e-08
region O 0 9.045869830970332e-08
devoid O 0 5.6229904288329635e-08
of O 0 2.2651682751728686e-09
any O 0 6.914361527776691e-09
positional O 0 1.853436174314993e-06
candidate O 0 4.132666163059184e-06
genes O 0 3.333124595883419e-06
. O 0 1.7378314396410133e-06

Molecular O 0 2.5628198272897862e-05
analysis O 0 2.651041768331197e-07
of O 0 2.674770449573316e-08
the O 0 5.93668296744454e-08
APC B-Disease 0 2.0440049866010668e-06
gene O 0 3.329129754092719e-07
in O 0 1.7342831171163198e-08
205 O 0 5.4701509100141266e-08
families O 0 6.312611766645659e-09
: O 0 5.756508159038276e-09
extended O 0 1.0881432643827793e-07
genotype O 0 1.7515280887892004e-06
- O 0 1.8105698472936638e-05
phenotype O 0 1.6815841945572174e-06
correlations O 0 3.229356764222757e-07
in O 0 9.738771922229716e-08
FAP B-Disease 0 2.257146888950956e-06
and O 0 6.300498789357789e-09
evidence O 0 3.1904414665717695e-09
for O 0 6.907015515089654e-10
the O 0 2.1890704804405914e-09
role O 0 2.7609088348867772e-08
of O 0 8.14968803553029e-09
APC B-Disease 0 3.487542016955558e-06
amino O 0 4.2929565324811847e-07
acid O 0 7.898363946878817e-06
changes O 0 5.992420483380556e-06
in O 0 0.008477550931274891
colorectal B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999961853027344
predisposition O 1 0.9943801760673523
. O 0 6.86438288539648e-05

BACKGROUND O 0 5.8517725847195834e-05
/ O 0 1.5629144400008954e-05
AIMS O 0 3.2240443488262827e-06
The O 0 4.4875727667204046e-07
development O 0 6.19708998783608e-06
of O 0 0.018893500789999962
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999972581863403
and O 0 7.043331038403267e-07
a O 0 3.5868006875716674e-07
variable O 0 6.398682330654992e-07
range O 0 1.1155360368775291e-07
of O 0 6.973220934014535e-08
extracolonic O 0 0.0003308919258415699
manifestations O 0 0.0003083221963606775
in O 0 0.0008500014082528651
familial B-Disease 1 0.9999231100082397
adenomatous I-Disease 1 0.9998273849487305
polyposis I-Disease 1 0.9999476671218872
( O 0 5.408086144598201e-05
FAP B-Disease 0 0.0012745725689455867
) O 0 1.3253206532226613e-07
is O 0 3.2373861813539406e-08
the O 0 7.702103843598707e-09
result O 0 2.3405442917123764e-08
of O 0 1.9260273376175974e-09
the O 0 6.897661819493806e-08
dominant O 0 2.538236731197685e-05
inheritance O 0 0.0005160836153663695
of O 0 0.00031759991543367505
adenomatous B-Disease 1 0.9998809099197388
polyposis I-Disease 1 0.999760091304779
coli I-Disease 1 0.9994844198226929
( O 0 6.367979949573055e-06
APC B-Disease 0 0.00017696571012493223
) O 0 1.0273619182044058e-06
gene O 0 4.1317263821838424e-05
mutations O 0 0.00024674893938936293
. O 0 6.139687229733681e-06

In O 0 1.6496288708367501e-06
this O 0 4.2747682726940184e-08
study O 0 2.1299113583950202e-08
, O 0 2.405957655327029e-09
direct O 0 4.073948733918087e-09
mutation O 0 9.295335701153817e-08
analysis O 0 2.9445477167655554e-09
of O 0 9.84337944487379e-10
the O 0 1.1376005026875191e-08
APC B-Disease 0 4.80780101952405e-07
gene O 0 1.1734996263612629e-07
was O 0 4.79724405977322e-07
performed O 0 3.632137790532397e-08
to O 0 1.8231157694614808e-09
determine O 0 3.128089787196586e-08
genotype O 0 1.1806710062955972e-06
- O 0 6.9561106101900805e-06
phenotype O 0 5.813096208839852e-07
correlations O 0 9.062586059371824e-08
for O 0 8.545558927153252e-09
nine O 0 9.550971213911907e-08
extracolonic O 0 1.533256727270782e-05
manifestations O 0 1.4937861578800948e-06
and O 0 2.0659879140794146e-08
to O 0 4.915920115422523e-09
investigate O 0 1.1172330971476185e-07
the O 0 9.792621114002031e-08
incidence O 0 1.4772473150514998e-05
of O 0 4.9790525480375436e-08
APC B-Disease 0 3.637647387222387e-05
mutations O 0 1.5378493117168546e-05
in O 0 2.387778749834979e-06
non O 0 0.003388629760593176
- O 1 0.9997307658195496
FAP O 1 0.9994099140167236
colorectal B-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9999825954437256
. O 0 0.0001578860537847504

METHODS O 0 3.092654424108332e-06
The O 0 3.231158984817739e-07
APC B-Disease 0 1.0186508916376624e-05
gene O 0 1.4533152352669276e-06
was O 0 1.2062664609402418e-06
analysed O 0 2.28438651106444e-07
in O 0 2.409825938798349e-08
190 O 0 5.493089716424038e-08
unrelated O 0 6.110955155236297e-07
FAP B-Disease 0 6.941081210243283e-06
and O 0 5.861768670456513e-08
15 O 0 1.588567329235957e-06
non O 0 0.0003240892547182739
- O 1 0.9997095465660095
FAP O 1 0.9996453523635864
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999971389770508
patients O 0 0.0001699704007478431
using O 0 4.2027909330499824e-07
denaturing O 0 0.00019118012278340757
gradient O 0 3.129145625280216e-05
gel O 0 1.9906794477719814e-05
electrophoresis O 0 2.4100111204461427e-06
, O 0 8.488797220707056e-09
the O 0 2.2551582823382432e-09
protein O 0 2.466305026871396e-08
truncation O 0 2.7338441555002646e-07
test O 0 4.4782698438439184e-08
, O 0 1.754156375710636e-09
and O 0 6.969810839585477e-10
direct O 0 2.6343368375592036e-08
sequencing O 0 1.4161765875542187e-06
. O 0 9.96272206066351e-07

RESULTS O 0 7.096321496646851e-05
Chain O 0 1.1404590622987598e-05
terminating O 0 2.001673692575423e-06
signals O 0 6.62656816530216e-07
were O 0 2.21171791991992e-08
only O 0 9.257892230607467e-09
identified O 0 3.1847952186581097e-07
in O 0 1.6442449179976393e-07
patients O 0 3.5863186553797277e-07
belonging O 0 1.090959074190323e-07
to O 0 4.415453336292785e-09
the O 0 3.1278040069082635e-07
FAP B-Disease 0 5.959833652013913e-05
group O 0 3.6483436360867927e-07
( O 0 4.7068485997669995e-08
105 O 0 1.258553083971492e-06
patients O 0 1.527215317764785e-05
) O 0 2.1811783312841726e-07
. O 0 8.392302675019891e-07

Amino O 0 2.2304047888610512e-05
acid O 0 1.0147105058422312e-05
changes O 0 1.7642949501350813e-07
were O 0 3.47293003244431e-08
identified O 0 1.205696662509581e-07
in O 0 1.9147249119555454e-08
four O 0 6.759064063999176e-08
patients O 0 2.7485830855766835e-07
, O 0 3.4260836390132e-09
three O 0 1.328333665284731e-09
of O 0 1.4713609219896284e-09
whom O 0 4.925345464812381e-08
belonged O 0 1.7781562178242893e-07
to O 0 1.905324786832807e-09
the O 0 2.483127659047568e-08
non O 0 4.596972758008633e-07
- O 0 0.0001966615382116288
FAP O 0 0.0001100192530429922
group O 0 1.805462670745328e-05
of O 0 0.0009311434114351869
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999970197677612
patients O 1 0.769472062587738
. O 0 3.410668432479724e-05

Genotype O 0 0.003172942204400897
- O 0 0.00471179885789752
phenotype O 0 0.0002332734875380993
correlations O 0 9.618448530090973e-06
identified O 0 1.5558491668343777e-06
significant O 0 1.1510248754120767e-07
differences O 0 5.359925694392587e-07
in O 0 1.9547816521026107e-07
the O 0 3.071673759791338e-08
nature O 0 4.703384348658801e-08
of O 0 4.124582009268352e-09
certain O 0 2.3447533692433353e-08
extracolonic O 0 6.774570647394285e-05
manifestations O 0 1.8475599063094705e-05
in O 0 6.3597867665521335e-06
FAP B-Disease 0 0.0005720758344978094
patients O 0 4.7980129238567315e-06
belonging O 0 2.1449798737194214e-07
to O 0 1.3912780261193802e-08
three O 0 3.3820529665717913e-07
mutation O 0 2.7875572413904592e-05
subgroups O 0 1.229127974511357e-05
. O 0 2.8627437131945044e-06

CONCLUSIONS O 0 1.6189280358958058e-05
Extended O 0 5.3230819503369275e-06
genotype O 0 9.533278353046626e-05
- O 0 0.00011666920181596652
phenotype O 0 6.596495040867012e-06
correlations O 0 4.028101443509513e-07
made O 0 7.184139150240298e-08
in O 0 5.4459885490132365e-08
this O 0 1.1897600238341965e-08
study O 0 2.675454169320801e-08
may O 0 2.2632734797412013e-08
have O 0 4.939414433025036e-10
the O 0 1.4742458365191169e-09
potential O 0 6.008423980574662e-09
to O 0 5.324770069314866e-10
determine O 0 3.494456946029345e-09
the O 0 2.9047637628565326e-09
most O 0 1.067808286236982e-09
appropriate O 0 2.6292004129402358e-09
surveillance O 0 2.551982731802127e-07
and O 0 1.7360104465069526e-08
prophylactic O 0 8.278571840492077e-06
treatment O 0 2.719844997045584e-05
regimens O 0 4.9991681407846045e-06
for O 0 6.191684054357438e-09
those O 0 1.3271061582997845e-08
patients O 0 1.8230268494789925e-07
with O 0 3.269586201781749e-08
mutations O 0 3.4296990634175017e-06
associated O 0 3.1903616104500543e-07
with O 0 2.56636269568844e-07
life O 0 4.9092137487605214e-05
threatening O 0 0.012218430638313293
conditions O 0 0.005175244994461536
. O 0 5.910126219532685e-06

This O 0 2.866585475658212e-07
study O 0 1.3899258988203655e-07
also O 0 1.7193659829217722e-08
provided O 0 9.750309892808673e-09
evidence O 0 5.6610174326010565e-09
for O 0 2.846918478738303e-09
the O 0 2.7638224153747615e-08
pathological O 0 6.668060905212769e-06
nature O 0 4.7489066901107435e-08
of O 0 4.332735059620063e-09
amino O 0 9.067358774927925e-08
acid O 0 5.145234354131389e-07
changes O 0 3.5182271318490166e-08
in O 0 2.7207606834167564e-08
APC O 0 1.2153401485193172e-06
associated O 0 5.962578342177949e-08
with O 0 7.4443478048635825e-09
both O 0 1.984352948625201e-08
FAP B-Disease 0 1.1979701412201393e-05
and O 0 2.7629087639979844e-07
non O 0 0.000858139363117516
- O 1 0.9998175501823425
FAP O 1 0.9996860027313232
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999961853027344
patients O 0 0.08267583698034286
. O 0 1.5743603398732375e-06
. O 0 1.996872697418439e-06

Inherited B-Disease 1 0.9987469911575317
colorectal I-Disease 1 0.9999836683273315
polyposis I-Disease 1 0.999555766582489
and O 1 0.8959969878196716
cancer B-Disease 1 0.9997842907905579
risk O 0 0.0003510894894134253
of O 0 8.975319332193976e-08
the O 0 1.0153676157642622e-06
APC O 0 0.0001349842787021771
I1307K O 0 0.00011609743523877114
polymorphism O 0 7.523206295445561e-05
. O 0 5.422964022727683e-06

Germ O 0 0.005560833495110273
- O 0 0.00013455723819788545
line O 0 3.2405237107013818e-06
and O 0 2.9600796480622193e-08
somatic O 0 7.80335199124238e-07
truncating O 0 8.9355698946747e-06
mutations O 0 1.3551440360970446e-06
of O 0 6.363323201696858e-09
the O 0 3.8551974057554617e-08
APC B-Disease 0 2.962217422464164e-06
gene O 0 9.958620950101249e-08
are O 0 1.5830503574676413e-09
thought O 0 2.988489811173167e-08
to O 0 2.1760582669116957e-08
initiate O 0 0.0003428986528888345
colorectal B-Disease 1 0.9999964237213135
tumor I-Disease 1 0.999818742275238
formation O 0 0.18406744301319122
in O 0 0.002641502069309354
familial B-Disease 1 0.9999366998672485
adenomatous I-Disease 1 0.9999207258224487
polyposis I-Disease 1 0.9999849796295166
syndrome I-Disease 1 0.9999661445617676
and O 0 0.002049471251666546
sporadic O 1 0.9973676800727844
colorectal O 1 0.9999955892562866
carcinogenesis O 1 0.9990731477737427
, O 0 5.970926576992497e-05
respectively O 0 5.295091978041455e-05
. O 0 7.049391570035368e-06

Recently O 0 0.00021553719125222415
, O 0 4.6920408180994855e-07
an O 0 1.621412195618177e-07
isoleucine O 0 0.00012448041525203735
- O 0 4.1782357584452257e-05
- O 0 9.872474038274959e-06
> O 0 5.649548029396101e-07
lysine O 0 3.5681691201716603e-07
polymorphism O 0 6.627029165429121e-07
at O 0 2.4033039380810806e-07
codon O 0 9.104294349526754e-07
1307 O 0 4.319244908401743e-06
( O 0 1.6956439807813695e-08
I1307K O 0 2.1823080942340312e-07
) O 0 1.9282182517343927e-09
of O 0 7.277404234784512e-10
the O 0 1.1892676177183148e-08
APC B-Disease 0 7.919685458546155e-07
gene O 0 1.125512554267516e-07
has O 0 3.124190328662735e-08
been O 0 2.1857589516116604e-08
identified O 0 1.3604289250679358e-08
in O 0 3.5183864710575108e-09
6 O 0 2.158765788351502e-08
% O 0 2.4672448528662017e-09
- O 0 3.786599904742616e-07
7 O 0 2.9604636964108977e-08
% O 0 5.352293608318348e-10
of O 0 1.070410315939796e-09
the O 0 1.7423262832494402e-08
Ashkenazi O 0 5.900923497392796e-06
Jewish O 0 8.76882666034362e-07
population O 0 2.927341995473398e-07
. O 0 9.932061857398367e-07

To O 0 4.880965889242361e-07
assess O 0 2.7936671358474996e-06
the O 0 2.4262914166683913e-07
risk O 0 1.414106350239308e-06
of O 0 5.215561316163075e-09
this O 0 7.2174151100057315e-09
common O 0 1.378816136821115e-07
APC B-Disease 0 2.0314577341196127e-05
allelic O 0 5.359548958949745e-05
variant O 0 0.006499048788100481
in O 0 0.0010117528727278113
colorectal O 1 0.9999949932098389
carcinogenesis O 1 0.9747995138168335
, O 0 9.148255912805325e-07
we O 0 2.4173480994704732e-08
have O 0 4.496497840733582e-09
analyzed O 0 3.820361627049351e-08
a O 0 3.1127939337238786e-08
large O 0 6.45452828962334e-08
cohort O 0 1.2771696447089198e-06
of O 0 1.471541288822209e-08
unselected O 0 2.216106076957658e-05
Ashkenazi O 0 2.1086523702251725e-05
Jewish O 0 1.0946521342702908e-06
subjects O 0 7.54235145450366e-07
with O 0 4.709965196525445e-06
adenomatous B-Disease 1 0.9904621243476868
polyps I-Disease 0 0.2349645346403122
and O 0 2.3369991595245665e-06
. O 0 9.443186172575224e-06
or O 1 0.8729905486106873
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999982118606567
, I-Disease 0 6.765602620362188e-07
for O 0 1.4933752012780133e-08
the O 0 3.3868684568005847e-07
APC O 0 5.728430915041827e-05
I1307K O 0 4.465665915631689e-05
polymorphism O 0 2.9150691261747852e-05
. O 0 3.0751964459341252e-06

The O 0 4.378005542093888e-06
APC O 0 5.175338446861133e-05
I1307K O 0 2.1957530407235026e-05
allele O 0 3.410956651350716e-06
was O 0 7.576604730274994e-06
identified O 0 4.244520823704079e-07
in O 0 2.9177252613976634e-08
48 O 0 6.241533867523685e-08
( O 0 3.5148717270061525e-09
10 O 0 7.492681142196034e-09
. O 0 1.0719160004057926e-09
1 O 0 7.955557990158013e-09
% O 0 1.6675024694379204e-09
) O 0 2.5902706646263596e-09
of O 0 1.3588987712864764e-08
476 O 0 8.83903521753382e-06
patients O 0 2.7151723770657554e-05
. O 0 1.2804173366021132e-06

Compared O 0 2.5759873096831143e-06
with O 0 2.4678108445641556e-08
the O 0 1.1887165030088909e-08
frequency O 0 4.7307356254577826e-08
in O 0 4.828549116098202e-09
two O 0 9.668247313854295e-10
separate O 0 6.180310041514758e-09
population O 0 3.971189599383251e-09
control O 0 1.3894951678139478e-07
groups O 0 2.3068420507144083e-09
, O 0 2.6962978516564817e-09
the O 0 1.611748245977651e-08
APC O 0 1.0150685056942166e-06
I1307K O 0 8.456107707388583e-07
allele O 0 1.637937572240844e-07
is O 0 1.691957685068246e-08
associated O 0 1.3759978934047012e-08
with O 0 2.171504753789577e-09
an O 0 1.1121215948151075e-08
estimated O 0 4.5550780924941137e-08
relative O 0 3.601890057325363e-07
risk O 0 1.5557557162537705e-06
of O 0 1.8146586455713987e-08
1 O 0 3.353441115905298e-06
. O 0 1.3682326880370965e-06

5 O 0 0.00010491688590263948
- O 0 0.0010338353458791971
1 O 0 1.96849196072435e-05
. O 0 4.575751518132165e-06

7 O 0 0.00020187924383208156
for O 0 0.00010255438974127173
colorectal B-Disease 1 0.9999822378158569
neoplasia I-Disease 1 0.9936493039131165
( O 0 1.7652571386861382e-06
both O 0 2.713272579057957e-06
P O 0 0.007769225165247917
= O 0 3.978435051976703e-05
. O 0 3.800615502314031e-07
01 O 0 7.621599797857925e-05
) O 0 3.297132309398876e-07
. O 0 8.30219789804687e-07

Furthermore O 0 1.2430698006937746e-05
, O 0 2.6478252834749583e-07
compared O 0 2.2821741652023775e-07
with O 0 3.890632527259186e-08
noncarriers O 0 3.733708945219405e-05
, O 0 1.0424508900541696e-07
APC O 0 1.9710539618245093e-06
I1307K O 0 9.725886229716707e-07
carriers O 0 3.992217330051062e-07
had O 0 4.5109146640243125e-08
increased O 0 9.725848570951712e-09
numbers O 0 1.375808977854831e-08
of O 0 2.2438880975528264e-08
adenomas B-Disease 0 0.002032157965004444
and O 0 0.0005672629922628403
colorectal B-Disease 1 0.9999973773956299
cancers I-Disease 1 0.999724805355072
per O 0 1.086213524104096e-05
patient O 0 0.0003273607580922544
( O 0 4.411170948515064e-07
P O 0 0.00015789658937137574
= O 0 1.0385218729425105e-06
. O 0 1.8285911451698666e-08
03 O 0 3.9714799981993565e-07
) O 0 2.3533186510604764e-09
, O 0 8.8980800505567e-10
as O 0 1.3382821517637922e-09
well O 0 1.0080499768250206e-09
as O 0 2.6575808220741237e-09
a O 0 4.437507783450201e-08
younger O 0 3.3331264148728224e-07
age O 0 1.2865227745351149e-06
at O 0 1.8172471754951403e-05
diagnosis O 0 0.005442311521619558
. O 0 2.3257266548171174e-06

We O 0 2.1390080746641615e-06
conclude O 0 2.0479619706748053e-06
that O 0 3.730347231112319e-08
the O 0 9.851539317651259e-08
APC O 0 5.891578439332079e-06
I1307K O 0 5.134850198373897e-06
variant O 0 1.3599624253401998e-05
leads O 0 1.1005117812601384e-06
to O 0 8.93587923656014e-08
increased O 0 4.399719909997657e-05
adenoma B-Disease 1 0.9998549222946167
formation O 0 8.435146446572617e-05
and O 0 2.8239837135402013e-08
directly O 0 6.692776555183855e-09
contributes O 0 7.003662538807021e-09
to O 0 1.2679713945473736e-09
3 O 0 1.3448410385308307e-08
% O 0 2.214925354238062e-09
- O 0 1.3611872873298125e-07
4 O 0 1.1986660553020556e-08
% O 0 9.813310164474842e-10
of O 0 1.677259997556746e-09
all O 0 4.797229991027052e-08
Ashkenazi O 0 0.07521552592515945
Jewish O 1 0.9976102113723755
colorectal B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999923706054688
. O 0 0.00026412049192003906

The O 0 9.889981811284088e-07
estimated O 0 4.5291056949281483e-07
relative O 0 1.8667121821636101e-06
risk O 0 5.226795565249631e-06
for O 0 3.312919716336182e-08
carriers O 0 7.457747415173799e-06
may O 0 2.832232439686777e-07
justify O 0 4.320828850268299e-08
specific O 0 5.1890287622313735e-09
clinical O 0 4.528539818693389e-07
screening O 0 9.891267183093078e-08
for O 0 6.245493566758853e-10
the O 0 9.745341200684265e-10
360 O 0 3.800293857381121e-09
, O 0 1.9393793238009494e-09
000 O 0 1.8475496688097337e-09
Americans O 0 1.2704527430074108e-09
expected O 0 5.637462940910609e-09
to O 0 1.4449511587244501e-09
harbor O 0 5.163726655155187e-07
this O 0 7.676332347550385e-10
allele O 0 5.296633798224093e-09
, O 0 1.7166552623848474e-09
and O 0 4.031619038613599e-09
genetic O 0 1.5743752612706885e-07
testing O 0 1.508986429143988e-07
in O 0 2.434643153748084e-09
the O 0 2.025663858873372e-09
setting O 0 1.7203699798074013e-08
of O 0 5.537204916805649e-09
long O 0 1.1401526762711e-06
- O 0 1.930948747030925e-05
term O 0 1.2011786338916863e-06
- O 0 2.8014574127155356e-06
outcome O 0 1.283669206486593e-07
studies O 0 1.9866440936766594e-08
may O 0 2.6470191372141016e-08
impact O 0 1.7624853398956475e-07
significantly O 0 3.465711779426783e-05
on O 1 0.6625709533691406
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999979734420776
prevention O 0 0.17759859561920166
in O 0 1.4312448683995171e-06
this O 0 8.030416154269915e-08
population O 0 2.4128388531607925e-07
. O 0 1.175936745312356e-06

Localization O 0 4.4507611164590344e-05
of O 0 5.153100914867537e-07
human O 0 9.861039416136919e-07
BRCA1 O 0 3.9776801713742316e-05
and O 0 8.97895020557371e-08
its O 0 8.705320198032496e-08
loss O 0 1.9388018699828535e-05
in O 0 1.2868230214735377e-07
high O 0 4.2828261939575896e-05
- O 0 8.77568672876805e-05
grade O 0 4.180699397693388e-05
, O 0 1.3792974584703188e-07
non B-Disease 0 2.7502203010953963e-05
- I-Disease 1 0.9721898436546326
inherited I-Disease 1 0.9996302127838135
breast I-Disease 1 0.9998175501823425
carcinomas I-Disease 1 0.9999295473098755
. O 0 0.00010521524382056668

Although O 0 1.4418349110201234e-06
the O 0 1.0686893858746771e-07
link O 0 6.263727527766605e-07
between O 0 1.8517972932841076e-07
the O 0 2.001414031838067e-06
BRCA1 O 0 0.012086410075426102
tumour B-Disease 1 0.9998636245727539
- O 0 0.00013985941768623888
suppressor O 0 1.636786873859819e-05
gene O 0 1.265492755919695e-06
and O 0 8.522430334778619e-07
hereditary B-Disease 1 0.9989732503890991
breast I-Disease 1 0.9999626874923706
and I-Disease 1 0.9997765421867371
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999988079071045
is O 0 6.180652235343587e-06
established O 0 4.425210704539495e-07
, O 0 9.661506261693376e-09
the O 0 7.20613568816475e-09
role O 0 1.2519340941707924e-07
, O 0 1.9835848519278443e-08
if O 0 1.8977808213804792e-09
any O 0 6.159653342940885e-10
, O 0 1.417322259555931e-09
of O 0 3.421871230813167e-09
BRCA1 O 0 2.618632606754545e-06
in O 0 8.492170167073709e-08
non B-Disease 0 8.463954145554453e-06
- I-Disease 1 0.7289971113204956
familial I-Disease 1 0.9984779953956604
cancers I-Disease 1 0.9997623562812805
is O 0 1.0889839359151665e-05
unclear O 0 9.84420421445975e-06
. O 0 2.8952765660505975e-06

BRCA1 O 0 0.10332103818655014
mutations O 0 0.0006251443410292268
are O 0 1.8012639202424907e-07
rare O 0 1.3645292256114772e-06
in O 0 8.548819891984749e-07
sporadic B-Disease 0 0.0017065565334632993
cancers I-Disease 1 0.9957460761070251
, O 0 6.574529720637656e-07
but O 0 4.5276718196873844e-07
loss O 0 9.16738008527318e-06
of O 0 3.025453665372879e-08
BRCA1 O 0 1.3697961549041793e-05
resulting O 0 2.207257807640417e-07
from O 0 3.006155324669635e-08
reduced O 0 3.7555631138275203e-07
expression O 0 6.96110191711341e-08
or O 0 1.9046064281269537e-08
incorrect O 0 1.1377756692354524e-07
subcellular O 0 5.697845040231186e-07
localization O 0 2.243577228000504e-06
is O 0 4.2062552552124544e-08
postulated O 0 6.641176497623746e-08
to O 0 7.491676723425655e-10
be O 0 2.1136978833879994e-09
important O 0 3.7209653136471843e-09
in O 0 5.1272568413196495e-08
non B-Disease 0 2.8433764782676008e-06
- I-Disease 0 0.08282597362995148
familial I-Disease 1 0.995219886302948
breast I-Disease 1 0.9998045563697815
and I-Disease 1 0.9895775318145752
ovarian I-Disease 1 0.9999971389770508
cancers I-Disease 1 0.9999696016311646
. O 0 0.0005061049596406519

Epigenetic O 0 0.004608896095305681
loss O 0 0.018079597502946854
, O 0 7.071868708408147e-07
however O 0 1.9983423271696665e-07
, O 0 5.400650238129856e-08
has O 0 7.719742001199847e-08
not O 0 1.5327831226485955e-09
received O 0 1.2447951114324951e-08
general O 0 1.299044249947201e-08
acceptance O 0 1.3865299308690737e-07
due O 0 7.792896212777123e-07
to O 0 4.826946842229063e-09
controversy O 0 6.542481401083933e-08
regarding O 0 4.535024356044914e-09
the O 0 5.0546327123868195e-09
subcellular O 0 1.575779720042192e-07
localization O 0 1.9007057971975883e-07
of O 0 1.9790309835343578e-08
BRCA1 O 0 2.2440094653575215e-06
proteins O 0 2.353858619130733e-08
, O 0 9.865130934372246e-09
reports O 0 9.754272056738955e-09
of O 0 1.5317543899939778e-09
which O 0 1.173859587311199e-08
have O 0 2.9732172279750557e-09
ranged O 0 1.071377297989784e-07
from O 0 3.87801346590777e-09
exclusively O 0 2.1425341500957984e-08
nuclear O 0 6.972855317144422e-06
, O 0 5.928023849577357e-09
to O 0 2.235910567804922e-09
conditionally O 0 1.77192441697116e-06
nuclear O 0 2.330553797946777e-06
, O 0 5.777605949219833e-09
to O 0 1.6547563319591063e-09
the O 0 4.8958138876287194e-08
ER O 0 0.00010356069833505899
/ O 0 1.6129588402691297e-06
golgi O 0 2.9609227567561902e-05
, O 0 6.83644030274877e-09
to O 0 1.9598276335131004e-09
cytoplasmic O 0 1.599075147851181e-07
invaginations O 0 2.110818059009034e-06
into O 0 2.4156243227935192e-08
the O 0 1.2869212184796197e-07
nucleus O 0 3.73958778254746e-06
. O 0 1.0881458365474828e-06

In O 0 9.01225064353639e-07
an O 0 6.295047683124722e-08
attempt O 0 1.9798451944552653e-07
to O 0 9.172977932792037e-09
resolve O 0 3.3892820283654146e-07
this O 0 4.5860057973357016e-09
issue O 0 1.653211079144512e-08
, O 0 6.5148717531826605e-09
we O 0 2.492940298637336e-09
have O 0 3.0567801623249125e-09
comprehensively O 0 1.1693231272147386e-06
characterized O 0 2.4745852442720206e-06
19 O 0 2.5344136247440474e-06
anti O 0 0.00014843270764686167
- O 0 0.0035895169712603092
BRCA1 O 0 0.0004651915514841676
antibodies O 0 1.2110120223951526e-05
. O 0 1.158593590844248e-06

These O 0 1.3574084789524932e-07
reagents O 0 2.9015757263550768e-06
detect O 0 4.601618456945289e-06
a O 0 2.1594293286852917e-07
220 O 0 1.8453589234468382e-07
- O 0 3.6833771446254104e-06
kD O 0 3.1553363442071714e-06
protein O 0 1.1698300994567035e-07
localized O 0 2.7716782824427355e-07
in O 0 1.0245226889082915e-08
discrete O 0 9.217951912887656e-08
nuclear O 0 1.659949930399307e-06
foci O 0 7.976238407536584e-07
in O 0 1.7980452682309078e-08
all O 0 4.659202357260028e-09
epithelial O 0 1.0102378837473225e-05
cell O 0 4.884841837338172e-05
lines O 0 2.601608912300435e-06
, O 0 1.5549037613027394e-08
including O 0 5.943024738996883e-09
those O 0 9.67790203532104e-09
derived O 0 1.2548626671105012e-07
from O 0 4.15459408031893e-06
breast B-Disease 1 0.970538854598999
malignancies I-Disease 0 0.20627325773239136
. O 0 1.0581202332105022e-05

Immunohistochemical O 0 0.0007481883512809873
staining O 0 0.0001254220405826345
of O 0 1.4063007256481797e-06
human O 0 4.424869257491082e-05
breast O 1 0.9258495569229126
specimens O 0 2.3637290723854676e-05
also O 0 1.8642624581843847e-06
revealed O 0 6.235765613382682e-05
BRCA1 O 0 0.000673099362757057
nuclear O 0 0.00034015782875940204
foci O 0 0.0001164980058092624
in O 0 1.309464823862072e-05
benign O 1 0.9407082796096802
breast O 1 0.9933080673217773
, O 0 1.881750904431101e-05
invasive B-Disease 1 0.8950213193893433
lobular I-Disease 1 0.9997883439064026
cancers I-Disease 1 0.999580442905426
and O 0 4.741317388834432e-05
low B-Disease 1 0.617782711982727
- I-Disease 1 0.9931821227073669
grade I-Disease 1 0.9706202745437622
ductal I-Disease 1 0.9993528723716736
carcinomas I-Disease 1 0.9999040365219116
. O 0 0.00016229892207775265

Conversely O 0 4.632165655493736e-05
, O 0 7.762070595163095e-07
BRCA1 O 0 2.1850642951903865e-05
expression O 0 1.8340057295063161e-06
was O 0 1.3910591405874584e-05
reduced O 0 7.844179776839155e-07
or O 0 3.6393632996123415e-08
undetectable O 0 2.6454904400452506e-06
in O 0 5.4246811487246305e-09
the O 0 3.872514309222197e-09
majority O 0 6.8053207513685265e-09
of O 0 1.1076231487550103e-08
high O 0 0.0001072575687430799
- O 0 0.005752209573984146
grade O 0 0.0012136854929849505
, O 0 1.3499339729605708e-05
ductal B-Disease 1 0.9979521632194519
carcinomas I-Disease 1 0.9999470710754395
, O 0 1.1888886319866288e-06
suggesting O 0 6.208987883837835e-07
that O 0 4.953937260410157e-09
absence O 0 8.735409551263729e-08
of O 0 3.095186684731743e-08
BRCA1 O 0 4.691415961133316e-05
may O 0 1.1312945957797638e-07
contribute O 0 4.523732943795267e-09
to O 0 1.56413582086401e-09
the O 0 1.7668636331791276e-08
pathogenesis O 0 2.4544920051994268e-06
of O 0 2.187951819720979e-09
a O 0 5.3243397246660606e-08
significant O 0 8.295195641494502e-08
percentage O 0 4.925392431687214e-07
of O 0 1.278767172152584e-07
sporadic B-Disease 0 0.01078705582767725
breast I-Disease 1 0.999798595905304
cancers I-Disease 1 0.998895525932312
. O 0 1.3930990689914324e-06
. O 0 1.1435447504482e-06

